Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request cder_mpl1p_wp074

Request ID: cder_mpl1p_wp074

Request Description: This report presents the results from the sensitivity analyses examining the rates of cancer among individuals exposed to loop diuretics in the Sentinel Distributed Database (SDD). Follow-up began at 730 days after the first valid loop diuretic dispensing.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.2.4, with custom programming.

Data Source: We distributed this query to six Sentinel Data Partners (DPs) on January 20, 2023. These Data Partners are a subset of the SDD, including data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage. The study period included data from January 1, 2000 to February 28, 2022. Please, see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We separately identified individuals with incident and prevalent use of loop diuretics, including bumetanide, torsemide or furosemide. Incident cohorts were identified as patients with an exposure and no evidence of exposure in the prior 365 days. Prevalent cohorts were likewise identified but without the latter requirement. In these cohorts, we evaluated the occurrence of liver, bladder, colorectal, or esophageal cancer from 730 days post-exposure through the end of follow-up time. This is a Type 2 analysis in the query Request Package (QRP) documentation.

Loop Diuretics Exposure: We defined the loop diuretics, bumetanide, furosemide, and torsemide, using outpatient dispensing data and National Drug Codes (NDCs). Only the first qualifying (index) dispensing of bumetanide, furosemide, or torsemide was included; cohort re-entry was not allowed. We defined dosage for loop diuretics as Oral Furosemide Equivalents[1] as follows:

1 mg oral bumetanide = 80mg oral furosemide
1 mg oral torsemide = 4mg oral furosemide
1 mg oral ethacrynic acid = .8 mg oral furosemide

Please see Appendix C for a list of non-proprietary and proprietary names of medical products.

Outcomes of Interest: We defined the outcomes, liver cancer, bladder cancer, colorectal cancer, and esophageal cancer, using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. We identified each cancer outcome as follows:

1) ***Liver cancer:*** We defined liver cancer outcome as evidence of at least two codes of hepatocellular carcinoma within anytime of each other. We defined liver cancer washout as having no evidence of liver cancer within 365 days prior to index date.
2) ***Colorectal cancer:*** We defined colorectal cancer outcome as evidence of two codes of colorectal cancer within 2 months of each other. We defined colorectal cancer washout as having no evidence of colorectal cancer within 365 days prior to index date.
3) ***Bladder cancer:*** We defined bladder cancer outcome as evidence of bladder cancer diagnosis code, and bladder cancer washout as having no evidence of bladder cancer within 365 days prior to index date.
4) ***Esophageal cancer:*** We defined esophageal cancer outcome as evidence of esophageal cancer diagnosis code, and esophageal cancer washout as having no evidence of esophageal cancer within 365 days prior to index date.

Please see Appendix G for ICD-9-CM and ICD-10-CM codes used to define outcomes of interest in this request; see Appendix H for ICD-9-CM and ICD-10-CM codes used to define outcome incidence criteria in this request.

Overview for Request cder_mpl1p_wp074

Cohort Eligibility Criteria: There were two groups of cohorts: the exposure cohorts with washout, and the exposure cohorts without washout. For each cohort, we required members to be enrolled in health plans with medical and drug coverage for at least 365 days prior to index date; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. We included individuals in the following age groups: <20, 20-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+ years.

For the exposure cohorts with washout, we required no evidence of any loop diuretic (bumetanide, furosemide, or torsemide) in the 365 days before the first qualifying index dispensing, regardless of which loop diuretic was the index exposure. For the exposure cohort without washout, no exclusion for exposure codes was considered. For both exposure cohorts, we excluded members with evidence of cancer, chemotherapy, or radiation treatments in the 365 days prior to index and up to 730 days after index.

Please, see Appendix B for anniversary codes used to identify the background population. See Appendix D for non-proprietary and proprietary names of medical products used to define exposure incidence criteria in this request. See Appendices I and J for non-proprietary and proprietary names, and ICD-9-CM, ICD-10-CM, International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II HCPCS) codes used to define exclusion criteria in this request.

Follow-Up Time: Using custom programming , we assessed follow-up time accrued by cumulative dose, cumulative duration, and N-Nitroso-dimethylamine (NDMA) impurity categories for bumetanide, torsemide, and furosemide use.

For each exposure cohort, patients began accruing follow-up time 730 days after the index date (lag period). For stratifications by cumulative dose and impurity, patients began accruing follow-up time to the cumulative dose or impurity category reached at the end of the lag period.

Follow-up time continued to accrue until first occurrence of any of the following: 1) disenrollment, 2) the end date of the data provided by each Data Partner (see Appendix A), 3) the end of the exposure episode, 4) evidence of any cancer, chemotherapy, or radiation treatment, 5) evidence of outcome of interest, or 6) death.

Cumulative Dose Calculation: Cumulative dose of an individual's exposure to loop diuretics was calculated, starting from the index dispensing date to the end of follow-up time. Cumulative dose was calculated in three steps: First, by multiplying the amount supplied of the dispensing by the strength of loop diuretic in the drug dispensed. Then, cumulative dose was divided by the days' supply of the dispensing to get the daily dose. Finally, daily dose was added cumulatively to accurately capture transitions of individuals between cumulative dose categories.

Cumulative Days' Supply Calculation **:** Cumulative days' supply was calculated by cumulatively summating the days of supply of each dispensing.

NDMA Impurity Calculation: NDMA impurity was calculated as an individual's exposure to specific impurity identified bumetanide NDCs, from index dispensing date to the end of follow-up time. Impurity was calculated by multiplying the concentration of NDMA per unit of bumetanide in an impurity identified drug, the strength of bumetanide in that drug, and the number of tablets dispensed.

Overview for Request cder_mpl1p_wp074

NDMA Impurity Calculation: NDMA impurity was calculated as an individual's exposure to specific impurity identified bumetanide NDCs from index dispensing date to the end of follow-up time. Impurity was calculated by multiplying the concentration of NDMA impurity by the number of tablets dispensed and by the dosage per tablet (equivalent to dividing the furosemide-equivalent strength by 80).

We defined the following cumulative dose categories: 0 - <30,000, 30,000 - <60,000, 60,000 - <90,000, 90,000 - <120,000, 120,000 - <150,000, 150,000 - <180,000, 180,000 - <210,000 and ≥ 210,000 mg, and the following cumulative days supplied categories: 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, and 7+ years.

We defined the following imurity categories: 0, >0 - <700,000, 700,000 - <1,000,000, 1,000,000 - <1,500,000, 1,500,000 - <2,000,000, and ≥ 2,000,000 parts per million.

Within each cumulative dose, days' supply, and impurity category, follow-up time began accruing at 730 days after the first valid loop diuretic dispensing until the upper bound of a category was reached, moving to, and restarting in the next category.

Please, see Appendix E for non-proprietary and proprietary names of medical products used to define exposure censoring criteria in this request. See Appendix F for a list of CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, and ICD-10-PCS used to define exposure censoring criteria in this request.

Baseline Characteristics: Age was assessed on the date of cohort entry. We assessed the following baseline health characteristics in the 365 days prior to the index date of loop diuretic dispensing: achalasia, alcoholic cirrhosis of the liver, alcoholic hepatitis, alcoholic liver damage, alcoholic liver disease, alcohol-related disorders, alpha 1-antitrypsin deficiency, Barrett's esophagus, biliary cirrhosis, bladder stones, cholangitis, cholelithiasis, cirrhosis, chronic obstructive pulmonary disease, colon cancer screening, cystitis, diabetes, Crohn's disease, ulcerative colitis, dyslipoproteinemia, family history of colorectal cancer, gastroesophageal reflux disease, glycogen storage disease, hepatitis B infection, hepatitis C infection, congestive heart failure, hemochromatosis, human papillomavirus, hypertension, liver flukes, non-alcoholic steatohepatitis, obesity, Plummer-Vinson syndrome, porphyria cutanea tarda, history of smoking, smoking in the past year, tylosis, tyrosinemia, urinary incontinence, urolithiasis, urinary tract infections, viral hepatitis, and Wilson's disease. We also assessed the following medical product use in the 365 days prior to the index date of loop diuretic dispensing: 5-alpha reductase inhibitors, antidiabetic drugs, acetylsalicylic acid, glucocorticoids, hormone replacement therapy, non-aspirin non-steroidal anti-inflammatory drugs (non-ASA NSAIDs), spironolactone, selective serotonin reuptake inhibitors, statins, long-term anabolic steroids, metformin.

Please, see Appendices K for CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, ICD-10-PCS codes used to define baseline characteristics in this request. See Appendix L for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Primary Analyses: In the primary analyses, we evaluated cancer rates in the background population and among users of loop diuretics with follow-up beginning at 365 days after the first valid loop diuretic dispensing. Please, see the accompanying report, cder_mpl1p_wp065, run 1, for details and results from the primary analyses.

Please see Appendices M, N, and O for the specifications of parameters, baseline characteristics, and design diagrams for this request.

Limitations: Algorithms to define exposures, outcomes, inclusion and exclusion criteria, and baseline characteristics are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind. Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1]Anisman SD, Erickson SB, Morden NE. How to prescribe loop diuretics in oedema. BMJ. 2019 Feb 21;364:l359.

Sentinel

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table 1a Aggregated Baseline Characteristics of Bumetanide Users (Washout) and Bumetanide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 1b Aggregated Baseline Characteristics of Torsemide Users (Washout) and Torsemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 1c Aggregated Baseline Characteristics of Furosemide Users (Washout) and Furosemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 2 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 3 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

Table 4 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race

Table 5 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex

Table 6 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group

Table 7 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 8 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 9 Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 10a Summary of Time to End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 10b Summary of Time to End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 10c Summary of Time to End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 10d Summary of Time to End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 11a Summary of Reasons for End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 11b Summary of Reasons for End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 11c Summary of Reasons for End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 11d Summary of Reasons for End of At-Risk Period for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 12a Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table of Contents

Table 12b Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 12c Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 12d Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 13a Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 13b Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 13c Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 13d Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 14a Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 14b Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 14c Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 14d Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 15a Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 15b Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 15c Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table 15d Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)

Table 16a Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

Table 16b Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose

Table 16c Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration

Table of Contents

Table 16d	Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)
Table 17a	Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022
Table 17b	Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose
Table 17c	Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration
Table 17d	Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretics Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)
Table 18	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022
Appendix A	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 20, 2023)
Appendix B	List of Ages Used to Define Exposures in this Request
Appendix C	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
Appendix D	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Incidence Criteria in this Request
Appendix E	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request
Appendix F	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request
Appendix G	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Codes Used to Define Outcomes in this Request
Appendix H	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcome Incidence Criteria in this Request
Appendix I	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this
Appendix J	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request
Appendix K	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Table of Contents

Appendix L List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix M Specifications Used to Define Parameters for this Request

Appendix N Specifications Used to Define Parameters for Baseline Characteristics for this Request

Appendix O Design Diagrams of Cohort Entry Requirements and Index Exposure

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.
Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Characteristics of Bumetanide Users (Washout) and Bumetanide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Bumetanide Users (Washout)		Bumetanide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Unique patients	172,936	N/A	681,044	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Age (years)	70.6	13.3	71.9	13.1
Age	**Number**	**Percent**	**Number**	**Percent**
0-19 years	222	0.1%	426	0.1%
20-34 years	*****	*****	*****	*****
35-44 years	*****	*****	*****	*****
45-54 years	*****	*****	*****	*****
55-64 years	*****	*****	100,447	14.7%
65-74 years	51,897	30.0%	204,530	30.0%
75-84 years	43,240	25.0%	174,141	25.6%
≥ 85 years	*****	*****	*****	*****
Sex				
Female	104,995	60.7%	406,044	59.6%
Male	67,941	39.3%	275,000	40.4%
Race[1]				
American Indian or Alaska Native	*****	*****	*****	*****
Asian	*****	*****	*****	*****
Black or African American	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****
Unknown	*****	*****	*****	*****
White	114,151	66.0%	473,057	69.5%
Hispanic origin				
Yes	3,998	2.3%	14,188	2.1%
No	133,358	77.1%	554,962	81.5%
Unknown	35,580	20.6%	111,894	16.4%
Year				
2000	0	0.0%	41	0.0%
2001	276	0.2%	2,170	0.3%
2002	379	0.2%	1,511	0.2%
2003	353	0.2%	1,306	0.2%
2004	389	0.2%	1,393	0.2%
2005	284	0.2%	1,195	0.2%
2006	74	0.0%	212	0.0%
2007	1,003	0.6%	5,302	0.8%
2008	1,746	1.0%	7,055	1.0%
2009	3,246	1.9%	11,643	1.7%
2010	3,341	1.9%	8,606	1.3%
2011	13,144	7.6%	89,252	13.1%

Table 1a. Aggregated Baseline Characteristics of Bumetanide Users (Washout) and Bumetanide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Bumetanide Users (Washout)		Bumetanide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
2012	12,893	7.5%	44,420	6.5%
2013	13,799	8.0%	47,669	7.0%
2014	11,973	6.9%	47,160	6.9%
2015	13,760	8.0%	48,968	7.2%
2016	14,513	8.4%	53,496	7.9%
2017	15,155	8.8%	56,307	8.3%
2018	14,583	8.4%	55,005	8.1%
2019	16,100	9.3%	60,041	8.8%
2020	15,943	9.2%	61,573	9.0%
2021	19,460	11.3%	73,661	10.8%
2022	522	0.3%	3,058	0.4%
Health Characteristics				
Achalasia	204	0.1%	960	0.1%
Alchoholic Cirrhosis of the Liver	1,223	0.7%	7,780	1.1%
Alcoholic Hepatitis	397	0.2%	1,564	0.2%
Alcoholic Liver Damage	359	0.2%	1,898	0.3%
Alcoholic Liver Disease	1,585	0.9%	9,158	1.3%
Alchohol-related Disorders	3,643	2.1%	14,996	2.2%
Alpha 1-antitrypsin Deficiency	87	0.1%	493	0.1%
Barrett's Esophagus	1,765	1.0%	7,843	1.2%
Biliary cirrhosis	226	0.1%	1,381	0.2%
Bladder Stones	8,067	4.7%	34,672	5.1%
Cholangitis	247	0.1%	1,075	0.2%
Cholelithiasis	75	0.0%	387	0.1%
Cirrhosis	3,698	2.1%	24,119	3.5%
Chronic Obstructive Pulmonary Disease	54,947	31.8%	275,974	40.5%
Colon Cancer Scerening	22,358	12.9%	94,061	13.8%
Cystitis	8,641	5.0%	36,708	5.4%
Diabetes	84,099	48.6%	386,564	56.8%
Crohn's Disease	892	0.5%	3,507	0.5%
Ulecrative Colitis	1,455	0.8%	5,831	0.9%
Dyslipoproteinemia	122,383	70.8%	510,679	75.0%
Family history of colorectal cancer	2,122	1.2%	8,568	1.3%
Gastroesophageal reflux disease	55,585	32.1%	244,409	35.9%
Glycogen storage disease	*****	0.0%	31	0.0%
Hepatitis B Infection	607	0.4%	2,663	0.4%
Hepatitis C Infection	2,526	1.5%	11,013	1.6%
Congestive Heart Failure	78,100	45.2%	434,798	63.8%
Hemochromatosis	271	0.2%	1,167	0.2%

Table 1a. Aggregated Baseline Characteristics of Bumetanide Users (Washout) and Bumetanide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Bumetanide Users (Washout)		Bumetanide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Human papillomavirus	246	0.1%	796	0.1%
Hypertension	151,310	87.5%	623,051	91.5%
Liver flukes	*****	0.0%	*****	0.0%
Non-alcoholic steatohepatitis	6,913	4.0%	31,947	4.7%
Obesity	55,134	31.9%	261,558	38.4%
Plummer-Vinson syndrome	55	0.0%	250	0.0%
Porphyria cutnea tarda	*****	0.0%	53	0.0%
History of smoking	70,012	40.5%	282,112	41.4%
Smoking in the past year	50,265	29.1%	216,360	31.8%
Tylosis	4,752	2.7%	22,855	3.4%
Tyrosinemia	0	0.0%	0	0.0%
Urinary Incontinence	13,048	7.5%	54,790	8.0%
Urolithiasis	1,126	0.7%	4,574	0.7%
Urinary Tract Infections	43,166	25.0%	192,816	28.3%
Viral Hepatitis	434	0.3%	1,733	0.3%
Wilson's Disease	44	0.0%	192	0.0%

Table 1a. Aggregated Baseline Characteristics of Bumetanide Users (Washout) and Bumetanide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Bumetanide Users (Washout)		Bumetanide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Medical Product Use				
5-alpha reductase inhibitors	5,393	3.1%	25,696	3.8%
Antidiabetic Drugs	46,703	27.0%	215,440	31.6%
Acetylsalicylic Acid	2,011	1.2%	9,312	1.4%
Glucocorticoids	77,648	44.9%	352,027	51.7%
Hormone Replacement Therapy	12,594	7.3%	49,238	7.2%
Non-ASA NSAIDs	46,926	27.1%	178,811	26.3%
Spironolactone	13,115	7.6%	121,758	17.9%
Selective Serotonin Reuptake Inhibitors	36,140	20.9%	167,947	24.7%
Statins	95,681	55.3%	436,612	64.1%
Long-term anabolic steroids	4,361	2.5%	24,295	3.6%
Metformin	31,836	18.4%	132,486	19.5%

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Baseline Characteristics of Torsemide Users (Washout) and Torsemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Torsemide Users (Washout)		Torsemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Unique patients	172,362	N/A	680,304	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Age (years)	71.4	12.8	72.3	12.8
Age	**Number**	**Percent**	**Number**	**Percent**
0-19 years	101	0.1%	159	0.0%
20-34 years	*****	*****	*****	*****
35-44 years	*****	*****	*****	*****
45-54 years	*****	*****	*****	*****
55-64 years	*****	*****	95,451	14.0%
65-74 years	52,227	30.3%	207,704	30.5%
75-84 years	*****	*****	181,097	26.6%
≥ 85 years	*****	*****	122,668	18.0%
Sex				
Female	102,292	59.3%	394,345	58.0%
Male	70,070	40.7%	285,959	42.0%
Race[1]				
American Indian or Alaska Native	*****	*****	*****	*****
Asian	*****	*****	*****	*****
Black or African American	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****
Unknown	*****	*****	*****	*****
White	114,319	66.3%	473,367	69.6%
Hispanic origin				
Yes	2,866	1.7%	9,681	1.4%
No	132,072	76.6%	548,089	80.6%
Unknown	37,424	21.7%	122,534	18.0%
Year				
2000	0	0.0%	37	0.0%
2001	358	0.2%	2,018	0.3%
2002	421	0.2%	1,600	0.2%
2003	374	0.2%	1,534	0.2%
2004	429	0.2%	1,532	0.2%
2005	283	0.2%	1,057	0.2%
2006	80	0.0%	190	0.0%
2007	1,241	0.7%	6,795	1.0%
2008	1,690	1.0%	6,680	1.0%
2009	3,262	1.9%	12,648	1.9%
2010	2,847	1.7%	7,589	1.1%
2011	10,635	6.2%	77,543	11.4%

Table 1b. Aggregated Baseline Characteristics of Torsemide Users (Washout) and Torsemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Torsemide Users (Washout)		Torsemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
2012	10,297	6.0%	36,146	5.3%
2013	10,837	6.3%	38,295	5.6%
2014	11,977	6.9%	50,033	7.4%
2015	12,742	7.4%	46,277	6.8%
2016	13,455	7.8%	49,843	7.3%
2017	14,121	8.2%	54,041	7.9%
2018	15,820	9.2%	58,455	8.6%
2019	17,267	10.0%	64,059	9.4%
2020	18,728	10.9%	70,857	10.4%
2021	24,826	14.4%	89,494	13.2%
2022	672	0.4%	3,581	0.5%
Health Characteristics				
Achalasia	194	0.1%	925	0.1%
Alchoholic Cirrhosis of the Liver	859	0.5%	5,643	0.8%
Alcoholic Hepatitis	236	0.1%	1,030	0.2%
Alcoholic Liver Damage	247	0.1%	1,258	0.2%
Alcoholic Liver Disease	1,122	0.7%	6,766	1.0%
Alchohol-related Disorders	3,032	1.8%	12,765	1.9%
Alpha 1-antitrypsin Deficiency	90	0.1%	393	0.1%
Barrett's Esophagus	1,906	1.1%	8,021	1.2%
Biliary cirrhosis	220	0.1%	1,167	0.2%
Bladder Stones	7,518	4.4%	32,460	4.8%
Cholangitis	208	0.1%	952	0.1%
Cholelithiasis	75	0.0%	328	0.0%
Cirrhosis	2,944	1.7%	20,209	3.0%
Chronic Obstructive Pulmonary Disease	47,489	27.6%	249,602	36.7%
Colon Cancer Scerening	21,854	12.7%	92,277	13.6%
Cystitis	8,304	4.8%	35,717	5.3%
Diabetes	82,058	47.6%	379,119	55.7%
Crohn's Disease	847	0.5%	3,286	0.5%
Ulecrative Colitis	1,222	0.7%	5,167	0.8%
Dyslipoproteinemia	125,125	72.6%	520,443	76.5%
Family history of colorectal cancer	2,290	1.3%	8,960	1.3%
Gastroesophageal reflux disease	52,105	30.2%	232,183	34.1%
Glycogen storage disease	*****	0.0%	28	0.0%
Hepatitis B Infection	485	0.3%	2,176	0.3%
Hepatitis C Infection	1,964	1.1%	8,972	1.3%
Congestive Heart Failure	70,533	40.9%	426,273	62.7%
Hemochromatosis	302	0.2%	1,176	0.2%

Table 1b. Aggregated Baseline Characteristics of Torsemide Users (Washout) and Torsemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Torsemide Users (Washout)		Torsemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Human papillomavirus	260	0.2%	802	0.1%
Hypertension	152,831	88.7%	625,426	91.9%
Liver flukes	*****	0.0%	15	0.0%
Non-alcoholic steatohepatitis	6,116	3.5%	29,411	4.3%
Obesity	52,568	30.5%	253,545	37.3%
Plummer-Vinson syndrome	45	0.0%	271	0.0%
Porphyria cutnea tarda	13	0.0%	48	0.0%
History of smoking	68,095	39.5%	280,368	41.2%
Smoking in the past year	47,191	27.4%	211,928	31.2%
Tylosis	5,251	3.0%	24,709	3.6%
Tyrosinemia	*****	0.0%	*****	0.0%
Urinary Incontinence	12,422	7.2%	52,534	7.7%
Urolithiasis	1,145	0.7%	4,479	0.7%
Urinary Tract Infections	37,539	21.8%	169,491	24.9%
Viral Hepatitis	380	0.2%	1,623	0.2%
Wilson's Disease	36	0.0%	166	0.0%

Table 1b. Aggregated Baseline Characteristics of Torsemide Users (Washout) and Torsemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Torsemide Users (Washout)		Torsemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Medical Product Use				
5-alpha reductase inhibitors	6,117	3.5%	28,165	4.1%
Antidiabetic Drugs	47,347	27.5%	215,652	31.7%
Acetylsalicylic Acid	1,878	1.1%	8,832	1.3%
Glucocorticoids	75,659	43.9%	341,766	50.2%
Hormone Replacement Therapy	12,415	7.2%	47,745	7.0%
Non-ASA NSAIDs	44,420	25.8%	167,050	24.6%
Spironolactone	15,034	8.7%	131,001	19.3%
Selective Serotonin Reuptake Inhibitors	34,119	19.8%	157,926	23.2%
Statins	100,636	58.4%	450,711	66.3%
Long-term anabolic steroids	4,092	2.4%	23,003	3.4%
Metformin	32,189	18.7%	132,402	19.5%

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Baseline Characteristics of Furosemide Users (Washout) and Furosemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Furosemide Users (Washout)		Furosemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Unique patients	5,031,471	N/A	8,853,836	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Age (years)	70.7	13.6	71.2	13.5
Age	**Number**	**Percent**	**Number**	**Percent**
0-19 years	*****	*****	*****	*****
20-34 years	*****	*****	*****	*****
35-44 years	213,510	4.2%	315,849	3.6%
45-54 years	452,526	9.0%	*****	*****
55-64 years	718,788	14.3%	*****	*****
65-74 years	1,441,346	28.6%	2,622,140	29.6%
75-84 years	1,230,807	24.5%	2,116,125	23.9%
≥ 85 years	870,150	17.3%	1,616,053	18.3%
Sex				
Female	3,150,993	62.6%	5,533,790	62.5%
Male	1,880,478	37.4%	3,320,046	37.5%
Race[1]				
American Indian or Alaska Native	*****	*****	*****	*****
Asian	83,025	1.7%	122,704	1.4%
Black or African American	559,140	11.1%	1,040,342	11.8%
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****
Unknown	1,064,141	21.1%	1,716,528	19.4%
White	3,293,461	65.5%	5,920,596	66.9%
Hispanic origin				
Yes	111,148	2.2%	183,994	2.1%
No	3,821,196	75.9%	6,886,009	77.8%
Unknown	1,099,127	21.8%	1,783,833	20.1%
Year				
2000	37	0.0%	2,415	0.0%
2001	16,274	0.3%	60,285	0.7%
2002	16,408	0.3%	22,508	0.3%
2003	14,879	0.3%	20,012	0.2%
2004	14,982	0.3%	19,998	0.2%
2005	11,671	0.2%	16,927	0.2%
2006	3,555	0.1%	4,076	0.0%
2007	37,193	0.7%	109,987	1.2%
2008	60,469	1.2%	136,867	1.5%
2009	105,709	2.1%	221,621	2.5%
2010	99,856	2.0%	146,168	1.7%
2011	434,534	8.6%	1,640,014	18.5%

Table 1c. Aggregated Baseline Characteristics of Furosemide Users (Washout) and Furosemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Furosemide Users (Washout)		Furosemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
2012	419,688	8.3%	671,072	7.6%
2013	411,372	8.2%	643,012	7.3%
2014	432,838	8.6%	733,658	8.3%
2015	435,710	8.7%	655,621	7.4%
2016	429,280	8.5%	643,483	7.3%
2017	417,839	8.3%	611,790	6.9%
2018	413,542	8.2%	594,660	6.7%
2019	404,123	8.0%	577,417	6.5%
2020	384,839	7.6%	595,446	6.7%
2021	454,722	9.0%	694,618	7.8%
2022	11,951	0.2%	32,181	0.4%
Health Characteristics				
Achalasia	5,800	0.1%	9,921	0.1%
Alchoholic Cirrhosis of the Liver	45,902	0.9%	89,891	1.0%
Alcoholic Hepatitis	16,168	0.3%	24,270	0.3%
Alcoholic Liver Damage	12,474	0.2%	21,959	0.2%
Alcoholic Liver Disease	58,073	1.2%	108,447	1.2%
Alchohol-related Disorders	124,502	2.5%	194,766	2.2%
Alpha 1-antitrypsin Deficiency	2,646	0.1%	4,551	0.1%
Barrett's Esophagus	51,825	1.0%	87,165	1.0%
Biliary cirrhosis	7,132	0.1%	13,604	0.2%
Bladder Stones	199,093	4.0%	338,268	3.8%
Cholangitis	7,812	0.2%	12,635	0.1%
Cholelithiasis	2,875	0.1%	5,241	0.1%
Cirrhosis	106,864	2.1%	207,308	2.3%
Chronic Obstructive Pulmonary Disease	1,432,062	28.5%	2,662,146	30.1%
Colon Cancer Scerening	622,541	12.4%	1,123,996	12.7%
Cystitis	224,021	4.5%	358,482	4.0%
Diabetes	2,075,721	41.3%	4,017,531	45.4%
Crohn's Disease	24,146	0.5%	40,793	0.5%
Ulecrative Colitis	40,481	0.8%	68,790	0.8%
Dyslipoproteinemia	3,361,793	66.8%	6,045,874	68.3%
Family history of colorectal cancer	61,934	1.2%	101,941	1.2%
Gastroesophageal reflux disease	1,528,121	30.4%	2,627,063	29.7%
Glycogen storage disease	108	0.0%	182	0.0%
Hepatitis B Infection	15,593	0.3%	27,382	0.3%
Hepatitis C Infection	72,747	1.4%	125,514	1.4%
Congestive Heart Failure	1,736,586	34.5%	3,646,744	41.2%
Hemochromatosis	7,316	0.1%	12,185	0.1%

Table 1c. Aggregated Baseline Characteristics of Furosemide Users (Washout) and Furosemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Furosemide Users (Washout)		Furosemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Human papillomavirus	8,740	0.2%	13,896	0.2%
Hypertension	4,217,216	83.8%	7,611,865	86.0%
Liver flukes	75	0.0%	132	0.0%
Non-alcoholic steatohepatitis	181,047	3.6%	312,294	3.5%
Obesity	1,292,555	25.7%	2,319,170	26.2%
Plummer-Vinson syndrome	902	0.0%	1,464	0.0%
Porphyria cutnea tarda	237	0.0%	375	0.0%
History of smoking	1,899,864	37.8%	2,885,534	32.6%
Smoking in the past year	1,365,050	27.1%	2,156,634	24.4%
Tylosis	116,444	2.3%	182,994	2.1%
Tyrosinemia	*****	0.0%	12	0.0%
Urinary Incontinence	377,746	7.5%	629,559	7.1%
Urolithiasis	22,219	0.4%	34,046	0.4%
Urinary Tract Infections	1,163,122	23.1%	2,059,829	23.3%
Viral Hepatitis	8,542	0.2%	14,662	0.2%
Wilson's Disease	1,045	0.0%	1,896	0.0%

Table 1c. Aggregated Baseline Characteristics of Furosemide Users (Washout) and Furosemide Users (No Washout) in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Furosemide Users (Washout)		Furosemide Users (No Washout)	
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**
Medical Product Use				
5-alpha reductase inhibitors	152,908	3.0%	277,291	3.1%
Antidiabetic Drugs	1,253,902	24.9%	2,454,967	27.7%
Acetylsalicylic Acid	64,704	1.3%	123,947	1.4%
Glucocorticoids	2,206,887	43.9%	3,997,981	45.2%
Hormone Replacement Therapy	367,912	7.3%	643,082	7.3%
Non-ASA NSAIDs	1,470,600	29.2%	2,494,152	28.2%
Spironolactone	223,132	4.4%	736,275	8.3%
Selective Serotonin Reuptake Inhibitors	1,116,799	22.2%	2,083,051	23.5%
Statins	2,733,540	54.3%	5,175,316	58.5%
Long-term anabolic steroids	115,289	2.3%	234,995	2.7%
Metformin	934,229	18.6%	1,725,271	19.5%

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	142,052,084	76	4.39	201,498.5	0.01	3.77	403,207,018.7
Bumetanide Users (No Washout)	681,044	145,886,512	380	5.58	694,580.4	0.03	5.47	423,488,059.5
Torsemide Users (Washout)	172,362	142,052,084	57	3.31	187,763.7	0.00	3.04	403,220,608.6
Torsemide Users (No Washout)	680,304	145,886,512	280	4.12	662,786.2	0.02	4.22	423,529,490.1
Furosemide Users (Washout)	5,031,471	142,052,084	3,174	6.31	6,487,281.7	0.22	4.89	399,244,718.5
Furosemide Users (No Washout)	8,853,836	145,886,512	6,240	7.05	12,261,365.0	0.43	5.09	400,535,781.1
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	142,052,084	179	10.35	201,498.5	0.01	8.88	403,207,018.7
Bumetanide Users (No Washout)	681,044	145,886,512	677	9.94	694,580.4	0.05	9.75	423,488,059.5
Torsemide Users (Washout)	172,362	142,052,084	174	10.10	187,763.7	0.01	9.27	403,220,608.6
Torsemide Users (No Washout)	680,304	145,886,512	677	9.95	662,786.2	0.05	10.21	423,529,490.1
Furosemide Users (Washout)	5,031,471	142,052,084	5,808	11.54	6,487,281.7	0.41	8.95	399,244,718.5
Furosemide Users (No Washout)	8,853,836	145,886,512	11,744	13.26	12,261,365.0	0.81	9.58	400,535,781.1
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	142,052,084	393	22.73	201,498.5	0.03	19.50	403,207,018.7
Bumetanide Users (No Washout)	681,044	145,886,512	1,526	22.41	694,580.4	0.10	21.97	423,488,059.5
Torsemide Users (Washout)	172,362	142,052,084	338	19.61	187,763.7	0.02	18.00	403,220,608.6
Torsemide Users (No Washout)	680,304	145,886,512	1,393	20.48	662,786.2	0.10	21.02	423,529,490.1
Furosemide Users (Washout)	5,031,471	142,052,084	11,518	22.89	6,487,281.7	0.81	17.75	399,244,718.5
Furosemide Users (No Washout)	8,853,836	145,886,512	25,258	28.53	12,261,365.0	1.73	20.60	400,535,781.1
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	142,052,084	100	5.78	201,498.5	0.01	4.96	403,207,018.7
Bumetanide Users (No Washout)	681,044	145,886,512	403	5.92	694,580.4	0.03	5.80	423,488,059.5
Torsemide Users (Washout)	172,362	142,052,084	86	4.99	187,763.7	0.01	4.58	403,220,608.6
Torsemide Users (No Washout)	680,304	145,886,512	366	5.38	662,786.2	0.03	5.52	423,529,490.1
Furosemide Users (Washout)	5,031,471	142,052,084	2,692	5.35	6,487,281.7	0.19	4.15	399,244,718.5
Furosemide Users (No Washout)	8,853,836	145,886,512	5,653	6.38	12,261,365.0	0.39	4.61	400,535,781.1

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-19 years	222	31,526,558	0	0.00	381.0	0.00	0.00	84,963,328.8
20-34 years	*****	35,361,961	0	0.00	3,770.3	0.00	0.00	67,887,433.2
35-44 years	*****	24,598,271	*****	1.44	*****	0.00	1.02	50,286,093.6
45-54 years	*****	24,659,469	0	0.00	20,779.4	0.00	0.00	53,786,997.2
55-64 years	*****	20,846,271	*****	5.83	*****	0.01	5.25	46,495,861.6
65-74 years	51,897	24,022,855	32	6.17	68,322.2	0.01	4.68	58,897,643.8
75-84 years	43,240	11,820,564	22	5.09	50,526.3	0.02	4.35	29,313,223.3
≥ 85 years	*****	4,974,025	*****	2.22	*****	0.01	3.10	11,576,437.2
Bumetanide Users (No Washout)								
0-19 years	426	31,531,413	0	0.00	672.3	0.00	0.00	84,990,350.6
20-34 years	*****	35,398,195	*****	2.99	*****	0.00	2.26	68,064,228.6
35-44 years	*****	24,732,457	*****	1.99	*****	0.00	1.43	50,849,917.7
45-54 years	*****	25,058,232	32	6.06	71,435.6	0.01	4.48	55,305,128.8
55-64 years	100,447	21,643,761	86	8.56	105,704.6	0.04	8.14	49,377,448.1
65-74 years	204,530	25,545,767	169	8.26	244,297.9	0.07	6.92	64,705,580.7
75-84 years	174,141	13,270,788	66	3.79	167,116.8	0.05	3.95	34,625,986.2
≥ 85 years	*****	6,180,125	*****	1.72	*****	0.03	3.06	15,569,418.9
Torsemide Users (Washout)								
0-19 years	101	31,526,558	0	0.00	249.5	0.00	0.00	84,963,534.7
20-34 years	*****	35,361,981	0	0.00	2,904.7	0.00	0.00	67,888,020.7
35-44 years	*****	24,598,434	0	0.00	8,166.8	0.00	0.00	50,287,334.6
45-54 years	*****	24,659,689	0	0.00	18,421.9	0.00	0.00	53,788,375.9
55-64 years	*****	20,846,748	13	5.42	24,255.2	0.01	5.36	46,498,803.5
65-74 years	52,227	24,023,412	19	3.64	64,053.5	0.01	2.97	58,901,164.9
75-84 years	*****	11,821,393	*****	4.99	*****	0.02	4.55	29,315,937.7
≥ 85 years	*****	4,974,297	*****	0.72	*****	0.00	1.04	11,577,436.6

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-19 years	159	31,531,413	0	0.00	333.7	0.00	0.00	84,991,025.2
20-34 years	*****	35,398,235	*****	1.68	*****	0.00	1.35	68,066,231.1
35-44 years	*****	24,732,724	*****	3.78	*****	0.00	2.86	50,854,539.9
45-54 years	*****	25,058,898	*****	4.72	*****	0.01	3.71	55,316,866.0
55-64 years	95,451	21,645,841	51	5.34	94,176.6	0.02	5.42	49,397,502.2
65-74 years	207,704	25,548,001	109	5.25	236,367.8	0.04	4.61	64,714,725.2
75-84 years	181,097	13,271,247	76	4.20	169,245.1	0.06	4.49	34,620,824.0
≥ 85 years	122,668	6,179,895	13	1.06	68,742.6	0.02	1.89	15,567,776.4
Furosemide Users (Washout)								
0-19 years	*****	31,526,558	0	0.00	22,724.6	0.00	0.00	84,942,776.8
20-34 years	*****	35,358,969	13	1.40	145,515.0	0.00	0.89	67,796,762.8
35-44 years	213,510	24,568,078	47	2.20	332,629.9	0.02	1.41	50,064,834.6
45-54 years	452,526	24,594,324	344	7.60	694,518.7	0.14	4.95	53,367,063.9
55-64 years	718,788	20,727,815	709	9.86	876,042.1	0.34	8.09	45,866,146.7
65-74 years	1,441,346	23,912,503	1,253	8.69	2,115,618.6	0.52	5.92	57,979,799.5
75-84 years	1,230,807	11,566,758	630	5.12	1,612,794.7	0.54	3.91	28,264,934.0
≥ 85 years	870,150	4,811,763	178	2.05	687,438.2	0.37	2.59	10,962,400.1
Furosemide Users (No Washout)								
0-19 years	*****	31,531,413	*****	0.64	*****	0.00	0.32	84,943,007.7
20-34 years	*****	35,394,392	*****	2.00	*****	0.01	1.20	67,819,248.6
35-44 years	315,849	24,683,438	92	2.91	532,284.3	0.04	1.73	50,109,732.4
45-54 years	*****	24,924,405	713	9.39	1,275,615.1	0.29	5.59	53,462,546.0
55-64 years	*****	21,335,553	1,470	11.41	1,756,807.2	0.69	8.37	46,027,646.2
65-74 years	2,622,140	25,173,707	2,508	9.56	4,196,823.6	1.00	5.98	58,457,169.8
75-84 years	2,116,125	12,496,003	1,137	5.37	2,949,263.3	0.91	3.86	28,562,706.4
≥ 85 years	1,616,053	5,593,051	295	1.83	1,319,819.8	0.53	2.24	11,153,724.1

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-19 years	222	31,526,558	0	0.00	381.0	0.00	0.00	84,963,328.8
20-34 years	*****	35,361,961	*****	7.17	*****	0.00	5.30	67,887,433.2
35-44 years	*****	24,598,271	0	0.00	9,763.6	0.00	0.00	50,286,093.6
45-54 years	*****	24,659,469	*****	5.30	*****	0.00	3.85	53,786,997.2
55-64 years	*****	20,846,271	*****	6.61	*****	0.01	5.95	46,495,861.6
65-74 years	51,897	24,022,855	70	13.49	68,322.2	0.03	10.25	58,897,643.8
75-84 years	43,240	11,820,564	55	12.72	50,526.3	0.05	10.89	29,313,223.3
≥ 85 years	*****	4,974,025	27	9.99	19,367.3	0.05	13.94	11,576,437.2
Bumetanide Users (No Washout)								
0-19 years	426	31,531,413	0	0.00	672.3	0.00	0.00	84,990,350.6
20-34 years	*****	35,398,195	*****	4.48	*****	0.00	3.39	68,064,228.6
35-44 years	*****	24,732,457	*****	1.99	*****	0.00	1.43	50,849,917.7
45-54 years	*****	25,058,232	*****	5.49	*****	0.01	4.06	55,305,128.8
55-64 years	100,447	21,643,761	81	8.06	105,704.6	0.04	7.66	49,377,448.1
65-74 years	204,530	25,545,767	255	12.47	244,297.9	0.10	10.44	64,705,580.7
75-84 years	174,141	13,270,788	231	13.27	167,116.8	0.17	13.82	34,625,986.2
≥ 85 years	*****	6,180,125	74	6.08	68,526.9	0.12	10.80	15,569,418.9
Torsemide Users (Washout)								
0-19 years	101	31,526,558	0	0.00	249.5	0.00	0.00	84,963,534.7
20-34 years	*****	35,361,981	*****	4.39	*****	0.00	3.44	67,888,020.7
35-44 years	*****	24,598,434	0	0.00	8,166.8	0.00	0.00	50,287,334.6
45-54 years	*****	24,659,689	*****	5.75	*****	0.00	4.34	53,788,375.9
55-64 years	*****	20,846,748	*****	5.42	*****	0.01	5.36	46,498,803.5
65-74 years	52,227	24,023,412	66	12.64	64,053.5	0.03	10.30	58,901,164.9
75-84 years	*****	11,821,393	59	12.79	50,502.8	0.05	11.68	29,315,937.7
≥ 85 years	*****	4,974,297	27	9.77	19,209.4	0.05	14.06	11,577,436.6

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-19 years	159	31,531,413	0	0.00	333.7	0.00	0.00	84,991,025.2
20-34 years	*****	35,398,235	*****	1.68	*****	0.00	1.35	68,066,231.1
35-44 years	*****	24,732,724	*****	1.62	*****	0.00	1.23	50,854,539.9
45-54 years	*****	25,058,898	*****	6.77	*****	0.01	5.32	55,316,866.0
55-64 years	95,451	21,645,841	54	5.66	94,176.6	0.02	5.73	49,397,502.2
65-74 years	207,704	25,548,001	262	12.61	236,367.8	0.10	11.08	64,714,725.2
75-84 years	181,097	13,271,247	232	12.81	169,245.1	0.17	13.71	34,620,824.0
≥ 85 years	122,668	6,179,895	92	7.50	68,742.6	0.15	13.38	15,567,776.4
Furosemide Users (Washout)								
0-19 years	*****	31,526,558	*****	0.86	*****	0.00	0.44	84,942,776.8
20-34 years	*****	35,358,969	*****	2.16	*****	0.01	1.37	67,796,762.8
35-44 years	213,510	24,568,078	55	2.58	332,629.9	0.02	1.65	50,064,834.6
45-54 years	452,526	24,594,324	227	5.02	694,518.7	0.09	3.27	53,367,063.9
55-64 years	718,788	20,727,815	556	7.74	876,042.1	0.27	6.35	45,866,146.7
65-74 years	1,441,346	23,912,503	2,230	15.47	2,115,618.6	0.93	10.54	57,979,799.5
75-84 years	1,230,807	11,566,758	1,979	16.08	1,612,794.7	1.71	12.27	28,264,934.0
≥ 85 years	870,150	4,811,763	740	8.50	687,438.2	1.54	10.76	10,962,400.1
Furosemide Users (No Washout)								
0-19 years	*****	31,531,413	*****	0.64	31,567.6	0.00	0.32	84,943,007.7
20-34 years	*****	35,394,392	27	2.25	199,184.0	0.01	1.36	67,819,248.6
35-44 years	315,849	24,683,438	103	3.26	532,284.3	0.04	1.94	50,109,732.4
45-54 years	*****	24,924,405	468	6.17	*****	0.19	3.67	53,462,546.0
55-64 years	*****	21,335,553	*****	8.97	*****	0.54	6.58	46,027,646.2
65-74 years	2,622,140	25,173,707	4,488	17.12	4,196,823.6	1.78	10.69	58,457,169.8
75-84 years	2,116,125	12,496,003	3,907	18.46	2,949,263.3	3.13	13.25	28,562,706.4
≥ 85 years	1,616,053	5,593,051	1,594	9.86	1,319,819.8	2.85	12.08	11,153,724.1

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-19 years	222	31,526,558	0	0.00	381.0	0.00	0.00	84,963,328.8
20-34 years	*****	35,361,961	0	0.00	3,770.3	0.00	0.00	67,887,433.2
35-44 years	*****	24,598,271	*****	5.75	*****	0.00	4.10	50,286,093.6
45-54 years	*****	24,659,469	*****	11.93	*****	0.01	8.66	53,786,997.2
55-64 years	*****	20,846,271	46	17.89	28,588.4	0.02	16.09	46,495,861.6
65-74 years	51,897	24,022,855	140	26.98	68,322.2	0.06	20.49	58,897,643.8
75-84 years	43,240	11,820,564	131	30.30	50,526.3	0.11	25.93	29,313,223.3
≥ 85 years	*****	4,974,025	54	19.98	19,367.3	0.11	27.88	11,576,437.2
Bumetanide Users (No Washout)								
0-19 years	426	31,531,413	0	0.00	672.3	0.00	0.00	84,990,350.6
20-34 years	*****	35,398,195	*****	5.97	*****	0.00	4.52	68,064,228.6
35-44 years	*****	24,732,457	*****	5.96	*****	0.00	4.29	50,849,917.7
45-54 years	*****	25,058,232	76	14.38	71,435.6	0.03	10.64	55,305,128.8
55-64 years	100,447	21,643,761	178	17.72	105,704.6	0.08	16.84	49,377,448.1
65-74 years	204,530	25,545,767	566	27.67	244,297.9	0.22	23.17	64,705,580.7
75-84 years	174,141	13,270,788	499	28.65	167,116.8	0.38	29.86	34,625,986.2
≥ 85 years	*****	6,180,125	191	15.68	68,526.9	0.31	27.87	15,569,418.9
Torsemide Users (Washout)								
0-19 years	101	31,526,558	0	0.00	249.5	0.00	0.00	84,963,534.7
20-34 years	*****	35,361,981	0	0.00	2,904.7	0.00	0.00	67,888,020.7
35-44 years	*****	24,598,434	*****	3.29	*****	0.00	2.45	50,287,334.6
45-54 years	*****	24,659,689	*****	10.78	*****	0.01	8.14	53,788,375.9
55-64 years	*****	20,846,748	29	12.08	24,255.2	0.01	11.96	46,498,803.5
65-74 years	52,227	24,023,412	107	20.49	64,053.5	0.04	16.70	58,901,164.9
75-84 years	*****	11,821,393	140	30.35	50,502.8	0.12	27.72	29,315,937.7
≥ 85 years	*****	4,974,297	45	16.29	19,209.4	0.09	23.43	11,577,436.6

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-19 years	159	31,531,413	0	0.00	333.7	0.00	0.00	84,991,025.2
20-34 years	*****	35,398,235	*****	3.35	*****	0.00	2.69	68,066,231.1
35-44 years	*****	24,732,724	*****	4.32	*****	0.00	3.27	50,854,539.9
45-54 years	*****	25,058,898	*****	12.51	*****	0.02	9.83	55,316,866.0
55-64 years	95,451	21,645,841	142	14.88	94,176.6	0.07	15.08	49,397,502.2
65-74 years	207,704	25,548,001	510	24.55	236,367.8	0.20	21.58	64,714,725.2
75-84 years	181,097	13,271,247	467	25.79	169,245.1	0.35	27.59	34,620,824.0
≥ 85 years	122,668	6,179,895	203	16.55	68,742.6	0.33	29.53	15,567,776.4
Furosemide Users (Washout)								
0-19 years	*****	31,526,558	0	0.00	22,724.6	0.00	0.00	84,942,776.8
20-34 years	*****	35,358,969	17	1.83	145,515.0	0.00	1.17	67,796,762.8
35-44 years	213,510	24,568,078	126	5.90	332,629.9	0.05	3.79	50,064,834.6
45-54 years	452,526	24,594,324	558	12.33	694,518.7	0.23	8.03	53,367,063.9
55-64 years	718,788	20,727,815	1,171	16.29	876,042.1	0.56	13.37	45,866,146.7
65-74 years	1,441,346	23,912,503	4,075	28.27	2,115,618.6	1.70	19.26	57,979,799.5
75-84 years	1,230,807	11,566,758	4,014	32.61	1,612,794.7	3.47	24.89	28,264,934.0
≥ 85 years	870,150	4,811,763	1,557	17.89	687,438.2	3.24	22.65	10,962,400.1
Furosemide Users (No Washout)								
0-19 years	*****	31,531,413	0	0.00	31,567.6	0.00	0.00	84,943,007.7
20-34 years	*****	35,394,392	34	2.83	199,184.0	0.01	1.71	67,819,248.6
35-44 years	315,849	24,683,438	238	7.54	532,284.3	0.10	4.47	50,109,732.4
45-54 years	*****	24,924,405	1,144	15.07	1,275,615.1	0.46	8.97	53,462,546.0
55-64 years	*****	21,335,553	2,651	20.57	1,756,807.2	1.24	15.09	46,027,646.2
65-74 years	2,622,140	25,173,707	8,956	34.16	4,196,823.6	3.56	21.34	58,457,169.8
75-84 years	2,116,125	12,496,003	8,449	39.93	2,949,263.3	6.76	28.65	28,562,706.4
≥ 85 years	1,616,053	5,593,051	3,786	23.43	1,319,819.8	6.77	28.69	11,153,724.1

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-19 years	222	31,526,558	0	0.00	381.0	0.00	0.00	84,963,328.8
20-34 years	*****	35,361,961	0	0.00	3,770.3	0.00	0.00	67,887,433.2
35-44 years	*****	24,598,271	0	0.00	9,763.6	0.00	0.00	50,286,093.6
45-54 years	*****	24,659,469	*****	6.63	*****	0.00	4.81	53,786,997.2
55-64 years	*****	20,846,271	18	7.00	28,588.4	0.01	6.30	46,495,861.6
65-74 years	51,897	24,022,855	38	7.32	68,322.2	0.02	5.56	58,897,643.8
75-84 years	43,240	11,820,564	28	6.48	50,526.3	0.02	5.54	29,313,223.3
≥ 85 years	*****	4,974,025	*****	2.22	*****	0.01	3.10	11,576,437.2
Bumetanide Users (No Washout)								
0-19 years	426	31,531,413	0	0.00	672.3	0.00	0.00	84,990,350.6
20-34 years	*****	35,398,195	*****	1.49	*****	0.00	1.13	68,064,228.6
35-44 years	*****	24,732,457	*****	4.47	*****	0.00	3.22	50,849,917.7
45-54 years	*****	25,058,232	38	7.19	71,435.6	0.02	5.32	55,305,128.8
55-64 years	100,447	21,643,761	57	5.67	105,704.6	0.03	5.39	49,377,448.1
65-74 years	204,530	25,545,767	159	7.77	244,297.9	0.06	6.51	64,705,580.7
75-84 years	174,141	13,270,788	103	5.91	167,116.8	0.08	6.16	34,625,986.2
≥ 85 years	*****	6,180,125	*****	2.96	*****	0.06	5.25	15,569,418.9
Torsemide Users (Washout)								
0-19 years	101	31,526,558	0	0.00	249.5	0.00	0.00	84,963,534.7
20-34 years	*****	35,361,981	0	0.00	2,904.7	0.00	0.00	67,888,020.7
35-44 years	*****	24,598,434	*****	1.64	*****	0.00	1.22	50,287,334.6
45-54 years	*****	24,659,689	*****	5.03	*****	0.00	3.80	53,788,375.9
55-64 years	*****	20,846,748	*****	4.17	*****	0.00	4.12	46,498,803.5
65-74 years	52,227	24,023,412	30	5.74	64,053.5	0.01	4.68	58,901,164.9
75-84 years	*****	11,821,393	22	4.77	50,502.8	0.02	4.36	29,315,937.7
≥ 85 years	*****	4,974,297	16	5.79	19,209.4	0.03	8.33	11,577,436.6

Table 3. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Age Group

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-19 years	159	31,531,413	0	0.00	333.7	0.00	0.00	84,991,025.2
20-34 years	*****	35,398,235	*****	5.03	*****	0.00	4.04	68,066,231.1
35-44 years	*****	24,732,724	*****	1.62	*****	0.00	1.23	50,854,539.9
45-54 years	*****	25,058,898	*****	6.36	*****	0.01	5.00	55,316,866.0
55-64 years	95,451	21,645,841	51	5.34	94,176.6	0.02	5.42	49,397,502.2
65-74 years	207,704	25,548,001	133	6.40	236,367.8	0.05	5.63	64,714,725.2
75-84 years	181,097	13,271,247	91	5.02	169,245.1	0.07	5.38	34,620,824.0
≥ 85 years	122,668	6,179,895	54	4.40	68,742.6	0.09	7.86	15,567,776.4
Furosemide Users (Washout)								
0-19 years	*****	31,526,558	0	0.00	22,724.6	0.00	0.00	84,942,776.8
20-34 years	*****	35,358,969	15	1.62	145,515.0	0.00	1.03	67,796,762.8
35-44 years	213,510	24,568,078	35	1.64	332,629.9	0.01	1.05	50,064,834.6
45-54 years	452,526	24,594,324	187	4.13	694,518.7	0.08	2.69	53,367,063.9
55-64 years	718,788	20,727,815	370	5.15	876,042.1	0.18	4.22	45,866,146.7
65-74 years	1,441,346	23,912,503	991	6.88	2,115,618.6	0.41	4.68	57,979,799.5
75-84 years	1,230,807	11,566,758	783	6.36	1,612,794.7	0.68	4.85	28,264,934.0
≥ 85 years	870,150	4,811,763	311	3.57	687,438.2	0.65	4.52	10,962,400.1
Furosemide Users (No Washout)								
0-19 years	*****	31,531,413	*****	0.64	*****	0.00	0.32	84,943,007.7
20-34 years	*****	35,394,392	*****	2.16	*****	0.01	1.31	67,819,248.6
35-44 years	315,849	24,683,438	79	2.50	532,284.3	0.03	1.48	50,109,732.4
45-54 years	*****	24,924,405	380	5.01	1,275,615.1	0.15	2.98	53,462,546.0
55-64 years	*****	21,335,553	792	6.15	1,756,807.2	0.37	4.51	46,027,646.2
65-74 years	2,622,140	25,173,707	2,118	8.08	4,196,823.6	0.84	5.05	58,457,169.8
75-84 years	2,116,125	12,496,003	1,564	7.39	2,949,263.3	1.25	5.30	28,562,706.4
≥ 85 years	1,616,053	5,593,051	693	4.29	1,319,819.8	1.24	5.25	11,153,724.1

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	692.4	0.00	0.00	1,014,599.7
Asian	*****	1,741,509	*****	18.41	*****	0.02	16.63	5,617,988.2
Black or African American	*****	5,758,414	*****	4.82	*****	0.02	3.92	21,256,900.6
Native Hawaiian or Other Pacific Islander	*****	127,312	0	0.00	245.9	0.00	0.00	370,323.8
Unknown	*****	99,144,426	*****	2.57	*****	0.00	2.58	258,351,176.8
White	114,151	35,005,236	53	4.64	137,762.3	0.02	3.85	116,596,029.6
Bumetanide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	3.93	*****	0.03	4.13	1,124,886.8
Asian	*****	1,776,034	*****	10.70	*****	0.05	11.22	5,893,870.2
Black or African American	*****	6,219,889	*****	4.85	*****	0.07	4.23	23,930,736.0
Native Hawaiian or Other Pacific Islander	*****	131,296	0	0.00	642.9	0.00	0.00	389,220.6
Unknown	*****	99,855,526	44	3.98	92,398.5	0.00	4.76	261,607,031.0
White	473,057	37,612,218	285	6.02	492,812.4	0.08	5.78	130,542,314.9
Torsemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	695.6	0.00	0.00	1,014,671.1
Asian	*****	1,741,509	*****	9.65	*****	0.01	8.94	5,618,364.2
Black or African American	*****	5,758,414	*****	2.93	*****	0.01	2.48	21,258,341.8
Native Hawaiian or Other Pacific Islander	*****	127,312	0	0.00	186.6	0.00	0.00	370,358.0
Unknown	*****	99,144,426	*****	1.44	*****	0.00	1.54	258,354,703.3
White	114,319	35,005,236	44	3.85	128,068.0	0.01	3.44	116,604,170.2
Torsemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	3.48	*****	0.03	3.77	1,124,295.7
Asian	*****	1,776,034	*****	4.68	*****	0.02	4.79	5,896,210.0
Black or African American	*****	6,219,889	37	4.38	94,434.7	0.06	3.92	23,938,536.2
Native Hawaiian or Other Pacific Islander	*****	131,296	0	0.00	502.4	0.00	0.00	389,453.3
Unknown	*****	99,855,526	*****	2.31	*****	0.00	2.86	261,607,075.8
White	473,367	37,612,218	213	4.50	467,941.8	0.06	4.55	130,573,919.1

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	*****	14.59	*****	1.38	9.88	991,082.3
Asian	83,025	1,741,509	117	14.09	117,338.9	0.67	9.97	5,533,279.1
Black or African American	559,140	5,758,414	354	6.33	804,242.6	0.61	4.40	20,785,233.3
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	3.53	*****	0.16	2.84	365,640.6
Unknown	1,064,141	99,144,426	523	4.91	1,131,509.1	0.05	4.62	257,441,416.2
White	3,293,461	35,005,236	2,140	6.50	4,388,669.9	0.61	4.88	114,128,066.9
Furosemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	16.20	*****	2.47	9.74	991,081.2
Asian	122,704	1,776,034	196	15.97	185,933.2	1.10	10.54	5,539,331.6
Black or African American	1,040,342	6,219,889	735	7.06	1,682,396.3	1.18	4.37	20,890,184.4
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	4.34	*****	0.30	3.52	367,051.0
Unknown	1,716,528	99,855,526	906	5.28	1,803,660.1	0.09	5.02	257,717,641.7
White	5,920,596	37,612,218	4,327	7.31	8,504,112.4	1.15	5.09	115,030,491.4
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	692.4	0.00	0.00	1,014,599.7
Asian	*****	1,741,509	*****	9.20	*****	0.01	8.32	5,617,988.2
Black or African American	*****	5,758,414	*****	8.20	*****	0.03	6.66	21,256,900.6
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	44.25	*****	0.08	40.68	370,323.8
Unknown	*****	99,144,426	14	4.00	34,861.7	0.00	4.02	258,351,176.8
White	114,151	35,005,236	145	12.70	137,762.3	0.04	10.53	116,596,029.6
Bumetanide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	0	0.00	2,421.1	0.00	0.00	1,124,886.8
Asian	*****	1,776,034	*****	8.02	*****	0.03	8.41	5,893,870.2
Black or African American	*****	6,219,889	*****	5.66	*****	0.08	4.94	23,930,736.0
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	26.70	*****	0.15	31.11	389,220.6
Unknown	*****	99,855,526	68	6.15	92,398.5	0.01	7.36	261,607,031.0
White	473,057	37,612,218	552	11.67	492,812.4	0.15	11.20	130,542,314.9

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	695.6	0.00	0.00	1,014,671.1
Asian	*****	1,741,509	*****	4.83	*****	0.01	4.47	5,618,364.2
Black or African American	*****	5,758,414	*****	7.82	*****	0.03	6.61	21,258,341.8
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	51.02	*****	0.08	53.60	370,358.0
Unknown	*****	99,144,426	24	6.93	32,368.2	0.00	7.41	258,354,703.3
White	114,319	35,005,236	132	11.55	128,068.0	0.04	10.31	116,604,170.2
Torsemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	10.43	*****	0.10	11.30	1,124,295.7
Asian	*****	1,776,034	*****	3.12	*****	0.01	3.20	5,896,210.0
Black or African American	*****	6,219,889	*****	8.05	*****	0.11	7.20	23,938,536.2
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	29.72	*****	0.15	39.81	389,453.3
Unknown	*****	99,855,526	85	7.56	90,992.3	0.01	9.34	261,607,075.8
White	473,367	37,612,218	517	10.92	467,941.8	0.14	11.05	130,573,919.1
Furosemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	22	8.45	38,477.8	0.80	5.72	991,082.3
Asian	83,025	1,741,509	88	10.60	117,338.9	0.51	7.50	5,533,279.1
Black or African American	559,140	5,758,414	473	8.46	804,242.6	0.82	5.88	20,785,233.3
Native Hawaiian or Other Pacific Islander	*****	127,312	12	21.18	7,043.4	0.94	17.04	365,640.6
Unknown	1,064,141	99,144,426	765	7.19	1,131,509.1	0.08	6.76	257,441,416.2
White	3,293,461	35,005,236	4,448	13.51	4,388,669.9	1.27	10.14	114,128,066.9
Furosemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	48	10.80	73,909.3	1.65	6.49	991,081.2
Asian	122,704	1,776,034	153	12.47	185,933.2	0.86	8.23	5,539,331.6
Black or African American	1,040,342	6,219,889	1,027	9.87	1,682,396.3	1.65	6.10	20,890,184.4
Native Hawaiian or Other Pacific Islander	*****	131,296	13	14.12	11,353.8	0.99	11.45	367,051.0
Unknown	1,716,528	99,855,526	1,349	7.86	1,803,660.1	0.14	7.48	257,717,641.7
White	5,920,596	37,612,218	9,154	15.46	8,504,112.4	2.43	10.76	115,030,491.4

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native	*****	275,187	*****	16.53	*****	0.04	14.44	1,014,599.7
Asian	*****	1,741,509	*****	27.61	*****	0.03	24.95	5,617,988.2
Black or African American	*****	5,758,414	50	24.10	25,531.4	0.09	19.58	21,256,900.6
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	44.25	*****	0.08	40.68	370,323.8
Unknown	*****	99,144,426	*****	11.99	*****	0.00	12.05	258,351,176.8
White	114,151	35,005,236	293	25.67	137,762.3	0.08	21.27	116,596,029.6
Bumetanide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	31.45	*****	0.27	33.04	1,124,886.8
Asian	*****	1,776,034	*****	24.07	*****	0.10	25.24	5,893,870.2
Black or African American	*****	6,219,889	209	24.13	99,175.1	0.34	21.07	23,930,736.0
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	13.35	*****	0.08	15.55	389,220.6
Unknown	*****	99,855,526	142	12.84	92,398.5	0.01	15.37	261,607,031.0
White	473,057	37,612,218	1,148	24.27	492,812.4	0.31	23.29	130,542,314.9
Torsemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	*****	14.64	*****	0.04	14.38	1,014,671.1
Asian	*****	1,741,509	*****	19.31	*****	0.02	17.88	5,618,364.2
Black or African American	*****	5,758,414	58	28.35	24,208.5	0.10	23.96	21,258,341.8
Native Hawaiian or Other Pacific Islander	*****	127,312	0	0.00	186.6	0.00	0.00	370,358.0
Unknown	*****	99,144,426	*****	9.24	*****	0.00	9.89	258,354,703.3
White	114,319	35,005,236	243	21.26	128,068.0	0.07	18.97	116,604,170.2
Torsemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	17.39	*****	0.17	18.83	1,124,295.7
Asian	*****	1,776,034	*****	14.03	*****	0.05	14.38	5,896,210.0
Black or African American	*****	6,219,889	221	26.16	94,434.7	0.36	23.40	23,938,536.2
Native Hawaiian or Other Pacific Islander	*****	131,296	0	0.00	502.4	0.00	0.00	389,453.3
Unknown	*****	99,855,526	*****	9.51	*****	0.01	11.76	261,607,075.8
White	473,367	37,612,218	1,051	22.20	467,941.8	0.28	22.46	130,573,919.1

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	*****	26.88	*****	2.54	18.19	991,082.3
Asian	83,025	1,741,509	193	23.25	117,338.9	1.11	16.45	5,533,279.1
Black or African American	559,140	5,758,414	1,412	25.25	804,242.6	2.45	17.56	20,785,233.3
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	17.65	*****	0.79	14.20	365,640.6
Unknown	1,064,141	99,144,426	1,243	11.68	1,131,509.1	0.13	10.99	257,441,416.2
White	3,293,461	35,005,236	8,590	26.08	4,388,669.9	2.45	19.57	114,128,066.9
Furosemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	142	31.94	73,909.3	4.87	19.21	991,081.2
Asian	122,704	1,776,034	342	27.87	185,933.2	1.93	18.39	5,539,331.6
Black or African American	1,040,342	6,219,889	3,357	32.27	1,682,396.3	5.40	19.95	20,890,184.4
Native Hawaiian or Other Pacific Islander	*****	131,296	22	23.89	11,353.8	1.68	19.38	367,051.0
Unknown	1,716,528	99,855,526	2,396	13.96	1,803,660.1	0.24	13.28	257,717,641.7
White	5,920,596	37,612,218	18,999	32.09	8,504,112.4	5.05	22.34	115,030,491.4
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	692.4	0.00	0.00	1,014,599.7
Asian	*****	1,741,509	*****	9.20	*****	0.01	8.32	5,617,988.2
Black or African American	*****	5,758,414	18	8.68	25,531.4	0.03	7.05	21,256,900.6
Native Hawaiian or Other Pacific Islander	*****	127,312	0	0.00	245.9	0.00	0.00	370,323.8
Unknown	*****	99,144,426	*****	3.42	*****	0.00	3.44	258,351,176.8
White	114,151	35,005,236	68	5.96	137,762.3	0.02	4.94	116,596,029.6
Bumetanide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	0	0.00	2,421.1	0.00	0.00	1,124,886.8
Asian	*****	1,776,034	*****	2.67	*****	0.01	2.80	5,893,870.2
Black or African American	*****	6,219,889	65	7.50	99,175.1	0.10	6.55	23,930,736.0
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	13.35	*****	0.08	15.55	389,220.6
Unknown	*****	99,855,526	*****	3.80	*****	0.00	4.55	261,607,031.0
White	473,057	37,612,218	293	6.19	492,812.4	0.08	5.95	130,542,314.9

Table 4. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 Patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	0	0.00	695.6	0.00	0.00	1,014,671.1
Asian	*****	1,741,509	0	0.00	2,236.9	0.00	0.00	5,618,364.2
Black or African American	*****	5,758,414	*****	2.93	*****	0.01	2.48	21,258,341.8
Native Hawaiian or Other Pacific Islander	*****	127,312	0	0.00	186.6	0.00	0.00	370,358.0
Unknown	*****	99,144,426	*****	3.75	*****	0.00	4.02	258,354,703.3
White	114,319	35,005,236	67	5.86	128,068.0	0.02	5.23	116,604,170.2
Torsemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	0	0.00	2,655.5	0.00	0.00	1,124,295.7
Asian	*****	1,776,034	*****	1.56	*****	0.01	1.60	5,896,210.0
Black or African American	*****	6,219,889	42	4.97	94,434.7	0.07	4.45	23,938,536.2
Native Hawaiian or Other Pacific Islander	*****	131,296	0	0.00	502.4	0.00	0.00	389,453.3
Unknown	*****	99,855,526	*****	2.58	*****	0.00	3.19	261,607,075.8
White	473,367	37,612,218	294	6.21	467,941.8	0.08	6.28	130,573,919.1
Furosemide Users (Washout)								
American Indian or Alaska Native	*****	275,187	*****	4.22	*****	0.40	2.86	991,082.3
Asian	83,025	1,741,509	46	5.54	117,338.9	0.26	3.92	5,533,279.1
Black or African American	559,140	5,758,414	279	4.99	804,242.6	0.48	3.47	20,785,233.3
Native Hawaiian or Other Pacific Islander	*****	127,312	*****	3.53	*****	0.16	2.84	365,640.6
Unknown	1,064,141	99,144,426	308	2.89	1,131,509.1	0.03	2.72	257,441,416.2
White	3,293,461	35,005,236	2,046	6.21	4,388,669.9	0.58	4.66	114,128,066.9
Furosemide Users (No Washout)								
American Indian or Alaska Native	*****	291,549	*****	5.40	*****	0.82	3.25	991,081.2
Asian	122,704	1,776,034	82	6.68	185,933.2	0.46	4.41	5,539,331.6
Black or African American	1,040,342	6,219,889	625	6.01	1,682,396.3	1.00	3.71	20,890,184.4
Native Hawaiian or Other Pacific Islander	*****	131,296	*****	6.51	*****	0.46	5.28	367,051.0
Unknown	1,716,528	99,855,526	577	3.36	1,803,660.1	0.06	3.20	257,717,641.7
White	5,920,596	37,612,218	4,339	7.33	8,504,112.4	1.15	5.10	115,030,491.4

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	449.9	0.00	0.00	553,326.9
Male	*****	124,043	0	0.00	242.5	0.00	0.00	461,272.7
Asian								
Female	*****	912,654	*****	17.15	*****	0.02	14.38	3,050,444.3
Male	*****	828,855	*****	19.86	*****	0.02	19.73	2,567,543.9
Black or African American								
Female	*****	3,334,812	*****	3.74	*****	0.01	2.78	12,358,726.5
Male	*****	2,423,602	*****	6.77	*****	0.02	6.62	8,898,174.1
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	125.5	0.00	0.00	178,247.8
Male	*****	65,061	0	0.00	120.4	0.00	0.00	192,076.0
Unknown								
Female	*****	49,048,423	*****	1.99	*****	0.00	1.83	126,016,397.7
Male	*****	50,096,003	*****	3.34	*****	0.00	3.84	132,334,779.0
White								
Female	69,929	19,762,194	20	2.86	91,478.6	0.01	2.19	66,987,317.5
Male	44,222	15,243,042	33	7.46	46,283.8	0.02	7.13	49,608,712.1
Bumetanide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	0	0.00	*****	0.00	0.00	622,225.1
Male	*****	130,563	*****	9.81	*****	0.08	11.74	502,661.7
Asian								
Female	*****	930,842	*****	7.70	*****	0.03	7.70	3,210,426.0
Male	*****	845,192	*****	13.96	*****	0.06	15.46	2,683,444.1

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Black or African American								
Female	54,689	3,638,829	19	3.47	68,682.5	0.05	2.77	14,208,494.8
Male	31,923	2,581,060	23	7.20	30,492.6	0.09	7.54	9,722,241.2
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	279.9	0.00	0.00	186,528.2
Male	*****	67,403	0	0.00	363.0	0.00	0.00	202,692.4
Unknown								
Female	*****	49,452,984	17	2.81	56,500.6	0.00	3.01	127,939,582.4
Male	*****	50,402,542	27	5.39	35,897.9	0.01	7.52	133,667,448.6
White								
Female	285,194	21,372,135	117	4.10	328,283.9	0.05	3.56	76,071,235.5
Male	187,863	16,240,083	168	8.94	164,528.5	0.10	10.21	54,471,079.4
Torsemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	430.1	0.00	0.00	553,378.6
Male	*****	124,043	0	0.00	265.6	0.00	0.00	461,292.5
Asian								
Female	*****	912,654	*****	9.12	*****	0.01	7.78	3,050,678.3
Male	*****	828,855	*****	10.26	*****	0.01	10.52	2,567,685.9
Black or African American								
Female	*****	3,334,812	*****	0.76	*****	0.00	0.59	12,359,701.3
Male	*****	2,423,602	*****	6.88	*****	0.02	6.97	8,898,640.5
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	78.2	0.00	0.00	178,282.6
Male	*****	65,061	0	0.00	108.3	0.00	0.00	192,075.4
Unknown								
Female	*****	49,048,423	*****	0.53	*****	0.00	0.51	126,019,100.1
Male	*****	50,096,003	*****	2.52	*****	0.00	3.09	132,335,603.2
White								
Female	68,752	19,762,194	22	3.20	84,575.0	0.01	2.60	66,992,034.6
Male	45,567	15,243,042	22	4.83	43,493.0	0.01	5.06	49,612,135.6

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	*****	6.07	*****	0.06	6.15	622,048.8
Male	*****	130,563	0	0.00	*****	0.00	0.00	502,246.9
Asian								
Female	*****	930,842	*****	3.03	*****	0.01	2.85	3,211,684.8
Male	*****	845,192	*****	6.42	*****	0.02	7.26	2,684,525.1
Black or African American								
Female	*****	3,638,829	16	3.03	64,971.7	0.04	2.46	14,214,867.1
Male	*****	2,581,060	21	6.63	29,463.0	0.08	7.13	9,723,669.1
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	206.3	0.00	0.00	186,647.8
Male	*****	67,403	0	0.00	296.1	0.00	0.00	202,805.5
Unknown								
Female	*****	49,452,984	*****	1.36	*****	0.00	1.49	127,945,034.4
Male	*****	50,402,542	*****	3.35	*****	0.00	4.82	133,662,041.3
White								
Female	277,522	21,372,135	101	3.64	306,485.3	0.05	3.30	76,106,116.0
Male	195,845	16,240,083	112	5.72	161,456.5	0.07	6.94	54,467,803.1
Furosemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	*****	12.50	*****	1.32	8.18	538,217.1
Male	*****	124,043	*****	17.92	*****	1.45	12.83	452,865.2
Asian								
Female	48,189	912,654	51	10.58	71,972.0	0.56	7.09	2,997,779.8
Male	34,836	828,855	66	18.95	45,366.9	0.80	14.55	2,535,499.3
Black or African American								
Female	375,790	3,334,812	170	4.52	573,421.9	0.51	2.96	12,020,281.5
Male	183,350	2,423,602	184	10.04	230,820.7	0.76	7.97	8,764,951.8

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	*****	4.02	*****	0.16	3.10	176,088.0
Male	*****	65,061	*****	3.15	*****	0.15	2.62	189,552.7
Unknown								
Female	619,750	49,048,423	199	3.21	700,030.7	0.04	2.84	125,437,229.2
Male	444,391	50,096,003	324	7.29	431,478.4	0.06	7.51	132,004,187.0
White								
Female	2,088,782	19,762,194	922	4.41	2,930,225.4	0.47	3.15	65,322,691.1
Male	1,204,679	15,243,042	1,218	10.11	1,458,444.5	0.80	8.35	48,805,375.9
Furosemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	*****	14.00	*****	2.36	8.09	538,212.0
Male	*****	130,563	*****	19.64	*****	2.60	12.63	452,869.1
Asian								
Female	69,702	930,842	75	10.76	111,937.5	0.81	6.70	2,999,930.4
Male	53,002	845,192	121	22.83	73,995.7	1.43	16.35	2,539,401.1
Black or African American								
Female	696,688	3,638,829	351	5.04	1,192,956.5	0.96	2.94	12,087,103.9
Male	343,654	2,581,060	384	11.17	489,439.8	1.49	7.85	8,803,080.5
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	*****	7.60	*****	0.47	5.75	176,574.7
Male	*****	67,403	*****	1.90	*****	0.15	1.63	190,476.3
Unknown								
Female	992,652	49,452,984	354	3.57	1,106,735.8	0.07	3.20	125,593,361.0
Male	723,876	50,402,542	552	7.63	696,924.3	0.11	7.92	132,124,280.7
White								
Female	3,743,656	21,372,135	1,853	4.95	5,677,304.1	0.87	3.26	65,849,914.1
Male	2,176,940	16,240,083	2,474	11.36	2,826,808.2	1.52	8.75	49,180,577.3

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	449.9	0.00	0.00	553,326.9
Male	*****	124,043	0	0.00	242.5	0.00	0.00	461,272.7
Asian								
Female	*****	912,654	0	0.00	*****	0.00	0.00	3,050,444.3
Male	*****	828,855	*****	19.86	*****	0.02	19.73	2,567,543.9
Black or African American								
Female	*****	3,334,812	*****	5.24	*****	0.02	3.89	12,358,726.5
Male	*****	2,423,602	*****	13.54	*****	0.04	13.24	8,898,174.1
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	*****	0.00	0.00	178,247.8
Male	*****	65,061	*****	72.99	*****	0.15	83.06	192,076.0
Unknown								
Female	*****	49,048,423	*****	1.49	*****	0.00	1.37	126,016,397.7
Male	*****	50,096,003	*****	7.36	*****	0.00	8.46	132,334,779.0
White								
Female	69,929	19,762,194	59	8.44	91,478.6	0.03	6.45	66,987,317.5
Male	44,222	15,243,042	86	19.45	46,283.8	0.06	18.58	49,608,712.1
Bumetanide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	0	0.00	1,569.2	0.00	0.00	622,225.1
Male	*****	130,563	0	0.00	851.9	0.00	0.00	502,661.7
Asian								
Female	*****	930,842	0	0.00	*****	0.00	0.00	3,210,426.0
Male	*****	845,192	*****	16.75	*****	0.07	18.55	2,683,444.1
Black or African American								
Female	54,689	3,638,829	26	4.75	68,682.5	0.07	3.79	14,208,494.8
Male	31,923	2,581,060	23	7.20	30,492.6	0.09	7.54	9,722,241.2

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	*****	0.00	0.00	186,528.2
Male	*****	67,403	*****	41.15	*****	0.30	55.09	202,692.4
Unknown								
Female	*****	49,452,984	24	3.97	56,500.6	0.00	4.25	127,939,582.4
Male	*****	50,402,542	44	8.78	35,897.9	0.01	12.26	133,667,448.6
White								
Female	285,194	21,372,135	218	7.64	328,283.9	0.10	6.64	76,071,235.5
Male	187,863	16,240,083	334	17.78	164,528.5	0.21	20.30	54,471,079.4
Torsemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	430.1	0.00	0.00	553,378.6
Male	*****	124,043	0	0.00	265.6	0.00	0.00	461,292.5
Asian								
Female	*****	912,654	0	0.00	*****	0.00	0.00	3,050,678.3
Male	*****	828,855	*****	10.26	*****	0.01	10.52	2,567,685.9
Black or African American								
Female	*****	3,334,812	*****	7.58	*****	0.03	5.87	12,359,701.3
Male	*****	2,423,602	*****	8.26	*****	0.02	8.37	8,898,640.5
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	*****	0.00	0.00	178,282.6
Male	*****	65,061	*****	84.03	*****	0.15	92.30	192,075.4
Unknown								
Female	*****	49,048,423	*****	3.20	*****	0.00	3.09	126,019,100.1
Male	*****	50,096,003	*****	11.34	*****	0.00	13.92	132,335,603.2
White								
Female	68,752	19,762,194	52	7.56	84,575.0	0.03	6.15	66,992,034.6
Male	45,567	15,243,042	80	17.56	43,493.0	0.05	18.39	49,612,135.6

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	0	0.00	*****	0.00	0.00	622,048.8
Male	*****	130,563	*****	24.45	*****	0.23	29.11	502,246.9
Asian								
Female	*****	930,842	*****	3.03	*****	0.01	2.85	3,211,684.8
Male	*****	845,192	*****	3.21	*****	0.01	3.63	2,684,525.1
Black or African American								
Female	*****	3,638,829	*****	6.06	*****	0.09	4.93	14,214,867.1
Male	*****	2,581,060	*****	11.37	*****	0.14	12.22	9,723,669.1
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	*****	0.00	0.00	186,647.8
Male	*****	67,403	*****	46.51	*****	0.30	67.53	202,805.5
Unknown								
Female	*****	49,452,984	25	4.25	53,678.3	0.01	4.66	127,945,034.4
Male	*****	50,402,542	60	11.18	37,314.0	0.01	16.08	133,662,041.3
White								
Female	277,522	21,372,135	189	6.81	306,485.3	0.09	6.17	76,106,116.0
Male	195,845	16,240,083	328	16.75	161,456.5	0.20	20.32	54,467,803.1
Furosemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	*****	5.00	*****	0.53	3.27	538,217.1
Male	*****	124,043	*****	13.94	*****	1.13	9.98	452,865.2
Asian								
Female	48,189	912,654	27	5.60	71,972.0	0.30	3.75	2,997,779.8
Male	34,836	828,855	61	17.51	45,366.9	0.74	13.45	2,535,499.3
Black or African American								
Female	375,790	3,334,812	253	6.73	573,421.9	0.76	4.41	12,020,281.5
Male	183,350	2,423,602	220	12.00	230,820.7	0.91	9.53	8,764,951.8

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	3,228.3	0.00	0.00	176,088.0
Male	*****	65,061	12	37.75	3,815.1	1.84	31.45	189,552.7
Unknown								
Female	619,750	49,048,423	224	3.61	700,030.7	0.05	3.20	125,437,229.2
Male	444,391	50,096,003	541	12.17	431,478.4	0.11	12.54	132,004,187.0
White								
Female	2,088,782	19,762,194	1,618	7.75	2,930,225.4	0.82	5.52	65,322,691.1
Male	1,204,679	15,243,042	2,830	23.49	1,458,444.5	1.86	19.40	48,805,375.9
Furosemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	19	7.00	46,978.8	1.18	4.04	538,212.0
Male	*****	130,563	29	16.75	26,930.4	2.22	10.77	452,869.1
Asian								
Female	69,702	930,842	49	7.03	111,937.5	0.53	4.38	2,999,930.4
Male	53,002	845,192	104	19.62	73,995.7	1.23	14.05	2,539,401.1
Black or African American								
Female	696,688	3,638,829	517	7.42	1,192,956.5	1.42	4.33	12,087,103.9
Male	343,654	2,581,060	510	14.84	489,439.8	1.98	10.42	8,803,080.5
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	5,217.9	0.00	0.00	176,574.7
Male	*****	67,403	13	24.70	6,136.0	1.93	21.19	190,476.3
Unknown								
Female	992,652	49,452,984	416	4.19	1,106,735.8	0.08	3.76	125,593,361.0
Male	723,876	50,402,542	933	12.89	696,924.3	0.19	13.39	132,124,280.7
White								
Female	3,743,656	21,372,135	3,442	9.19	5,677,304.1	1.61	6.06	65,849,914.1
Male	2,176,940	16,240,083	5,712	26.24	2,826,808.2	3.52	20.21	49,180,577.3

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	*****	27.03	*****	0.07	22.23	553,326.9
Male	*****	124,043	0	0.00	*****	0.00	0.00	461,272.7
Asian								
Female	*****	912,654	*****	17.15	*****	0.02	14.38	3,050,444.3
Male	*****	828,855	*****	39.72	*****	0.05	39.45	2,567,543.9
Black or African American								
Female	*****	3,334,812	32	23.96	17,979.0	0.10	17.80	12,358,726.5
Male	*****	2,423,602	18	24.37	7,552.4	0.07	23.83	8,898,174.1
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	*****	112.36	*****	0.16	79.71	178,247.8
Male	*****	65,061	0	0.00	*****	0.00	0.00	192,076.0
Unknown								
Female	*****	49,048,423	*****	12.45	*****	0.01	11.44	126,016,397.7
Male	*****	50,096,003	*****	11.37	*****	0.00	13.07	132,334,779.0
White								
Female	69,929	19,762,194	189	27.03	91,478.6	0.10	20.66	66,987,317.5
Male	44,222	15,243,042	104	23.52	46,283.8	0.07	22.47	49,608,712.1
Bumetanide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	*****	26.23	*****	0.25	25.49	622,225.1
Male	*****	130,563	*****	39.25	*****	0.31	46.96	502,661.7
Asian								
Female	*****	930,842	*****	17.96	*****	0.08	17.97	3,210,426.0
Male	*****	845,192	*****	30.71	*****	0.13	34.00	2,683,444.1
Black or African American								
Female	54,689	3,638,829	139	25.42	68,682.5	0.38	20.24	14,208,494.8
Male	31,923	2,581,060	70	21.93	30,492.6	0.27	22.96	9,722,241.2

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	*****	38.02	*****	0.16	35.73	186,528.2
Male	*****	67,403	0	0.00	*****	0.00	0.00	202,692.4
Unknown								
Female	*****	49,452,984	77	12.73	56,500.6	0.02	13.63	127,939,582.4
Male	*****	50,402,542	65	12.97	35,897.9	0.01	18.11	133,667,448.6
White								
Female	285,194	21,372,135	742	26.02	328,283.9	0.35	22.60	76,071,235.5
Male	187,863	16,240,083	406	21.61	164,528.5	0.25	24.68	54,471,079.4
Torsemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	*****	0.00	0.00	553,378.6
Male	*****	124,043	*****	36.76	*****	0.08	37.66	461,292.5
Asian								
Female	*****	912,654	*****	9.12	*****	0.01	7.78	3,050,678.3
Male	*****	828,855	*****	30.77	*****	0.04	31.55	2,567,685.9
Black or African American								
Female	*****	3,334,812	42	31.83	17,037.4	0.13	24.65	12,359,701.3
Male	*****	2,423,602	16	22.03	7,171.1	0.07	22.31	8,898,640.5
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	78.2	0.00	0.00	178,282.6
Male	*****	65,061	0	0.00	108.3	0.00	0.00	192,075.4
Unknown								
Female	*****	49,048,423	18	9.60	19,434.7	0.00	9.26	126,019,100.1
Male	*****	50,096,003	14	8.82	12,933.5	0.00	10.82	132,335,603.2
White								
Female	68,752	19,762,194	154	22.40	84,575.0	0.08	18.21	66,992,034.6
Male	45,567	15,243,042	89	19.53	43,493.0	0.06	20.46	49,612,135.6

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	*****	12.14	*****	0.12	12.31	622,048.8
Male	*****	130,563	*****	24.45	*****	0.23	29.11	502,246.9
Asian								
Female	*****	930,842	*****	12.12	*****	0.04	11.41	3,211,684.8
Male	*****	845,192	*****	16.06	*****	0.06	18.15	2,684,525.1
Black or African American								
Female	*****	3,638,829	143	27.08	64,971.7	0.39	22.01	14,214,867.1
Male	*****	2,581,060	78	24.63	29,463.0	0.30	26.47	9,723,669.1
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	206.3	0.00	0.00	186,647.8
Male	*****	67,403	0	0.00	296.1	0.00	0.00	202,805.5
Unknown								
Female	*****	49,452,984	*****	9.52	*****	0.01	10.43	127,945,034.4
Male	*****	50,402,542	*****	9.50	*****	0.01	13.67	133,662,041.3
White								
Female	277,522	21,372,135	646	23.28	306,485.3	0.30	21.08	76,106,116.0
Male	195,845	16,240,083	405	20.68	161,456.5	0.25	25.08	54,467,803.1
Furosemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	*****	30.01	*****	3.18	19.63	538,217.1
Male	*****	124,043	*****	21.91	14,028.9	1.77	15.68	452,865.2
Asian								
Female	48,189	912,654	106	22.00	71,972.0	1.16	14.73	2,997,779.8
Male	34,836	828,855	87	24.97	45,366.9	1.05	19.18	2,535,499.3
Black or African American								
Female	375,790	3,334,812	933	24.83	573,421.9	2.80	16.27	12,020,281.5
Male	183,350	2,423,602	479	26.12	230,820.7	1.98	20.75	8,764,951.8

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	*****	20.10	*****	0.80	15.49	176,088.0
Male	*****	65,061	*****	15.73	*****	0.77	13.11	189,552.7
Unknown								
Female	619,750	49,048,423	660	10.65	700,030.7	0.13	9.43	125,437,229.2
Male	444,391	50,096,003	583	13.12	431,478.4	0.12	13.51	132,004,187.0
White								
Female	2,088,782	19,762,194	5,321	25.47	2,930,225.4	2.69	18.16	65,322,691.1
Male	1,204,679	15,243,042	3,269	27.14	1,458,444.5	2.14	22.41	48,805,375.9
Furosemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	97	35.73	46,978.8	6.03	20.65	538,212.0
Male	*****	130,563	45	26.00	26,930.4	3.45	16.71	452,869.1
Asian								
Female	69,702	930,842	182	26.11	111,937.5	1.96	16.26	2,999,930.4
Male	53,002	845,192	160	30.19	73,995.7	1.89	21.62	2,539,401.1
Black or African American								
Female	696,688	3,638,829	2,210	31.72	1,192,956.5	6.07	18.53	12,087,103.9
Male	343,654	2,581,060	1,147	33.38	489,439.8	4.44	23.43	8,803,080.5
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	*****	22.80	*****	1.41	17.25	176,574.7
Male	*****	67,403	*****	24.70	*****	1.93	21.19	190,476.3
Unknown								
Female	992,652	49,452,984	1,268	12.77	1,106,735.8	0.26	11.46	125,593,361.0
Male	723,876	50,402,542	1,128	15.58	696,924.3	0.22	16.19	132,124,280.7
White								
Female	3,743,656	21,372,135	11,848	31.65	5,677,304.1	5.54	20.87	65,849,914.1
Male	2,176,940	16,240,083	7,151	32.85	2,826,808.2	4.40	25.30	49,180,577.3

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	449.9	0.00	0.00	553,326.9
Male	*****	124,043	0	0.00	242.5	0.00	0.00	461,272.7
Asian								
Female	*****	912,654	*****	17.15	*****	0.02	14.38	3,050,444.3
Male	*****	828,855	0	0.00	*****	0.00	0.00	2,567,543.9
Black or African American								
Female	*****	3,334,812	*****	7.49	*****	0.03	5.56	12,358,726.5
Male	*****	2,423,602	*****	10.83	*****	0.03	10.59	8,898,174.1
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	125.5	0.00	0.00	178,247.8
Male	*****	65,061	0	0.00	120.4	0.00	0.00	192,076.0
Unknown								
Female	*****	49,048,423	*****	1.00	*****	0.00	0.92	126,016,397.7
Male	*****	50,096,003	*****	6.69	*****	0.00	7.69	132,334,779.0
White								
Female	69,929	19,762,194	24	3.43	91,478.6	0.01	2.62	66,987,317.5
Male	44,222	15,243,042	44	9.95	46,283.8	0.03	9.51	49,608,712.1
Bumetanide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	0	0.00	1,569.2	0.00	0.00	622,225.1
Male	*****	130,563	0	0.00	851.9	0.00	0.00	502,661.7
Asian								
Female	*****	930,842	*****	5.13	*****	0.02	5.13	3,210,426.0
Male	*****	845,192	0	0.00	*****	0.00	0.00	2,683,444.1
Black or African American								
Female	54,689	3,638,829	36	6.58	68,682.5	0.10	5.24	14,208,494.8
Male	31,923	2,581,060	29	9.08	30,492.6	0.11	9.51	9,722,241.2

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	*****	0.00	0.00	186,528.2
Male	*****	67,403	*****	20.58	*****	0.15	27.54	202,692.4
Unknown								
Female	*****	49,452,984	*****	2.31	*****	0.00	2.48	127,939,582.4
Male	*****	50,402,542	*****	5.59	*****	0.01	7.80	133,667,448.6
White								
Female	285,194	21,372,135	128	4.49	328,283.9	0.06	3.90	76,071,235.5
Male	187,863	16,240,083	165	8.78	164,528.5	0.10	10.03	54,471,079.4
Torsemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	0	0.00	430.1	0.00	0.00	553,378.6
Male	*****	124,043	0	0.00	265.6	0.00	0.00	461,292.5
Asian								
Female	*****	912,654	0	0.00	1,286.1	0.00	0.00	3,050,678.3
Male	*****	828,855	0	0.00	950.8	0.00	0.00	2,567,685.9
Black or African American								
Female	*****	3,334,812	*****	4.55	*****	0.02	3.52	12,359,701.3
Male	*****	2,423,602	0	0.00	*****	0.00	0.00	8,898,640.5
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	78.2	0.00	0.00	178,282.6
Male	*****	65,061	0	0.00	108.3	0.00	0.00	192,075.4
Unknown								
Female	*****	49,048,423	*****	0.53	*****	0.00	0.51	126,019,100.1
Male	*****	50,096,003	*****	7.56	*****	0.00	9.28	132,335,603.2
White								
Female	68,752	19,762,194	30	4.36	84,575.0	0.02	3.55	66,992,034.6
Male	45,567	15,243,042	37	8.12	43,493.0	0.02	8.51	49,612,135.6

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	0	0.00	1,625.0	0.00	0.00	622,048.8
Male	*****	130,563	0	0.00	1,030.5	0.00	0.00	502,246.9
Asian								
Female	*****	930,842	0	0.00	*****	0.00	0.00	3,211,684.8
Male	*****	845,192	*****	3.21	*****	0.01	3.63	2,684,525.1
Black or African American								
Female	*****	3,638,829	26	4.92	64,971.7	0.07	4.00	14,214,867.1
Male	*****	2,581,060	16	5.05	29,463.0	0.06	5.43	9,723,669.1
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	206.3	0.00	0.00	186,647.8
Male	*****	67,403	0	0.00	296.1	0.00	0.00	202,805.5
Unknown								
Female	*****	49,452,984	*****	1.19	*****	0.00	1.30	127,945,034.4
Male	*****	50,402,542	*****	4.10	*****	0.00	5.90	133,662,041.3
White								
Female	277,522	21,372,135	151	5.44	306,485.3	0.07	4.93	76,106,116.0
Male	195,845	16,240,083	143	7.30	161,456.5	0.09	8.86	54,467,803.1
Furosemide Users (Washout)								
American Indian or Alaska Native								
Female	*****	151,144	*****	0.63	*****	0.07	0.41	538,217.1
Male	*****	124,043	*****	9.96	*****	0.81	7.13	452,865.2
Asian								
Female	48,189	912,654	22	4.57	71,972.0	0.24	3.06	2,997,779.8
Male	34,836	828,855	24	6.89	45,366.9	0.29	5.29	2,535,499.3
Black or African American								
Female	375,790	3,334,812	143	3.81	573,421.9	0.43	2.49	12,020,281.5
Male	183,350	2,423,602	136	7.42	230,820.7	0.56	5.89	8,764,951.8

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander								
Female	*****	62,251	0	0.00	*****	0.00	0.00	176,088.0
Male	*****	65,061	*****	6.29	*****	0.31	5.24	189,552.7
Unknown								
Female	619,750	49,048,423	123	1.98	700,030.7	0.03	1.76	125,437,229.2
Male	444,391	50,096,003	185	4.16	431,478.4	0.04	4.29	132,004,187.0
White								
Female	2,088,782	19,762,194	935	4.48	2,930,225.4	0.47	3.19	65,322,691.1
Male	1,204,679	15,243,042	1,111	9.22	1,458,444.5	0.73	7.62	48,805,375.9

Table 5. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race and Sex[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (No Washout)								
American Indian or Alaska Native								
Female	*****	160,986	*****	1.84	*****	0.31	1.06	538,212.0
Male	*****	130,563	*****	10.98	*****	1.46	7.06	452,869.1
Asian								
Female	69,702	930,842	40	5.74	111,937.5	0.43	3.57	2,999,930.4
Male	53,002	845,192	42	7.92	73,995.7	0.50	5.68	2,539,401.1
Black or African American								
Female	696,688	3,638,829	348	5.00	1,192,956.5	0.96	2.92	12,087,103.9
Male	343,654	2,581,060	277	8.06	489,439.8	1.07	5.66	8,803,080.5
Native Hawaiian or Other Pacific Islander								
Female	*****	63,893	0	0.00	*****	0.00	0.00	176,574.7
Male	*****	67,403	*****	11.40	*****	0.89	9.78	190,476.3
Unknown								
Female	992,652	49,452,984	226	2.28	1,106,735.8	0.05	2.04	125,593,361.0
Male	723,876	50,402,542	351	4.85	696,924.3	0.07	5.04	132,124,280.7
White								
Female	3,743,656	21,372,135	1,993	5.32	5,677,304.1	0.93	3.51	65,849,914.1
Male	2,176,940	16,240,083	2,346	10.78	2,826,808.2	1.44	8.30	49,180,577.3

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	13.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	25.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	89.4	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	124.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	96.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	25.9	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	0.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	31.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	56.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	92.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	33.6	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.5	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	30.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	71.1	N/A	0.00	N/A
65-74 years	*****	N/A	*****	31.95	*****	N/A	21.23	N/A
75-84 years	*****	N/A	0	0.00	539.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	29.24	*****	N/A	44.30	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	18.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	37.2	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	138.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	307.9	N/A	0.00	N/A
75-84 years	*****	N/A	*****	31.25	*****	N/A	30.51	N/A
≥ 85 years	*****	N/A	*****	48.08	*****	N/A	78.26	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	501.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	971.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,957.0	N/A	0.00	N/A
55-64 years	*****	N/A	*****	4.44	*****	N/A	3.13	N/A
65-74 years	*****	N/A	*****	2.39	*****	N/A	1.74	N/A
75-84 years	*****	N/A	*****	6.61	*****	N/A	4.88	N/A
≥ 85 years	*****	N/A	*****	5.65	*****	N/A	6.65	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	248.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	708.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,193.4	N/A	0.00	N/A
55-64 years	*****	N/A	*****	32.70	*****	N/A	31.84	N/A
65-74 years	*****	N/A	0	0.00	2,310.2	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,166.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	325.9	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	11.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	24.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	18.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.0	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	3.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	13.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	45.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	101.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,205.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,574.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,835.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	2.07	*****	N/A	2.26	N/A
65-74 years	*****	N/A	*****	3.09	*****	N/A	2.68	N/A
75-84 years	*****	N/A	*****	7.17	*****	N/A	5.90	N/A
≥ 85 years	*****	N/A	0	0.00	1,581.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	139.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	406.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,292.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,731.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	3,350.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	12.40	*****	N/A	13.12	N/A
75-84 years	*****	N/A	*****	5.51	*****	N/A	6.28	N/A
≥ 85 years	*****	N/A	0	0.00	444.6	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	91.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	903.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,522.3	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	5,537.6	N/A	0.00	N/A
55-64 years	*****	N/A	*****	3.16	*****	N/A	2.27	N/A
65-74 years	*****	N/A	*****	4.69	*****	N/A	3.02	N/A
75-84 years	*****	N/A	*****	3.31	*****	N/A	2.50	N/A
≥ 85 years	*****	N/A	*****	0.63	*****	N/A	0.80	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	436.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	10.15	*****	N/A	6.31	N/A
45-54 years	*****	N/A	0	0.00	4,320.7	N/A	0.00	N/A
55-64 years	*****	N/A	*****	10.03	*****	N/A	8.77	N/A
65-74 years	*****	N/A	15	9.04	19,305.0	N/A	7.77	N/A
75-84 years	*****	N/A	*****	7.38	*****	N/A	8.03	N/A
≥ 85 years	*****	N/A	*****	3.78	*****	N/A	7.79	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bumetanide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	92.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	249.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	288.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	499.9	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	307.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	81.3	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	19.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	187.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	205.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	29.67	*****	N/A	39.58	N/A
75-84 years	*****	N/A	0	0.00	100.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	38.4	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	6.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	66.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	118.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	227.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	10.02	*****	N/A	7.52	N/A
75-84 years	*****	N/A	*****	7.44	*****	N/A	6.89	N/A
≥ 85 years	*****	N/A	*****	8.84	*****	N/A	15.52	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	46.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	124.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	225.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	364.1	N/A	0.00	N/A
65-74 years	*****	N/A	*****	9.86	*****	N/A	9.11	N/A
75-84 years	*****	N/A	*****	18.15	*****	N/A	20.68	N/A
≥ 85 years	*****	N/A	*****	27.40	*****	N/A	48.92	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	25.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,264.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	3,531.0	N/A	0.00	N/A
45-54 years	*****	N/A	*****	6.03	*****	N/A	3.91	N/A
55-64 years	*****	N/A	*****	3.10	*****	N/A	2.36	N/A
65-74 years	*****	N/A	*****	4.12	*****	N/A	3.05	N/A
75-84 years	*****	N/A	*****	3.99	*****	N/A	3.38	N/A
≥ 85 years	*****	N/A	*****	1.33	*****	N/A	1.76	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	733.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,762.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.21	*****	N/A	1.82	N/A
55-64 years	*****	N/A	14	19.27	6,816.6	N/A	20.54	N/A
65-74 years	*****	N/A	*****	7.69	*****	N/A	8.31	N/A
75-84 years	*****	N/A	0	0.00	4,054.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	990.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	52.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	136.1	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	57.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.3	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	0.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	79.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	158.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	109.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	182.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,044.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	5,135.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.02	*****	N/A	1.78	N/A
55-64 years	*****	N/A	*****	3.59	*****	N/A	4.37	N/A
65-74 years	*****	N/A	*****	4.45	*****	N/A	4.35	N/A
75-84 years	*****	N/A	*****	2.84	*****	N/A	2.87	N/A
≥ 85 years	*****	N/A	*****	2.48	*****	N/A	4.45	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	254.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	867.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,724.2	N/A	0.00	N/A
45-54 years	*****	N/A	*****	4.96	*****	N/A	5.72	N/A
55-64 years	*****	N/A	*****	5.49	*****	N/A	8.28	N/A
65-74 years	*****	N/A	*****	7.62	*****	N/A	9.93	N/A
75-84 years	*****	N/A	*****	8.02	*****	N/A	12.28	N/A
≥ 85 years	*****	N/A	0	0.00	*****	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,454.2	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.25	*****	N/A	1.27	N/A
45-54 years	*****	N/A	*****	5.49	*****	N/A	3.18	N/A
55-64 years	*****	N/A	19	6.97	36,519.3	N/A	5.20	N/A
65-74 years	*****	N/A	55	6.61	119,523.4	N/A	4.60	N/A
75-84 years	*****	N/A	24	2.87	94,279.2	N/A	2.55	N/A
≥ 85 years	*****	N/A	11	1.51	45,486.1	N/A	2.42	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	40.2	N/A	0.00	N/A
20-34 years	*****	N/A	*****	23.04	*****	N/A	15.09	N/A
35-44 years	*****	N/A	*****	8.51	*****	N/A	5.35	N/A
45-54 years	*****	N/A	15	12.50	17,202.5	N/A	8.72	N/A
55-64 years	*****	N/A	37	13.94	27,321.5	N/A	13.54	N/A
65-74 years	*****	N/A	82	12.09	68,141.9	N/A	12.03	N/A
75-84 years	*****	N/A	25	4.86	35,658.0	N/A	7.01	N/A
≥ 85 years	*****	N/A	*****	1.56	*****	N/A	4.33	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	14.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	22.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	53.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	82.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	126.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	95.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	36.1	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	47.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.3	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	109.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	39.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	5.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	7.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	30.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	35.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	77.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	416.2	N/A	0.00	N/A
75-84 years	*****	N/A	*****	25.19	*****	N/A	20.45	N/A
≥ 85 years	*****	N/A	0	0.00	230.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	10.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	56.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.5	N/A	0.00	N/A
65-74 years	*****	N/A	*****	28.65	*****	N/A	27.38	N/A
75-84 years	*****	N/A	0	0.00	371.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	95.0	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	34.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	340.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	938.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,846.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	2,607.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	5,432.4	N/A	0.00	N/A
75-84 years	*****	N/A	*****	3.03	*****	N/A	2.34	N/A
≥ 85 years	*****	N/A	0	0.00	1,563.1	N/A	0.00	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	252.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	480.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,100.6	N/A	0.00	N/A
55-64 years	*****	N/A	*****	21.10	*****	N/A	22.36	N/A
65-74 years	*****	N/A	*****	8.08	*****	N/A	8.11	N/A
75-84 years	*****	N/A	0	0.00	1,277.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	239.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	3.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	20.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	16.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	24.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	13.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	5.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	47.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	8.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	61.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,960.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,104.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	3,969.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	3.08	*****	N/A	2.64	N/A
75-84 years	*****	N/A	0	0.00	3,405.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1,351.3	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	78.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	295.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,177.3	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,886.1	N/A	0.00	N/A
55-64 years	*****	N/A	*****	4.21	*****	N/A	6.34	N/A
65-74 years	*****	N/A	0	0.00	2,846.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	9.24	*****	N/A	10.39	N/A
≥ 85 years	*****	N/A	0	0.00	573.1	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	47.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	781.2	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,152.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,671.9	N/A	0.00	N/A
55-64 years	*****	N/A	*****	9.17	*****	N/A	7.02	N/A
65-74 years	*****	N/A	*****	2.39	*****	N/A	1.66	N/A
75-84 years	*****	N/A	11	5.02	27,390.5	N/A	4.02	N/A
≥ 85 years	*****	N/A	*****	0.62	*****	N/A	0.81	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	397.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,376.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	3,614.0	N/A	0.00	N/A
55-64 years	*****	N/A	*****	5.46	*****	N/A	5.19	N/A
65-74 years	*****	N/A	*****	5.88	*****	N/A	5.46	N/A
75-84 years	*****	N/A	*****	5.91	*****	N/A	7.16	N/A
≥ 85 years	*****	N/A	*****	1.70	*****	N/A	3.55	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	84.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	254.9	N/A	0.00	N/A
55-64 years	*****	N/A	*****	39.22	*****	N/A	40.06	N/A
65-74 years	*****	N/A	0	0.00	507.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	350.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	129.6	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	63.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	203.4	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	180.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	367.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	152.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	28.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	15.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	112.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	176.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,203.3	N/A	0.00	N/A
75-84 years	*****	N/A	*****	8.52	*****	N/A	7.48	N/A
≥ 85 years	*****	N/A	0	0.00	604.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	32.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	186.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	241.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	9.95	*****	N/A	10.43	N/A
75-84 years	*****	N/A	*****	10.56	*****	N/A	10.70	N/A
≥ 85 years	*****	N/A	0	0.00	327.1	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	42.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,020.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,979.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.15	*****	N/A	1.41	N/A
55-64 years	*****	N/A	*****	2.24	*****	N/A	1.76	N/A
65-74 years	*****	N/A	*****	4.18	*****	N/A	3.25	N/A
75-84 years	*****	N/A	*****	4.70	*****	N/A	3.87	N/A
≥ 85 years	*****	N/A	0	0.00	5,493.5	N/A	0.00	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	23.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,294.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	6.91	*****	N/A	5.97	N/A
55-64 years	*****	N/A	*****	11.46	*****	N/A	12.41	N/A
65-74 years	*****	N/A	*****	7.61	*****	N/A	8.26	N/A
75-84 years	*****	N/A	*****	3.56	*****	N/A	4.68	N/A
≥ 85 years	*****	N/A	0	0.00	926.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	5.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	33.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	94.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	49.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	19.4	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	10.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	157.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	72.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	12.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	88.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,454.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	4,500.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.14	*****	N/A	1.94	N/A
55-64 years	*****	N/A	*****	1.41	*****	N/A	1.77	N/A
65-74 years	*****	N/A	*****	1.76	*****	N/A	1.77	N/A
75-84 years	*****	N/A	*****	1.93	*****	N/A	1.97	N/A
≥ 85 years	*****	N/A	0	0.00	4,609.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	110.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	761.8	N/A	0.00	N/A
35-44 years	*****	N/A	*****	3.07	*****	N/A	3.39	N/A
45-54 years	*****	N/A	*****	3.54	*****	N/A	4.11	N/A
55-64 years	*****	N/A	*****	3.20	*****	N/A	5.08	N/A
65-74 years	*****	N/A	*****	1.54	*****	N/A	2.14	N/A
75-84 years	*****	N/A	*****	8.59	*****	N/A	13.03	N/A
≥ 85 years	*****	N/A	0	0.00	1,647.5	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	48.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	8.87	*****	N/A	4.80	N/A
35-44 years	*****	N/A	*****	7.92	*****	N/A	4.50	N/A
45-54 years	*****	N/A	*****	3.76	*****	N/A	2.34	N/A
55-64 years	*****	N/A	16	6.74	30,109.4	N/A	5.31	N/A
65-74 years	*****	N/A	34	4.17	112,143.0	N/A	3.03	N/A
75-84 years	*****	N/A	35	4.14	93,267.7	N/A	3.75	N/A
≥ 85 years	*****	N/A	*****	1.11	*****	N/A	1.78	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	20.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,181.6	N/A	0.00	N/A
35-44 years	*****	N/A	*****	9.38	*****	N/A	6.29	N/A
45-54 years	*****	N/A	*****	9.39	*****	N/A	6.91	N/A
55-64 years	*****	N/A	17	6.81	24,241.0	N/A	7.01	N/A
65-74 years	*****	N/A	55	7.69	69,087.6	N/A	7.96	N/A
75-84 years	*****	N/A	22	3.89	37,790.1	N/A	5.82	N/A
≥ 85 years	*****	N/A	*****	1.78	*****	N/A	5.05	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	540.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,440.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.05	*****	N/A	3.56	N/A
55-64 years	*****	N/A	*****	19.68	*****	N/A	12.46	N/A
65-74 years	*****	N/A	*****	16.38	*****	N/A	10.22	N/A
75-84 years	*****	N/A	*****	12.44	*****	N/A	8.39	N/A
≥ 85 years	*****	N/A	*****	4.66	*****	N/A	5.38	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	322.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	902.6	N/A	0.00	N/A
45-54 years	*****	N/A	*****	32.05	*****	N/A	17.61	N/A
55-64 years	*****	N/A	*****	15.01	*****	N/A	10.51	N/A
65-74 years	*****	N/A	*****	12.25	*****	N/A	8.96	N/A
75-84 years	*****	N/A	*****	23.18	*****	N/A	18.78	N/A
≥ 85 years	*****	N/A	*****	27.32	*****	N/A	36.59	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	42.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	489.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,068.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	9.23	*****	N/A	5.57	N/A
55-64 years	*****	N/A	*****	10.78	*****	N/A	6.97	N/A
65-74 years	*****	N/A	13	10.99	20,894.7	N/A	6.22	N/A
75-84 years	*****	N/A	25	14.23	29,183.7	N/A	8.57	N/A
≥ 85 years	*****	N/A	*****	6.74	*****	N/A	6.40	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	104.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	426.0	N/A	0.00	N/A
35-44 years	*****	N/A	*****	16.16	*****	N/A	10.71	N/A
45-54 years	*****	N/A	*****	28.49	*****	N/A	19.21	N/A
55-64 years	*****	N/A	*****	23.09	*****	N/A	17.59	N/A
65-74 years	*****	N/A	21	20.56	15,049.8	N/A	13.95	N/A
75-84 years	*****	N/A	18	15.29	16,251.4	N/A	11.08	N/A
≥ 85 years	*****	N/A	16	20.17	7,108.4	N/A	22.51	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1,818.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.14	*****	N/A	1.30	N/A
35-44 years	*****	N/A	*****	2.16	*****	N/A	1.13	N/A
45-54 years	*****	N/A	11	3.11	66,483.5	N/A	1.65	N/A
55-64 years	*****	N/A	44	7.56	89,139.3	N/A	4.94	N/A
65-74 years	*****	N/A	58	5.22	171,903.9	N/A	3.37	N/A
75-84 years	*****	N/A	33	3.83	129,428.5	N/A	2.55	N/A
≥ 85 years	*****	N/A	17	3.01	56,100.9	N/A	3.03	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	906.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.80	*****	N/A	2.92	N/A
35-44 years	*****	N/A	*****	2.11	*****	N/A	1.20	N/A
45-54 years	*****	N/A	23	10.00	38,248.0	N/A	6.01	N/A
55-64 years	*****	N/A	61	15.98	48,947.3	N/A	12.46	N/A
65-74 years	*****	N/A	69	11.41	72,330.9	N/A	9.54	N/A
75-84 years	*****	N/A	22	6.26	37,616.5	N/A	5.85	N/A
≥ 85 years	*****	N/A	*****	3.74	*****	N/A	5.43	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	35.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	126.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	317.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,495.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	11.88	*****	N/A	9.56	N/A
≥ 85 years	*****	N/A	0	0.00	175.2	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	31.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	222.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	563.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	7.63	*****	N/A	5.34	N/A
75-84 years	*****	N/A	0	0.00	996.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	117.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	7,272.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	41,822.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	0.69	*****	N/A	0.59	N/A
45-54 years	*****	N/A	21	1.74	146,116.2	N/A	1.44	N/A
55-64 years	*****	N/A	45	3.23	126,983.2	N/A	3.54	N/A
65-74 years	*****	N/A	61	6.46	122,885.4	N/A	4.96	N/A
75-84 years	*****	N/A	50	6.00	114,434.9	N/A	4.37	N/A
≥ 85 years	*****	N/A	17	2.56	55,804.7	N/A	3.05	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	7,750.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.81	*****	N/A	0.82	N/A
35-44 years	*****	N/A	*****	2.61	*****	N/A	2.41	N/A
45-54 years	*****	N/A	72	8.43	92,748.7	N/A	7.76	N/A
55-64 years	*****	N/A	114	8.43	111,169.2	N/A	10.25	N/A
65-74 years	*****	N/A	80	8.88	94,198.6	N/A	8.49	N/A
75-84 years	*****	N/A	41	7.52	58,051.7	N/A	7.06	N/A
≥ 85 years	*****	N/A	*****	2.52	*****	N/A	3.91	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	2,867.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.53	*****	N/A	0.69	N/A
35-44 years	*****	N/A	*****	1.24	*****	N/A	0.60	N/A
45-54 years	*****	N/A	64	6.27	198,147.7	N/A	3.23	N/A
55-64 years	*****	N/A	129	7.13	277,380.5	N/A	4.65	N/A
65-74 years	*****	N/A	403	6.61	1,007,636.0	N/A	4.00	N/A
75-84 years	*****	N/A	251	4.15	869,400.8	N/A	2.89	N/A
≥ 85 years	*****	N/A	66	1.26	432,213.0	N/A	1.53	N/A
White, Male								
0-19 years	742	N/A	0	0.00	1,955.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.00	*****	N/A	2.42	N/A
35-44 years	*****	N/A	20	7.19	54,487.8	N/A	3.67	N/A
45-54 years	*****	N/A	143	17.77	143,466.9	N/A	9.97	N/A
55-64 years	*****	N/A	300	19.07	208,391.1	N/A	14.40	N/A
65-74 years	*****	N/A	535	12.08	595,059.1	N/A	8.99	N/A
75-84 years	*****	N/A	179	5.44	347,765.0	N/A	5.15	N/A
≥ 85 years	*****	N/A	37	2.34	90,785.6	N/A	4.08	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	841.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,397.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.82	*****	N/A	3.55	N/A
55-64 years	*****	N/A	11	25.34	8,079.6	N/A	13.61	N/A
65-74 years	*****	N/A	17	19.86	15,729.2	N/A	10.81	N/A
75-84 years	*****	N/A	*****	9.00	*****	N/A	5.52	N/A
≥ 85 years	*****	N/A	*****	5.68	*****	N/A	5.83	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	5.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	595.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	11.92	*****	N/A	5.41	N/A
45-54 years	*****	N/A	*****	26.94	*****	N/A	13.55	N/A
55-64 years	*****	N/A	*****	23.06	*****	N/A	14.10	N/A
65-74 years	*****	N/A	*****	17.10	*****	N/A	10.99	N/A
75-84 years	*****	N/A	*****	20.08	*****	N/A	15.83	N/A
≥ 85 years	*****	N/A	*****	17.09	*****	N/A	23.19	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	67.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	710.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,642.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	5.69	*****	N/A	3.23	N/A
55-64 years	*****	N/A	*****	6.16	*****	N/A	3.74	N/A
65-74 years	*****	N/A	27	14.81	34,480.4	N/A	7.83	N/A
75-84 years	*****	N/A	32	12.95	43,965.7	N/A	7.28	N/A
≥ 85 years	*****	N/A	13	6.41	22,621.8	N/A	5.75	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	724.7	N/A	0.00	N/A
35-44 years	*****	N/A	*****	9.40	*****	N/A	5.76	N/A
45-54 years	*****	N/A	12	48.86	4,007.8	N/A	29.94	N/A
55-64 years	*****	N/A	11	23.92	6,756.8	N/A	16.28	N/A
65-74 years	*****	N/A	44	26.76	25,886.5	N/A	17.00	N/A
75-84 years	*****	N/A	32	18.96	24,528.8	N/A	13.05	N/A
≥ 85 years	*****	N/A	21	18.92	10,219.9	N/A	20.55	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	2,138.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.09	*****	N/A	1.30	N/A
35-44 years	*****	N/A	*****	2.38	*****	N/A	1.15	N/A
45-54 years	*****	N/A	27	4.06	136,602.8	N/A	1.98	N/A
55-64 years	*****	N/A	89	7.65	201,893.0	N/A	4.41	N/A
65-74 years	*****	N/A	126	5.80	382,543.6	N/A	3.29	N/A
75-84 years	*****	N/A	68	4.42	264,189.2	N/A	2.57	N/A
≥ 85 years	*****	N/A	30	3.00	113,730.2	N/A	2.64	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	1,269.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	8.61	*****	N/A	4.00	N/A
35-44 years	*****	N/A	*****	2.79	*****	N/A	1.39	N/A
45-54 years	*****	N/A	51	11.27	84,486.7	N/A	6.04	N/A
55-64 years	*****	N/A	133	17.97	108,293.5	N/A	12.28	N/A
65-74 years	*****	N/A	140	12.04	157,476.4	N/A	8.89	N/A
75-84 years	*****	N/A	42	6.90	71,970.2	N/A	5.84	N/A
≥ 85 years	*****	N/A	*****	3.46	*****	N/A	4.56	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	40.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	57.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	244.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	703.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	6.38	*****	N/A	4.11	N/A
75-84 years	*****	N/A	*****	16.86	*****	N/A	13.74	N/A
≥ 85 years	*****	N/A	0	0.00	275.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	17.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	86.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	419.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	1,072.8	N/A	0.00	N/A
65-74 years	*****	N/A	*****	4.49	*****	N/A	3.38	N/A
75-84 years	*****	N/A	0	0.00	1,399.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	177.6	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	10,216.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.44	*****	N/A	0.40	N/A
35-44 years	*****	N/A	12	1.23	113,130.1	N/A	1.06	N/A
45-54 years	*****	N/A	34	1.85	219,720.7	N/A	1.55	N/A
55-64 years	*****	N/A	85	3.68	210,654.0	N/A	4.04	N/A
65-74 years	*****	N/A	120	7.18	216,120.6	N/A	5.55	N/A
75-84 years	*****	N/A	79	5.44	192,726.5	N/A	4.10	N/A
≥ 85 years	*****	N/A	22	1.90	94,296.5	N/A	2.33	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	11,136.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.21	*****	N/A	1.19	N/A
35-44 years	*****	N/A	18	3.61	54,482.0	N/A	3.30	N/A
45-54 years	*****	N/A	116	8.85	143,759.3	N/A	8.07	N/A
55-64 years	*****	N/A	191	8.75	181,148.0	N/A	10.54	N/A
65-74 years	*****	N/A	150	9.52	164,967.6	N/A	9.09	N/A
75-84 years	*****	N/A	64	6.76	94,808.9	N/A	6.75	N/A
≥ 85 years	*****	N/A	11	2.21	29,838.5	N/A	3.69	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	3,667.8	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.57	*****	N/A	0.68	N/A
35-44 years	*****	N/A	11	1.53	161,033.5	N/A	0.68	N/A
45-54 years	*****	N/A	144	8.07	383,382.4	N/A	3.76	N/A
55-64 years	*****	N/A	324	9.56	589,126.5	N/A	5.50	N/A
65-74 years	*****	N/A	802	7.27	2,008,484.5	N/A	3.99	N/A
75-84 years	*****	N/A	455	4.37	1,618,445.6	N/A	2.81	N/A
≥ 85 years	*****	N/A	113	1.15	854,187.7	N/A	1.32	N/A
White, Male								
0-19 years	*****	N/A	*****	10.41	*****	N/A	3.42	N/A
20-34 years	*****	N/A	*****	5.89	*****	N/A	2.56	N/A
35-44 years	*****	N/A	37	8.21	98,920.8	N/A	3.74	N/A
45-54 years	*****	N/A	320	22.09	289,828.1	N/A	11.04	N/A
55-64 years	*****	N/A	616	21.01	438,058.6	N/A	14.06	N/A
65-74 years	*****	N/A	1,070	13.25	1,176,639.7	N/A	9.09	N/A
75-84 years	*****	N/A	350	6.18	620,487.5	N/A	5.64	N/A
≥ 85 years	*****	N/A	73	2.38	172,618.7	N/A	4.23	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	13.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	25.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	89.4	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	124.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	96.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	25.9	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	0.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	31.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	56.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	92.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	33.6	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.5	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	30.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	71.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	471.1	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	539.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	225.7	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	18.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	37.2	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	138.1	N/A	0.00	N/A
65-74 years	*****	N/A	*****	37.74	*****	N/A	32.47	N/A
75-84 years	*****	N/A	*****	31.25	*****	N/A	30.51	N/A
≥ 85 years	*****	N/A	0	0.00	127.8	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	36.76	*****	N/A	19.95	N/A
35-44 years	*****	N/A	0	0.00	971.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,957.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	3,196.7	N/A	0.00	N/A
65-74 years	*****	N/A	*****	7.18	*****	N/A	5.22	N/A
75-84 years	*****	N/A	*****	3.30	*****	N/A	2.44	N/A
≥ 85 years	*****	N/A	*****	11.30	*****	N/A	13.30	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	248.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	708.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,193.4	N/A	0.00	N/A
55-64 years	*****	N/A	*****	26.16	*****	N/A	25.48	N/A
65-74 years	*****	N/A	*****	8.09	*****	N/A	8.66	N/A
75-84 years	*****	N/A	*****	29.46	*****	N/A	34.29	N/A
≥ 85 years	*****	N/A	0	0.00	325.9	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	11.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	24.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	18.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.0	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	3.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	13.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	45.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	1,111.11	*****	N/A	9,223.48	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	101.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,205.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,574.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,835.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	2.07	*****	N/A	2.26	N/A
65-74 years	*****	N/A	*****	3.09	*****	N/A	2.68	N/A
75-84 years	*****	N/A	*****	3.59	*****	N/A	2.95	N/A
≥ 85 years	*****	N/A	0	0.00	1,581.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	139.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	406.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,292.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,731.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	2.23	*****	N/A	2.99	N/A
65-74 years	*****	N/A	*****	15.50	*****	N/A	16.39	N/A
75-84 years	*****	N/A	*****	16.53	*****	N/A	18.83	N/A
≥ 85 years	*****	N/A	*****	22.45	*****	N/A	44.98	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	91.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	903.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,522.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	15.08	*****	N/A	9.03	N/A
55-64 years	*****	N/A	*****	6.32	*****	N/A	4.54	N/A
65-74 years	*****	N/A	16	7.50	33,063.4	N/A	4.84	N/A
75-84 years	*****	N/A	15	7.09	28,008.6	N/A	5.36	N/A
≥ 85 years	*****	N/A	19	11.94	12,533.1	N/A	15.16	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	35.71	*****	N/A	22.93	N/A
35-44 years	*****	N/A	0	0.00	1,583.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	10.44	*****	N/A	6.94	N/A
55-64 years	*****	N/A	*****	11.70	*****	N/A	10.23	N/A
65-74 years	*****	N/A	42	25.30	19,305.0	N/A	21.76	N/A
75-84 years	*****	N/A	30	24.61	11,210.4	N/A	26.76	N/A
≥ 85 years	*****	N/A	*****	5.67	*****	N/A	11.68	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bumetanide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	92.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	249.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	288.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	499.9	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	307.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	81.3	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	19.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	187.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	205.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	252.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	100.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	38.4	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	6.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	66.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	118.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	227.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,330.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,451.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	644.4	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	*****	270.27	*****	N/A	214.27	N/A
35-44 years	*****	N/A	0	0.00	124.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	225.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	364.1	N/A	0.00	N/A
65-74 years	*****	N/A	*****	19.72	*****	N/A	18.21	N/A
75-84 years	*****	N/A	*****	18.15	*****	N/A	20.68	N/A
≥ 85 years	*****	N/A	*****	13.70	*****	N/A	24.46	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	25.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	12.35	*****	N/A	7.91	N/A
35-44 years	*****	N/A	*****	4.56	*****	N/A	2.83	N/A
45-54 years	*****	N/A	*****	2.01	*****	N/A	1.30	N/A
55-64 years	*****	N/A	*****	1.03	*****	N/A	0.79	N/A
65-74 years	*****	N/A	*****	4.71	*****	N/A	3.48	N/A
75-84 years	*****	N/A	*****	6.39	*****	N/A	5.40	N/A
≥ 85 years	*****	N/A	*****	7.98	*****	N/A	10.56	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	733.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,762.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.21	*****	N/A	1.82	N/A
55-64 years	*****	N/A	*****	6.88	*****	N/A	7.34	N/A
65-74 years	*****	N/A	*****	6.73	*****	N/A	7.28	N/A
75-84 years	*****	N/A	*****	16.63	*****	N/A	22.20	N/A
≥ 85 years	*****	N/A	*****	5.44	*****	N/A	10.10	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	52.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	136.1	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	57.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.3	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	0.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
55-64 years	*****	N/A	*****	123.46	*****	N/A	126.27	N/A
65-74 years	*****	N/A	0	0.00	158.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	109.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	370.37	*****	N/A	5,525.72	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	182.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,044.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	5,135.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.03	*****	N/A	2.66	N/A
55-64 years	*****	N/A	*****	3.59	*****	N/A	4.37	N/A
65-74 years	*****	N/A	*****	8.01	*****	N/A	7.83	N/A
75-84 years	*****	N/A	*****	5.69	*****	N/A	5.75	N/A
≥ 85 years	*****	N/A	*****	1.24	*****	N/A	2.22	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	254.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	867.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,724.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	6,992.3	N/A	0.00	N/A
55-64 years	*****	N/A	*****	3.43	*****	N/A	5.17	N/A
65-74 years	*****	N/A	18	15.24	9,066.8	N/A	19.85	N/A
75-84 years	*****	N/A	17	22.72	4,885.5	N/A	34.80	N/A
≥ 85 years	*****	N/A	*****	10.44	*****	N/A	27.73	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,454.2	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.25	*****	N/A	1.27	N/A
45-54 years	*****	N/A	11	8.63	22,010.6	N/A	5.00	N/A
55-64 years	*****	N/A	24	8.80	36,519.3	N/A	6.57	N/A
65-74 years	*****	N/A	76	9.14	119,523.4	N/A	6.36	N/A
75-84 years	*****	N/A	72	8.62	94,279.2	N/A	7.64	N/A
≥ 85 years	*****	N/A	34	4.67	45,486.1	N/A	7.47	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	40.2	N/A	0.00	N/A
20-34 years	*****	N/A	*****	11.52	*****	N/A	7.55	N/A
35-44 years	*****	N/A	*****	5.68	*****	N/A	3.57	N/A
45-54 years	*****	N/A	13	10.84	17,202.5	N/A	7.56	N/A
55-64 years	*****	N/A	40	15.07	27,321.5	N/A	14.64	N/A
65-74 years	*****	N/A	135	19.91	68,141.9	N/A	19.81	N/A
75-84 years	*****	N/A	117	22.74	35,658.0	N/A	32.81	N/A
≥ 85 years	*****	N/A	26	10.13	9,235.8	N/A	28.15	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	14.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	22.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	53.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	82.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	126.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	95.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	36.1	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	47.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.3	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	109.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	39.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	5.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	7.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	30.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	35.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	77.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	416.2	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	488.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	230.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	10.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	56.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	365.2	N/A	0.00	N/A
75-84 years	*****	N/A	*****	31.85	*****	N/A	26.94	N/A
≥ 85 years	*****	N/A	0	0.00	95.0	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	34.4	N/A	0.00	N/A
20-34 years	*****	N/A	*****	49.75	*****	N/A	29.40	N/A
35-44 years	*****	N/A	0	0.00	938.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,846.7	N/A	0.00	N/A
55-64 years	*****	N/A	*****	5.03	*****	N/A	3.83	N/A
65-74 years	*****	N/A	*****	7.08	*****	N/A	5.52	N/A
75-84 years	*****	N/A	*****	9.08	*****	N/A	7.02	N/A
≥ 85 years	*****	N/A	*****	11.72	*****	N/A	12.79	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	252.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	480.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	22.15	*****	N/A	18.17	N/A
55-64 years	*****	N/A	0	0.00	1,341.8	N/A	0.00	N/A
65-74 years	*****	N/A	*****	12.13	*****	N/A	12.16	N/A
75-84 years	*****	N/A	*****	6.98	*****	N/A	7.83	N/A
≥ 85 years	*****	N/A	0	0.00	239.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	3.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	20.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	16.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	24.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	13.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	5.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	47.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	1,111.11	*****	N/A	1,122.81	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	61.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,960.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,104.6	N/A	0.00	N/A
55-64 years	*****	N/A	*****	4.31	*****	N/A	5.04	N/A
65-74 years	*****	N/A	*****	3.08	*****	N/A	2.64	N/A
75-84 years	*****	N/A	*****	7.05	*****	N/A	5.87	N/A
≥ 85 years	*****	N/A	*****	5.13	*****	N/A	7.40	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	78.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	295.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,177.3	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,886.1	N/A	0.00	N/A
55-64 years	*****	N/A	*****	8.42	*****	N/A	12.69	N/A
65-74 years	*****	N/A	*****	23.24	*****	N/A	28.11	N/A
75-84 years	*****	N/A	*****	27.73	*****	N/A	31.16	N/A
≥ 85 years	*****	N/A	0	0.00	*****	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	47.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	781.2	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,152.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.58	*****	N/A	2.14	N/A
55-64 years	*****	N/A	*****	1.83	*****	N/A	1.40	N/A
65-74 years	*****	N/A	20	9.58	30,135.4	N/A	6.64	N/A
75-84 years	*****	N/A	18	8.21	27,390.5	N/A	6.57	N/A
≥ 85 years	*****	N/A	12	7.45	12,271.9	N/A	9.78	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	397.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,376.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	19.96	*****	N/A	13.84	N/A
55-64 years	*****	N/A	*****	9.10	*****	N/A	8.65	N/A
65-74 years	*****	N/A	31	18.23	18,302.9	N/A	16.94	N/A
75-84 years	*****	N/A	28	20.69	11,180.9	N/A	25.04	N/A
≥ 85 years	*****	N/A	11	18.68	2,820.8	N/A	39.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	84.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	254.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	249.6	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	507.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	350.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	129.6	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	63.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	63.69	*****	N/A	49.17	N/A
55-64 years	*****	N/A	*****	48.54	*****	N/A	55.49	N/A
65-74 years	*****	N/A	*****	23.20	*****	N/A	27.22	N/A
75-84 years	*****	N/A	0	0.00	152.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	28.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	15.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	112.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	176.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	10.81	*****	N/A	8.31	N/A
75-84 years	*****	N/A	0	0.00	1,337.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	604.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	32.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	186.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	241.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	959.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	10.56	*****	N/A	10.70	N/A
≥ 85 years	*****	N/A	0	0.00	327.1	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	42.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	14.75	*****	N/A	9.80	N/A
35-44 years	*****	N/A	*****	4.93	*****	N/A	3.36	N/A
45-54 years	*****	N/A	*****	6.46	*****	N/A	4.23	N/A
55-64 years	*****	N/A	*****	2.24	*****	N/A	1.76	N/A
65-74 years	*****	N/A	11	6.57	21,510.6	N/A	5.11	N/A
75-84 years	*****	N/A	*****	7.83	*****	N/A	6.45	N/A
≥ 85 years	*****	N/A	*****	5.71	*****	N/A	7.28	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	23.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,294.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.51	*****	N/A	9.96	N/A
55-64 years	*****	N/A	*****	8.60	*****	N/A	9.31	N/A
65-74 years	*****	N/A	14	13.33	9,686.7	N/A	14.45	N/A
75-84 years	*****	N/A	11	19.56	4,271.9	N/A	25.75	N/A
≥ 85 years	*****	N/A	0	0.00	926.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	5.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	33.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	94.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	49.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	19.4	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	10.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.2	N/A	0.00	N/A
65-74 years	*****	N/A	*****	58.82	*****	N/A	63.70	N/A
75-84 years	*****	N/A	0	0.00	72.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	294.12	*****	N/A	776.96	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	88.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,454.4	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.38	*****	N/A	2.22	N/A
45-54 years	*****	N/A	*****	2.14	*****	N/A	1.94	N/A
55-64 years	*****	N/A	*****	1.41	*****	N/A	1.77	N/A
65-74 years	*****	N/A	*****	2.64	*****	N/A	2.65	N/A
75-84 years	*****	N/A	*****	7.71	*****	N/A	7.88	N/A
≥ 85 years	*****	N/A	*****	11.65	*****	N/A	19.52	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	110.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	761.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,947.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	4.72	*****	N/A	5.49	N/A
55-64 years	*****	N/A	*****	5.76	*****	N/A	9.14	N/A
65-74 years	*****	N/A	25	19.24	9,334.3	N/A	26.78	N/A
75-84 years	*****	N/A	19	23.32	5,373.7	N/A	35.36	N/A
≥ 85 years	*****	N/A	*****	7.48	*****	N/A	18.21	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	48.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,081.4	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.64	*****	N/A	1.50	N/A
45-54 years	*****	N/A	*****	2.82	*****	N/A	1.75	N/A
55-64 years	*****	N/A	11	4.63	30,109.4	N/A	3.65	N/A
65-74 years	*****	N/A	69	8.47	112,143.0	N/A	6.15	N/A
75-84 years	*****	N/A	69	8.16	93,267.7	N/A	7.40	N/A
≥ 85 years	*****	N/A	36	4.99	45,045.8	N/A	7.99	N/A
White, Male								
0-19 years	13	N/A	0	0.00	20.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,181.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	4,770.7	N/A	0.00	N/A
45-54 years	*****	N/A	15	14.09	14,466.3	N/A	10.37	N/A
55-64 years	*****	N/A	23	9.21	24,241.0	N/A	9.49	N/A
65-74 years	*****	N/A	137	19.16	69,087.6	N/A	19.83	N/A
75-84 years	*****	N/A	114	20.15	37,790.1	N/A	30.17	N/A
≥ 85 years	*****	N/A	39	13.88	9,898.4	N/A	39.40	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	540.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,440.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.05	*****	N/A	3.56	N/A
55-64 years	*****	N/A	*****	3.94	*****	N/A	2.49	N/A
65-74 years	*****	N/A	*****	4.10	*****	N/A	2.55	N/A
75-84 years	*****	N/A	*****	4.98	*****	N/A	3.36	N/A
≥ 85 years	*****	N/A	*****	9.33	*****	N/A	10.76	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	322.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	902.6	N/A	0.00	N/A
45-54 years	*****	N/A	*****	8.01	*****	N/A	4.40	N/A
55-64 years	*****	N/A	*****	20.01	*****	N/A	14.01	N/A
65-74 years	*****	N/A	*****	12.25	*****	N/A	8.96	N/A
75-84 years	*****	N/A	*****	13.91	*****	N/A	11.27	N/A
≥ 85 years	*****	N/A	*****	27.32	*****	N/A	36.59	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	42.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	489.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,068.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,795.0	N/A	0.00	N/A
55-64 years	*****	N/A	*****	10.78	*****	N/A	6.97	N/A
65-74 years	*****	N/A	*****	4.23	*****	N/A	2.39	N/A
75-84 years	*****	N/A	16	9.11	29,183.7	N/A	5.48	N/A
≥ 85 years	*****	N/A	*****	2.70	*****	N/A	2.56	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	104.4	N/A	0.00	N/A
20-34 years	*****	N/A	*****	38.02	*****	N/A	23.47	N/A
35-44 years	*****	N/A	*****	16.16	*****	N/A	10.71	N/A
45-54 years	*****	N/A	0	0.00	2,081.7	N/A	0.00	N/A
55-64 years	*****	N/A	*****	7.70	*****	N/A	5.86	N/A
65-74 years	*****	N/A	14	13.71	15,049.8	N/A	9.30	N/A
75-84 years	*****	N/A	26	22.08	16,251.4	N/A	16.00	N/A
≥ 85 years	*****	N/A	17	21.43	7,108.4	N/A	23.92	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1,818.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.09	*****	N/A	0.87	N/A
35-44 years	*****	N/A	*****	3.79	*****	N/A	1.97	N/A
45-54 years	*****	N/A	*****	1.98	*****	N/A	1.05	N/A
55-64 years	*****	N/A	33	5.67	89,139.3	N/A	3.70	N/A
65-74 years	*****	N/A	75	6.75	171,903.9	N/A	4.36	N/A
75-84 years	*****	N/A	93	10.79	129,428.5	N/A	7.19	N/A
≥ 85 years	*****	N/A	36	6.38	56,100.9	N/A	6.42	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	906.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.90	*****	N/A	1.46	N/A
35-44 years	*****	N/A	*****	2.11	*****	N/A	1.20	N/A
45-54 years	*****	N/A	11	4.78	38,248.0	N/A	2.88	N/A
55-64 years	*****	N/A	33	8.64	48,947.3	N/A	6.74	N/A
65-74 years	*****	N/A	83	13.72	72,330.9	N/A	11.48	N/A
75-84 years	*****	N/A	68	19.35	37,616.5	N/A	18.08	N/A
≥ 85 years	*****	N/A	22	16.46	9,204.3	N/A	23.90	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	35.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	126.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	317.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,495.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,046.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	175.2	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	31.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	222.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	52.22	*****	N/A	35.52	N/A
65-74 years	*****	N/A	*****	53.44	*****	N/A	37.39	N/A
75-84 years	*****	N/A	*****	27.75	*****	N/A	30.09	N/A
≥ 85 years	*****	N/A	0	0.00	117.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	*****	2.19	*****	N/A	1.38	N/A
20-34 years	*****	N/A	*****	0.26	*****	N/A	0.24	N/A
35-44 years	*****	N/A	*****	0.83	*****	N/A	0.71	N/A
45-54 years	*****	N/A	22	1.82	146,116.2	N/A	1.51	N/A
55-64 years	*****	N/A	25	1.79	126,983.2	N/A	1.97	N/A
65-74 years	*****	N/A	57	6.04	122,885.4	N/A	4.64	N/A
75-84 years	*****	N/A	69	8.28	114,434.9	N/A	6.03	N/A
≥ 85 years	*****	N/A	43	6.47	55,804.7	N/A	7.71	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	7,750.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.42	*****	N/A	2.45	N/A
35-44 years	*****	N/A	*****	0.29	*****	N/A	0.27	N/A
45-54 years	*****	N/A	29	3.39	92,748.7	N/A	3.13	N/A
55-64 years	*****	N/A	108	7.99	111,169.2	N/A	9.71	N/A
65-74 years	*****	N/A	200	22.21	94,198.6	N/A	21.23	N/A
75-84 years	*****	N/A	143	26.22	58,051.7	N/A	24.63	N/A
≥ 85 years	*****	N/A	57	20.53	17,896.2	N/A	31.85	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	2,867.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.05	*****	N/A	1.39	N/A
35-44 years	*****	N/A	17	3.51	99,397.8	N/A	1.71	N/A
45-54 years	*****	N/A	70	6.86	198,147.7	N/A	3.53	N/A
55-64 years	*****	N/A	116	6.41	277,380.5	N/A	4.18	N/A
65-74 years	*****	N/A	542	8.89	1,007,636.0	N/A	5.38	N/A
75-84 years	*****	N/A	588	9.72	869,400.8	N/A	6.76	N/A
≥ 85 years	*****	N/A	279	5.35	432,213.0	N/A	6.46	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	1,955.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	7.50	*****	N/A	3.63	N/A
35-44 years	*****	N/A	21	7.55	54,487.8	N/A	3.85	N/A
45-54 years	*****	N/A	86	10.68	143,466.9	N/A	5.99	N/A
55-64 years	*****	N/A	230	14.62	208,391.1	N/A	11.04	N/A
65-74 years	*****	N/A	1,241	28.01	595,059.1	N/A	20.86	N/A
75-84 years	*****	N/A	968	29.41	347,765.0	N/A	27.83	N/A
≥ 85 years	*****	N/A	278	17.58	90,785.6	N/A	30.62	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	841.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,397.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.72	*****	N/A	5.32	N/A
55-64 years	*****	N/A	*****	4.61	*****	N/A	2.48	N/A
65-74 years	*****	N/A	*****	7.01	*****	N/A	3.81	N/A
75-84 years	*****	N/A	*****	6.00	*****	N/A	3.68	N/A
≥ 85 years	*****	N/A	*****	11.35	*****	N/A	11.66	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	5.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	595.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,847.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	4.49	*****	N/A	2.26	N/A
55-64 years	*****	N/A	*****	14.41	*****	N/A	8.81	N/A
65-74 years	*****	N/A	12	20.52	9,097.0	N/A	13.19	N/A
75-84 years	*****	N/A	*****	22.95	*****	N/A	18.09	N/A
≥ 85 years	*****	N/A	*****	25.64	*****	N/A	34.78	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	67.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	710.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,642.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	3,100.7	N/A	0.00	N/A
55-64 years	*****	N/A	*****	9.24	*****	N/A	5.61	N/A
65-74 years	*****	N/A	*****	4.94	*****	N/A	2.61	N/A
75-84 years	*****	N/A	24	9.71	43,965.7	N/A	5.46	N/A
≥ 85 years	*****	N/A	13	6.41	22,621.8	N/A	5.75	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	23.87	*****	N/A	13.80	N/A
35-44 years	*****	N/A	*****	9.40	*****	N/A	5.76	N/A
45-54 years	*****	N/A	0	0.00	4,007.8	N/A	0.00	N/A
55-64 years	*****	N/A	*****	6.52	*****	N/A	4.44	N/A
65-74 years	*****	N/A	30	18.25	25,886.5	N/A	11.59	N/A
75-84 years	*****	N/A	43	25.47	24,528.8	N/A	17.53	N/A
≥ 85 years	*****	N/A	26	23.43	10,219.9	N/A	25.44	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	2,138.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.32	*****	N/A	0.97	N/A
35-44 years	*****	N/A	13	4.42	61,052.5	N/A	2.13	N/A
45-54 years	*****	N/A	21	3.16	136,602.8	N/A	1.54	N/A
55-64 years	*****	N/A	76	6.54	201,893.0	N/A	3.76	N/A
65-74 years	*****	N/A	156	7.18	382,543.6	N/A	4.08	N/A
75-84 years	*****	N/A	165	10.73	264,189.2	N/A	6.25	N/A
≥ 85 years	*****	N/A	83	8.31	113,730.2	N/A	7.30	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	1,269.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.72	*****	N/A	0.80	N/A
35-44 years	*****	N/A	*****	4.46	*****	N/A	2.23	N/A
45-54 years	*****	N/A	33	7.29	84,486.7	N/A	3.91	N/A
55-64 years	*****	N/A	80	10.81	108,293.5	N/A	7.39	N/A
65-74 years	*****	N/A	202	17.37	157,476.4	N/A	12.83	N/A
75-84 years	*****	N/A	148	24.31	71,970.2	N/A	20.56	N/A
≥ 85 years	*****	N/A	38	16.42	17,558.9	N/A	21.64	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	40.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	57.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	244.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	703.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	2,435.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,456.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	275.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	17.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	86.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	419.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	37.59	*****	N/A	27.96	N/A
65-74 years	*****	N/A	*****	31.45	*****	N/A	23.63	N/A
75-84 years	*****	N/A	*****	19.23	*****	N/A	21.44	N/A
≥ 85 years	*****	N/A	0	0.00	177.6	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	*****	1.61	*****	N/A	0.98	N/A
20-34 years	*****	N/A	*****	0.44	*****	N/A	0.40	N/A
35-44 years	*****	N/A	*****	0.72	*****	N/A	0.62	N/A
45-54 years	*****	N/A	40	2.18	219,720.7	N/A	1.82	N/A
55-64 years	*****	N/A	45	1.95	210,654.0	N/A	2.14	N/A
65-74 years	*****	N/A	121	7.24	216,120.6	N/A	5.60	N/A
75-84 years	*****	N/A	120	8.27	192,726.5	N/A	6.23	N/A
≥ 85 years	*****	N/A	80	6.89	94,296.5	N/A	8.48	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	11,136.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.41	*****	N/A	2.38	N/A
35-44 years	*****	N/A	*****	0.80	*****	N/A	0.73	N/A
45-54 years	*****	N/A	48	3.66	143,759.3	N/A	3.34	N/A
55-64 years	*****	N/A	179	8.20	181,148.0	N/A	9.88	N/A
65-74 years	*****	N/A	324	20.57	164,967.6	N/A	19.64	N/A
75-84 years	*****	N/A	278	29.37	94,808.9	N/A	29.32	N/A
≥ 85 years	*****	N/A	96	19.26	29,838.5	N/A	32.17	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	3,667.8	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.14	*****	N/A	1.36	N/A
35-44 years	*****	N/A	34	4.72	161,033.5	N/A	2.11	N/A
45-54 years	*****	N/A	134	7.51	383,382.4	N/A	3.50	N/A
55-64 years	*****	N/A	274	8.08	589,126.5	N/A	4.65	N/A
65-74 years	*****	N/A	1,120	10.15	2,008,484.5	N/A	5.58	N/A
75-84 years	*****	N/A	1,225	11.77	1,618,445.6	N/A	7.57	N/A
≥ 85 years	*****	N/A	647	6.58	854,187.7	N/A	7.57	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	2,927.4	N/A	0.00	N/A
20-34 years	*****	N/A	*****	6.73	*****	N/A	2.93	N/A
35-44 years	*****	N/A	36	7.98	98,920.8	N/A	3.64	N/A
45-54 years	*****	N/A	188	12.98	289,828.1	N/A	6.49	N/A
55-64 years	*****	N/A	486	16.57	438,058.6	N/A	11.09	N/A
65-74 years	*****	N/A	2,501	30.96	1,176,639.7	N/A	21.26	N/A
75-84 years	*****	N/A	1,889	33.34	620,487.5	N/A	30.44	N/A
≥ 85 years	*****	N/A	604	19.70	172,618.7	N/A	34.99	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	13.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	25.6	N/A	0.00	N/A
45-54 years	*****	N/A	*****	232.56	*****	N/A	111.83	N/A
55-64 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	124.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	96.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	25.9	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	0.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	31.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	56.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	92.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	33.6	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.5	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	30.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	71.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	471.1	N/A	0.00	N/A
75-84 years	*****	N/A	*****	26.18	*****	N/A	18.53	N/A
≥ 85 years	*****	N/A	*****	29.24	*****	N/A	44.30	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	18.8	N/A	0.00	N/A
35-44 years	*****	N/A	*****	322.58	*****	N/A	177.86	N/A
45-54 years	*****	N/A	0	0.00	37.2	N/A	0.00	N/A
55-64 years	*****	N/A	*****	98.04	*****	N/A	72.39	N/A
65-74 years	*****	N/A	*****	37.74	*****	N/A	32.47	N/A
75-84 years	*****	N/A	0	0.00	327.8	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	48.08	*****	N/A	78.26	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	501.3	N/A	0.00	N/A
35-44 years	*****	N/A	*****	16.56	*****	N/A	10.29	N/A
45-54 years	*****	N/A	*****	15.97	*****	N/A	10.22	N/A
55-64 years	*****	N/A	*****	8.89	*****	N/A	6.26	N/A
65-74 years	*****	N/A	13	31.12	5,751.1	N/A	22.60	N/A
75-84 years	*****	N/A	12	39.63	4,096.2	N/A	29.30	N/A
≥ 85 years	*****	N/A	*****	11.30	*****	N/A	13.30	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	248.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	708.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	10.79	*****	N/A	8.38	N/A
55-64 years	*****	N/A	*****	26.16	*****	N/A	25.48	N/A
65-74 years	*****	N/A	*****	28.33	*****	N/A	30.30	N/A
75-84 years	*****	N/A	*****	36.82	*****	N/A	42.86	N/A
≥ 85 years	*****	N/A	*****	20.45	*****	N/A	30.69	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	11.6	N/A	0.00	N/A
55-64 years	*****	N/A	*****	909.09	*****	N/A	416.90	N/A
65-74 years	*****	N/A	0	0.00	56.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	18.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.0	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	3.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	13.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	45.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	101.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,205.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,574.2	N/A	0.00	N/A
45-54 years	*****	N/A	*****	5.24	*****	N/A	4.14	N/A
55-64 years	*****	N/A	*****	8.28	*****	N/A	9.03	N/A
65-74 years	*****	N/A	*****	21.64	*****	N/A	18.75	N/A
75-84 years	*****	N/A	*****	32.27	*****	N/A	26.55	N/A
≥ 85 years	*****	N/A	*****	14.60	*****	N/A	18.98	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	139.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	406.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,292.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.02	*****	N/A	10.98	N/A
55-64 years	*****	N/A	*****	6.69	*****	N/A	8.96	N/A
65-74 years	*****	N/A	*****	18.60	*****	N/A	19.67	N/A
75-84 years	*****	N/A	*****	22.04	*****	N/A	25.10	N/A
≥ 85 years	*****	N/A	*****	11.22	*****	N/A	22.49	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	91.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	903.3	N/A	0.00	N/A
35-44 years	*****	N/A	*****	7.20	*****	N/A	3.96	N/A
45-54 years	*****	N/A	*****	9.05	*****	N/A	5.42	N/A
55-64 years	*****	N/A	16	25.27	8,819.1	N/A	18.14	N/A
65-74 years	*****	N/A	65	30.48	33,063.4	N/A	19.66	N/A
75-84 years	*****	N/A	69	32.62	28,008.6	N/A	24.64	N/A
≥ 85 years	*****	N/A	35	21.99	12,533.1	N/A	27.93	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	436.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	10.15	*****	N/A	6.31	N/A
45-54 years	*****	N/A	*****	20.88	*****	N/A	13.89	N/A
55-64 years	*****	N/A	15	25.06	6,842.1	N/A	21.92	N/A
65-74 years	*****	N/A	41	24.70	19,305.0	N/A	21.24	N/A
75-84 years	*****	N/A	31	25.43	11,210.4	N/A	27.65	N/A
≥ 85 years	*****	N/A	*****	18.90	*****	N/A	38.94	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bumetanide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	92.2	N/A	0.00	N/A
45-54 years	*****	N/A	*****	66.23	*****	N/A	40.14	N/A
55-64 years	*****	N/A	*****	74.91	*****	N/A	69.26	N/A
65-74 years	*****	N/A	*****	20.41	*****	N/A	20.00	N/A
75-84 years	*****	N/A	0	0.00	307.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	81.3	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	*****	476.19	*****	N/A	524.78	N/A
35-44 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	67.11	*****	N/A	53.21	N/A
55-64 years	*****	N/A	*****	48.54	*****	N/A	48.79	N/A
65-74 years	*****	N/A	0	0.00	252.7	N/A	0.00	N/A
75-84 years	*****	N/A	*****	52.08	*****	N/A	100.01	N/A
≥ 85 years	*****	N/A	0	0.00	38.4	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	6.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	66.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	118.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	227.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	20.04	*****	N/A	15.03	N/A
75-84 years	*****	N/A	*****	29.76	*****	N/A	27.57	N/A
≥ 85 years	*****	N/A	*****	8.84	*****	N/A	15.52	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	46.7	N/A	0.00	N/A
35-44 years	*****	N/A	*****	106.38	*****	N/A	80.20	N/A
45-54 years	*****	N/A	0	0.00	225.6	N/A	0.00	N/A
55-64 years	*****	N/A	*****	25.58	*****	N/A	27.46	N/A
65-74 years	*****	N/A	*****	29.59	*****	N/A	27.32	N/A
75-84 years	*****	N/A	*****	18.15	*****	N/A	20.68	N/A
≥ 85 years	*****	N/A	*****	54.79	*****	N/A	97.83	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	25.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	24.69	*****	N/A	15.82	N/A
35-44 years	*****	N/A	*****	9.12	*****	N/A	5.66	N/A
45-54 years	*****	N/A	*****	20.11	*****	N/A	13.03	N/A
55-64 years	*****	N/A	18	18.58	12,718.5	N/A	14.15	N/A
65-74 years	*****	N/A	45	26.51	22,981.1	N/A	19.58	N/A
75-84 years	*****	N/A	44	35.14	14,805.4	N/A	29.72	N/A
≥ 85 years	*****	N/A	18	23.94	5,684.4	N/A	31.67	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	18.08	*****	N/A	13.63	N/A
35-44 years	*****	N/A	0	0.00	2,762.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	15.50	*****	N/A	12.76	N/A
55-64 years	*****	N/A	21	28.90	6,816.6	N/A	30.81	N/A
65-74 years	*****	N/A	28	26.92	9,621.8	N/A	29.10	N/A
75-84 years	*****	N/A	*****	18.48	*****	N/A	24.66	N/A
≥ 85 years	*****	N/A	*****	16.31	*****	N/A	30.29	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	*****	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.0	N/A	0.00	N/A
55-64 years	*****	N/A	*****	303.03	*****	N/A	189.75	N/A
65-74 years	*****	N/A	0	0.00	136.1	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	57.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.3	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	0.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	79.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	158.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	109.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	182.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,044.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	5,135.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	5.06	*****	N/A	4.44	N/A
55-64 years	*****	N/A	14	10.05	11,446.5	N/A	12.23	N/A
65-74 years	*****	N/A	24	21.37	11,487.1	N/A	20.89	N/A
75-84 years	*****	N/A	25	23.69	10,441.6	N/A	23.94	N/A
≥ 85 years	*****	N/A	*****	11.17	*****	N/A	20.01	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	254.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	867.6	N/A	0.00	N/A
35-44 years	*****	N/A	*****	3.21	*****	N/A	3.67	N/A
45-54 years	*****	N/A	*****	12.40	*****	N/A	14.30	N/A
55-64 years	*****	N/A	12	8.24	9,665.0	N/A	12.42	N/A
65-74 years	*****	N/A	22	18.63	9,066.8	N/A	24.26	N/A
75-84 years	*****	N/A	17	22.72	4,885.5	N/A	34.80	N/A
≥ 85 years	*****	N/A	*****	7.83	*****	N/A	20.80	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,454.2	N/A	0.00	N/A
35-44 years	*****	N/A	*****	9.00	*****	N/A	5.08	N/A
45-54 years	*****	N/A	17	13.33	22,010.6	N/A	7.72	N/A
55-64 years	*****	N/A	55	20.17	36,519.3	N/A	15.06	N/A
65-74 years	*****	N/A	256	30.79	119,523.4	N/A	21.42	N/A
75-84 years	*****	N/A	280	33.53	94,279.2	N/A	29.70	N/A
≥ 85 years	*****	N/A	130	17.87	45,486.1	N/A	28.58	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	40.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,325.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	11.35	*****	N/A	7.14	N/A
45-54 years	*****	N/A	25	20.84	17,202.5	N/A	14.53	N/A
55-64 years	*****	N/A	53	19.97	27,321.5	N/A	19.40	N/A
65-74 years	*****	N/A	185	27.29	68,141.9	N/A	27.15	N/A
75-84 years	*****	N/A	116	22.55	35,658.0	N/A	32.53	N/A
≥ 85 years	*****	N/A	23	8.96	9,235.8	N/A	24.90	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	14.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	22.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	53.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	82.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	126.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	95.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	36.1	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	47.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.3	N/A	0.00	N/A
65-74 years	*****	N/A	*****	113.64	*****	N/A	91.23	N/A
75-84 years	*****	N/A	0	0.00	39.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	5.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	7.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	30.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	35.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	77.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	416.2	N/A	0.00	N/A
75-84 years	*****	N/A	*****	25.19	*****	N/A	20.45	N/A
≥ 85 years	*****	N/A	0	0.00	230.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	10.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	56.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	365.2	N/A	0.00	N/A
75-84 years	*****	N/A	*****	63.69	*****	N/A	53.88	N/A
≥ 85 years	*****	N/A	*****	61.35	*****	N/A	105.24	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	34.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	340.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	17.18	*****	N/A	10.65	N/A
45-54 years	*****	N/A	*****	8.55	*****	N/A	5.41	N/A
55-64 years	*****	N/A	*****	15.08	*****	N/A	11.50	N/A
65-74 years	*****	N/A	14	33.06	5,432.4	N/A	25.77	N/A
75-84 years	*****	N/A	22	66.61	4,274.1	N/A	51.47	N/A
≥ 85 years	*****	N/A	*****	5.86	*****	N/A	6.40	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	252.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	480.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.07	*****	N/A	9.09	N/A
55-64 years	*****	N/A	*****	14.06	*****	N/A	14.90	N/A
65-74 years	*****	N/A	*****	28.29	*****	N/A	28.38	N/A
75-84 years	*****	N/A	*****	27.93	*****	N/A	31.31	N/A
≥ 85 years	*****	N/A	*****	41.75	*****	N/A	83.51	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	3.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	20.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	16.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	24.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	13.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	5.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	47.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	8.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	61.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,960.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	8.64	*****	N/A	7.31	N/A
55-64 years	*****	N/A	*****	4.31	*****	N/A	5.04	N/A
65-74 years	*****	N/A	*****	18.50	*****	N/A	15.84	N/A
75-84 years	*****	N/A	*****	21.16	*****	N/A	17.62	N/A
≥ 85 years	*****	N/A	*****	5.13	*****	N/A	7.40	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	78.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	295.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,177.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	13.80	*****	N/A	13.86	N/A
55-64 years	*****	N/A	*****	4.21	*****	N/A	6.34	N/A
65-74 years	*****	N/A	*****	11.62	*****	N/A	14.05	N/A
75-84 years	*****	N/A	*****	9.24	*****	N/A	10.39	N/A
≥ 85 years	*****	N/A	*****	20.53	*****	N/A	34.90	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	47.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	781.2	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,152.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.58	*****	N/A	2.14	N/A
55-64 years	*****	N/A	*****	9.17	*****	N/A	7.02	N/A
65-74 years	*****	N/A	49	23.47	30,135.4	N/A	16.26	N/A
75-84 years	*****	N/A	72	32.85	27,390.5	N/A	26.29	N/A
≥ 85 years	*****	N/A	27	16.76	12,271.9	N/A	22.00	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	397.0	N/A	0.00	N/A
35-44 years	*****	N/A	*****	11.39	*****	N/A	7.26	N/A
45-54 years	*****	N/A	*****	19.96	*****	N/A	13.84	N/A
55-64 years	*****	N/A	15	27.31	5,783.4	N/A	25.94	N/A
65-74 years	*****	N/A	26	15.29	18,302.9	N/A	14.21	N/A
75-84 years	*****	N/A	31	22.91	11,180.9	N/A	27.73	N/A
≥ 85 years	*****	N/A	11	18.68	2,820.8	N/A	39.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	84.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	254.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	249.6	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	507.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	48.78	*****	N/A	57.05	N/A
≥ 85 years	*****	N/A	0	0.00	129.6	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	63.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	63.69	*****	N/A	49.17	N/A
55-64 years	*****	N/A	0	0.00	180.2	N/A	0.00	N/A
65-74 years	*****	N/A	*****	23.20	*****	N/A	27.22	N/A
75-84 years	*****	N/A	*****	35.21	*****	N/A	65.74	N/A
≥ 85 years	*****	N/A	0	0.00	28.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	15.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	112.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	176.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	10.81	*****	N/A	8.31	N/A
75-84 years	*****	N/A	*****	17.04	*****	N/A	14.96	N/A
≥ 85 years	*****	N/A	*****	11.75	*****	N/A	16.56	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	32.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	51.02	*****	N/A	53.77	N/A
55-64 years	*****	N/A	0	0.00	241.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	959.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	31.68	*****	N/A	32.11	N/A
≥ 85 years	*****	N/A	*****	17.86	*****	N/A	30.57	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	42.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,020.0	N/A	0.00	N/A
35-44 years	*****	N/A	*****	4.93	*****	N/A	3.36	N/A
45-54 years	*****	N/A	*****	10.76	*****	N/A	7.05	N/A
55-64 years	*****	N/A	15	16.83	11,339.7	N/A	13.23	N/A
65-74 years	*****	N/A	47	28.05	21,510.6	N/A	21.85	N/A
75-84 years	*****	N/A	53	41.51	15,492.6	N/A	34.21	N/A
≥ 85 years	*****	N/A	22	31.39	5,493.5	N/A	40.05	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	23.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	17.57	*****	N/A	12.62	N/A
35-44 years	*****	N/A	*****	11.20	*****	N/A	8.72	N/A
45-54 years	*****	N/A	*****	13.82	*****	N/A	11.95	N/A
55-64 years	*****	N/A	16	22.93	6,446.5	N/A	24.82	N/A
65-74 years	*****	N/A	30	28.56	9,686.7	N/A	30.97	N/A
75-84 years	*****	N/A	20	35.56	4,271.9	N/A	46.82	N/A
≥ 85 years	*****	N/A	*****	16.20	*****	N/A	32.37	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	5.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	33.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	94.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	49.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	19.4	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	10.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	157.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	72.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	12.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	88.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,454.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	4,500.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	6.42	*****	N/A	5.83	N/A
55-64 years	*****	N/A	*****	5.64	*****	N/A	7.10	N/A
65-74 years	*****	N/A	19	16.74	11,317.3	N/A	16.79	N/A
75-84 years	*****	N/A	14	13.49	10,152.7	N/A	13.79	N/A
≥ 85 years	*****	N/A	*****	11.65	*****	N/A	19.52	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	110.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	761.8	N/A	0.00	N/A
35-44 years	*****	N/A	*****	3.07	*****	N/A	3.39	N/A
45-54 years	*****	N/A	*****	8.25	*****	N/A	9.60	N/A
55-64 years	*****	N/A	*****	5.76	*****	N/A	9.14	N/A
65-74 years	*****	N/A	19	14.62	9,334.3	N/A	20.35	N/A
75-84 years	*****	N/A	*****	8.59	*****	N/A	13.03	N/A
≥ 85 years	*****	N/A	*****	19.94	*****	N/A	48.56	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	48.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,081.4	N/A	0.00	N/A
35-44 years	*****	N/A	*****	5.28	*****	N/A	3.00	N/A
45-54 years	*****	N/A	12	11.28	17,123.3	N/A	7.01	N/A
55-64 years	*****	N/A	42	17.68	30,109.4	N/A	13.95	N/A
65-74 years	*****	N/A	217	26.64	112,143.0	N/A	19.35	N/A
75-84 years	*****	N/A	253	29.92	93,267.7	N/A	27.13	N/A
≥ 85 years	*****	N/A	120	16.62	45,045.8	N/A	26.64	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	20.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	12.17	*****	N/A	8.46	N/A
35-44 years	*****	N/A	*****	6.25	*****	N/A	4.19	N/A
45-54 years	*****	N/A	23	21.61	14,466.3	N/A	15.90	N/A
55-64 years	*****	N/A	52	20.82	24,241.0	N/A	21.45	N/A
65-74 years	*****	N/A	176	24.61	69,087.6	N/A	25.47	N/A
75-84 years	*****	N/A	112	19.79	37,790.1	N/A	29.64	N/A
≥ 85 years	*****	N/A	39	13.88	9,898.4	N/A	39.40	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	540.7	N/A	0.00	N/A
35-44 years	*****	N/A	*****	14.03	*****	N/A	6.94	N/A
45-54 years	*****	N/A	*****	21.14	*****	N/A	10.68	N/A
55-64 years	*****	N/A	*****	27.55	*****	N/A	17.44	N/A
65-74 years	*****	N/A	18	36.86	7,827.9	N/A	22.99	N/A
75-84 years	*****	N/A	17	42.29	5,956.2	N/A	28.54	N/A
≥ 85 years	*****	N/A	*****	9.33	*****	N/A	10.76	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	322.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	902.6	N/A	0.00	N/A
45-54 years	*****	N/A	*****	24.04	*****	N/A	13.20	N/A
55-64 years	*****	N/A	*****	40.02	*****	N/A	28.02	N/A
65-74 years	*****	N/A	*****	24.51	*****	N/A	17.92	N/A
75-84 years	*****	N/A	*****	13.91	*****	N/A	11.27	N/A
≥ 85 years	*****	N/A	0	0.00	*****	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	42.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	489.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,068.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	9.23	*****	N/A	5.57	N/A
55-64 years	*****	N/A	*****	10.78	*****	N/A	6.97	N/A
65-74 years	*****	N/A	28	23.68	20,894.7	N/A	13.40	N/A
75-84 years	*****	N/A	48	27.32	29,183.7	N/A	16.45	N/A
≥ 85 years	*****	N/A	27	18.21	15,627.5	N/A	17.28	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	104.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	426.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	933.5	N/A	0.00	N/A
45-54 years	*****	N/A	*****	21.37	*****	N/A	14.41	N/A
55-64 years	*****	N/A	*****	7.70	*****	N/A	5.86	N/A
65-74 years	*****	N/A	26	25.46	15,049.8	N/A	17.28	N/A
75-84 years	*****	N/A	38	32.27	16,251.4	N/A	23.38	N/A
≥ 85 years	*****	N/A	18	22.69	7,108.4	N/A	25.32	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1,818.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.14	*****	N/A	1.30	N/A
35-44 years	*****	N/A	11	5.95	35,515.6	N/A	3.10	N/A
45-54 years	*****	N/A	59	16.67	66,483.5	N/A	8.87	N/A
55-64 years	*****	N/A	123	21.14	89,139.3	N/A	13.80	N/A
65-74 years	*****	N/A	286	25.75	171,903.9	N/A	16.64	N/A
75-84 years	*****	N/A	327	37.93	129,428.5	N/A	25.26	N/A
≥ 85 years	*****	N/A	124	21.97	56,100.9	N/A	22.10	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	906.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.80	*****	N/A	2.92	N/A
35-44 years	*****	N/A	*****	9.51	*****	N/A	5.39	N/A
45-54 years	*****	N/A	35	15.22	38,248.0	N/A	9.15	N/A
55-64 years	*****	N/A	93	24.36	48,947.3	N/A	19.00	N/A
65-74 years	*****	N/A	197	32.57	72,330.9	N/A	27.24	N/A
75-84 years	*****	N/A	115	32.72	37,616.5	N/A	30.57	N/A
≥ 85 years	*****	N/A	28	20.95	9,204.3	N/A	30.42	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	35.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
45-54 years	*****	N/A	*****	101.01	*****	N/A	79.21	N/A
55-64 years	*****	N/A	0	0.00	317.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	21.10	*****	N/A	13.38	N/A
75-84 years	*****	N/A	*****	11.88	*****	N/A	9.56	N/A
≥ 85 years	*****	N/A	*****	32.57	*****	N/A	57.09	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	31.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	222.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	563.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	22.90	*****	N/A	16.03	N/A
75-84 years	*****	N/A	*****	18.50	*****	N/A	20.06	N/A
≥ 85 years	*****	N/A	0	0.00	117.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	7,272.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.26	*****	N/A	0.24	N/A
35-44 years	*****	N/A	22	3.04	84,712.1	N/A	2.60	N/A
45-54 years	*****	N/A	67	5.55	146,116.2	N/A	4.59	N/A
55-64 years	*****	N/A	97	6.96	126,983.2	N/A	7.64	N/A
65-74 years	*****	N/A	169	17.90	122,885.4	N/A	13.75	N/A
75-84 years	*****	N/A	207	24.84	114,434.9	N/A	18.09	N/A
≥ 85 years	*****	N/A	97	14.60	55,804.7	N/A	17.38	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	7,750.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.81	*****	N/A	0.82	N/A
35-44 years	*****	N/A	20	5.81	37,399.8	N/A	5.35	N/A
45-54 years	*****	N/A	65	7.61	92,748.7	N/A	7.01	N/A
55-64 years	*****	N/A	129	9.54	111,169.2	N/A	11.60	N/A
65-74 years	*****	N/A	192	21.32	94,198.6	N/A	20.38	N/A
75-84 years	*****	N/A	125	22.92	58,051.7	N/A	21.53	N/A
≥ 85 years	*****	N/A	51	18.37	17,896.2	N/A	28.50	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	2,867.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	4.07	*****	N/A	1.85	N/A
35-44 years	*****	N/A	39	8.05	99,397.8	N/A	3.92	N/A
45-54 years	*****	N/A	165	16.17	198,147.7	N/A	8.33	N/A
55-64 years	*****	N/A	343	18.96	277,380.5	N/A	12.37	N/A
65-74 years	*****	N/A	1,750	28.69	1,007,636.0	N/A	17.37	N/A
75-84 years	*****	N/A	2,098	34.68	869,400.8	N/A	24.13	N/A
≥ 85 years	*****	N/A	918	17.59	432,213.0	N/A	21.24	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	1,955.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.50	*****	N/A	1.21	N/A
35-44 years	*****	N/A	24	8.63	54,487.8	N/A	4.40	N/A
45-54 years	*****	N/A	156	19.38	143,466.9	N/A	10.87	N/A
55-64 years	*****	N/A	367	23.32	208,391.1	N/A	17.61	N/A
65-74 years	*****	N/A	1,396	31.51	595,059.1	N/A	23.46	N/A
75-84 years	*****	N/A	1,033	31.38	347,765.0	N/A	29.70	N/A
≥ 85 years	*****	N/A	291	18.40	90,785.6	N/A	32.05	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	841.9	N/A	0.00	N/A
35-44 years	*****	N/A	*****	27.32	*****	N/A	12.51	N/A
45-54 years	*****	N/A	*****	19.54	*****	N/A	8.87	N/A
55-64 years	*****	N/A	*****	23.04	*****	N/A	12.38	N/A
65-74 years	*****	N/A	36	42.05	15,729.2	N/A	22.89	N/A
75-84 years	*****	N/A	34	51.02	10,862.9	N/A	31.30	N/A
≥ 85 years	*****	N/A	*****	25.54	*****	N/A	26.23	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	5.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	595.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	11.92	*****	N/A	5.41	N/A
45-54 years	*****	N/A	*****	13.47	*****	N/A	6.78	N/A
55-64 years	*****	N/A	*****	28.83	*****	N/A	17.63	N/A
65-74 years	*****	N/A	21	35.91	9,097.0	N/A	23.08	N/A
75-84 years	*****	N/A	*****	28.69	*****	N/A	22.61	N/A
≥ 85 years	*****	N/A	0	0.00	862.5	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	67.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	710.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,642.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	5.69	*****	N/A	3.23	N/A
55-64 years	*****	N/A	*****	18.48	*****	N/A	11.22	N/A
65-74 years	*****	N/A	49	26.87	34,480.4	N/A	14.21	N/A
75-84 years	*****	N/A	85	34.40	43,965.7	N/A	19.33	N/A
≥ 85 years	*****	N/A	41	20.22	22,621.8	N/A	18.12	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	724.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,736.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	24.43	*****	N/A	14.97	N/A
55-64 years	*****	N/A	*****	19.57	*****	N/A	13.32	N/A
65-74 years	*****	N/A	46	27.98	25,886.5	N/A	17.77	N/A
75-84 years	*****	N/A	71	42.06	24,528.8	N/A	28.95	N/A
≥ 85 years	*****	N/A	28	25.23	10,219.9	N/A	27.40	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	2,138.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	6.18	*****	N/A	2.60	N/A
35-44 years	*****	N/A	19	6.45	61,052.5	N/A	3.11	N/A
45-54 years	*****	N/A	126	18.93	136,602.8	N/A	9.22	N/A
55-64 years	*****	N/A	287	24.68	201,893.0	N/A	14.22	N/A
65-74 years	*****	N/A	736	33.87	382,543.6	N/A	19.24	N/A
75-84 years	*****	N/A	708	46.05	264,189.2	N/A	26.80	N/A
≥ 85 years	*****	N/A	326	32.64	113,730.2	N/A	28.66	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	1,269.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	8.61	*****	N/A	4.00	N/A
35-44 years	*****	N/A	24	13.39	35,896.7	N/A	6.69	N/A
45-54 years	*****	N/A	103	22.76	84,486.7	N/A	12.19	N/A
55-64 years	*****	N/A	229	30.94	108,293.5	N/A	21.15	N/A
65-74 years	*****	N/A	464	39.90	157,476.4	N/A	29.46	N/A
75-84 years	*****	N/A	261	42.88	71,970.2	N/A	36.27	N/A
≥ 85 years	*****	N/A	61	26.36	17,558.9	N/A	34.74	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	40.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	57.5	N/A	0.00	N/A
45-54 years	*****	N/A	*****	55.56	*****	N/A	40.83	N/A
55-64 years	*****	N/A	*****	21.23	*****	N/A	14.22	N/A
65-74 years	*****	N/A	*****	19.13	*****	N/A	12.32	N/A
75-84 years	*****	N/A	*****	25.30	*****	N/A	20.60	N/A
≥ 85 years	*****	N/A	*****	22.52	*****	N/A	36.28	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	17.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	86.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	419.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	25.06	*****	N/A	18.64	N/A
65-74 years	*****	N/A	*****	22.46	*****	N/A	16.88	N/A
75-84 years	*****	N/A	*****	32.05	*****	N/A	35.74	N/A
≥ 85 years	*****	N/A	*****	30.03	*****	N/A	56.30	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	10,216.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.65	*****	N/A	0.60	N/A
35-44 years	*****	N/A	31	3.18	113,130.1	N/A	2.74	N/A
45-54 years	*****	N/A	107	5.83	219,720.7	N/A	4.87	N/A
55-64 years	*****	N/A	200	8.66	210,654.0	N/A	9.49	N/A
65-74 years	*****	N/A	317	18.96	216,120.6	N/A	14.67	N/A
75-84 years	*****	N/A	390	26.86	192,726.5	N/A	20.24	N/A
≥ 85 years	*****	N/A	220	18.95	94,296.5	N/A	23.33	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	11,136.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.60	*****	N/A	0.60	N/A
35-44 years	*****	N/A	29	5.82	54,482.0	N/A	5.32	N/A
45-54 years	*****	N/A	126	9.61	143,759.3	N/A	8.76	N/A
55-64 years	*****	N/A	259	11.87	181,148.0	N/A	14.30	N/A
65-74 years	*****	N/A	350	22.22	164,967.6	N/A	21.22	N/A
75-84 years	*****	N/A	269	28.42	94,808.9	N/A	28.37	N/A
≥ 85 years	*****	N/A	94	18.86	29,838.5	N/A	31.50	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	3,667.8	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.93	*****	N/A	1.70	N/A
35-44 years	*****	N/A	69	9.58	161,033.5	N/A	4.28	N/A
45-54 years	*****	N/A	331	18.56	383,382.4	N/A	8.63	N/A
55-64 years	*****	N/A	782	23.06	589,126.5	N/A	13.27	N/A
65-74 years	*****	N/A	3,863	35.02	2,008,484.5	N/A	19.23	N/A
75-84 years	*****	N/A	4,446	42.72	1,618,445.6	N/A	27.47	N/A
≥ 85 years	*****	N/A	2,347	23.86	854,187.7	N/A	27.48	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	2,927.4	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.89	*****	N/A	2.56	N/A
35-44 years	*****	N/A	62	13.75	98,920.8	N/A	6.27	N/A
45-54 years	*****	N/A	335	23.12	289,828.1	N/A	11.56	N/A
55-64 years	*****	N/A	856	29.19	438,058.6	N/A	19.54	N/A
65-74 years	*****	N/A	3,066	37.96	1,176,639.7	N/A	26.06	N/A
75-84 years	*****	N/A	2,167	38.25	620,487.5	N/A	34.92	N/A
≥ 85 years	*****	N/A	658	21.46	172,618.7	N/A	38.12	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	13.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	25.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	89.4	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	124.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	96.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	25.9	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	0.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	31.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	56.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	92.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	33.6	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.5	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	333.33	*****	N/A	326.06	N/A
55-64 years	*****	N/A	0	0.00	71.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	471.1	N/A	0.00	N/A
75-84 years	*****	N/A	*****	26.18	*****	N/A	18.53	N/A
≥ 85 years	*****	N/A	0	0.00	225.7	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	18.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	37.2	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	138.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	307.9	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	327.8	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	127.8	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	501.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	971.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.99	*****	N/A	5.11	N/A
55-64 years	*****	N/A	*****	4.44	*****	N/A	3.13	N/A
65-74 years	*****	N/A	*****	14.36	*****	N/A	10.43	N/A
75-84 years	*****	N/A	*****	6.61	*****	N/A	4.88	N/A
≥ 85 years	*****	N/A	0	0.00	1,503.7	N/A	0.00	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	248.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	708.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	21.57	*****	N/A	16.76	N/A
55-64 years	*****	N/A	*****	13.08	*****	N/A	12.74	N/A
65-74 years	*****	N/A	*****	4.05	*****	N/A	4.33	N/A
75-84 years	*****	N/A	*****	22.09	*****	N/A	25.72	N/A
≥ 85 years	*****	N/A	0	0.00	325.9	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	11.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	24.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	18.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.0	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	3.8	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	13.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	56.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	45.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	101.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,205.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,574.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	4,835.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	2.07	*****	N/A	2.26	N/A
65-74 years	*****	N/A	0	0.00	3,733.7	N/A	0.00	N/A
75-84 years	*****	N/A	*****	3.59	*****	N/A	2.95	N/A
≥ 85 years	*****	N/A	0	0.00	1,581.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	139.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	406.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,292.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.02	*****	N/A	10.98	N/A
55-64 years	*****	N/A	*****	11.15	*****	N/A	14.93	N/A
65-74 years	*****	N/A	*****	3.10	*****	N/A	3.28	N/A
75-84 years	*****	N/A	*****	5.51	*****	N/A	6.28	N/A
≥ 85 years	*****	N/A	0	0.00	444.6	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	91.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	903.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,522.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	6.03	*****	N/A	3.61	N/A
55-64 years	*****	N/A	*****	4.74	*****	N/A	3.40	N/A
65-74 years	*****	N/A	*****	4.22	*****	N/A	2.72	N/A
75-84 years	*****	N/A	*****	3.31	*****	N/A	2.50	N/A
≥ 85 years	*****	N/A	*****	1.89	*****	N/A	2.39	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.6	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	436.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,583.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.48	*****	N/A	2.31	N/A
55-64 years	*****	N/A	*****	10.03	*****	N/A	8.77	N/A
65-74 years	*****	N/A	21	12.65	19,305.0	N/A	10.88	N/A
75-84 years	*****	N/A	13	10.66	11,210.4	N/A	11.60	N/A
≥ 85 years	*****	N/A	*****	5.67	*****	N/A	11.68	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Bumetanide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	92.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	249.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	288.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	499.9	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	307.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	81.3	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	19.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	187.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	205.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	252.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	100.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	38.4	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	6.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	50.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	66.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	86.96	*****	N/A	84.09	N/A
55-64 years	*****	N/A	0	0.00	227.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,330.3	N/A	0.00	N/A
75-84 years	*****	N/A	*****	7.44	*****	N/A	6.89	N/A
≥ 85 years	*****	N/A	0	0.00	644.4	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	46.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	124.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	225.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	364.1	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,098.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	966.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	408.9	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	25.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,264.0	N/A	0.00	N/A
35-44 years	*****	N/A	*****	13.68	*****	N/A	8.50	N/A
45-54 years	*****	N/A	*****	8.04	*****	N/A	5.21	N/A
55-64 years	*****	N/A	*****	5.16	*****	N/A	3.93	N/A
65-74 years	*****	N/A	13	7.66	22,981.1	N/A	5.66	N/A
75-84 years	*****	N/A	*****	6.39	*****	N/A	5.40	N/A
≥ 85 years	*****	N/A	*****	3.99	*****	N/A	5.28	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	29.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	18.08	*****	N/A	13.63	N/A
35-44 years	*****	N/A	*****	15.58	*****	N/A	10.86	N/A
45-54 years	*****	N/A	*****	13.29	*****	N/A	10.94	N/A
55-64 years	*****	N/A	*****	4.13	*****	N/A	4.40	N/A
65-74 years	*****	N/A	*****	6.73	*****	N/A	7.28	N/A
75-84 years	*****	N/A	*****	12.93	*****	N/A	17.27	N/A
≥ 85 years	*****	N/A	*****	10.88	*****	N/A	20.19	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	52.7	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	136.1	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	57.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	15.3	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	0.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
55-64 years	*****	N/A	*****	123.46	*****	N/A	126.27	N/A
65-74 years	*****	N/A	0	0.00	158.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	109.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	182.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,044.6	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.14	*****	N/A	1.95	N/A
45-54 years	*****	N/A	*****	1.01	*****	N/A	0.89	N/A
55-64 years	*****	N/A	*****	4.31	*****	N/A	5.24	N/A
65-74 years	*****	N/A	*****	0.89	*****	N/A	0.87	N/A
75-84 years	*****	N/A	*****	3.79	*****	N/A	3.83	N/A
≥ 85 years	*****	N/A	*****	1.24	*****	N/A	2.22	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	254.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	867.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,724.2	N/A	0.00	N/A
45-54 years	*****	N/A	*****	8.68	*****	N/A	10.01	N/A
55-64 years	*****	N/A	*****	5.49	*****	N/A	8.28	N/A
65-74 years	*****	N/A	*****	7.62	*****	N/A	9.93	N/A
75-84 years	*****	N/A	*****	5.35	*****	N/A	8.19	N/A
≥ 85 years	*****	N/A	0	0.00	1,442.4	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,454.2	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.25	*****	N/A	1.27	N/A
45-54 years	*****	N/A	*****	5.49	*****	N/A	3.18	N/A
55-64 years	*****	N/A	*****	2.57	*****	N/A	1.92	N/A
65-74 years	*****	N/A	51	6.13	119,523.4	N/A	4.27	N/A
75-84 years	*****	N/A	40	4.79	94,279.2	N/A	4.24	N/A
≥ 85 years	*****	N/A	22	3.02	45,486.1	N/A	4.84	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	40.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,325.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.84	*****	N/A	1.78	N/A
45-54 years	*****	N/A	12	10.00	17,202.5	N/A	6.98	N/A
55-64 years	*****	N/A	27	10.17	27,321.5	N/A	9.88	N/A
65-74 years	*****	N/A	78	11.50	68,141.9	N/A	11.45	N/A
75-84 years	*****	N/A	39	7.58	35,658.0	N/A	10.94	N/A
≥ 85 years	*****	N/A	*****	3.12	*****	N/A	8.66	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	14.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	22.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	53.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	82.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	126.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	95.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	36.1	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	13.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	47.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.3	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	109.6	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	39.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	5.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	7.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	30.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	35.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	77.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	416.2	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	488.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	230.8	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	10.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	12.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	56.5	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.5	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	365.2	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	371.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	95.0	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	34.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	340.1	N/A	0.00	N/A
35-44 years	*****	N/A	*****	17.18	*****	N/A	10.65	N/A
45-54 years	*****	N/A	*****	8.55	*****	N/A	5.41	N/A
55-64 years	*****	N/A	*****	10.05	*****	N/A	7.67	N/A
65-74 years	*****	N/A	0	0.00	5,432.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	4,274.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	*****	11.72	*****	N/A	12.79	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	252.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	480.4	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	1,100.6	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	1,341.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	2,466.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,277.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	239.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	3.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	20.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	16.4	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	24.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	13.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
45-54 years	*****	N/A	0	0.00	5.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	16.8	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	47.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	8.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	61.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	792.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,960.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	2.88	*****	N/A	2.44	N/A
55-64 years	*****	N/A	0	0.00	3,969.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	3,788.9	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	3,405.7	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1,351.3	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	78.0	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	295.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,177.3	N/A	0.00	N/A
45-54 years	*****	N/A	*****	6.90	*****	N/A	6.93	N/A
55-64 years	*****	N/A	*****	10.53	*****	N/A	15.86	N/A
65-74 years	*****	N/A	*****	5.81	*****	N/A	7.03	N/A
75-84 years	*****	N/A	*****	13.86	*****	N/A	15.58	N/A
≥ 85 years	*****	N/A	0	0.00	573.1	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	47.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	781.2	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,152.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.58	*****	N/A	2.14	N/A
55-64 years	*****	N/A	*****	1.83	*****	N/A	1.40	N/A
65-74 years	*****	N/A	*****	4.79	*****	N/A	3.32	N/A
75-84 years	*****	N/A	*****	3.65	*****	N/A	2.92	N/A
≥ 85 years	*****	N/A	*****	6.21	*****	N/A	8.15	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	17.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	397.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,376.9	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.98	*****	N/A	5.53	N/A
55-64 years	*****	N/A	*****	3.64	*****	N/A	3.46	N/A
65-74 years	*****	N/A	18	10.59	18,302.9	N/A	9.83	N/A
75-84 years	*****	N/A	11	8.13	11,180.9	N/A	9.84	N/A
≥ 85 years	*****	N/A	*****	6.79	*****	N/A	14.18	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Torsemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	48.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	84.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	254.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	249.6	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	507.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	350.5	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	129.6	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	35.4	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	63.9	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	203.4	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	180.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	367.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	152.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	28.2	N/A	0.00	N/A
Asian, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	15.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	56.1	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	112.7	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	176.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,203.3	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,337.1	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	604.0	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	32.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	74.7	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	186.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	241.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	9.95	*****	N/A	10.43	N/A
75-84 years	*****	N/A	0	0.00	934.4	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	327.1	N/A	0.00	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	42.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,020.0	N/A	0.00	N/A
35-44 years	*****	N/A	*****	4.93	*****	N/A	3.36	N/A
45-54 years	*****	N/A	*****	8.61	*****	N/A	5.64	N/A
55-64 years	*****	N/A	*****	6.73	*****	N/A	5.29	N/A
65-74 years	*****	N/A	*****	4.18	*****	N/A	3.25	N/A
75-84 years	*****	N/A	*****	3.92	*****	N/A	3.23	N/A
≥ 85 years	*****	N/A	*****	4.28	*****	N/A	5.46	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	23.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	35.15	*****	N/A	25.24	N/A
35-44 years	*****	N/A	0	0.00	2,294.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	9.21	*****	N/A	7.97	N/A
55-64 years	*****	N/A	*****	2.87	*****	N/A	3.10	N/A
65-74 years	*****	N/A	*****	4.76	*****	N/A	5.16	N/A
75-84 years	*****	N/A	*****	3.56	*****	N/A	4.68	N/A
≥ 85 years	*****	N/A	*****	5.40	*****	N/A	10.79	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	5.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	0.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	33.9	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	94.7	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	49.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	19.4	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
20-34 years	0	N/A	0	NaN	0.0	N/A	NaN	N/A
35-44 years	*****	N/A	0	0.00	4.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	10.0	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	39.2	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	157.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	72.9	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	12.9	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	88.2	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	1,454.4	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.38	*****	N/A	2.22	N/A
45-54 years	*****	N/A	*****	1.07	*****	N/A	0.97	N/A
55-64 years	*****	N/A	*****	1.41	*****	N/A	1.77	N/A
65-74 years	*****	N/A	*****	0.88	*****	N/A	0.88	N/A
75-84 years	*****	N/A	*****	1.93	*****	N/A	1.97	N/A
≥ 85 years	*****	N/A	0	0.00	4,609.5	N/A	0.00	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	110.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	761.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,947.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	5.89	*****	N/A	6.86	N/A
55-64 years	*****	N/A	*****	6.40	*****	N/A	10.15	N/A
65-74 years	*****	N/A	*****	3.08	*****	N/A	4.29	N/A
75-84 years	*****	N/A	*****	3.68	*****	N/A	5.58	N/A
≥ 85 years	*****	N/A	0	0.00	1,647.5	N/A	0.00	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	48.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	2,081.4	N/A	0.00	N/A
35-44 years	*****	N/A	*****	2.64	*****	N/A	1.50	N/A
45-54 years	*****	N/A	*****	5.64	*****	N/A	3.50	N/A
55-64 years	*****	N/A	14	5.89	30,109.4	N/A	4.65	N/A
65-74 years	*****	N/A	43	5.28	112,143.0	N/A	3.83	N/A
75-84 years	*****	N/A	46	5.44	93,267.7	N/A	4.93	N/A
≥ 85 years	*****	N/A	41	5.68	45,045.8	N/A	9.10	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	20.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	12.17	*****	N/A	8.46	N/A
35-44 years	*****	N/A	0	0.00	4,770.7	N/A	0.00	N/A
45-54 years	*****	N/A	11	10.33	14,466.3	N/A	7.60	N/A
55-64 years	*****	N/A	17	6.81	24,241.0	N/A	7.01	N/A
65-74 years	*****	N/A	72	10.07	69,087.6	N/A	10.42	N/A
75-84 years	*****	N/A	33	5.83	37,790.1	N/A	8.73	N/A
≥ 85 years	*****	N/A	*****	3.20	*****	N/A	9.09	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	540.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,440.3	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,810.1	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	4,014.2	N/A	0.00	N/A
65-74 years	*****	N/A	*****	2.05	*****	N/A	1.28	N/A
75-84 years	*****	N/A	0	0.00	5,956.2	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	1,858.8	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	1.8	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	322.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	902.6	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	2,272.0	N/A	0.00	N/A
55-64 years	*****	N/A	*****	5.00	*****	N/A	3.50	N/A
65-74 years	*****	N/A	*****	18.38	*****	N/A	13.44	N/A
75-84 years	*****	N/A	*****	13.91	*****	N/A	11.27	N/A
≥ 85 years	*****	N/A	0	0.00	546.5	N/A	0.00	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	42.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	489.8	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,068.4	N/A	0.00	N/A
45-54 years	*****	N/A	*****	9.23	*****	N/A	5.57	N/A
55-64 years	*****	N/A	0	0.00	2,870.4	N/A	0.00	N/A
65-74 years	*****	N/A	*****	3.38	*****	N/A	1.91	N/A
75-84 years	*****	N/A	12	6.83	29,183.7	N/A	4.11	N/A
≥ 85 years	*****	N/A	*****	3.37	*****	N/A	3.20	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	104.4	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	426.0	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	933.5	N/A	0.00	N/A
45-54 years	*****	N/A	*****	7.12	*****	N/A	4.80	N/A
55-64 years	*****	N/A	0	0.00	3,411.7	N/A	0.00	N/A
65-74 years	*****	N/A	*****	6.85	*****	N/A	4.65	N/A
75-84 years	*****	N/A	14	11.89	16,251.4	N/A	8.61	N/A
≥ 85 years	*****	N/A	*****	2.52	*****	N/A	2.81	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	1,818.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	3.14	*****	N/A	1.30	N/A
35-44 years	*****	N/A	*****	1.08	*****	N/A	0.56	N/A
45-54 years	*****	N/A	15	4.24	66,483.5	N/A	2.26	N/A
55-64 years	*****	N/A	24	4.12	89,139.3	N/A	2.69	N/A
65-74 years	*****	N/A	43	3.87	171,903.9	N/A	2.50	N/A
75-84 years	*****	N/A	38	4.41	129,428.5	N/A	2.94	N/A
≥ 85 years	*****	N/A	18	3.19	56,100.9	N/A	3.21	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	906.5	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.90	*****	N/A	1.46	N/A
35-44 years	*****	N/A	*****	1.06	*****	N/A	0.60	N/A
45-54 years	*****	N/A	19	8.26	38,248.0	N/A	4.97	N/A
55-64 years	*****	N/A	31	8.12	48,947.3	N/A	6.33	N/A
65-74 years	*****	N/A	45	7.44	72,330.9	N/A	6.22	N/A
75-84 years	*****	N/A	32	9.11	37,616.5	N/A	8.51	N/A
≥ 85 years	*****	N/A	*****	5.24	*****	N/A	7.61	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	35.3	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	29.2	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	126.3	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	317.0	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	1,495.0	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,046.3	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	175.2	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	11.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	31.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	222.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	26.11	*****	N/A	17.76	N/A
65-74 years	*****	N/A	0	0.00	1,872.0	N/A	0.00	N/A
75-84 years	*****	N/A	*****	9.25	*****	N/A	10.03	N/A
≥ 85 years	*****	N/A	0	0.00	117.1	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	7,272.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.78	*****	N/A	0.72	N/A
35-44 years	*****	N/A	*****	0.69	*****	N/A	0.59	N/A
45-54 years	*****	N/A	15	1.24	146,116.2	N/A	1.03	N/A
55-64 years	*****	N/A	21	1.51	126,983.2	N/A	1.65	N/A
65-74 years	*****	N/A	30	3.18	122,885.4	N/A	2.44	N/A
75-84 years	*****	N/A	40	4.80	114,434.9	N/A	3.50	N/A
≥ 85 years	*****	N/A	*****	1.35	*****	N/A	1.61	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Unknown, Male								
0-19 years	*****	N/A	0	0.00	7,750.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	12,263.6	N/A	0.00	N/A
35-44 years	*****	N/A	*****	1.45	*****	N/A	1.34	N/A
45-54 years	*****	N/A	24	2.81	92,748.7	N/A	2.59	N/A
55-64 years	*****	N/A	53	3.92	111,169.2	N/A	4.77	N/A
65-74 years	*****	N/A	64	7.11	94,198.6	N/A	6.79	N/A
75-84 years	*****	N/A	31	5.68	58,051.7	N/A	5.34	N/A
≥ 85 years	*****	N/A	*****	2.88	*****	N/A	4.47	N/A
White, Female								
0-19 years	*****	N/A	0	0.00	2,867.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.53	*****	N/A	0.69	N/A
35-44 years	*****	N/A	*****	2.06	*****	N/A	1.01	N/A
45-54 years	*****	N/A	41	4.02	198,147.7	N/A	2.07	N/A
55-64 years	*****	N/A	74	4.09	277,380.5	N/A	2.67	N/A
65-74 years	*****	N/A	298	4.89	1,007,636.0	N/A	2.96	N/A
75-84 years	*****	N/A	323	5.34	869,400.8	N/A	3.72	N/A
≥ 85 years	*****	N/A	186	3.56	432,213.0	N/A	4.30	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	1,955.7	N/A	0.00	N/A
20-34 years	*****	N/A	*****	6.25	*****	N/A	3.02	N/A
35-44 years	*****	N/A	12	4.32	54,487.8	N/A	2.20	N/A
45-54 years	*****	N/A	71	8.82	143,466.9	N/A	4.95	N/A
55-64 years	*****	N/A	165	10.49	208,391.1	N/A	7.92	N/A
65-74 years	*****	N/A	493	11.13	595,059.1	N/A	8.28	N/A
75-84 years	*****	N/A	289	8.78	347,765.0	N/A	8.31	N/A
≥ 85 years	*****	N/A	76	4.80	90,785.6	N/A	8.37	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Furosemide Users (No Washout)								
American Indian or Alaska Native, Female								
0-19 years	*****	N/A	0	0.00	0.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	841.9	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	2,397.1	N/A	0.00	N/A
45-54 years	*****	N/A	*****	3.91	*****	N/A	1.77	N/A
55-64 years	*****	N/A	0	0.00	8,079.6	N/A	0.00	N/A
65-74 years	*****	N/A	*****	3.50	*****	N/A	1.91	N/A
75-84 years	*****	N/A	*****	1.50	*****	N/A	0.92	N/A
≥ 85 years	*****	N/A	0	0.00	3,431.8	N/A	0.00	N/A
American Indian or Alaska Native, Male								
0-19 years	*****	N/A	0	0.00	5.9	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	595.1	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,847.8	N/A	0.00	N/A
45-54 years	*****	N/A	*****	8.98	*****	N/A	4.52	N/A
55-64 years	*****	N/A	*****	2.88	*****	N/A	1.76	N/A
65-74 years	*****	N/A	*****	17.10	*****	N/A	10.99	N/A
75-84 years	*****	N/A	*****	14.34	*****	N/A	11.30	N/A
≥ 85 years	*****	N/A	*****	8.55	*****	N/A	11.59	N/A
Asian, Female								
0-19 years	*****	N/A	0	0.00	67.7	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	710.5	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	1,642.7	N/A	0.00	N/A
45-54 years	*****	N/A	*****	11.38	*****	N/A	6.45	N/A
55-64 years	*****	N/A	0	0.00	5,348.0	N/A	0.00	N/A
65-74 years	*****	N/A	*****	4.94	*****	N/A	2.61	N/A
75-84 years	*****	N/A	19	7.69	43,965.7	N/A	4.32	N/A
≥ 85 years	*****	N/A	*****	4.93	*****	N/A	4.42	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Asian, Male								
0-19 years	*****	N/A	0	0.00	134.5	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	724.7	N/A	0.00	N/A
35-44 years	*****	N/A	*****	9.40	*****	N/A	5.76	N/A
45-54 years	*****	N/A	*****	8.14	*****	N/A	4.99	N/A
55-64 years	*****	N/A	*****	2.17	*****	N/A	1.48	N/A
65-74 years	*****	N/A	16	9.73	25,886.5	N/A	6.18	N/A
75-84 years	*****	N/A	18	10.66	24,528.8	N/A	7.34	N/A
≥ 85 years	*****	N/A	*****	3.60	*****	N/A	3.91	N/A
Black or African American, Female								
0-19 years	*****	N/A	0	0.00	2,138.1	N/A	0.00	N/A
20-34 years	*****	N/A	*****	2.32	*****	N/A	0.97	N/A
35-44 years	*****	N/A	*****	2.72	*****	N/A	1.31	N/A
45-54 years	*****	N/A	37	5.56	136,602.8	N/A	2.71	N/A
55-64 years	*****	N/A	49	4.21	201,893.0	N/A	2.43	N/A
65-74 years	*****	N/A	108	4.97	382,543.6	N/A	2.82	N/A
75-84 years	*****	N/A	101	6.57	264,189.2	N/A	3.82	N/A
≥ 85 years	*****	N/A	42	4.21	113,730.2	N/A	3.69	N/A
Black or African American, Male								
0-19 years	*****	N/A	0	0.00	1,269.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.17	*****	N/A	2.40	N/A
35-44 years	*****	N/A	*****	3.91	*****	N/A	1.95	N/A
45-54 years	*****	N/A	38	8.40	84,486.7	N/A	4.50	N/A
55-64 years	*****	N/A	61	8.24	108,293.5	N/A	5.63	N/A
65-74 years	*****	N/A	97	8.34	157,476.4	N/A	6.16	N/A
75-84 years	*****	N/A	59	9.69	71,970.2	N/A	8.20	N/A
≥ 85 years	*****	N/A	12	5.19	17,558.9	N/A	6.83	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
Native Hawaiian or Other Pacific Islander, Female								
0-19 years	*****	N/A	0	0.00	4.1	N/A	0.00	N/A
20-34 years	*****	N/A	0	0.00	40.6	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	57.5	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	244.9	N/A	0.00	N/A
55-64 years	*****	N/A	0	0.00	703.4	N/A	0.00	N/A
65-74 years	*****	N/A	0	0.00	2,435.8	N/A	0.00	N/A
75-84 years	*****	N/A	0	0.00	1,456.0	N/A	0.00	N/A
≥ 85 years	*****	N/A	0	0.00	275.6	N/A	0.00	N/A
Native Hawaiian or Other Pacific Islander, Male								
0-19 years	*****	N/A	0	0.00	0.0	N/A	NaN	N/A
20-34 years	*****	N/A	0	0.00	17.7	N/A	0.00	N/A
35-44 years	*****	N/A	0	0.00	86.8	N/A	0.00	N/A
45-54 years	*****	N/A	0	0.00	419.5	N/A	0.00	N/A
55-64 years	*****	N/A	*****	37.59	*****	N/A	27.96	N/A
65-74 years	*****	N/A	*****	4.49	*****	N/A	3.38	N/A
75-84 years	*****	N/A	*****	12.82	*****	N/A	14.30	N/A
≥ 85 years	*****	N/A	0	0.00	177.6	N/A	0.00	N/A
Unknown, Female								
0-19 years	*****	N/A	0	0.00	10,216.6	N/A	0.00	N/A
20-34 years	*****	N/A	*****	0.87	*****	N/A	0.80	N/A
35-44 years	*****	N/A	*****	1.03	*****	N/A	0.88	N/A
45-54 years	*****	N/A	19	1.04	219,720.7	N/A	0.86	N/A
55-64 years	*****	N/A	37	1.60	210,654.0	N/A	1.76	N/A
65-74 years	*****	N/A	60	3.59	216,120.6	N/A	2.78	N/A
75-84 years	*****	N/A	63	4.34	192,726.5	N/A	3.27	N/A
≥ 85 years	*****	N/A	33	2.84	94,296.5	N/A	3.50	N/A
Unknown, Male								
0-19 years	*****	N/A	0	0.00	11,136.0	N/A	0.00	N/A
20-34 years	*****	N/A	*****	1.81	*****	N/A	1.79	N/A

Table 6. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Race, Sex, and Age Group[1]

	Number of Patients	Number of Eligible Members[2]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[2]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[2]
35-44 years	*****	N/A	*****	1.41	*****	N/A	1.28	N/A
45-54 years	*****	N/A	44	3.36	143,759.3	N/A	3.06	N/A
55-64 years	*****	N/A	98	4.49	181,148.0	N/A	5.41	N/A
65-74 years	*****	N/A	130	8.25	164,967.6	N/A	7.88	N/A
75-84 years	*****	N/A	55	5.81	94,808.9	N/A	5.80	N/A
≥ 85 years	*****	N/A	14	2.81	29,838.5	N/A	4.69	N/A
White, Female								
0-19 years	*****	N/A	*****	7.76	*****	N/A	2.73	N/A
20-34 years	*****	N/A	*****	2.36	*****	N/A	1.02	N/A
35-44 years	*****	N/A	18	2.50	161,033.5	N/A	1.12	N/A
45-54 years	*****	N/A	85	4.77	383,382.4	N/A	2.22	N/A
55-64 years	*****	N/A	169	4.98	589,126.5	N/A	2.87	N/A
65-74 years	*****	N/A	630	5.71	2,008,484.5	N/A	3.14	N/A
75-84 years	*****	N/A	656	6.30	1,618,445.6	N/A	4.05	N/A
≥ 85 years	*****	N/A	428	4.35	854,187.7	N/A	5.01	N/A
White, Male								
0-19 years	*****	N/A	0	0.00	2,927.4	N/A	0.00	N/A
20-34 years	*****	N/A	*****	5.89	*****	N/A	2.56	N/A
35-44 years	*****	N/A	28	6.21	98,920.8	N/A	2.83	N/A
45-54 years	*****	N/A	150	10.35	289,828.1	N/A	5.18	N/A
55-64 years	*****	N/A	373	12.72	438,058.6	N/A	8.51	N/A
65-74 years	*****	N/A	1,054	13.05	1,176,639.7	N/A	8.96	N/A
75-84 years	*****	N/A	585	10.33	620,487.5	N/A	9.43	N/A
≥ 85 years	*****	N/A	149	4.86	172,618.7	N/A	8.63	N/A

[1]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[2]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

N/A: Not Applicable

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	142,052,084	40	2.31	122,614.6	0.00	3.26	403,207,018.7
30,000 - <60,000 mg	*****	142,052,084	*****	2.02	*****	0.00	3.51	403,207,018.7
60,000 - <90,000 mg	*****	142,052,084	*****	3.18	*****	0.00	5.07	403,207,018.7
90,000 - <120,000 mg	*****	142,052,084	*****	2.83	*****	0.00	4.76	403,207,018.7
120,000 - <150,000 mg	*****	142,052,084	*****	3.35	*****	0.00	5.61	403,207,018.7
150,000 - <180,000 mg	*****	142,052,084	*****	3.64	*****	0.00	6.86	403,207,018.7
180,000 - <210,000 mg	*****	142,052,084	*****	5.11	*****	0.00	9.97	403,207,018.7
≥ 210,000 mg	*****	142,052,084	*****	4.64	*****	0.00	2.60	403,207,018.7
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	145,886,512	124	1.82	265,170.2	0.01	4.68	423,488,059.5
30,000 - <60,000 mg	304,791	145,886,512	61	2.00	101,232.7	0.00	6.03	423,488,059.5
60,000 - <90,000 mg	201,271	145,886,512	41	2.04	80,575.2	0.00	5.09	423,488,059.5
90,000 - <120,000 mg	141,898	145,886,512	30	2.11	56,933.9	0.00	5.27	423,488,059.5
120,000 - <150,000 mg	104,735	145,886,512	28	2.67	45,569.5	0.00	6.14	423,488,059.5
150,000 - <180,000 mg	*****	145,886,512	*****	3.31	*****	0.00	8.16	423,488,059.5
180,000 - <210,000 mg	*****	145,886,512	*****	1.65	*****	0.00	4.17	423,488,059.5
≥ 210,000 mg	47,345	145,886,512	60	12.67	89,266.5	0.00	6.72	423,488,059.5
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	142,052,084	38	2.20	119,822.2	0.00	3.17	403,220,608.6
30,000 - <60,000 mg	*****	142,052,084	*****	1.38	*****	0.00	2.03	403,220,608.6
60,000 - <90,000 mg	*****	142,052,084	*****	2.19	*****	0.00	3.16	403,220,608.6
90,000 - <120,000 mg	*****	142,052,084	*****	2.23	*****	0.00	3.79	403,220,608.6
120,000 - <150,000 mg	*****	142,052,084	*****	1.14	*****	0.00	2.17	403,220,608.6
150,000 - <180,000 mg	*****	142,052,084	*****	3.32	*****	0.00	7.07	403,220,608.6
180,000 - <210,000 mg	*****	142,052,084	0	0.00	2,030.8	0.00	0.00	403,220,608.6
≥ 210,000 mg	*****	142,052,084	*****	6.17	*****	0.00	3.90	403,220,608.6
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	145,886,512	94	1.38	258,565.0	0.01	3.64	423,529,490.1
30,000 - <60,000 mg	297,231	145,886,512	36	1.21	110,688.2	0.00	3.25	423,529,490.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
60,000 - <90,000 mg	191,137	145,886,512	36	1.88	80,834.9	0.00	4.45	423,529,490.1
90,000 - <120,000 mg	132,972	145,886,512	24	1.80	51,366.2	0.00	4.67	423,529,490.1
120,000 - <150,000 mg	97,900	145,886,512	16	1.63	37,766.0	0.00	4.24	423,529,490.1
150,000 - <180,000 mg	73,732	145,886,512	20	2.71	25,858.7	0.00	7.73	423,529,490.1
180,000 - <210,000 mg	57,843	145,886,512	15	2.59	19,506.2	0.00	7.69	423,529,490.1
≥ 210,000 mg	46,087	145,886,512	39	8.46	78,200.9	0.00	4.99	423,529,490.1
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	142,052,084	2,333	4.64	5,115,064.6	0.16	4.56	399,244,718.5
30,000 - <60,000 mg	664,489	142,052,084	555	8.35	916,201.5	0.04	6.06	399,244,718.5
60,000 - <90,000 mg	230,504	142,052,084	162	7.03	274,061.8	0.01	5.91	399,244,718.5
90,000 - <120,000 mg	97,370	142,052,084	70	7.19	99,944.2	0.00	7.00	399,244,718.5
120,000 - <150,000 mg	46,460	142,052,084	28	6.03	40,877.7	0.00	6.85	399,244,718.5
150,000 - <180,000 mg	24,013	142,052,084	15	6.25	18,388.7	0.00	8.16	399,244,718.5
180,000 - <210,000 mg	*****	142,052,084	*****	4.41	*****	0.00	6.40	399,244,718.5
≥ 210,000 mg	*****	142,052,084	*****	5.84	*****	0.00	3.74	399,244,718.5
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	145,886,512	3,580	4.04	7,706,081.0	0.25	4.65	400,535,781.1
30,000 - <60,000 mg	1,997,151	145,886,512	1,520	7.61	2,600,697.9	0.10	5.84	400,535,781.1
60,000 - <90,000 mg	852,245	145,886,512	575	6.75	1,012,305.6	0.04	5.68	400,535,781.1
90,000 - <120,000 mg	422,980	145,886,512	273	6.45	445,375.0	0.02	6.13	400,535,781.1
120,000 - <150,000 mg	231,140	145,886,512	123	5.32	218,044.9	0.01	5.64	400,535,781.1
150,000 - <180,000 mg	133,068	145,886,512	78	5.86	109,917.7	0.01	7.10	400,535,781.1
180,000 - <210,000 mg	81,274	145,886,512	32	3.94	62,733.7	0.00	5.10	400,535,781.1
≥ 210,000 mg	53,201	145,886,512	59	11.09	106,209.2	0.00	5.56	400,535,781.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	142,052,084	103	5.96	122,614.6	0.01	8.40	403,207,018.7
30,000 - <60,000 mg	*****	142,052,084	25	5.04	28,453.4	0.00	8.79	403,207,018.7
60,000 - <90,000 mg	*****	142,052,084	17	6.01	17,734.1	0.00	9.59	403,207,018.7
90,000 - <120,000 mg	*****	142,052,084	*****	5.66	*****	0.00	9.52	403,207,018.7
120,000 - <150,000 mg	*****	142,052,084	*****	5.02	*****	0.00	8.42	403,207,018.7
150,000 - <180,000 mg	*****	142,052,084	0	0.00	4,375.9	0.00	0.00	403,207,018.7
180,000 - <210,000 mg	*****	142,052,084	*****	8.51	*****	0.00	16.62	403,207,018.7
≥ 210,000 mg	*****	142,052,084	13	30.16	7,678.7	0.00	16.93	403,207,018.7
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	145,886,512	230	3.38	265,170.2	0.02	8.67	423,488,059.5
30,000 - <60,000 mg	304,791	145,886,512	93	3.05	101,232.7	0.01	9.19	423,488,059.5
60,000 - <90,000 mg	201,271	145,886,512	88	4.37	80,575.2	0.01	10.92	423,488,059.5
90,000 - <120,000 mg	141,898	145,886,512	65	4.58	56,933.9	0.00	11.42	423,488,059.5
120,000 - <150,000 mg	104,735	145,886,512	47	4.49	45,569.5	0.00	10.31	423,488,059.5
150,000 - <180,000 mg	*****	145,886,512	27	3.43	31,880.1	0.00	8.47	423,488,059.5
180,000 - <210,000 mg	*****	145,886,512	30	4.96	23,952.2	0.00	12.52	423,488,059.5
≥ 210,000 mg	47,345	145,886,512	97	20.49	89,266.5	0.01	10.87	423,488,059.5
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	142,052,084	109	6.32	119,822.2	0.01	9.10	403,220,608.6
30,000 - <60,000 mg	*****	142,052,084	28	6.42	29,624.1	0.00	9.45	403,220,608.6
60,000 - <90,000 mg	*****	142,052,084	21	9.22	15,799.6	0.00	13.29	403,220,608.6
90,000 - <120,000 mg	*****	142,052,084	*****	4.46	*****	0.00	7.59	403,220,608.6
120,000 - <150,000 mg	*****	142,052,084	*****	6.85	*****	0.00	13.00	403,220,608.6
150,000 - <180,000 mg	*****	142,052,084	*****	1.66	*****	0.00	3.54	403,220,608.6
180,000 - <210,000 mg	*****	142,052,084	*****	2.28	*****	0.00	4.92	403,220,608.6
≥ 210,000 mg	*****	142,052,084	*****	6.17	*****	0.00	3.90	403,220,608.6
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	145,886,512	239	3.51	258,565.0	0.02	9.24	423,529,490.1
30,000 - <60,000 mg	297,231	145,886,512	121	4.07	110,688.2	0.01	10.93	423,529,490.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
60,000 - <90,000 mg	191,137	145,886,512	92	4.81	80,834.9	0.01	11.38	423,529,490.1
90,000 - <120,000 mg	132,972	145,886,512	48	3.61	51,366.2	0.00	9.34	423,529,490.1
120,000 - <150,000 mg	97,900	145,886,512	53	5.41	37,766.0	0.00	14.03	423,529,490.1
150,000 - <180,000 mg	73,732	145,886,512	19	2.58	25,858.7	0.00	7.35	423,529,490.1
180,000 - <210,000 mg	57,843	145,886,512	36	6.22	19,506.2	0.00	18.46	423,529,490.1
≥ 210,000 mg	46,087	145,886,512	69	14.97	78,200.9	0.00	8.82	423,529,490.1
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	142,052,084	4,467	8.88	5,115,064.6	0.31	8.73	399,244,718.5
30,000 - <60,000 mg	664,489	142,052,084	881	13.26	916,201.5	0.06	9.62	399,244,718.5
60,000 - <90,000 mg	230,504	142,052,084	292	12.67	274,061.8	0.02	10.65	399,244,718.5
90,000 - <120,000 mg	97,370	142,052,084	95	9.76	99,944.2	0.01	9.51	399,244,718.5
120,000 - <150,000 mg	46,460	142,052,084	36	7.75	40,877.7	0.00	8.81	399,244,718.5
150,000 - <180,000 mg	24,013	142,052,084	13	5.41	18,388.7	0.00	7.07	399,244,718.5
180,000 - <210,000 mg	*****	142,052,084	12	8.82	9,370.0	0.00	12.81	399,244,718.5
≥ 210,000 mg	*****	142,052,084	12	14.01	13,373.1	0.00	8.97	399,244,718.5
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	145,886,512	7,083	8.00	7,706,081.0	0.49	9.19	400,535,781.1
30,000 - <60,000 mg	1,997,151	145,886,512	2,681	13.42	2,600,697.9	0.18	10.31	400,535,781.1
60,000 - <90,000 mg	852,245	145,886,512	1,065	12.50	1,012,305.6	0.07	10.52	400,535,781.1
90,000 - <120,000 mg	422,980	145,886,512	441	10.43	445,375.0	0.03	9.90	400,535,781.1
120,000 - <150,000 mg	231,140	145,886,512	198	8.57	218,044.9	0.01	9.08	400,535,781.1
150,000 - <180,000 mg	133,068	145,886,512	102	7.67	109,917.7	0.01	9.28	400,535,781.1
180,000 - <210,000 mg	81,274	145,886,512	65	8.00	62,733.7	0.00	10.36	400,535,781.1
≥ 210,000 mg	53,201	145,886,512	109	20.49	106,209.2	0.01	10.26	400,535,781.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	142,052,084	212	12.26	122,614.6	0.01	17.29	403,207,018.7
30,000 - <60,000 mg	*****	142,052,084	64	12.90	28,453.4	0.00	22.49	403,207,018.7
60,000 - <90,000 mg	*****	142,052,084	38	13.44	17,734.1	0.00	21.43	403,207,018.7
90,000 - <120,000 mg	*****	142,052,084	22	12.44	10,505.1	0.00	20.94	403,207,018.7
120,000 - <150,000 mg	*****	142,052,084	21	17.58	7,127.5	0.00	29.46	403,207,018.7
150,000 - <180,000 mg	*****	142,052,084	*****	13.33	*****	0.00	25.14	403,207,018.7
180,000 - <210,000 mg	*****	142,052,084	*****	8.51	*****	0.00	16.62	403,207,018.7
≥ 210,000 mg	*****	142,052,084	20	46.40	7,678.7	0.00	26.05	403,207,018.7
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	145,886,512	516	7.58	265,170.2	0.04	19.46	423,488,059.5
30,000 - <60,000 mg	304,791	145,886,512	235	7.71	101,232.7	0.02	23.21	423,488,059.5
60,000 - <90,000 mg	201,271	145,886,512	200	9.94	80,575.2	0.01	24.82	423,488,059.5
90,000 - <120,000 mg	141,898	145,886,512	148	10.43	56,933.9	0.01	26.00	423,488,059.5
120,000 - <150,000 mg	104,735	145,886,512	120	11.46	45,569.5	0.01	26.33	423,488,059.5
150,000 - <180,000 mg	*****	145,886,512	61	7.76	31,880.1	0.00	19.13	423,488,059.5
180,000 - <210,000 mg	*****	145,886,512	59	9.75	23,952.2	0.00	24.63	423,488,059.5
≥ 210,000 mg	47,345	145,886,512	187	39.50	89,266.5	0.01	20.95	423,488,059.5
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	142,052,084	199	11.55	119,822.2	0.01	16.61	403,220,608.6
30,000 - <60,000 mg	*****	142,052,084	67	15.37	29,624.1	0.00	22.62	403,220,608.6
60,000 - <90,000 mg	*****	142,052,084	25	10.97	15,799.6	0.00	15.82	403,220,608.6
90,000 - <120,000 mg	*****	142,052,084	15	11.16	7,910.2	0.00	18.96	403,220,608.6
120,000 - <150,000 mg	*****	142,052,084	*****	10.28	*****	0.00	19.50	403,220,608.6
150,000 - <180,000 mg	*****	142,052,084	*****	11.63	*****	0.00	24.76	403,220,608.6
180,000 - <210,000 mg	*****	142,052,084	*****	9.13	*****	0.00	19.70	403,220,608.6
≥ 210,000 mg	*****	142,052,084	12	36.99	5,133.3	0.00	23.38	403,220,608.6
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	145,886,512	500	7.35	258,565.0	0.03	19.34	423,529,490.1
30,000 - <60,000 mg	297,231	145,886,512	253	8.51	110,688.2	0.02	22.86	423,529,490.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
60,000 - <90,000 mg	191,137	145,886,512	177	9.26	80,834.9	0.01	21.90	423,529,490.1
90,000 - <120,000 mg	132,972	145,886,512	108	8.12	51,366.2	0.01	21.03	423,529,490.1
120,000 - <150,000 mg	97,900	145,886,512	98	10.01	37,766.0	0.01	25.95	423,529,490.1
150,000 - <180,000 mg	73,732	145,886,512	62	8.41	25,858.7	0.00	23.98	423,529,490.1
180,000 - <210,000 mg	57,843	145,886,512	33	5.71	19,506.2	0.00	16.92	423,529,490.1
≥ 210,000 mg	46,087	145,886,512	162	35.15	78,200.9	0.01	20.72	423,529,490.1
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	142,052,084	8,750	17.39	5,115,064.6	0.62	17.11	399,244,718.5
30,000 - <60,000 mg	664,489	142,052,084	1,879	28.28	916,201.5	0.13	20.51	399,244,718.5
60,000 - <90,000 mg	230,504	142,052,084	535	23.21	274,061.8	0.04	19.52	399,244,718.5
90,000 - <120,000 mg	97,370	142,052,084	177	18.18	99,944.2	0.01	17.71	399,244,718.5
120,000 - <150,000 mg	46,460	142,052,084	81	17.43	40,877.7	0.01	19.82	399,244,718.5
150,000 - <180,000 mg	24,013	142,052,084	49	20.41	18,388.7	0.00	26.65	399,244,718.5
180,000 - <210,000 mg	*****	142,052,084	20	14.71	9,370.0	0.00	21.34	399,244,718.5
≥ 210,000 mg	*****	142,052,084	27	31.53	13,373.1	0.00	20.19	399,244,718.5
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	145,886,512	14,937	16.87	7,706,081.0	1.02	19.38	400,535,781.1
30,000 - <60,000 mg	1,997,151	145,886,512	5,942	29.75	2,600,697.9	0.41	22.85	400,535,781.1
60,000 - <90,000 mg	852,245	145,886,512	2,259	26.51	1,012,305.6	0.15	22.32	400,535,781.1
90,000 - <120,000 mg	422,980	145,886,512	964	22.79	445,375.0	0.07	21.64	400,535,781.1
120,000 - <150,000 mg	231,140	145,886,512	490	21.20	218,044.9	0.03	22.47	400,535,781.1
150,000 - <180,000 mg	133,068	145,886,512	263	19.76	109,917.7	0.02	23.93	400,535,781.1
180,000 - <210,000 mg	81,274	145,886,512	148	18.21	62,733.7	0.01	23.59	400,535,781.1
≥ 210,000 mg	53,201	145,886,512	255	47.93	106,209.2	0.02	24.01	400,535,781.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	142,052,084	57	3.30	122,614.6	0.00	4.65	403,207,018.7
30,000 - <60,000 mg	*****	142,052,084	15	3.02	28,453.4	0.00	5.27	403,207,018.7
60,000 - <90,000 mg	*****	142,052,084	*****	2.48	*****	0.00	3.95	403,207,018.7
90,000 - <120,000 mg	*****	142,052,084	*****	3.39	*****	0.00	5.71	403,207,018.7
120,000 - <150,000 mg	*****	142,052,084	*****	2.51	*****	0.00	4.21	403,207,018.7
150,000 - <180,000 mg	*****	142,052,084	*****	3.64	*****	0.00	6.86	403,207,018.7
180,000 - <210,000 mg	*****	142,052,084	*****	8.51	*****	0.00	16.62	403,207,018.7
≥ 210,000 mg	*****	142,052,084	*****	9.28	*****	0.00	5.21	403,207,018.7
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	145,886,512	116	1.70	265,170.2	0.01	4.37	423,488,059.5
30,000 - <60,000 mg	304,791	145,886,512	70	2.30	101,232.7	0.00	6.91	423,488,059.5
60,000 - <90,000 mg	201,271	145,886,512	39	1.94	80,575.2	0.00	4.84	423,488,059.5
90,000 - <120,000 mg	141,898	145,886,512	36	2.54	56,933.9	0.00	6.32	423,488,059.5
120,000 - <150,000 mg	104,735	145,886,512	29	2.77	45,569.5	0.00	6.36	423,488,059.5
150,000 - <180,000 mg	*****	145,886,512	22	2.80	31,880.1	0.00	6.90	423,488,059.5
180,000 - <210,000 mg	*****	145,886,512	19	3.14	23,952.2	0.00	7.93	423,488,059.5
≥ 210,000 mg	47,345	145,886,512	72	15.21	89,266.5	0.00	8.07	423,488,059.5
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	142,052,084	49	2.84	119,822.2	0.00	4.09	403,220,608.6
30,000 - <60,000 mg	*****	142,052,084	*****	2.29	*****	0.00	3.38	403,220,608.6
60,000 - <90,000 mg	*****	142,052,084	14	6.15	15,799.6	0.00	8.86	403,220,608.6
90,000 - <120,000 mg	*****	142,052,084	*****	3.72	*****	0.00	6.32	403,220,608.6
120,000 - <150,000 mg	*****	142,052,084	*****	2.28	*****	0.00	4.33	403,220,608.6
150,000 - <180,000 mg	*****	142,052,084	0	0.00	2,827.4	0.00	0.00	403,220,608.6
180,000 - <210,000 mg	*****	142,052,084	*****	9.13	*****	0.00	19.70	403,220,608.6
≥ 210,000 mg	*****	142,052,084	*****	6.17	*****	0.00	3.90	403,220,608.6
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	145,886,512	100	1.47	258,565.0	0.01	3.87	423,529,490.1
30,000 - <60,000 mg	297,231	145,886,512	41	1.38	110,688.2	0.00	3.70	423,529,490.1

Table 7. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
60,000 - <90,000 mg	191,137	145,886,512	62	3.24	80,834.9	0.00	7.67	423,529,490.1
90,000 - <120,000 mg	132,972	145,886,512	39	2.93	51,366.2	0.00	7.59	423,529,490.1
120,000 - <150,000 mg	97,900	145,886,512	30	3.06	37,766.0	0.00	7.94	423,529,490.1
150,000 - <180,000 mg	73,732	145,886,512	15	2.03	25,858.7	0.00	5.80	423,529,490.1
180,000 - <210,000 mg	57,843	145,886,512	15	2.59	19,506.2	0.00	7.69	423,529,490.1
≥ 210,000 mg	46,087	145,886,512	64	13.89	78,200.9	0.00	8.18	423,529,490.1
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	142,052,084	1,898	3.77	5,115,064.6	0.13	3.71	399,244,718.5
30,000 - <60,000 mg	664,489	142,052,084	531	7.99	916,201.5	0.04	5.80	399,244,718.5
60,000 - <90,000 mg	230,504	142,052,084	156	6.77	274,061.8	0.01	5.69	399,244,718.5
90,000 - <120,000 mg	97,370	142,052,084	56	5.75	99,944.2	0.00	5.60	399,244,718.5
120,000 - <150,000 mg	46,460	142,052,084	29	6.24	40,877.7	0.00	7.09	399,244,718.5
150,000 - <180,000 mg	24,013	142,052,084	11	4.58	18,388.7	0.00	5.98	399,244,718.5
180,000 - <210,000 mg	*****	142,052,084	*****	2.21	*****	0.00	3.20	399,244,718.5
≥ 210,000 mg	*****	142,052,084	*****	9.34	*****	0.00	5.98	399,244,718.5
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	145,886,512	2,983	3.37	7,706,081.0	0.20	3.87	400,535,781.1
30,000 - <60,000 mg	1,997,151	145,886,512	1,439	7.21	2,600,697.9	0.10	5.53	400,535,781.1
60,000 - <90,000 mg	852,245	145,886,512	600	7.04	1,012,305.6	0.04	5.93	400,535,781.1
90,000 - <120,000 mg	422,980	145,886,512	305	7.21	445,375.0	0.02	6.85	400,535,781.1
120,000 - <150,000 mg	231,140	145,886,512	152	6.58	218,044.9	0.01	6.97	400,535,781.1
150,000 - <180,000 mg	133,068	145,886,512	81	6.09	109,917.7	0.01	7.37	400,535,781.1
180,000 - <210,000 mg	81,274	145,886,512	30	3.69	62,733.7	0.00	4.78	400,535,781.1
≥ 210,000 mg	53,201	145,886,512	63	11.84	106,209.2	0.00	5.93	400,535,781.1

*Lower order categories include patients in the higher order categories

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	142,052,084	44	2.54	125,379.6	0.00	3.51	403,207,018.7
1-2 years	43,206	142,052,084	11	2.55	31,345.8	0.00	3.51	403,207,018.7
2-3 years	*****	142,052,084	*****	4.25	*****	0.00	3.80	403,207,018.7
3-4 years	*****	142,052,084	*****	4.81	*****	0.00	4.59	403,207,018.7
4-5 years	*****	142,052,084	*****	7.38	*****	0.00	7.48	403,207,018.7
5-6 years	*****	142,052,084	*****	7.20	*****	0.00	7.63	403,207,018.7
6-7 years	*****	142,052,084	*****	7.23	*****	0.00	8.02	403,207,018.7
7+ years	*****	142,052,084	0	0.00	975.4	0.00	0.00	403,207,018.7
Bumetanide Users (No Washout)								
0-1 years	681,044	145,886,512	157	2.31	295,001.5	0.01	5.32	423,488,059.5
1-2 years	231,141	145,886,512	81	3.50	133,612.6	0.01	6.06	423,488,059.5
2-3 years	120,390	145,886,512	73	6.06	133,250.5	0.01	5.48	423,488,059.5
3-4 years	60,491	145,886,512	29	4.79	65,442.0	0.00	4.43	423,488,059.5
4-5 years	31,830	145,886,512	23	7.23	32,404.4	0.00	7.10	423,488,059.5
5-6 years	*****	145,886,512	*****	6.37	*****	0.00	6.44	423,488,059.5
6-7 years	*****	145,886,512	*****	3.20	*****	0.00	3.36	423,488,059.5
7+ years	*****	145,886,512	*****	5.81	*****	0.00	3.39	423,488,059.5
Torsemide Users (Washout)								
0-1 years	172,362	142,052,084	37	2.15	109,082.2	0.00	3.39	403,220,608.6
1-2 years	*****	142,052,084	*****	1.47	*****	0.00	2.29	403,220,608.6
2-3 years	*****	142,052,084	*****	2.97	*****	0.00	2.78	403,220,608.6
3-4 years	*****	142,052,084	*****	3.44	*****	0.00	3.40	403,220,608.6
4-5 years	*****	142,052,084	*****	3.36	*****	0.00	3.45	403,220,608.6
5-6 years	*****	142,052,084	0	0.00	2,924.0	0.00	0.00	403,220,608.6
6-7 years	*****	142,052,084	0	0.00	1,393.6	0.00	0.00	403,220,608.6
7+ years	*****	142,052,084	0	0.00	1,131.9	0.00	0.00	403,220,608.6

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-1 years	680,304	145,886,512	99	1.46	251,522.6	0.01	3.94	423,529,490.1
1-2 years	249,185	145,886,512	61	2.45	129,542.7	0.00	4.71	423,529,490.1
2-3 years	131,368	145,886,512	60	4.57	137,438.2	0.00	4.37	423,529,490.1
3-4 years	66,841	145,886,512	28	4.19	68,341.6	0.00	4.10	423,529,490.1
4-5 years	35,645	145,886,512	13	3.65	35,865.0	0.00	3.62	423,529,490.1
5-6 years	*****	145,886,512	*****	4.57	*****	0.00	4.61	423,529,490.1
6-7 years	*****	145,886,512	*****	4.64	*****	0.00	4.86	423,529,490.1
7+ years	*****	145,886,512	*****	8.33	*****	0.00	4.88	423,529,490.1
Furosemide Users (Washout)								
0-1 years	5,031,471	142,052,084	1,437	2.86	3,510,497.2	0.10	4.09	399,244,718.5
1-2 years	1,570,858	142,052,084	666	4.24	1,074,009.9	0.05	6.20	399,244,718.5
2-3 years	857,233	142,052,084	552	6.44	929,103.2	0.04	5.94	399,244,718.5
3-4 years	462,012	142,052,084	273	5.91	473,771.2	0.02	5.76	399,244,718.5
4-5 years	253,038	142,052,084	136	5.37	248,069.2	0.01	5.48	399,244,718.5
5-6 years	138,456	142,052,084	53	3.83	130,962.6	0.00	4.05	399,244,718.5
6-7 years	73,838	142,052,084	32	4.33	66,348.1	0.00	4.82	399,244,718.5
7+ years	37,943	142,052,084	25	6.59	54,520.3	0.00	4.59	399,244,718.5
Furosemide Users (No Washout)								
0-1 years	8,853,836	145,886,512	1,919	2.17	4,485,636.2	0.13	4.28	400,535,781.1
1-2 years	3,756,719	145,886,512	1,335	3.55	2,203,170.4	0.09	6.06	400,535,781.1
2-3 years	2,243,787	145,886,512	1,435	6.40	2,444,001.3	0.10	5.87	400,535,781.1
3-4 years	1,290,390	145,886,512	723	5.60	1,359,302.4	0.05	5.32	400,535,781.1
4-5 years	759,943	145,886,512	387	5.09	777,857.2	0.03	4.98	400,535,781.1
5-6 years	451,504	145,886,512	208	4.61	452,325.8	0.01	4.60	400,535,781.1
6-7 years	267,682	145,886,512	127	4.74	258,231.0	0.01	4.92	400,535,781.1
7+ years	157,482	145,886,512	106	6.73	280,840.7	0.01	3.77	400,535,781.1

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	142,052,084	105	6.07	125,379.6	0.01	8.37	403,207,018.7
1-2 years	43,206	142,052,084	25	5.79	31,345.8	0.00	7.98	403,207,018.7
2-3 years	*****	142,052,084	27	12.76	23,683.2	0.00	11.40	403,207,018.7
3-4 years	*****	142,052,084	*****	11.54	*****	0.00	11.01	403,207,018.7
4-5 years	*****	142,052,084	*****	11.06	*****	0.00	11.22	403,207,018.7
5-6 years	*****	142,052,084	*****	7.20	*****	0.00	7.63	403,207,018.7
6-7 years	*****	142,052,084	*****	7.23	*****	0.00	8.02	403,207,018.7
7+ years	*****	142,052,084	*****	14.45	*****	0.00	10.25	403,207,018.7
Bumetanide Users (No Washout)								
0-1 years	681,044	145,886,512	258	3.79	295,001.5	0.02	8.75	423,488,059.5
1-2 years	231,141	145,886,512	120	5.19	133,612.6	0.01	8.98	423,488,059.5
2-3 years	120,390	145,886,512	148	12.29	133,250.5	0.01	11.11	423,488,059.5
3-4 years	60,491	145,886,512	75	12.40	65,442.0	0.01	11.46	423,488,059.5
4-5 years	31,830	145,886,512	39	12.25	32,404.4	0.00	12.04	423,488,059.5
5-6 years	*****	145,886,512	12	6.95	17,082.7	0.00	7.02	423,488,059.5
6-7 years	*****	145,886,512	12	12.81	8,932.6	0.00	13.43	423,488,059.5
7+ years	*****	145,886,512	13	25.17	8,854.2	0.00	14.68	423,488,059.5
Torsemide Users (Washout)								
0-1 years	172,362	142,052,084	100	5.80	109,082.2	0.01	9.17	403,220,608.6
1-2 years	*****	142,052,084	26	5.47	30,502.5	0.00	8.52	403,220,608.6
2-3 years	*****	142,052,084	26	11.02	25,162.3	0.00	10.33	403,220,608.6
3-4 years	*****	142,052,084	*****	11.17	*****	0.00	11.05	403,220,608.6
4-5 years	*****	142,052,084	*****	8.40	*****	0.00	8.62	403,220,608.6
5-6 years	*****	142,052,084	*****	9.59	*****	0.00	10.26	403,220,608.6
6-7 years	*****	142,052,084	0	0.00	1,393.6	0.00	0.00	403,220,608.6
7+ years	*****	142,052,084	*****	12.48	*****	0.00	8.83	403,220,608.6

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-1 years	680,304	145,886,512	229	3.37	251,522.6	0.02	9.10	423,529,490.1
1-2 years	249,185	145,886,512	140	5.62	129,542.7	0.01	10.81	423,529,490.1
2-3 years	131,368	145,886,512	147	11.19	137,438.2	0.01	10.70	423,529,490.1
3-4 years	66,841	145,886,512	93	13.91	68,341.6	0.01	13.61	423,529,490.1
4-5 years	35,645	145,886,512	29	8.14	35,865.0	0.00	8.09	423,529,490.1
5-6 years	*****	145,886,512	20	10.16	19,540.7	0.00	10.24	423,529,490.1
6-7 years	*****	145,886,512	*****	8.35	*****	0.00	8.75	423,529,490.1
7+ years	*****	145,886,512	*****	16.66	*****	0.00	9.75	423,529,490.1
Furosemide Users (Washout)								
0-1 years	5,031,471	142,052,084	2,940	5.84	3,510,497.2	0.21	8.37	399,244,718.5
1-2 years	1,570,858	142,052,084	1,040	6.62	1,074,009.9	0.07	9.68	399,244,718.5
2-3 years	857,233	142,052,084	909	10.60	929,103.2	0.06	9.78	399,244,718.5
3-4 years	462,012	142,052,084	467	10.11	473,771.2	0.03	9.86	399,244,718.5
4-5 years	253,038	142,052,084	214	8.46	248,069.2	0.02	8.63	399,244,718.5
5-6 years	138,456	142,052,084	130	9.39	130,962.6	0.01	9.93	399,244,718.5
6-7 years	73,838	142,052,084	63	8.53	66,348.1	0.00	9.50	399,244,718.5
7+ years	37,943	142,052,084	45	11.86	54,520.3	0.00	8.25	399,244,718.5
Furosemide Users (No Washout)								
0-1 years	8,853,836	145,886,512	3,812	4.31	4,485,636.2	0.26	8.50	400,535,781.1
1-2 years	3,756,719	145,886,512	2,306	6.14	2,203,170.4	0.16	10.47	400,535,781.1
2-3 years	2,243,787	145,886,512	2,646	11.79	2,444,001.3	0.18	10.83	400,535,781.1
3-4 years	1,290,390	145,886,512	1,357	10.52	1,359,302.4	0.09	9.98	400,535,781.1
4-5 years	759,943	145,886,512	731	9.62	777,857.2	0.05	9.40	400,535,781.1
5-6 years	451,504	145,886,512	431	9.55	452,325.8	0.03	9.53	400,535,781.1
6-7 years	267,682	145,886,512	207	7.73	258,231.0	0.01	8.02	400,535,781.1
7+ years	157,482	145,886,512	254	16.13	280,840.7	0.02	9.04	400,535,781.1

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	142,052,084	225	13.01	125,379.6	0.02	17.95	403,207,018.7
1-2 years	43,206	142,052,084	59	13.66	31,345.8	0.00	18.82	403,207,018.7
2-3 years	*****	142,052,084	62	29.29	23,683.2	0.00	26.18	403,207,018.7
3-4 years	*****	142,052,084	19	18.27	10,896.4	0.00	17.44	403,207,018.7
4-5 years	*****	142,052,084	17	31.35	5,348.5	0.00	31.78	403,207,018.7
5-6 years	*****	142,052,084	*****	28.82	*****	0.00	30.50	403,207,018.7
6-7 years	*****	142,052,084	0	0.00	1,246.9	0.00	0.00	403,207,018.7
7+ years	*****	142,052,084	*****	43.35	*****	0.00	30.76	403,207,018.7
Bumetanide Users (No Washout)								
0-1 years	681,044	145,886,512	602	8.84	295,001.5	0.04	20.41	423,488,059.5
1-2 years	231,141	145,886,512	286	12.37	133,612.6	0.02	21.41	423,488,059.5
2-3 years	120,390	145,886,512	340	28.24	133,250.5	0.02	25.52	423,488,059.5
3-4 years	60,491	145,886,512	148	24.47	65,442.0	0.01	22.62	423,488,059.5
4-5 years	31,830	145,886,512	76	23.88	32,404.4	0.01	23.45	423,488,059.5
5-6 years	*****	145,886,512	28	16.22	17,082.7	0.00	16.39	423,488,059.5
6-7 years	*****	145,886,512	20	21.34	8,932.6	0.00	22.39	423,488,059.5
7+ years	*****	145,886,512	26	50.34	8,854.2	0.00	29.36	423,488,059.5
Torsemide Users (Washout)								
0-1 years	172,362	142,052,084	180	10.44	109,082.2	0.01	16.50	403,220,608.6
1-2 years	*****	142,052,084	54	11.37	30,502.5	0.00	17.70	403,220,608.6
2-3 years	*****	142,052,084	57	24.15	25,162.3	0.00	22.65	403,220,608.6
3-4 years	*****	142,052,084	22	18.90	11,768.7	0.00	18.69	403,220,608.6
4-5 years	*****	142,052,084	*****	16.81	*****	0.00	17.25	403,220,608.6
5-6 years	*****	142,052,084	*****	28.77	*****	0.00	30.78	403,220,608.6
6-7 years	*****	142,052,084	*****	19.33	*****	0.00	21.53	403,220,608.6
7+ years	*****	142,052,084	*****	37.45	*****	0.00	26.50	403,220,608.6

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-1 years	680,304	145,886,512	477	7.01	251,522.6	0.03	18.96	423,529,490.1
1-2 years	249,185	145,886,512	292	11.72	129,542.7	0.02	22.54	423,529,490.1
2-3 years	131,368	145,886,512	319	24.28	137,438.2	0.02	23.21	423,529,490.1
3-4 years	66,841	145,886,512	146	21.84	68,341.6	0.01	21.36	423,529,490.1
4-5 years	35,645	145,886,512	69	19.36	35,865.0	0.00	19.24	423,529,490.1
5-6 years	*****	145,886,512	43	21.85	19,540.7	0.00	22.01	423,529,490.1
6-7 years	*****	145,886,512	24	22.26	10,284.0	0.00	23.34	423,529,490.1
7+ years	*****	145,886,512	23	38.31	10,251.4	0.00	22.44	423,529,490.1
Furosemide Users (Washout)								
0-1 years	5,031,471	142,052,084	5,630	11.19	3,510,497.2	0.40	16.04	399,244,718.5
1-2 years	1,570,858	142,052,084	2,100	13.37	1,074,009.9	0.15	19.55	399,244,718.5
2-3 years	857,233	142,052,084	1,910	22.28	929,103.2	0.13	20.56	399,244,718.5
3-4 years	462,012	142,052,084	911	19.72	473,771.2	0.06	19.23	399,244,718.5
4-5 years	253,038	142,052,084	516	20.39	248,069.2	0.04	20.80	399,244,718.5
5-6 years	138,456	142,052,084	240	17.33	130,962.6	0.02	18.33	399,244,718.5
6-7 years	73,838	142,052,084	115	15.57	66,348.1	0.01	17.33	399,244,718.5
7+ years	37,943	142,052,084	96	25.30	54,520.3	0.01	17.61	399,244,718.5
Furosemide Users (No Washout)								
0-1 years	8,853,836	145,886,512	7,763	8.77	4,485,636.2	0.53	17.31	400,535,781.1
1-2 years	3,756,719	145,886,512	4,868	12.96	2,203,170.4	0.33	22.10	400,535,781.1
2-3 years	2,243,787	145,886,512	5,990	26.70	2,444,001.3	0.41	24.51	400,535,781.1
3-4 years	1,290,390	145,886,512	2,961	22.95	1,359,302.4	0.20	21.78	400,535,781.1
4-5 years	759,943	145,886,512	1,713	22.54	777,857.2	0.12	22.02	400,535,781.1
5-6 years	451,504	145,886,512	894	19.80	452,325.8	0.06	19.76	400,535,781.1
6-7 years	267,682	145,886,512	494	18.45	258,231.0	0.03	19.13	400,535,781.1
7+ years	157,482	145,886,512	575	36.51	280,840.7	0.04	20.47	400,535,781.1

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	142,052,084	62	3.59	125,379.6	0.00	4.94	403,207,018.7
1-2 years	43,206	142,052,084	16	3.70	31,345.8	0.00	5.10	403,207,018.7
2-3 years	*****	142,052,084	*****	4.72	*****	0.00	4.22	403,207,018.7
3-4 years	*****	142,052,084	*****	7.69	*****	0.00	7.34	403,207,018.7
4-5 years	*****	142,052,084	*****	3.69	*****	0.00	3.74	403,207,018.7
5-6 years	*****	142,052,084	*****	3.60	*****	0.00	3.81	403,207,018.7
6-7 years	*****	142,052,084	*****	7.23	*****	0.00	8.02	403,207,018.7
7+ years	*****	142,052,084	0	0.00	975.4	0.00	0.00	403,207,018.7
Bumetanide Users (No Washout)								
0-1 years	681,044	145,886,512	148	2.17	295,001.5	0.01	5.02	423,488,059.5
1-2 years	231,141	145,886,512	87	3.76	133,612.6	0.01	6.51	423,488,059.5
2-3 years	120,390	145,886,512	89	7.39	133,250.5	0.01	6.68	423,488,059.5
3-4 years	60,491	145,886,512	44	7.27	65,442.0	0.00	6.72	423,488,059.5
4-5 years	31,830	145,886,512	22	6.91	32,404.4	0.00	6.79	423,488,059.5
5-6 years	*****	145,886,512	*****	4.06	*****	0.00	4.10	423,488,059.5
6-7 years	*****	145,886,512	*****	5.34	*****	0.00	5.60	423,488,059.5
7+ years	*****	145,886,512	*****	1.94	*****	0.00	1.13	423,488,059.5
Torsemide Users (Washout)								
0-1 years	172,362	142,052,084	43	2.49	109,082.2	0.00	3.94	403,220,608.6
1-2 years	*****	142,052,084	15	3.16	30,502.5	0.00	4.92	403,220,608.6
2-3 years	*****	142,052,084	17	7.20	25,162.3	0.00	6.76	403,220,608.6
3-4 years	*****	142,052,084	*****	4.30	*****	0.00	4.25	403,220,608.6
4-5 years	*****	142,052,084	*****	5.04	*****	0.00	5.17	403,220,608.6
5-6 years	*****	142,052,084	*****	6.39	*****	0.00	6.84	403,220,608.6
6-7 years	*****	142,052,084	0	0.00	1,393.6	0.00	0.00	403,220,608.6
7+ years	*****	142,052,084	*****	12.48	*****	0.00	8.83	403,220,608.6

Table 8. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Torsemide Users (No Washout)								
0-1 years	680,304	145,886,512	106	1.56	251,522.6	0.01	4.21	423,529,490.1
1-2 years	249,185	145,886,512	85	3.41	129,542.7	0.01	6.56	423,529,490.1
2-3 years	131,368	145,886,512	88	6.70	137,438.2	0.01	6.40	423,529,490.1
3-4 years	66,841	145,886,512	46	6.88	68,341.6	0.00	6.73	423,529,490.1
4-5 years	35,645	145,886,512	19	5.33	35,865.0	0.00	5.30	423,529,490.1
5-6 years	*****	145,886,512	11	5.59	19,540.7	0.00	5.63	423,529,490.1
6-7 years	*****	145,886,512	*****	2.78	*****	0.00	2.92	423,529,490.1
7+ years	*****	145,886,512	*****	13.32	*****	0.00	7.80	423,529,490.1
Furosemide Users (Washout)								
0-1 years	5,031,471	142,052,084	1,135	2.26	3,510,497.2	0.08	3.23	399,244,718.5
1-2 years	1,570,858	142,052,084	549	3.49	1,074,009.9	0.04	5.11	399,244,718.5
2-3 years	857,233	142,052,084	501	5.84	929,103.2	0.04	5.39	399,244,718.5
3-4 years	462,012	142,052,084	286	6.19	473,771.2	0.02	6.04	399,244,718.5
4-5 years	253,038	142,052,084	120	4.74	248,069.2	0.01	4.84	399,244,718.5
5-6 years	138,456	142,052,084	56	4.04	130,962.6	0.00	4.28	399,244,718.5
6-7 years	73,838	142,052,084	29	3.93	66,348.1	0.00	4.37	399,244,718.5
7+ years	37,943	142,052,084	16	4.22	54,520.3	0.00	2.93	399,244,718.5
Furosemide Users (No Washout)								
0-1 years	8,853,836	145,886,512	1,493	1.69	4,485,636.2	0.10	3.33	400,535,781.1
1-2 years	3,756,719	145,886,512	1,081	2.88	2,203,170.4	0.07	4.91	400,535,781.1
2-3 years	2,243,787	145,886,512	1,318	5.87	2,444,001.3	0.09	5.39	400,535,781.1
3-4 years	1,290,390	145,886,512	846	6.56	1,359,302.4	0.06	6.22	400,535,781.1
4-5 years	759,943	145,886,512	474	6.24	777,857.2	0.03	6.09	400,535,781.1
5-6 years	451,504	145,886,512	229	5.07	452,325.8	0.02	5.06	400,535,781.1
6-7 years	267,682	145,886,512	100	3.74	258,231.0	0.01	3.87	400,535,781.1
7+ years	157,482	145,886,512	112	7.11	280,840.7	0.01	3.99	400,535,781.1

* Lower order categories include patients in the higher order categories

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	142,052,084	*****	4.03	*****	0.00	3.47	403,207,018.7
>0 - <700,000 ppm	*****	142,052,084	*****	2.78	*****	0.00	4.11	403,207,018.7
700,000 - 1,000,000 ppm	*****	142,052,084	*****	2.91	*****	0.00	4.32	403,207,018.7
1,000,000 - 1,500,000 ppm	*****	142,052,084	*****	18.56	*****	0.00	22.89	403,207,018.7
1,500,000 - 2,000,000 ppm	*****	142,052,084	0	0.00	452.5	0.00	0.00	403,207,018.7
≥ 2,000,000 ppm	*****	142,052,084	*****	34.25	*****	0.00	27.42	403,207,018.7
Bumetanide Users (No Washout)								
0 ppm	*****	145,886,512	294	5.37	*****	0.02	5.46	423,488,059.5
>0 - <700,000 ppm	*****	145,886,512	75	3.31	*****	0.01	5.63	423,488,059.5
700,000 - 1,000,000 ppm	*****	145,886,512	*****	1.51	*****	0.00	2.96	423,488,059.5
1,000,000 - 1,500,000 ppm	*****	145,886,512	*****	4.63	*****	0.00	6.89	423,488,059.5
1,500,000 - 2,000,000 ppm	*****	145,886,512	0	0.00	2,935.9	0.00	0.00	423,488,059.5
≥ 2,000,000 ppm	*****	145,886,512	*****	13.40	*****	0.00	11.00	423,488,059.5
Torsemide Users (Washout)								
0 ppm	172,362	142,052,084	57	3.31	187,763.7	0.00	3.04	403,220,608.6
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
Torsemide Users (No Washout)								
0 ppm	680,304	145,886,512	280	4.12	662,786.2	0.02	4.22	423,529,490.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
Furosemide Users (Washout)								
0 ppm	5,031,471	142,052,084	3,174	6.31	6,487,281.7	0.22	4.89	399,244,718.5
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
Furosemide Users (No Washout)								
0 ppm	8,853,836	145,886,512	6,240	7.05	12,261,365.0	0.43	5.09	400,535,781.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	142,052,084	*****	10.16	*****	0.01	8.74	403,207,018.7
>0 - <700,000 ppm	*****	142,052,084	*****	6.38	*****	0.00	9.42	403,207,018.7
700,000 - 1,000,000 ppm	*****	142,052,084	*****	5.82	*****	0.00	8.65	403,207,018.7
1,000,000 - 1,500,000 ppm	*****	142,052,084	*****	6.19	*****	0.00	7.63	403,207,018.7
1,500,000 - 2,000,000 ppm	*****	142,052,084	*****	15.70	*****	0.00	22.10	403,207,018.7
≥ 2,000,000 ppm	292	142,052,084	0	0.00	364.7	0.00	0.00	403,207,018.7
Bumetanide Users (No Washout)								
0 ppm	*****	145,886,512	*****	9.37	*****	0.04	9.53	423,488,059.5
>0 - <700,000 ppm	*****	145,886,512	*****	6.17	*****	0.01	10.51	423,488,059.5
700,000 - 1,000,000 ppm	*****	145,886,512	*****	6.53	*****	0.00	12.83	423,488,059.5
1,000,000 - 1,500,000 ppm	*****	145,886,512	*****	5.56	*****	0.00	8.27	423,488,059.5

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
1,500,000 - 2,000,000 ppm	*****	145,886,512	*****	6.45	*****	0.00	10.22	423,488,059.5
≥ 2,000,000 ppm	*****	145,886,512	*****	8.93	*****	0.00	7.34	423,488,059.5
Torsemide Users (Washout)								
0 ppm	172,362	142,052,084	174	10.10	187,763.7	0.01	9.27	403,220,608.6
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
Torsemide Users (No Washout)								
0 ppm	680,304	145,886,512	677	9.95	662,786.2	0.05	10.21	423,529,490.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
Furosemide Users (Washout)								
0 ppm	5,031,471	142,052,084	5,808	11.54	6,487,281.7	0.41	8.95	399,244,718.5
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
Furosemide Users (No Washout)								
0 ppm	8,853,836	145,886,512	11,744	13.26	12,261,365.0	0.81	9.58	400,535,781.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	142,052,084	*****	22.49	*****	0.02	19.34	403,207,018.7
>0 - <700,000 ppm	*****	142,052,084	*****	12.93	*****	0.01	19.09	403,207,018.7
700,000 - 1,000,000 ppm	*****	142,052,084	*****	23.27	*****	0.00	34.58	403,207,018.7
1,000,000 - 1,500,000 ppm	*****	142,052,084	*****	24.75	*****	0.00	30.52	403,207,018.7
1,500,000 - 2,000,000 ppm	*****	142,052,084	*****	15.70	*****	0.00	22.10	403,207,018.7
≥ 2,000,000 ppm	292	142,052,084	0	0.00	364.7	0.00	0.00	403,207,018.7
Bumetanide Users (No Washout)								
0 ppm	*****	145,886,512	*****	21.55	*****	0.08	21.92	423,488,059.5
>0 - <700,000 ppm	*****	145,886,512	*****	12.92	*****	0.02	22.01	423,488,059.5
700,000 - 1,000,000 ppm	*****	145,886,512	24	12.05	10,134.5	0.00	23.68	423,488,059.5
1,000,000 - 1,500,000 ppm	*****	145,886,512	*****	18.54	*****	0.00	27.56	423,488,059.5
1,500,000 - 2,000,000 ppm	*****	145,886,512	*****	12.90	*****	0.00	20.44	423,488,059.5
≥ 2,000,000 ppm	*****	145,886,512	*****	13.40	*****	0.00	11.00	423,488,059.5
Torsemide Users (Washout)								
0 ppm	172,362	142,052,084	338	19.61	187,763.7	0.02	18.00	403,220,608.6
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
Torsemide Users (No Washout)								
0 ppm	680,304	145,886,512	1,393	20.48	662,786.2	0.10	21.02	423,529,490.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
Furosemide Users (Washout)								
0 ppm	5,031,471	142,052,084	11,518	22.89	6,487,281.7	0.81	17.75	399,244,718.5
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
Furosemide Users (No Washout)								
0 ppm	8,853,836	145,886,512	25,258	28.53	12,261,365.0	1.73	20.60	400,535,781.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	142,052,084	*****	6.05	*****	0.01	5.20	403,207,018.7
>0 - <700,000 ppm	*****	142,052,084	*****	2.78	*****	0.00	4.11	403,207,018.7
700,000 - 1,000,000 ppm	*****	142,052,084	0	0.00	2,313.2	0.00	0.00	403,207,018.7
1,000,000 - 1,500,000 ppm	*****	142,052,084	*****	6.19	*****	0.00	7.63	403,207,018.7
1,500,000 - 2,000,000 ppm	*****	142,052,084	*****	15.70	*****	0.00	22.10	403,207,018.7
≥ 2,000,000 ppm	*****	142,052,084	0	0.00	364.7	0.00	0.00	403,207,018.7

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Bumetanide Users (No Washout)								
0 ppm	*****	145,886,512	*****	5.85	*****	0.02	5.94	423,488,059.5
>0 - <700,000 ppm	*****	145,886,512	*****	2.78	*****	0.00	4.73	423,488,059.5
700,000 - 1,000,000 ppm	*****	145,886,512	*****	4.02	*****	0.00	7.89	423,488,059.5
1,000,000 - 1,500,000 ppm	*****	145,886,512	*****	7.42	*****	0.00	11.02	423,488,059.5
1,500,000 - 2,000,000 ppm	*****	145,886,512	*****	4.30	*****	0.00	6.81	423,488,059.5
≥ 2,000,000 ppm	*****	145,886,512	*****	8.93	*****	0.00	7.34	423,488,059.5
Torsemide Users (Washout)								
0 ppm	172,362	142,052,084	86	4.99	187,763.7	0.01	4.58	403,220,608.6
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	403,220,608.6
Torsemide Users (No Washout)								
0 ppm	680,304	145,886,512	366	5.38	662,786.2	0.03	5.52	423,529,490.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	423,529,490.1
Furosemide Users (Washout)								
0 ppm	5,031,471	142,052,084	2,692	5.35	6,487,281.7	0.19	4.15	399,244,718.5
>0 - <700,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
700,000 - 1,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,000,000 - 1,500,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
1,500,000 - 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5
≥ 2,000,000 ppm	0	142,052,084	0	NaN	.	0.00	NaN	399,244,718.5

Table 9. Summary of Users of Loop Diuretics in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Patients	Number of Eligible Members[1]	Number of Patients with an Event	Number of Patients with an Event per 10,000 patients	Total Patient-Years at Risk	Number of Patients with an Event per 10,000 Eligible Members[1]	Event Rate per 10,000 Patient-Years at Risk	Total Eligible Member-Years[1]
Furosemide Users (No Washout)								
0 ppm	8,853,836	145,886,512	5,653	6.38	12,261,365.0	0.39	4.61	400,535,781.1
>0 - <700,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
700,000 - 1,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,000,000 - 1,500,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
1,500,000 - 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1
≥ 2,000,000 ppm	0	145,886,512	0	NaN	.	0.00	NaN	400,535,781.1

* Lower order categories include patients in the higher order categories

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 10a. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome									
Bumetanide Users (Washout)	172,936	115,566	66.8%	19,194	11.1%	13,046	7.5%	8,788	5.1%
Bumetanide Users (No	681,044	483,424	71.0%	69,178	10.2%	44,914	6.6%	29,022	4.3%
Torsemide Users (Washout)	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
Torsemide Users (No Washout)	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
Furosemide Users (Washout)	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
Furosemide Users (No Washout)	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
Bladder Cancer Outcome									
Bumetanide Users (Washout)	172,936	115,566	66.8%	19,194	11.1%	13,046	7.5%	8,788	5.1%
Bumetanide Users (No	681,044	483,424	71.0%	69,178	10.2%	44,914	6.6%	29,022	4.3%
Torsemide Users (Washout)	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
Torsemide Users (No Washout)	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
Furosemide Users (Washout)	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
Furosemide Users (No Washout)	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
Colorectal Cancer Outcome									
Bumetanide Users (Washout)	172,936	115,566	66.8%	19,194	11.1%	13,046	7.5%	8,788	5.1%
Bumetanide Users (No	681,044	483,424	71.0%	69,178	10.2%	44,914	6.6%	29,022	4.3%
Torsemide Users (Washout)	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
Torsemide Users (No Washout)	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
Furosemide Users (Washout)	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
Furosemide Users (No Washout)	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
Esophageal Cancer Outcome									
Bumetanide Users (Washout)	172,936	115,566	66.8%	19,194	11.1%	13,046	7.5%	8,788	5.1%
Bumetanide Users (No	681,044	483,424	71.0%	69,178	10.2%	44,914	6.6%	29,022	4.3%
Torsemide Users (Washout)	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
Torsemide Users (No Washout)	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
Furosemide Users (Washout)	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
Furosemide Users (No Washout)	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%

Table 10a. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	5,864	3.4%	3,909	2.3%	2,945	1.7%	3,624	2.1%
Bumetanide Users (No Washout)	19,002	2.8%	12,743	1.9%	8,888	1.3%	13,873	2.0%
Torsemide Users (Washout)	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
Torsemide Users (No Washout)	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
Furosemide Users (Washout)	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
Furosemide Users (No Washout)	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	5,864	3.4%	3,909	2.3%	2,945	1.7%	3,624	2.1%
Bumetanide Users (No Washout)	19,002	2.8%	12,743	1.9%	8,888	1.3%	13,873	2.0%
Torsemide Users (Washout)	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
Torsemide Users (No Washout)	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
Furosemide Users (Washout)	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
Furosemide Users (No Washout)	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	5,864	3.4%	3,909	2.3%	2,945	1.7%	3,624	2.1%
Bumetanide Users (No Washout)	19,002	2.8%	12,743	1.9%	8,888	1.3%	13,873	2.0%
Torsemide Users (Washout)	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
Torsemide Users (No Washout)	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
Furosemide Users (Washout)	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
Furosemide Users (No Washout)	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	5,864	3.4%	3,909	2.3%	2,945	1.7%	3,624	2.1%
Bumetanide Users (No Washout)	19,002	2.8%	12,743	1.9%	8,888	1.3%	13,873	2.0%
Torsemide Users (Washout)	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
Torsemide Users (No Washout)	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
Furosemide Users (Washout)	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
Furosemide Users (No Washout)	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%

Table 10a. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	620	6,459	425.6	689.9
Bumetanide Users (No Washout)	0	0	0	496	6,568	372.5	662.6
Torsemide Users (Washout)	0	0	0	568	6,363	397.9	662.4
Torsemide Users (No Washout)	0	0	0	462	6,412	355.8	644.7
Furosemide Users (Washout)	0	0	66	712	6,567	470.9	720.8
Furosemide Users (No Washout)	0	0	89	756	6,576	505.8	767.5
Bladder Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	620	6,459	425.6	689.9
Bumetanide Users (No Washout)	0	0	0	496	6,568	372.5	662.6
Torsemide Users (Washout)	0	0	0	568	6,363	397.9	662.4
Torsemide Users (No Washout)	0	0	0	462	6,412	355.8	644.7
Furosemide Users (Washout)	0	0	66	712	6,567	470.9	720.8
Furosemide Users (No Washout)	0	0	89	756	6,576	505.8	767.5
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	620	6,459	425.6	689.9
Bumetanide Users (No Washout)	0	0	0	496	6,568	372.5	662.6
Torsemide Users (Washout)	0	0	0	568	6,363	397.9	662.4
Torsemide Users (No Washout)	0	0	0	462	6,412	355.8	644.7
Furosemide Users (Washout)	0	0	66	712	6,567	470.9	720.8
Furosemide Users (No Washout)	0	0	89	756	6,576	505.8	767.5
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	620	6,459	425.6	689.9
Bumetanide Users (No Washout)	0	0	0	496	6,568	372.5	662.6
Torsemide Users (Washout)	0	0	0	568	6,363	397.9	662.4
Torsemide Users (No Washout)	0	0	0	462	6,412	355.8	644.7
Furosemide Users (Washout)	0	0	66	712	6,567	470.9	720.8
Furosemide Users (No Washout)	0	0	89	756	6,576	505.8	767.5

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome									
Bumetanide Users (Washout)									
0 - <30,000 mg	172,933	137,613	79.6%	12,623	7.3%	7,996	4.6%	5,223	3.0%
30,000 - <60,000 mg	*****	40,128	80.9%	5,006	10.1%	2,345	4.7%	897	1.8%
60,000 - <90,000 mg	*****	21,020	74.4%	5,300	18.8%	1,051	3.7%	399	1.4%
90,000 - <120,000 mg	*****	13,869	78.4%	2,930	16.6%	471	2.7%	194	1.1%
120,000 - <150,000 mg	*****	9,761	81.7%	1,696	14.2%	262	2.2%	101	0.8%
150,000 - <180,000 mg	*****	7,112	86.2%	906	11.0%	119	1.4%	46	0.6%
180,000 - <210,000 mg	*****	5,175	88.1%	537	9.1%	88	1.5%	34	0.6%
≥ 210,000 mg	*****	1,806	41.9%	1,001	23.2%	645	15.0%	388	9.0%
Bumetanide Users (No Washout)									
0 - <30,000 mg	681,031	603,743	88.7%	29,058	4.3%	17,737	2.6%	11,058	1.6%
30,000 - <60,000 mg	304,791	272,603	89.4%	16,224	5.3%	8,257	2.7%	3,095	1.0%
60,000 - <90,000 mg	201,271	169,055	84.0%	23,650	11.8%	4,414	2.2%	1,642	0.8%
90,000 - <120,000 mg	141,898	122,481	86.3%	14,663	10.3%	2,384	1.7%	978	0.7%
120,000 - <150,000 mg	104,735	92,223	88.1%	9,407	9.0%	1,537	1.5%	629	0.6%
150,000 - <180,000 mg	*****	71,020	90.3%	5,740	7.3%	866	1.1%	420	0.5%
180,000 - <210,000 mg	*****	55,426	91.6%	3,734	6.2%	645	1.1%	315	0.5%
≥ 210,000 mg	47,345	19,886	42.0%	10,673	22.5%	6,468	13.7%	4,109	8.7%
Torsemide Users (Washout)									
0 - <30,000 mg	172,357	136,740	79.3%	13,628	7.9%	8,312	4.8%	4,928	2.9%
30,000 - <60,000 mg	*****	33,075	75.9%	5,600	12.8%	2,910	6.7%	942	2.2%
60,000 - <90,000 mg	*****	15,938	70.0%	5,046	22.1%	1,100	4.8%	333	1.5%
90,000 - <120,000 mg	*****	10,263	76.4%	2,558	19.0%	364	2.7%	113	0.8%
120,000 - <150,000 mg	*****	7,168	81.8%	1,313	15.0%	165	1.9%	49	0.6%
150,000 - <180,000 mg	*****	5,129	85.2%	747	12.4%	84	1.4%	28	0.5%
180,000 - <210,000 mg	*****	3,820	87.2%	437	10.0%	58	1.3%	38	0.9%
≥ 210,000 mg	*****	1,532	47.2%	763	23.5%	427	13.2%	234	7.2%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0 - <30,000 mg	680,286	603,626	88.7%	30,022	4.4%	18,185	2.7%	10,438	1.5%
30,000 - <60,000 mg	297,231	259,981	87.5%	19,525	6.6%	10,236	3.4%	3,199	1.1%
60,000 - <90,000 mg	191,137	156,211	81.7%	26,618	13.9%	4,857	2.5%	1,519	0.8%
90,000 - <120,000 mg	132,972	113,119	85.1%	15,824	11.9%	2,273	1.7%	790	0.6%
120,000 - <150,000 mg	97,900	85,768	87.6%	9,752	10.0%	1,277	1.3%	479	0.5%
150,000 - <180,000 mg	73,732	66,508	90.2%	5,871	8.0%	706	1.0%	277	0.4%
180,000 - <210,000 mg	57,843	53,044	91.7%	3,810	6.6%	490	0.8%	236	0.4%
≥ 210,000 mg	46,087	21,669	47.0%	9,979	21.7%	5,657	12.3%	3,657	7.9%
Furosemide Users (Washout)									
0 - <30,000 mg	5,031,366	3,499,014	69.5%	561,459	11.2%	383,151	7.6%	219,018	4.4%
30,000 - <60,000 mg	664,489	307,465	46.3%	171,902	25.9%	123,187	18.5%	32,111	4.8%
60,000 - <90,000 mg	230,504	106,720	46.3%	79,650	34.6%	33,647	14.6%	6,109	2.7%
90,000 - <120,000 mg	97,370	51,832	53.2%	33,571	34.5%	9,253	9.5%	1,640	1.7%
120,000 - <150,000 mg	46,460	28,674	61.7%	14,504	31.2%	2,421	5.2%	477	1.0%
150,000 - <180,000 mg	24,013	16,626	69.2%	6,198	25.8%	843	3.5%	213	0.9%
180,000 - <210,000 mg	*****	10,187	74.9%	2,918	21.5%	323	2.4%	90	0.7%
≥ 210,000 mg	*****	3,936	46.0%	2,274	26.6%	1,093	12.8%	593	6.9%
Furosemide Users (No Washout)									
0 - <30,000 mg	8,853,716	6,527,739	73.7%	881,526	10.0%	615,871	7.0%	308,234	3.5%
30,000 - <60,000 mg	1,997,151	1,009,683	50.6%	444,804	22.3%	362,499	18.2%	87,008	4.4%
60,000 - <90,000 mg	852,245	392,017	46.0%	288,734	33.9%	129,950	15.2%	22,474	2.6%
90,000 - <120,000 mg	422,980	218,641	51.7%	145,038	34.3%	45,642	10.8%	7,646	1.8%
120,000 - <150,000 mg	231,140	134,416	58.2%	75,696	32.7%	16,048	6.9%	2,592	1.1%
150,000 - <180,000 mg	133,068	87,619	65.8%	37,891	28.5%	5,194	3.9%	1,308	1.0%
180,000 - <210,000 mg	81,274	57,030	70.2%	20,607	25.4%	2,351	2.9%	727	0.9%
≥ 210,000 mg	53,201	19,258	36.2%	13,205	24.8%	8,169	15.4%	5,775	10.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome									
Bumetanide Users (Washout)									
0 - <30,000 mg	172,933	137,613	79.6%	12,623	7.3%	7,996	4.6%	5,223	3.0%
30,000 - <60,000 mg	*****	40,128	80.9%	5,006	10.1%	2,345	4.7%	897	1.8%
60,000 - <90,000 mg	*****	21,020	74.4%	5,300	18.8%	1,051	3.7%	399	1.4%
90,000 - <120,000 mg	*****	13,869	78.4%	2,930	16.6%	471	2.7%	194	1.1%
120,000 - <150,000 mg	*****	9,761	81.7%	1,696	14.2%	262	2.2%	101	0.8%
150,000 - <180,000 mg	*****	7,112	86.2%	906	11.0%	119	1.4%	46	0.6%
180,000 - <210,000 mg	*****	5,175	88.1%	537	9.1%	88	1.5%	34	0.6%
≥ 210,000 mg	*****	1,806	41.9%	1,001	23.2%	645	15.0%	388	9.0%
Bumetanide Users (No Washout)									
0 - <30,000 mg	681,031	603,743	88.7%	29,058	4.3%	17,737	2.6%	11,058	1.6%
30,000 - <60,000 mg	304,791	272,603	89.4%	16,224	5.3%	8,257	2.7%	3,095	1.0%
60,000 - <90,000 mg	201,271	169,055	84.0%	23,650	11.8%	4,414	2.2%	1,642	0.8%
90,000 - <120,000 mg	141,898	122,481	86.3%	14,663	10.3%	2,384	1.7%	978	0.7%
120,000 - <150,000 mg	104,735	92,223	88.1%	9,407	9.0%	1,537	1.5%	629	0.6%
150,000 - <180,000 mg	*****	71,020	90.3%	5,740	7.3%	866	1.1%	420	0.5%
180,000 - <210,000 mg	*****	55,426	91.6%	3,734	6.2%	645	1.1%	315	0.5%
≥ 210,000 mg	47,345	19,886	42.0%	10,673	22.5%	6,468	13.7%	4,109	8.7%
Torsemide Users (Washout)									
0 - <30,000 mg	172,357	136,740	79.3%	13,628	7.9%	8,312	4.8%	4,928	2.9%
30,000 - <60,000 mg	*****	33,075	75.9%	5,600	12.8%	2,910	6.7%	942	2.2%
60,000 - <90,000 mg	*****	15,938	70.0%	5,046	22.1%	1,100	4.8%	333	1.5%
90,000 - <120,000 mg	*****	10,263	76.4%	2,558	19.0%	364	2.7%	113	0.8%
120,000 - <150,000 mg	*****	7,168	81.8%	1,313	15.0%	165	1.9%	49	0.6%
150,000 - <180,000 mg	*****	5,129	85.2%	747	12.4%	84	1.4%	28	0.5%
180,000 - <210,000 mg	*****	3,820	87.2%	437	10.0%	58	1.3%	38	0.9%
≥ 210,000 mg	*****	1,532	47.2%	763	23.5%	427	13.2%	234	7.2%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0 - <30,000 mg	680,286	603,626	88.7%	30,022	4.4%	18,185	2.7%	10,438	1.5%
30,000 - <60,000 mg	297,231	259,981	87.5%	19,525	6.6%	10,236	3.4%	3,199	1.1%
60,000 - <90,000 mg	191,137	156,211	81.7%	26,618	13.9%	4,857	2.5%	1,519	0.8%
90,000 - <120,000 mg	132,972	113,119	85.1%	15,824	11.9%	2,273	1.7%	790	0.6%
120,000 - <150,000 mg	97,900	85,768	87.6%	9,752	10.0%	1,277	1.3%	479	0.5%
150,000 - <180,000 mg	73,732	66,508	90.2%	5,871	8.0%	706	1.0%	277	0.4%
180,000 - <210,000 mg	57,843	53,044	91.7%	3,810	6.6%	490	0.8%	236	0.4%
≥ 210,000 mg	46,087	21,669	47.0%	9,979	21.7%	5,657	12.3%	3,657	7.9%
Furosemide Users (Washout)									
0 - <30,000 mg	5,031,366	3,499,014	69.5%	561,459	11.2%	383,151	7.6%	219,018	4.4%
30,000 - <60,000 mg	664,489	307,465	46.3%	171,902	25.9%	123,187	18.5%	32,111	4.8%
60,000 - <90,000 mg	230,504	106,720	46.3%	79,650	34.6%	33,647	14.6%	6,109	2.7%
90,000 - <120,000 mg	97,370	51,832	53.2%	33,571	34.5%	9,253	9.5%	1,640	1.7%
120,000 - <150,000 mg	46,460	28,674	61.7%	14,504	31.2%	2,421	5.2%	477	1.0%
150,000 - <180,000 mg	24,013	16,626	69.2%	6,198	25.8%	843	3.5%	213	0.9%
180,000 - <210,000 mg	*****	10,187	74.9%	2,918	21.5%	323	2.4%	90	0.7%
≥ 210,000 mg	*****	3,936	46.0%	2,274	26.6%	1,093	12.8%	593	6.9%
Furosemide Users (No Washout)									
0 - <30,000 mg	8,853,716	6,527,739	73.7%	881,526	10.0%	615,871	7.0%	308,234	3.5%
30,000 - <60,000 mg	1,997,151	1,009,683	50.6%	444,804	22.3%	362,499	18.2%	87,008	4.4%
60,000 - <90,000 mg	852,245	392,017	46.0%	288,734	33.9%	129,950	15.2%	22,474	2.6%
90,000 - <120,000 mg	422,980	218,641	51.7%	145,038	34.3%	45,642	10.8%	7,646	1.8%
120,000 - <150,000 mg	231,140	134,416	58.2%	75,696	32.7%	16,048	6.9%	2,592	1.1%
150,000 - <180,000 mg	133,068	87,619	65.8%	37,891	28.5%	5,194	3.9%	1,308	1.0%
180,000 - <210,000 mg	81,274	57,030	70.2%	20,607	25.4%	2,351	2.9%	727	0.9%
≥ 210,000 mg	53,201	19,258	36.2%	13,205	24.8%	8,169	15.4%	5,775	10.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome									
Bumetanide Users (Washout)									
0 - <30,000 mg	172,933	137,613	79.6%	12,623	7.3%	7,996	4.6%	5,223	3.0%
30,000 - <60,000 mg	*****	40,128	80.9%	5,006	10.1%	2,345	4.7%	897	1.8%
60,000 - <90,000 mg	*****	21,020	74.4%	5,300	18.8%	1,051	3.7%	399	1.4%
90,000 - <120,000 mg	*****	13,869	78.4%	2,930	16.6%	471	2.7%	194	1.1%
120,000 - <150,000 mg	*****	9,761	81.7%	1,696	14.2%	262	2.2%	101	0.8%
150,000 - <180,000 mg	*****	7,112	86.2%	906	11.0%	119	1.4%	46	0.6%
180,000 - <210,000 mg	*****	5,175	88.1%	537	9.1%	88	1.5%	34	0.6%
≥ 210,000 mg	*****	1,806	41.9%	1,001	23.2%	645	15.0%	388	9.0%
Bumetanide Users (No Washout)									
0 - <30,000 mg	681,031	603,743	88.7%	29,058	4.3%	17,737	2.6%	11,058	1.6%
30,000 - <60,000 mg	304,791	272,603	89.4%	16,224	5.3%	8,257	2.7%	3,095	1.0%
60,000 - <90,000 mg	201,271	169,055	84.0%	23,650	11.8%	4,414	2.2%	1,642	0.8%
90,000 - <120,000 mg	141,898	122,481	86.3%	14,663	10.3%	2,384	1.7%	978	0.7%
120,000 - <150,000 mg	104,735	92,223	88.1%	9,407	9.0%	1,537	1.5%	629	0.6%
150,000 - <180,000 mg	*****	71,020	90.3%	5,740	7.3%	866	1.1%	420	0.5%
180,000 - <210,000 mg	*****	55,426	91.6%	3,734	6.2%	645	1.1%	315	0.5%
≥ 210,000 mg	47,345	19,886	42.0%	10,673	22.5%	6,468	13.7%	4,109	8.7%
Torsemide Users (Washout)									
0 - <30,000 mg	172,357	136,740	79.3%	13,628	7.9%	8,312	4.8%	4,928	2.9%
30,000 - <60,000 mg	*****	33,075	75.9%	5,600	12.8%	2,910	6.7%	942	2.2%
60,000 - <90,000 mg	*****	15,938	70.0%	5,046	22.1%	1,100	4.8%	333	1.5%
90,000 - <120,000 mg	*****	10,263	76.4%	2,558	19.0%	364	2.7%	113	0.8%
120,000 - <150,000 mg	*****	7,168	81.8%	1,313	15.0%	165	1.9%	49	0.6%
150,000 - <180,000 mg	*****	5,129	85.2%	747	12.4%	84	1.4%	28	0.5%
180,000 - <210,000 mg	*****	3,820	87.2%	437	10.0%	58	1.3%	38	0.9%
≥ 210,000 mg	*****	1,532	47.2%	763	23.5%	427	13.2%	234	7.2%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0 - <30,000 mg	680,286	603,626	88.7%	30,022	4.4%	18,185	2.7%	10,438	1.5%
30,000 - <60,000 mg	297,231	259,981	87.5%	19,525	6.6%	10,236	3.4%	3,199	1.1%
60,000 - <90,000 mg	191,137	156,211	81.7%	26,618	13.9%	4,857	2.5%	1,519	0.8%
90,000 - <120,000 mg	132,972	113,119	85.1%	15,824	11.9%	2,273	1.7%	790	0.6%
120,000 - <150,000 mg	97,900	85,768	87.6%	9,752	10.0%	1,277	1.3%	479	0.5%
150,000 - <180,000 mg	73,732	66,508	90.2%	5,871	8.0%	706	1.0%	277	0.4%
180,000 - <210,000 mg	57,843	53,044	91.7%	3,810	6.6%	490	0.8%	236	0.4%
≥ 210,000 mg	46,087	21,669	47.0%	9,979	21.7%	5,657	12.3%	3,657	7.9%
Furosemide Users (Washout)									
0 - <30,000 mg	5,031,366	3,499,014	69.5%	561,459	11.2%	383,151	7.6%	219,018	4.4%
30,000 - <60,000 mg	664,489	307,465	46.3%	171,902	25.9%	123,187	18.5%	32,111	4.8%
60,000 - <90,000 mg	230,504	106,720	46.3%	79,650	34.6%	33,647	14.6%	6,109	2.7%
90,000 - <120,000 mg	97,370	51,832	53.2%	33,571	34.5%	9,253	9.5%	1,640	1.7%
120,000 - <150,000 mg	46,460	28,674	61.7%	14,504	31.2%	2,421	5.2%	477	1.0%
150,000 - <180,000 mg	24,013	16,626	69.2%	6,198	25.8%	843	3.5%	213	0.9%
180,000 - <210,000 mg	*****	10,187	74.9%	2,918	21.5%	323	2.4%	90	0.7%
≥ 210,000 mg	*****	3,936	46.0%	2,274	26.6%	1,093	12.8%	593	6.9%
Furosemide Users (No Washout)									
0 - <30,000 mg	8,853,716	6,527,739	73.7%	881,526	10.0%	615,871	7.0%	308,234	3.5%
30,000 - <60,000 mg	1,997,151	1,009,683	50.6%	444,804	22.3%	362,499	18.2%	87,008	4.4%
60,000 - <90,000 mg	852,245	392,017	46.0%	288,734	33.9%	129,950	15.2%	22,474	2.6%
90,000 - <120,000 mg	422,980	218,641	51.7%	145,038	34.3%	45,642	10.8%	7,646	1.8%
120,000 - <150,000 mg	231,140	134,416	58.2%	75,696	32.7%	16,048	6.9%	2,592	1.1%
150,000 - <180,000 mg	133,068	87,619	65.8%	37,891	28.5%	5,194	3.9%	1,308	1.0%
180,000 - <210,000 mg	81,274	57,030	70.2%	20,607	25.4%	2,351	2.9%	727	0.9%
≥ 210,000 mg	53,201	19,258	36.2%	13,205	24.8%	8,169	15.4%	5,775	10.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome									
Bumetanide Users (Washout)									
0 - <30,000 mg	172,933	137,613	79.6%	12,623	7.3%	7,996	4.6%	5,223	3.0%
30,000 - <60,000 mg	*****	40,128	80.9%	5,006	10.1%	2,345	4.7%	897	1.8%
60,000 - <90,000 mg	*****	21,020	74.4%	5,300	18.8%	1,051	3.7%	399	1.4%
90,000 - <120,000 mg	*****	13,869	78.4%	2,930	16.6%	471	2.7%	194	1.1%
120,000 - <150,000 mg	*****	9,761	81.7%	1,696	14.2%	262	2.2%	101	0.8%
150,000 - <180,000 mg	*****	7,112	86.2%	906	11.0%	119	1.4%	46	0.6%
180,000 - <210,000 mg	*****	5,175	88.1%	537	9.1%	88	1.5%	34	0.6%
≥ 210,000 mg	*****	1,806	41.9%	1,001	23.2%	645	15.0%	388	9.0%
Bumetanide Users (No Washout)									
0 - <30,000 mg	681,031	603,743	88.7%	29,058	4.3%	17,737	2.6%	11,058	1.6%
30,000 - <60,000 mg	304,791	272,603	89.4%	16,224	5.3%	8,257	2.7%	3,095	1.0%
60,000 - <90,000 mg	201,271	169,055	84.0%	23,650	11.8%	4,414	2.2%	1,642	0.8%
90,000 - <120,000 mg	141,898	122,481	86.3%	14,663	10.3%	2,384	1.7%	978	0.7%
120,000 - <150,000 mg	104,735	92,223	88.1%	9,407	9.0%	1,537	1.5%	629	0.6%
150,000 - <180,000 mg	*****	71,020	90.3%	5,740	7.3%	866	1.1%	420	0.5%
180,000 - <210,000 mg	*****	55,426	91.6%	3,734	6.2%	645	1.1%	315	0.5%
≥ 210,000 mg	47,345	19,886	42.0%	10,673	22.5%	6,468	13.7%	4,109	8.7%
Torsemide Users (Washout)									
0 - <30,000 mg	172,357	136,740	79.3%	13,628	7.9%	8,312	4.8%	4,928	2.9%
30,000 - <60,000 mg	*****	33,075	75.9%	5,600	12.8%	2,910	6.7%	942	2.2%
60,000 - <90,000 mg	*****	15,938	70.0%	5,046	22.1%	1,100	4.8%	333	1.5%
90,000 - <120,000 mg	*****	10,263	76.4%	2,558	19.0%	364	2.7%	113	0.8%
120,000 - <150,000 mg	*****	7,168	81.8%	1,313	15.0%	165	1.9%	49	0.6%
150,000 - <180,000 mg	*****	5,129	85.2%	747	12.4%	84	1.4%	28	0.5%
180,000 - <210,000 mg	*****	3,820	87.2%	437	10.0%	58	1.3%	38	0.9%
≥ 210,000 mg	*****	1,532	47.2%	763	23.5%	427	13.2%	234	7.2%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0 - <30,000 mg	680,286	603,626	88.7%	30,022	4.4%	18,185	2.7%	10,438	1.5%
30,000 - <60,000 mg	297,231	259,981	87.5%	19,525	6.6%	10,236	3.4%	3,199	1.1%
60,000 - <90,000 mg	191,137	156,211	81.7%	26,618	13.9%	4,857	2.5%	1,519	0.8%
90,000 - <120,000 mg	132,972	113,119	85.1%	15,824	11.9%	2,273	1.7%	790	0.6%
120,000 - <150,000 mg	97,900	85,768	87.6%	9,752	10.0%	1,277	1.3%	479	0.5%
150,000 - <180,000 mg	73,732	66,508	90.2%	5,871	8.0%	706	1.0%	277	0.4%
180,000 - <210,000 mg	57,843	53,044	91.7%	3,810	6.6%	490	0.8%	236	0.4%
≥ 210,000 mg	46,087	21,669	47.0%	9,979	21.7%	5,657	12.3%	3,657	7.9%
Furosemide Users (Washout)									
0 - <30,000 mg	5,031,366	3,499,014	69.5%	561,459	11.2%	383,151	7.6%	219,018	4.4%
30,000 - <60,000 mg	664,489	307,465	46.3%	171,902	25.9%	123,187	18.5%	32,111	4.8%
60,000 - <90,000 mg	230,504	106,720	46.3%	79,650	34.6%	33,647	14.6%	6,109	2.7%
90,000 - <120,000 mg	97,370	51,832	53.2%	33,571	34.5%	9,253	9.5%	1,640	1.7%
120,000 - <150,000 mg	46,460	28,674	61.7%	14,504	31.2%	2,421	5.2%	477	1.0%
150,000 - <180,000 mg	24,013	16,626	69.2%	6,198	25.8%	843	3.5%	213	0.9%
180,000 - <210,000 mg	*****	10,187	74.9%	2,918	21.5%	323	2.4%	90	0.7%
≥ 210,000 mg	*****	3,936	46.0%	2,274	26.6%	1,093	12.8%	593	6.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Number of Episodes by Episode Length							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)									
0 - <30,000 mg	8,853,716	6,527,739	73.7%	881,526	10.0%	615,871	7.0%	308,234	3.5%
30,000 - <60,000 mg	1,997,151	1,009,683	50.6%	444,804	22.3%	362,499	18.2%	87,008	4.4%
60,000 - <90,000 mg	852,245	392,017	46.0%	288,734	33.9%	129,950	15.2%	22,474	2.6%
90,000 - <120,000 mg	422,980	218,641	51.7%	145,038	34.3%	45,642	10.8%	7,646	1.8%
120,000 - <150,000 mg	231,140	134,416	58.2%	75,696	32.7%	16,048	6.9%	2,592	1.1%
150,000 - <180,000 mg	133,068	87,619	65.8%	37,891	28.5%	5,194	3.9%	1,308	1.0%
180,000 - <210,000 mg	81,274	57,030	70.2%	20,607	25.4%	2,351	2.9%	727	0.9%
≥ 210,000 mg	53,201	19,258	36.2%	13,205	24.8%	8,169	15.4%	5,775	10.9%

* Lower order categories include patients in the higher order categories

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	3,367	1.9%	2,258	1.3%	1,725	1.0%	2,128	1.2%
30,000 - <60,000 mg	495	1.0%	303	0.6%	219	0.4%	*****	*****
60,000 - <90,000 mg	211	0.7%	143	0.5%	57	0.2%	*****	*****
90,000 - <120,000 mg	106	0.6%	47	0.3%	28	0.2%	*****	*****
120,000 - <150,000 mg	52	0.4%	37	0.3%	23	0.2%	*****	*****
150,000 - <180,000 mg	31	0.4%	14	0.2%	12	0.1%	*****	*****
180,000 - <210,000 mg	18	0.3%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	221	5.1%	137	3.2%	68	1.6%	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	7,039	1.0%	4,642	0.7%	3,320	0.5%	4,434	0.7%
30,000 - <60,000 mg	1,759	0.6%	1,070	0.4%	763	0.3%	1,020	0.3%
60,000 - <90,000 mg	934	0.5%	644	0.3%	398	0.2%	534	0.3%
90,000 - <120,000 mg	540	0.4%	315	0.2%	208	0.1%	329	0.2%
120,000 - <150,000 mg	366	0.3%	233	0.2%	159	0.2%	181	0.2%
150,000 - <180,000 mg	218	0.3%	148	0.2%	100	0.1%	*****	*****
180,000 - <210,000 mg	173	0.3%	86	0.1%	69	0.1%	*****	*****
≥ 210,000 mg	2,426	5.1%	1,584	3.3%	1,035	2.2%	1,164	2.5%
Torsemide Users (Washout)								
0 - <30,000 mg	3,305	1.9%	2,247	1.3%	1,390	0.8%	1,807	1.0%
30,000 - <60,000 mg	507	1.2%	251	0.6%	160	0.4%	*****	*****
60,000 - <90,000 mg	179	0.8%	87	0.4%	58	0.3%	*****	*****
90,000 - <120,000 mg	65	0.5%	35	0.3%	20	0.1%	*****	*****
120,000 - <150,000 mg	32	0.4%	16	0.2%	*****	*****	*****	*****
150,000 - <180,000 mg	19	0.3%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	146	4.5%	75	2.3%	40	1.2%	*****	*****

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	6,707	1.0%	4,552	0.7%	2,758	0.4%	3,998	0.6%
30,000 - <60,000 mg	1,844	0.6%	1,039	0.3%	634	0.2%	773	0.3%
60,000 - <90,000 mg	787	0.4%	485	0.3%	303	0.2%	357	0.2%
90,000 - <120,000 mg	432	0.3%	230	0.2%	145	0.1%	159	0.1%
120,000 - <150,000 mg	271	0.3%	161	0.2%	104	0.1%	88	0.1%
150,000 - <180,000 mg	172	0.2%	90	0.1%	53	0.1%	55	0.1%
180,000 - <210,000 mg	122	0.2%	70	0.1%	34	0.1%	37	0.1%
≥ 210,000 mg	2,047	4.4%	1,330	2.9%	826	1.8%	922	2.0%
Furosemide Users (Washout)								
0 - <30,000 mg	141,414	2.8%	92,668	1.8%	58,863	1.2%	75,779	1.5%
30,000 - <60,000 mg	17,707	2.7%	6,432	1.0%	3,137	0.5%	2,548	0.4%
60,000 - <90,000 mg	2,550	1.1%	1,035	0.4%	445	0.2%	348	0.2%
90,000 - <120,000 mg	638	0.7%	235	0.2%	118	0.1%	83	0.1%
120,000 - <150,000 mg	211	0.5%	95	0.2%	39	0.1%	39	0.1%
150,000 - <180,000 mg	82	0.3%	31	0.1%	*****	*****	*****	*****
180,000 - <210,000 mg	42	0.3%	24	0.2%	*****	*****	*****	*****
≥ 210,000 mg	320	3.7%	169	2.0%	87	1.0%	*****	*****
Furosemide Users (No Washout)								
0 - <30,000 mg	194,007	2.2%	127,968	1.4%	81,446	0.9%	116,925	1.3%
30,000 - <60,000 mg	52,815	2.6%	19,165	1.0%	10,977	0.5%	10,200	0.5%
60,000 - <90,000 mg	10,059	1.2%	4,542	0.5%	2,674	0.3%	1,795	0.2%
90,000 - <120,000 mg	3,530	0.8%	1,246	0.3%	679	0.2%	558	0.1%
120,000 - <150,000 mg	1,229	0.5%	617	0.3%	337	0.1%	205	0.1%
150,000 - <180,000 mg	602	0.5%	268	0.2%	97	0.1%	89	0.1%
180,000 - <210,000 mg	312	0.4%	137	0.2%	64	0.1%	46	0.1%
≥ 210,000 mg	2,801	5.3%	1,866	3.5%	1,137	2.1%	990	1.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	3,367	1.9%	2,258	1.3%	1,725	1.0%	2,128	1.2%
30,000 - <60,000 mg	495	1.0%	303	0.6%	219	0.4%	*****	*****
60,000 - <90,000 mg	211	0.7%	143	0.5%	57	0.2%	*****	*****
90,000 - <120,000 mg	106	0.6%	47	0.3%	28	0.2%	*****	*****
120,000 - <150,000 mg	52	0.4%	37	0.3%	23	0.2%	*****	*****
150,000 - <180,000 mg	31	0.4%	14	0.2%	12	0.1%	*****	*****
180,000 - <210,000 mg	18	0.3%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	221	5.1%	137	3.2%	68	1.6%	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	7,039	1.0%	4,642	0.7%	3,320	0.5%	4,434	0.7%
30,000 - <60,000 mg	1,759	0.6%	1,070	0.4%	763	0.3%	1,020	0.3%
60,000 - <90,000 mg	934	0.5%	644	0.3%	398	0.2%	534	0.3%
90,000 - <120,000 mg	540	0.4%	315	0.2%	208	0.1%	329	0.2%
120,000 - <150,000 mg	366	0.3%	233	0.2%	159	0.2%	181	0.2%
150,000 - <180,000 mg	218	0.3%	148	0.2%	100	0.1%	*****	*****
180,000 - <210,000 mg	173	0.3%	86	0.1%	69	0.1%	*****	*****
≥ 210,000 mg	2,426	5.1%	1,584	3.3%	1,035	2.2%	1,164	2.5%
Torsemide Users (Washout)								
0 - <30,000 mg	3,305	1.9%	2,247	1.3%	1,390	0.8%	1,807	1.0%
30,000 - <60,000 mg	507	1.2%	251	0.6%	160	0.4%	*****	*****
60,000 - <90,000 mg	179	0.8%	87	0.4%	58	0.3%	*****	*****
90,000 - <120,000 mg	65	0.5%	35	0.3%	20	0.1%	*****	*****
120,000 - <150,000 mg	32	0.4%	16	0.2%	*****	*****	*****	*****
150,000 - <180,000 mg	19	0.3%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	146	4.5%	75	2.3%	40	1.2%	*****	*****

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	6,707	1.0%	4,552	0.7%	2,758	0.4%	3,998	0.6%
30,000 - <60,000 mg	1,844	0.6%	1,039	0.3%	634	0.2%	773	0.3%
60,000 - <90,000 mg	787	0.4%	485	0.3%	303	0.2%	357	0.2%
90,000 - <120,000 mg	432	0.3%	230	0.2%	145	0.1%	159	0.1%
120,000 - <150,000 mg	271	0.3%	161	0.2%	104	0.1%	88	0.1%
150,000 - <180,000 mg	172	0.2%	90	0.1%	53	0.1%	55	0.1%
180,000 - <210,000 mg	122	0.2%	70	0.1%	34	0.1%	37	0.1%
≥ 210,000 mg	2,047	4.4%	1,330	2.9%	826	1.8%	922	2.0%
Furosemide Users (Washout)								
0 - <30,000 mg	141,414	2.8%	92,668	1.8%	58,863	1.2%	75,779	1.5%
30,000 - <60,000 mg	17,707	2.7%	6,432	1.0%	3,137	0.5%	2,548	0.4%
60,000 - <90,000 mg	2,550	1.1%	1,035	0.4%	445	0.2%	348	0.2%
90,000 - <120,000 mg	638	0.7%	235	0.2%	118	0.1%	83	0.1%
120,000 - <150,000 mg	211	0.5%	95	0.2%	39	0.1%	39	0.1%
150,000 - <180,000 mg	82	0.3%	31	0.1%	*****	*****	*****	*****
180,000 - <210,000 mg	42	0.3%	24	0.2%	*****	*****	*****	*****
≥ 210,000 mg	320	3.7%	169	2.0%	87	1.0%	*****	*****
Furosemide Users (No Washout)								
0 - <30,000 mg	194,007	2.2%	127,968	1.4%	81,446	0.9%	116,925	1.3%
30,000 - <60,000 mg	52,815	2.6%	19,165	1.0%	10,977	0.5%	10,200	0.5%
60,000 - <90,000 mg	10,059	1.2%	4,542	0.5%	2,674	0.3%	1,795	0.2%
90,000 - <120,000 mg	3,530	0.8%	1,246	0.3%	679	0.2%	558	0.1%
120,000 - <150,000 mg	1,229	0.5%	617	0.3%	337	0.1%	205	0.1%
150,000 - <180,000 mg	602	0.5%	268	0.2%	97	0.1%	89	0.1%
180,000 - <210,000 mg	312	0.4%	137	0.2%	64	0.1%	46	0.1%
≥ 210,000 mg	2,801	5.3%	1,866	3.5%	1,137	2.1%	990	1.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	3,367	1.9%	2,258	1.3%	1,725	1.0%	2,128	1.2%
30,000 - <60,000 mg	495	1.0%	303	0.6%	219	0.4%	*****	*****
60,000 - <90,000 mg	211	0.7%	143	0.5%	57	0.2%	*****	*****
90,000 - <120,000 mg	106	0.6%	47	0.3%	28	0.2%	*****	*****
120,000 - <150,000 mg	52	0.4%	37	0.3%	23	0.2%	*****	*****
150,000 - <180,000 mg	31	0.4%	14	0.2%	12	0.1%	*****	*****
180,000 - <210,000 mg	18	0.3%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	221	5.1%	137	3.2%	68	1.6%	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	7,039	1.0%	4,642	0.7%	3,320	0.5%	4,434	0.7%
30,000 - <60,000 mg	1,759	0.6%	1,070	0.4%	763	0.3%	1,020	0.3%
60,000 - <90,000 mg	934	0.5%	644	0.3%	398	0.2%	534	0.3%
90,000 - <120,000 mg	540	0.4%	315	0.2%	208	0.1%	329	0.2%
120,000 - <150,000 mg	366	0.3%	233	0.2%	159	0.2%	181	0.2%
150,000 - <180,000 mg	218	0.3%	148	0.2%	100	0.1%	*****	*****
180,000 - <210,000 mg	173	0.3%	86	0.1%	69	0.1%	*****	*****
≥ 210,000 mg	2,426	5.1%	1,584	3.3%	1,035	2.2%	1,164	2.5%
Torsemide Users (Washout)								
0 - <30,000 mg	3,305	1.9%	2,247	1.3%	1,390	0.8%	1,807	1.0%
30,000 - <60,000 mg	507	1.2%	251	0.6%	160	0.4%	*****	*****
60,000 - <90,000 mg	179	0.8%	87	0.4%	58	0.3%	*****	*****
90,000 - <120,000 mg	65	0.5%	35	0.3%	20	0.1%	*****	*****
120,000 - <150,000 mg	32	0.4%	16	0.2%	*****	*****	*****	*****
150,000 - <180,000 mg	19	0.3%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	146	4.5%	75	2.3%	40	1.2%	*****	*****

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	6,707	1.0%	4,552	0.7%	2,758	0.4%	3,998	0.6%
30,000 - <60,000 mg	1,844	0.6%	1,039	0.3%	634	0.2%	773	0.3%
60,000 - <90,000 mg	787	0.4%	485	0.3%	303	0.2%	357	0.2%
90,000 - <120,000 mg	432	0.3%	230	0.2%	145	0.1%	159	0.1%
120,000 - <150,000 mg	271	0.3%	161	0.2%	104	0.1%	88	0.1%
150,000 - <180,000 mg	172	0.2%	90	0.1%	53	0.1%	55	0.1%
180,000 - <210,000 mg	122	0.2%	70	0.1%	34	0.1%	37	0.1%
≥ 210,000 mg	2,047	4.4%	1,330	2.9%	826	1.8%	922	2.0%
Furosemide Users (Washout)								
0 - <30,000 mg	141,414	2.8%	92,668	1.8%	58,863	1.2%	75,779	1.5%
30,000 - <60,000 mg	17,707	2.7%	6,432	1.0%	3,137	0.5%	2,548	0.4%
60,000 - <90,000 mg	2,550	1.1%	1,035	0.4%	445	0.2%	348	0.2%
90,000 - <120,000 mg	638	0.7%	235	0.2%	118	0.1%	83	0.1%
120,000 - <150,000 mg	211	0.5%	95	0.2%	39	0.1%	39	0.1%
150,000 - <180,000 mg	82	0.3%	31	0.1%	*****	*****	*****	*****
180,000 - <210,000 mg	42	0.3%	24	0.2%	*****	*****	*****	*****
≥ 210,000 mg	320	3.7%	169	2.0%	87	1.0%	*****	*****
Furosemide Users (No Washout)								
0 - <30,000 mg	194,007	2.2%	127,968	1.4%	81,446	0.9%	116,925	1.3%
30,000 - <60,000 mg	52,815	2.6%	19,165	1.0%	10,977	0.5%	10,200	0.5%
60,000 - <90,000 mg	10,059	1.2%	4,542	0.5%	2,674	0.3%	1,795	0.2%
90,000 - <120,000 mg	3,530	0.8%	1,246	0.3%	679	0.2%	558	0.1%
120,000 - <150,000 mg	1,229	0.5%	617	0.3%	337	0.1%	205	0.1%
150,000 - <180,000 mg	602	0.5%	268	0.2%	97	0.1%	89	0.1%
180,000 - <210,000 mg	312	0.4%	137	0.2%	64	0.1%	46	0.1%
≥ 210,000 mg	2,801	5.3%	1,866	3.5%	1,137	2.1%	990	1.9%

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	3,367	1.9%	2,258	1.3%	1,725	1.0%	2,128	1.2%
30,000 - <60,000 mg	495	1.0%	303	0.6%	219	0.4%	*****	*****
60,000 - <90,000 mg	211	0.7%	143	0.5%	57	0.2%	*****	*****
90,000 - <120,000 mg	106	0.6%	47	0.3%	28	0.2%	*****	*****
120,000 - <150,000 mg	52	0.4%	37	0.3%	23	0.2%	*****	*****
150,000 - <180,000 mg	31	0.4%	14	0.2%	12	0.1%	*****	*****
180,000 - <210,000 mg	18	0.3%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	221	5.1%	137	3.2%	68	1.6%	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	7,039	1.0%	4,642	0.7%	3,320	0.5%	4,434	0.7%
30,000 - <60,000 mg	1,759	0.6%	1,070	0.4%	763	0.3%	1,020	0.3%
60,000 - <90,000 mg	934	0.5%	644	0.3%	398	0.2%	534	0.3%
90,000 - <120,000 mg	540	0.4%	315	0.2%	208	0.1%	329	0.2%
120,000 - <150,000 mg	366	0.3%	233	0.2%	159	0.2%	181	0.2%
150,000 - <180,000 mg	218	0.3%	148	0.2%	100	0.1%	*****	*****
180,000 - <210,000 mg	173	0.3%	86	0.1%	69	0.1%	*****	*****
≥ 210,000 mg	2,426	5.1%	1,584	3.3%	1,035	2.2%	1,164	2.5%
Torsemide Users (Washout)								
0 - <30,000 mg	3,305	1.9%	2,247	1.3%	1,390	0.8%	1,807	1.0%
30,000 - <60,000 mg	507	1.2%	251	0.6%	160	0.4%	*****	*****
60,000 - <90,000 mg	179	0.8%	87	0.4%	58	0.3%	*****	*****
90,000 - <120,000 mg	65	0.5%	35	0.3%	20	0.1%	*****	*****
120,000 - <150,000 mg	32	0.4%	16	0.2%	*****	*****	*****	*****
150,000 - <180,000 mg	19	0.3%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	146	4.5%	75	2.3%	40	1.2%	*****	*****

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	6,707	1.0%	4,552	0.7%	2,758	0.4%	3,998	0.6%
30,000 - <60,000 mg	1,844	0.6%	1,039	0.3%	634	0.2%	773	0.3%
60,000 - <90,000 mg	787	0.4%	485	0.3%	303	0.2%	357	0.2%
90,000 - <120,000 mg	432	0.3%	230	0.2%	145	0.1%	159	0.1%
120,000 - <150,000 mg	271	0.3%	161	0.2%	104	0.1%	88	0.1%
150,000 - <180,000 mg	172	0.2%	90	0.1%	53	0.1%	55	0.1%
180,000 - <210,000 mg	122	0.2%	70	0.1%	34	0.1%	37	0.1%
≥ 210,000 mg	2,047	4.4%	1,330	2.9%	826	1.8%	922	2.0%
Furosemide Users (Washout)								
0 - <30,000 mg	141,414	2.8%	92,668	1.8%	58,863	1.2%	75,779	1.5%
30,000 - <60,000 mg	17,707	2.7%	6,432	1.0%	3,137	0.5%	2,548	0.4%
60,000 - <90,000 mg	2,550	1.1%	1,035	0.4%	445	0.2%	348	0.2%
90,000 - <120,000 mg	638	0.7%	235	0.2%	118	0.1%	83	0.1%
120,000 - <150,000 mg	211	0.5%	95	0.2%	39	0.1%	39	0.1%
150,000 - <180,000 mg	82	0.3%	31	0.1%	*****	*****	*****	*****
180,000 - <210,000 mg	42	0.3%	24	0.2%	*****	*****	*****	*****
≥ 210,000 mg	320	3.7%	169	2.0%	87	1.0%	*****	*****

Table 10b. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Episodes by Episode Length							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 - <30,000 mg	194,007	2.2%	127,968	1.4%	81,446	0.9%	116,925	1.3%
30,000 - <60,000 mg	52,815	2.6%	19,165	1.0%	10,977	0.5%	10,200	0.5%
60,000 - <90,000 mg	10,059	1.2%	4,542	0.5%	2,674	0.3%	1,795	0.2%
90,000 - <120,000 mg	3,530	0.8%	1,246	0.3%	679	0.2%	558	0.1%
120,000 - <150,000 mg	1,229	0.5%	617	0.3%	337	0.1%	205	0.1%
150,000 - <180,000 mg	602	0.5%	268	0.2%	97	0.1%	89	0.1%
180,000 - <210,000 mg	312	0.4%	137	0.2%	64	0.1%	46	0.1%
≥ 210,000 mg	2,801	5.3%	1,866	3.5%	1,137	2.1%	990	1.9%

* Lower order categories include patients in the higher order categories

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome									
Bumetanide Users (Washout)									
0-1 years	172,936	136,678	79.0%	12,987	7.5%	8,224	4.8%	5,359	3.1%
1-2 years	*****	32,634	75.5%	6,381	14.8%	1,925	4.5%	909	2.1%
2-3 years	*****	7,669	36.2%	11,578	54.7%	974	4.6%	440	2.1%
3-4 years	*****	3,710	35.7%	6,025	57.9%	358	3.4%	135	1.3%
4-5 years	*****	2,069	38.2%	3,055	56.3%	173	3.2%	59	1.1%
5-6 years	*****	1,118	40.3%	1,534	55.3%	80	2.9%	22	0.8%
6-7 years	*****	576	41.6%	761	55.0%	30	2.2%	*****	*****
7+ years	*****	315	45.5%	183	26.4%	126	18.2%	50	7.2%
Bumetanide Users (No Washout)									
0-1 years	681,044	594,445	87.3%	32,969	4.8%	19,872	2.9%	12,317	1.8%
1-2 years	231,141	188,840	81.7%	25,565	11.1%	7,885	3.4%	3,580	1.5%
2-3 years	120,390	43,515	36.1%	67,179	55.8%	4,854	4.0%	1,957	1.6%
3-4 years	60,491	21,311	35.2%	34,899	57.7%	2,081	3.4%	862	1.4%
4-5 years	31,830	11,302	35.5%	18,778	59.0%	912	2.9%	377	1.2%
5-6 years	*****	6,178	35.8%	10,232	59.3%	456	2.6%	207	1.2%
6-7 years	*****	3,394	36.2%	5,598	59.7%	228	2.4%	89	0.9%
7+ years	*****	1,988	38.5%	1,250	24.2%	971	18.8%	808	15.6%
Torsemide Users (Washout)									
0-1 years	172,362	140,253	81.4%	12,073	7.0%	7,245	4.2%	4,540	2.6%
1-2 years	*****	37,216	78.3%	6,285	13.2%	1,955	4.1%	891	1.9%
2-3 years	*****	8,758	37.1%	13,060	55.3%	913	3.9%	417	1.8%
3-4 years	*****	4,378	37.6%	6,572	56.5%	362	3.1%	167	1.4%
4-5 years	*****	2,250	37.8%	3,404	57.2%	171	2.9%	63	1.1%
5-6 years	*****	1,251	40.0%	1,743	55.7%	77	2.5%	33	1.1%
6-7 years	*****	620	39.9%	891	57.4%	21	1.4%	*****	*****
7+ years	*****	372	46.4%	226	28.2%	129	16.1%	52	6.5%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0-1 years	680,304	605,885	89.1%	29,155	4.3%	16,963	2.5%	10,379	1.5%
1-2 years	249,185	208,158	83.5%	25,860	10.4%	7,308	2.9%	3,318	1.3%
2-3 years	131,368	48,914	37.2%	73,861	56.2%	4,475	3.4%	1,791	1.4%
3-4 years	66,841	24,175	36.2%	38,887	58.2%	2,005	3.0%	806	1.2%
4-5 years	35,645	12,539	35.2%	21,274	59.7%	999	2.8%	369	1.0%
5-6 years	*****	6,991	35.5%	11,712	59.5%	519	2.6%	229	1.2%
6-7 years	*****	3,879	36.0%	6,494	60.2%	227	2.1%	98	0.9%
7+ years	*****	2,322	38.7%	1,506	25.1%	1,065	17.7%	930	15.5%
Furosemide Users (Washout)									
0-1 years	5,031,471	3,999,849	79.5%	378,353	7.5%	236,504	4.7%	152,835	3.0%
1-2 years	1,570,858	1,181,778	75.2%	256,970	16.4%	65,244	4.2%	30,540	1.9%
2-3 years	857,233	288,631	33.7%	503,974	58.8%	35,276	4.1%	14,054	1.6%
3-4 years	462,012	159,642	34.6%	275,333	59.6%	15,198	3.3%	6,060	1.3%
4-5 years	253,038	90,394	35.7%	150,618	59.5%	6,999	2.8%	2,747	1.1%
5-6 years	138,456	52,072	37.6%	80,817	58.4%	3,344	2.4%	1,314	0.9%
6-7 years	73,838	29,977	40.6%	41,538	56.3%	1,485	2.0%	547	0.7%
7+ years	37,943	16,900	44.5%	10,891	28.7%	6,211	16.4%	2,876	7.6%
Furosemide Users (No Washout)									
0-1 years	8,853,836	7,543,453	85.2%	491,068	5.5%	298,502	3.4%	188,204	2.1%
1-2 years	3,756,719	3,007,620	80.1%	488,439	13.0%	127,314	3.4%	57,900	1.5%
2-3 years	2,243,787	708,874	31.6%	1,378,981	61.5%	84,128	3.7%	32,174	1.4%
3-4 years	1,290,390	405,324	31.4%	810,233	62.8%	40,779	3.2%	15,764	1.2%
4-5 years	759,943	240,655	31.7%	480,771	63.3%	21,263	2.8%	8,475	1.1%
5-6 years	451,504	144,497	32.0%	286,359	63.4%	11,714	2.6%	4,531	1.0%
6-7 years	267,682	88,966	33.2%	168,781	63.1%	5,769	2.2%	2,377	0.9%
7+ years	157,482	56,991	36.2%	39,813	25.3%	28,684	18.2%	27,174	17.3%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome									
Bumetanide Users (Washout)									
0-1 years	172,936	136,678	79.0%	12,987	7.5%	8,224	4.8%	5,359	3.1%
1-2 years	43,206	32,634	75.5%	6,381	14.8%	1,925	4.5%	909	2.1%
2-3 years	*****	7,669	36.2%	11,578	54.7%	974	4.6%	440	2.1%
3-4 years	*****	3,710	35.7%	6,025	57.9%	358	3.4%	135	1.3%
4-5 years	*****	2,069	38.2%	3,055	56.3%	173	3.2%	59	1.1%
5-6 years	*****	1,118	40.3%	1,534	55.3%	80	2.9%	22	0.8%
6-7 years	*****	576	41.6%	761	55.0%	30	2.2%	*****	*****
7+ years	*****	315	45.5%	183	26.4%	126	18.2%	50	7.2%
Bumetanide Users (No Washout)									
0-1 years	681,044	594,445	87.3%	32,969	4.8%	19,872	2.9%	12,317	1.8%
1-2 years	231,141	188,840	81.7%	25,565	11.1%	7,885	3.4%	3,580	1.5%
2-3 years	120,390	43,515	36.1%	67,179	55.8%	4,854	4.0%	1,957	1.6%
3-4 years	60,491	21,311	35.2%	34,899	57.7%	2,081	3.4%	862	1.4%
4-5 years	31,830	11,302	35.5%	18,778	59.0%	912	2.9%	377	1.2%
5-6 years	*****	6,178	35.8%	10,232	59.3%	456	2.6%	207	1.2%
6-7 years	*****	3,394	36.2%	5,598	59.7%	228	2.4%	89	0.9%
7+ years	*****	1,988	38.5%	1,250	24.2%	971	18.8%	808	15.6%
Torsemide Users (Washout)									
0-1 years	172,362	140,253	81.4%	12,073	7.0%	7,245	4.2%	4,540	2.6%
1-2 years	*****	37,216	78.3%	6,285	13.2%	1,955	4.1%	891	1.9%
2-3 years	*****	8,758	37.1%	13,060	55.3%	913	3.9%	417	1.8%
3-4 years	*****	4,378	37.6%	6,572	56.5%	362	3.1%	167	1.4%
4-5 years	*****	2,250	37.8%	3,404	57.2%	171	2.9%	63	1.1%
5-6 years	*****	1,251	40.0%	1,743	55.7%	77	2.5%	33	1.1%
6-7 years	*****	620	39.9%	891	57.4%	21	1.4%	*****	*****
7+ years	*****	372	46.4%	226	28.2%	129	16.1%	52	6.5%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0-1 years	680,304	605,885	89.1%	29,155	4.3%	16,963	2.5%	10,379	1.5%
1-2 years	249,185	208,158	83.5%	25,860	10.4%	7,308	2.9%	3,318	1.3%
2-3 years	131,368	48,914	37.2%	73,861	56.2%	4,475	3.4%	1,791	1.4%
3-4 years	66,841	24,175	36.2%	38,887	58.2%	2,005	3.0%	806	1.2%
4-5 years	35,645	12,539	35.2%	21,274	59.7%	999	2.8%	369	1.0%
5-6 years	*****	6,991	35.5%	11,712	59.5%	519	2.6%	229	1.2%
6-7 years	*****	3,879	36.0%	6,494	60.2%	227	2.1%	98	0.9%
7+ years	*****	2,322	38.7%	1,506	25.1%	1,065	17.7%	930	15.5%
Furosemide Users (Washout)									
0-1 years	5,031,471	3,999,849	79.5%	378,353	7.5%	236,504	4.7%	152,835	3.0%
1-2 years	1,570,858	1,181,778	75.2%	256,970	16.4%	65,244	4.2%	30,540	1.9%
2-3 years	857,233	288,631	33.7%	503,974	58.8%	35,276	4.1%	14,054	1.6%
3-4 years	462,012	159,642	34.6%	275,333	59.6%	15,198	3.3%	6,060	1.3%
4-5 years	253,038	90,394	35.7%	150,618	59.5%	6,999	2.8%	2,747	1.1%
5-6 years	138,456	52,072	37.6%	80,817	58.4%	3,344	2.4%	1,314	0.9%
6-7 years	73,838	29,977	40.6%	41,538	56.3%	1,485	2.0%	547	0.7%
7+ years	37,943	16,900	44.5%	10,891	28.7%	6,211	16.4%	2,876	7.6%
Furosemide Users (No Washout)									
0-1 years	8,853,836	7,543,453	85.2%	491,068	5.5%	298,502	3.4%	188,204	2.1%
1-2 years	3,756,719	3,007,620	80.1%	488,439	13.0%	127,314	3.4%	57,900	1.5%
2-3 years	2,243,787	708,874	31.6%	1,378,981	61.5%	84,128	3.7%	32,174	1.4%
3-4 years	1,290,390	405,324	31.4%	810,233	62.8%	40,779	3.2%	15,764	1.2%
4-5 years	759,943	240,655	31.7%	480,771	63.3%	21,263	2.8%	8,475	1.1%
5-6 years	451,504	144,497	32.0%	286,359	63.4%	11,714	2.6%	4,531	1.0%
6-7 years	267,682	88,966	33.2%	168,781	63.1%	5,769	2.2%	2,377	0.9%
7+ years	157,482	56,991	36.2%	39,813	25.3%	28,684	18.2%	27,174	17.3%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome									
Bumetanide Users (Washout)									
0-1 years	172,936	136,678	79.0%	12,987	7.5%	8,224	4.8%	5,359	3.1%
1-2 years	43,206	32,634	75.5%	6,381	14.8%	1,925	4.5%	909	2.1%
2-3 years	*****	7,669	36.2%	11,578	54.7%	974	4.6%	440	2.1%
3-4 years	*****	3,710	35.7%	6,025	57.9%	358	3.4%	135	1.3%
4-5 years	*****	2,069	38.2%	3,055	56.3%	173	3.2%	59	1.1%
5-6 years	*****	1,118	40.3%	1,534	55.3%	80	2.9%	22	0.8%
6-7 years	*****	576	41.6%	761	55.0%	30	2.2%	*****	*****
7+ years	*****	315	45.5%	183	26.4%	126	18.2%	50	7.2%
Bumetanide Users (No Washout)									
0-1 years	681,044	594,445	87.3%	32,969	4.8%	19,872	2.9%	12,317	1.8%
1-2 years	231,141	188,840	81.7%	25,565	11.1%	7,885	3.4%	3,580	1.5%
2-3 years	120,390	43,515	36.1%	67,179	55.8%	4,854	4.0%	1,957	1.6%
3-4 years	60,491	21,311	35.2%	34,899	57.7%	2,081	3.4%	862	1.4%
4-5 years	31,830	11,302	35.5%	18,778	59.0%	912	2.9%	377	1.2%
5-6 years	*****	6,178	35.8%	10,232	59.3%	456	2.6%	207	1.2%
6-7 years	*****	3,394	36.2%	5,598	59.7%	228	2.4%	89	0.9%
7+ years	*****	1,988	38.5%	1,250	24.2%	971	18.8%	808	15.6%
Torsemide Users (Washout)									
0-1 years	172,362	140,253	81.4%	12,073	7.0%	7,245	4.2%	4,540	2.6%
1-2 years	*****	37,216	78.3%	6,285	13.2%	1,955	4.1%	891	1.9%
2-3 years	*****	8,758	37.1%	13,060	55.3%	913	3.9%	417	1.8%
3-4 years	*****	4,378	37.6%	6,572	56.5%	362	3.1%	167	1.4%
4-5 years	*****	2,250	37.8%	3,404	57.2%	171	2.9%	63	1.1%
5-6 years	*****	1,251	40.0%	1,743	55.7%	77	2.5%	33	1.1%
6-7 years	*****	620	39.9%	891	57.4%	21	1.4%	*****	*****
7+ years	*****	372	46.4%	226	28.2%	129	16.1%	52	6.5%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0-1 years	680,304	605,885	89.1%	29,155	4.3%	16,963	2.5%	10,379	1.5%
1-2 years	249,185	208,158	83.5%	25,860	10.4%	7,308	2.9%	3,318	1.3%
2-3 years	131,368	48,914	37.2%	73,861	56.2%	4,475	3.4%	1,791	1.4%
3-4 years	66,841	24,175	36.2%	38,887	58.2%	2,005	3.0%	806	1.2%
4-5 years	35,645	12,539	35.2%	21,274	59.7%	999	2.8%	369	1.0%
5-6 years	*****	6,991	35.5%	11,712	59.5%	519	2.6%	229	1.2%
6-7 years	*****	3,879	36.0%	6,494	60.2%	227	2.1%	98	0.9%
7+ years	*****	2,322	38.7%	1,506	25.1%	1,065	17.7%	930	15.5%
Furosemide Users (Washout)									
0-1 years	5,031,471	3,999,849	79.5%	378,353	7.5%	236,504	4.7%	152,835	3.0%
1-2 years	1,570,858	1,181,778	75.2%	256,970	16.4%	65,244	4.2%	30,540	1.9%
2-3 years	857,233	288,631	33.7%	503,974	58.8%	35,276	4.1%	14,054	1.6%
3-4 years	462,012	159,642	34.6%	275,333	59.6%	15,198	3.3%	6,060	1.3%
4-5 years	253,038	90,394	35.7%	150,618	59.5%	6,999	2.8%	2,747	1.1%
5-6 years	138,456	52,072	37.6%	80,817	58.4%	3,344	2.4%	1,314	0.9%
6-7 years	73,838	29,977	40.6%	41,538	56.3%	1,485	2.0%	547	0.7%
7+ years	37,943	16,900	44.5%	10,891	28.7%	6,211	16.4%	2,876	7.6%
Furosemide Users (No Washout)									
0-1 years	8,853,836	7,543,453	85.2%	491,068	5.5%	298,502	3.4%	188,204	2.1%
1-2 years	3,756,719	3,007,620	80.1%	488,439	13.0%	127,314	3.4%	57,900	1.5%
2-3 years	2,243,787	708,874	31.6%	1,378,981	61.5%	84,128	3.7%	32,174	1.4%
3-4 years	1,290,390	405,324	31.4%	810,233	62.8%	40,779	3.2%	15,764	1.2%
4-5 years	759,943	240,655	31.7%	480,771	63.3%	21,263	2.8%	8,475	1.1%
5-6 years	451,504	144,497	32.0%	286,359	63.4%	11,714	2.6%	4,531	1.0%
6-7 years	267,682	88,966	33.2%	168,781	63.1%	5,769	2.2%	2,377	0.9%
7+ years	157,482	56,991	36.2%	39,813	25.3%	28,684	18.2%	27,174	17.3%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome									
Bumetanide Users (Washout)									
0-1 years	172,936	136,678	79.0%	12,987	7.5%	8,224	4.8%	5,359	3.1%
1-2 years	43,206	32,634	75.5%	6,381	14.8%	1,925	4.5%	909	2.1%
2-3 years	*****	7,669	36.2%	11,578	54.7%	974	4.6%	440	2.1%
3-4 years	*****	3,710	35.7%	6,025	57.9%	358	3.4%	135	1.3%
4-5 years	*****	2,069	38.2%	3,055	56.3%	173	3.2%	59	1.1%
5-6 years	*****	1,118	40.3%	1,534	55.3%	80	2.9%	22	0.8%
6-7 years	*****	576	41.6%	761	55.0%	30	2.2%	*****	*****
7+ years	*****	315	45.5%	183	26.4%	126	18.2%	50	7.2%
Bumetanide Users (No Washout)									
0-1 years	681,044	594,445	87.3%	32,969	4.8%	19,872	2.9%	12,317	1.8%
1-2 years	231,141	188,840	81.7%	25,565	11.1%	7,885	3.4%	3,580	1.5%
2-3 years	120,390	43,515	36.1%	67,179	55.8%	4,854	4.0%	1,957	1.6%
3-4 years	60,491	21,311	35.2%	34,899	57.7%	2,081	3.4%	862	1.4%
4-5 years	31,830	11,302	35.5%	18,778	59.0%	912	2.9%	377	1.2%
5-6 years	*****	6,178	35.8%	10,232	59.3%	456	2.6%	207	1.2%
6-7 years	*****	3,394	36.2%	5,598	59.7%	228	2.4%	89	0.9%
7+ years	*****	1,988	38.5%	1,250	24.2%	971	18.8%	808	15.6%
Torsemide Users (Washout)									
0-1 years	172,362	140,253	81.4%	12,073	7.0%	7,245	4.2%	4,540	2.6%
1-2 years	*****	37,216	78.3%	6,285	13.2%	1,955	4.1%	891	1.9%
2-3 years	*****	8,758	37.1%	13,060	55.3%	913	3.9%	417	1.8%
3-4 years	*****	4,378	37.6%	6,572	56.5%	362	3.1%	167	1.4%
4-5 years	*****	2,250	37.8%	3,404	57.2%	171	2.9%	63	1.1%
5-6 years	*****	1,251	40.0%	1,743	55.7%	77	2.5%	33	1.1%
6-7 years	*****	620	39.9%	891	57.4%	21	1.4%	*****	*****
7+ years	*****	372	46.4%	226	28.2%	129	16.1%	52	6.5%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Number of Users by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)									
0-1 years	680,304	605,885	89.1%	29,155	4.3%	16,963	2.5%	10,379	1.5%
1-2 years	249,185	208,158	83.5%	25,860	10.4%	7,308	2.9%	3,318	1.3%
2-3 years	131,368	48,914	37.2%	73,861	56.2%	4,475	3.4%	1,791	1.4%
3-4 years	66,841	24,175	36.2%	38,887	58.2%	2,005	3.0%	806	1.2%
4-5 years	35,645	12,539	35.2%	21,274	59.7%	999	2.8%	369	1.0%
5-6 years	*****	6,991	35.5%	11,712	59.5%	519	2.6%	229	1.2%
6-7 years	*****	3,879	36.0%	6,494	60.2%	227	2.1%	98	0.9%
7+ years	*****	2,322	38.7%	1,506	25.1%	1,065	17.7%	930	15.5%
Furosemide Users (Washout)									
0-1 years	5,031,471	3,999,849	79.5%	378,353	7.5%	236,504	4.7%	152,835	3.0%
1-2 years	1,570,858	1,181,778	75.2%	256,970	16.4%	65,244	4.2%	30,540	1.9%
2-3 years	857,233	288,631	33.7%	503,974	58.8%	35,276	4.1%	14,054	1.6%
3-4 years	462,012	159,642	34.6%	275,333	59.6%	15,198	3.3%	6,060	1.3%
4-5 years	253,038	90,394	35.7%	150,618	59.5%	6,999	2.8%	2,747	1.1%
5-6 years	138,456	52,072	37.6%	80,817	58.4%	3,344	2.4%	1,314	0.9%
6-7 years	73,838	29,977	40.6%	41,538	56.3%	1,485	2.0%	547	0.7%
7+ years	37,943	16,900	44.5%	10,891	28.7%	6,211	16.4%	2,876	7.6%
Furosemide Users (No Washout)									
0-1 years	8,853,836	7,543,453	85.2%	491,068	5.5%	298,502	3.4%	188,204	2.1%
1-2 years	3,756,719	3,007,620	80.1%	488,439	13.0%	127,314	3.4%	57,900	1.5%
2-3 years	2,243,787	708,874	31.6%	1,378,981	61.5%	84,128	3.7%	32,174	1.4%
3-4 years	1,290,390	405,324	31.4%	810,233	62.8%	40,779	3.2%	15,764	1.2%
4-5 years	759,943	240,655	31.7%	480,771	63.3%	21,263	2.8%	8,475	1.1%
5-6 years	451,504	144,497	32.0%	286,359	63.4%	11,714	2.6%	4,531	1.0%
6-7 years	267,682	88,966	33.2%	168,781	63.1%	5,769	2.2%	2,377	0.9%
7+ years	157,482	56,991	36.2%	39,813	25.3%	28,684	18.2%	27,174	17.3%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	3,448	2.0%	2,321	1.3%	1,754	1.0%	2,165	1.3%
1-2 years	545	1.3%	326	0.8%	228	0.5%	258	0.6%
2-3 years	231	1.1%	127	0.6%	64	0.3%	*****	*****
3-4 years	82	0.8%	42	0.4%	24	0.2%	*****	*****
4-5 years	33	0.6%	21	0.4%	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	7,874	1.2%	5,072	0.7%	3,678	0.5%	4,817	0.7%
1-2 years	1,964	0.8%	1,287	0.6%	830	0.4%	1,190	0.5%
2-3 years	1,090	0.9%	688	0.6%	413	0.3%	694	0.6%
3-4 years	506	0.8%	319	0.5%	219	0.4%	294	0.5%
4-5 years	204	0.6%	140	0.4%	90	0.3%	27	0.1%
5-6 years	104	0.6%	69	0.4%	*****	*****	*****	*****
6-7 years	48	0.5%	*****	*****	*****	*****	*****	*****
7+ years	70	1.4%	41	0.8%	22	0.4%	*****	*****
Torsemide Users (Washout)								
0-1 years	3,101	1.8%	2,104	1.2%	1,320	0.8%	1,726	1.0%
1-2 years	504	1.1%	297	0.6%	169	0.4%	*****	*****
2-3 years	210	0.9%	113	0.5%	68	0.3%	*****	*****
3-4 years	73	0.6%	42	0.4%	27	0.2%	*****	*****
4-5 years	33	0.6%	17	0.3%	*****	*****	*****	*****
5-6 years	13	0.4%	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	6,713	1.0%	4,534	0.7%	2,755	0.4%	3,920	0.6%
1-2 years	1,776	0.7%	1,130	0.5%	683	0.3%	952	0.4%
2-3 years	966	0.7%	565	0.4%	349	0.3%	447	0.3%
3-4 years	418	0.6%	252	0.4%	148	0.2%	150	0.2%
4-5 years	202	0.6%	135	0.4%	107	0.3%	20	0.1%
5-6 years	127	0.6%	86	0.4%	*****	*****	*****	*****
6-7 years	70	0.6%	*****	*****	*****	*****	*****	*****
7+ years	74	1.2%	65	1.1%	20	0.3%	*****	*****
Furosemide Users (Washout)								
0-1 years	100,446	2.0%	65,988	1.3%	42,192	0.8%	55,304	1.1%
1-2 years	16,300	1.0%	9,251	0.6%	5,219	0.3%	5,556	0.4%
2-3 years	7,247	0.8%	3,926	0.5%	2,214	0.3%	1,911	0.2%
3-4 years	2,903	0.6%	1,579	0.3%	782	0.2%	515	0.1%
4-5 years	1,267	0.5%	641	0.3%	244	0.1%	128	0.1%
5-6 years	578	0.4%	235	0.2%	52	0.0%	44	0.0%
6-7 years	203	0.3%	44	0.1%	24	0.0%	20	0.0%
7+ years	510	1.3%	294	0.8%	141	0.4%	120	0.3%
Furosemide Users (No Washout)								
0-1 years	123,374	1.4%	81,918	0.9%	52,601	0.6%	74,716	0.8%
1-2 years	31,225	0.8%	18,609	0.5%	11,024	0.3%	14,588	0.4%
2-3 years	16,916	0.8%	9,940	0.4%	5,838	0.3%	6,936	0.3%
3-4 years	8,277	0.6%	4,546	0.4%	2,838	0.2%	2,629	0.2%
4-5 years	4,204	0.6%	2,446	0.3%	1,724	0.2%	405	0.1%
5-6 years	2,451	0.5%	1,638	0.4%	140	0.0%	174	0.0%
6-7 years	1,506	0.6%	144	0.1%	71	0.0%	68	0.0%
7+ years	2,056	1.3%	1,379	0.9%	811	0.5%	574	0.4%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	3,448	2.0%	2,321	1.3%	1,754	1.0%	2,165	1.3%
1-2 years	545	1.3%	326	0.8%	228	0.5%	258	0.6%
2-3 years	231	1.1%	127	0.6%	64	0.3%	*****	*****
3-4 years	82	0.8%	42	0.4%	24	0.2%	*****	*****
4-5 years	33	0.6%	21	0.4%	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	7,874	1.2%	5,072	0.7%	3,678	0.5%	4,817	0.7%
1-2 years	1,964	0.8%	1,287	0.6%	830	0.4%	1,190	0.5%
2-3 years	1,090	0.9%	688	0.6%	413	0.3%	694	0.6%
3-4 years	506	0.8%	319	0.5%	219	0.4%	294	0.5%
4-5 years	204	0.6%	140	0.4%	90	0.3%	27	0.1%
5-6 years	104	0.6%	69	0.4%	*****	*****	*****	*****
6-7 years	48	0.5%	*****	*****	*****	*****	*****	*****
7+ years	70	1.4%	41	0.8%	22	0.4%	*****	*****
Torsemide Users (Washout)								
0-1 years	3,101	1.8%	2,104	1.2%	1,320	0.8%	1,726	1.0%
1-2 years	504	1.1%	297	0.6%	169	0.4%	*****	*****
2-3 years	210	0.9%	113	0.5%	68	0.3%	*****	*****
3-4 years	73	0.6%	42	0.4%	27	0.2%	*****	*****
4-5 years	33	0.6%	17	0.3%	*****	*****	*****	*****
5-6 years	13	0.4%	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	6,713	1.0%	4,534	0.7%	2,755	0.4%	3,920	0.6%
1-2 years	1,776	0.7%	1,130	0.5%	683	0.3%	952	0.4%
2-3 years	966	0.7%	565	0.4%	349	0.3%	447	0.3%
3-4 years	418	0.6%	252	0.4%	148	0.2%	150	0.2%
4-5 years	202	0.6%	135	0.4%	107	0.3%	20	0.1%
5-6 years	127	0.6%	86	0.4%	*****	*****	*****	*****
6-7 years	70	0.6%	*****	*****	*****	*****	*****	*****
7+ years	74	1.2%	65	1.1%	20	0.3%	*****	*****
Furosemide Users (Washout)								
0-1 years	100,446	2.0%	65,988	1.3%	42,192	0.8%	55,304	1.1%
1-2 years	16,300	1.0%	9,251	0.6%	5,219	0.3%	5,556	0.4%
2-3 years	7,247	0.8%	3,926	0.5%	2,214	0.3%	1,911	0.2%
3-4 years	2,903	0.6%	1,579	0.3%	782	0.2%	515	0.1%
4-5 years	1,267	0.5%	641	0.3%	244	0.1%	128	0.1%
5-6 years	578	0.4%	235	0.2%	52	0.0%	44	0.0%
6-7 years	203	0.3%	44	0.1%	24	0.0%	20	0.0%
7+ years	510	1.3%	294	0.8%	141	0.4%	120	0.3%
Furosemide Users (No Washout)								
0-1 years	123,374	1.4%	81,918	0.9%	52,601	0.6%	74,716	0.8%
1-2 years	31,225	0.8%	18,609	0.5%	11,024	0.3%	14,588	0.4%
2-3 years	16,916	0.8%	9,940	0.4%	5,838	0.3%	6,936	0.3%
3-4 years	8,277	0.6%	4,546	0.4%	2,838	0.2%	2,629	0.2%
4-5 years	4,204	0.6%	2,446	0.3%	1,724	0.2%	405	0.1%
5-6 years	2,451	0.5%	1,638	0.4%	140	0.0%	174	0.0%
6-7 years	1,506	0.6%	144	0.1%	71	0.0%	68	0.0%
7+ years	2,056	1.3%	1,379	0.9%	811	0.5%	574	0.4%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	3,448	2.0%	2,321	1.3%	1,754	1.0%	2,165	1.3%
1-2 years	545	1.3%	326	0.8%	228	0.5%	258	0.6%
2-3 years	231	1.1%	127	0.6%	64	0.3%	*****	*****
3-4 years	82	0.8%	42	0.4%	24	0.2%	*****	*****
4-5 years	33	0.6%	21	0.4%	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	7,874	1.2%	5,072	0.7%	3,678	0.5%	4,817	0.7%
1-2 years	1,964	0.8%	1,287	0.6%	830	0.4%	1,190	0.5%
2-3 years	1,090	0.9%	688	0.6%	413	0.3%	694	0.6%
3-4 years	506	0.8%	319	0.5%	219	0.4%	294	0.5%
4-5 years	204	0.6%	140	0.4%	90	0.3%	27	0.1%
5-6 years	104	0.6%	69	0.4%	*****	*****	*****	*****
6-7 years	48	0.5%	*****	*****	*****	*****	*****	*****
7+ years	70	1.4%	41	0.8%	22	0.4%	*****	*****
Torsemide Users (Washout)								
0-1 years	3,101	1.8%	2,104	1.2%	1,320	0.8%	1,726	1.0%
1-2 years	504	1.1%	297	0.6%	169	0.4%	*****	*****
2-3 years	210	0.9%	113	0.5%	68	0.3%	*****	*****
3-4 years	73	0.6%	42	0.4%	27	0.2%	*****	*****
4-5 years	33	0.6%	17	0.3%	*****	*****	*****	*****
5-6 years	13	0.4%	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	6,713	1.0%	4,534	0.7%	2,755	0.4%	3,920	0.6%
1-2 years	1,776	0.7%	1,130	0.5%	683	0.3%	952	0.4%
2-3 years	966	0.7%	565	0.4%	349	0.3%	447	0.3%
3-4 years	418	0.6%	252	0.4%	148	0.2%	150	0.2%
4-5 years	202	0.6%	135	0.4%	107	0.3%	20	0.1%
5-6 years	127	0.6%	86	0.4%	*****	*****	*****	*****
6-7 years	70	0.6%	*****	*****	*****	*****	*****	*****
7+ years	74	1.2%	65	1.1%	20	0.3%	*****	*****
Furosemide Users (Washout)								
0-1 years	100,446	2.0%	65,988	1.3%	42,192	0.8%	55,304	1.1%
1-2 years	16,300	1.0%	9,251	0.6%	5,219	0.3%	5,556	0.4%
2-3 years	7,247	0.8%	3,926	0.5%	2,214	0.3%	1,911	0.2%
3-4 years	2,903	0.6%	1,579	0.3%	782	0.2%	515	0.1%
4-5 years	1,267	0.5%	641	0.3%	244	0.1%	128	0.1%
5-6 years	578	0.4%	235	0.2%	52	0.0%	44	0.0%
6-7 years	203	0.3%	44	0.1%	24	0.0%	20	0.0%
7+ years	510	1.3%	294	0.8%	141	0.4%	120	0.3%
Furosemide Users (No Washout)								
0-1 years	123,374	1.4%	81,918	0.9%	52,601	0.6%	74,716	0.8%
1-2 years	31,225	0.8%	18,609	0.5%	11,024	0.3%	14,588	0.4%
2-3 years	16,916	0.8%	9,940	0.4%	5,838	0.3%	6,936	0.3%
3-4 years	8,277	0.6%	4,546	0.4%	2,838	0.2%	2,629	0.2%
4-5 years	4,204	0.6%	2,446	0.3%	1,724	0.2%	405	0.1%
5-6 years	2,451	0.5%	1,638	0.4%	140	0.0%	174	0.0%
6-7 years	1,506	0.6%	144	0.1%	71	0.0%	68	0.0%
7+ years	2,056	1.3%	1,379	0.9%	811	0.5%	574	0.4%

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	3,448	2.0%	2,321	1.3%	1,754	1.0%	2,165	1.3%
1-2 years	545	1.3%	326	0.8%	228	0.5%	258	0.6%
2-3 years	231	1.1%	127	0.6%	64	0.3%	*****	*****
3-4 years	82	0.8%	42	0.4%	24	0.2%	*****	*****
4-5 years	33	0.6%	21	0.4%	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	7,874	1.2%	5,072	0.7%	3,678	0.5%	4,817	0.7%
1-2 years	1,964	0.8%	1,287	0.6%	830	0.4%	1,190	0.5%
2-3 years	1,090	0.9%	688	0.6%	413	0.3%	694	0.6%
3-4 years	506	0.8%	319	0.5%	219	0.4%	294	0.5%
4-5 years	204	0.6%	140	0.4%	90	0.3%	27	0.1%
5-6 years	104	0.6%	69	0.4%	*****	*****	*****	*****
6-7 years	48	0.5%	*****	*****	*****	*****	*****	*****
7+ years	70	1.4%	41	0.8%	22	0.4%	*****	*****
Torsemide Users (Washout)								
0-1 years	3,101	1.8%	2,104	1.2%	1,320	0.8%	1,726	1.0%
1-2 years	504	1.1%	297	0.6%	169	0.4%	*****	*****
2-3 years	210	0.9%	113	0.5%	68	0.3%	*****	*****
3-4 years	73	0.6%	42	0.4%	27	0.2%	*****	*****
4-5 years	33	0.6%	17	0.3%	*****	*****	*****	*****
5-6 years	13	0.4%	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****

Table 10c. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	6,713	1.0%	4,534	0.7%	2,755	0.4%	3,920	0.6%
1-2 years	1,776	0.7%	1,130	0.5%	683	0.3%	952	0.4%
2-3 years	966	0.7%	565	0.4%	349	0.3%	447	0.3%
3-4 years	418	0.6%	252	0.4%	148	0.2%	150	0.2%
4-5 years	202	0.6%	135	0.4%	107	0.3%	20	0.1%
5-6 years	127	0.6%	86	0.4%	*****	*****	*****	*****
6-7 years	70	0.6%	*****	*****	*****	*****	*****	*****
7+ years	74	1.2%	65	1.1%	20	0.3%	*****	*****
Furosemide Users (Washout)								
0-1 years	100,446	2.0%	65,988	1.3%	42,192	0.8%	55,304	1.1%
1-2 years	16,300	1.0%	9,251	0.6%	5,219	0.3%	5,556	0.4%
2-3 years	7,247	0.8%	3,926	0.5%	2,214	0.3%	1,911	0.2%
3-4 years	2,903	0.6%	1,579	0.3%	782	0.2%	515	0.1%
4-5 years	1,267	0.5%	641	0.3%	244	0.1%	128	0.1%
5-6 years	578	0.4%	235	0.2%	52	0.0%	44	0.0%
6-7 years	203	0.3%	44	0.1%	24	0.0%	20	0.0%
7+ years	510	1.3%	294	0.8%	141	0.4%	120	0.3%
Furosemide Users (No Washout)								
0-1 years	123,374	1.4%	81,918	0.9%	52,601	0.6%	74,716	0.8%
1-2 years	31,225	0.8%	18,609	0.5%	11,024	0.3%	14,588	0.4%
2-3 years	16,916	0.8%	9,940	0.4%	5,838	0.3%	6,936	0.3%
3-4 years	8,277	0.6%	4,546	0.4%	2,838	0.2%	2,629	0.2%
4-5 years	4,204	0.6%	2,446	0.3%	1,724	0.2%	405	0.1%
5-6 years	2,451	0.5%	1,638	0.4%	140	0.0%	174	0.0%
6-7 years	1,506	0.6%	144	0.1%	71	0.0%	68	0.0%
7+ years	2,056	1.3%	1,379	0.9%	811	0.5%	574	0.4%

* Lower order categories include patients in the higher order categories

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome									
Bumetanide Users (Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)									
0 ppm	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)									
0 ppm	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)									
0 ppm	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)									
0 ppm	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome									
Bumetanide Users (Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)									
0 ppm	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)									
0 ppm	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)									
0 ppm	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)									
0 ppm	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome									
Bumetanide Users (Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)									
0 ppm	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)									
0 ppm	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)									
0 ppm	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)									
0 ppm	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome									
Bumetanide Users (Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)									
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Number of Episodes by Follow-up Time							
		0-364 days		365-729 days		730-1,094 days		1,095-1,460 days	
	Total Number of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)									
0 ppm	172,362	117,787	68.3%	19,247	11.2%	12,364	7.2%	8,103	4.7%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)									
0 ppm	680,304	489,741	72.0%	68,739	10.1%	43,105	6.3%	27,536	4.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)									
0 ppm	5,031,471	3,207,436	63.7%	590,047	11.7%	407,458	8.1%	281,829	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)									
0 ppm	8,853,836	5,542,875	62.6%	1,038,131	11.7%	720,711	8.1%	492,873	5.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)								
0 ppm	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)								
0 ppm	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	5,536	3.2%	3,820	2.2%	2,418	1.4%	3,087	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	18,182	2.7%	12,588	1.9%	7,924	1.2%	12,489	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	196,957	3.9%	136,377	2.7%	90,720	1.8%	120,647	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 10d. Summary of Time to End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Episodes by Follow-up Time							
	1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 ppm	347,435	3.9%	251,230	2.8%	170,658	1.9%	289,923	3.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 11a. Summary of Reasons for End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome							
Bumetanide Users (Washout)	172,936	0	0.0%	76	0.0%	20,908	12.1%
Bumetanide Users (No Washout)	681,044	0	0.0%	380	0.1%	79,926	11.7%
Torsemide Users (Washout)	172,362	0	0.0%	57	0.0%	20,378	11.8%
Torsemide Users (No Washout)	680,304	0	0.0%	280	0.0%	79,236	11.6%
Furosemide Users (Washout)	5,031,471	0	0.0%	3,174	0.1%	651,012	12.9%
Furosemide Users (No Washout)	8,853,836	0	0.0%	6,240	0.1%	1,323,893	15.0%
Bladder Cancer Outcome							
Bumetanide Users (Washout)	172,936	0	0.0%	179	0.1%	20,908	12.1%
Bumetanide Users (No Washout)	681,044	0	0.0%	677	0.1%	79,926	11.7%
Torsemide Users (Washout)	172,362	0	0.0%	174	0.1%	20,378	11.8%
Torsemide Users (No Washout)	680,304	0	0.0%	677	0.1%	79,236	11.6%
Furosemide Users (Washout)	5,031,471	0	0.0%	5,808	0.1%	651,012	12.9%
Furosemide Users (No Washout)	8,853,836	0	0.0%	11,744	0.1%	1,323,893	15.0%
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	172,936	0	0.0%	393	0.2%	20,908	12.1%
Bumetanide Users (No Washout)	681,044	0	0.0%	1,526	0.2%	79,926	11.7%
Torsemide Users (Washout)	172,362	0	0.0%	338	0.2%	20,378	11.8%
Torsemide Users (No Washout)	680,304	0	0.0%	1,393	0.2%	79,236	11.6%
Furosemide Users (Washout)	5,031,471	0	0.0%	11,518	0.2%	651,012	12.9%
Furosemide Users (No Washout)	8,853,836	0	0.0%	25,258	0.3%	1,323,893	15.0%
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	172,936	0	0.0%	100	0.1%	20,908	12.1%
Bumetanide Users (No Washout)	681,044	0	0.0%	403	0.1%	79,926	11.7%
Torsemide Users (Washout)	172,362	0	0.0%	86	0.0%	20,378	11.8%
Torsemide Users (No Washout)	680,304	0	0.0%	366	0.1%	79,236	11.6%
Furosemide Users (Washout)	5,031,471	0	0.0%	2,692	0.1%	651,012	12.9%
Furosemide Users (No Washout)	8,853,836	0	0.0%	5,653	0.1%	1,323,893	15.0%

Table 11a. Summary of Reasons for End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	47,064	27.2%	105,300	60.9%	56,703	32.8%	0	0.0%
Bumetanide Users (No Washout)	250,564	36.8%	356,075	52.3%	184,360	27.1%	0	0.0%
Torsemide Users (Washout)	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
Torsemide Users (No Washout)	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
Furosemide Users (Washout)	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
Furosemide Users (No Washout)	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	47,064	27.2%	105,300	60.9%	56,703	32.8%	0	0.0%
Bumetanide Users (No Washout)	250,564	36.8%	356,075	52.3%	184,360	27.1%	0	0.0%
Torsemide Users (Washout)	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
Torsemide Users (No Washout)	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
Furosemide Users (Washout)	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
Furosemide Users (No Washout)	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	47,064	27.2%	105,300	60.9%	56,703	32.8%	0	0.0%
Bumetanide Users (No Washout)	250,564	36.8%	356,075	52.3%	184,360	27.1%	0	0.0%
Torsemide Users (Washout)	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
Torsemide Users (No Washout)	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
Furosemide Users (Washout)	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
Furosemide Users (No Washout)	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	47,064	27.2%	105,300	60.9%	56,703	32.8%	0	0.0%
Bumetanide Users (No Washout)	250,564	36.8%	356,075	52.3%	184,360	27.1%	0	0.0%
Torsemide Users (Washout)	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
Torsemide Users (No Washout)	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%

Table 11a. Summary of Reasons for End of At-Risk Period for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Furosemide Users (Washout)	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
Furosemide Users (No Washout)	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of request-defined event.

[4]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[5]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[6]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[7]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[8]Represents episodes censored due to user-specified study end date.

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome							
Bumetanide Users (Washout)							
0 - <30,000 mg	172,933	49,624	28.7%	40	0.0%	12,623	7.3%
30,000 - <60,000 mg	*****	28,261	57.0%	*****	*****	2,968	6.0%
60,000 - <90,000 mg	*****	17,683	62.6%	*****	*****	1,910	6.8%
90,000 - <120,000 mg	*****	11,949	67.6%	*****	*****	1,109	6.3%
120,000 - <150,000 mg	*****	8,248	69.0%	*****	*****	727	6.1%
150,000 - <180,000 mg	*****	5,876	71.2%	*****	*****	453	5.5%
180,000 - <210,000 mg	*****	4,301	73.2%	*****	*****	312	5.3%
≥ 210,000 mg	*****	0	0.0%	*****	*****	806	18.7%
Bumetanide Users (No Washout)							
0 - <30,000 mg	681,031	304,808	44.8%	124	0.0%	29,236	4.3%
30,000 - <60,000 mg	304,791	201,269	66.0%	61	0.0%	11,958	3.9%
60,000 - <90,000 mg	201,271	141,915	70.5%	41	0.0%	9,643	4.8%
90,000 - <120,000 mg	141,898	104,740	73.8%	30	0.0%	6,677	4.7%
120,000 - <150,000 mg	104,735	78,629	75.1%	28	0.0%	5,579	5.3%
150,000 - <180,000 mg	*****	60,543	77.0%	26	0.0%	3,762	4.8%
180,000 - <210,000 mg	*****	47,301	78.1%	*****	*****	2,772	4.6%
≥ 210,000 mg	47,345	0	0.0%	60	0.1%	10,299	21.8%
Torsemide Users (Washout)							
0 - <30,000 mg	172,357	43,595	25.3%	38	0.0%	13,000	7.5%
30,000 - <60,000 mg	*****	22,778	52.2%	*****	*****	3,223	7.4%
60,000 - <90,000 mg	*****	13,444	59.0%	*****	*****	1,767	7.8%
90,000 - <120,000 mg	*****	8,759	65.2%	*****	*****	871	6.5%
120,000 - <150,000 mg	*****	6,015	68.7%	*****	*****	461	5.3%
150,000 - <180,000 mg	*****	4,384	72.8%	*****	*****	293	4.9%
180,000 - <210,000 mg	*****	3,238	73.9%	0	0.0%	221	5.0%
≥ 210,000 mg	*****	0	0.0%	*****	*****	542	16.7%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)							
0 - <30,000 mg	680,286	297,240	43.7%	94	0.0%	29,678	4.4%
30,000 - <60,000 mg	297,231	191,132	64.3%	36	0.0%	13,681	4.6%
60,000 - <90,000 mg	191,137	132,995	69.6%	36	0.0%	10,091	5.3%
90,000 - <120,000 mg	132,972	97,901	73.6%	24	0.0%	6,302	4.7%
120,000 - <150,000 mg	97,900	73,715	75.3%	16	0.0%	4,737	4.8%
150,000 - <180,000 mg	73,732	57,858	78.5%	20	0.0%	3,057	4.1%
180,000 - <210,000 mg	57,843	46,043	79.6%	15	0.0%	2,328	4.0%
≥ 210,000 mg	46,087	0	0.0%	39	0.1%	9,362	20.3%
Furosemide Users (Washout)							
0 - <30,000 mg	5,031,366	664,577	13.2%	2,333	0.0%	514,919	10.2%
30,000 - <60,000 mg	664,489	230,598	34.7%	555	0.1%	92,410	13.9%
60,000 - <90,000 mg	230,504	97,567	42.3%	162	0.1%	26,606	11.5%
90,000 - <120,000 mg	97,370	46,157	47.4%	70	0.1%	9,386	9.6%
120,000 - <150,000 mg	46,460	24,014	51.7%	28	0.1%	3,824	8.2%
150,000 - <180,000 mg	24,013	13,702	57.1%	15	0.1%	1,748	7.3%
180,000 - <210,000 mg	*****	8,278	60.9%	*****	*****	919	6.8%
≥ 210,000 mg	*****	0	0.0%	*****	*****	1,200	14.0%
Furosemide Users (No Washout)							
0 - <30,000 mg	8,853,716	1,997,430	22.6%	3,580	0.0%	827,962	9.4%
30,000 - <60,000 mg	1,997,151	852,435	42.7%	1,520	0.1%	291,650	14.6%
60,000 - <90,000 mg	852,245	423,312	49.7%	575	0.1%	108,722	12.8%
90,000 - <120,000 mg	422,980	230,704	54.5%	273	0.1%	46,135	10.9%
120,000 - <150,000 mg	231,140	133,091	57.6%	123	0.1%	22,058	9.5%
150,000 - <180,000 mg	133,068	81,409	61.2%	78	0.1%	10,968	8.2%
180,000 - <210,000 mg	81,274	52,558	64.7%	32	0.0%	6,276	7.7%
≥ 210,000 mg	53,201	0	0.0%	59	0.1%	10,122	19.0%
Bladder Cancer Outcome							

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Bumetanide Users (Washout)							
0 - <30,000 mg	172,933	49,624	28.7%	103	0.1%	12,623	7.3%
30,000 - <60,000 mg	*****	28,261	57.0%	25	0.1%	2,968	6.0%
60,000 - <90,000 mg	*****	17,683	62.6%	17	0.1%	1,910	6.8%
90,000 - <120,000 mg	*****	11,949	67.6%	*****	*****	1,109	6.3%
120,000 - <150,000 mg	*****	8,248	69.0%	*****	*****	727	6.1%
150,000 - <180,000 mg	*****	5,876	71.2%	0	0.0%	453	5.5%
180,000 - <210,000 mg	*****	4,301	73.2%	*****	*****	312	5.3%
≥ 210,000 mg	*****	0	0.0%	13	0.3%	806	18.7%
Bumetanide Users (No Washout)							
0 - <30,000 mg	681,031	304,808	44.8%	230	0.0%	29,236	4.3%
30,000 - <60,000 mg	304,791	201,269	66.0%	93	0.0%	11,958	3.9%
60,000 - <90,000 mg	201,271	141,915	70.5%	88	0.0%	9,643	4.8%
90,000 - <120,000 mg	141,898	104,740	73.8%	65	0.0%	6,677	4.7%
120,000 - <150,000 mg	104,735	78,629	75.1%	47	0.0%	5,579	5.3%
150,000 - <180,000 mg	*****	60,543	77.0%	27	0.0%	3,762	4.8%
180,000 - <210,000 mg	*****	47,301	78.1%	30	0.0%	2,772	4.6%
≥ 210,000 mg	47,345	0	0.0%	97	0.2%	10,299	21.8%
Torsemide Users (Washout)							
0 - <30,000 mg	172,357	43,595	25.3%	109	0.1%	13,000	7.5%
30,000 - <60,000 mg	*****	22,778	52.2%	28	0.1%	3,223	7.4%
60,000 - <90,000 mg	*****	13,444	59.0%	21	0.1%	1,767	7.8%
90,000 - <120,000 mg	*****	8,759	65.2%	*****	*****	871	6.5%
120,000 - <150,000 mg	*****	6,015	68.7%	*****	*****	461	5.3%
150,000 - <180,000 mg	*****	4,384	72.8%	*****	*****	293	4.9%
180,000 - <210,000 mg	*****	3,238	73.9%	*****	*****	221	5.0%
≥ 210,000 mg	*****	0	0.0%	*****	*****	542	16.7%
Torsemide Users (No Washout)							

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0 - <30,000 mg	680,286	297,240	43.7%	239	0.0%	29,678	4.4%
30,000 - <60,000 mg	297,231	191,132	64.3%	121	0.0%	13,681	4.6%
60,000 - <90,000 mg	191,137	132,995	69.6%	92	0.0%	10,091	5.3%
90,000 - <120,000 mg	132,972	97,901	73.6%	48	0.0%	6,302	4.7%
120,000 - <150,000 mg	97,900	73,715	75.3%	53	0.1%	4,737	4.8%
150,000 - <180,000 mg	73,732	57,858	78.5%	19	0.0%	3,057	4.1%
180,000 - <210,000 mg	57,843	46,043	79.6%	36	0.1%	2,328	4.0%
≥ 210,000 mg	46,087	0	0.0%	69	0.1%	9,362	20.3%
Furosemide Users (Washout)							
0 - <30,000 mg	5,031,366	664,577	13.2%	4,467	0.1%	514,919	10.2%
30,000 - <60,000 mg	664,489	230,598	34.7%	881	0.1%	92,410	13.9%
60,000 - <90,000 mg	230,504	97,567	42.3%	292	0.1%	26,606	11.5%
90,000 - <120,000 mg	97,370	46,157	47.4%	95	0.1%	9,386	9.6%
120,000 - <150,000 mg	46,460	24,014	51.7%	36	0.1%	3,824	8.2%
150,000 - <180,000 mg	24,013	13,702	57.1%	13	0.1%	1,748	7.3%
180,000 - <210,000 mg	*****	8,278	60.9%	12	0.1%	919	6.8%
≥ 210,000 mg	*****	0	0.0%	12	0.1%	1,200	14.0%
Furosemide Users (No Washout)							
0 - <30,000 mg	8,853,716	1,997,430	22.6%	7,083	0.1%	827,962	9.4%
30,000 - <60,000 mg	1,997,151	852,435	42.7%	2,681	0.1%	291,650	14.6%
60,000 - <90,000 mg	852,245	423,312	49.7%	1,065	0.1%	108,722	12.8%
90,000 - <120,000 mg	422,980	230,704	54.5%	441	0.1%	46,135	10.9%
120,000 - <150,000 mg	231,140	133,091	57.6%	198	0.1%	22,058	9.5%
150,000 - <180,000 mg	133,068	81,409	61.2%	102	0.1%	10,968	8.2%
180,000 - <210,000 mg	81,274	52,558	64.7%	65	0.1%	6,276	7.7%
≥ 210,000 mg	53,201	0	0.0%	109	0.2%	10,122	19.0%
Colorectal Cancer Outcome							
Bumetanide Users (Washout)							

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0 - <30,000 mg	172,933	49,624	28.7%	212	0.1%	12,623	7.3%
30,000 - <60,000 mg	*****	28,261	57.0%	64	0.1%	2,968	6.0%
60,000 - <90,000 mg	*****	17,683	62.6%	38	0.1%	1,910	6.8%
90,000 - <120,000 mg	*****	11,949	67.6%	22	0.1%	1,109	6.3%
120,000 - <150,000 mg	*****	8,248	69.0%	21	0.2%	727	6.1%
150,000 - <180,000 mg	*****	5,876	71.2%	11	0.1%	453	5.5%
180,000 - <210,000 mg	*****	4,301	73.2%	*****	*****	312	5.3%
≥ 210,000 mg	*****	0	0.0%	20	0.5%	806	18.7%
Bumetanide Users (No Washout)							
0 - <30,000 mg	681,031	304,808	44.8%	516	0.1%	29,236	4.3%
30,000 - <60,000 mg	304,791	201,269	66.0%	235	0.1%	11,958	3.9%
60,000 - <90,000 mg	201,271	141,915	70.5%	200	0.1%	9,643	4.8%
90,000 - <120,000 mg	141,898	104,740	73.8%	148	0.1%	6,677	4.7%
120,000 - <150,000 mg	104,735	78,629	75.1%	120	0.1%	5,579	5.3%
150,000 - <180,000 mg	*****	60,543	77.0%	61	0.1%	3,762	4.8%
180,000 - <210,000 mg	*****	47,301	78.1%	59	0.1%	2,772	4.6%
≥ 210,000 mg	47,345	0	0.0%	187	0.4%	10,299	21.8%
Torsemide Users (Washout)							
0 - <30,000 mg	172,357	43,595	25.3%	199	0.1%	13,000	7.5%
30,000 - <60,000 mg	*****	22,778	52.2%	67	0.2%	3,223	7.4%
60,000 - <90,000 mg	*****	13,444	59.0%	25	0.1%	1,767	7.8%
90,000 - <120,000 mg	*****	8,759	65.2%	15	0.1%	871	6.5%
120,000 - <150,000 mg	*****	6,015	68.7%	*****	*****	461	5.3%
150,000 - <180,000 mg	*****	4,384	72.8%	*****	*****	293	4.9%
180,000 - <210,000 mg	*****	3,238	73.9%	*****	*****	221	5.0%
≥ 210,000 mg	*****	0	0.0%	12	0.4%	542	16.7%
Torsemide Users (No Washout)							
0 - <30,000 mg	680,286	297,240	43.7%	500	0.1%	29,678	4.4%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
30,000 - <60,000 mg	297,231	191,132	64.3%	253	0.1%	13,681	4.6%
60,000 - <90,000 mg	191,137	132,995	69.6%	177	0.1%	10,091	5.3%
90,000 - <120,000 mg	132,972	97,901	73.6%	108	0.1%	6,302	4.7%
120,000 - <150,000 mg	97,900	73,715	75.3%	98	0.1%	4,737	4.8%
150,000 - <180,000 mg	73,732	57,858	78.5%	62	0.1%	3,057	4.1%
180,000 - <210,000 mg	57,843	46,043	79.6%	33	0.1%	2,328	4.0%
≥ 210,000 mg	46,087	0	0.0%	162	0.4%	9,362	20.3%
Furosemide Users (Washout)							
0 - <30,000 mg	5,031,366	664,577	13.2%	8,750	0.2%	514,919	10.2%
30,000 - <60,000 mg	664,489	230,598	34.7%	1,879	0.3%	92,410	13.9%
60,000 - <90,000 mg	230,504	97,567	42.3%	535	0.2%	26,606	11.5%
90,000 - <120,000 mg	97,370	46,157	47.4%	177	0.2%	9,386	9.6%
120,000 - <150,000 mg	46,460	24,014	51.7%	81	0.2%	3,824	8.2%
150,000 - <180,000 mg	24,013	13,702	57.1%	49	0.2%	1,748	7.3%
180,000 - <210,000 mg	*****	8,278	60.9%	20	0.1%	919	6.8%
≥ 210,000 mg	*****	0	0.0%	27	0.3%	1,200	14.0%
Furosemide Users (No Washout)							
0 - <30,000 mg	8,853,716	1,997,430	22.6%	14,937	0.2%	827,962	9.4%
30,000 - <60,000 mg	1,997,151	852,435	42.7%	5,942	0.3%	291,650	14.6%
60,000 - <90,000 mg	852,245	423,312	49.7%	2,259	0.3%	108,722	12.8%
90,000 - <120,000 mg	422,980	230,704	54.5%	964	0.2%	46,135	10.9%
120,000 - <150,000 mg	231,140	133,091	57.6%	490	0.2%	22,058	9.5%
150,000 - <180,000 mg	133,068	81,409	61.2%	263	0.2%	10,968	8.2%
180,000 - <210,000 mg	81,274	52,558	64.7%	148	0.2%	6,276	7.7%
≥ 210,000 mg	53,201	0	0.0%	255	0.5%	10,122	19.0%
Esophageal Cancer Outcome							
Bumetanide Users (Washout)							
0 - <30,000 mg	172,933	49,624	28.7%	57	0.0%	12,623	7.3%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
30,000 - <60,000 mg	*****	28,261	57.0%	15	0.0%	2,968	6.0%
60,000 - <90,000 mg	*****	17,683	62.6%	*****	*****	1,910	6.8%
90,000 - <120,000 mg	*****	11,949	67.6%	*****	*****	1,109	6.3%
120,000 - <150,000 mg	*****	8,248	69.0%	*****	*****	727	6.1%
150,000 - <180,000 mg	*****	5,876	71.2%	*****	*****	453	5.5%
180,000 - <210,000 mg	*****	4,301	73.2%	*****	*****	312	5.3%
≥ 210,000 mg	*****	0	0.0%	*****	*****	806	18.7%
Bumetanide Users (No Washout)							
0 - <30,000 mg	681,031	304,808	44.8%	116	0.0%	29,236	4.3%
30,000 - <60,000 mg	304,791	201,269	66.0%	70	0.0%	11,958	3.9%
60,000 - <90,000 mg	201,271	141,915	70.5%	39	0.0%	9,643	4.8%
90,000 - <120,000 mg	141,898	104,740	73.8%	36	0.0%	6,677	4.7%
120,000 - <150,000 mg	104,735	78,629	75.1%	29	0.0%	5,579	5.3%
150,000 - <180,000 mg	*****	60,543	77.0%	22	0.0%	3,762	4.8%
180,000 - <210,000 mg	*****	47,301	78.1%	19	0.0%	2,772	4.6%
≥ 210,000 mg	47,345	0	0.0%	72	0.2%	10,299	21.8%
Torsemide Users (Washout)							
0 - <30,000 mg	172,357	43,595	25.3%	49	0.0%	13,000	7.5%
30,000 - <60,000 mg	*****	22,778	52.2%	*****	*****	3,223	7.4%
60,000 - <90,000 mg	*****	13,444	59.0%	14	0.1%	1,767	7.8%
90,000 - <120,000 mg	*****	8,759	65.2%	*****	*****	871	6.5%
120,000 - <150,000 mg	*****	6,015	68.7%	*****	*****	461	5.3%
150,000 - <180,000 mg	*****	4,384	72.8%	0	0.0%	293	4.9%
180,000 - <210,000 mg	*****	3,238	73.9%	*****	*****	221	5.0%
≥ 210,000 mg	*****	0	0.0%	*****	*****	542	16.7%
Torsemide Users (No Washout)							
0 - <30,000 mg	680,286	297,240	43.7%	100	0.0%	29,678	4.4%
30,000 - <60,000 mg	297,231	191,132	64.3%	41	0.0%	13,681	4.6%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

		Censoring Reason					
		End of Exposure Episode[2]		Occurence of Event[3]		Occurence of Request-Defined Censoring Criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
60,000 - <90,000 mg	191,137	132,995	69.6%	62	0.0%	10,091	5.3%
90,000 - <120,000 mg	132,972	97,901	73.6%	39	0.0%	6,302	4.7%
120,000 - <150,000 mg	97,900	73,715	75.3%	30	0.0%	4,737	4.8%
150,000 - <180,000 mg	73,732	57,858	78.5%	15	0.0%	3,057	4.1%
180,000 - <210,000 mg	57,843	46,043	79.6%	15	0.0%	2,328	4.0%
≥ 210,000 mg	46,087	0	0.0%	64	0.1%	9,362	20.3%
Furosemide Users (Washout)							
0 - <30,000 mg	5,031,366	664,577	13.2%	1,898	0.0%	514,919	10.2%
30,000 - <60,000 mg	664,489	230,598	34.7%	531	0.1%	92,410	13.9%
60,000 - <90,000 mg	230,504	97,567	42.3%	156	0.1%	26,606	11.5%
90,000 - <120,000 mg	97,370	46,157	47.4%	56	0.1%	9,386	9.6%
120,000 - <150,000 mg	46,460	24,014	51.7%	29	0.1%	3,824	8.2%
150,000 - <180,000 mg	24,013	13,702	57.1%	11	0.0%	1,748	7.3%
180,000 - <210,000 mg	*****	8,278	60.9%	*****	*****	919	6.8%
≥ 210,000 mg	*****	0	0.0%	*****	*****	1,200	14.0%
Furosemide Users (No Washout)							
0 - <30,000 mg	8,853,716	1,997,430	22.6%	2,983	0.0%	827,962	9.4%
30,000 - <60,000 mg	1,997,151	852,435	42.7%	1,439	0.1%	291,650	14.6%
60,000 - <90,000 mg	852,245	423,312	49.7%	600	0.1%	108,722	12.8%
90,000 - <120,000 mg	422,980	230,704	54.5%	305	0.1%	46,135	10.9%
120,000 - <150,000 mg	231,140	133,091	57.6%	152	0.1%	22,058	9.5%
150,000 - <180,000 mg	133,068	81,409	61.2%	81	0.1%	10,968	8.2%
180,000 - <210,000 mg	81,274	52,558	64.7%	30	0.0%	6,276	7.7%
≥ 210,000 mg	53,201	0	0.0%	63	0.1%	10,122	19.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	33,751	19.5%	77,075	44.6%	39,691	23.0%	0	0.0%
30,000 - <60,000 mg	5,900	11.9%	12,560	25.3%	7,189	14.5%	0	0.0%
60,000 - <90,000 mg	2,834	10.0%	5,878	20.8%	3,487	12.3%	0	0.0%
90,000 - <120,000 mg	1,517	8.6%	3,118	17.6%	1,918	10.8%	0	0.0%
120,000 - <150,000 mg	965	8.1%	2,028	17.0%	1,274	10.7%	0	0.0%
150,000 - <180,000 mg	621	7.5%	1,322	16.0%	868	10.5%	0	0.0%
180,000 - <210,000 mg	410	7.0%	860	14.6%	576	9.8%	0	0.0%
≥ 210,000 mg	1,066	24.7%	2,459	57.1%	1,700	39.4%	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	144,776	21.3%	205,050	30.1%	100,865	14.8%	0	0.0%
30,000 - <60,000 mg	37,926	12.4%	54,203	17.8%	28,470	9.3%	0	0.0%
60,000 - <90,000 mg	21,008	10.4%	29,192	14.5%	15,567	7.7%	0	0.0%
90,000 - <120,000 mg	12,687	8.9%	18,090	12.7%	9,889	7.0%	0	0.0%
120,000 - <150,000 mg	8,690	8.3%	12,138	11.6%	6,903	6.6%	0	0.0%
150,000 - <180,000 mg	6,035	7.7%	8,500	10.8%	4,976	6.3%	0	0.0%
180,000 - <210,000 mg	4,554	7.5%	6,082	10.0%	3,509	5.8%	0	0.0%
≥ 210,000 mg	14,888	31.4%	22,820	48.2%	14,181	30.0%	0	0.0%
Torsemide Users (Washout)								
0 - <30,000 mg	29,183	16.9%	85,638	49.7%	49,198	28.5%	0	0.0%
30,000 - <60,000 mg	4,885	11.2%	12,720	29.2%	8,028	18.4%	0	0.0%
60,000 - <90,000 mg	2,276	10.0%	5,308	23.3%	3,479	15.3%	0	0.0%
90,000 - <120,000 mg	1,198	8.9%	2,614	19.5%	1,748	13.0%	0	0.0%
120,000 - <150,000 mg	654	7.5%	1,629	18.6%	1,114	12.7%	0	0.0%
150,000 - <180,000 mg	419	7.0%	929	15.4%	648	10.8%	0	0.0%
180,000 - <210,000 mg	282	6.4%	649	14.8%	446	10.2%	0	0.0%
≥ 210,000 mg	835	25.7%	1,884	58.1%	1,335	41.2%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0 - <30,000 mg	128,701	18.9%	224,674	33.0%	121,748	17.9%	0	0.0%
30,000 - <60,000 mg	35,228	11.9%	57,452	19.3%	32,809	11.0%	0	0.0%
60,000 - <90,000 mg	18,822	9.8%	29,491	15.4%	17,071	8.9%	0	0.0%
90,000 - <120,000 mg	11,377	8.6%	17,556	13.2%	10,494	7.9%	0	0.0%
120,000 - <150,000 mg	7,746	7.9%	11,844	12.1%	7,173	7.3%	0	0.0%
150,000 - <180,000 mg	5,084	6.9%	7,831	10.6%	4,880	6.6%	0	0.0%
180,000 - <210,000 mg	3,850	6.7%	5,738	9.9%	3,497	6.0%	0	0.0%
≥ 210,000 mg	14,731	32.0%	22,464	48.7%	14,259	30.9%	0	0.0%
Furosemide Users (Washout)								
0 - <30,000 mg	1,118,038	22.2%	2,734,480	54.3%	1,336,205	26.6%	0	0.0%
30,000 - <60,000 mg	115,567	17.4%	228,717	34.4%	138,185	20.8%	0	0.0%
60,000 - <90,000 mg	35,124	15.2%	72,175	31.3%	47,431	20.6%	0	0.0%
90,000 - <120,000 mg	13,476	13.8%	28,830	29.6%	19,841	20.4%	0	0.0%
120,000 - <150,000 mg	5,668	12.2%	13,174	28.4%	9,352	20.1%	0	0.0%
150,000 - <180,000 mg	2,641	11.0%	6,016	25.1%	4,297	17.9%	0	0.0%
180,000 - <210,000 mg	1,320	9.7%	3,143	23.1%	2,255	16.6%	0	0.0%
≥ 210,000 mg	1,721	20.1%	5,788	67.6%	3,358	39.2%	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	1,953,351	22.1%	4,073,493	46.0%	1,834,241	20.7%	0	0.0%
30,000 - <60,000 mg	336,889	16.9%	525,844	26.3%	263,211	13.2%	0	0.0%
60,000 - <90,000 mg	127,734	15.0%	197,231	23.1%	107,143	12.6%	0	0.0%
90,000 - <120,000 mg	57,979	13.7%	90,577	21.4%	51,751	12.2%	0	0.0%
120,000 - <150,000 mg	28,834	12.5%	48,313	20.9%	29,443	12.7%	0	0.0%
150,000 - <180,000 mg	15,192	11.4%	26,110	19.6%	16,666	12.5%	0	0.0%
180,000 - <210,000 mg	8,582	10.6%	14,241	17.5%	8,721	10.7%	0	0.0%
≥ 210,000 mg	14,318	26.9%	29,533	55.5%	17,786	33.4%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	33,751	19.5%	77,075	44.6%	39,691	23.0%	0	0.0%
30,000 - <60,000 mg	5,900	11.9%	12,560	25.3%	7,189	14.5%	0	0.0%
60,000 - <90,000 mg	2,834	10.0%	5,878	20.8%	3,487	12.3%	0	0.0%
90,000 - <120,000 mg	1,517	8.6%	3,118	17.6%	1,918	10.8%	0	0.0%
120,000 - <150,000 mg	965	8.1%	2,028	17.0%	1,274	10.7%	0	0.0%
150,000 - <180,000 mg	621	7.5%	1,322	16.0%	868	10.5%	0	0.0%
180,000 - <210,000 mg	410	7.0%	860	14.6%	576	9.8%	0	0.0%
≥ 210,000 mg	1,066	24.7%	2,459	57.1%	1,700	39.4%	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	144,776	21.3%	205,050	30.1%	100,865	14.8%	0	0.0%
30,000 - <60,000 mg	37,926	12.4%	54,203	17.8%	28,470	9.3%	0	0.0%
60,000 - <90,000 mg	21,008	10.4%	29,192	14.5%	15,567	7.7%	0	0.0%
90,000 - <120,000 mg	12,687	8.9%	18,090	12.7%	9,889	7.0%	0	0.0%
120,000 - <150,000 mg	8,690	8.3%	12,138	11.6%	6,903	6.6%	0	0.0%
150,000 - <180,000 mg	6,035	7.7%	8,500	10.8%	4,976	6.3%	0	0.0%
180,000 - <210,000 mg	4,554	7.5%	6,082	10.0%	3,509	5.8%	0	0.0%
≥ 210,000 mg	14,888	31.4%	22,820	48.2%	14,181	30.0%	0	0.0%
Torsemide Users (Washout)								
0 - <30,000 mg	29,183	16.9%	85,638	49.7%	49,198	28.5%	0	0.0%
30,000 - <60,000 mg	4,885	11.2%	12,720	29.2%	8,028	18.4%	0	0.0%
60,000 - <90,000 mg	2,276	10.0%	5,308	23.3%	3,479	15.3%	0	0.0%
90,000 - <120,000 mg	1,198	8.9%	2,614	19.5%	1,748	13.0%	0	0.0%
120,000 - <150,000 mg	654	7.5%	1,629	18.6%	1,114	12.7%	0	0.0%
150,000 - <180,000 mg	419	7.0%	929	15.4%	648	10.8%	0	0.0%
180,000 - <210,000 mg	282	6.4%	649	14.8%	446	10.2%	0	0.0%
≥ 210,000 mg	835	25.7%	1,884	58.1%	1,335	41.2%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0 - <30,000 mg	128,701	18.9%	224,674	33.0%	121,748	17.9%	0	0.0%
30,000 - <60,000 mg	35,228	11.9%	57,452	19.3%	32,809	11.0%	0	0.0%
60,000 - <90,000 mg	18,822	9.8%	29,491	15.4%	17,071	8.9%	0	0.0%
90,000 - <120,000 mg	11,377	8.6%	17,556	13.2%	10,494	7.9%	0	0.0%
120,000 - <150,000 mg	7,746	7.9%	11,844	12.1%	7,173	7.3%	0	0.0%
150,000 - <180,000 mg	5,084	6.9%	7,831	10.6%	4,880	6.6%	0	0.0%
180,000 - <210,000 mg	3,850	6.7%	5,738	9.9%	3,497	6.0%	0	0.0%
≥ 210,000 mg	14,731	32.0%	22,464	48.7%	14,259	30.9%	0	0.0%
Furosemide Users (Washout)								
0 - <30,000 mg	1,118,038	22.2%	2,734,480	54.3%	1,336,205	26.6%	0	0.0%
30,000 - <60,000 mg	115,567	17.4%	228,717	34.4%	138,185	20.8%	0	0.0%
60,000 - <90,000 mg	35,124	15.2%	72,175	31.3%	47,431	20.6%	0	0.0%
90,000 - <120,000 mg	13,476	13.8%	28,830	29.6%	19,841	20.4%	0	0.0%
120,000 - <150,000 mg	5,668	12.2%	13,174	28.4%	9,352	20.1%	0	0.0%
150,000 - <180,000 mg	2,641	11.0%	6,016	25.1%	4,297	17.9%	0	0.0%
180,000 - <210,000 mg	1,320	9.7%	3,143	23.1%	2,255	16.6%	0	0.0%
≥ 210,000 mg	1,721	20.1%	5,788	67.6%	3,358	39.2%	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	1,953,351	22.1%	4,073,493	46.0%	1,834,241	20.7%	0	0.0%
30,000 - <60,000 mg	336,889	16.9%	525,844	26.3%	263,211	13.2%	0	0.0%
60,000 - <90,000 mg	127,734	15.0%	197,231	23.1%	107,143	12.6%	0	0.0%
90,000 - <120,000 mg	57,979	13.7%	90,577	21.4%	51,751	12.2%	0	0.0%
120,000 - <150,000 mg	28,834	12.5%	48,313	20.9%	29,443	12.7%	0	0.0%
150,000 - <180,000 mg	15,192	11.4%	26,110	19.6%	16,666	12.5%	0	0.0%
180,000 - <210,000 mg	8,582	10.6%	14,241	17.5%	8,721	10.7%	0	0.0%
≥ 210,000 mg	14,318	26.9%	29,533	55.5%	17,786	33.4%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	33,751	19.5%	77,075	44.6%	39,691	23.0%	0	0.0%
30,000 - <60,000 mg	5,900	11.9%	12,560	25.3%	7,189	14.5%	0	0.0%
60,000 - <90,000 mg	2,834	10.0%	5,878	20.8%	3,487	12.3%	0	0.0%
90,000 - <120,000 mg	1,517	8.6%	3,118	17.6%	1,918	10.8%	0	0.0%
120,000 - <150,000 mg	965	8.1%	2,028	17.0%	1,274	10.7%	0	0.0%
150,000 - <180,000 mg	621	7.5%	1,322	16.0%	868	10.5%	0	0.0%
180,000 - <210,000 mg	410	7.0%	860	14.6%	576	9.8%	0	0.0%
≥ 210,000 mg	1,066	24.7%	2,459	57.1%	1,700	39.4%	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	144,776	21.3%	205,050	30.1%	100,865	14.8%	0	0.0%
30,000 - <60,000 mg	37,926	12.4%	54,203	17.8%	28,470	9.3%	0	0.0%
60,000 - <90,000 mg	21,008	10.4%	29,192	14.5%	15,567	7.7%	0	0.0%
90,000 - <120,000 mg	12,687	8.9%	18,090	12.7%	9,889	7.0%	0	0.0%
120,000 - <150,000 mg	8,690	8.3%	12,138	11.6%	6,903	6.6%	0	0.0%
150,000 - <180,000 mg	6,035	7.7%	8,500	10.8%	4,976	6.3%	0	0.0%
180,000 - <210,000 mg	4,554	7.5%	6,082	10.0%	3,509	5.8%	0	0.0%
≥ 210,000 mg	14,888	31.4%	22,820	48.2%	14,181	30.0%	0	0.0%
Torsemide Users (Washout)								
0 - <30,000 mg	29,183	16.9%	85,638	49.7%	49,198	28.5%	0	0.0%
30,000 - <60,000 mg	4,885	11.2%	12,720	29.2%	8,028	18.4%	0	0.0%
60,000 - <90,000 mg	2,276	10.0%	5,308	23.3%	3,479	15.3%	0	0.0%
90,000 - <120,000 mg	1,198	8.9%	2,614	19.5%	1,748	13.0%	0	0.0%
120,000 - <150,000 mg	654	7.5%	1,629	18.6%	1,114	12.7%	0	0.0%
150,000 - <180,000 mg	419	7.0%	929	15.4%	648	10.8%	0	0.0%
180,000 - <210,000 mg	282	6.4%	649	14.8%	446	10.2%	0	0.0%
≥ 210,000 mg	835	25.7%	1,884	58.1%	1,335	41.2%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0 - <30,000 mg	128,701	18.9%	224,674	33.0%	121,748	17.9%	0	0.0%
30,000 - <60,000 mg	35,228	11.9%	57,452	19.3%	32,809	11.0%	0	0.0%
60,000 - <90,000 mg	18,822	9.8%	29,491	15.4%	17,071	8.9%	0	0.0%
90,000 - <120,000 mg	11,377	8.6%	17,556	13.2%	10,494	7.9%	0	0.0%
120,000 - <150,000 mg	7,746	7.9%	11,844	12.1%	7,173	7.3%	0	0.0%
150,000 - <180,000 mg	5,084	6.9%	7,831	10.6%	4,880	6.6%	0	0.0%
180,000 - <210,000 mg	3,850	6.7%	5,738	9.9%	3,497	6.0%	0	0.0%
≥ 210,000 mg	14,731	32.0%	22,464	48.7%	14,259	30.9%	0	0.0%
Furosemide Users (Washout)								
0 - <30,000 mg	1,118,038	22.2%	2,734,480	54.3%	1,336,205	26.6%	0	0.0%
30,000 - <60,000 mg	115,567	17.4%	228,717	34.4%	138,185	20.8%	0	0.0%
60,000 - <90,000 mg	35,124	15.2%	72,175	31.3%	47,431	20.6%	0	0.0%
90,000 - <120,000 mg	13,476	13.8%	28,830	29.6%	19,841	20.4%	0	0.0%
120,000 - <150,000 mg	5,668	12.2%	13,174	28.4%	9,352	20.1%	0	0.0%
150,000 - <180,000 mg	2,641	11.0%	6,016	25.1%	4,297	17.9%	0	0.0%
180,000 - <210,000 mg	1,320	9.7%	3,143	23.1%	2,255	16.6%	0	0.0%
≥ 210,000 mg	1,721	20.1%	5,788	67.6%	3,358	39.2%	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	1,953,351	22.1%	4,073,493	46.0%	1,834,241	20.7%	0	0.0%
30,000 - <60,000 mg	336,889	16.9%	525,844	26.3%	263,211	13.2%	0	0.0%
60,000 - <90,000 mg	127,734	15.0%	197,231	23.1%	107,143	12.6%	0	0.0%
90,000 - <120,000 mg	57,979	13.7%	90,577	21.4%	51,751	12.2%	0	0.0%
120,000 - <150,000 mg	28,834	12.5%	48,313	20.9%	29,443	12.7%	0	0.0%
150,000 - <180,000 mg	15,192	11.4%	26,110	19.6%	16,666	12.5%	0	0.0%
180,000 - <210,000 mg	8,582	10.6%	14,241	17.5%	8,721	10.7%	0	0.0%
≥ 210,000 mg	14,318	26.9%	29,533	55.5%	17,786	33.4%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	33,751	19.5%	77,075	44.6%	39,691	23.0%	0	0.0%
30,000 - <60,000 mg	5,900	11.9%	12,560	25.3%	7,189	14.5%	0	0.0%
60,000 - <90,000 mg	2,834	10.0%	5,878	20.8%	3,487	12.3%	0	0.0%
90,000 - <120,000 mg	1,517	8.6%	3,118	17.6%	1,918	10.8%	0	0.0%
120,000 - <150,000 mg	965	8.1%	2,028	17.0%	1,274	10.7%	0	0.0%
150,000 - <180,000 mg	621	7.5%	1,322	16.0%	868	10.5%	0	0.0%
180,000 - <210,000 mg	410	7.0%	860	14.6%	576	9.8%	0	0.0%
≥ 210,000 mg	1,066	24.7%	2,459	57.1%	1,700	39.4%	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	144,776	21.3%	205,050	30.1%	100,865	14.8%	0	0.0%
30,000 - <60,000 mg	37,926	12.4%	54,203	17.8%	28,470	9.3%	0	0.0%
60,000 - <90,000 mg	21,008	10.4%	29,192	14.5%	15,567	7.7%	0	0.0%
90,000 - <120,000 mg	12,687	8.9%	18,090	12.7%	9,889	7.0%	0	0.0%
120,000 - <150,000 mg	8,690	8.3%	12,138	11.6%	6,903	6.6%	0	0.0%
150,000 - <180,000 mg	6,035	7.7%	8,500	10.8%	4,976	6.3%	0	0.0%
180,000 - <210,000 mg	4,554	7.5%	6,082	10.0%	3,509	5.8%	0	0.0%
≥ 210,000 mg	14,888	31.4%	22,820	48.2%	14,181	30.0%	0	0.0%
Torsemide Users (Washout)								
0 - <30,000 mg	29,183	16.9%	85,638	49.7%	49,198	28.5%	0	0.0%
30,000 - <60,000 mg	4,885	11.2%	12,720	29.2%	8,028	18.4%	0	0.0%
60,000 - <90,000 mg	2,276	10.0%	5,308	23.3%	3,479	15.3%	0	0.0%
90,000 - <120,000 mg	1,198	8.9%	2,614	19.5%	1,748	13.0%	0	0.0%
120,000 - <150,000 mg	654	7.5%	1,629	18.6%	1,114	12.7%	0	0.0%
150,000 - <180,000 mg	419	7.0%	929	15.4%	648	10.8%	0	0.0%
180,000 - <210,000 mg	282	6.4%	649	14.8%	446	10.2%	0	0.0%
≥ 210,000 mg	835	25.7%	1,884	58.1%	1,335	41.2%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0 - <30,000 mg	128,701	18.9%	224,674	33.0%	121,748	17.9%	0	0.0%
30,000 - <60,000 mg	35,228	11.9%	57,452	19.3%	32,809	11.0%	0	0.0%
60,000 - <90,000 mg	18,822	9.8%	29,491	15.4%	17,071	8.9%	0	0.0%
90,000 - <120,000 mg	11,377	8.6%	17,556	13.2%	10,494	7.9%	0	0.0%
120,000 - <150,000 mg	7,746	7.9%	11,844	12.1%	7,173	7.3%	0	0.0%
150,000 - <180,000 mg	5,084	6.9%	7,831	10.6%	4,880	6.6%	0	0.0%
180,000 - <210,000 mg	3,850	6.7%	5,738	9.9%	3,497	6.0%	0	0.0%
≥ 210,000 mg	14,731	32.0%	22,464	48.7%	14,259	30.9%	0	0.0%
Furosemide Users (Washout)								
0 - <30,000 mg	1,118,038	22.2%	2,734,480	54.3%	1,336,205	26.6%	0	0.0%
30,000 - <60,000 mg	115,567	17.4%	228,717	34.4%	138,185	20.8%	0	0.0%
60,000 - <90,000 mg	35,124	15.2%	72,175	31.3%	47,431	20.6%	0	0.0%
90,000 - <120,000 mg	13,476	13.8%	28,830	29.6%	19,841	20.4%	0	0.0%
120,000 - <150,000 mg	5,668	12.2%	13,174	28.4%	9,352	20.1%	0	0.0%
150,000 - <180,000 mg	2,641	11.0%	6,016	25.1%	4,297	17.9%	0	0.0%
180,000 - <210,000 mg	1,320	9.7%	3,143	23.1%	2,255	16.6%	0	0.0%
≥ 210,000 mg	1,721	20.1%	5,788	67.6%	3,358	39.2%	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	1,953,351	22.1%	4,073,493	46.0%	1,834,241	20.7%	0	0.0%
30,000 - <60,000 mg	336,889	16.9%	525,844	26.3%	263,211	13.2%	0	0.0%
60,000 - <90,000 mg	127,734	15.0%	197,231	23.1%	107,143	12.6%	0	0.0%
90,000 - <120,000 mg	57,979	13.7%	90,577	21.4%	51,751	12.2%	0	0.0%
120,000 - <150,000 mg	28,834	12.5%	48,313	20.9%	29,443	12.7%	0	0.0%
150,000 - <180,000 mg	15,192	11.4%	26,110	19.6%	16,666	12.5%	0	0.0%

Table 11b. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Censoring Reason							
	Evidence of Death[5]		Disenrollment[6]		End of Data Partner Data[7]		End of Query Period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
180,000 - <210,000 mg	8,582	10.6%	14,241	17.5%	8,721	10.7%	0	0.0%
≥ 210,000 mg	14,318	26.9%	29,533	55.5%	17,786	33.4%	0	0.0%

* Lower order categories include patients in the higher order categories

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of request-defined event.

[4]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

[5]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[6]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[7]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[8]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome							
Bumetanide Users (Washout)							
0-1 years	172,936	43,206	25.0%	44	0.0%	12,906	7.5%
1-2 years	43,206	*****	*****	11	0.0%	3,313	7.7%
2-3 years	*****	*****	*****	*****	*****	2,599	12.3%
3-4 years	*****	*****	*****	*****	*****	1,131	10.9%
4-5 years	*****	*****	*****	*****	*****	511	9.4%
5-6 years	*****	*****	*****	*****	*****	240	8.6%
6-7 years	*****	*****	*****	*****	*****	124	9.0%
7+ years	*****	0	0.0%	0	0.0%	84	12.1%
Bumetanide Users (No Washout)							
0-1 years	681,044	231,141	33.9%	157	0.0%	32,757	4.8%
1-2 years	231,141	120,390	52.1%	81	0.0%	16,303	7.1%
2-3 years	120,390	60,491	50.2%	73	0.1%	16,614	13.8%
3-4 years	60,491	31,830	52.6%	29	0.0%	7,457	12.3%
4-5 years	31,830	*****	*****	23	0.1%	3,420	10.7%
5-6 years	*****	*****	*****	11	0.1%	1,685	9.8%
6-7 years	*****	*****	*****	*****	*****	908	9.7%
7+ years	*****	0	0.0%	*****	*****	782	15.1%
Torsemide Users (Washout)							
0-1 years	172,362	*****	*****	37	0.0%	11,693	6.8%
1-2 years	*****	*****	*****	*****	*****	3,461	7.3%
2-3 years	*****	*****	*****	*****	*****	2,890	12.2%
3-4 years	*****	*****	*****	*****	*****	1,243	10.7%
4-5 years	*****	*****	*****	*****	*****	587	9.9%
5-6 years	*****	*****	*****	0	0.0%	289	9.2%
6-7 years	*****	*****	*****	0	0.0%	98	6.3%
7+ years	*****	0	0.0%	0	0.0%	117	14.6%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)							
0-1 years	680,304	249,185	36.6%	99	0.0%	28,418	4.2%
1-2 years	249,185	131,368	52.7%	61	0.0%	16,687	6.7%
2-3 years	131,368	66,841	50.9%	60	0.0%	18,036	13.7%
3-4 years	66,841	35,645	53.3%	28	0.0%	8,243	12.3%
4-5 years	35,645	*****	*****	13	0.0%	3,833	10.8%
5-6 years	*****	*****	*****	*****	*****	2,021	10.3%
6-7 years	*****	*****	*****	*****	*****	1,002	9.3%
7+ years	*****	0	0.0%	*****	*****	996	16.6%
Furosemide Users (Washout)							
0-1 years	5,031,471	1,570,858	31.2%	1,437	0.0%	348,861	6.9%
1-2 years	1,570,858	857,233	54.6%	666	0.0%	113,887	7.2%
2-3 years	857,233	462,012	53.9%	552	0.1%	97,811	11.4%
3-4 years	462,012	253,038	54.8%	273	0.1%	46,148	10.0%
4-5 years	253,038	138,456	54.7%	136	0.1%	23,124	9.1%
5-6 years	138,456	73,838	53.3%	53	0.0%	11,417	8.2%
6-7 years	73,838	37,943	51.4%	32	0.0%	5,627	7.6%
7+ years	37,943	0	0.0%	25	0.1%	4,137	10.9%
Furosemide Users (No Washout)							
0-1 years	8,853,836	3,756,719	42.4%	1,919	0.0%	461,608	5.2%
1-2 years	3,756,719	2,243,787	59.7%	1,335	0.0%	256,311	6.8%
2-3 years	2,243,787	1,290,390	57.5%	1,435	0.1%	292,803	13.0%
3-4 years	1,290,390	759,943	58.9%	723	0.1%	146,623	11.4%
4-5 years	759,943	451,504	59.4%	387	0.1%	78,398	10.3%
5-6 years	451,504	267,682	59.3%	208	0.0%	42,731	9.5%
6-7 years	267,682	157,482	58.8%	127	0.0%	22,986	8.6%
7+ years	157,482	0	0.0%	106	0.1%	22,433	14.2%
Bladder Cancer Outcome							

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Bumetanide Users (Washout)							
0-1 years	172,936	43,206	25.0%	105	0.1%	12,906	7.5%
1-2 years	43,206	*****	*****	25	0.1%	3,313	7.7%
2-3 years	*****	*****	*****	27	0.1%	2,599	12.3%
3-4 years	*****	*****	*****	12	0.1%	1,131	10.9%
4-5 years	*****	*****	*****	*****	*****	511	9.4%
5-6 years	*****	*****	*****	*****	*****	240	8.6%
6-7 years	*****	*****	*****	*****	*****	124	9.0%
7+ years	*****	0	0.0%	*****	*****	84	12.1%
Bumetanide Users (No Washout)							
0-1 years	681,044	231,141	33.9%	258	0.0%	32,757	4.8%
1-2 years	231,141	120,390	52.1%	120	0.1%	16,303	7.1%
2-3 years	120,390	60,491	50.2%	148	0.1%	16,614	13.8%
3-4 years	60,491	31,830	52.6%	75	0.1%	7,457	12.3%
4-5 years	31,830	*****	*****	39	0.1%	3,420	10.7%
5-6 years	*****	*****	*****	12	0.1%	1,685	9.8%
6-7 years	*****	*****	*****	12	0.1%	908	9.7%
7+ years	*****	0	0.0%	13	0.3%	782	15.1%
Torsemide Users (Washout)							
0-1 years	172,362	*****	*****	100	0.1%	11,693	6.8%
1-2 years	*****	*****	*****	26	0.1%	3,461	7.3%
2-3 years	*****	*****	*****	26	0.1%	2,890	12.2%
3-4 years	*****	*****	*****	13	0.1%	1,243	10.7%
4-5 years	*****	*****	*****	*****	*****	587	9.9%
5-6 years	*****	*****	*****	*****	*****	289	9.2%
6-7 years	*****	*****	*****	0	0.0%	98	6.3%
7+ years	*****	0	0.0%	*****	*****	117	14.6%
Torsemide Users (No Washout)							

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0-1 years	680,304	249,185	36.6%	229	0.0%	28,418	4.2%
1-2 years	249,185	131,368	52.7%	140	0.1%	16,687	6.7%
2-3 years	131,368	66,841	50.9%	147	0.1%	18,036	13.7%
3-4 years	66,841	35,645	53.3%	93	0.1%	8,243	12.3%
4-5 years	35,645	*****	*****	29	0.1%	3,833	10.8%
5-6 years	*****	*****	*****	20	0.1%	2,021	10.3%
6-7 years	*****	*****	*****	*****	*****	1,002	9.3%
7+ years	*****	0	0.0%	*****	*****	996	16.6%
Furosemide Users (Washout)							
0-1 years	5,031,471	1,570,858	31.2%	2,940	0.1%	348,861	6.9%
1-2 years	1,570,858	857,233	54.6%	1,040	0.1%	113,887	7.2%
2-3 years	857,233	462,012	53.9%	909	0.1%	97,811	11.4%
3-4 years	462,012	253,038	54.8%	467	0.1%	46,148	10.0%
4-5 years	253,038	138,456	54.7%	214	0.1%	23,124	9.1%
5-6 years	138,456	73,838	53.3%	130	0.1%	11,417	8.2%
6-7 years	73,838	37,943	51.4%	63	0.1%	5,627	7.6%
7+ years	37,943	0	0.0%	45	0.1%	4,137	10.9%
Furosemide Users (No Washout)							
0-1 years	8,853,836	3,756,719	42.4%	3,812	0.0%	461,608	5.2%
1-2 years	3,756,719	2,243,787	59.7%	2,306	0.1%	256,311	6.8%
2-3 years	2,243,787	1,290,390	57.5%	2,646	0.1%	292,803	13.0%
3-4 years	1,290,390	759,943	58.9%	1,357	0.1%	146,623	11.4%
4-5 years	759,943	451,504	59.4%	731	0.1%	78,398	10.3%
5-6 years	451,504	267,682	59.3%	431	0.1%	42,731	9.5%
6-7 years	267,682	157,482	58.8%	207	0.1%	22,986	8.6%
7+ years	157,482	0	0.0%	254	0.2%	22,433	14.2%
Colorectal Cancer Outcome							
Bumetanide Users (Washout)							

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0-1 years	172,936	43,206	25.0%	225	0.1%	12,906	7.5%
1-2 years	43,206	*****	*****	59	0.1%	3,313	7.7%
2-3 years	*****	*****	*****	62	0.3%	2,599	12.3%
3-4 years	*****	*****	*****	19	0.2%	1,131	10.9%
4-5 years	*****	*****	*****	17	0.3%	511	9.4%
5-6 years	*****	*****	*****	*****	*****	240	8.6%
6-7 years	*****	*****	*****	0	0.0%	124	9.0%
7+ years	*****	0	0.0%	*****	*****	84	12.1%
Bumetanide Users (No Washout)							
0-1 years	681,044	231,141	33.9%	602	0.1%	32,757	4.8%
1-2 years	231,141	120,390	52.1%	286	0.1%	16,303	7.1%
2-3 years	120,390	60,491	50.2%	340	0.3%	16,614	13.8%
3-4 years	60,491	31,830	52.6%	148	0.2%	7,457	12.3%
4-5 years	31,830	*****	*****	76	0.2%	3,420	10.7%
5-6 years	*****	*****	*****	28	0.2%	1,685	9.8%
6-7 years	*****	*****	*****	20	0.2%	908	9.7%
7+ years	*****	0	0.0%	26	0.5%	782	15.1%
Torsemide Users (Washout)							
0-1 years	172,362	*****	*****	180	0.1%	11,693	6.8%
1-2 years	*****	*****	*****	54	0.1%	3,461	7.3%
2-3 years	*****	*****	*****	57	0.2%	2,890	12.2%
3-4 years	*****	*****	*****	22	0.2%	1,243	10.7%
4-5 years	*****	*****	*****	*****	*****	587	9.9%
5-6 years	*****	*****	*****	*****	*****	289	9.2%
6-7 years	*****	*****	*****	*****	*****	98	6.3%
7+ years	*****	0	0.0%	*****	*****	117	14.6%
Torsemide Users (No Washout)							
0-1 years	680,304	249,185	36.6%	477	0.1%	28,418	4.2%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
1-2 years	249,185	131,368	52.7%	292	0.1%	16,687	6.7%
2-3 years	131,368	66,841	50.9%	319	0.2%	18,036	13.7%
3-4 years	66,841	35,645	53.3%	146	0.2%	8,243	12.3%
4-5 years	35,645	*****	*****	69	0.2%	3,833	10.8%
5-6 years	*****	*****	*****	43	0.2%	2,021	10.3%
6-7 years	*****	*****	*****	24	0.2%	1,002	9.3%
7+ years	*****	0	0.0%	23	0.4%	996	16.6%
Furosemide Users (Washout)							
0-1 years	5,031,471	1,570,858	31.2%	5,630	0.1%	348,861	6.9%
1-2 years	1,570,858	857,233	54.6%	2,100	0.1%	113,887	7.2%
2-3 years	857,233	462,012	53.9%	1,910	0.2%	97,811	11.4%
3-4 years	462,012	253,038	54.8%	911	0.2%	46,148	10.0%
4-5 years	253,038	138,456	54.7%	516	0.2%	23,124	9.1%
5-6 years	138,456	73,838	53.3%	240	0.2%	11,417	8.2%
6-7 years	73,838	37,943	51.4%	115	0.2%	5,627	7.6%
7+ years	37,943	0	0.0%	96	0.3%	4,137	10.9%
Furosemide Users (No Washout)							
0-1 years	8,853,836	3,756,719	42.4%	7,763	0.1%	461,608	5.2%
1-2 years	3,756,719	2,243,787	59.7%	4,868	0.1%	256,311	6.8%
2-3 years	2,243,787	1,290,390	57.5%	5,990	0.3%	292,803	13.0%
3-4 years	1,290,390	759,943	58.9%	2,961	0.2%	146,623	11.4%
4-5 years	759,943	451,504	59.4%	1,713	0.2%	78,398	10.3%
5-6 years	451,504	267,682	59.3%	894	0.2%	42,731	9.5%
6-7 years	267,682	157,482	58.8%	494	0.2%	22,986	8.6%
7+ years	157,482	0	0.0%	575	0.4%	22,433	14.2%
Esophageal Cancer Outcome							
Bumetanide Users (Washout)							
0-1 years	172,936	*****	*****	62	0.0%	12,906	7.5%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
1-2 years	43,206	*****	*****	16	0.0%	3,313	7.7%
2-3 years	*****	*****	*****	*****	*****	2,599	12.3%
3-4 years	*****	*****	*****	*****	*****	1,131	10.9%
4-5 years	*****	*****	*****	*****	*****	511	9.4%
5-6 years	*****	*****	*****	*****	*****	240	8.6%
6-7 years	*****	*****	*****	*****	*****	124	9.0%
7+ years	*****	0	0.0%	0	0.0%	84	12.1%
Bumetanide Users (No Washout)							
0-1 years	681,044	231,141	33.9%	148	0.0%	32,757	4.8%
1-2 years	231,141	120,390	52.1%	87	0.0%	16,303	7.1%
2-3 years	120,390	60,491	50.2%	89	0.1%	16,614	13.8%
3-4 years	60,491	31,830	52.6%	44	0.1%	7,457	12.3%
4-5 years	31,830	*****	*****	22	0.1%	3,420	10.7%
5-6 years	*****	*****	*****	*****	*****	1,685	9.8%
6-7 years	*****	*****	*****	*****	*****	908	9.7%
7+ years	*****	0	0.0%	*****	*****	782	15.1%
Torsemide Users (Washout)							
0-1 years	172,362	*****	*****	43	0.0%	11,693	6.8%
1-2 years	*****	*****	*****	15	0.0%	3,461	7.3%
2-3 years	*****	*****	*****	17	0.1%	2,890	12.2%
3-4 years	*****	*****	*****	*****	*****	1,243	10.7%
4-5 years	*****	*****	*****	*****	*****	587	9.9%
5-6 years	*****	*****	*****	*****	*****	289	9.2%
6-7 years	*****	*****	*****	0	0.0%	98	6.3%
7+ years	*****	0	0.0%	*****	*****	117	14.6%
Torsemide Users (No Washout)							
0-1 years	680,304	249,185	36.6%	106	0.0%	28,418	4.2%
1-2 years	249,185	131,368	52.7%	85	0.0%	16,687	6.7%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
2-3 years	131,368	66,841	50.9%	88	0.1%	18,036	13.7%
3-4 years	66,841	35,645	53.3%	46	0.1%	8,243	12.3%
4-5 years	35,645	*****	*****	19	0.1%	3,833	10.8%
5-6 years	*****	*****	*****	11	0.1%	2,021	10.3%
6-7 years	*****	*****	*****	*****	*****	1,002	9.3%
7+ years	*****	0	0.0%	*****	*****	996	16.6%
Furosemide Users (Washout)							
0-1 years	5,031,471	1,570,858	31.2%	1,135	0.0%	348,861	6.9%
1-2 years	1,570,858	857,233	54.6%	549	0.0%	113,887	7.2%
2-3 years	857,233	462,012	53.9%	501	0.1%	97,811	11.4%
3-4 years	462,012	253,038	54.8%	286	0.1%	46,148	10.0%
4-5 years	253,038	138,456	54.7%	120	0.0%	23,124	9.1%
5-6 years	138,456	73,838	53.3%	56	0.0%	11,417	8.2%
6-7 years	73,838	37,943	51.4%	29	0.0%	5,627	7.6%
7+ years	37,943	0	0.0%	16	0.0%	4,137	10.9%
Furosemide Users (No Washout)							
0-1 years	8,853,836	3,756,719	42.4%	1,493	0.0%	461,608	5.2%
1-2 years	3,756,719	2,243,787	59.7%	1,081	0.0%	256,311	6.8%
2-3 years	2,243,787	1,290,390	57.5%	1,318	0.1%	292,803	13.0%
3-4 years	1,290,390	759,943	58.9%	846	0.1%	146,623	11.4%
4-5 years	759,943	451,504	59.4%	474	0.1%	78,398	10.3%
5-6 years	451,504	267,682	59.3%	229	0.1%	42,731	9.5%
6-7 years	267,682	157,482	58.8%	100	0.0%	22,986	8.6%
7+ years	157,482	0	0.0%	112	0.1%	22,433	14.2%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	35,918	20.8%	81,068	46.9%	41,416	23.9%	0	0.0%
1-2 years	6,109	14.1%	12,705	29.4%	7,430	17.2%	0	0.0%
2-3 years	2,652	12.5%	5,569	26.3%	3,537	16.7%	0	0.0%
3-4 years	1,215	11.7%	2,661	25.6%	1,812	17.4%	0	0.0%
4-5 years	602	11.1%	1,534	28.3%	1,103	20.3%	0	0.0%
5-6 years	307	11.1%	851	30.7%	638	23.0%	0	0.0%
6-7 years	146	10.5%	421	30.4%	341	24.6%	0	0.0%
7+ years	115	16.6%	491	71.0%	426	61.6%	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	177,317	26.0%	243,191	35.7%	118,866	17.5%	0	0.0%
1-2 years	39,085	16.9%	56,441	24.4%	30,412	13.2%	0	0.0%
2-3 years	17,639	14.7%	26,228	21.8%	15,058	12.5%	0	0.0%
3-4 years	8,423	13.9%	13,027	21.5%	7,966	13.2%	0	0.0%
4-5 years	3,967	12.5%	7,328	23.0%	4,764	15.0%	0	0.0%
5-6 years	2,146	12.4%	4,121	23.9%	2,854	16.5%	0	0.0%
6-7 years	1,046	11.2%	2,281	24.3%	1,664	17.8%	0	0.0%
7+ years	941	18.2%	3,458	67.0%	2,776	53.7%	0	0.0%
Torsemide Users (Washout)								
0-1 years	29,234	17.0%	83,081	48.2%	46,805	27.2%	0	0.0%
1-2 years	5,573	11.7%	14,826	31.2%	9,465	19.9%	0	0.0%
2-3 years	2,539	10.8%	6,520	27.6%	4,480	19.0%	0	0.0%
3-4 years	1,204	10.3%	3,254	28.0%	2,349	20.2%	0	0.0%
4-5 years	596	10.0%	1,654	27.8%	1,231	20.7%	0	0.0%
5-6 years	339	10.8%	951	30.4%	749	23.9%	0	0.0%
6-7 years	136	8.8%	513	33.1%	426	27.4%	0	0.0%
7+ years	111	13.9%	572	71.4%	491	61.3%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0-1 years	154,135	22.7%	249,111	36.6%	132,516	19.5%	0	0.0%
1-2 years	37,494	15.0%	64,009	25.7%	37,548	15.1%	0	0.0%
2-3 years	16,799	12.8%	29,909	22.8%	18,588	14.1%	0	0.0%
3-4 years	8,271	12.4%	14,849	22.2%	9,579	14.3%	0	0.0%
4-5 years	4,283	12.0%	7,961	22.3%	5,325	14.9%	0	0.0%
5-6 years	2,345	11.9%	4,591	23.3%	3,240	16.5%	0	0.0%
6-7 years	1,135	10.5%	2,668	24.7%	1,964	18.2%	0	0.0%
7+ years	1,077	17.9%	3,952	65.8%	3,171	52.8%	0	0.0%
Furosemide Users (Washout)								
0-1 years	878,615	17.5%	2,230,649	44.3%	1,045,737	20.8%	0	0.0%
1-2 years	200,462	12.8%	403,089	25.7%	214,539	13.7%	0	0.0%
2-3 years	100,783	11.8%	198,471	23.2%	117,949	13.8%	0	0.0%
3-4 years	54,485	11.8%	109,450	23.7%	70,590	15.3%	0	0.0%
4-5 years	29,458	11.6%	62,665	24.8%	43,230	17.1%	0	0.0%
5-6 years	15,615	11.3%	37,904	27.4%	27,926	20.2%	0	0.0%
6-7 years	7,867	10.7%	22,569	30.6%	17,539	23.8%	0	0.0%
7+ years	6,270	16.5%	27,526	72.5%	23,414	61.7%	0	0.0%
Furosemide Users (No Washout)								
0-1 years	1,458,472	16.5%	3,169,564	35.8%	1,368,002	15.5%	0	0.0%
1-2 years	475,970	12.7%	790,290	21.0%	366,369	9.8%	0	0.0%
2-3 years	258,913	11.5%	408,831	18.2%	202,537	9.0%	0	0.0%
3-4 years	149,365	11.6%	238,235	18.5%	126,929	9.8%	0	0.0%
4-5 years	87,069	11.5%	145,401	19.1%	83,816	11.0%	0	0.0%
5-6 years	51,544	11.4%	90,940	20.1%	58,544	13.0%	0	0.0%
6-7 years	29,466	11.0%	58,579	21.9%	40,176	15.0%	0	0.0%
7+ years	32,080	20.4%	103,502	65.7%	82,589	52.4%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	35,918	20.8%	81,068	46.9%	41,416	23.9%	0	0.0%
1-2 years	6,109	14.1%	12,705	29.4%	7,430	17.2%	0	0.0%
2-3 years	2,652	12.5%	5,569	26.3%	3,537	16.7%	0	0.0%
3-4 years	1,215	11.7%	2,661	25.6%	1,812	17.4%	0	0.0%
4-5 years	602	11.1%	1,534	28.3%	1,103	20.3%	0	0.0%
5-6 years	307	11.1%	851	30.7%	638	23.0%	0	0.0%
6-7 years	146	10.5%	421	30.4%	341	24.6%	0	0.0%
7+ years	115	16.6%	491	71.0%	426	61.6%	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	177,317	26.0%	243,191	35.7%	118,866	17.5%	0	0.0%
1-2 years	39,085	16.9%	56,441	24.4%	30,412	13.2%	0	0.0%
2-3 years	17,639	14.7%	26,228	21.8%	15,058	12.5%	0	0.0%
3-4 years	8,423	13.9%	13,027	21.5%	7,966	13.2%	0	0.0%
4-5 years	3,967	12.5%	7,328	23.0%	4,764	15.0%	0	0.0%
5-6 years	2,146	12.4%	4,121	23.9%	2,854	16.5%	0	0.0%
6-7 years	1,046	11.2%	2,281	24.3%	1,664	17.8%	0	0.0%
7+ years	941	18.2%	3,458	67.0%	2,776	53.7%	0	0.0%
Torsemide Users (Washout)								
0-1 years	29,234	17.0%	83,081	48.2%	46,805	27.2%	0	0.0%
1-2 years	5,573	11.7%	14,826	31.2%	9,465	19.9%	0	0.0%
2-3 years	2,539	10.8%	6,520	27.6%	4,480	19.0%	0	0.0%
3-4 years	1,204	10.3%	3,254	28.0%	2,349	20.2%	0	0.0%
4-5 years	596	10.0%	1,654	27.8%	1,231	20.7%	0	0.0%
5-6 years	339	10.8%	951	30.4%	749	23.9%	0	0.0%
6-7 years	136	8.8%	513	33.1%	426	27.4%	0	0.0%
7+ years	111	13.9%	572	71.4%	491	61.3%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0-1 years	154,135	22.7%	249,111	36.6%	132,516	19.5%	0	0.0%
1-2 years	37,494	15.0%	64,009	25.7%	37,548	15.1%	0	0.0%
2-3 years	16,799	12.8%	29,909	22.8%	18,588	14.1%	0	0.0%
3-4 years	8,271	12.4%	14,849	22.2%	9,579	14.3%	0	0.0%
4-5 years	4,283	12.0%	7,961	22.3%	5,325	14.9%	0	0.0%
5-6 years	2,345	11.9%	4,591	23.3%	3,240	16.5%	0	0.0%
6-7 years	1,135	10.5%	2,668	24.7%	1,964	18.2%	0	0.0%
7+ years	1,077	17.9%	3,952	65.8%	3,171	52.8%	0	0.0%
Furosemide Users (Washout)								
0-1 years	878,615	17.5%	2,230,649	44.3%	1,045,737	20.8%	0	0.0%
1-2 years	200,462	12.8%	403,089	25.7%	214,539	13.7%	0	0.0%
2-3 years	100,783	11.8%	198,471	23.2%	117,949	13.8%	0	0.0%
3-4 years	54,485	11.8%	109,450	23.7%	70,590	15.3%	0	0.0%
4-5 years	29,458	11.6%	62,665	24.8%	43,230	17.1%	0	0.0%
5-6 years	15,615	11.3%	37,904	27.4%	27,926	20.2%	0	0.0%
6-7 years	7,867	10.7%	22,569	30.6%	17,539	23.8%	0	0.0%
7+ years	6,270	16.5%	27,526	72.5%	23,414	61.7%	0	0.0%
Furosemide Users (No Washout)								
0-1 years	1,458,472	16.5%	3,169,564	35.8%	1,368,002	15.5%	0	0.0%
1-2 years	475,970	12.7%	790,290	21.0%	366,369	9.8%	0	0.0%
2-3 years	258,913	11.5%	408,831	18.2%	202,537	9.0%	0	0.0%
3-4 years	149,365	11.6%	238,235	18.5%	126,929	9.8%	0	0.0%
4-5 years	87,069	11.5%	145,401	19.1%	83,816	11.0%	0	0.0%
5-6 years	51,544	11.4%	90,940	20.1%	58,544	13.0%	0	0.0%
6-7 years	29,466	11.0%	58,579	21.9%	40,176	15.0%	0	0.0%
7+ years	32,080	20.4%	103,502	65.7%	82,589	52.4%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	35,918	20.8%	81,068	46.9%	41,416	23.9%	0	0.0%
1-2 years	6,109	14.1%	12,705	29.4%	7,430	17.2%	0	0.0%
2-3 years	2,652	12.5%	5,569	26.3%	3,537	16.7%	0	0.0%
3-4 years	1,215	11.7%	2,661	25.6%	1,812	17.4%	0	0.0%
4-5 years	602	11.1%	1,534	28.3%	1,103	20.3%	0	0.0%
5-6 years	307	11.1%	851	30.7%	638	23.0%	0	0.0%
6-7 years	146	10.5%	421	30.4%	341	24.6%	0	0.0%
7+ years	115	16.6%	491	71.0%	426	61.6%	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	177,317	26.0%	243,191	35.7%	118,866	17.5%	0	0.0%
1-2 years	39,085	16.9%	56,441	24.4%	30,412	13.2%	0	0.0%
2-3 years	17,639	14.7%	26,228	21.8%	15,058	12.5%	0	0.0%
3-4 years	8,423	13.9%	13,027	21.5%	7,966	13.2%	0	0.0%
4-5 years	3,967	12.5%	7,328	23.0%	4,764	15.0%	0	0.0%
5-6 years	2,146	12.4%	4,121	23.9%	2,854	16.5%	0	0.0%
6-7 years	1,046	11.2%	2,281	24.3%	1,664	17.8%	0	0.0%
7+ years	941	18.2%	3,458	67.0%	2,776	53.7%	0	0.0%
Torsemide Users (Washout)								
0-1 years	29,234	17.0%	83,081	48.2%	46,805	27.2%	0	0.0%
1-2 years	5,573	11.7%	14,826	31.2%	9,465	19.9%	0	0.0%
2-3 years	2,539	10.8%	6,520	27.6%	4,480	19.0%	0	0.0%
3-4 years	1,204	10.3%	3,254	28.0%	2,349	20.2%	0	0.0%
4-5 years	596	10.0%	1,654	27.8%	1,231	20.7%	0	0.0%
5-6 years	339	10.8%	951	30.4%	749	23.9%	0	0.0%
6-7 years	136	8.8%	513	33.1%	426	27.4%	0	0.0%
7+ years	111	13.9%	572	71.4%	491	61.3%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0-1 years	154,135	22.7%	249,111	36.6%	132,516	19.5%	0	0.0%
1-2 years	37,494	15.0%	64,009	25.7%	37,548	15.1%	0	0.0%
2-3 years	16,799	12.8%	29,909	22.8%	18,588	14.1%	0	0.0%
3-4 years	8,271	12.4%	14,849	22.2%	9,579	14.3%	0	0.0%
4-5 years	4,283	12.0%	7,961	22.3%	5,325	14.9%	0	0.0%
5-6 years	2,345	11.9%	4,591	23.3%	3,240	16.5%	0	0.0%
6-7 years	1,135	10.5%	2,668	24.7%	1,964	18.2%	0	0.0%
7+ years	1,077	17.9%	3,952	65.8%	3,171	52.8%	0	0.0%
Furosemide Users (Washout)								
0-1 years	878,615	17.5%	2,230,649	44.3%	1,045,737	20.8%	0	0.0%
1-2 years	200,462	12.8%	403,089	25.7%	214,539	13.7%	0	0.0%
2-3 years	100,783	11.8%	198,471	23.2%	117,949	13.8%	0	0.0%
3-4 years	54,485	11.8%	109,450	23.7%	70,590	15.3%	0	0.0%
4-5 years	29,458	11.6%	62,665	24.8%	43,230	17.1%	0	0.0%
5-6 years	15,615	11.3%	37,904	27.4%	27,926	20.2%	0	0.0%
6-7 years	7,867	10.7%	22,569	30.6%	17,539	23.8%	0	0.0%
7+ years	6,270	16.5%	27,526	72.5%	23,414	61.7%	0	0.0%
Furosemide Users (No Washout)								
0-1 years	1,458,472	16.5%	3,169,564	35.8%	1,368,002	15.5%	0	0.0%
1-2 years	475,970	12.7%	790,290	21.0%	366,369	9.8%	0	0.0%
2-3 years	258,913	11.5%	408,831	18.2%	202,537	9.0%	0	0.0%
3-4 years	149,365	11.6%	238,235	18.5%	126,929	9.8%	0	0.0%
4-5 years	87,069	11.5%	145,401	19.1%	83,816	11.0%	0	0.0%
5-6 years	51,544	11.4%	90,940	20.1%	58,544	13.0%	0	0.0%
6-7 years	29,466	11.0%	58,579	21.9%	40,176	15.0%	0	0.0%
7+ years	32,080	20.4%	103,502	65.7%	82,589	52.4%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	35,918	20.8%	81,068	46.9%	41,416	23.9%	0	0.0%
1-2 years	6,109	14.1%	12,705	29.4%	7,430	17.2%	0	0.0%
2-3 years	2,652	12.5%	5,569	26.3%	3,537	16.7%	0	0.0%
3-4 years	1,215	11.7%	2,661	25.6%	1,812	17.4%	0	0.0%
4-5 years	602	11.1%	1,534	28.3%	1,103	20.3%	0	0.0%
5-6 years	307	11.1%	851	30.7%	638	23.0%	0	0.0%
6-7 years	146	10.5%	421	30.4%	341	24.6%	0	0.0%
7+ years	115	16.6%	491	71.0%	426	61.6%	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	177,317	26.0%	243,191	35.7%	118,866	17.5%	0	0.0%
1-2 years	39,085	16.9%	56,441	24.4%	30,412	13.2%	0	0.0%
2-3 years	17,639	14.7%	26,228	21.8%	15,058	12.5%	0	0.0%
3-4 years	8,423	13.9%	13,027	21.5%	7,966	13.2%	0	0.0%
4-5 years	3,967	12.5%	7,328	23.0%	4,764	15.0%	0	0.0%
5-6 years	2,146	12.4%	4,121	23.9%	2,854	16.5%	0	0.0%
6-7 years	1,046	11.2%	2,281	24.3%	1,664	17.8%	0	0.0%
7+ years	941	18.2%	3,458	67.0%	2,776	53.7%	0	0.0%
Torsemide Users (Washout)								
0-1 years	29,234	17.0%	83,081	48.2%	46,805	27.2%	0	0.0%
1-2 years	5,573	11.7%	14,826	31.2%	9,465	19.9%	0	0.0%
2-3 years	2,539	10.8%	6,520	27.6%	4,480	19.0%	0	0.0%
3-4 years	1,204	10.3%	3,254	28.0%	2,349	20.2%	0	0.0%
4-5 years	596	10.0%	1,654	27.8%	1,231	20.7%	0	0.0%
5-6 years	339	10.8%	951	30.4%	749	23.9%	0	0.0%
6-7 years	136	8.8%	513	33.1%	426	27.4%	0	0.0%
7+ years	111	13.9%	572	71.4%	491	61.3%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (No Washout)								
0-1 years	154,135	22.7%	249,111	36.6%	132,516	19.5%	0	0.0%
1-2 years	37,494	15.0%	64,009	25.7%	37,548	15.1%	0	0.0%
2-3 years	16,799	12.8%	29,909	22.8%	18,588	14.1%	0	0.0%
3-4 years	8,271	12.4%	14,849	22.2%	9,579	14.3%	0	0.0%
4-5 years	4,283	12.0%	7,961	22.3%	5,325	14.9%	0	0.0%
5-6 years	2,345	11.9%	4,591	23.3%	3,240	16.5%	0	0.0%
6-7 years	1,135	10.5%	2,668	24.7%	1,964	18.2%	0	0.0%
7+ years	1,077	17.9%	3,952	65.8%	3,171	52.8%	0	0.0%
Furosemide Users (Washout)								
0-1 years	878,615	17.5%	2,230,649	44.3%	1,045,737	20.8%	0	0.0%
1-2 years	200,462	12.8%	403,089	25.7%	214,539	13.7%	0	0.0%
2-3 years	100,783	11.8%	198,471	23.2%	117,949	13.8%	0	0.0%
3-4 years	54,485	11.8%	109,450	23.7%	70,590	15.3%	0	0.0%
4-5 years	29,458	11.6%	62,665	24.8%	43,230	17.1%	0	0.0%
5-6 years	15,615	11.3%	37,904	27.4%	27,926	20.2%	0	0.0%
6-7 years	7,867	10.7%	22,569	30.6%	17,539	23.8%	0	0.0%
7+ years	6,270	16.5%	27,526	72.5%	23,414	61.7%	0	0.0%
Furosemide Users (No Washout)								
0-1 years	1,458,472	16.5%	3,169,564	35.8%	1,368,002	15.5%	0	0.0%
1-2 years	475,970	12.7%	790,290	21.0%	366,369	9.8%	0	0.0%
2-3 years	258,913	11.5%	408,831	18.2%	202,537	9.0%	0	0.0%
3-4 years	149,365	11.6%	238,235	18.5%	126,929	9.8%	0	0.0%
4-5 years	87,069	11.5%	145,401	19.1%	83,816	11.0%	0	0.0%
5-6 years	51,544	11.4%	90,940	20.1%	58,544	13.0%	0	0.0%

Table 11c. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
6-7 years	29,466	11.0%	58,579	21.9%	40,176	15.0%	0	0.0%
7+ years	32,080	20.4%	103,502	65.7%	82,589	52.4%	0	0.0%

* Lower order categories include patients in the higher order categories

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of request-defined event.

[4]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

[5]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[6]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[7]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[8]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome							
Bumetanide Users (Washout)							
0 ppm	*****	22,009	16.4%	54	0.0%	16,035	12.0%
>0 - <700,000 ppm	*****	3,438	5.6%	17	0.0%	4,377	7.2%
700,000 - 1,000,000 ppm	*****	1,616	47.0%	*****	*****	255	7.4%
1,000,000 - 1,500,000 ppm	*****	637	39.4%	*****	*****	147	9.1%
1,500,000 - 2,000,000 ppm	*****	292	45.8%	0	0.0%	48	7.5%
≥ 2,000,000 ppm	*****	0	0.0%	*****	*****	46	15.8%
Bumetanide Users (No Washout)							
0 ppm	*****	93,193	17.0%	294	0.1%	61,468	11.2%
>0 - <700,000 ppm	*****	19,916	8.8%	75	0.0%	15,660	6.9%
700,000 - 1,000,000 ppm	*****	10,785	54.2%	*****	*****	1,233	6.2%
1,000,000 - 1,500,000 ppm	*****	4,652	43.1%	*****	*****	895	8.3%
1,500,000 - 2,000,000 ppm	*****	2,237	48.1%	0	0.0%	360	7.7%
≥ 2,000,000 ppm	*****	0	0.0%	*****	*****	310	13.8%
Torsemide Users (Washout)							
0 ppm	172,362	0	0.0%	57	0.0%	20,378	11.8%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)							
0 ppm	680,304	0	0.0%	280	0.0%	79,236	11.6%
>0 - <700,000 ppm	0						
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Furosemide Users (Washout)							
0 ppm	5,031,471	0	0.0%	3,174	0.1%	651,012	12.9%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)							
0 ppm	8,853,836	0	0.0%	6,240	0.1%	1,323,893	15.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome							
Bumetanide Users (Washout)							
0 ppm	*****	22,009	16.4%	136	0.1%	16,035	12.0%
>0 - <700,000 ppm	*****	3,438	5.6%	39	0.1%	4,377	7.2%
700,000 - 1,000,000 ppm	*****	1,616	47.0%	*****	*****	255	7.4%
1,000,000 - 1,500,000 ppm	*****	637	39.4%	*****	*****	147	9.1%
1,500,000 - 2,000,000 ppm	*****	292	45.8%	*****	*****	48	7.5%
≥ 2,000,000 ppm	*****	0	0.0%	0	0.0%	46	15.8%
Bumetanide Users (No Washout)							
0 ppm	*****	93,193	17.0%	513	0.1%	61,468	11.2%
>0 - <700,000 ppm	*****	19,916	8.8%	140	0.1%	15,660	6.9%
700,000 - 1,000,000 ppm	*****	10,785	54.2%	13	0.1%	1,233	6.2%
1,000,000 - 1,500,000 ppm	*****	4,652	43.1%	*****	*****	895	8.3%
1,500,000 - 2,000,000 ppm	*****	2,237	48.1%	*****	*****	360	7.7%
≥ 2,000,000 ppm	*****	0	0.0%	*****	*****	310	13.8%

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (Washout)							
0 ppm	172,362	0	0.0%	174	0.1%	20,378	11.8%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)							
0 ppm	680,304	0	0.0%	677	0.1%	79,236	11.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)							
0 ppm	5,031,471	0	0.0%	5,808	0.1%	651,012	12.9%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)							
0 ppm	8,853,836	0	0.0%	11,744	0.1%	1,323,893	15.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome							

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Bumetanide Users (Washout)							
0 ppm	*****	22,009	16.4%	301	0.2%	16,035	12.0%
>0 - <700,000 ppm	*****	3,438	5.6%	79	0.1%	4,377	7.2%
700,000 - 1,000,000 ppm	*****	1,616	47.0%	*****	*****	255	7.4%
1,000,000 - 1,500,000 ppm	*****	637	39.4%	*****	*****	147	9.1%
1,500,000 - 2,000,000 ppm	*****	292	45.8%	*****	*****	48	7.5%
≥ 2,000,000 ppm	*****	0	0.0%	0	0.0%	46	15.8%
Bumetanide Users (No Washout)							
0 ppm	*****	93,193	17.0%	1,180	0.2%	61,468	11.2%
>0 - <700,000 ppm	*****	19,916	8.8%	293	0.1%	15,660	6.9%
700,000 - 1,000,000 ppm	*****	10,785	54.2%	24	0.1%	1,233	6.2%
1,000,000 - 1,500,000 ppm	*****	4,652	43.1%	20	0.2%	895	8.3%
1,500,000 - 2,000,000 ppm	*****	2,237	48.1%	*****	*****	360	7.7%
≥ 2,000,000 ppm	*****	0	0.0%	*****	*****	310	13.8%
Torsemide Users (Washout)							
0 ppm	172,362	0	0.0%	338	0.2%	20,378	11.8%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)							
0 ppm	680,304	0	0.0%	1,393	0.2%	79,236	11.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)							

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0 ppm	5,031,471	0	0.0%	11,518	0.2%	651,012	12.9%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)							
0 ppm	8,853,836	0	0.0%	25,258	0.3%	1,323,893	15.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome							
Bumetanide Users (Washout)							
0 ppm	*****	22,009	16.4%	81	0.1%	16,035	12.0%
>0 - <700,000 ppm	*****	3,438	5.6%	17	0.0%	4,377	7.2%
700,000 - 1,000,000 ppm	*****	1,616	47.0%	0	0.0%	255	7.4%
1,000,000 - 1,500,000 ppm	*****	637	39.4%	*****	*****	147	9.1%
1,500,000 - 2,000,000 ppm	*****	292	45.8%	*****	*****	48	7.5%
≥ 2,000,000 ppm	*****	0	0.0%	0	0.0%	46	15.8%
Bumetanide Users (No Washout)							
0 ppm	*****	93,193	17.0%	320	0.1%	61,468	11.2%
>0 - <700,000 ppm	*****	19,916	8.8%	63	0.0%	15,660	6.9%
700,000 - 1,000,000 ppm	*****	10,785	54.2%	*****	*****	1,233	6.2%
1,000,000 - 1,500,000 ppm	*****	4,652	43.1%	*****	*****	895	8.3%
1,500,000 - 2,000,000 ppm	*****	2,237	48.1%	*****	*****	360	7.7%
≥ 2,000,000 ppm	*****	0	0.0%	*****	*****	310	13.8%
Torsemide Users (Washout)							

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

		Censoring Reason					
		End of exposure episode[2]		Occurence of event[3]		Occurence of request-defined censoring criteria[4]	
	Total Number of Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
0 ppm	172,362	0	0.0%	86	0.0%	20,378	11.8%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)							
0 ppm	680,304	0	0.0%	366	0.1%	79,236	11.6%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)							
0 ppm	5,031,471	0	0.0%	2,692	0.1%	651,012	12.9%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)							
0 ppm	8,853,836	0	0.0%	5,653	0.1%	1,323,893	15.0%
>0 - <700,000 ppm	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	34,692	25.9%	62,115	46.4%	24,234	18.1%	0	0.0%
>0 - <700,000 ppm	11,750	19.2%	40,878	66.9%	30,594	50.1%	0	0.0%
700,000 - 1,000,000 ppm	317	9.2%	1,240	36.1%	1,012	29.4%	0	0.0%
1,000,000 - 1,500,000 ppm	189	11.7%	640	39.6%	512	31.7%	0	0.0%
1,500,000 - 2,000,000 ppm	61	9.6%	240	37.7%	193	30.3%	0	0.0%
≥ 2,000,000 ppm	55	18.8%	187	64.0%	158	54.1%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	191,300	34.9%	209,170	38.2%	75,443	13.8%	0	0.0%
>0 - <700,000 ppm	54,941	24.2%	134,134	59.1%	98,802	43.6%	0	0.0%
700,000 - 1,000,000 ppm	2,005	10.1%	5,866	29.5%	4,617	23.2%	0	0.0%
1,000,000 - 1,500,000 ppm	1,343	12.4%	3,903	36.2%	3,084	28.6%	0	0.0%
1,500,000 - 2,000,000 ppm	481	10.3%	1,563	33.6%	1,267	27.2%	0	0.0%
≥ 2,000,000 ppm	494	22.1%	1,439	64.3%	1,147	51.2%	0	0.0%
Torsemide Users (Washout)								
0 ppm	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
>0 - <700,000 ppm								
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Furosemide Users (Washout)								
0 ppm	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	34,692	25.9%	62,115	46.4%	24,234	18.1%	0	0.0%
>0 - <700,000 ppm	11,750	19.2%	40,878	66.9%	30,594	50.1%	0	0.0%
700,000 - 1,000,000 ppm	317	9.2%	1,240	36.1%	1,012	29.4%	0	0.0%
1,000,000 - 1,500,000 ppm	189	11.7%	640	39.6%	512	31.7%	0	0.0%
1,500,000 - 2,000,000 ppm	61	9.6%	240	37.7%	193	30.3%	0	0.0%
≥ 2,000,000 ppm	55	18.8%	187	64.0%	158	54.1%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	191,300	34.9%	209,170	38.2%	75,443	13.8%	0	0.0%
>0 - <700,000 ppm	54,941	24.2%	134,134	59.1%	98,802	43.6%	0	0.0%
700,000 - 1,000,000 ppm	2,005	10.1%	5,866	29.5%	4,617	23.2%	0	0.0%
1,000,000 - 1,500,000 ppm	1,343	12.4%	3,903	36.2%	3,084	28.6%	0	0.0%
1,500,000 - 2,000,000 ppm	481	10.3%	1,563	33.6%	1,267	27.2%	0	0.0%
≥ 2,000,000 ppm	494	22.1%	1,439	64.3%	1,147	51.2%	0	0.0%

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (Washout)								
0 ppm	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	34,692	25.9%	62,115	46.4%	24,234	18.1%	0	0.0%
>0 - <700,000 ppm	11,750	19.2%	40,878	66.9%	30,594	50.1%	0	0.0%
700,000 - 1,000,000 ppm	317	9.2%	1,240	36.1%	1,012	29.4%	0	0.0%
1,000,000 - 1,500,000 ppm	189	11.7%	640	39.6%	512	31.7%	0	0.0%
1,500,000 - 2,000,000 ppm	61	9.6%	240	37.7%	193	30.3%	0	0.0%
≥ 2,000,000 ppm	55	18.8%	187	64.0%	158	54.1%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	191,300	34.9%	209,170	38.2%	75,443	13.8%	0	0.0%
>0 - <700,000 ppm	54,941	24.2%	134,134	59.1%	98,802	43.6%	0	0.0%
700,000 - 1,000,000 ppm	2,005	10.1%	5,866	29.5%	4,617	23.2%	0	0.0%
1,000,000 - 1,500,000 ppm	1,343	12.4%	3,903	36.2%	3,084	28.6%	0	0.0%
1,500,000 - 2,000,000 ppm	481	10.3%	1,563	33.6%	1,267	27.2%	0	0.0%
≥ 2,000,000 ppm	494	22.1%	1,439	64.3%	1,147	51.2%	0	0.0%
Torsemide Users (Washout)								
0 ppm	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Furosemide Users (Washout)								
0 ppm	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	34,692	25.9%	62,115	46.4%	24,234	18.1%	0	0.0%
>0 - <700,000 ppm	11,750	19.2%	40,878	66.9%	30,594	50.1%	0	0.0%
700,000 - 1,000,000 ppm	317	9.2%	1,240	36.1%	1,012	29.4%	0	0.0%
1,000,000 - 1,500,000 ppm	189	11.7%	640	39.6%	512	31.7%	0	0.0%
1,500,000 - 2,000,000 ppm	61	9.6%	240	37.7%	193	30.3%	0	0.0%
≥ 2,000,000 ppm	55	18.8%	187	64.0%	158	54.1%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	191,300	34.9%	209,170	38.2%	75,443	13.8%	0	0.0%
>0 - <700,000 ppm	54,941	24.2%	134,134	59.1%	98,802	43.6%	0	0.0%
700,000 - 1,000,000 ppm	2,005	10.1%	5,866	29.5%	4,617	23.2%	0	0.0%
1,000,000 - 1,500,000 ppm	1,343	12.4%	3,903	36.2%	3,084	28.6%	0	0.0%
1,500,000 - 2,000,000 ppm	481	10.3%	1,563	33.6%	1,267	27.2%	0	0.0%
≥ 2,000,000 ppm	494	22.1%	1,439	64.3%	1,147	51.2%	0	0.0%

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
Torsemide Users (Washout)								
0 ppm	39,732	23.1%	111,371	64.6%	65,996	38.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	225,539	33.2%	377,050	55.4%	211,931	31.2%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	1,293,555	25.7%	3,092,323	61.5%	1,560,924	31.0%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	2,542,879	28.7%	5,005,342	56.5%	2,328,962	26.3%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

Table 11d. Summary of Reasons for End of At-Risk Period[1] for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Censoring Reason							
	Evidence of death[5]		Disenrollment[6]		End of data partner data[7]		End of query period[8]	
	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users	Number of Users	Percent of Total Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of request-defined event.

[4]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

[5]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[6]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[7]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[8]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 12a. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	681,044	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	172,362	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	680,304	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	5,031,471	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	8,853,836	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	681,044	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	172,362	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	680,304	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	5,031,471	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	8,853,836	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	681,044	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	172,362	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	680,304	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	5,031,471	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	8,853,836	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	681,044	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	172,362	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	680,304	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	5,031,471	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	8,853,836	0	0	NaN	0	NaN	0	NaN

Table 12a. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12a. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bumetanide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bladder Cancer Outcome							
Bumetanide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bumetanide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bumetanide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bumetanide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Torsemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Furosemide Users (No Washout)	NaN	NaN	NaN	NaN	NaN	NaN	NaN

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

NaN: Not a Number

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	49,624	46,742	94.2%	1,495	3.0%	701	1.4%
30,000 - <60,000 mg	*****	28,261	24,682	87.3%	2,289	8.1%	1,031	3.6%
60,000 - <90,000 mg	*****	17,683	13,250	74.9%	3,865	21.9%	458	2.6%
90,000 - <120,000 mg	*****	11,949	9,485	79.4%	2,242	18.8%	181	1.5%
120,000 - <150,000 mg	*****	8,248	6,867	83.3%	1,268	15.4%	85	1.0%
150,000 - <180,000 mg	*****	5,876	5,134	87.4%	677	11.5%	49	0.8%
180,000 - <210,000 mg	*****	4,301	3,905	90.8%	376	8.7%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	304,808	297,890	97.7%	3,668	1.2%	1,687	0.6%
30,000 - <60,000 mg	304,791	201,269	189,766	94.3%	7,005	3.5%	3,639	1.8%
60,000 - <90,000 mg	201,271	141,915	122,107	86.0%	17,473	12.3%	1,892	1.3%
90,000 - <120,000 mg	141,898	104,740	92,412	88.2%	11,179	10.7%	894	0.9%
120,000 - <150,000 mg	104,735	78,629	71,020	90.3%	6,970	8.9%	489	0.6%
150,000 - <180,000 mg	*****	60,543	55,918	92.4%	4,266	7.0%	263	0.4%
180,000 - <210,000 mg	*****	47,301	44,454	94.0%	2,649	5.6%	149	0.3%
≥ 210,000 mg	47,345	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	43,595	39,724	91.1%	1,932	4.4%	1,138	2.6%
30,000 - <60,000 mg	*****	22,778	18,478	81.1%	2,380	10.4%	1,585	7.0%
60,000 - <90,000 mg	*****	13,444	9,150	68.1%	3,616	26.9%	573	4.3%
90,000 - <120,000 mg	*****	8,759	6,658	76.0%	1,914	21.9%	166	1.9%
120,000 - <150,000 mg	*****	6,015	4,946	82.2%	987	16.4%	66	1.1%
150,000 - <180,000 mg	*****	4,384	3,782	86.3%	569	13.0%	*****	*****
180,000 - <210,000 mg	*****	3,238	2,895	89.4%	323	10.0%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	297,240	287,644	96.8%	4,918	1.7%	2,871	1.0%
30,000 - <60,000 mg	297,231	191,132	175,877	92.0%	8,451	4.4%	5,580	2.9%
60,000 - <90,000 mg	191,137	132,995	109,652	82.4%	20,243	15.2%	2,600	2.0%
90,000 - <120,000 mg	132,972	97,901	84,297	86.1%	12,339	12.6%	1,077	1.1%
120,000 - <150,000 mg	97,900	73,715	65,607	89.0%	7,492	10.2%	493	0.7%
150,000 - <180,000 mg	73,732	57,858	53,001	91.6%	4,549	7.9%	246	0.4%
180,000 - <210,000 mg	57,843	46,043	43,018	93.4%	2,834	6.2%	140	0.3%
≥ 210,000 mg	46,087	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	664,577	429,047	64.6%	89,421	13.5%	87,362	13.1%
30,000 - <60,000 mg	664,489	230,598	79,107	34.3%	57,761	25.0%	75,222	32.6%
60,000 - <90,000 mg	230,504	97,567	27,258	27.9%	45,135	46.3%	22,534	23.1%
90,000 - <120,000 mg	97,370	46,157	18,066	39.1%	21,692	47.0%	5,866	12.7%
120,000 - <150,000 mg	46,460	24,014	12,452	51.9%	10,091	42.0%	1,314	5.5%
150,000 - <180,000 mg	24,013	13,702	8,629	63.0%	4,607	33.6%	424	3.1%
180,000 - <210,000 mg	*****	8,278	5,960	72.0%	2,171	26.2%	120	1.4%
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,997,430	1,491,165	74.7%	192,102	9.6%	204,267	10.2%
30,000 - <60,000 mg	1,997,151	852,435	382,885	44.9%	161,078	18.9%	245,471	28.8%
60,000 - <90,000 mg	852,245	423,312	136,551	32.3%	181,765	42.9%	92,907	21.9%
90,000 - <120,000 mg	422,980	230,704	94,180	40.8%	100,788	43.7%	32,436	14.1%
120,000 - <150,000 mg	231,140	133,091	67,092	50.4%	54,978	41.3%	9,989	7.5%
150,000 - <180,000 mg	133,068	81,409	48,404	59.5%	29,675	36.5%	2,904	3.6%
180,000 - <210,000 mg	81,274	52,558	34,971	66.5%	16,236	30.9%	1,158	2.2%
≥ 210,000 mg	53,201	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	49,624	46,742	94.2%	1,495	3.0%	701	1.4%
30,000 - <60,000 mg	*****	28,261	24,682	87.3%	2,289	8.1%	1,031	3.6%
60,000 - <90,000 mg	*****	17,683	13,250	74.9%	3,865	21.9%	458	2.6%
90,000 - <120,000 mg	*****	11,949	9,485	79.4%	2,242	18.8%	181	1.5%
120,000 - <150,000 mg	*****	8,248	6,867	83.3%	1,268	15.4%	85	1.0%
150,000 - <180,000 mg	*****	5,876	5,134	87.4%	677	11.5%	49	0.8%
180,000 - <210,000 mg	*****	4,301	3,905	90.8%	376	8.7%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	304,808	297,890	97.7%	3,668	1.2%	1,687	0.6%
30,000 - <60,000 mg	304,791	201,269	189,766	94.3%	7,005	3.5%	3,639	1.8%
60,000 - <90,000 mg	201,271	141,915	122,107	86.0%	17,473	12.3%	1,892	1.3%
90,000 - <120,000 mg	141,898	104,740	92,412	88.2%	11,179	10.7%	894	0.9%
120,000 - <150,000 mg	104,735	78,629	71,020	90.3%	6,970	8.9%	489	0.6%
150,000 - <180,000 mg	*****	60,543	55,918	92.4%	4,266	7.0%	263	0.4%
180,000 - <210,000 mg	*****	47,301	44,454	94.0%	2,649	5.6%	149	0.3%
≥ 210,000 mg	47,345	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	43,595	39,724	91.1%	1,932	4.4%	1,138	2.6%
30,000 - <60,000 mg	*****	22,778	18,478	81.1%	2,380	10.4%	1,585	7.0%
60,000 - <90,000 mg	*****	13,444	9,150	68.1%	3,616	26.9%	573	4.3%
90,000 - <120,000 mg	*****	8,759	6,658	76.0%	1,914	21.9%	166	1.9%
120,000 - <150,000 mg	*****	6,015	4,946	82.2%	987	16.4%	66	1.1%
150,000 - <180,000 mg	*****	4,384	3,782	86.3%	569	13.0%	*****	*****
180,000 - <210,000 mg	*****	3,238	2,895	89.4%	323	10.0%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 - <30,000 mg	680,286	297,240	287,644	96.8%	4,918	1.7%	2,871	1.0%
30,000 - <60,000 mg	297,231	191,132	175,877	92.0%	8,451	4.4%	5,580	2.9%
60,000 - <90,000 mg	191,137	132,995	109,652	82.4%	20,243	15.2%	2,600	2.0%
90,000 - <120,000 mg	132,972	97,901	84,297	86.1%	12,339	12.6%	1,077	1.1%
120,000 - <150,000 mg	97,900	73,715	65,607	89.0%	7,492	10.2%	493	0.7%
150,000 - <180,000 mg	73,732	57,858	53,001	91.6%	4,549	7.9%	246	0.4%
180,000 - <210,000 mg	57,843	46,043	43,018	93.4%	2,834	6.2%	140	0.3%
≥ 210,000 mg	46,087	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	664,577	429,047	64.6%	89,421	13.5%	87,362	13.1%
30,000 - <60,000 mg	664,489	230,598	79,107	34.3%	57,761	25.0%	75,222	32.6%
60,000 - <90,000 mg	230,504	97,567	27,258	27.9%	45,135	46.3%	22,534	23.1%
90,000 - <120,000 mg	97,370	46,157	18,066	39.1%	21,692	47.0%	5,866	12.7%
120,000 - <150,000 mg	46,460	24,014	12,452	51.9%	10,091	42.0%	1,314	5.5%
150,000 - <180,000 mg	24,013	13,702	8,629	63.0%	4,607	33.6%	424	3.1%
180,000 - <210,000 mg	*****	8,278	5,960	72.0%	2,171	26.2%	120	1.4%
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,997,430	1,491,165	74.7%	192,102	9.6%	204,267	10.2%
30,000 - <60,000 mg	1,997,151	852,435	382,885	44.9%	161,078	18.9%	245,471	28.8%
60,000 - <90,000 mg	852,245	423,312	136,551	32.3%	181,765	42.9%	92,907	21.9%
90,000 - <120,000 mg	422,980	230,704	94,180	40.8%	100,788	43.7%	32,436	14.1%
120,000 - <150,000 mg	231,140	133,091	67,092	50.4%	54,978	41.3%	9,989	7.5%
150,000 - <180,000 mg	133,068	81,409	48,404	59.5%	29,675	36.5%	2,904	3.6%
180,000 - <210,000 mg	81,274	52,558	34,971	66.5%	16,236	30.9%	1,158	2.2%
≥ 210,000 mg	53,201	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	49,624	46,742	94.2%	1,495	3.0%	701	1.4%
30,000 - <60,000 mg	*****	28,261	24,682	87.3%	2,289	8.1%	1,031	3.6%
60,000 - <90,000 mg	*****	17,683	13,250	74.9%	3,865	21.9%	458	2.6%
90,000 - <120,000 mg	*****	11,949	9,485	79.4%	2,242	18.8%	181	1.5%
120,000 - <150,000 mg	*****	8,248	6,867	83.3%	1,268	15.4%	85	1.0%
150,000 - <180,000 mg	*****	5,876	5,134	87.4%	677	11.5%	49	0.8%
180,000 - <210,000 mg	*****	4,301	3,905	90.8%	376	8.7%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	304,808	297,890	97.7%	3,668	1.2%	1,687	0.6%
30,000 - <60,000 mg	304,791	201,269	189,766	94.3%	7,005	3.5%	3,639	1.8%
60,000 - <90,000 mg	201,271	141,915	122,107	86.0%	17,473	12.3%	1,892	1.3%
90,000 - <120,000 mg	141,898	104,740	92,412	88.2%	11,179	10.7%	894	0.9%
120,000 - <150,000 mg	104,735	78,629	71,020	90.3%	6,970	8.9%	489	0.6%
150,000 - <180,000 mg	*****	60,543	55,918	92.4%	4,266	7.0%	263	0.4%
180,000 - <210,000 mg	*****	47,301	44,454	94.0%	2,649	5.6%	149	0.3%
≥ 210,000 mg	47,345	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	43,595	39,724	91.1%	1,932	4.4%	1,138	2.6%
30,000 - <60,000 mg	*****	22,778	18,478	81.1%	2,380	10.4%	1,585	7.0%
60,000 - <90,000 mg	*****	13,444	9,150	68.1%	3,616	26.9%	573	4.3%
90,000 - <120,000 mg	*****	8,759	6,658	76.0%	1,914	21.9%	166	1.9%
120,000 - <150,000 mg	*****	6,015	4,946	82.2%	987	16.4%	66	1.1%
150,000 - <180,000 mg	*****	4,384	3,782	86.3%	569	13.0%	*****	*****
180,000 - <210,000 mg	*****	3,238	2,895	89.4%	323	10.0%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	297,240	287,644	96.8%	4,918	1.7%	2,871	1.0%
30,000 - <60,000 mg	297,231	191,132	175,877	92.0%	8,451	4.4%	5,580	2.9%
60,000 - <90,000 mg	191,137	132,995	109,652	82.4%	20,243	15.2%	2,600	2.0%
90,000 - <120,000 mg	132,972	97,901	84,297	86.1%	12,339	12.6%	1,077	1.1%
120,000 - <150,000 mg	97,900	73,715	65,607	89.0%	7,492	10.2%	493	0.7%
150,000 - <180,000 mg	73,732	57,858	53,001	91.6%	4,549	7.9%	246	0.4%
180,000 - <210,000 mg	57,843	46,043	43,018	93.4%	2,834	6.2%	140	0.3%
≥ 210,000 mg	46,087	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	664,577	429,047	64.6%	89,421	13.5%	87,362	13.1%
30,000 - <60,000 mg	664,489	230,598	79,107	34.3%	57,761	25.0%	75,222	32.6%
60,000 - <90,000 mg	230,504	97,567	27,258	27.9%	45,135	46.3%	22,534	23.1%
90,000 - <120,000 mg	97,370	46,157	18,066	39.1%	21,692	47.0%	5,866	12.7%
120,000 - <150,000 mg	46,460	24,014	12,452	51.9%	10,091	42.0%	1,314	5.5%
150,000 - <180,000 mg	24,013	13,702	8,629	63.0%	4,607	33.6%	424	3.1%
180,000 - <210,000 mg	*****	8,278	5,960	72.0%	2,171	26.2%	120	1.4%
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,997,430	1,491,165	74.7%	192,102	9.6%	204,267	10.2%
30,000 - <60,000 mg	1,997,151	852,435	382,885	44.9%	161,078	18.9%	245,471	28.8%
60,000 - <90,000 mg	852,245	423,312	136,551	32.3%	181,765	42.9%	92,907	21.9%
90,000 - <120,000 mg	422,980	230,704	94,180	40.8%	100,788	43.7%	32,436	14.1%
120,000 - <150,000 mg	231,140	133,091	67,092	50.4%	54,978	41.3%	9,989	7.5%
150,000 - <180,000 mg	133,068	81,409	48,404	59.5%	29,675	36.5%	2,904	3.6%
180,000 - <210,000 mg	81,274	52,558	34,971	66.5%	16,236	30.9%	1,158	2.2%
≥ 210,000 mg	53,201	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	49,624	46,742	94.2%	1,495	3.0%	701	1.4%
30,000 - <60,000 mg	*****	28,261	24,682	87.3%	2,289	8.1%	1,031	3.6%
60,000 - <90,000 mg	*****	17,683	13,250	74.9%	3,865	21.9%	458	2.6%
90,000 - <120,000 mg	*****	11,949	9,485	79.4%	2,242	18.8%	181	1.5%
120,000 - <150,000 mg	*****	8,248	6,867	83.3%	1,268	15.4%	85	1.0%
150,000 - <180,000 mg	*****	5,876	5,134	87.4%	677	11.5%	49	0.8%
180,000 - <210,000 mg	*****	4,301	3,905	90.8%	376	8.7%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	304,808	297,890	97.7%	3,668	1.2%	1,687	0.6%
30,000 - <60,000 mg	304,791	201,269	189,766	94.3%	7,005	3.5%	3,639	1.8%
60,000 - <90,000 mg	201,271	141,915	122,107	86.0%	17,473	12.3%	1,892	1.3%
90,000 - <120,000 mg	141,898	104,740	92,412	88.2%	11,179	10.7%	894	0.9%
120,000 - <150,000 mg	104,735	78,629	71,020	90.3%	6,970	8.9%	489	0.6%
150,000 - <180,000 mg	*****	60,543	55,918	92.4%	4,266	7.0%	263	0.4%
180,000 - <210,000 mg	*****	47,301	44,454	94.0%	2,649	5.6%	149	0.3%
≥ 210,000 mg	47,345	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	43,595	39,724	91.1%	1,932	4.4%	1,138	2.6%
30,000 - <60,000 mg	*****	22,778	18,478	81.1%	2,380	10.4%	1,585	7.0%
60,000 - <90,000 mg	*****	13,444	9,150	68.1%	3,616	26.9%	573	4.3%
90,000 - <120,000 mg	*****	8,759	6,658	76.0%	1,914	21.9%	166	1.9%
120,000 - <150,000 mg	*****	6,015	4,946	82.2%	987	16.4%	66	1.1%
150,000 - <180,000 mg	*****	4,384	3,782	86.3%	569	13.0%	*****	*****
180,000 - <210,000 mg	*****	3,238	2,895	89.4%	323	10.0%	*****	*****
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End Of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	297,240	287,644	96.8%	4,918	1.7%	2,871	1.0%
30,000 - <60,000 mg	297,231	191,132	175,877	92.0%	8,451	4.4%	5,580	2.9%
60,000 - <90,000 mg	191,137	132,995	109,652	82.4%	20,243	15.2%	2,600	2.0%
90,000 - <120,000 mg	132,972	97,901	84,297	86.1%	12,339	12.6%	1,077	1.1%
120,000 - <150,000 mg	97,900	73,715	65,607	89.0%	7,492	10.2%	493	0.7%
150,000 - <180,000 mg	73,732	57,858	53,001	91.6%	4,549	7.9%	246	0.4%
180,000 - <210,000 mg	57,843	46,043	43,018	93.4%	2,834	6.2%	140	0.3%
≥ 210,000 mg	46,087	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	664,577	429,047	64.6%	89,421	13.5%	87,362	13.1%
30,000 - <60,000 mg	664,489	230,598	79,107	34.3%	57,761	25.0%	75,222	32.6%
60,000 - <90,000 mg	230,504	97,567	27,258	27.9%	45,135	46.3%	22,534	23.1%
90,000 - <120,000 mg	97,370	46,157	18,066	39.1%	21,692	47.0%	5,866	12.7%
120,000 - <150,000 mg	46,460	24,014	12,452	51.9%	10,091	42.0%	1,314	5.5%
150,000 - <180,000 mg	24,013	13,702	8,629	63.0%	4,607	33.6%	424	3.1%
180,000 - <210,000 mg	*****	8,278	5,960	72.0%	2,171	26.2%	120	1.4%
≥ 210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,997,430	1,491,165	74.7%	192,102	9.6%	204,267	10.2%
30,000 - <60,000 mg	1,997,151	852,435	382,885	44.9%	161,078	18.9%	245,471	28.8%
60,000 - <90,000 mg	852,245	423,312	136,551	32.3%	181,765	42.9%	92,907	21.9%
90,000 - <120,000 mg	422,980	230,704	94,180	40.8%	100,788	43.7%	32,436	14.1%
120,000 - <150,000 mg	231,140	133,091	67,092	50.4%	54,978	41.3%	9,989	7.5%
150,000 - <180,000 mg	133,068	81,409	48,404	59.5%	29,675	36.5%	2,904	3.6%
180,000 - <210,000 mg	81,274	52,558	34,971	66.5%	16,236	30.9%	1,158	2.2%
≥ 210,000 mg	53,201	0	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	321	0.6%	170	0.3%	98	0.2%	58	0.1%	39	0.1%
30,000 - <60,000 mg	158	0.6%	68	0.2%	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	72	0.4%	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 - <30,000 mg	730	0.2%	375	0.1%	226	0.1%	131	0.0%	101	0.0%
30,000 - <60,000 mg	521	0.3%	195	0.1%	100	0.0%	24	0.0%	19	0.0%
60,000 - <90,000 mg	259	0.2%	110	0.1%	47	0.0%	16	0.0%	11	0.0%
90,000 - <120,000 mg	151	0.1%	55	0.1%	24	0.0%	*****	*****	*****	*****
120,000 - <150,000 mg	96	0.1%	25	0.0%	15	0.0%	*****	*****	*****	*****
150,000 - <180,000 mg	60	0.1%	19	0.0%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	32	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 - <30,000 mg	441	1.0%	188	0.4%	99	0.2%	50	0.1%	23	0.1%
30,000 - <60,000 mg	212	0.9%	93	0.4%	19	0.1%	*****	*****	*****	*****
60,000 - <90,000 mg	74	0.6%	20	0.1%	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	945	0.3%	433	0.1%	222	0.1%	122	0.0%	85	0.0%
30,000 - <60,000 mg	709	0.4%	344	0.2%	98	0.1%	39	0.0%	34	0.0%
60,000 - <90,000 mg	321	0.2%	110	0.1%	36	0.0%	22	0.0%	11	0.0%
90,000 - <120,000 mg	116	0.1%	51	0.1%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	75	0.1%	27	0.0%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	41	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	37	0.1%	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 - <30,000 mg	28,886	4.3%	14,638	2.2%	7,954	1.2%	4,124	0.6%	3,145	0.5%
30,000 - <60,000 mg	9,818	4.3%	7,057	3.1%	1,107	0.5%	332	0.1%	194	0.1%
60,000 - <90,000 mg	1,861	1.9%	593	0.6%	116	0.1%	43	0.0%	27	0.0%
90,000 - <120,000 mg	387	0.8%	97	0.2%	28	0.1%	*****	*****	*****	*****
120,000 - <150,000 mg	104	0.4%	37	0.2%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 - <30,000 mg	54,727	2.7%	26,351	1.3%	14,404	0.7%	7,844	0.4%	6,570	0.3%
30,000 - <60,000 mg	31,049	3.6%	25,680	3.0%	4,107	0.5%	1,368	0.2%	797	0.1%
60,000 - <90,000 mg	7,994	1.9%	3,090	0.7%	657	0.2%	233	0.1%	115	0.0%
90,000 - <120,000 mg	2,351	1.0%	686	0.3%	162	0.1%	69	0.0%	32	0.0%
120,000 - <150,000 mg	701	0.5%	230	0.2%	67	0.1%	18	0.0%	16	0.0%
150,000 - <180,000 mg	310	0.4%	92	0.1%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	141	0.3%	26	0.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	321	0.6%	170	0.3%	98	0.2%	58	0.1%	39	0.1%
30,000 - <60,000 mg	158	0.6%	68	0.2%	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	72	0.4%	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 - <30,000 mg	730	0.2%	375	0.1%	226	0.1%	131	0.0%	101	0.0%
30,000 - <60,000 mg	521	0.3%	195	0.1%	100	0.0%	24	0.0%	19	0.0%
60,000 - <90,000 mg	259	0.2%	110	0.1%	47	0.0%	16	0.0%	11	0.0%
90,000 - <120,000 mg	151	0.1%	55	0.1%	24	0.0%	*****	*****	*****	*****
120,000 - <150,000 mg	96	0.1%	25	0.0%	15	0.0%	*****	*****	*****	*****
150,000 - <180,000 mg	60	0.1%	19	0.0%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	32	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 - <30,000 mg	441	1.0%	188	0.4%	99	0.2%	50	0.1%	23	0.1%
30,000 - <60,000 mg	212	0.9%	93	0.4%	19	0.1%	*****	*****	*****	*****
60,000 - <90,000 mg	74	0.6%	20	0.1%	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	945	0.3%	433	0.1%	222	0.1%	122	0.0%	85	0.0%
30,000 - <60,000 mg	709	0.4%	344	0.2%	98	0.1%	39	0.0%	34	0.0%
60,000 - <90,000 mg	321	0.2%	110	0.1%	36	0.0%	22	0.0%	11	0.0%
90,000 - <120,000 mg	116	0.1%	51	0.1%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	75	0.1%	27	0.0%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	41	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	37	0.1%	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 - <30,000 mg	28,886	4.3%	14,638	2.2%	7,954	1.2%	4,124	0.6%	3,145	0.5%
30,000 - <60,000 mg	9,818	4.3%	7,057	3.1%	1,107	0.5%	332	0.1%	194	0.1%
60,000 - <90,000 mg	1,861	1.9%	593	0.6%	116	0.1%	43	0.0%	27	0.0%
90,000 - <120,000 mg	387	0.8%	97	0.2%	28	0.1%	*****	*****	*****	*****
120,000 - <150,000 mg	104	0.4%	37	0.2%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 - <30,000 mg	54,727	2.7%	26,351	1.3%	14,404	0.7%	7,844	0.4%	6,570	0.3%
30,000 - <60,000 mg	31,049	3.6%	25,680	3.0%	4,107	0.5%	1,368	0.2%	797	0.1%
60,000 - <90,000 mg	7,994	1.9%	3,090	0.7%	657	0.2%	233	0.1%	115	0.0%
90,000 - <120,000 mg	2,351	1.0%	686	0.3%	162	0.1%	69	0.0%	32	0.0%
120,000 - <150,000 mg	701	0.5%	230	0.2%	67	0.1%	18	0.0%	16	0.0%
150,000 - <180,000 mg	310	0.4%	92	0.1%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	141	0.3%	26	0.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	321	0.6%	170	0.3%	98	0.2%	58	0.1%	39	0.1%
30,000 - <60,000 mg	158	0.6%	68	0.2%	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	72	0.4%	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 - <30,000 mg	730	0.2%	375	0.1%	226	0.1%	131	0.0%	101	0.0%
30,000 - <60,000 mg	521	0.3%	195	0.1%	100	0.0%	24	0.0%	19	0.0%
60,000 - <90,000 mg	259	0.2%	110	0.1%	47	0.0%	16	0.0%	11	0.0%
90,000 - <120,000 mg	151	0.1%	55	0.1%	24	0.0%	*****	*****	*****	*****
120,000 - <150,000 mg	96	0.1%	25	0.0%	15	0.0%	*****	*****	*****	*****
150,000 - <180,000 mg	60	0.1%	19	0.0%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	32	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 - <30,000 mg	441	1.0%	188	0.4%	99	0.2%	50	0.1%	23	0.1%
30,000 - <60,000 mg	212	0.9%	93	0.4%	19	0.1%	*****	*****	*****	*****
60,000 - <90,000 mg	74	0.6%	20	0.1%	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	945	0.3%	433	0.1%	222	0.1%	122	0.0%	85	0.0%
30,000 - <60,000 mg	709	0.4%	344	0.2%	98	0.1%	39	0.0%	34	0.0%
60,000 - <90,000 mg	321	0.2%	110	0.1%	36	0.0%	22	0.0%	11	0.0%
90,000 - <120,000 mg	116	0.1%	51	0.1%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	75	0.1%	27	0.0%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	41	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	37	0.1%	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 - <30,000 mg	28,886	4.3%	14,638	2.2%	7,954	1.2%	4,124	0.6%	3,145	0.5%
30,000 - <60,000 mg	9,818	4.3%	7,057	3.1%	1,107	0.5%	332	0.1%	194	0.1%
60,000 - <90,000 mg	1,861	1.9%	593	0.6%	116	0.1%	43	0.0%	27	0.0%
90,000 - <120,000 mg	387	0.8%	97	0.2%	28	0.1%	*****	*****	*****	*****
120,000 - <150,000 mg	104	0.4%	37	0.2%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 - <30,000 mg	54,727	2.7%	26,351	1.3%	14,404	0.7%	7,844	0.4%	6,570	0.3%
30,000 - <60,000 mg	31,049	3.6%	25,680	3.0%	4,107	0.5%	1,368	0.2%	797	0.1%
60,000 - <90,000 mg	7,994	1.9%	3,090	0.7%	657	0.2%	233	0.1%	115	0.0%
90,000 - <120,000 mg	2,351	1.0%	686	0.3%	162	0.1%	69	0.0%	32	0.0%
120,000 - <150,000 mg	701	0.5%	230	0.2%	67	0.1%	18	0.0%	16	0.0%
150,000 - <180,000 mg	310	0.4%	92	0.1%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	141	0.3%	26	0.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	321	0.6%	170	0.3%	98	0.2%	58	0.1%	39	0.1%
30,000 - <60,000 mg	158	0.6%	68	0.2%	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	72	0.4%	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 - <30,000 mg	730	0.2%	375	0.1%	226	0.1%	131	0.0%	101	0.0%
30,000 - <60,000 mg	521	0.3%	195	0.1%	100	0.0%	24	0.0%	19	0.0%
60,000 - <90,000 mg	259	0.2%	110	0.1%	47	0.0%	16	0.0%	11	0.0%
90,000 - <120,000 mg	151	0.1%	55	0.1%	24	0.0%	*****	*****	*****	*****
120,000 - <150,000 mg	96	0.1%	25	0.0%	15	0.0%	*****	*****	*****	*****
150,000 - <180,000 mg	60	0.1%	19	0.0%	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	32	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 - <30,000 mg	441	1.0%	188	0.4%	99	0.2%	50	0.1%	23	0.1%
30,000 - <60,000 mg	212	0.9%	93	0.4%	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	74	0.6%	20	0.1%	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	945	0.3%	433	0.1%	222	0.1%	122	0.0%	85	0.0%
30,000 - <60,000 mg	709	0.4%	344	0.2%	98	0.1%	39	0.0%	34	0.0%
60,000 - <90,000 mg	321	0.2%	110	0.1%	36	0.0%	22	0.0%	11	0.0%
90,000 - <120,000 mg	116	0.1%	51	0.1%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	75	0.1%	27	0.0%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	41	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 - <30,000 mg	28,886	4.3%	14,638	2.2%	7,954	1.2%	4,124	0.6%	3,145	0.5%
30,000 - <60,000 mg	9,818	4.3%	7,057	3.1%	1,107	0.5%	332	0.1%	194	0.1%
60,000 - <90,000 mg	1,861	1.9%	593	0.6%	116	0.1%	43	0.0%	27	0.0%
90,000 - <120,000 mg	387	0.8%	97	0.2%	28	0.1%	*****	*****	*****	*****
120,000 - <150,000 mg	104	0.4%	37	0.2%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 - <30,000 mg	54,727	2.7%	26,351	1.3%	14,404	0.7%	7,844	0.4%	6,570	0.3%
30,000 - <60,000 mg	31,049	3.6%	25,680	3.0%	4,107	0.5%	1,368	0.2%	797	0.1%
60,000 - <90,000 mg	7,994	1.9%	3,090	0.7%	657	0.2%	233	0.1%	115	0.0%
90,000 - <120,000 mg	2,351	1.0%	686	0.3%	162	0.1%	69	0.0%	32	0.0%
120,000 - <150,000 mg	701	0.5%	230	0.2%	67	0.1%	18	0.0%	16	0.0%
150,000 - <180,000 mg	310	0.4%	92	0.1%	*****	*****	*****	*****	*****	*****

Table 12b. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	141	0.3%	26	0.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

[1] Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	43,206	40,314	93.3%	1,503	3.5%	679	1.6%
1-2 years	43,206	*****	16,775	79.2%	3,578	16.9%	579	2.7%
2-3 years	*****	*****	0	0.0%	9,929	95.5%	353	3.4%
3-4 years	*****	*****	0	0.0%	5,258	97.0%	131	2.4%
4-5 years	*****	*****	0	0.0%	2,711	97.7%	50	1.8%
5-6 years	*****	*****	0	0.0%	1,353	97.8%	*****	*****
6-7 years	*****	*****	0	0.0%	679	98.1%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	231,141	223,450	96.7%	4,209	1.8%	1,751	0.8%
1-2 years	231,141	120,390	102,414	85.1%	14,392	12.0%	2,537	2.1%
2-3 years	120,390	60,491	0	0.0%	58,061	96.0%	1,865	3.1%
3-4 years	60,491	31,830	0	0.0%	30,830	96.9%	795	2.5%
4-5 years	31,830	*****	0	0.0%	16,840	97.6%	337	2.0%
5-6 years	*****	*****	0	0.0%	9,184	98.0%	152	1.6%
6-7 years	*****	*****	0	0.0%	5,083	98.4%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0-1 years	172,362	*****	44,678	94.0%	1,459	3.1%	660	1.4%
1-2 years	*****	*****	19,181	81.3%	3,524	14.9%	618	2.6%
2-3 years	*****	*****	0	0.0%	11,225	96.5%	324	2.8%
3-4 years	*****	*****	0	0.0%	5,786	97.2%	119	2.0%
4-5 years	*****	*****	0	0.0%	3,054	97.6%	59	1.9%
5-6 years	*****	*****	0	0.0%	1,532	98.7%	*****	*****
6-7 years	*****	*****	0	0.0%	*****	*****	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,185	241,594	97.0%	4,267	1.7%	1,697	0.7%
1-2 years	249,185	131,368	113,050	86.1%	14,845	11.3%	2,439	1.9%
2-3 years	131,368	66,841	0	0.0%	64,524	96.5%	1,815	2.7%
3-4 years	66,841	35,645	0	0.0%	34,642	97.2%	785	2.2%
4-5 years	35,645	*****	0	0.0%	19,229	97.7%	371	1.9%
5-6 years	*****	*****	0	0.0%	10,579	98.1%	165	1.5%
6-7 years	*****	*****	0	0.0%	5,925	98.7%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0-1 years	5,031,471	1,570,858	1,416,253	90.2%	70,395	4.5%	37,351	2.4%
1-2 years	1,570,858	857,233	652,061	76.1%	167,215	19.5%	24,226	2.8%
2-3 years	857,233	462,012	0	0.0%	441,493	95.6%	14,777	3.2%
3-4 years	462,012	253,038	0	0.0%	245,083	96.9%	5,979	2.4%
4-5 years	253,038	138,456	0	0.0%	135,277	97.7%	2,465	1.8%
5-6 years	138,456	73,838	0	0.0%	72,480	98.2%	1,071	1.5%
6-7 years	73,838	37,943	0	0.0%	37,483	98.8%	378	1.0%
7+ years	37,943	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,756,719	3,528,939	93.9%	108,110	2.9%	53,709	1.4%
1-2 years	3,756,719	2,243,787	1,838,078	81.9%	322,686	14.4%	52,728	2.3%
2-3 years	2,243,787	1,290,390	0	0.0%	1,235,756	95.8%	39,030	3.0%
3-4 years	1,290,390	759,943	0	0.0%	734,789	96.7%	18,553	2.4%
4-5 years	759,943	451,504	0	0.0%	439,681	97.4%	8,990	2.0%
5-6 years	451,504	267,682	0	0.0%	261,826	97.8%	4,549	1.7%
6-7 years	267,682	157,482	0	0.0%	155,104	98.5%	1,936	1.2%
7+ years	157,482	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	43,206	40,314	93.3%	1,503	3.5%	679	1.6%
1-2 years	43,206	*****	16,775	79.2%	3,578	16.9%	579	2.7%
2-3 years	*****	*****	0	0.0%	9,929	95.5%	353	3.4%
3-4 years	*****	*****	0	0.0%	5,258	97.0%	131	2.4%
4-5 years	*****	*****	0	0.0%	2,711	97.7%	50	1.8%
5-6 years	*****	*****	0	0.0%	1,353	97.8%	*****	*****
6-7 years	*****	*****	0	0.0%	679	98.1%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	231,141	223,450	96.7%	4,209	1.8%	1,751	0.8%
1-2 years	231,141	120,390	102,414	85.1%	14,392	12.0%	2,537	2.1%
2-3 years	120,390	60,491	0	0.0%	58,061	96.0%	1,865	3.1%
3-4 years	60,491	31,830	0	0.0%	30,830	96.9%	795	2.5%
4-5 years	31,830	*****	0	0.0%	16,840	97.6%	337	2.0%
5-6 years	*****	*****	0	0.0%	9,184	98.0%	*****	*****
6-7 years	*****	*****	0	0.0%	5,083	98.4%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0-1 years	172,362	*****	44,678	94.0%	1,459	3.1%	660	1.4%
1-2 years	*****	*****	19,181	81.3%	3,524	14.9%	618	2.6%
2-3 years	*****	*****	0	0.0%	11,225	96.5%	324	2.8%
3-4 years	*****	*****	0	0.0%	5,786	97.2%	119	2.0%
4-5 years	*****	*****	0	0.0%	3,054	97.6%	59	1.9%
5-6 years	*****	*****	0	0.0%	1,532	98.7%	*****	*****
6-7 years	*****	*****	0	0.0%	*****	*****	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,185	241,594	97.0%	4,267	1.7%	1,697	0.7%
1-2 years	249,185	131,368	113,050	86.1%	14,845	11.3%	2,439	1.9%
2-3 years	131,368	66,841	0	0.0%	64,524	96.5%	1,815	2.7%
3-4 years	66,841	35,645	0	0.0%	34,642	97.2%	785	2.2%
4-5 years	35,645	*****	0	0.0%	19,229	97.7%	371	1.9%
5-6 years	*****	*****	0	0.0%	10,579	98.1%	*****	*****
6-7 years	*****	*****	0	0.0%	5,925	98.7%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0-1 years	5,031,471	1,570,858	1,416,253	90.2%	70,395	4.5%	37,351	2.4%
1-2 years	1,570,858	857,233	652,061	76.1%	167,215	19.5%	24,226	2.8%
2-3 years	857,233	462,012	0	0.0%	441,493	95.6%	14,777	3.2%
3-4 years	462,012	253,038	0	0.0%	245,083	96.9%	5,979	2.4%
4-5 years	253,038	138,456	0	0.0%	135,277	97.7%	2,465	1.8%
5-6 years	138,456	73,838	0	0.0%	72,480	98.2%	1,071	1.5%
6-7 years	73,838	37,943	0	0.0%	37,483	98.8%	378	1.0%
7+ years	37,943	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,756,719	3,528,939	93.9%	108,110	2.9%	53,709	1.4%
1-2 years	3,756,719	2,243,787	1,838,078	81.9%	322,686	14.4%	52,728	2.3%
2-3 years	2,243,787	1,290,390	0	0.0%	1,235,756	95.8%	39,030	3.0%
3-4 years	1,290,390	759,943	0	0.0%	734,789	96.7%	18,553	2.4%
4-5 years	759,943	451,504	0	0.0%	439,681	97.4%	8,990	2.0%
5-6 years	451,504	267,682	0	0.0%	261,826	97.8%	4,549	1.7%
6-7 years	267,682	157,482	0	0.0%	155,104	98.5%	1,936	1.2%
7+ years	157,482	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	43,206	40,314	93.3%	1,503	3.5%	679	1.6%
1-2 years	43,206	*****	16,775	79.2%	3,578	16.9%	579	2.7%
2-3 years	*****	*****	0	0.0%	9,929	95.5%	353	3.4%
3-4 years	*****	*****	0	0.0%	5,258	97.0%	131	2.4%
4-5 years	*****	*****	0	0.0%	2,711	97.7%	50	1.8%
5-6 years	*****	*****	0	0.0%	1,353	97.8%	*****	*****
6-7 years	*****	*****	0	0.0%	679	98.1%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	231,141	223,450	96.7%	4,209	1.8%	1,751	0.8%
1-2 years	231,141	120,390	102,414	85.1%	14,392	12.0%	2,537	2.1%
2-3 years	120,390	60,491	0	0.0%	58,061	96.0%	1,865	3.1%
3-4 years	60,491	31,830	0	0.0%	30,830	96.9%	795	2.5%
4-5 years	31,830	*****	0	0.0%	16,840	97.6%	337	2.0%
5-6 years	*****	*****	0	0.0%	9,184	98.0%	152	1.6%
6-7 years	*****	*****	0	0.0%	5,083	98.4%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0-1 years	172,362	*****	44,678	94.0%	1,459	3.1%	660	1.4%
1-2 years	*****	*****	19,181	81.3%	3,524	14.9%	618	2.6%
2-3 years	*****	*****	0	0.0%	11,225	96.5%	324	2.8%
3-4 years	*****	*****	0	0.0%	5,786	97.2%	119	2.0%
4-5 years	*****	*****	0	0.0%	3,054	97.6%	59	1.9%
5-6 years	*****	*****	0	0.0%	1,532	98.7%	*****	*****
6-7 years	*****	*****	0	0.0%	*****	*****	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,185	241,594	97.0%	4,267	1.7%	1,697	0.7%
1-2 years	249,185	131,368	113,050	86.1%	14,845	11.3%	2,439	1.9%
2-3 years	131,368	66,841	0	0.0%	64,524	96.5%	1,815	2.7%
3-4 years	66,841	35,645	0	0.0%	34,642	97.2%	785	2.2%
4-5 years	35,645	*****	0	0.0%	19,229	97.7%	371	1.9%
5-6 years	*****	*****	0	0.0%	10,579	98.1%	165	1.5%
6-7 years	*****	*****	0	0.0%	5,925	98.7%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0-1 years	5,031,471	1,570,858	1,416,253	90.2%	70,395	4.5%	37,351	2.4%
1-2 years	1,570,858	857,233	652,061	76.1%	167,215	19.5%	24,226	2.8%
2-3 years	857,233	462,012	0	0.0%	441,493	95.6%	14,777	3.2%
3-4 years	462,012	253,038	0	0.0%	245,083	96.9%	5,979	2.4%
4-5 years	253,038	138,456	0	0.0%	135,277	97.7%	2,465	1.8%
5-6 years	138,456	73,838	0	0.0%	72,480	98.2%	1,071	1.5%
6-7 years	73,838	37,943	0	0.0%	37,483	98.8%	378	1.0%
7+ years	37,943	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,756,719	3,528,939	93.9%	108,110	2.9%	53,709	1.4%
1-2 years	3,756,719	2,243,787	1,838,078	81.9%	322,686	14.4%	52,728	2.3%
2-3 years	2,243,787	1,290,390	0	0.0%	1,235,756	95.8%	39,030	3.0%
3-4 years	1,290,390	759,943	0	0.0%	734,789	96.7%	18,553	2.4%
4-5 years	759,943	451,504	0	0.0%	439,681	97.4%	8,990	2.0%
5-6 years	451,504	267,682	0	0.0%	261,826	97.8%	4,549	1.7%
6-7 years	267,682	157,482	0	0.0%	155,104	98.5%	1,936	1.2%
7+ years	157,482	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	43,206	40,314	93.3%	1,503	3.5%	679	1.6%
1-2 years	43,206	*****	16,775	79.2%	3,578	16.9%	579	2.7%
2-3 years	*****	*****	0	0.0%	9,929	95.5%	353	3.4%
3-4 years	*****	*****	0	0.0%	5,258	97.0%	131	2.4%
4-5 years	*****	*****	0	0.0%	2,711	97.7%	50	1.8%
5-6 years	*****	*****	0	0.0%	1,353	97.8%	*****	*****
6-7 years	*****	*****	0	0.0%	679	98.1%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	231,141	223,450	96.7%	4,209	1.8%	1,751	0.8%
1-2 years	231,141	120,390	102,414	85.1%	14,392	12.0%	2,537	2.1%
2-3 years	120,390	60,491	0	0.0%	58,061	96.0%	1,865	3.1%
3-4 years	60,491	31,830	0	0.0%	30,830	96.9%	795	2.5%
4-5 years	31,830	*****	0	0.0%	16,840	97.6%	337	2.0%
5-6 years	*****	*****	0	0.0%	9,184	98.0%	152	1.6%
6-7 years	*****	*****	0	0.0%	5,083	98.4%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0-1 years	172,362	*****	44,678	94.0%	1,459	3.1%	660	1.4%
1-2 years	*****	*****	19,181	81.3%	3,524	14.9%	618	2.6%
2-3 years	*****	*****	0	0.0%	11,225	96.5%	324	2.8%
3-4 years	*****	*****	0	0.0%	5,786	97.2%	119	2.0%
4-5 years	*****	*****	0	0.0%	3,054	97.6%	59	1.9%
5-6 years	*****	*****	0	0.0%	1,532	98.7%	*****	*****
6-7 years	*****	*****	0	0.0%	*****	*****	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,185	241,594	97.0%	4,267	1.7%	1,697	0.7%
1-2 years	249,185	131,368	113,050	86.1%	14,845	11.3%	2,439	1.9%
2-3 years	131,368	66,841	0	0.0%	64,524	96.5%	1,815	2.7%
3-4 years	66,841	35,645	0	0.0%	34,642	97.2%	785	2.2%
4-5 years	35,645	*****	0	0.0%	19,229	97.7%	371	1.9%
5-6 years	*****	*****	0	0.0%	10,579	98.1%	165	1.5%
6-7 years	*****	*****	0	0.0%	5,925	98.7%	*****	*****
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0-1 years	5,031,471	1,570,858	1,416,253	90.2%	70,395	4.5%	37,351	2.4%
1-2 years	1,570,858	857,233	652,061	76.1%	167,215	19.5%	24,226	2.8%
2-3 years	857,233	462,012	0	0.0%	441,493	95.6%	14,777	3.2%
3-4 years	462,012	253,038	0	0.0%	245,083	96.9%	5,979	2.4%
4-5 years	253,038	138,456	0	0.0%	135,277	97.7%	2,465	1.8%
5-6 years	138,456	73,838	0	0.0%	72,480	98.2%	1,071	1.5%
6-7 years	73,838	37,943	0	0.0%	37,483	98.8%	378	1.0%
7+ years	37,943	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,756,719	3,528,939	93.9%	108,110	2.9%	53,709	1.4%
1-2 years	3,756,719	2,243,787	1,838,078	81.9%	322,686	14.4%	52,728	2.3%
2-3 years	2,243,787	1,290,390	0	0.0%	1,235,756	95.8%	39,030	3.0%
3-4 years	1,290,390	759,943	0	0.0%	734,789	96.7%	18,553	2.4%
4-5 years	759,943	451,504	0	0.0%	439,681	97.4%	8,990	2.0%
5-6 years	451,504	267,682	0	0.0%	261,826	97.8%	4,549	1.7%
6-7 years	267,682	157,482	0	0.0%	155,104	98.5%	1,936	1.2%
7+ years	157,482	0	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	328	0.8%	174	0.4%	121	0.3%	43	0.1%	44	0.1%
1-2 years	149	0.7%	55	0.3%	21	0.1%	*****	*****	*****	*****
2-3 years	86	0.8%	19	0.2%	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0-1 years	817	0.4%	427	0.2%	263	0.1%	122	0.1%	102	0.0%
1-2 years	649	0.5%	210	0.2%	117	0.1%	44	0.0%	27	0.0%
2-3 years	356	0.6%	116	0.2%	51	0.1%	26	0.0%	16	0.0%
3-4 years	144	0.5%	35	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	57	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0-1 years	376	0.8%	188	0.4%	79	0.2%	42	0.1%	*****	*****
1-2 years	173	0.7%	64	0.3%	*****	*****	*****	*****	*****	*****
2-3 years	60	0.5%	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	32	0.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	806	0.3%	437	0.2%	191	0.1%	113	0.0%	80	0.0%
1-2 years	663	0.5%	208	0.2%	93	0.1%	42	0.0%	28	0.0%
2-3 years	315	0.5%	110	0.2%	38	0.1%	21	0.0%	18	0.0%
3-4 years	146	0.4%	47	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	58	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0-1 years	21,186	1.3%	11,981	0.8%	6,877	0.4%	3,750	0.2%	3,065	0.2%
1-2 years	8,058	0.9%	3,240	0.4%	1,347	0.2%	634	0.1%	452	0.1%
2-3 years	3,580	0.8%	1,264	0.3%	528	0.1%	230	0.0%	140	0.0%
3-4 years	1,323	0.5%	405	0.2%	162	0.1%	49	0.0%	37	0.0%
4-5 years	515	0.4%	136	0.1%	44	0.0%	*****	*****	13	0.0%
5-6 years	216	0.3%	49	0.1%	*****	*****	*****	*****	*****	*****
6-7 years	59	0.2%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0-1 years	29,401	0.8%	16,716	0.4%	9,630	0.3%	5,426	0.1%	4,788	0.1%
1-2 years	17,092	0.8%	7,067	0.3%	3,235	0.1%	1,656	0.1%	1,245	0.1%
2-3 years	9,285	0.7%	3,478	0.3%	1,577	0.1%	756	0.1%	508	0.0%
3-4 years	4,128	0.5%	1,489	0.2%	588	0.1%	262	0.0%	134	0.0%
4-5 years	1,878	0.4%	602	0.1%	230	0.1%	88	0.0%	35	0.0%
5-6 years	932	0.3%	257	0.1%	*****	*****	*****	*****	*****	*****
6-7 years	321	0.2%	89	0.1%	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	328	0.8%	174	0.4%	121	0.3%	43	0.1%	44	0.1%
1-2 years	149	0.7%	55	0.3%	21	0.1%	*****	*****	*****	*****
2-3 years	86	0.8%	19	0.2%	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0-1 years	817	0.4%	427	0.2%	263	0.1%	122	0.1%	102	0.0%
1-2 years	649	0.5%	210	0.2%	117	0.1%	44	0.0%	27	0.0%
2-3 years	356	0.6%	116	0.2%	51	0.1%	26	0.0%	16	0.0%
3-4 years	144	0.5%	35	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	57	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0-1 years	376	0.8%	188	0.4%	79	0.2%	42	0.1%	*****	*****
1-2 years	173	0.7%	64	0.3%	*****	*****	*****	*****	*****	*****
2-3 years	60	0.5%	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	32	0.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	806	0.3%	437	0.2%	191	0.1%	113	0.0%	80	0.0%
1-2 years	663	0.5%	208	0.2%	93	0.1%	42	0.0%	28	0.0%
2-3 years	315	0.5%	110	0.2%	38	0.1%	21	0.0%	18	0.0%
3-4 years	146	0.4%	47	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	58	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0-1 years	21,186	1.3%	11,981	0.8%	6,877	0.4%	3,750	0.2%	3,065	0.2%
1-2 years	8,058	0.9%	3,240	0.4%	1,347	0.2%	634	0.1%	452	0.1%
2-3 years	3,580	0.8%	1,264	0.3%	528	0.1%	230	0.0%	140	0.0%
3-4 years	1,323	0.5%	405	0.2%	162	0.1%	49	0.0%	37	0.0%
4-5 years	515	0.4%	136	0.1%	44	0.0%	*****	*****	*****	*****
5-6 years	216	0.3%	49	0.1%	*****	*****	*****	*****	*****	*****
6-7 years	59	0.2%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0-1 years	29,401	0.8%	16,716	0.4%	9,630	0.3%	5,426	0.1%	4,788	0.1%
1-2 years	17,092	0.8%	7,067	0.3%	3,235	0.1%	1,656	0.1%	1,245	0.1%
2-3 years	9,285	0.7%	3,478	0.3%	1,577	0.1%	756	0.1%	508	0.0%
3-4 years	4,128	0.5%	1,489	0.2%	588	0.1%	262	0.0%	134	0.0%
4-5 years	1,878	0.4%	602	0.1%	230	0.1%	88	0.0%	35	0.0%
5-6 years	932	0.3%	257	0.1%	83	0.0%	20	0.0%	15	0.0%
6-7 years	321	0.2%	89	0.1%	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	328	0.8%	174	0.4%	121	0.3%	43	0.1%	44	0.1%
1-2 years	149	0.7%	55	0.3%	21	0.1%	*****	*****	*****	*****
2-3 years	86	0.8%	19	0.2%	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0-1 years	817	0.4%	427	0.2%	263	0.1%	122	0.1%	102	0.0%
1-2 years	649	0.5%	210	0.2%	117	0.1%	44	0.0%	27	0.0%
2-3 years	356	0.6%	116	0.2%	51	0.1%	26	0.0%	16	0.0%
3-4 years	144	0.5%	35	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	57	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0-1 years	376	0.8%	188	0.4%	79	0.2%	42	0.1%	*****	*****
1-2 years	173	0.7%	64	0.3%	25	0.1%	*****	*****	*****	*****
2-3 years	60	0.5%	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	32	0.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	806	0.3%	437	0.2%	191	0.1%	113	0.0%	80	0.0%
1-2 years	663	0.5%	208	0.2%	93	0.1%	42	0.0%	28	0.0%
2-3 years	315	0.5%	110	0.2%	38	0.1%	21	0.0%	18	0.0%
3-4 years	146	0.4%	47	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	58	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0-1 years	21,186	1.3%	11,981	0.8%	6,877	0.4%	3,750	0.2%	3,065	0.2%
1-2 years	8,058	0.9%	3,240	0.4%	1,347	0.2%	634	0.1%	452	0.1%
2-3 years	3,580	0.8%	1,264	0.3%	528	0.1%	230	0.0%	140	0.0%
3-4 years	1,323	0.5%	405	0.2%	162	0.1%	49	0.0%	37	0.0%
4-5 years	515	0.4%	136	0.1%	44	0.0%	*****	*****	*****	*****
5-6 years	216	0.3%	49	0.1%	*****	*****	*****	*****	*****	*****
6-7 years	59	0.2%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0-1 years	29,401	0.8%	16,716	0.4%	9,630	0.3%	5,426	0.1%	4,788	0.1%
1-2 years	17,092	0.8%	7,067	0.3%	3,235	0.1%	1,656	0.1%	1,245	0.1%
2-3 years	9,285	0.7%	3,478	0.3%	1,577	0.1%	756	0.1%	508	0.0%
3-4 years	4,128	0.5%	1,489	0.2%	588	0.1%	262	0.0%	134	0.0%
4-5 years	1,878	0.4%	602	0.1%	230	0.1%	88	0.0%	35	0.0%
5-6 years	932	0.3%	257	0.1%	83	0.0%	20	0.0%	15	0.0%
6-7 years	321	0.2%	89	0.1%	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	328	0.8%	174	0.4%	121	0.3%	43	0.1%	44	0.1%
1-2 years	149	0.7%	55	0.3%	21	0.1%	*****	*****	*****	*****
2-3 years	86	0.8%	19	0.2%	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0-1 years	817	0.4%	427	0.2%	263	0.1%	122	0.1%	102	0.0%
1-2 years	649	0.5%	210	0.2%	117	0.1%	44	0.0%	27	0.0%
2-3 years	356	0.6%	116	0.2%	51	0.1%	26	0.0%	16	0.0%
3-4 years	144	0.5%	35	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	57	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0-1 years	376	0.8%	188	0.4%	79	0.2%	42	0.1%	*****	*****
1-2 years	173	0.7%	64	0.3%	25	0.1%	*****	*****	*****	*****
2-3 years	60	0.5%	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	32	0.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	806	0.3%	437	0.2%	191	0.1%	113	0.0%	80	0.0%
1-2 years	663	0.5%	208	0.2%	93	0.1%	42	0.0%	28	0.0%
2-3 years	315	0.5%	110	0.2%	38	0.1%	21	0.0%	18	0.0%
3-4 years	146	0.4%	47	0.1%	*****	*****	*****	*****	*****	*****
4-5 years	58	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0-1 years	21,186	1.3%	11,981	0.8%	6,877	0.4%	3,750	0.2%	3,065	0.2%
1-2 years	8,058	0.9%	3,240	0.4%	1,347	0.2%	634	0.1%	452	0.1%
2-3 years	3,580	0.8%	1,264	0.3%	528	0.1%	230	0.0%	140	0.0%
3-4 years	1,323	0.5%	405	0.2%	162	0.1%	49	0.0%	37	0.0%
4-5 years	515	0.4%	136	0.1%	44	0.0%	*****	*****	*****	*****
5-6 years	216	0.3%	49	0.1%	*****	*****	*****	*****	*****	*****
6-7 years	59	0.2%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0-1 years	29,401	0.8%	16,716	0.4%	9,630	0.3%	5,426	0.1%	4,788	0.1%
1-2 years	17,092	0.8%	7,067	0.3%	3,235	0.1%	1,656	0.1%	1,245	0.1%
2-3 years	9,285	0.7%	3,478	0.3%	1,577	0.1%	756	0.1%	508	0.0%
3-4 years	4,128	0.5%	1,489	0.2%	588	0.1%	262	0.0%	134	0.0%
4-5 years	1,878	0.4%	602	0.1%	230	0.1%	88	0.0%	35	0.0%
5-6 years	932	0.3%	257	0.1%	83	0.0%	20	0.0%	15	0.0%

Table 12c. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	321	0.2%	89	0.1%	*****	*****	*****	*****	*****	*****
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	22,009	17,068	77.6%	1,791	8.1%	1,314	6.0%
>0 - <700,000 ppm	*****	3,438	2,182	63.5%	720	20.9%	347	10.1%
700,000 - 1,000,000 ppm	*****	1,616	1,450	89.7%	134	8.3%	*****	*****
1,000,000 - 1,500,000 ppm	*****	637	501	78.6%	116	18.2%	*****	*****
1,500,000 - 2,000,000 ppm	*****	292	254	87.0%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	93,193	73,033	78.4%	6,503	7.0%	4,746	5.1%
>0 - <700,000 ppm	*****	19,916	14,383	72.2%	3,282	16.5%	1,490	7.5%
700,000 - 1,000,000 ppm	*****	10,785	10,120	93.8%	560	5.2%	87	0.8%
1,000,000 - 1,500,000 ppm	*****	4,652	3,965	85.2%	593	12.7%	78	1.7%
1,500,000 - 2,000,000 ppm	*****	2,237	2,017	90.2%	193	8.6%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 ppm	172,362	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	5,031,471	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	22,009	17,068	77.6%	1,791	8.1%	1,314	6.0%
>0 - <700,000 ppm	*****	3,438	2,182	63.5%	720	20.9%	347	10.1%
700,000 - 1,000,000 ppm	*****	1,616	1,450	89.7%	134	8.3%	*****	*****
1,000,000 - 1,500,000 ppm	*****	637	501	78.6%	116	18.2%	*****	*****
1,500,000 - 2,000,000 ppm	*****	292	254	87.0%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	93,193	73,033	78.4%	6,503	7.0%	4,746	5.1%
>0 - <700,000 ppm	*****	19,916	14,383	72.2%	3,282	16.5%	1,490	7.5%
700,000 - 1,000,000 ppm	*****	10,785	10,120	93.8%	560	5.2%	87	0.8%
1,000,000 - 1,500,000 ppm	*****	4,652	3,965	85.2%	593	12.7%	78	1.7%
1,500,000 - 2,000,000 ppm	*****	2,237	2,017	90.2%	193	8.6%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	172,362	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	22,009	17,068	77.6%	1,791	8.1%	1,314	6.0%
>0 - <700,000 ppm	*****	3,438	2,182	63.5%	720	20.9%	347	10.1%
700,000 - 1,000,000 ppm	*****	1,616	1,450	89.7%	134	8.3%	*****	*****
1,000,000 - 1,500,000 ppm	*****	637	501	78.6%	116	18.2%	*****	*****
1,500,000 - 2,000,000 ppm	*****	292	254	87.0%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	93,193	73,033	78.4%	6,503	7.0%	4,746	5.1%
>0 - <700,000 ppm	*****	19,916	14,383	72.2%	3,282	16.5%	1,490	7.5%
700,000 - 1,000,000 ppm	*****	10,785	10,120	93.8%	560	5.2%	87	0.8%
1,000,000 - 1,500,000 ppm	*****	4,652	3,965	85.2%	593	12.7%	78	1.7%
1,500,000 - 2,000,000 ppm	*****	2,237	2,017	90.2%	193	8.6%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								
0 ppm	172,362	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	5,031,471	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	22,009	17,068	77.6%	1,791	8.1%	1,314	6.0%
>0 - <700,000 ppm	*****	3,438	2,182	63.5%	720	20.9%	347	10.1%
700,000 - 1,000,000 ppm	*****	1,616	1,450	89.7%	134	8.3%	*****	*****
1,000,000 - 1,500,000 ppm	*****	637	501	78.6%	116	18.2%	*****	*****
1,500,000 - 2,000,000 ppm	*****	292	254	87.0%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	93,193	73,033	78.4%	6,503	7.0%	4,746	5.1%
>0 - <700,000 ppm	*****	19,916	14,383	72.2%	3,282	16.5%	1,490	7.5%
700,000 - 1,000,000 ppm	*****	10,785	10,120	93.8%	560	5.2%	87	0.8%
1,000,000 - 1,500,000 ppm	*****	4,652	3,965	85.2%	593	12.7%	78	1.7%
1,500,000 - 2,000,000 ppm	*****	2,237	2,017	90.2%	193	8.6%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)								

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End Of Exposure Episode by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Exposure Episode[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	172,362	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	0	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	807	3.7%	503	2.3%	275	1.2%	143	0.6%	108	0.5%
>0 - <700,000 ppm	129	3.8%	45	1.3%	15	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	3,895	4.2%	2,026	2.2%	1,671	1.8%	702	0.8%	617	0.7%
>0 - <700,000 ppm	536	2.7%	180	0.9%	44	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	807	3.7%	503	2.3%	275	1.2%	143	0.6%	108	0.5%
>0 - <700,000 ppm	129	3.8%	45	1.3%	15	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	3,895	4.2%	2,026	2.2%	1,671	1.8%	702	0.8%	617	0.7%
>0 - <700,000 ppm	536	2.7%	180	0.9%	44	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	807	3.7%	503	2.3%	275	1.2%	143	0.6%	108	0.5%
>0 - <700,000 ppm	129	3.8%	45	1.3%	15	0.4%	0	0.0%	0	0.0%

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	3,895	4.2%	2,026	2.2%	1,671	1.8%	702	0.8%	617	0.7%
>0 - <700,000 ppm	536	2.7%	180	0.9%	44	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	807	3.7%	503	2.3%	275	1.2%	143	0.6%	108	0.5%
>0 - <700,000 ppm	129	3.8%	45	1.3%	15	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	3,895	4.2%	2,026	2.2%	1,671	1.8%	702	0.8%	617	0.7%
>0 - <700,000 ppm	536	2.7%	180	0.9%	44	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12d. Summary of Time to End of At-Risk Period due to End Of Exposure Episode for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End Of Exposure Episode by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 13a. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	76	27	35.5%	18	23.7%	*****	*****
Bumetanide Users (No Washout)	681,044	380	151	39.7%	91	23.9%	44	11.6%
Torsemide Users (Washout)	172,362	57	26	45.6%	15	26.3%	*****	*****
Torsemide Users (No Washout)	680,304	280	122	43.6%	67	23.9%	33	11.8%
Furosemide Users (Washout)	5,031,471	3,174	1,177	37.1%	783	24.7%	502	15.8%
Furosemide Users (No Washout)	8,853,836	6,240	2,214	35.5%	1,506	24.1%	944	15.1%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	179	73	40.8%	30	16.8%	33	18.4%
Bumetanide Users (No Washout)	681,044	677	255	37.7%	149	22.0%	115	17.0%
Torsemide Users (Washout)	172,362	174	64	36.8%	34	19.5%	31	17.8%
Torsemide Users (No Washout)	680,304	677	271	40.0%	161	23.8%	98	14.5%
Furosemide Users (Washout)	5,031,471	5,808	2,117	36.4%	1,411	24.3%	960	16.5%
Furosemide Users (No Washout)	8,853,836	11,744	4,305	36.7%	2,773	23.6%	1,791	15.3%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	393	144	36.6%	93	23.7%	55	14.0%
Bumetanide Users (No Washout)	681,044	1,526	592	38.8%	348	22.8%	225	14.7%
Torsemide Users (Washout)	172,362	338	117	34.6%	100	29.6%	44	13.0%
Torsemide Users (No Washout)	680,304	1,393	556	39.9%	334	24.0%	194	13.9%
Furosemide Users (Washout)	5,031,471	11,518	4,169	36.2%	2,697	23.4%	1,769	15.4%
Furosemide Users (No Washout)	8,853,836	25,258	9,258	36.7%	5,772	22.9%	3,794	15.0%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	100	38	38.0%	30	30.0%	15	15.0%
Bumetanide Users (No Washout)	681,044	403	156	38.7%	103	25.6%	72	17.9%
Torsemide Users (Washout)	172,362	86	31	36.0%	27	31.4%	11	12.8%
Torsemide Users (No Washout)	680,304	366	136	37.2%	100	27.3%	52	14.2%
Furosemide Users (Washout)	5,031,471	2,692	974	36.2%	626	23.3%	469	17.4%
Furosemide Users (No Washout)	8,853,836	5,653	1,842	32.6%	1,259	22.3%	1,138	20.1%

Table 13a. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	11	14.5%	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)	30	7.9%	34	8.9%	*****	*****	13	3.4%	*****	*****
Torsemide Users (Washout)	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (No Washout)	22	7.9%	20	7.1%	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)	290	9.1%	183	5.8%	131	4.1%	53	1.7%	55	1.7%
Furosemide Users (No Washout)	593	9.5%	412	6.6%	273	4.4%	155	2.5%	143	2.3%
Bladder Cancer Outcome										
Bumetanide Users (Washout)	22	12.3%	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)	64	9.5%	32	4.7%	24	3.5%	13	1.9%	25	3.7%
Torsemide Users (Washout)	17	9.8%	15	8.6%	*****	*****	*****	*****	*****	*****
Torsemide Users (No Washout)	55	8.1%	42	6.2%	15	2.2%	19	2.8%	16	2.4%
Furosemide Users (Washout)	576	9.9%	336	5.8%	198	3.4%	104	1.8%	106	1.8%
Furosemide Users (No Washout)	1,151	9.8%	689	5.9%	455	3.9%	280	2.4%	300	2.6%
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	41	10.4%	21	5.3%	19	4.8%	*****	*****	*****	*****
Bumetanide Users (No Washout)	156	10.2%	79	5.2%	53	3.5%	35	2.3%	38	2.5%
Torsemide Users (Washout)	29	8.6%	17	5.0%	17	5.0%	*****	*****	*****	*****
Torsemide Users (No Washout)	119	8.5%	59	4.2%	55	3.9%	35	2.5%	41	2.9%
Furosemide Users (Washout)	1,200	10.4%	769	6.7%	418	3.6%	271	2.4%	225	2.0%
Furosemide Users (No Washout)	2,472	9.8%	1,573	6.2%	1,001	4.0%	682	2.7%	706	2.8%
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)	33	8.2%	14	3.5%	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (No Washout)	38	10.4%	14	3.8%	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)	275	10.2%	168	6.2%	85	3.2%	45	1.7%	50	1.9%
Furosemide Users (No Washout)	612	10.8%	342	6.0%	196	3.5%	122	2.2%	142	2.5%

Table 13a. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	3	260	560	1,154	2,620	769.8	659.7
Bumetanide Users (No Washout)	2	210	476	1,085	3,893	726.1	681.4
Torsemide Users (Washout)	19	204	389	784	1,500	510.5	402.5
Torsemide Users (No Washout)	7	202	440	968	3,588	669.3	652.8
Furosemide Users (Washout)	2	222	550	1,021	3,937	716.1	639.2
Furosemide Users (No Washout)	2	236	569	1,101	4,329	764.0	681.8
Bladder Cancer Outcome							
Bumetanide Users (Washout)	5	215	601	1,089	4,323	726.9	657.5
Bumetanide Users (No Washout)	4	221	558	1,030	4,323	752.0	700.0
Torsemide Users (Washout)	3	263	559	1,153	3,011	770.7	665.3
Torsemide Users (No Washout)	2	204	489	999	3,227	701.4	667.7
Furosemide Users (Washout)	2	236	546	1,034	4,684	724.2	639.7
Furosemide Users (No Washout)	2	227	549	1,078	4,684	752.5	685.9
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	2	219	522	1,141	3,831	762.0	702.1
Bumetanide Users (No Washout)	2	203	520	1,046	4,238	727.7	686.2
Torsemide Users (Washout)	3	251	498	1,036	3,273	730.4	653.6
Torsemide Users (No Washout)	2	212	489	1,016	3,867	717.6	691.4
Furosemide Users (Washout)	2	233	562	1,095	5,356	750.2	663.9
Furosemide Users (No Washout)	2	225	559	1,109	5,356	767.7	701.6
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	2	154	509	851	3,258	632.1	614.5
Bumetanide Users (No Washout)	2	189	501	935	3,258	650.7	588.3
Torsemide Users (Washout)	8	254	518	878	3,114	672.3	592.0
Torsemide Users (No Washout)	4	241	514	944	4,252	700.0	660.7
Furosemide Users (Washout)	2	245	573	1,049	6,057	738.9	663.6
Furosemide Users (No Washout)	2	266	645	1,095	6,057	791.7	674.5

[1]Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	40	15	37.5%	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	124	44	35.5%	33	26.6%	15	12.1%
30,000 - <60,000 mg	304,791	61	33	54.1%	16	26.2%	*****	*****
60,000 - <90,000 mg	201,271	41	29	70.7%	*****	*****	*****	*****
90,000 - <120,000 mg	141,898	30	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	104,735	28	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	26	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	47,345	60	30	50.0%	14	23.3%	*****	*****
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	38	20	52.6%	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	0	0	NaN	0	NaN	0	NaN
≥ 210,000 mg	*****	*****	0	0.0%	*****	*****	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	94	45	47.9%	21	22.3%	13	13.8%
30,000 - <60,000 mg	297,231	36	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	191,137	36	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	132,972	24	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	97,900	16	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	73,732	20	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	57,843	15	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	46,087	39	13	33.3%	13	33.3%	*****	*****
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	2,333	994	42.6%	576	24.7%	328	14.1%
30,000 - <60,000 mg	664,489	555	324	58.4%	153	27.6%	39	7.0%
60,000 - <90,000 mg	230,504	162	109	67.3%	40	24.7%	*****	*****
90,000 - <120,000 mg	97,370	70	54	77.1%	*****	*****	*****	*****
120,000 - <150,000 mg	46,460	28	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	24,013	15	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	3,580	1,576	44.0%	884	24.7%	457	12.8%
30,000 - <60,000 mg	1,997,151	1,520	851	56.0%	431	28.4%	124	8.2%
60,000 - <90,000 mg	852,245	575	377	65.6%	146	25.4%	33	5.7%
90,000 - <120,000 mg	422,980	273	190	69.6%	58	21.2%	*****	*****
120,000 - <150,000 mg	231,140	123	100	81.3%	*****	*****	*****	*****
150,000 - <180,000 mg	133,068	78	62	79.5%	*****	*****	*****	*****
180,000 - <210,000 mg	81,274	32	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	53,201	59	25	42.4%	13	22.0%	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	103	49	47.6%	17	16.5%	12	11.7%
30,000 - <60,000 mg	*****	25	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	*****	17	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	0	0	NaN	0	NaN	0	NaN
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	13	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	230	100	43.5%	48	20.9%	35	15.2%
30,000 - <60,000 mg	304,791	93	52	55.9%	18	19.4%	*****	*****
60,000 - <90,000 mg	201,271	88	59	67.0%	11	12.5%	*****	*****
90,000 - <120,000 mg	141,898	65	46	70.8%	*****	*****	*****	*****
120,000 - <150,000 mg	104,735	47	36	76.6%	*****	*****	*****	*****
150,000 - <180,000 mg	*****	27	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	*****	30	28	93.3%	0	0.0%	*****	*****
≥ 210,000 mg	47,345	97	41	42.3%	22	22.7%	14	14.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	109	43	39.4%	20	18.3%	15	13.8%
30,000 - <60,000 mg	*****	28	17	60.7%	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	21	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	0	0.0%	*****	*****	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	239	107	44.8%	53	22.2%	28	11.7%
30,000 - <60,000 mg	297,231	121	73	60.3%	26	21.5%	*****	*****
60,000 - <90,000 mg	191,137	92	60	65.2%	*****	*****	*****	*****
90,000 - <120,000 mg	132,972	48	35	72.9%	11	22.9%	0	0.0%
120,000 - <150,000 mg	97,900	53	41	77.4%	*****	*****	*****	*****
150,000 - <180,000 mg	73,732	19	19	100.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	57,843	36	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	46,087	69	33	47.8%	20	29.0%	*****	*****
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	4,467	1,842	41.2%	1,099	24.6%	667	14.9%
30,000 - <60,000 mg	664,489	881	480	54.5%	271	30.8%	91	10.3%
60,000 - <90,000 mg	230,504	292	201	68.8%	71	24.3%	*****	*****
90,000 - <120,000 mg	97,370	95	69	72.6%	*****	*****	*****	*****
120,000 - <150,000 mg	46,460	36	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	24,013	13	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	*****	12	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	*****	12	*****	*****	*****	*****	*****	*****
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	7,083	3,132	44.2%	1,760	24.8%	949	13.4%
30,000 - <60,000 mg	1,997,151	2,681	1,503	56.1%	728	27.2%	255	9.5%
60,000 - <90,000 mg	852,245	1,065	702	65.9%	254	23.8%	60	5.6%
90,000 - <120,000 mg	422,980	441	313	71.0%	90	20.4%	*****	*****
120,000 - <150,000 mg	231,140	198	148	74.7%	37	18.7%	*****	*****
150,000 - <180,000 mg	133,068	102	84	82.4%	*****	*****	*****	*****
180,000 - <210,000 mg	81,274	65	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	53,201	109	39	35.8%	34	31.2%	14	12.8%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	212	79	37.3%	51	24.1%	31	14.6%
30,000 - <60,000 mg	*****	64	37	57.8%	*****	*****	*****	*****
60,000 - <90,000 mg	*****	38	26	68.4%	*****	*****	*****	*****
90,000 - <120,000 mg	*****	22	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	21	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	*****	20	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	516	207	40.1%	126	24.4%	72	14.0%
30,000 - <60,000 mg	304,791	235	142	60.4%	43	18.3%	24	10.2%
60,000 - <90,000 mg	201,271	200	141	70.5%	27	13.5%	*****	*****
90,000 - <120,000 mg	141,898	148	103	69.6%	21	14.2%	*****	*****
120,000 - <150,000 mg	104,735	120	93	77.5%	12	10.0%	*****	*****
150,000 - <180,000 mg	*****	61	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	59	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	47,345	187	84	44.9%	43	23.0%	25	13.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	199	71	35.7%	51	25.6%	31	15.6%
30,000 - <60,000 mg	*****	67	36	53.7%	20	29.9%	*****	*****
60,000 - <90,000 mg	*****	25	14	56.0%	*****	*****	*****	*****
90,000 - <120,000 mg	*****	15	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	12	*****	*****	*****	*****	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	500	217	43.4%	111	22.2%	71	14.2%
30,000 - <60,000 mg	297,231	253	143	56.5%	57	22.5%	26	10.3%
60,000 - <90,000 mg	191,137	177	121	68.4%	33	18.6%	*****	*****
90,000 - <120,000 mg	132,972	108	87	80.6%	*****	*****	*****	*****
120,000 - <150,000 mg	97,900	98	84	85.7%	*****	*****	*****	*****
150,000 - <180,000 mg	73,732	62	49	79.0%	*****	*****	0	0.0%
180,000 - <210,000 mg	57,843	33	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	46,087	162	66	40.7%	43	26.5%	19	11.7%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	8,750	3,601	41.2%	2,104	24.0%	1,271	14.5%
30,000 - <60,000 mg	664,489	1,879	995	53.0%	556	29.6%	185	9.8%
60,000 - <90,000 mg	230,504	535	339	63.4%	139	26.0%	41	7.7%
90,000 - <120,000 mg	97,370	177	124	70.1%	39	22.0%	*****	*****
120,000 - <150,000 mg	46,460	81	60	74.1%	*****	*****	*****	*****
150,000 - <180,000 mg	24,013	49	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	20	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	*****	27	17	63.0%	*****	*****	*****	*****
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	14,937	6,700	44.9%	3,559	23.8%	2,013	13.5%
30,000 - <60,000 mg	1,997,151	5,942	3,220	54.2%	1,684	28.3%	606	10.2%
60,000 - <90,000 mg	852,245	2,259	1,456	64.5%	548	24.3%	172	7.6%
90,000 - <120,000 mg	422,980	964	672	69.7%	211	21.9%	51	5.3%
120,000 - <150,000 mg	231,140	490	363	74.1%	96	19.6%	18	3.7%
150,000 - <180,000 mg	133,068	263	214	81.4%	28	10.6%	*****	*****
180,000 - <210,000 mg	81,274	148	123	83.1%	*****	*****	*****	*****
≥ 210,000 mg	53,201	255	111	43.5%	66	25.9%	39	15.3%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	57	25	43.9%	17	29.8%	*****	*****
30,000 - <60,000 mg	*****	15	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	116	51	44.0%	29	25.0%	14	12.1%
30,000 - <60,000 mg	304,791	70	40	57.1%	12	17.1%	*****	*****
60,000 - <90,000 mg	201,271	39	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	141,898	36	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	104,735	29	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	22	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	19	*****	*****	0	0.0%	0	0.0%
≥ 210,000 mg	47,345	72	32	44.4%	18	25.0%	11	15.3%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	49	22	44.9%	14	28.6%	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	*****	14	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	0	0	NaN	0	NaN	0	NaN
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	100	51	51.0%	25	25.0%	*****	*****
30,000 - <60,000 mg	297,231	41	26	63.4%	*****	*****	*****	*****
60,000 - <90,000 mg	191,137	62	38	61.3%	*****	*****	*****	*****
90,000 - <120,000 mg	132,972	39	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	97,900	30	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	73,732	15	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	57,843	15	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	46,087	64	30	46.9%	14	21.9%	*****	*****
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,898	796	41.9%	436	23.0%	300	15.8%
30,000 - <60,000 mg	664,489	531	303	57.1%	140	26.4%	59	11.1%
60,000 - <90,000 mg	230,504	156	112	71.8%	29	18.6%	*****	*****
90,000 - <120,000 mg	97,370	56	41	73.2%	*****	*****	0	0.0%
120,000 - <150,000 mg	46,460	29	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	24,013	11	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	2,983	1,294	43.4%	672	22.5%	500	16.8%
30,000 - <60,000 mg	1,997,151	1,439	759	52.7%	431	30.0%	153	10.6%
60,000 - <90,000 mg	852,245	600	407	67.8%	141	23.5%	31	5.2%
90,000 - <120,000 mg	422,980	305	201	65.9%	73	23.9%	*****	*****
120,000 - <150,000 mg	231,140	152	117	77.0%	*****	*****	*****	*****
150,000 - <180,000 mg	133,068	81	64	79.0%	*****	*****	*****	*****
180,000 - <210,000 mg	81,274	30	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	53,201	63	28	44.4%	16	25.4%	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
30,000 - <60,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
60,000 - <90,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 - <30,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
Torsemide Users (Washout)										
0 - <30,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
30,000 - <60,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
60,000 - <90,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
60,000 - <90,000 mg	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
Furosemide Users (Washout)										
0 - <30,000 mg	193	8.3%	112	4.8%	67	2.9%	29	1.2%	34	1.5%
30,000 - <60,000 mg	26	4.7%	*****	*****	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0 - <30,000 mg	290	8.1%	166	4.6%	93	2.6%	58	1.6%	56	1.6%
30,000 - <60,000 mg	71	4.7%	16	1.1%	16	1.1%	*****	*****	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
150,000 - <180,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	11	10.7%	*****	*****	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
60,000 - <90,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	23	10.0%	*****	*****	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0 - <30,000 mg	11	10.1%	*****	*****	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
60,000 - <90,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	19	7.9%	18	7.5%	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
90,000 - <120,000 mg	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Furosemide Users (Washout)										
0 - <30,000 mg	383	8.6%	220	4.9%	120	2.7%	68	1.5%	68	1.5%
30,000 - <60,000 mg	26	3.0%	*****	*****	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0 - <30,000 mg	527	7.4%	311	4.4%	184	2.6%	111	1.6%	109	1.5%
30,000 - <60,000 mg	110	4.1%	48	1.8%	*****	*****	*****	*****	11	0.4%
60,000 - <90,000 mg	27	2.5%	*****	*****	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	19	9.0%	11	5.2%	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
60,000 - <90,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	49	9.5%	25	4.8%	20	3.9%	*****	*****	*****	*****
30,000 - <60,000 mg	12	5.1%	*****	*****	0	0.0%	*****	*****	*****	*****
60,000 - <90,000 mg	15	7.5%	*****	*****	*****	*****	*****	*****	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
≥ 210,000 mg	19	10.2%	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0 - <30,000 mg	18	9.0%	*****	*****	11	5.5%	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
60,000 - <90,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	39	7.8%	20	4.0%	22	4.4%	*****	*****	*****	*****
30,000 - <60,000 mg	13	5.1%	*****	*****	*****	*****	*****	*****	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	16	9.9%	*****	*****	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)										
0 - <30,000 mg	757	8.7%	474	5.4%	250	2.9%	158	1.8%	135	1.5%
30,000 - <60,000 mg	81	4.3%	35	1.9%	13	0.7%	*****	*****	*****	*****
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
90,000 - <120,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0 - <30,000 mg	1,126	7.5%	682	4.6%	376	2.5%	257	1.7%	224	1.5%
30,000 - <60,000 mg	231	3.9%	101	1.7%	60	1.0%	22	0.4%	18	0.3%
60,000 - <90,000 mg	53	2.3%	15	0.7%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	18	1.9%	*****	*****	*****	*****	*****	*****	0	0.0%
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	20	7.8%	*****	*****	*****	*****	*****	*****	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
30,000 - <60,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
60,000 - <90,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 - <30,000 mg	11	9.5%	*****	*****	*****	*****	*****	*****	*****	*****
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
60,000 - <90,000 mg	0	0.0%	*****	*****	0	0.0%	*****	*****	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 - <30,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
30,000 - <60,000 mg	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
60,000 - <90,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
30,000 - <60,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
60,000 - <90,000 mg	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
90,000 - <120,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
120,000 - <150,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****
180,000 - <210,000 mg	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)										
0 - <30,000 mg	165	8.7%	103	5.4%	47	2.5%	22	1.2%	29	1.5%
30,000 - <60,000 mg	17	3.2%	*****	*****	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
90,000 - <120,000 mg	0	0.0%	*****	*****	*****	*****	0	0.0%	*****	*****
120,000 - <150,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****

Table 13b. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 - <30,000 mg	229	7.7%	140	4.7%	66	2.2%	37	1.2%	45	1.5%
30,000 - <60,000 mg	58	4.0%	24	1.7%	*****	*****	*****	*****	0	0.0%
60,000 - <90,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
150,000 - <180,000 mg	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
180,000 - <210,000 mg	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	*****	*****

* Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	44	17	38.6%	*****	*****	*****	*****
1-2 years	43,206	*****	*****	*****	*****	*****	*****	*****
2-3 years	*****	*****	*****	*****	*****	*****	0	0.0%
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	157	62	39.5%	40	25.5%	19	12.1%
1-2 years	231,141	81	50	61.7%	18	22.2%	*****	*****
2-3 years	120,390	73	59	80.8%	*****	*****	*****	*****
3-4 years	60,491	29	*****	*****	*****	*****	*****	*****
4-5 years	31,830	23	*****	*****	*****	*****	*****	*****
5-6 years	*****	11	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)								
0-1 years	172,362	37	18	48.6%	*****	*****	*****	*****
1-2 years	*****	*****	*****	*****	*****	*****	0	0.0%
2-3 years	*****	*****	*****	*****	*****	*****	0	0.0%
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	*****	*****
5-6 years	*****	0	0	NaN	0	NaN	0	NaN
6-7 years	*****	0	0	NaN	0	NaN	0	NaN
7+ years	*****	0	0	NaN	0	NaN	0	NaN

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	99	48	48.5%	23	23.2%	13	13.1%
1-2 years	249,185	61	41	67.2%	*****	*****	*****	*****
2-3 years	131,368	60	49	81.7%	*****	*****	*****	*****
3-4 years	66,841	28	*****	*****	*****	*****	*****	*****
4-5 years	35,645	13	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)								
0-1 years	5,031,471	1,437	604	42.0%	331	23.0%	213	14.8%
1-2 years	1,570,858	666	433	65.0%	125	18.8%	51	7.7%
2-3 years	857,233	552	432	78.3%	76	13.8%	26	4.7%
3-4 years	462,012	273	238	87.2%	*****	*****	*****	*****
4-5 years	253,038	136	121	89.0%	*****	*****	*****	*****
5-6 years	138,456	53	41	77.4%	*****	*****	*****	*****
6-7 years	73,838	32	*****	*****	*****	*****	0	0.0%
7+ years	37,943	25	*****	*****	*****	*****	*****	*****
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,919	815	42.5%	441	23.0%	271	14.1%
1-2 years	3,756,719	1,335	892	66.8%	244	18.3%	94	7.0%
2-3 years	2,243,787	1,435	1,130	78.7%	199	13.9%	50	3.5%
3-4 years	1,290,390	723	586	81.1%	99	13.7%	21	2.9%
4-5 years	759,943	387	334	86.3%	36	9.3%	*****	*****
5-6 years	451,504	208	173	83.2%	*****	*****	*****	*****
6-7 years	267,682	127	111	87.4%	*****	*****	*****	*****
7+ years	157,482	106	55	51.9%	32	30.2%	*****	*****

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	105	50	47.6%	15	14.3%	12	11.4%
1-2 years	43,206	25	*****	*****	*****	*****	*****	*****
2-3 years	*****	27	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	*****	*****	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	681,044	258	113	43.8%	51	19.8%	37	14.3%
1-2 years	231,141	120	76	63.3%	20	16.7%	*****	*****
2-3 years	120,390	148	102	68.9%	33	22.3%	*****	*****
3-4 years	60,491	75	52	69.3%	*****	*****	*****	*****
4-5 years	31,830	39	*****	*****	*****	*****	*****	*****
5-6 years	*****	12	*****	*****	*****	*****	*****	*****
6-7 years	*****	12	*****	*****	*****	*****	*****	*****
7+ years	*****	13	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)								
0-1 years	172,362	100	38	38.0%	18	18.0%	14	14.0%
1-2 years	*****	26	*****	*****	*****	*****	*****	*****
2-3 years	*****	26	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	0	0	NaN	0	NaN	0	NaN
7+ years	*****	*****	0	0.0%	0	0.0%	*****	*****

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	229	97	42.4%	53	23.1%	26	11.4%
1-2 years	249,185	140	99	70.7%	23	16.4%	*****	*****
2-3 years	131,368	147	120	81.6%	*****	*****	*****	*****
3-4 years	66,841	93	74	79.6%	*****	*****	*****	*****
4-5 years	35,645	29	*****	*****	*****	*****	*****	*****
5-6 years	*****	20	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)								
0-1 years	5,031,471	2,940	1,164	39.6%	722	24.6%	462	15.7%
1-2 years	1,570,858	1,040	659	63.4%	214	20.6%	84	8.1%
2-3 years	857,233	909	725	79.8%	134	14.7%	28	3.1%
3-4 years	462,012	467	384	82.2%	63	13.5%	*****	*****
4-5 years	253,038	214	177	82.7%	*****	*****	*****	*****
5-6 years	138,456	130	116	89.2%	*****	*****	0	0.0%
6-7 years	73,838	63	*****	*****	*****	*****	*****	*****
7+ years	37,943	45	24	53.3%	*****	*****	*****	*****
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,812	1,554	40.8%	932	24.4%	569	14.9%
1-2 years	3,756,719	2,306	1,522	66.0%	440	19.1%	160	6.9%
2-3 years	2,243,787	2,646	2,120	80.1%	361	13.6%	74	2.8%
3-4 years	1,290,390	1,357	1,091	80.4%	185	13.6%	46	3.4%
4-5 years	759,943	731	611	83.6%	90	12.3%	16	2.2%
5-6 years	451,504	431	379	87.9%	*****	*****	*****	*****
6-7 years	267,682	207	177	85.5%	18	8.7%	*****	*****
7+ years	157,482	254	105	41.3%	77	30.3%	48	18.9%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	225	80	35.6%	57	25.3%	36	16.0%
1-2 years	43,206	59	32	54.2%	13	22.0%	*****	*****
2-3 years	*****	62	46	74.2%	*****	*****	*****	*****
3-4 years	*****	19	*****	*****	*****	*****	*****	*****
4-5 years	*****	17	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	0	0	NaN	0	NaN	0	NaN
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0-1 years	681,044	602	248	41.2%	142	23.6%	86	14.3%
1-2 years	231,141	286	177	61.9%	51	17.8%	26	9.1%
2-3 years	120,390	340	270	79.4%	32	9.4%	12	3.5%
3-4 years	60,491	148	120	81.1%	17	11.5%	*****	*****
4-5 years	31,830	76	61	80.3%	*****	*****	*****	*****
5-6 years	*****	28	*****	*****	*****	*****	0	0.0%
6-7 years	*****	20	*****	*****	*****	*****	0	0.0%
7+ years	*****	26	15	57.7%	*****	*****	*****	*****
Torsemide Users (Washout)								
0-1 years	172,362	180	67	37.2%	43	23.9%	27	15.0%
1-2 years	*****	54	27	50.0%	*****	*****	*****	*****
2-3 years	*****	57	44	77.2%	*****	*****	*****	*****
3-4 years	*****	22	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	477	201	42.1%	107	22.4%	70	14.7%
1-2 years	249,185	292	183	62.7%	54	18.5%	26	8.9%
2-3 years	131,368	319	255	79.9%	41	12.9%	*****	*****
3-4 years	66,841	146	121	82.9%	*****	*****	*****	*****
4-5 years	35,645	69	*****	*****	*****	*****	0	0.0%
5-6 years	*****	43	*****	*****	*****	*****	*****	*****
6-7 years	*****	24	*****	*****	*****	*****	0	0.0%
7+ years	*****	23	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)								
0-1 years	5,031,471	5,630	2,260	40.1%	1,347	23.9%	835	14.8%
1-2 years	1,570,858	2,100	1,320	62.9%	423	20.1%	171	8.1%
2-3 years	857,233	1,910	1,485	77.7%	277	14.5%	81	4.2%
3-4 years	462,012	911	711	78.0%	147	16.1%	25	2.7%
4-5 years	253,038	516	428	82.9%	60	11.6%	*****	*****
5-6 years	138,456	240	209	87.1%	*****	*****	*****	*****
6-7 years	73,838	115	*****	*****	*****	*****	*****	*****
7+ years	37,943	96	51	53.1%	34	35.4%	*****	*****
Furosemide Users (No Washout)								
0-1 years	8,853,836	7,763	3,237	41.7%	1,812	23.3%	1,130	14.6%
1-2 years	3,756,719	4,868	3,191	65.6%	922	18.9%	362	7.4%
2-3 years	2,243,787	5,990	4,816	80.4%	771	12.9%	217	3.6%
3-4 years	1,290,390	2,961	2,401	81.1%	395	13.3%	84	2.8%
4-5 years	759,943	1,713	1,394	81.4%	208	12.1%	62	3.6%
5-6 years	451,504	894	758	84.8%	95	10.6%	25	2.8%
6-7 years	267,682	494	440	89.1%	38	7.7%	*****	*****
7+ years	157,482	575	227	39.5%	187	32.5%	111	19.3%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	62	27	43.5%	17	27.4%	*****	*****
1-2 years	43,206	16	*****	*****	*****	*****	0	0.0%
2-3 years	*****	*****	*****	*****	*****	*****	0	0.0%
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0-1 years	681,044	148	69	46.6%	32	21.6%	23	15.5%
1-2 years	231,141	87	53	60.9%	19	21.8%	*****	*****
2-3 years	120,390	89	69	77.5%	*****	*****	*****	*****
3-4 years	60,491	44	*****	*****	*****	*****	0	0.0%
4-5 years	31,830	22	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%
Torsemide Users (Washout)								
0-1 years	172,362	43	21	48.8%	*****	*****	*****	*****
1-2 years	*****	15	*****	*****	*****	*****	*****	*****
2-3 years	*****	17	*****	*****	*****	*****	0	0.0%
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	0	0	NaN	0	NaN	0	NaN
7+ years	*****	*****	0	0.0%	0	0.0%	*****	*****

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	106	55	51.9%	27	25.5%	12	11.3%
1-2 years	249,185	85	49	57.6%	17	20.0%	*****	*****
2-3 years	131,368	88	68	77.3%	*****	*****	*****	*****
3-4 years	66,841	46	*****	*****	*****	*****	0	0.0%
4-5 years	35,645	19	*****	*****	*****	*****	0	0.0%
5-6 years	*****	11	11	100.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****
Furosemide Users (Washout)								
0-1 years	5,031,471	1,135	453	39.9%	260	22.9%	176	15.5%
1-2 years	1,570,858	549	369	67.2%	96	17.5%	56	10.2%
2-3 years	857,233	501	397	79.2%	66	13.2%	20	4.0%
3-4 years	462,012	286	229	80.1%	37	12.9%	*****	*****
4-5 years	253,038	120	102	85.0%	*****	*****	*****	*****
5-6 years	138,456	56	*****	*****	*****	*****	*****	*****
6-7 years	73,838	29	29	100.0%	0	0.0%	0	0.0%
7+ years	37,943	16	*****	*****	*****	*****	*****	*****
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,493	608	40.7%	336	22.5%	243	16.3%
1-2 years	3,756,719	1,081	714	66.0%	180	16.7%	107	9.9%
2-3 years	2,243,787	1,318	1,027	77.9%	185	14.0%	60	4.6%
3-4 years	1,290,390	846	673	79.6%	124	14.7%	30	3.5%
4-5 years	759,943	474	408	86.1%	48	10.1%	*****	*****
5-6 years	451,504	229	193	84.3%	23	10.0%	*****	*****
6-7 years	267,682	100	87	87.0%	*****	*****	*****	*****
7+ years	157,482	112	51	45.5%	31	27.7%	17	15.2%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	*****	*****	*****	*****	0	0.0%	*****	*****	*****	*****
1-2 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
2-3 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
t)										
0-1 years	13	8.3%	*****	*****	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
2-3 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0-1 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1-2 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
2-3 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
6-7 years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
1-2 years	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****
2-3 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
3-4 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (Washout)										
0-1 years	127	8.8%	72	5.0%	51	3.5%	18	1.3%	21	1.5%
1-2 years	26	3.9%	13	2.0%	*****	*****	*****	*****	*****	*****
2-3 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0-1 years	172	9.0%	96	5.0%	61	3.2%	31	1.6%	32	1.7%
1-2 years	39	2.9%	29	2.2%	22	1.6%	*****	*****	*****	*****
2-3 years	30	2.1%	11	0.8%	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	13	12.4%	*****	*****	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
2-3 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	27	10.5%	11	4.3%	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
2-3 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0-1 years	*****	*****	11	11.0%	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
2-3 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	18	7.9%	18	7.9%	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
2-3 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
3-4 years	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (Washout)										
0-1 years	262	8.9%	152	5.2%	81	2.8%	50	1.7%	47	1.6%
1-2 years	40	3.8%	16	1.5%	13	1.3%	*****	*****	*****	*****
2-3 years	*****	*****	11	1.2%	*****	*****	*****	*****	0	0.0%
3-4 years	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0-1 years	322	8.4%	196	5.1%	107	2.8%	70	1.8%	62	1.6%
1-2 years	73	3.2%	44	1.9%	28	1.2%	20	0.9%	19	0.8%
2-3 years	33	1.2%	33	1.2%	12	0.5%	*****	*****	*****	*****
3-4 years	13	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	20	8.9%	11	4.9%	11	4.9%	*****	*****	*****	*****
1-2 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
2-3 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	57	9.5%	26	4.3%	20	3.3%	11	1.8%	12	2.0%
1-2 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
2-3 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	0	0.0%	*****	*****	*****	*****
4-5 years	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0-1 years	17	9.4%	*****	*****	*****	*****	*****	*****	*****	*****
1-2 years	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
2-3 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	37	7.8%	20	4.2%	21	4.4%	*****	*****	*****	*****
1-2 years	11	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
2-3 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
4-5 years	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (Washout)										
0-1 years	512	9.1%	316	5.6%	173	3.1%	94	1.7%	93	1.7%
1-2 years	94	4.5%	50	2.4%	20	1.0%	*****	*****	*****	*****
2-3 years	38	2.0%	15	0.8%	*****	*****	*****	*****	*****	*****
3-4 years	11	1.2%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
5-6 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (No Washout)										
0-1 years	668	8.6%	423	5.4%	231	3.0%	129	1.7%	133	1.7%
1-2 years	190	3.9%	86	1.8%	60	1.2%	36	0.7%	21	0.4%
2-3 years	85	1.4%	44	0.7%	34	0.6%	*****	*****	*****	*****
3-4 years	40	1.4%	20	0.7%	*****	*****	*****	*****	*****	*****
4-5 years	27	1.6%	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
1-2 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
2-3 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0-1 years	13	8.8%	*****	*****	*****	*****	*****	*****	*****	*****
1-2 years	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****
2-3 years	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0-1 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
1-2 years	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
2-3 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
3-4 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
4-5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
1-2 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
2-3 years	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
3-4 years	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
4-5 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
5-6 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Furosemide Users (Washout)										
0-1 years	110	9.7%	70	6.2%	32	2.8%	12	1.1%	22	1.9%
1-2 years	15	2.7%	*****	*****	*****	*****	*****	*****	*****	*****
2-3 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
4-5 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
6-7 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	*****	*****	0	0.0%	*****	*****
Furosemide Users (No Washout)										
0-1 years	135	9.0%	85	5.7%	37	2.5%	19	1.3%	30	2.0%
1-2 years	39	3.6%	18	1.7%	*****	*****	*****	*****	*****	*****
2-3 years	23	1.7%	*****	*****	*****	*****	*****	*****	*****	*****
3-4 years	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
4-5 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****

Table 13c. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	*****	*****	0	0.0%	*****	*****

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	54	18	33.3%	12	22.2%	*****	*****
>0 - <700,000 ppm	*****	17	10	58.8%	4	23.5%	2	11.8%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)								
0 ppm	*****	294	111	37.8%	72	24.5%	42	14.3%
>0 - <700,000 ppm	*****	75	48	64.0%	18	24.0%	5	6.7%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
1,500,000 - 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
Torsemide Users (Washout)								
0 ppm	172,362	57	26	45.6%	15	26.3%	*****	*****
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	280	122	43.6%	67	23.9%	33	11.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	5,031,471	3,174	1,177	37.1%	783	24.7%	502	15.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	6,240	2,214	35.5%	1,506	24.1%	944	15.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	136	60	44.1%	24	17.6%	21	15.4%
>0 - <700,000 ppm	*****	39	21	53.8%	6	15.4%	9	23.1%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	513	195	38.0%	118	23.0%	88	17.2%
>0 - <700,000 ppm	*****	140	81	57.9%	23	16.4%	26	18.6%
700,000 - 1,000,000 ppm	*****	13	*****	*****	*****	*****	*****	*****
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	*****	*****

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	172,362	174	64	36.8%	34	19.5%	31	17.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	677	271	40.0%	161	23.8%	98	14.5%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	5,808	2,117	36.4%	1,411	24.3%	960	16.5%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	11,744	4,305	36.7%	2,773	23.6%	1,791	15.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	301	112	37.2%	73	24.3%	39	13.0%
>0 - <700,000 ppm	*****	79	41	51.9%	19	24.1%	11	13.9%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	*****	*****
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	1,180	459	38.9%	278	23.6%	175	14.8%
>0 - <700,000 ppm	*****	293	161	54.9%	75	25.6%	36	12.3%
700,000 - 1,000,000 ppm	*****	24	*****	*****	*****	*****	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	*****	*****	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 2,000,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)								
0 ppm	172,362	338	117	34.6%	100	29.6%	44	13.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	1,393	556	39.9%	334	24.0%	194	13.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	5,031,471	11,518	4,169	36.2%	2,697	23.4%	1,769	15.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	25,258	9,258	36.7%	5,772	22.9%	3,794	15.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	81	33	40.7%	23	28.4%	11	13.6%
>0 - <700,000 ppm	*****	17	7	41.2%	5	29.4%	5	29.4%
700,000 - 1,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	0	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)								
0 ppm	*****	320	128	40.0%	76	23.8%	54	16.9%
>0 - <700,000 ppm	*****	63	37	58.7%	19	30.2%	7	11.1%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	*****	*****	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	*****	*****
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	*****	*****
Torsemide Users (Washout)								

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	172,362	86	31	36.0%	27	31.4%	11	12.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	366	136	37.2%	100	27.3%	52	14.2%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	2,692	974	36.2%	626	23.3%	469	17.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Event by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Event[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 ppm	8,853,836	5,653	1,842	32.6%	1,259	22.3%	1,138	20.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	*****	*****	*****	*****	0	0.0%	*****	*****	*****	*****
>0 - <700,000 ppm	0	0.0%	1	5.9%	0	0.0%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	22	7.5%	23	7.8%	*****	*****	11	3.7%	*****	*****
>0 - <700,000 ppm	3	4.0%	1	1.3%	0	0.0%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	22	7.9%	20	7.1%	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	290	9.1%	183	5.8%	131	4.1%	53	1.7%	55	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	593	9.5%	412	6.6%	273	4.4%	155	2.5%	143	2.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	16	11.8%	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	2	5.1%	1	2.6%	0	0.0%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	49	9.6%	24	4.7%	15	2.9%	*****	*****	*****	*****
>0 - <700,000 ppm	7	5.0%	2	1.4%	1	0.7%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	17	9.8%	15	8.6%	*****	*****	*****	*****	*****	*****

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	55	8.1%	42	6.2%	15	2.2%	19	2.8%	16	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	576	9.9%	336	5.8%	198	3.4%	104	1.8%	106	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	1,151	9.8%	689	5.9%	455	3.9%	280	2.4%	300	2.6%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	31	10.3%	17	5.6%	13	4.3%	*****	*****	*****	*****
>0 - <700,000 ppm	8	10.1%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	125	10.6%	59	5.0%	39	3.3%	20	1.7%	25	2.1%
>0 - <700,000 ppm	18	6.1%	2	0.7%	1	0.3%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	29	8.6%	17	5.0%	17	5.0%	*****	*****	*****	*****
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	119	8.5%	59	4.2%	55	3.9%	35	2.5%	41	2.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	1,200	10.4%	769	6.7%	418	3.6%	271	2.4%	225	2.0%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	2,472	9.8%	1,573	6.2%	1,001	4.0%	682	2.7%	706	2.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bumetanide Users (No Washout)										
0 ppm	29	9.1%	12	3.8%	13	4.1%	*****	*****	*****	*****
>0 - <700,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	38	10.4%	14	3.8%	*****	*****	*****	*****	*****	*****
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	275	10.2%	168	6.2%	85	3.2%	45	1.7%	50	1.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 13d. Summary of Time to End of At-Risk Period due to Cancer Outcome for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Event by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 ppm	612	10.8%	342	6.0%	196	3.5%	122	2.2%	142	2.5%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

* Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 14a. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	20,908	8,116	38.8%	5,103	24.4%	3,109	14.9%
Bumetanide Users (No Washout)	681,044	79,926	32,484	40.6%	19,134	23.9%	11,445	14.3%
Torsemide Users (Washout)	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
Torsemide Users (No Washout)	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
Furosemide Users (Washout)	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
Furosemide Users (No Washout)	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	20,908	8,116	38.8%	5,103	24.4%	3,109	14.9%
Bumetanide Users (No Washout)	681,044	79,926	32,484	40.6%	19,134	23.9%	11,445	14.3%
Torsemide Users (Washout)	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
Torsemide Users (No Washout)	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
Furosemide Users (Washout)	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
Furosemide Users (No Washout)	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	20,908	8,116	38.8%	5,103	24.4%	3,109	14.9%
Bumetanide Users (No Washout)	681,044	79,926	32,484	40.6%	19,134	23.9%	11,445	14.3%
Torsemide Users (Washout)	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
Torsemide Users (No Washout)	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
Furosemide Users (Washout)	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
Furosemide Users (No Washout)	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	20,908	8,116	38.8%	5,103	24.4%	3,109	14.9%
Bumetanide Users (No Washout)	681,044	79,926	32,484	40.6%	19,134	23.9%	11,445	14.3%
Torsemide Users (Washout)	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
Torsemide Users (No Washout)	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
Furosemide Users (Washout)	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
Furosemide Users (No Washout)	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%

Table 14a. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	1,949	9.3%	1,140	5.5%	730	3.5%	433	2.1%	328	1.6%
Bumetanide Users (No Washout)	6,936	8.7%	4,248	5.3%	2,675	3.3%	1,530	1.9%	1,474	1.8%
Torsemide Users (Washout)	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
Torsemide Users (No Washout)	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
Furosemide Users (Washout)	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
Furosemide Users (No Washout)	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
Bladder Cancer Outcome										
Bumetanide Users (Washout)	1,949	9.3%	1,140	5.5%	730	3.5%	433	2.1%	328	1.6%
Bumetanide Users (No Washout)	6,936	8.7%	4,248	5.3%	2,675	3.3%	1,530	1.9%	1,474	1.8%
Torsemide Users (Washout)	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
Torsemide Users (No Washout)	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
Furosemide Users (Washout)	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
Furosemide Users (No Washout)	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	1,949	9.3%	1,140	5.5%	730	3.5%	433	2.1%	328	1.6%
Bumetanide Users (No Washout)	6,936	8.7%	4,248	5.3%	2,675	3.3%	1,530	1.9%	1,474	1.8%
Torsemide Users (Washout)	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
Torsemide Users (No Washout)	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
Furosemide Users (Washout)	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
Furosemide Users (No Washout)	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	1,949	9.3%	1,140	5.5%	730	3.5%	433	2.1%	328	1.6%
Bumetanide Users (No Washout)	6,936	8.7%	4,248	5.3%	2,675	3.3%	1,530	1.9%	1,474	1.8%
Torsemide Users (Washout)	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
Torsemide Users (No Washout)	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
Furosemide Users (Washout)	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
Furosemide Users (No Washout)	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%

Table 14a. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	2	215	514	1,002	5,861	701.0	639.3
Bumetanide Users (No Washout)	2	200	486	973	6,426	685.6	646.0
Torsemide Users (Washout)	2	204	493	976	4,716	683.6	632.9
Torsemide Users (No Washout)	2	195	475	958	5,421	676.1	643.3
Furosemide Users (Washout)	2	216	518	1,022	6,445	709.2	645.9
Furosemide Users (No Washout)	2	217	529	1,058	6,507	734.7	676.6
Bladder Cancer Outcome							
Bumetanide Users (Washout)	2	215	514	1,002	5,861	701.0	639.3
Bumetanide Users (No Washout)	2	200	486	973	6,426	685.6	646.0
Torsemide Users (Washout)	2	204	493	976	4,716	683.6	632.9
Torsemide Users (No Washout)	2	195	475	958	5,421	676.1	643.3
Furosemide Users (Washout)	2	216	518	1,022	6,445	709.2	645.9
Furosemide Users (No Washout)	2	217	529	1,058	6,507	734.7	676.6
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	2	215	514	1,002	5,861	701.0	639.3
Bumetanide Users (No Washout)	2	200	486	973	6,426	685.6	646.0
Torsemide Users (Washout)	2	204	493	976	4,716	683.6	632.9
Torsemide Users (No Washout)	2	195	475	958	5,421	676.1	643.3
Furosemide Users (Washout)	2	216	518	1,022	6,445	709.2	645.9
Furosemide Users (No Washout)	2	217	529	1,058	6,507	734.7	676.6
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	2	215	514	1,002	5,861	701.0	639.3
Bumetanide Users (No Washout)	2	200	486	973	6,426	685.6	646.0
Torsemide Users (Washout)	2	204	493	976	4,716	683.6	632.9
Torsemide Users (No Washout)	2	195	475	958	5,421	676.1	643.3
Furosemide Users (Washout)	2	216	518	1,022	6,445	709.2	645.9
Furosemide Users (No Washout)	2	217	529	1,058	6,507	734.7	676.6

[1]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	12,623	5,161	40.9%	3,062	24.3%	1,802	14.3%
30,000 - <60,000 mg	*****	2,968	1,705	57.4%	699	23.6%	270	9.1%
60,000 - <90,000 mg	*****	1,910	1,315	68.8%	320	16.8%	134	7.0%
90,000 - <120,000 mg	*****	1,109	831	74.9%	155	14.0%	58	5.2%
120,000 - <150,000 mg	*****	727	572	78.7%	85	11.7%	42	5.8%
150,000 - <180,000 mg	*****	453	390	86.1%	34	7.5%	13	2.9%
180,000 - <210,000 mg	*****	312	261	83.7%	26	8.3%	12	3.8%
≥ 210,000 mg	*****	806	386	47.9%	191	23.7%	112	13.9%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	29,236	12,649	43.3%	7,017	24.0%	3,971	13.6%
30,000 - <60,000 mg	304,791	11,958	6,961	58.2%	2,578	21.6%	1,143	9.6%
60,000 - <90,000 mg	201,271	9,643	6,721	69.7%	1,587	16.5%	594	6.2%
90,000 - <120,000 mg	141,898	6,677	5,040	75.5%	889	13.3%	369	5.5%
120,000 - <150,000 mg	104,735	5,579	4,471	80.1%	597	10.7%	258	4.6%
150,000 - <180,000 mg	*****	3,762	3,100	82.4%	364	9.7%	142	3.8%
180,000 - <210,000 mg	*****	2,772	2,315	83.5%	209	7.5%	118	4.3%
≥ 210,000 mg	47,345	10,299	4,457	43.3%	2,589	25.1%	1,410	13.7%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	13,000	5,571	42.9%	3,148	24.2%	1,744	13.4%
30,000 - <60,000 mg	*****	3,223	1,932	59.9%	720	22.3%	278	8.6%
60,000 - <90,000 mg	*****	1,767	1,230	69.6%	320	18.1%	112	6.3%
90,000 - <120,000 mg	*****	871	673	77.3%	128	14.7%	44	5.1%
120,000 - <150,000 mg	*****	461	380	82.4%	58	12.6%	*****	*****
150,000 - <180,000 mg	*****	293	242	82.6%	32	10.9%	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	*****	221	183	82.8%	21	9.5%	*****	*****
≥ 210,000 mg	*****	542	241	44.5%	151	27.9%	78	14.4%
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	29,678	13,389	45.1%	6,977	23.5%	3,888	13.1%
30,000 - <60,000 mg	297,231	13,681	8,248	60.3%	3,049	22.3%	1,152	8.4%
60,000 - <90,000 mg	191,137	10,091	7,337	72.7%	1,646	16.3%	514	5.1%
90,000 - <120,000 mg	132,972	6,302	4,907	77.9%	848	13.5%	298	4.7%
120,000 - <150,000 mg	97,900	4,737	3,881	81.9%	507	10.7%	176	3.7%
150,000 - <180,000 mg	73,732	3,057	2,569	84.0%	298	9.7%	91	3.0%
180,000 - <210,000 mg	57,843	2,328	1,964	84.4%	204	8.8%	75	3.2%
≥ 210,000 mg	46,087	9,362	4,216	45.0%	2,353	25.1%	1,223	13.1%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	514,919	220,477	42.8%	125,757	24.4%	72,382	14.1%
30,000 - <60,000 mg	664,489	92,410	51,123	55.3%	25,706	27.8%	9,360	10.1%
60,000 - <90,000 mg	230,504	26,606	17,420	65.5%	6,488	24.4%	1,768	6.6%
90,000 - <120,000 mg	97,370	9,386	6,799	72.4%	1,866	19.9%	476	5.1%
120,000 - <150,000 mg	46,460	3,824	3,005	78.6%	591	15.5%	147	3.8%
150,000 - <180,000 mg	24,013	1,748	1,439	82.3%	213	12.2%	61	3.5%
180,000 - <210,000 mg	*****	919	788	85.7%	101	11.0%	19	2.1%
≥ 210,000 mg	*****	1,200	602	50.2%	310	25.8%	142	11.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	827,962	377,406	45.6%	200,256	24.2%	108,496	13.1%
30,000 - <60,000 mg	1,997,151	291,650	161,361	55.3%	80,461	27.6%	28,707	9.8%
60,000 - <90,000 mg	852,245	108,722	70,590	64.9%	26,533	24.4%	7,181	6.6%
90,000 - <120,000 mg	422,980	46,135	32,910	71.3%	9,483	20.6%	2,376	5.2%
120,000 - <150,000 mg	231,140	22,058	17,000	77.1%	3,694	16.7%	827	3.7%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
150,000 - <180,000 mg	133,068	10,968	8,869	80.9%	1,415	12.9%	412	3.8%
180,000 - <210,000 mg	81,274	6,276	5,207	83.0%	750	12.0%	185	2.9%
≥ 210,000 mg	53,201	10,122	4,349	43.0%	2,552	25.2%	1,498	14.8%
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	12,623	5,161	40.9%	3,062	24.3%	1,802	14.3%
30,000 - <60,000 mg	*****	2,968	1,705	57.4%	699	23.6%	270	9.1%
60,000 - <90,000 mg	*****	1,910	1,315	68.8%	320	16.8%	134	7.0%
90,000 - <120,000 mg	*****	1,109	831	74.9%	155	14.0%	58	5.2%
120,000 - <150,000 mg	*****	727	572	78.7%	85	11.7%	42	5.8%
150,000 - <180,000 mg	*****	453	390	86.1%	34	7.5%	13	2.9%
180,000 - <210,000 mg	*****	312	261	83.7%	26	8.3%	12	3.8%
≥ 210,000 mg	*****	806	386	47.9%	191	23.7%	112	13.9%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	29,236	12,649	43.3%	7,017	24.0%	3,971	13.6%
30,000 - <60,000 mg	304,791	11,958	6,961	58.2%	2,578	21.6%	1,143	9.6%
60,000 - <90,000 mg	201,271	9,643	6,721	69.7%	1,587	16.5%	594	6.2%
90,000 - <120,000 mg	141,898	6,677	5,040	75.5%	889	13.3%	369	5.5%
120,000 - <150,000 mg	104,735	5,579	4,471	80.1%	597	10.7%	258	4.6%
150,000 - <180,000 mg	*****	3,762	3,100	82.4%	364	9.7%	142	3.8%
180,000 - <210,000 mg	*****	2,772	2,315	83.5%	209	7.5%	118	4.3%
≥ 210,000 mg	47,345	10,299	4,457	43.3%	2,589	25.1%	1,410	13.7%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	13,000	5,571	42.9%	3,148	24.2%	1,744	13.4%
30,000 - <60,000 mg	*****	3,223	1,932	59.9%	720	22.3%	278	8.6%
60,000 - <90,000 mg	*****	1,767	1,230	69.6%	320	18.1%	112	6.3%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
90,000 - <120,000 mg	*****	871	673	77.3%	128	14.7%	44	5.1%
120,000 - <150,000 mg	*****	461	380	82.4%	58	12.6%	*****	*****
150,000 - <180,000 mg	*****	293	242	82.6%	32	10.9%	*****	*****
180,000 - <210,000 mg	*****	221	183	82.8%	21	9.5%	*****	*****
≥ 210,000 mg	*****	542	241	44.5%	151	27.9%	78	14.4%
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	29,678	13,389	45.1%	6,977	23.5%	3,888	13.1%
30,000 - <60,000 mg	297,231	13,681	8,248	60.3%	3,049	22.3%	1,152	8.4%
60,000 - <90,000 mg	191,137	10,091	7,337	72.7%	1,646	16.3%	514	5.1%
90,000 - <120,000 mg	132,972	6,302	4,907	77.9%	848	13.5%	298	4.7%
120,000 - <150,000 mg	97,900	4,737	3,881	81.9%	507	10.7%	176	3.7%
150,000 - <180,000 mg	73,732	3,057	2,569	84.0%	298	9.7%	91	3.0%
180,000 - <210,000 mg	57,843	2,328	1,964	84.4%	204	8.8%	75	3.2%
≥ 210,000 mg	46,087	9,362	4,216	45.0%	2,353	25.1%	1,223	13.1%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	514,919	220,477	42.8%	125,757	24.4%	72,382	14.1%
30,000 - <60,000 mg	664,489	92,410	51,123	55.3%	25,706	27.8%	9,360	10.1%
60,000 - <90,000 mg	230,504	26,606	17,420	65.5%	6,488	24.4%	1,768	6.6%
90,000 - <120,000 mg	97,370	9,386	6,799	72.4%	1,866	19.9%	476	5.1%
120,000 - <150,000 mg	46,460	3,824	3,005	78.6%	591	15.5%	147	3.8%
150,000 - <180,000 mg	24,013	1,748	1,439	82.3%	213	12.2%	61	3.5%
180,000 - <210,000 mg	*****	919	788	85.7%	101	11.0%	19	2.1%
≥ 210,000 mg	*****	1,200	602	50.2%	310	25.8%	142	11.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	827,962	377,406	45.6%	200,256	24.2%	108,496	13.1%
30,000 - <60,000 mg	1,997,151	291,650	161,361	55.3%	80,461	27.6%	28,707	9.8%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
60,000 - <90,000 mg	852,245	108,722	70,590	64.9%	26,533	24.4%	7,181	6.6%
90,000 - <120,000 mg	422,980	46,135	32,910	71.3%	9,483	20.6%	2,376	5.2%
120,000 - <150,000 mg	231,140	22,058	17,000	77.1%	3,694	16.7%	827	3.7%
150,000 - <180,000 mg	133,068	10,968	8,869	80.9%	1,415	12.9%	412	3.8%
180,000 - <210,000 mg	81,274	6,276	5,207	83.0%	750	12.0%	185	2.9%
≥ 210,000 mg	53,201	10,122	4,349	43.0%	2,552	25.2%	1,498	14.8%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	12,623	5,161	40.9%	3,062	24.3%	1,802	14.3%
30,000 - <60,000 mg	*****	2,968	1,705	57.4%	699	23.6%	270	9.1%
60,000 - <90,000 mg	*****	1,910	1,315	68.8%	320	16.8%	134	7.0%
90,000 - <120,000 mg	*****	1,109	831	74.9%	155	14.0%	58	5.2%
120,000 - <150,000 mg	*****	727	572	78.7%	85	11.7%	42	5.8%
150,000 - <180,000 mg	*****	453	390	86.1%	34	7.5%	13	2.9%
180,000 - <210,000 mg	*****	312	261	83.7%	26	8.3%	12	3.8%
≥ 210,000 mg	*****	806	386	47.9%	191	23.7%	112	13.9%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	29,236	12,649	43.3%	7,017	24.0%	3,971	13.6%
30,000 - <60,000 mg	304,791	11,958	6,961	58.2%	2,578	21.6%	1,143	9.6%
60,000 - <90,000 mg	201,271	9,643	6,721	69.7%	1,587	16.5%	594	6.2%
90,000 - <120,000 mg	141,898	6,677	5,040	75.5%	889	13.3%	369	5.5%
120,000 - <150,000 mg	104,735	5,579	4,471	80.1%	597	10.7%	258	4.6%
150,000 - <180,000 mg	*****	3,762	3,100	82.4%	364	9.7%	142	3.8%
180,000 - <210,000 mg	*****	2,772	2,315	83.5%	209	7.5%	118	4.3%
≥ 210,000 mg	47,345	10,299	4,457	43.3%	2,589	25.1%	1,410	13.7%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	13,000	5,571	42.9%	3,148	24.2%	1,744	13.4%
30,000 - <60,000 mg	*****	3,223	1,932	59.9%	720	22.3%	278	8.6%
60,000 - <90,000 mg	*****	1,767	1,230	69.6%	320	18.1%	112	6.3%
90,000 - <120,000 mg	*****	871	673	77.3%	128	14.7%	44	5.1%
120,000 - <150,000 mg	*****	461	380	82.4%	58	12.6%	16	3.5%
150,000 - <180,000 mg	*****	293	242	82.6%	32	10.9%	*****	*****
180,000 - <210,000 mg	*****	221	183	82.8%	21	9.5%	*****	*****
≥ 210,000 mg	*****	542	241	44.5%	151	27.9%	78	14.4%
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	29,678	13,389	45.1%	6,977	23.5%	3,888	13.1%
30,000 - <60,000 mg	297,231	13,681	8,248	60.3%	3,049	22.3%	1,152	8.4%
60,000 - <90,000 mg	191,137	10,091	7,337	72.7%	1,646	16.3%	514	5.1%
90,000 - <120,000 mg	132,972	6,302	4,907	77.9%	848	13.5%	298	4.7%
120,000 - <150,000 mg	97,900	4,737	3,881	81.9%	507	10.7%	176	3.7%
150,000 - <180,000 mg	73,732	3,057	2,569	84.0%	298	9.7%	91	3.0%
180,000 - <210,000 mg	57,843	2,328	1,964	84.4%	204	8.8%	75	3.2%
≥ 210,000 mg	46,087	9,362	4,216	45.0%	2,353	25.1%	1,223	13.1%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	514,919	220,477	42.8%	125,757	24.4%	72,382	14.1%
30,000 - <60,000 mg	664,489	92,410	51,123	55.3%	25,706	27.8%	9,360	10.1%
60,000 - <90,000 mg	230,504	26,606	17,420	65.5%	6,488	24.4%	1,768	6.6%
90,000 - <120,000 mg	97,370	9,386	6,799	72.4%	1,866	19.9%	476	5.1%
120,000 - <150,000 mg	46,460	3,824	3,005	78.6%	591	15.5%	147	3.8%
150,000 - <180,000 mg	24,013	1,748	1,439	82.3%	213	12.2%	61	3.5%
180,000 - <210,000 mg	*****	919	788	85.7%	101	11.0%	19	2.1%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 210,000 mg	*****	1,200	602	50.2%	310	25.8%	142	11.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	827,962	377,406	45.6%	200,256	24.2%	108,496	13.1%
30,000 - <60,000 mg	1,997,151	291,650	161,361	55.3%	80,461	27.6%	28,707	9.8%
60,000 - <90,000 mg	852,245	108,722	70,590	64.9%	26,533	24.4%	7,181	6.6%
90,000 - <120,000 mg	422,980	46,135	32,910	71.3%	9,483	20.6%	2,376	5.2%
120,000 - <150,000 mg	231,140	22,058	17,000	77.1%	3,694	16.7%	827	3.7%
150,000 - <180,000 mg	133,068	10,968	8,869	80.9%	1,415	12.9%	412	3.8%
180,000 - <210,000 mg	81,274	6,276	5,207	83.0%	750	12.0%	185	2.9%
≥ 210,000 mg	53,201	10,122	4,349	43.0%	2,552	25.2%	1,498	14.8%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	12,623	5,161	40.9%	3,062	24.3%	1,802	14.3%
30,000 - <60,000 mg	*****	2,968	1,705	57.4%	699	23.6%	270	9.1%
60,000 - <90,000 mg	*****	1,910	1,315	68.8%	320	16.8%	134	7.0%
90,000 - <120,000 mg	*****	1,109	831	74.9%	155	14.0%	58	5.2%
120,000 - <150,000 mg	*****	727	572	78.7%	85	11.7%	42	5.8%
150,000 - <180,000 mg	*****	453	390	86.1%	34	7.5%	13	2.9%
180,000 - <210,000 mg	*****	312	261	83.7%	26	8.3%	12	3.8%
≥ 210,000 mg	*****	806	386	47.9%	191	23.7%	112	13.9%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	29,236	12,649	43.3%	7,017	24.0%	3,971	13.6%
30,000 - <60,000 mg	304,791	11,958	6,961	58.2%	2,578	21.6%	1,143	9.6%
60,000 - <90,000 mg	201,271	9,643	6,721	69.7%	1,587	16.5%	594	6.2%
90,000 - <120,000 mg	141,898	6,677	5,040	75.5%	889	13.3%	369	5.5%
120,000 - <150,000 mg	104,735	5,579	4,471	80.1%	597	10.7%	258	4.6%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
150,000 - <180,000 mg	*****	3,762	3,100	82.4%	364	9.7%	142	3.8%
180,000 - <210,000 mg	*****	2,772	2,315	83.5%	209	7.5%	118	4.3%
≥ 210,000 mg	47,345	10,299	4,457	43.3%	2,589	25.1%	1,410	13.7%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	13,000	5,571	42.9%	3,148	24.2%	1,744	13.4%
30,000 - <60,000 mg	*****	3,223	1,932	59.9%	720	22.3%	278	8.6%
60,000 - <90,000 mg	*****	1,767	1,230	69.6%	320	18.1%	112	6.3%
90,000 - <120,000 mg	*****	871	673	77.3%	128	14.7%	44	5.1%
120,000 - <150,000 mg	*****	461	380	82.4%	58	12.6%	*****	*****
150,000 - <180,000 mg	*****	293	242	82.6%	32	10.9%	*****	*****
180,000 - <210,000 mg	*****	221	183	82.8%	21	9.5%	*****	*****
≥ 210,000 mg	*****	542	241	44.5%	151	27.9%	78	14.4%
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	29,678	13,389	45.1%	6,977	23.5%	3,888	13.1%
30,000 - <60,000 mg	297,231	13,681	8,248	60.3%	3,049	22.3%	1,152	8.4%
60,000 - <90,000 mg	191,137	10,091	7,337	72.7%	1,646	16.3%	514	5.1%
90,000 - <120,000 mg	132,972	6,302	4,907	77.9%	848	13.5%	298	4.7%
120,000 - <150,000 mg	97,900	4,737	3,881	81.9%	507	10.7%	176	3.7%
150,000 - <180,000 mg	73,732	3,057	2,569	84.0%	298	9.7%	91	3.0%
180,000 - <210,000 mg	57,843	2,328	1,964	84.4%	204	8.8%	75	3.2%
≥ 210,000 mg	46,087	9,362	4,216	45.0%	2,353	25.1%	1,223	13.1%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	514,919	220,477	42.8%	125,757	24.4%	72,382	14.1%
30,000 - <60,000 mg	664,489	92,410	51,123	55.3%	25,706	27.8%	9,360	10.1%
60,000 - <90,000 mg	230,504	26,606	17,420	65.5%	6,488	24.4%	1,768	6.6%
90,000 - <120,000 mg	97,370	9,386	6,799	72.4%	1,866	19.9%	476	5.1%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
120,000 - <150,000 mg	46,460	3,824	3,005	78.6%	591	15.5%	147	3.8%
150,000 - <180,000 mg	24,013	1,748	1,439	82.3%	213	12.2%	61	3.5%
180,000 - <210,000 mg	*****	919	788	85.7%	101	11.0%	19	2.1%
≥ 210,000 mg	*****	1,200	602	50.2%	310	25.8%	142	11.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	827,962	377,406	45.6%	200,256	24.2%	108,496	13.1%
30,000 - <60,000 mg	1,997,151	291,650	161,361	55.3%	80,461	27.6%	28,707	9.8%
60,000 - <90,000 mg	852,245	108,722	70,590	64.9%	26,533	24.4%	7,181	6.6%
90,000 - <120,000 mg	422,980	46,135	32,910	71.3%	9,483	20.6%	2,376	5.2%
120,000 - <150,000 mg	231,140	22,058	17,000	77.1%	3,694	16.7%	827	3.7%
150,000 - <180,000 mg	133,068	10,968	8,869	80.9%	1,415	12.9%	412	3.8%
180,000 - <210,000 mg	81,274	6,276	5,207	83.0%	750	12.0%	185	2.9%
≥ 210,000 mg	53,201	10,122	4,349	43.0%	2,552	25.2%	1,498	14.8%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,131	9.0%	619	4.9%	419	3.3%	239	1.9%	190	1.5%
30,000 - <60,000 mg	127	4.3%	77	2.6%	34	1.1%	30	1.0%	26	0.9%
60,000 - <90,000 mg	72	3.8%	36	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	32	2.9%	18	1.6%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	11	1.5%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	51	6.3%	42	5.2%	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,431	8.3%	1,382	4.7%	867	3.0%	485	1.7%	434	1.5%
30,000 - <60,000 mg	559	4.7%	309	2.6%	183	1.5%	116	1.0%	109	0.9%
60,000 - <90,000 mg	331	3.4%	171	1.8%	132	1.4%	63	0.7%	44	0.5%
90,000 - <120,000 mg	182	2.7%	96	1.4%	49	0.7%	30	0.4%	22	0.3%
120,000 - <150,000 mg	100	1.8%	69	1.2%	44	0.8%	20	0.4%	20	0.4%
150,000 - <180,000 mg	78	2.1%	34	0.9%	17	0.5%	14	0.4%	13	0.3%
180,000 - <210,000 mg	63	2.3%	31	1.1%	17	0.6%	*****	*****	*****	*****
≥ 210,000 mg	825	8.0%	506	4.9%	256	2.5%	152	1.5%	104	1.0%
Torsemide Users (Washout)										
0 - <30,000 mg	1,102	8.5%	655	5.0%	408	3.1%	190	1.5%	182	1.4%
30,000 - <60,000 mg	153	4.7%	67	2.1%	35	1.1%	21	0.7%	17	0.5%
60,000 - <90,000 mg	50	2.8%	33	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	35	6.5%	21	3.9%	*****	*****	*****	*****	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,351	7.9%	1,394	4.7%	827	2.8%	430	1.4%	422	1.4%
30,000 - <60,000 mg	561	4.1%	316	2.3%	163	1.2%	118	0.9%	74	0.5%
60,000 - <90,000 mg	276	2.7%	155	1.5%	75	0.7%	50	0.5%	38	0.4%
90,000 - <120,000 mg	123	2.0%	59	0.9%	43	0.7%	*****	*****	*****	*****
120,000 - <150,000 mg	83	1.8%	43	0.9%	21	0.4%	15	0.3%	11	0.2%
150,000 - <180,000 mg	42	1.4%	29	0.9%	11	0.4%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	23	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	728	7.8%	414	4.4%	222	2.4%	122	1.3%	84	0.9%
Furosemide Users (Washout)										
0 - <30,000 mg	42,485	8.3%	24,978	4.9%	14,158	2.7%	7,804	1.5%	6,878	1.3%
30,000 - <60,000 mg	3,566	3.9%	1,489	1.6%	649	0.7%	309	0.3%	208	0.2%
60,000 - <90,000 mg	561	2.1%	228	0.9%	80	0.3%	33	0.1%	28	0.1%
90,000 - <120,000 mg	159	1.7%	54	0.6%	17	0.2%	*****	*****	*****	*****
120,000 - <150,000 mg	47	1.2%	19	0.5%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	14	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	71	5.9%	32	2.7%	*****	*****	*****	*****	15	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	61,182	7.4%	36,242	4.4%	21,245	2.6%	12,088	1.5%	11,047	1.3%
30,000 - <60,000 mg	11,857	4.1%	4,920	1.7%	2,336	0.8%	1,157	0.4%	851	0.3%
60,000 - <90,000 mg	2,473	2.3%	1,064	1.0%	502	0.5%	247	0.2%	132	0.1%
90,000 - <120,000 mg	775	1.7%	335	0.7%	139	0.3%	71	0.2%	46	0.1%
120,000 - <150,000 mg	294	1.3%	137	0.6%	61	0.3%	29	0.1%	16	0.1%
150,000 - <180,000 mg	148	1.3%	75	0.7%	28	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	88	1.4%	26	0.4%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	849	8.4%	433	4.3%	244	2.4%	116	1.1%	81	0.8%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,131	9.0%	619	4.9%	419	3.3%	239	1.9%	190	1.5%
30,000 - <60,000 mg	127	4.3%	77	2.6%	34	1.1%	30	1.0%	26	0.9%
60,000 - <90,000 mg	72	3.8%	36	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	32	2.9%	18	1.6%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	11	1.5%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	51	6.3%	42	5.2%	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,431	8.3%	1,382	4.7%	867	3.0%	485	1.7%	434	1.5%
30,000 - <60,000 mg	559	4.7%	309	2.6%	183	1.5%	116	1.0%	109	0.9%
60,000 - <90,000 mg	331	3.4%	171	1.8%	132	1.4%	63	0.7%	44	0.5%
90,000 - <120,000 mg	182	2.7%	96	1.4%	49	0.7%	30	0.4%	22	0.3%
120,000 - <150,000 mg	100	1.8%	69	1.2%	44	0.8%	20	0.4%	20	0.4%
150,000 - <180,000 mg	78	2.1%	34	0.9%	17	0.5%	14	0.4%	13	0.3%
180,000 - <210,000 mg	63	2.3%	31	1.1%	17	0.6%	*****	*****	*****	*****
≥ 210,000 mg	825	8.0%	506	4.9%	256	2.5%	152	1.5%	104	1.0%
Torsemide Users (Washout)										
0 - <30,000 mg	1,102	8.5%	655	5.0%	408	3.1%	190	1.5%	182	1.4%
30,000 - <60,000 mg	153	4.7%	67	2.1%	35	1.1%	21	0.7%	17	0.5%
60,000 - <90,000 mg	50	2.8%	33	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	35	6.5%	21	3.9%	*****	*****	*****	*****	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,351	7.9%	1,394	4.7%	827	2.8%	430	1.4%	422	1.4%
30,000 - <60,000 mg	561	4.1%	316	2.3%	163	1.2%	118	0.9%	74	0.5%
60,000 - <90,000 mg	276	2.7%	155	1.5%	75	0.7%	50	0.5%	38	0.4%
90,000 - <120,000 mg	123	2.0%	59	0.9%	43	0.7%	*****	*****	*****	*****
120,000 - <150,000 mg	83	1.8%	43	0.9%	21	0.4%	15	0.3%	11	0.2%
150,000 - <180,000 mg	42	1.4%	29	0.9%	11	0.4%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	23	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	728	7.8%	414	4.4%	222	2.4%	122	1.3%	84	0.9%
Furosemide Users (Washout)										
0 - <30,000 mg	42,485	8.3%	24,978	4.9%	14,158	2.7%	7,804	1.5%	6,878	1.3%
30,000 - <60,000 mg	3,566	3.9%	1,489	1.6%	649	0.7%	309	0.3%	208	0.2%
60,000 - <90,000 mg	561	2.1%	228	0.9%	80	0.3%	33	0.1%	28	0.1%
90,000 - <120,000 mg	159	1.7%	54	0.6%	17	0.2%	*****	*****	*****	*****
120,000 - <150,000 mg	47	1.2%	19	0.5%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	14	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	71	5.9%	32	2.7%	20	1.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0 - <30,000 mg	61,182	7.4%	36,242	4.4%	21,245	2.6%	12,088	1.5%	11,047	1.3%
30,000 - <60,000 mg	11,857	4.1%	4,920	1.7%	2,336	0.8%	1,157	0.4%	851	0.3%
60,000 - <90,000 mg	2,473	2.3%	1,064	1.0%	502	0.5%	247	0.2%	132	0.1%
90,000 - <120,000 mg	775	1.7%	335	0.7%	139	0.3%	71	0.2%	46	0.1%
120,000 - <150,000 mg	294	1.3%	137	0.6%	61	0.3%	29	0.1%	16	0.1%
150,000 - <180,000 mg	148	1.3%	75	0.7%	28	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	88	1.4%	26	0.4%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	849	8.4%	433	4.3%	244	2.4%	116	1.1%	81	0.8%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,131	9.0%	619	4.9%	419	3.3%	239	1.9%	190	1.5%
30,000 - <60,000 mg	127	4.3%	77	2.6%	34	1.1%	30	1.0%	26	0.9%
60,000 - <90,000 mg	72	3.8%	36	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	32	2.9%	18	1.6%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	11	1.5%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	51	6.3%	42	5.2%	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,431	8.3%	1,382	4.7%	867	3.0%	485	1.7%	434	1.5%
30,000 - <60,000 mg	559	4.7%	309	2.6%	183	1.5%	116	1.0%	109	0.9%
60,000 - <90,000 mg	331	3.4%	171	1.8%	132	1.4%	63	0.7%	44	0.5%
90,000 - <120,000 mg	182	2.7%	96	1.4%	49	0.7%	30	0.4%	22	0.3%
120,000 - <150,000 mg	100	1.8%	69	1.2%	44	0.8%	20	0.4%	20	0.4%
150,000 - <180,000 mg	78	2.1%	34	0.9%	17	0.5%	14	0.4%	13	0.3%
180,000 - <210,000 mg	63	2.3%	31	1.1%	17	0.6%	*****	*****	*****	*****
≥ 210,000 mg	825	8.0%	506	4.9%	256	2.5%	152	1.5%	104	1.0%
Torsemide Users (Washout)										
0 - <30,000 mg	1,102	8.5%	655	5.0%	408	3.1%	190	1.5%	182	1.4%
30,000 - <60,000 mg	153	4.7%	67	2.1%	35	1.1%	21	0.7%	17	0.5%
60,000 - <90,000 mg	50	2.8%	33	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	35	6.5%	21	3.9%	*****	*****	*****	*****	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,351	7.9%	1,394	4.7%	827	2.8%	430	1.4%	422	1.4%
30,000 - <60,000 mg	561	4.1%	316	2.3%	163	1.2%	118	0.9%	74	0.5%
60,000 - <90,000 mg	276	2.7%	155	1.5%	75	0.7%	50	0.5%	38	0.4%
90,000 - <120,000 mg	123	2.0%	59	0.9%	43	0.7%	*****	*****	*****	*****
120,000 - <150,000 mg	83	1.8%	43	0.9%	21	0.4%	15	0.3%	11	0.2%
150,000 - <180,000 mg	42	1.4%	29	0.9%	11	0.4%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	23	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	728	7.8%	414	4.4%	222	2.4%	122	1.3%	84	0.9%
Furosemide Users (Washout)										
0 - <30,000 mg	42,485	8.3%	24,978	4.9%	14,158	2.7%	7,804	1.5%	6,878	1.3%
30,000 - <60,000 mg	3,566	3.9%	1,489	1.6%	649	0.7%	309	0.3%	208	0.2%
60,000 - <90,000 mg	561	2.1%	228	0.9%	80	0.3%	33	0.1%	28	0.1%
90,000 - <120,000 mg	159	1.7%	54	0.6%	17	0.2%	*****	*****	*****	*****
120,000 - <150,000 mg	47	1.2%	19	0.5%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	14	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	71	5.9%	32	2.7%	20	1.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0 - <30,000 mg	61,182	7.4%	36,242	4.4%	21,245	2.6%	12,088	1.5%	11,047	1.3%
30,000 - <60,000 mg	11,857	4.1%	4,920	1.7%	2,336	0.8%	1,157	0.4%	851	0.3%
60,000 - <90,000 mg	2,473	2.3%	1,064	1.0%	502	0.5%	247	0.2%	132	0.1%
90,000 - <120,000 mg	775	1.7%	335	0.7%	139	0.3%	71	0.2%	46	0.1%
120,000 - <150,000 mg	294	1.3%	137	0.6%	61	0.3%	29	0.1%	16	0.1%
150,000 - <180,000 mg	148	1.3%	75	0.7%	28	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	88	1.4%	26	0.4%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	849	8.4%	433	4.3%	244	2.4%	116	1.1%	81	0.8%

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,131	9.0%	619	4.9%	419	3.3%	239	1.9%	190	1.5%
30,000 - <60,000 mg	127	4.3%	77	2.6%	34	1.1%	30	1.0%	26	0.9%
60,000 - <90,000 mg	72	3.8%	36	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	32	2.9%	18	1.6%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	11	1.5%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 210,000 mg	51	6.3%	42	5.2%	*****	*****	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,431	8.3%	1,382	4.7%	867	3.0%	485	1.7%	434	1.5%
30,000 - <60,000 mg	559	4.7%	309	2.6%	183	1.5%	116	1.0%	109	0.9%
60,000 - <90,000 mg	331	3.4%	171	1.8%	132	1.4%	63	0.7%	44	0.5%
90,000 - <120,000 mg	182	2.7%	96	1.4%	49	0.7%	30	0.4%	22	0.3%
120,000 - <150,000 mg	100	1.8%	69	1.2%	44	0.8%	20	0.4%	20	0.4%
150,000 - <180,000 mg	78	2.1%	34	0.9%	17	0.5%	14	0.4%	13	0.3%
180,000 - <210,000 mg	63	2.3%	31	1.1%	17	0.6%	*****	*****	*****	*****
≥ 210,000 mg	825	8.0%	506	4.9%	256	2.5%	152	1.5%	104	1.0%
Torsemide Users (Washout)										
0 - <30,000 mg	1,102	8.5%	655	5.0%	408	3.1%	190	1.5%	182	1.4%
30,000 - <60,000 mg	153	4.7%	67	2.1%	35	1.1%	21	0.7%	17	0.5%
60,000 - <90,000 mg	50	2.8%	33	1.9%	*****	*****	*****	*****	*****	*****
90,000 - <120,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	35	6.5%	21	3.9%	*****	*****	*****	*****	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,351	7.9%	1,394	4.7%	827	2.8%	430	1.4%	422	1.4%
30,000 - <60,000 mg	561	4.1%	316	2.3%	163	1.2%	118	0.9%	74	0.5%
60,000 - <90,000 mg	276	2.7%	155	1.5%	75	0.7%	50	0.5%	38	0.4%
90,000 - <120,000 mg	123	2.0%	59	0.9%	43	0.7%	*****	*****	*****	*****
120,000 - <150,000 mg	83	1.8%	43	0.9%	21	0.4%	15	0.3%	11	0.2%
150,000 - <180,000 mg	42	1.4%	29	0.9%	11	0.4%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	23	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	728	7.8%	414	4.4%	222	2.4%	122	1.3%	84	0.9%
Furosemide Users (Washout)										
0 - <30,000 mg	42,485	8.3%	24,978	4.9%	14,158	2.7%	7,804	1.5%	6,878	1.3%
30,000 - <60,000 mg	3,566	3.9%	1,489	1.6%	649	0.7%	309	0.3%	208	0.2%
60,000 - <90,000 mg	561	2.1%	228	0.9%	80	0.3%	33	0.1%	28	0.1%
90,000 - <120,000 mg	159	1.7%	54	0.6%	17	0.2%	*****	*****	*****	*****
120,000 - <150,000 mg	47	1.2%	19	0.5%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	14	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	71	5.9%	32	2.7%	*****	*****	*****	*****	15	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	61,182	7.4%	36,242	4.4%	21,245	2.6%	12,088	1.5%	11,047	1.3%
30,000 - <60,000 mg	11,857	4.1%	4,920	1.7%	2,336	0.8%	1,157	0.4%	851	0.3%
60,000 - <90,000 mg	2,473	2.3%	1,064	1.0%	502	0.5%	247	0.2%	132	0.1%
90,000 - <120,000 mg	775	1.7%	335	0.7%	139	0.3%	71	0.2%	46	0.1%
120,000 - <150,000 mg	294	1.3%	137	0.6%	61	0.3%	29	0.1%	16	0.1%
150,000 - <180,000 mg	148	1.3%	75	0.7%	28	0.3%	*****	*****	*****	*****

Table 14b. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	88	1.4%	26	0.4%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	849	8.4%	433	4.3%	244	2.4%	116	1.1%	81	0.8%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	12,906	5,260	40.8%	3,149	24.4%	1,844	14.3%
1-2 years	43,206	3,313	1,973	59.6%	685	20.7%	310	9.4%
2-3 years	*****	2,599	1,954	75.2%	377	14.5%	131	5.0%
3-4 years	*****	1,131	896	79.2%	152	13.4%	34	3.0%
4-5 years	*****	511	422	82.6%	59	11.5%	15	2.9%
5-6 years	*****	240	199	82.9%	29	12.1%	*****	*****
6-7 years	*****	124	107	86.3%	*****	*****	*****	*****
7+ years	*****	84	46	54.8%	26	31.0%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	32,757	14,237	43.5%	7,881	24.1%	4,457	13.6%
1-2 years	231,141	16,303	10,432	64.0%	2,969	18.2%	1,389	8.5%
2-3 years	120,390	16,614	12,683	76.3%	2,384	14.3%	720	4.3%
3-4 years	60,491	7,457	5,863	78.6%	935	12.5%	267	3.6%
4-5 years	31,830	3,420	2,766	80.9%	433	12.7%	107	3.1%
5-6 years	*****	1,685	1,393	82.7%	204	12.1%	46	2.7%
6-7 years	*****	908	768	84.6%	105	11.6%	23	2.5%
7+ years	*****	782	394	50.4%	203	26.0%	129	16.5%
Torsemide Users (Washout)								
0-1 years	172,362	11,693	4,898	41.9%	2,830	24.2%	1,586	13.6%
1-2 years	*****	3,461	2,183	63.1%	686	19.8%	302	8.7%
2-3 years	*****	2,890	2,236	77.4%	398	13.8%	129	4.5%
3-4 years	*****	1,243	1,001	80.5%	158	12.7%	47	3.8%
4-5 years	*****	587	476	81.1%	76	12.9%	20	3.4%
5-6 years	*****	289	243	84.1%	34	11.8%	*****	*****

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	*****	98	80	81.6%	*****	*****	*****	*****
7+ years	*****	117	62	53.0%	31	26.5%	12	10.3%
Torsemide Users (No Washout)								
0-1 years	680,304	28,418	12,591	44.3%	6,660	23.4%	3,789	13.3%
1-2 years	249,185	16,687	11,093	66.5%	3,035	18.2%	1,210	7.3%
2-3 years	131,368	18,036	14,376	79.7%	2,344	13.0%	627	3.5%
3-4 years	66,841	8,243	6,658	80.8%	999	12.1%	298	3.6%
4-5 years	35,645	3,833	3,151	82.2%	456	11.9%	126	3.3%
5-6 years	*****	2,021	1,702	84.2%	227	11.2%	57	2.8%
6-7 years	*****	1,002	859	85.7%	96	9.6%	23	2.3%
7+ years	*****	996	481	48.3%	273	27.4%	150	15.1%
Furosemide Users (Washout)								
0-1 years	5,031,471	348,861	147,192	42.2%	83,733	24.0%	49,855	14.3%
1-2 years	1,570,858	113,887	74,533	65.4%	21,628	19.0%	8,878	7.8%
2-3 years	857,233	97,811	76,493	78.2%	13,992	14.3%	3,959	4.0%
3-4 years	462,012	46,148	37,506	81.3%	5,877	12.7%	1,521	3.3%
4-5 years	253,038	23,124	19,398	83.9%	2,648	11.5%	638	2.8%
5-6 years	138,456	11,417	9,703	85.0%	1,274	11.2%	271	2.4%
6-7 years	73,838	5,627	4,995	88.8%	472	8.4%	100	1.8%
7+ years	37,943	4,137	2,177	52.6%	1,169	28.3%	509	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	461,608	200,089	43.3%	109,146	23.6%	63,956	13.9%
1-2 years	3,756,719	256,311	171,439	66.9%	46,301	18.1%	18,621	7.3%
2-3 years	2,243,787	292,803	233,946	79.9%	38,328	13.1%	10,515	3.6%
3-4 years	1,290,390	146,623	119,643	81.6%	18,155	12.4%	4,606	3.1%
4-5 years	759,943	78,398	65,190	83.2%	9,047	11.5%	2,238	2.9%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
5-6 years	451,504	42,731	35,916	84.1%	4,869	11.4%	1,114	2.6%
6-7 years	267,682	22,986	19,953	86.8%	2,205	9.6%	501	2.2%
7+ years	157,482	22,433	10,608	47.3%	6,296	28.1%	3,532	15.7%
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	12,906	5,260	40.8%	3,149	24.4%	1,844	14.3%
1-2 years	43,206	3,313	1,973	59.6%	685	20.7%	310	9.4%
2-3 years	*****	2,599	1,954	75.2%	377	14.5%	131	5.0%
3-4 years	*****	1,131	896	79.2%	152	13.4%	34	3.0%
4-5 years	*****	511	422	82.6%	59	11.5%	15	2.9%
5-6 years	*****	240	199	82.9%	29	12.1%	*****	*****
6-7 years	*****	124	107	86.3%	*****	*****	*****	*****
7+ years	*****	84	46	54.8%	26	31.0%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	32,757	14,237	43.5%	7,881	24.1%	4,457	13.6%
1-2 years	231,141	16,303	10,432	64.0%	2,969	18.2%	1,389	8.5%
2-3 years	120,390	16,614	12,683	76.3%	2,384	14.3%	720	4.3%
3-4 years	60,491	7,457	5,863	78.6%	935	12.5%	267	3.6%
4-5 years	31,830	3,420	2,766	80.9%	433	12.7%	107	3.1%
5-6 years	*****	1,685	1,393	82.7%	204	12.1%	46	2.7%
6-7 years	*****	908	768	84.6%	105	11.6%	23	2.5%
7+ years	*****	782	394	50.4%	203	26.0%	129	16.5%
Torsemide Users (Washout)								
0-1 years	172,362	11,693	4,898	41.9%	2,830	24.2%	1,586	13.6%
1-2 years	*****	3,461	2,183	63.1%	686	19.8%	302	8.7%
2-3 years	*****	2,890	2,236	77.4%	398	13.8%	129	4.5%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
3-4 years	*****	1,243	1,001	80.5%	158	12.7%	47	3.8%
4-5 years	*****	587	476	81.1%	76	12.9%	20	3.4%
5-6 years	*****	289	243	84.1%	34	11.8%	*****	*****
6-7 years	*****	98	80	81.6%	*****	*****	*****	*****
7+ years	*****	117	62	53.0%	31	26.5%	12	10.3%
Torsemide Users (No Washout)								
0-1 years	680,304	28,418	12,591	44.3%	6,660	23.4%	3,789	13.3%
1-2 years	249,185	16,687	11,093	66.5%	3,035	18.2%	1,210	7.3%
2-3 years	131,368	18,036	14,376	79.7%	2,344	13.0%	627	3.5%
3-4 years	66,841	8,243	6,658	80.8%	999	12.1%	298	3.6%
4-5 years	35,645	3,833	3,151	82.2%	456	11.9%	126	3.3%
5-6 years	*****	2,021	1,702	84.2%	227	11.2%	57	2.8%
6-7 years	*****	1,002	859	85.7%	96	9.6%	23	2.3%
7+ years	*****	996	481	48.3%	273	27.4%	150	15.1%
Furosemide Users (Washout)								
0-1 years	5,031,471	348,861	147,192	42.2%	83,733	24.0%	49,855	14.3%
1-2 years	1,570,858	113,887	74,533	65.4%	21,628	19.0%	8,878	7.8%
2-3 years	857,233	97,811	76,493	78.2%	13,992	14.3%	3,959	4.0%
3-4 years	462,012	46,148	37,506	81.3%	5,877	12.7%	1,521	3.3%
4-5 years	253,038	23,124	19,398	83.9%	2,648	11.5%	638	2.8%
5-6 years	138,456	11,417	9,703	85.0%	1,274	11.2%	271	2.4%
6-7 years	73,838	5,627	4,995	88.8%	472	8.4%	100	1.8%
7+ years	37,943	4,137	2,177	52.6%	1,169	28.3%	509	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	461,608	200,089	43.3%	109,146	23.6%	63,956	13.9%
1-2 years	3,756,719	256,311	171,439	66.9%	46,301	18.1%	18,621	7.3%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
2-3 years	2,243,787	292,803	233,946	79.9%	38,328	13.1%	10,515	3.6%
3-4 years	1,290,390	146,623	119,643	81.6%	18,155	12.4%	4,606	3.1%
4-5 years	759,943	78,398	65,190	83.2%	9,047	11.5%	2,238	2.9%
5-6 years	451,504	42,731	35,916	84.1%	4,869	11.4%	1,114	2.6%
6-7 years	267,682	22,986	19,953	86.8%	2,205	9.6%	501	2.2%
7+ years	157,482	22,433	10,608	47.3%	6,296	28.1%	3,532	15.7%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	12,906	5,260	40.8%	3,149	24.4%	1,844	14.3%
1-2 years	43,206	3,313	1,973	59.6%	685	20.7%	310	9.4%
2-3 years	*****	2,599	1,954	75.2%	377	14.5%	131	5.0%
3-4 years	*****	1,131	896	79.2%	152	13.4%	34	3.0%
4-5 years	*****	511	422	82.6%	59	11.5%	15	2.9%
5-6 years	*****	240	199	82.9%	29	12.1%	*****	*****
6-7 years	*****	124	107	86.3%	*****	*****	*****	*****
7+ years	*****	84	46	54.8%	26	31.0%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	32,757	14,237	43.5%	7,881	24.1%	4,457	13.6%
1-2 years	231,141	16,303	10,432	64.0%	2,969	18.2%	1,389	8.5%
2-3 years	120,390	16,614	12,683	76.3%	2,384	14.3%	720	4.3%
3-4 years	60,491	7,457	5,863	78.6%	935	12.5%	267	3.6%
4-5 years	31,830	3,420	2,766	80.9%	433	12.7%	107	3.1%
5-6 years	*****	1,685	1,393	82.7%	204	12.1%	46	2.7%
6-7 years	*****	908	768	84.6%	105	11.6%	23	2.5%
7+ years	*****	782	394	50.4%	203	26.0%	129	16.5%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0-1 years	172,362	11,693	4,898	41.9%	2,830	24.2%	1,586	13.6%
1-2 years	*****	3,461	2,183	63.1%	686	19.8%	302	8.7%
2-3 years	*****	2,890	2,236	77.4%	398	13.8%	129	4.5%
3-4 years	*****	1,243	1,001	80.5%	158	12.7%	47	3.8%
4-5 years	*****	587	476	81.1%	76	12.9%	20	3.4%
5-6 years	*****	289	243	84.1%	34	11.8%	*****	*****
6-7 years	*****	98	80	81.6%	*****	*****	*****	*****
7+ years	*****	117	62	53.0%	31	26.5%	12	10.3%
Torsemide Users (No Washout)								
0-1 years	680,304	28,418	12,591	44.3%	6,660	23.4%	3,789	13.3%
1-2 years	249,185	16,687	11,093	66.5%	3,035	18.2%	1,210	7.3%
2-3 years	131,368	18,036	14,376	79.7%	2,344	13.0%	627	3.5%
3-4 years	66,841	8,243	6,658	80.8%	999	12.1%	298	3.6%
4-5 years	35,645	3,833	3,151	82.2%	456	11.9%	126	3.3%
5-6 years	*****	2,021	1,702	84.2%	227	11.2%	57	2.8%
6-7 years	*****	1,002	859	85.7%	96	9.6%	23	2.3%
7+ years	*****	996	481	48.3%	273	27.4%	150	15.1%
Furosemide Users (Washout)								
0-1 years	5,031,471	348,861	147,192	42.2%	83,733	24.0%	49,855	14.3%
1-2 years	1,570,858	113,887	74,533	65.4%	21,628	19.0%	8,878	7.8%
2-3 years	857,233	97,811	76,493	78.2%	13,992	14.3%	3,959	4.0%
3-4 years	462,012	46,148	37,506	81.3%	5,877	12.7%	1,521	3.3%
4-5 years	253,038	23,124	19,398	83.9%	2,648	11.5%	638	2.8%
5-6 years	138,456	11,417	9,703	85.0%	1,274	11.2%	271	2.4%
6-7 years	73,838	5,627	4,995	88.8%	472	8.4%	100	1.8%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
7+ years	37,943	4,137	2,177	52.6%	1,169	28.3%	509	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	461,608	200,089	43.3%	109,146	23.6%	63,956	13.9%
1-2 years	3,756,719	256,311	171,439	66.9%	46,301	18.1%	18,621	7.3%
2-3 years	2,243,787	292,803	233,946	79.9%	38,328	13.1%	10,515	3.6%
3-4 years	1,290,390	146,623	119,643	81.6%	18,155	12.4%	4,606	3.1%
4-5 years	759,943	78,398	65,190	83.2%	9,047	11.5%	2,238	2.9%
5-6 years	451,504	42,731	35,916	84.1%	4,869	11.4%	1,114	2.6%
6-7 years	267,682	22,986	19,953	86.8%	2,205	9.6%	501	2.2%
7+ years	157,482	22,433	10,608	47.3%	6,296	28.1%	3,532	15.7%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	12,906	5,260	40.8%	3,149	24.4%	1,844	14.3%
1-2 years	43,206	3,313	1,973	59.6%	685	20.7%	310	9.4%
2-3 years	*****	2,599	1,954	75.2%	377	14.5%	131	5.0%
3-4 years	*****	1,131	896	79.2%	152	13.4%	34	3.0%
4-5 years	*****	511	422	82.6%	59	11.5%	15	2.9%
5-6 years	*****	240	199	82.9%	29	12.1%	*****	*****
6-7 years	*****	124	107	86.3%	*****	*****	*****	*****
7+ years	*****	84	46	54.8%	26	31.0%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	32,757	14,237	43.5%	7,881	24.1%	4,457	13.6%
1-2 years	231,141	16,303	10,432	64.0%	2,969	18.2%	1,389	8.5%
2-3 years	120,390	16,614	12,683	76.3%	2,384	14.3%	720	4.3%
3-4 years	60,491	7,457	5,863	78.6%	935	12.5%	267	3.6%
4-5 years	31,830	3,420	2,766	80.9%	433	12.7%	107	3.1%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
5-6 years	*****	1,685	1,393	82.7%	204	12.1%	46	2.7%
6-7 years	*****	908	768	84.6%	105	11.6%	23	2.5%
7+ years	*****	782	394	50.4%	203	26.0%	129	16.5%
Torsemide Users (Washout)								
0-1 years	172,362	11,693	4,898	41.9%	2,830	24.2%	1,586	13.6%
1-2 years	*****	3,461	2,183	63.1%	686	19.8%	302	8.7%
2-3 years	*****	2,890	2,236	77.4%	398	13.8%	129	4.5%
3-4 years	*****	1,243	1,001	80.5%	158	12.7%	47	3.8%
4-5 years	*****	587	476	81.1%	76	12.9%	20	3.4%
5-6 years	*****	289	243	84.1%	34	11.8%	*****	*****
6-7 years	*****	98	80	81.6%	*****	*****	*****	*****
7+ years	*****	117	62	53.0%	31	26.5%	*****	*****
Torsemide Users (No Washout)								
0-1 years	680,304	28,418	12,591	44.3%	6,660	23.4%	3,789	13.3%
1-2 years	249,185	16,687	11,093	66.5%	3,035	18.2%	1,210	7.3%
2-3 years	131,368	18,036	14,376	79.7%	2,344	13.0%	627	3.5%
3-4 years	66,841	8,243	6,658	80.8%	999	12.1%	298	3.6%
4-5 years	35,645	3,833	3,151	82.2%	456	11.9%	126	3.3%
5-6 years	*****	2,021	1,702	84.2%	227	11.2%	57	2.8%
6-7 years	*****	1,002	859	85.7%	96	9.6%	23	2.3%
7+ years	*****	996	481	48.3%	273	27.4%	150	15.1%
Furosemide Users (Washout)								
0-1 years	5,031,471	348,861	147,192	42.2%	83,733	24.0%	49,855	14.3%
1-2 years	1,570,858	113,887	74,533	65.4%	21,628	19.0%	8,878	7.8%
2-3 years	857,233	97,811	76,493	78.2%	13,992	14.3%	3,959	4.0%
3-4 years	462,012	46,148	37,506	81.3%	5,877	12.7%	1,521	3.3%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurrence of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
4-5 years	253,038	23,124	19,398	83.9%	2,648	11.5%	638	2.8%
5-6 years	138,456	11,417	9,703	85.0%	1,274	11.2%	271	2.4%
6-7 years	73,838	5,627	4,995	88.8%	472	8.4%	100	1.8%
7+ years	37,943	4,137	2,177	52.6%	1,169	28.3%	509	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	461,608	200,089	43.3%	109,146	23.6%	63,956	13.9%
1-2 years	3,756,719	256,311	171,439	66.9%	46,301	18.1%	18,621	7.3%
2-3 years	2,243,787	292,803	233,946	79.9%	38,328	13.1%	10,515	3.6%
3-4 years	1,290,390	146,623	119,643	81.6%	18,155	12.4%	4,606	3.1%
4-5 years	759,943	78,398	65,190	83.2%	9,047	11.5%	2,238	2.9%
5-6 years	451,504	42,731	35,916	84.1%	4,869	11.4%	1,114	2.6%
6-7 years	267,682	22,986	19,953	86.8%	2,205	9.6%	501	2.2%
7+ years	157,482	22,433	10,608	47.3%	6,296	28.1%	3,532	15.7%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,159	9.0%	629	4.9%	424	3.3%	245	1.9%	196	1.5%
1-2 years	152	4.6%	100	3.0%	44	1.3%	25	0.8%	24	0.7%
2-3 years	64	2.5%	40	1.5%	17	0.7%	*****	*****	*****	*****
3-4 years	25	2.2%	11	1.0%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,694	8.2%	1,507	4.6%	968	3.0%	532	1.6%	481	1.5%
1-2 years	666	4.1%	387	2.4%	221	1.4%	129	0.8%	110	0.7%
2-3 years	358	2.2%	217	1.3%	119	0.7%	68	0.4%	65	0.4%
3-4 years	181	2.4%	94	1.3%	59	0.8%	36	0.5%	22	0.3%
4-5 years	57	1.7%	25	0.7%	19	0.6%	*****	*****	*****	*****
5-6 years	25	1.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)										
0-1 years	1,015	8.7%	606	5.2%	390	3.3%	185	1.6%	183	1.6%
1-2 years	147	4.2%	74	2.1%	40	1.2%	*****	*****	*****	*****
2-3 years	65	2.2%	34	1.2%	14	0.5%	*****	*****	*****	*****
3-4 years	23	1.9%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,319	8.2%	1,384	4.9%	821	2.9%	432	1.5%	422	1.5%
1-2 years	613	3.7%	334	2.0%	195	1.2%	128	0.8%	79	0.5%
2-3 years	322	1.8%	183	1.0%	82	0.5%	47	0.3%	55	0.3%
3-4 years	146	1.8%	69	0.8%	41	0.5%	20	0.2%	12	0.1%
4-5 years	49	1.3%	32	0.8%	*****	*****	*****	*****	*****	*****
5-6 years	18	0.9%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	63	6.3%	18	1.8%	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	29,843	8.6%	17,630	5.1%	10,060	2.9%	5,545	1.6%	5,003	1.4%
1-2 years	4,354	3.8%	2,306	2.0%	1,152	1.0%	587	0.5%	449	0.4%
2-3 years	1,773	1.8%	838	0.9%	435	0.4%	188	0.2%	133	0.1%
3-4 years	684	1.5%	309	0.7%	147	0.3%	72	0.2%	32	0.1%
4-5 years	274	1.2%	111	0.5%	33	0.1%	*****	*****	*****	*****
5-6 years	96	0.8%	44	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	43	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	180	4.4%	55	1.3%	29	0.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	37,948	8.2%	22,710	4.9%	13,315	2.9%	7,531	1.6%	6,913	1.5%
1-2 years	9,334	3.6%	5,011	2.0%	2,797	1.1%	1,533	0.6%	1,275	0.5%
2-3 years	4,833	1.7%	2,463	0.8%	1,449	0.5%	701	0.2%	568	0.2%
3-4 years	2,156	1.5%	1,064	0.7%	553	0.4%	286	0.2%	160	0.1%
4-5 years	1,112	1.4%	471	0.6%	204	0.3%	95	0.1%	41	0.1%
5-6 years	488	1.1%	239	0.6%	80	0.2%	14	0.0%	11	0.0%
6-7 years	216	0.9%	77	0.3%	15	0.1%	*****	*****	*****	*****
7+ years	1,486	6.6%	267	1.2%	138	0.6%	68	0.3%	38	0.2%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,159	9.0%	629	4.9%	424	3.3%	245	1.9%	196	1.5%
1-2 years	152	4.6%	100	3.0%	44	1.3%	25	0.8%	24	0.7%
2-3 years	64	2.5%	40	1.5%	17	0.7%	*****	*****	*****	*****
3-4 years	25	2.2%	11	1.0%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,694	8.2%	1,507	4.6%	968	3.0%	532	1.6%	481	1.5%
1-2 years	666	4.1%	387	2.4%	221	1.4%	129	0.8%	110	0.7%
2-3 years	358	2.2%	217	1.3%	119	0.7%	68	0.4%	65	0.4%
3-4 years	181	2.4%	94	1.3%	59	0.8%	36	0.5%	22	0.3%
4-5 years	57	1.7%	25	0.7%	19	0.6%	*****	*****	*****	*****
5-6 years	25	1.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)										
0-1 years	1,015	8.7%	606	5.2%	390	3.3%	185	1.6%	183	1.6%
1-2 years	147	4.2%	74	2.1%	40	1.2%	*****	*****	*****	*****
2-3 years	65	2.2%	34	1.2%	14	0.5%	*****	*****	*****	*****
3-4 years	23	1.9%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,319	8.2%	1,384	4.9%	821	2.9%	432	1.5%	422	1.5%
1-2 years	613	3.7%	334	2.0%	195	1.2%	128	0.8%	79	0.5%
2-3 years	322	1.8%	183	1.0%	82	0.5%	47	0.3%	55	0.3%
3-4 years	146	1.8%	69	0.8%	41	0.5%	20	0.2%	12	0.1%
4-5 years	49	1.3%	32	0.8%	*****	*****	*****	*****	*****	*****
5-6 years	18	0.9%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	63	6.3%	18	1.8%	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	29,843	8.6%	17,630	5.1%	10,060	2.9%	5,545	1.6%	5,003	1.4%
1-2 years	4,354	3.8%	2,306	2.0%	1,152	1.0%	587	0.5%	449	0.4%
2-3 years	1,773	1.8%	838	0.9%	435	0.4%	188	0.2%	133	0.1%
3-4 years	684	1.5%	309	0.7%	147	0.3%	72	0.2%	32	0.1%
4-5 years	274	1.2%	111	0.5%	33	0.1%	*****	*****	*****	*****
5-6 years	96	0.8%	44	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	43	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	180	4.4%	55	1.3%	29	0.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	37,948	8.2%	22,710	4.9%	13,315	2.9%	7,531	1.6%	6,913	1.5%
1-2 years	9,334	3.6%	5,011	2.0%	2,797	1.1%	1,533	0.6%	1,275	0.5%
2-3 years	4,833	1.7%	2,463	0.8%	1,449	0.5%	701	0.2%	568	0.2%
3-4 years	2,156	1.5%	1,064	0.7%	553	0.4%	286	0.2%	160	0.1%
4-5 years	1,112	1.4%	471	0.6%	204	0.3%	95	0.1%	41	0.1%
5-6 years	488	1.1%	239	0.6%	80	0.2%	14	0.0%	11	0.0%
6-7 years	216	0.9%	77	0.3%	15	0.1%	*****	*****	*****	*****
7+ years	1,486	6.6%	267	1.2%	138	0.6%	68	0.3%	38	0.2%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,159	9.0%	629	4.9%	424	3.3%	245	1.9%	196	1.5%
1-2 years	152	4.6%	100	3.0%	44	1.3%	25	0.8%	24	0.7%
2-3 years	64	2.5%	40	1.5%	17	0.7%	*****	*****	*****	*****
3-4 years	25	2.2%	11	1.0%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,694	8.2%	1,507	4.6%	968	3.0%	532	1.6%	481	1.5%
1-2 years	666	4.1%	387	2.4%	221	1.4%	129	0.8%	110	0.7%
2-3 years	358	2.2%	217	1.3%	119	0.7%	68	0.4%	65	0.4%
3-4 years	181	2.4%	94	1.3%	59	0.8%	36	0.5%	22	0.3%
4-5 years	57	1.7%	25	0.7%	19	0.6%	*****	*****	*****	*****
5-6 years	25	1.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)										
0-1 years	1,015	8.7%	606	5.2%	390	3.3%	185	1.6%	183	1.6%
1-2 years	147	4.2%	74	2.1%	40	1.2%	*****	*****	*****	*****
2-3 years	65	2.2%	34	1.2%	14	0.5%	*****	*****	*****	*****
3-4 years	23	1.9%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,319	8.2%	1,384	4.9%	821	2.9%	432	1.5%	422	1.5%
1-2 years	613	3.7%	334	2.0%	195	1.2%	128	0.8%	79	0.5%
2-3 years	322	1.8%	183	1.0%	82	0.5%	47	0.3%	55	0.3%
3-4 years	146	1.8%	69	0.8%	41	0.5%	20	0.2%	12	0.1%
4-5 years	49	1.3%	32	0.8%	*****	*****	*****	*****	*****	*****
5-6 years	18	0.9%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	63	6.3%	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	29,843	8.6%	17,630	5.1%	10,060	2.9%	5,545	1.6%	5,003	1.4%
1-2 years	4,354	3.8%	2,306	2.0%	1,152	1.0%	587	0.5%	449	0.4%
2-3 years	1,773	1.8%	838	0.9%	435	0.4%	188	0.2%	133	0.1%
3-4 years	684	1.5%	309	0.7%	147	0.3%	72	0.2%	32	0.1%
4-5 years	274	1.2%	111	0.5%	33	0.1%	*****	*****	*****	*****
5-6 years	96	0.8%	44	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	43	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	180	4.4%	55	1.3%	29	0.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	37,948	8.2%	22,710	4.9%	13,315	2.9%	7,531	1.6%	6,913	1.5%
1-2 years	9,334	3.6%	5,011	2.0%	2,797	1.1%	1,533	0.6%	1,275	0.5%
2-3 years	4,833	1.7%	2,463	0.8%	1,449	0.5%	701	0.2%	568	0.2%
3-4 years	2,156	1.5%	1,064	0.7%	553	0.4%	286	0.2%	160	0.1%
4-5 years	1,112	1.4%	471	0.6%	204	0.3%	95	0.1%	41	0.1%
5-6 years	488	1.1%	239	0.6%	80	0.2%	14	0.0%	11	0.0%
6-7 years	216	0.9%	77	0.3%	15	0.1%	*****	*****	*****	*****
7+ years	1,486	6.6%	267	1.2%	138	0.6%	68	0.3%	38	0.2%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,159	9.0%	629	4.9%	424	3.3%	245	1.9%	196	1.5%
1-2 years	152	4.6%	100	3.0%	44	1.3%	25	0.8%	24	0.7%
2-3 years	64	2.5%	40	1.5%	17	0.7%	*****	*****	*****	*****
3-4 years	25	2.2%	11	1.0%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
6-7 years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,694	8.2%	1,507	4.6%	968	3.0%	532	1.6%	481	1.5%
1-2 years	666	4.1%	387	2.4%	221	1.4%	129	0.8%	110	0.7%
2-3 years	358	2.2%	217	1.3%	119	0.7%	68	0.4%	65	0.4%
3-4 years	181	2.4%	94	1.3%	59	0.8%	36	0.5%	22	0.3%
4-5 years	57	1.7%	25	0.7%	19	0.6%	*****	*****	*****	*****
5-6 years	25	1.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Torsemide Users (Washout)										
0-1 years	1,015	8.7%	606	5.2%	390	3.3%	185	1.6%	183	1.6%
1-2 years	147	4.2%	74	2.1%	40	1.2%	*****	*****	*****	*****
2-3 years	65	2.2%	34	1.2%	14	0.5%	*****	*****	*****	*****
3-4 years	23	1.9%	*****	*****	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
5-6 years	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,319	8.2%	1,384	4.9%	821	2.9%	432	1.5%	422	1.5%
1-2 years	613	3.7%	334	2.0%	195	1.2%	128	0.8%	79	0.5%
2-3 years	322	1.8%	183	1.0%	82	0.5%	47	0.3%	55	0.3%
3-4 years	146	1.8%	69	0.8%	41	0.5%	20	0.2%	12	0.1%
4-5 years	49	1.3%	32	0.8%	*****	*****	*****	*****	*****	*****
5-6 years	18	0.9%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
7+ years	63	6.3%	18	1.8%	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	29,843	8.6%	17,630	5.1%	10,060	2.9%	5,545	1.6%	5,003	1.4%
1-2 years	4,354	3.8%	2,306	2.0%	1,152	1.0%	587	0.5%	449	0.4%
2-3 years	1,773	1.8%	838	0.9%	435	0.4%	188	0.2%	133	0.1%
3-4 years	684	1.5%	309	0.7%	147	0.3%	72	0.2%	32	0.1%
4-5 years	274	1.2%	111	0.5%	33	0.1%	*****	*****	*****	*****
5-6 years	96	0.8%	44	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	43	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	180	4.4%	55	1.3%	29	0.7%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	37,948	8.2%	22,710	4.9%	13,315	2.9%	7,531	1.6%	6,913	1.5%
1-2 years	9,334	3.6%	5,011	2.0%	2,797	1.1%	1,533	0.6%	1,275	0.5%
2-3 years	4,833	1.7%	2,463	0.8%	1,449	0.5%	701	0.2%	568	0.2%
3-4 years	2,156	1.5%	1,064	0.7%	553	0.4%	286	0.2%	160	0.1%
4-5 years	1,112	1.4%	471	0.6%	204	0.3%	95	0.1%	41	0.1%
5-6 years	488	1.1%	239	0.6%	80	0.2%	14	0.0%	11	0.0%

Table 14c. Summary of Time to End of At-Risk Period due to Occurrence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Occurence of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	216	0.9%	77	0.3%	15	0.1%	*****	*****	*****	*****
7+ years	1,486	6.6%	267	1.2%	138	0.6%	68	0.3%	38	0.2%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	16,035	6,153	38.4%	3,945	24.6%	2,354	14.7%
>0 - <700,000 ppm	*****	4,377	2,407	55.0%	1,138	26.0%	559	12.8%
700,000 - 1,000,000 ppm	*****	255	185	72.5%	54	21.2%	*****	*****
1,000,000 - 1,500,000 ppm	*****	147	104	70.7%	32	21.8%	*****	*****
1,500,000 - 2,000,000 ppm	*****	48	33	68.8%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	46	25	54.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	61,468	25,003	40.7%	14,791	24.1%	8,852	14.4%
>0 - <700,000 ppm	*****	15,660	8,889	56.8%	4,042	25.8%	1,810	11.6%
700,000 - 1,000,000 ppm	*****	1,233	969	78.6%	197	16.0%	55	4.5%
1,000,000 - 1,500,000 ppm	*****	895	670	74.9%	172	19.2%	39	4.4%
1,500,000 - 2,000,000 ppm	*****	360	272	75.6%	63	17.5%	*****	*****
≥ 2,000,000 ppm	*****	310	181	58.4%	74	23.9%	40	12.9%
Torsemide Users (Washout)								
0 ppm	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	16,035	6,153	38.4%	3,945	24.6%	2,354	14.7%
>0 - <700,000 ppm	*****	4,377	2,407	55.0%	1,138	26.0%	559	12.8%
700,000 - 1,000,000 ppm	*****	255	185	72.5%	54	21.2%	*****	*****
1,000,000 - 1,500,000 ppm	*****	147	104	70.7%	32	21.8%	*****	*****
1,500,000 - 2,000,000 ppm	*****	48	33	68.8%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	46	25	54.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)								

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	*****	61,468	25,003	40.7%	14,791	24.1%	8,852	14.4%
>0 - <700,000 ppm	*****	15,660	8,889	56.8%	4,042	25.8%	1,810	11.6%
700,000 - 1,000,000 ppm	*****	1,233	969	78.6%	197	16.0%	55	4.5%
1,000,000 - 1,500,000 ppm	*****	895	670	74.9%	172	19.2%	39	4.4%
1,500,000 - 2,000,000 ppm	*****	360	272	75.6%	63	17.5%	*****	*****
≥ 2,000,000 ppm	*****	310	181	58.4%	74	23.9%	40	12.9%
Torsemide Users (Washout)								
0 ppm	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	16,035	6,153	38.4%	3,945	24.6%	2,354	14.7%
>0 - <700,000 ppm	*****	4,377	2,407	55.0%	1,138	26.0%	559	12.8%
700,000 - 1,000,000 ppm	*****	255	185	72.5%	54	21.2%	*****	*****
1,000,000 - 1,500,000 ppm	*****	147	104	70.7%	32	21.8%	*****	*****
1,500,000 - 2,000,000 ppm	*****	48	33	68.8%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	46	25	54.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	61,468	25,003	40.7%	14,791	24.1%	8,852	14.4%
>0 - <700,000 ppm	*****	15,660	8,889	56.8%	4,042	25.8%	1,810	11.6%
700,000 - 1,000,000 ppm	*****	1,233	969	78.6%	197	16.0%	55	4.5%
1,000,000 - 1,500,000 ppm	*****	895	670	74.9%	172	19.2%	39	4.4%
1,500,000 - 2,000,000 ppm	*****	360	272	75.6%	63	17.5%	*****	*****
≥ 2,000,000 ppm	*****	310	181	58.4%	74	23.9%	40	12.9%
Torsemide Users (Washout)								
0 ppm	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	16,035	6,153	38.4%	3,945	24.6%	2,354	14.7%
>0 - <700,000 ppm	*****	4,377	2,407	55.0%	1,138	26.0%	559	12.8%
700,000 - 1,000,000 ppm	*****	255	185	72.5%	54	21.2%	*****	*****
1,000,000 - 1,500,000 ppm	*****	147	104	70.7%	32	21.8%	*****	*****
1,500,000 - 2,000,000 ppm	*****	48	33	68.8%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	46	25	54.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	61,468	25,003	40.7%	14,791	24.1%	8,852	14.4%
>0 - <700,000 ppm	*****	15,660	8,889	56.8%	4,042	25.8%	1,810	11.6%
700,000 - 1,000,000 ppm	*****	1,233	969	78.6%	197	16.0%	55	4.5%
1,000,000 - 1,500,000 ppm	*****	895	670	74.9%	172	19.2%	39	4.4%
1,500,000 - 2,000,000 ppm	*****	360	272	75.6%	63	17.5%	*****	*****
≥ 2,000,000 ppm	*****	310	181	58.4%	74	23.9%	40	12.9%
Torsemide Users (Washout)								
0 ppm	172,362	20,378	8,166	40.1%	4,939	24.2%	2,943	14.4%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	79,236	32,788	41.4%	18,952	23.9%	11,046	13.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	651,012	250,240	38.4%	155,578	23.9%	98,585	15.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	1,323,893	503,495	38.0%	308,711	23.3%	196,131	14.8%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,528	9.5%	885	5.5%	570	3.6%	338	2.1%	262	1.6%
>0 - <700,000 ppm	194	4.4%	63	1.4%	16	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,436	8.8%	3,217	5.2%	2,019	3.3%	1,106	1.8%	1,044	1.7%
>0 - <700,000 ppm	653	4.2%	201	1.3%	65	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	14	1.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,528	9.5%	885	5.5%	570	3.6%	338	2.1%	262	1.6%
>0 - <700,000 ppm	194	4.4%	63	1.4%	16	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,436	8.8%	3,217	5.2%	2,019	3.3%	1,106	1.8%	1,044	1.7%
>0 - <700,000 ppm	653	4.2%	201	1.3%	65	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	14	1.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,528	9.5%	885	5.5%	570	3.6%	338	2.1%	262	1.6%
>0 - <700,000 ppm	194	4.4%	63	1.4%	16	0.4%	0	0.0%	0	0.0%

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,436	8.8%	3,217	5.2%	2,019	3.3%	1,106	1.8%	1,044	1.7%
>0 - <700,000 ppm	653	4.2%	201	1.3%	65	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	14	1.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,528	9.5%	885	5.5%	570	3.6%	338	2.1%	262	1.6%
>0 - <700,000 ppm	194	4.4%	63	1.4%	16	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,436	8.8%	3,217	5.2%	2,019	3.3%	1,106	1.8%	1,044	1.7%
>0 - <700,000 ppm	653	4.2%	201	1.3%	65	0.4%	0	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	14	1.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,870	9.2%	1,116	5.5%	663	3.3%	362	1.8%	319	1.6%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	6,811	8.6%	4,185	5.3%	2,504	3.2%	1,510	1.9%	1,440	1.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	62,023	9.5%	38,346	5.9%	22,595	3.5%	12,543	1.9%	11,102	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 14d. Summary of Time to End of At-Risk Period due to Occurence Of Cancer, Radiation or Chemotherapy for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Occurence Of Request-Defined Censoring Criteria by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 ppm	125,402	9.5%	79,878	6.0%	50,361	3.8%	30,210	2.3%	29,705	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to occurrence of codes for any cancer, chemotherapy, or radiation treatment

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 15a. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	47,064	35,501	75.4%	4,094	8.7%	2,798	5.9%
Bumetanide Users (No Washout)	681,044	250,564	198,752	79.3%	19,171	7.7%	12,372	4.9%
Torsemide Users (Washout)	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
Torsemide Users (No Washout)	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
Furosemide Users (Washout)	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
Furosemide Users (No Washout)	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	47,064	35,501	75.4%	4,094	8.7%	2,798	5.9%
Bumetanide Users (No Washout)	681,044	250,564	198,752	79.3%	19,171	7.7%	12,372	4.9%
Torsemide Users (Washout)	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
Torsemide Users (No Washout)	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
Furosemide Users (Washout)	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
Furosemide Users (No Washout)	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	47,064	35,501	75.4%	4,094	8.7%	2,798	5.9%
Bumetanide Users (No Washout)	681,044	250,564	198,752	79.3%	19,171	7.7%	12,372	4.9%
Torsemide Users (Washout)	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
Torsemide Users (No Washout)	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
Furosemide Users (Washout)	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
Furosemide Users (No Washout)	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	47,064	35,501	75.4%	4,094	8.7%	2,798	5.9%
Bumetanide Users (No Washout)	681,044	250,564	198,752	79.3%	19,171	7.7%	12,372	4.9%
Torsemide Users (Washout)	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
Torsemide Users (No Washout)	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
Furosemide Users (Washout)	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
Furosemide Users (No Washout)	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%

Table 15a. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	1,816	3.9%	1,179	2.5%	774	1.6%	494	1.0%	408	0.9%
Bumetanide Users (No Washout)	7,830	3.1%	5,083	2.0%	3,214	1.3%	2,018	0.8%	2,124	0.8%
Torsemide Users (Washout)	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
Torsemide Users (No Washout)	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
Furosemide Users (Washout)	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
Furosemide Users (No Washout)	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
Bladder Cancer Outcome										
Bumetanide Users (Washout)	1,816	3.9%	1,179	2.5%	774	1.6%	494	1.0%	408	0.9%
Bumetanide Users (No Washout)	7,830	3.1%	5,083	2.0%	3,214	1.3%	2,018	0.8%	2,124	0.8%
Torsemide Users (Washout)	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
Torsemide Users (No Washout)	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
Furosemide Users (Washout)	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
Furosemide Users (No Washout)	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	1,816	3.9%	1,179	2.5%	774	1.6%	494	1.0%	408	0.9%
Bumetanide Users (No Washout)	7,830	3.1%	5,083	2.0%	3,214	1.3%	2,018	0.8%	2,124	0.8%
Torsemide Users (Washout)	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
Torsemide Users (No Washout)	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
Furosemide Users (Washout)	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
Furosemide Users (No Washout)	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	1,816	3.9%	1,179	2.5%	774	1.6%	494	1.0%	408	0.9%
Bumetanide Users (No Washout)	7,830	3.1%	5,083	2.0%	3,214	1.3%	2,018	0.8%	2,124	0.8%
Torsemide Users (Washout)	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
Torsemide Users (No Washout)	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
Furosemide Users (Washout)	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
Furosemide Users (No Washout)	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%

Table 15a. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	349	4,501	294.6	565.4
Bumetanide Users (No Washout)	0	0	0	217	6,446	247.6	528.6
Torsemide Users (Washout)	0	0	0	384	4,741	303.4	565.9
Torsemide Users (No Washout)	0	0	0	227	5,586	250.2	530.5
Furosemide Users (Washout)	0	0	0	452	6,377	332.2	593.5
Furosemide Users (No Washout)	0	0	0	547	6,512	383.4	655.8
Bladder Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	349	4,501	294.6	565.4
Bumetanide Users (No Washout)	0	0	0	217	6,446	247.6	528.6
Torsemide Users (Washout)	0	0	0	384	4,741	303.4	565.9
Torsemide Users (No Washout)	0	0	0	227	5,586	250.2	530.5
Furosemide Users (Washout)	0	0	0	452	6,377	332.2	593.5
Furosemide Users (No Washout)	0	0	0	547	6,512	383.4	655.8
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	349	4,501	294.6	565.4
Bumetanide Users (No Washout)	0	0	0	217	6,446	247.6	528.6
Torsemide Users (Washout)	0	0	0	384	4,741	303.4	565.9
Torsemide Users (No Washout)	0	0	0	227	5,586	250.2	530.5
Furosemide Users (Washout)	0	0	0	452	6,377	332.2	593.5
Furosemide Users (No Washout)	0	0	0	547	6,512	383.4	655.8
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	349	4,501	294.6	565.4
Bumetanide Users (No Washout)	0	0	0	217	6,446	247.6	528.6
Torsemide Users (Washout)	0	0	0	384	4,741	303.4	565.9
Torsemide Users (No Washout)	0	0	0	227	5,586	250.2	530.5
Furosemide Users (Washout)	0	0	0	452	6,377	332.2	593.5
Furosemide Users (No Washout)	0	0	0	547	6,512	383.4	655.8

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	33,751	28,024	83.0%	2,090	6.2%	1,358	4.0%
30,000 - <60,000 mg	*****	5,900	4,581	77.6%	620	10.5%	318	5.4%
60,000 - <90,000 mg	*****	2,834	2,170	76.6%	349	12.3%	150	5.3%
90,000 - <120,000 mg	*****	1,517	1,179	77.7%	186	12.3%	72	4.7%
120,000 - <150,000 mg	*****	965	766	79.4%	108	11.2%	45	4.7%
150,000 - <180,000 mg	*****	621	523	84.2%	60	9.7%	19	3.1%
180,000 - <210,000 mg	*****	410	337	82.2%	43	10.5%	*****	*****
≥ 210,000 mg	*****	1,066	462	43.3%	259	24.3%	164	15.4%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	144,776	129,185	89.2%	5,961	4.1%	3,773	2.6%
30,000 - <60,000 mg	304,791	37,926	32,374	85.4%	2,493	6.6%	1,322	3.5%
60,000 - <90,000 mg	201,271	21,008	17,396	82.8%	1,897	9.0%	767	3.7%
90,000 - <120,000 mg	141,898	12,687	10,581	83.4%	1,051	8.3%	462	3.6%
120,000 - <150,000 mg	104,735	8,690	7,208	82.9%	764	8.8%	307	3.5%
150,000 - <180,000 mg	*****	6,035	5,129	85.0%	463	7.7%	192	3.2%
180,000 - <210,000 mg	*****	4,554	3,822	83.9%	377	8.3%	166	3.6%
≥ 210,000 mg	47,345	14,888	6,716	45.1%	3,321	22.3%	2,096	14.1%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	29,183	24,006	82.3%	1,960	6.7%	1,219	4.2%
30,000 - <60,000 mg	*****	4,885	3,607	73.8%	651	13.3%	296	6.1%
60,000 - <90,000 mg	*****	2,276	1,689	74.2%	320	14.1%	135	5.9%
90,000 - <120,000 mg	*****	1,198	936	78.1%	165	13.8%	47	3.9%
120,000 - <150,000 mg	*****	654	543	83.0%	63	9.6%	28	4.3%
150,000 - <180,000 mg	*****	419	353	84.2%	43	10.3%	11	2.6%
180,000 - <210,000 mg	*****	282	234	83.0%	24	8.5%	*****	*****
≥ 210,000 mg	*****	835	422	50.5%	202	24.2%	105	12.6%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	128,701	114,597	89.0%	5,579	4.3%	3,353	2.6%
30,000 - <60,000 mg	297,231	35,228	29,820	84.6%	2,651	7.5%	1,215	3.4%
60,000 - <90,000 mg	191,137	18,822	15,788	83.9%	1,676	8.9%	649	3.4%
90,000 - <120,000 mg	132,972	11,377	9,604	84.4%	997	8.8%	347	3.1%
120,000 - <150,000 mg	97,900	7,746	6,552	84.6%	678	8.8%	245	3.2%
150,000 - <180,000 mg	73,732	5,084	4,378	86.1%	397	7.8%	138	2.7%
180,000 - <210,000 mg	57,843	3,850	3,308	85.9%	328	8.5%	108	2.8%
≥ 210,000 mg	46,087	14,731	7,522	51.1%	3,121	21.2%	1,735	11.8%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,118,038	895,188	80.1%	88,881	7.9%	53,989	4.8%
30,000 - <60,000 mg	664,489	115,567	64,912	56.2%	29,639	25.6%	12,096	10.5%
60,000 - <90,000 mg	230,504	35,124	21,949	62.5%	8,809	25.1%	2,753	7.8%
90,000 - <120,000 mg	97,370	13,476	9,357	69.4%	2,936	21.8%	782	5.8%
120,000 - <150,000 mg	46,460	5,668	4,288	75.7%	1,007	17.8%	242	4.3%
150,000 - <180,000 mg	24,013	2,641	2,107	79.8%	388	14.7%	92	3.5%
180,000 - <210,000 mg	*****	1,320	1,062	80.5%	178	13.5%	48	3.6%
≥ 210,000 mg	*****	1,721	776	45.1%	472	27.4%	248	14.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,953,351	1,601,113	82.0%	144,008	7.4%	83,471	4.3%
30,000 - <60,000 mg	1,997,151	336,889	197,071	58.5%	78,454	23.3%	32,758	9.7%
60,000 - <90,000 mg	852,245	127,734	78,864	61.7%	31,195	24.4%	10,217	8.0%
90,000 - <120,000 mg	422,980	57,979	38,953	67.2%	12,774	22.0%	3,808	6.6%
120,000 - <150,000 mg	231,140	28,834	20,570	71.3%	5,779	20.0%	1,499	5.2%
150,000 - <180,000 mg	133,068	15,192	11,531	75.9%	2,497	16.4%	670	4.4%
180,000 - <210,000 mg	81,274	8,582	6,687	77.9%	1,276	14.9%	349	4.1%
≥ 210,000 mg	53,201	14,318	5,555	38.8%	3,682	25.7%	2,270	15.9%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	33,751	28,024	83.0%	2,090	6.2%	1,358	4.0%
30,000 - <60,000 mg	*****	5,900	4,581	77.6%	620	10.5%	318	5.4%
60,000 - <90,000 mg	*****	2,834	2,170	76.6%	349	12.3%	150	5.3%
90,000 - <120,000 mg	*****	1,517	1,179	77.7%	186	12.3%	72	4.7%
120,000 - <150,000 mg	*****	965	766	79.4%	108	11.2%	45	4.7%
150,000 - <180,000 mg	*****	621	523	84.2%	60	9.7%	19	3.1%
180,000 - <210,000 mg	*****	410	337	82.2%	43	10.5%	*****	*****
≥ 210,000 mg	*****	1,066	462	43.3%	259	24.3%	164	15.4%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	144,776	129,185	89.2%	5,961	4.1%	3,773	2.6%
30,000 - <60,000 mg	304,791	37,926	32,374	85.4%	2,493	6.6%	1,322	3.5%
60,000 - <90,000 mg	201,271	21,008	17,396	82.8%	1,897	9.0%	767	3.7%
90,000 - <120,000 mg	141,898	12,687	10,581	83.4%	1,051	8.3%	462	3.6%
120,000 - <150,000 mg	104,735	8,690	7,208	82.9%	764	8.8%	307	3.5%
150,000 - <180,000 mg	*****	6,035	5,129	85.0%	463	7.7%	192	3.2%
180,000 - <210,000 mg	*****	4,554	3,822	83.9%	377	8.3%	166	3.6%
≥ 210,000 mg	47,345	14,888	6,716	45.1%	3,321	22.3%	2,096	14.1%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	29,183	24,006	82.3%	1,960	6.7%	1,219	4.2%
30,000 - <60,000 mg	*****	4,885	3,607	73.8%	651	13.3%	296	6.1%
60,000 - <90,000 mg	*****	2,276	1,689	74.2%	320	14.1%	135	5.9%
90,000 - <120,000 mg	*****	1,198	936	78.1%	165	13.8%	47	3.9%
120,000 - <150,000 mg	*****	654	543	83.0%	63	9.6%	28	4.3%
150,000 - <180,000 mg	*****	419	353	84.2%	43	10.3%	11	2.6%
180,000 - <210,000 mg	*****	282	234	83.0%	24	8.5%	*****	*****
≥ 210,000 mg	*****	835	422	50.5%	202	24.2%	105	12.6%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	128,701	114,597	89.0%	5,579	4.3%	3,353	2.6%
30,000 - <60,000 mg	297,231	35,228	29,820	84.6%	2,651	7.5%	1,215	3.4%
60,000 - <90,000 mg	191,137	18,822	15,788	83.9%	1,676	8.9%	649	3.4%
90,000 - <120,000 mg	132,972	11,377	9,604	84.4%	997	8.8%	347	3.1%
120,000 - <150,000 mg	97,900	7,746	6,552	84.6%	678	8.8%	245	3.2%
150,000 - <180,000 mg	73,732	5,084	4,378	86.1%	397	7.8%	138	2.7%
180,000 - <210,000 mg	57,843	3,850	3,308	85.9%	328	8.5%	108	2.8%
≥ 210,000 mg	46,087	14,731	7,522	51.1%	3,121	21.2%	1,735	11.8%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,118,038	895,188	80.1%	88,881	7.9%	53,989	4.8%
30,000 - <60,000 mg	664,489	115,567	64,912	56.2%	29,639	25.6%	12,096	10.5%
60,000 - <90,000 mg	230,504	35,124	21,949	62.5%	8,809	25.1%	2,753	7.8%
90,000 - <120,000 mg	97,370	13,476	9,357	69.4%	2,936	21.8%	782	5.8%
120,000 - <150,000 mg	46,460	5,668	4,288	75.7%	1,007	17.8%	242	4.3%
150,000 - <180,000 mg	24,013	2,641	2,107	79.8%	388	14.7%	92	3.5%
180,000 - <210,000 mg	*****	1,320	1,062	80.5%	178	13.5%	48	3.6%
≥ 210,000 mg	*****	1,721	776	45.1%	472	27.4%	248	14.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,953,351	1,601,113	82.0%	144,008	7.4%	83,471	4.3%
30,000 - <60,000 mg	1,997,151	336,889	197,071	58.5%	78,454	23.3%	32,758	9.7%
60,000 - <90,000 mg	852,245	127,734	78,864	61.7%	31,195	24.4%	10,217	8.0%
90,000 - <120,000 mg	422,980	57,979	38,953	67.2%	12,774	22.0%	3,808	6.6%
120,000 - <150,000 mg	231,140	28,834	20,570	71.3%	5,779	20.0%	1,499	5.2%
150,000 - <180,000 mg	133,068	15,192	11,531	75.9%	2,497	16.4%	670	4.4%
180,000 - <210,000 mg	81,274	8,582	6,687	77.9%	1,276	14.9%	349	4.1%
≥ 210,000 mg	53,201	14,318	5,555	38.8%	3,682	25.7%	2,270	15.9%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	33,751	28,024	83.0%	2,090	6.2%	1,358	4.0%
30,000 - <60,000 mg	*****	5,900	4,581	77.6%	620	10.5%	318	5.4%
60,000 - <90,000 mg	*****	2,834	2,170	76.6%	349	12.3%	150	5.3%
90,000 - <120,000 mg	*****	1,517	1,179	77.7%	186	12.3%	72	4.7%
120,000 - <150,000 mg	*****	965	766	79.4%	108	11.2%	45	4.7%
150,000 - <180,000 mg	*****	621	523	84.2%	60	9.7%	19	3.1%
180,000 - <210,000 mg	*****	410	337	82.2%	43	10.5%	*****	*****
≥ 210,000 mg	*****	1,066	462	43.3%	259	24.3%	164	15.4%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	144,776	129,185	89.2%	5,961	4.1%	3,773	2.6%
30,000 - <60,000 mg	304,791	37,926	32,374	85.4%	2,493	6.6%	1,322	3.5%
60,000 - <90,000 mg	201,271	21,008	17,396	82.8%	1,897	9.0%	767	3.7%
90,000 - <120,000 mg	141,898	12,687	10,581	83.4%	1,051	8.3%	462	3.6%
120,000 - <150,000 mg	104,735	8,690	7,208	82.9%	764	8.8%	307	3.5%
150,000 - <180,000 mg	*****	6,035	5,129	85.0%	463	7.7%	192	3.2%
180,000 - <210,000 mg	*****	4,554	3,822	83.9%	377	8.3%	166	3.6%
≥ 210,000 mg	47,345	14,888	6,716	45.1%	3,321	22.3%	2,096	14.1%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	29,183	24,006	82.3%	1,960	6.7%	1,219	4.2%
30,000 - <60,000 mg	*****	4,885	3,607	73.8%	651	13.3%	296	6.1%
60,000 - <90,000 mg	*****	2,276	1,689	74.2%	320	14.1%	135	5.9%
90,000 - <120,000 mg	*****	1,198	936	78.1%	165	13.8%	47	3.9%
120,000 - <150,000 mg	*****	654	543	83.0%	63	9.6%	28	4.3%
150,000 - <180,000 mg	*****	419	353	84.2%	43	10.3%	11	2.6%
180,000 - <210,000 mg	*****	282	234	83.0%	24	8.5%	*****	*****
≥ 210,000 mg	*****	835	422	50.5%	202	24.2%	105	12.6%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	128,701	114,597	89.0%	5,579	4.3%	3,353	2.6%
30,000 - <60,000 mg	297,231	35,228	29,820	84.6%	2,651	7.5%	1,215	3.4%
60,000 - <90,000 mg	191,137	18,822	15,788	83.9%	1,676	8.9%	649	3.4%
90,000 - <120,000 mg	132,972	11,377	9,604	84.4%	997	8.8%	347	3.1%
120,000 - <150,000 mg	97,900	7,746	6,552	84.6%	678	8.8%	245	3.2%
150,000 - <180,000 mg	73,732	5,084	4,378	86.1%	397	7.8%	138	2.7%
180,000 - <210,000 mg	57,843	3,850	3,308	85.9%	328	8.5%	108	2.8%
≥ 210,000 mg	46,087	14,731	7,522	51.1%	3,121	21.2%	1,735	11.8%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,118,038	895,188	80.1%	88,881	7.9%	53,989	4.8%
30,000 - <60,000 mg	664,489	115,567	64,912	56.2%	29,639	25.6%	12,096	10.5%
60,000 - <90,000 mg	230,504	35,124	21,949	62.5%	8,809	25.1%	2,753	7.8%
90,000 - <120,000 mg	97,370	13,476	9,357	69.4%	2,936	21.8%	782	5.8%
120,000 - <150,000 mg	46,460	5,668	4,288	75.7%	1,007	17.8%	242	4.3%
150,000 - <180,000 mg	24,013	2,641	2,107	79.8%	388	14.7%	92	3.5%
180,000 - <210,000 mg	*****	1,320	1,062	80.5%	178	13.5%	48	3.6%
≥ 210,000 mg	*****	1,721	776	45.1%	472	27.4%	248	14.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,953,351	1,601,113	82.0%	144,008	7.4%	83,471	4.3%
30,000 - <60,000 mg	1,997,151	336,889	197,071	58.5%	78,454	23.3%	32,758	9.7%
60,000 - <90,000 mg	852,245	127,734	78,864	61.7%	31,195	24.4%	10,217	8.0%
90,000 - <120,000 mg	422,980	57,979	38,953	67.2%	12,774	22.0%	3,808	6.6%
120,000 - <150,000 mg	231,140	28,834	20,570	71.3%	5,779	20.0%	1,499	5.2%
150,000 - <180,000 mg	133,068	15,192	11,531	75.9%	2,497	16.4%	670	4.4%
180,000 - <210,000 mg	81,274	8,582	6,687	77.9%	1,276	14.9%	349	4.1%
≥ 210,000 mg	53,201	14,318	5,555	38.8%	3,682	25.7%	2,270	15.9%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	33,751	28,024	83.0%	2,090	6.2%	1,358	4.0%
30,000 - <60,000 mg	*****	5,900	4,581	77.6%	620	10.5%	318	5.4%
60,000 - <90,000 mg	*****	2,834	2,170	76.6%	349	12.3%	150	5.3%
90,000 - <120,000 mg	*****	1,517	1,179	77.7%	186	12.3%	72	4.7%
120,000 - <150,000 mg	*****	965	766	79.4%	108	11.2%	45	4.7%
150,000 - <180,000 mg	*****	621	523	84.2%	60	9.7%	19	3.1%
180,000 - <210,000 mg	*****	410	337	82.2%	43	10.5%	*****	*****
≥ 210,000 mg	*****	1,066	462	43.3%	259	24.3%	164	15.4%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	144,776	129,185	89.2%	5,961	4.1%	3,773	2.6%
30,000 - <60,000 mg	304,791	37,926	32,374	85.4%	2,493	6.6%	1,322	3.5%
60,000 - <90,000 mg	201,271	21,008	17,396	82.8%	1,897	9.0%	767	3.7%
90,000 - <120,000 mg	141,898	12,687	10,581	83.4%	1,051	8.3%	462	3.6%
120,000 - <150,000 mg	104,735	8,690	7,208	82.9%	764	8.8%	307	3.5%
150,000 - <180,000 mg	*****	6,035	5,129	85.0%	463	7.7%	192	3.2%
180,000 - <210,000 mg	*****	4,554	3,822	83.9%	377	8.3%	166	3.6%
≥ 210,000 mg	47,345	14,888	6,716	45.1%	3,321	22.3%	2,096	14.1%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	29,183	24,006	82.3%	1,960	6.7%	1,219	4.2%
30,000 - <60,000 mg	*****	4,885	3,607	73.8%	651	13.3%	296	6.1%
60,000 - <90,000 mg	*****	2,276	1,689	74.2%	320	14.1%	135	5.9%
90,000 - <120,000 mg	*****	1,198	936	78.1%	165	13.8%	47	3.9%
120,000 - <150,000 mg	*****	654	543	83.0%	63	9.6%	28	4.3%
150,000 - <180,000 mg	*****	419	353	84.2%	43	10.3%	11	2.6%
180,000 - <210,000 mg	*****	282	234	83.0%	24	8.5%	*****	*****
≥ 210,000 mg	*****	835	422	50.5%	202	24.2%	105	12.6%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	128,701	114,597	89.0%	5,579	4.3%	3,353	2.6%
30,000 - <60,000 mg	297,231	35,228	29,820	84.6%	2,651	7.5%	1,215	3.4%
60,000 - <90,000 mg	191,137	18,822	15,788	83.9%	1,676	8.9%	649	3.4%
90,000 - <120,000 mg	132,972	11,377	9,604	84.4%	997	8.8%	347	3.1%
120,000 - <150,000 mg	97,900	7,746	6,552	84.6%	678	8.8%	245	3.2%
150,000 - <180,000 mg	73,732	5,084	4,378	86.1%	397	7.8%	138	2.7%
180,000 - <210,000 mg	57,843	3,850	3,308	85.9%	328	8.5%	108	2.8%
≥ 210,000 mg	46,087	14,731	7,522	51.1%	3,121	21.2%	1,735	11.8%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,118,038	895,188	80.1%	88,881	7.9%	53,989	4.8%
30,000 - <60,000 mg	664,489	115,567	64,912	56.2%	29,639	25.6%	12,096	10.5%
60,000 - <90,000 mg	230,504	35,124	21,949	62.5%	8,809	25.1%	2,753	7.8%
90,000 - <120,000 mg	97,370	13,476	9,357	69.4%	2,936	21.8%	782	5.8%
120,000 - <150,000 mg	46,460	5,668	4,288	75.7%	1,007	17.8%	242	4.3%
150,000 - <180,000 mg	24,013	2,641	2,107	79.8%	388	14.7%	92	3.5%
180,000 - <210,000 mg	*****	1,320	1,062	80.5%	178	13.5%	48	3.6%
≥ 210,000 mg	*****	1,721	776	45.1%	472	27.4%	248	14.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,953,351	1,601,113	82.0%	144,008	7.4%	83,471	4.3%
30,000 - <60,000 mg	1,997,151	336,889	197,071	58.5%	78,454	23.3%	32,758	9.7%
60,000 - <90,000 mg	852,245	127,734	78,864	61.7%	31,195	24.4%	10,217	8.0%
90,000 - <120,000 mg	422,980	57,979	38,953	67.2%	12,774	22.0%	3,808	6.6%
120,000 - <150,000 mg	231,140	28,834	20,570	71.3%	5,779	20.0%	1,499	5.2%
150,000 - <180,000 mg	133,068	15,192	11,531	75.9%	2,497	16.4%	670	4.4%
180,000 - <210,000 mg	81,274	8,582	6,687	77.9%	1,276	14.9%	349	4.1%
≥ 210,000 mg	53,201	14,318	5,555	38.8%	3,682	25.7%	2,270	15.9%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	881	2.6%	562	1.7%	377	1.1%	251	0.7%	208	0.6%
30,000 - <60,000 mg	160	2.7%	88	1.5%	60	1.0%	46	0.8%	27	0.5%
60,000 - <90,000 mg	74	2.6%	43	1.5%	34	1.2%	*****	*****	*****	*****
90,000 - <120,000 mg	39	2.6%	22	1.5%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	28	2.9%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	90	8.4%	47	4.4%	24	2.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,321	1.6%	1,508	1.0%	934	0.6%	565	0.4%	529	0.4%
30,000 - <60,000 mg	727	1.9%	438	1.2%	252	0.7%	170	0.4%	150	0.4%
60,000 - <90,000 mg	377	1.8%	232	1.1%	165	0.8%	90	0.4%	84	0.4%
90,000 - <120,000 mg	284	2.2%	136	1.1%	81	0.6%	44	0.3%	48	0.4%
120,000 - <150,000 mg	183	2.1%	108	1.2%	61	0.7%	32	0.4%	27	0.3%
150,000 - <180,000 mg	109	1.8%	59	1.0%	39	0.6%	29	0.5%	15	0.2%
180,000 - <210,000 mg	87	1.9%	56	1.2%	20	0.4%	*****	*****	*****	*****
≥ 210,000 mg	1,197	8.0%	707	4.7%	441	3.0%	228	1.5%	182	1.2%
Torsemide Users (Washout)										
0 - <30,000 mg	745	2.6%	507	1.7%	369	1.3%	211	0.7%	166	0.6%
30,000 - <60,000 mg	163	3.3%	88	1.8%	40	0.8%	*****	*****	*****	*****
60,000 - <90,000 mg	71	3.1%	35	1.5%	13	0.6%	*****	*****	*****	*****
90,000 - <120,000 mg	22	1.8%	17	1.4%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	56	6.7%	34	4.1%	*****	*****	*****	*****	*****	*****

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,001	1.6%	1,310	1.0%	864	0.7%	505	0.4%	492	0.4%
30,000 - <60,000 mg	679	1.9%	371	1.1%	232	0.7%	144	0.4%	116	0.3%
60,000 - <90,000 mg	331	1.8%	179	1.0%	105	0.6%	56	0.3%	38	0.2%
90,000 - <120,000 mg	209	1.8%	102	0.9%	58	0.5%	32	0.3%	28	0.2%
120,000 - <150,000 mg	125	1.6%	74	1.0%	36	0.5%	19	0.2%	17	0.2%
150,000 - <180,000 mg	70	1.4%	60	1.2%	27	0.5%	*****	*****	*****	*****
180,000 - <210,000 mg	53	1.4%	31	0.8%	11	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,047	7.1%	581	3.9%	378	2.6%	202	1.4%	145	1.0%
Furosemide Users (Washout)										
0 - <30,000 mg	33,546	3.0%	20,576	1.8%	12,903	1.2%	7,307	0.7%	5,648	0.5%
30,000 - <60,000 mg	5,036	4.4%	2,247	1.9%	979	0.8%	419	0.4%	239	0.2%
60,000 - <90,000 mg	992	2.8%	386	1.1%	150	0.4%	56	0.2%	29	0.1%
90,000 - <120,000 mg	233	1.7%	97	0.7%	43	0.3%	17	0.1%	11	0.1%
120,000 - <150,000 mg	77	1.4%	36	0.6%	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	43	1.6%	*****	*****	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	19	1.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	114	6.6%	56	3.3%	30	1.7%	14	0.8%	11	0.6%
Furosemide Users (No Washout)										
0 - <30,000 mg	50,524	2.6%	31,417	1.6%	19,755	1.0%	11,931	0.6%	11,132	0.6%
30,000 - <60,000 mg	14,773	4.4%	7,012	2.1%	3,673	1.1%	1,822	0.5%	1,326	0.4%
60,000 - <90,000 mg	4,088	3.2%	1,828	1.4%	860	0.7%	414	0.3%	268	0.2%
90,000 - <120,000 mg	1,361	2.3%	606	1.0%	272	0.5%	136	0.2%	69	0.1%
120,000 - <150,000 mg	509	1.8%	278	1.0%	122	0.4%	56	0.2%	21	0.1%
150,000 - <180,000 mg	281	1.8%	125	0.8%	60	0.4%	16	0.1%	12	0.1%
180,000 - <210,000 mg	163	1.9%	56	0.7%	30	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,326	9.3%	754	5.3%	424	3.0%	193	1.3%	114	0.8%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	881	2.6%	562	1.7%	377	1.1%	251	0.7%	208	0.6%
30,000 - <60,000 mg	160	2.7%	88	1.5%	60	1.0%	46	0.8%	27	0.5%
60,000 - <90,000 mg	74	2.6%	43	1.5%	34	1.2%	*****	*****	*****	*****
90,000 - <120,000 mg	39	2.6%	22	1.5%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	28	2.9%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	90	8.4%	47	4.4%	24	2.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,321	1.6%	1,508	1.0%	934	0.6%	565	0.4%	529	0.4%
30,000 - <60,000 mg	727	1.9%	438	1.2%	252	0.7%	170	0.4%	150	0.4%
60,000 - <90,000 mg	377	1.8%	232	1.1%	165	0.8%	90	0.4%	84	0.4%
90,000 - <120,000 mg	284	2.2%	136	1.1%	81	0.6%	44	0.3%	48	0.4%
120,000 - <150,000 mg	183	2.1%	108	1.2%	61	0.7%	32	0.4%	27	0.3%
150,000 - <180,000 mg	109	1.8%	59	1.0%	39	0.6%	29	0.5%	15	0.2%
180,000 - <210,000 mg	87	1.9%	56	1.2%	20	0.4%	*****	*****	*****	*****
≥ 210,000 mg	1,197	8.0%	707	4.7%	441	3.0%	228	1.5%	182	1.2%
Torsemide Users (Washout)										
0 - <30,000 mg	745	2.6%	507	1.7%	369	1.3%	211	0.7%	166	0.6%
30,000 - <60,000 mg	163	3.3%	88	1.8%	40	0.8%	*****	*****	*****	*****
60,000 - <90,000 mg	71	3.1%	35	1.5%	13	0.6%	*****	*****	*****	*****
90,000 - <120,000 mg	22	1.8%	17	1.4%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	56	6.7%	34	4.1%	*****	*****	*****	*****	*****	*****

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,001	1.6%	1,310	1.0%	864	0.7%	505	0.4%	492	0.4%
30,000 - <60,000 mg	679	1.9%	371	1.1%	232	0.7%	144	0.4%	116	0.3%
60,000 - <90,000 mg	331	1.8%	179	1.0%	105	0.6%	56	0.3%	38	0.2%
90,000 - <120,000 mg	209	1.8%	102	0.9%	58	0.5%	32	0.3%	28	0.2%
120,000 - <150,000 mg	125	1.6%	74	1.0%	36	0.5%	19	0.2%	17	0.2%
150,000 - <180,000 mg	70	1.4%	60	1.2%	27	0.5%	*****	*****	*****	*****
180,000 - <210,000 mg	53	1.4%	31	0.8%	11	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,047	7.1%	581	3.9%	378	2.6%	202	1.4%	145	1.0%
Furosemide Users (Washout)										
0 - <30,000 mg	33,546	3.0%	20,576	1.8%	12,903	1.2%	7,307	0.7%	5,648	0.5%
30,000 - <60,000 mg	5,036	4.4%	2,247	1.9%	979	0.8%	419	0.4%	239	0.2%
60,000 - <90,000 mg	992	2.8%	386	1.1%	150	0.4%	56	0.2%	29	0.1%
90,000 - <120,000 mg	233	1.7%	97	0.7%	43	0.3%	17	0.1%	11	0.1%
120,000 - <150,000 mg	77	1.4%	36	0.6%	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	43	1.6%	*****	*****	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	19	1.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	114	6.6%	56	3.3%	30	1.7%	14	0.8%	11	0.6%
Furosemide Users (No Washout)										
0 - <30,000 mg	50,524	2.6%	31,417	1.6%	19,755	1.0%	11,931	0.6%	11,132	0.6%
30,000 - <60,000 mg	14,773	4.4%	7,012	2.1%	3,673	1.1%	1,822	0.5%	1,326	0.4%
60,000 - <90,000 mg	4,088	3.2%	1,828	1.4%	860	0.7%	414	0.3%	268	0.2%
90,000 - <120,000 mg	1,361	2.3%	606	1.0%	272	0.5%	136	0.2%	69	0.1%
120,000 - <150,000 mg	509	1.8%	278	1.0%	122	0.4%	56	0.2%	21	0.1%
150,000 - <180,000 mg	281	1.8%	125	0.8%	60	0.4%	16	0.1%	12	0.1%
180,000 - <210,000 mg	163	1.9%	56	0.7%	30	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,326	9.3%	754	5.3%	424	3.0%	193	1.3%	114	0.8%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	881	2.6%	562	1.7%	377	1.1%	251	0.7%	208	0.6%
30,000 - <60,000 mg	160	2.7%	88	1.5%	60	1.0%	46	0.8%	27	0.5%
60,000 - <90,000 mg	74	2.6%	43	1.5%	34	1.2%	*****	*****	*****	*****
90,000 - <120,000 mg	39	2.6%	22	1.5%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	28	2.9%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	90	8.4%	47	4.4%	24	2.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,321	1.6%	1,508	1.0%	934	0.6%	565	0.4%	529	0.4%
30,000 - <60,000 mg	727	1.9%	438	1.2%	252	0.7%	170	0.4%	150	0.4%
60,000 - <90,000 mg	377	1.8%	232	1.1%	165	0.8%	90	0.4%	84	0.4%
90,000 - <120,000 mg	284	2.2%	136	1.1%	81	0.6%	44	0.3%	48	0.4%
120,000 - <150,000 mg	183	2.1%	108	1.2%	61	0.7%	32	0.4%	27	0.3%
150,000 - <180,000 mg	109	1.8%	59	1.0%	39	0.6%	29	0.5%	15	0.2%
180,000 - <210,000 mg	87	1.9%	56	1.2%	20	0.4%	*****	*****	*****	*****
≥ 210,000 mg	1,197	8.0%	707	4.7%	441	3.0%	228	1.5%	182	1.2%
Torsemide Users (Washout)										
0 - <30,000 mg	745	2.6%	507	1.7%	369	1.3%	211	0.7%	166	0.6%
30,000 - <60,000 mg	163	3.3%	88	1.8%	40	0.8%	*****	*****	*****	*****
60,000 - <90,000 mg	71	3.1%	35	1.5%	13	0.6%	*****	*****	*****	*****
90,000 - <120,000 mg	22	1.8%	17	1.4%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	56	6.7%	34	4.1%	*****	*****	*****	*****	*****	*****

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,001	1.6%	1,310	1.0%	864	0.7%	505	0.4%	492	0.4%
30,000 - <60,000 mg	679	1.9%	371	1.1%	232	0.7%	144	0.4%	116	0.3%
60,000 - <90,000 mg	331	1.8%	179	1.0%	105	0.6%	56	0.3%	38	0.2%
90,000 - <120,000 mg	209	1.8%	102	0.9%	58	0.5%	32	0.3%	28	0.2%
120,000 - <150,000 mg	125	1.6%	74	1.0%	36	0.5%	19	0.2%	17	0.2%
150,000 - <180,000 mg	70	1.4%	60	1.2%	27	0.5%	*****	*****	*****	*****
180,000 - <210,000 mg	53	1.4%	31	0.8%	11	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,047	7.1%	581	3.9%	378	2.6%	202	1.4%	145	1.0%
Furosemide Users (Washout)										
0 - <30,000 mg	33,546	3.0%	20,576	1.8%	12,903	1.2%	7,307	0.7%	5,648	0.5%
30,000 - <60,000 mg	5,036	4.4%	2,247	1.9%	979	0.8%	419	0.4%	239	0.2%
60,000 - <90,000 mg	992	2.8%	386	1.1%	150	0.4%	56	0.2%	29	0.1%
90,000 - <120,000 mg	233	1.7%	97	0.7%	43	0.3%	17	0.1%	11	0.1%
120,000 - <150,000 mg	77	1.4%	36	0.6%	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	43	1.6%	*****	*****	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	19	1.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	114	6.6%	56	3.3%	30	1.7%	14	0.8%	11	0.6%
Furosemide Users (No Washout)										
0 - <30,000 mg	50,524	2.6%	31,417	1.6%	19,755	1.0%	11,931	0.6%	11,132	0.6%
30,000 - <60,000 mg	14,773	4.4%	7,012	2.1%	3,673	1.1%	1,822	0.5%	1,326	0.4%
60,000 - <90,000 mg	4,088	3.2%	1,828	1.4%	860	0.7%	414	0.3%	268	0.2%
90,000 - <120,000 mg	1,361	2.3%	606	1.0%	272	0.5%	136	0.2%	69	0.1%
120,000 - <150,000 mg	509	1.8%	278	1.0%	122	0.4%	56	0.2%	21	0.1%
150,000 - <180,000 mg	281	1.8%	125	0.8%	60	0.4%	16	0.1%	12	0.1%
180,000 - <210,000 mg	163	1.9%	56	0.7%	30	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,326	9.3%	754	5.3%	424	3.0%	193	1.3%	114	0.8%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	881	2.6%	562	1.7%	377	1.1%	251	0.7%	208	0.6%
30,000 - <60,000 mg	160	2.7%	88	1.5%	60	1.0%	46	0.8%	27	0.5%
60,000 - <90,000 mg	74	2.6%	43	1.5%	34	1.2%	*****	*****	*****	*****
90,000 - <120,000 mg	39	2.6%	22	1.5%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	28	2.9%	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
≥ 210,000 mg	90	8.4%	47	4.4%	24	2.3%	*****	*****	*****	*****
Bumetanide Users (No Washout)										
0 - <30,000 mg	2,321	1.6%	1,508	1.0%	934	0.6%	565	0.4%	529	0.4%
30,000 - <60,000 mg	727	1.9%	438	1.2%	252	0.7%	170	0.4%	150	0.4%
60,000 - <90,000 mg	377	1.8%	232	1.1%	165	0.8%	90	0.4%	84	0.4%
90,000 - <120,000 mg	284	2.2%	136	1.1%	81	0.6%	44	0.3%	48	0.4%
120,000 - <150,000 mg	183	2.1%	108	1.2%	61	0.7%	32	0.4%	27	0.3%
150,000 - <180,000 mg	109	1.8%	59	1.0%	39	0.6%	29	0.5%	15	0.2%
180,000 - <210,000 mg	87	1.9%	56	1.2%	20	0.4%	*****	*****	*****	*****
≥ 210,000 mg	1,197	8.0%	707	4.7%	441	3.0%	228	1.5%	182	1.2%
Torsemide Users (Washout)										
0 - <30,000 mg	745	2.6%	507	1.7%	369	1.3%	211	0.7%	166	0.6%
30,000 - <60,000 mg	163	3.3%	88	1.8%	40	0.8%	*****	*****	*****	*****
60,000 - <90,000 mg	71	3.1%	35	1.5%	13	0.6%	*****	*****	*****	*****
90,000 - <120,000 mg	22	1.8%	17	1.4%	*****	*****	*****	*****	*****	*****
120,000 - <150,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
180,000 - <210,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 210,000 mg	56	6.7%	34	4.1%	*****	*****	*****	*****	*****	*****

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	2,001	1.6%	1,310	1.0%	864	0.7%	505	0.4%	492	0.4%
30,000 - <60,000 mg	679	1.9%	371	1.1%	232	0.7%	144	0.4%	116	0.3%
60,000 - <90,000 mg	331	1.8%	179	1.0%	105	0.6%	56	0.3%	38	0.2%
90,000 - <120,000 mg	209	1.8%	102	0.9%	58	0.5%	32	0.3%	28	0.2%
120,000 - <150,000 mg	125	1.6%	74	1.0%	36	0.5%	19	0.2%	17	0.2%
150,000 - <180,000 mg	70	1.4%	60	1.2%	27	0.5%	*****	*****	*****	*****
180,000 - <210,000 mg	53	1.4%	31	0.8%	11	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,047	7.1%	581	3.9%	378	2.6%	202	1.4%	145	1.0%
Furosemide Users (Washout)										
0 - <30,000 mg	33,546	3.0%	20,576	1.8%	12,903	1.2%	7,307	0.7%	5,648	0.5%
30,000 - <60,000 mg	5,036	4.4%	2,247	1.9%	979	0.8%	419	0.4%	239	0.2%
60,000 - <90,000 mg	992	2.8%	386	1.1%	150	0.4%	56	0.2%	29	0.1%
90,000 - <120,000 mg	233	1.7%	97	0.7%	43	0.3%	17	0.1%	11	0.1%
120,000 - <150,000 mg	77	1.4%	36	0.6%	*****	*****	*****	*****	0	0.0%
150,000 - <180,000 mg	43	1.6%	*****	*****	*****	*****	0	0.0%	*****	*****
180,000 - <210,000 mg	19	1.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	114	6.6%	56	3.3%	30	1.7%	14	0.8%	11	0.6%
Furosemide Users (No Washout)										
0 - <30,000 mg	50,524	2.6%	31,417	1.6%	19,755	1.0%	11,931	0.6%	11,132	0.6%
30,000 - <60,000 mg	14,773	4.4%	7,012	2.1%	3,673	1.1%	1,822	0.5%	1,326	0.4%
60,000 - <90,000 mg	4,088	3.2%	1,828	1.4%	860	0.7%	414	0.3%	268	0.2%
90,000 - <120,000 mg	1,361	2.3%	606	1.0%	272	0.5%	136	0.2%	69	0.1%
120,000 - <150,000 mg	509	1.8%	278	1.0%	122	0.4%	56	0.2%	21	0.1%
150,000 - <180,000 mg	281	1.8%	125	0.8%	60	0.4%	16	0.1%	12	0.1%

Table 15b. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	163	1.9%	56	0.7%	30	0.3%	*****	*****	*****	*****
≥ 210,000 mg	1,326	9.3%	754	5.3%	424	3.0%	193	1.3%	114	0.8%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	35,918	29,984	83.5%	2,159	6.0%	1,425	4.0%
1-2 years	43,206	6,109	4,690	76.8%	674	11.0%	316	5.2%
2-3 years	*****	2,652	1,846	69.6%	442	16.7%	177	6.7%
3-4 years	*****	1,215	904	74.4%	207	17.0%	61	5.0%
4-5 years	*****	602	481	79.9%	72	12.0%	34	5.6%
5-6 years	*****	307	246	80.1%	46	15.0%	*****	*****
6-7 years	*****	146	124	84.9%	*****	*****	*****	*****
7+ years	*****	115	65	56.5%	29	25.2%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	177,317	159,118	89.7%	7,047	4.0%	4,425	2.5%
1-2 years	231,141	39,085	32,192	82.4%	3,296	8.4%	1,545	4.0%
2-3 years	120,390	17,639	12,418	70.4%	3,055	17.3%	970	5.5%
3-4 years	60,491	8,423	6,081	72.2%	1,337	15.9%	471	5.6%
4-5 years	31,830	3,967	3,020	76.1%	608	15.3%	165	4.2%
5-6 years	*****	2,146	1,650	76.9%	340	15.8%	85	4.0%
6-7 years	*****	1,046	827	79.1%	149	14.2%	41	3.9%
7+ years	*****	941	425	45.2%	265	28.2%	166	17.6%
Torsemide Users (Washout)								
0-1 years	172,362	29,234	24,423	83.5%	1,810	6.2%	1,132	3.9%
1-2 years	*****	5,573	4,341	77.9%	568	10.2%	297	5.3%
2-3 years	*****	2,539	1,766	69.6%	446	17.6%	145	5.7%
3-4 years	*****	1,204	896	74.4%	195	16.2%	53	4.4%
4-5 years	*****	596	464	77.9%	77	12.9%	33	5.5%
5-6 years	*****	339	256	75.5%	*****	*****	*****	*****
6-7 years	*****	136	112	82.4%	*****	*****	*****	*****
7+ years	*****	111	61	55.0%	32	28.8%	*****	*****

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	154,135	139,464	90.5%	5,833	3.8%	3,464	2.2%
1-2 years	249,185	37,494	31,445	83.9%	2,956	7.9%	1,342	3.6%
2-3 years	131,368	16,799	12,228	72.8%	2,822	16.8%	806	4.8%
3-4 years	66,841	8,271	6,219	75.2%	1,302	15.7%	357	4.3%
4-5 years	35,645	4,283	3,265	76.2%	627	14.6%	219	5.1%
5-6 years	*****	2,345	1,779	75.9%	351	15.0%	101	4.3%
6-7 years	*****	1,135	914	80.5%	141	12.4%	54	4.8%
7+ years	*****	1,077	482	44.8%	308	28.6%	183	17.0%
Furosemide Users (Washout)								
0-1 years	5,031,471	878,615	751,191	85.5%	48,672	5.5%	30,780	3.5%
1-2 years	1,570,858	200,462	161,002	80.3%	21,113	10.5%	8,808	4.4%
2-3 years	857,233	100,783	73,409	72.8%	17,302	17.2%	5,158	5.1%
3-4 years	462,012	54,485	41,390	76.0%	8,741	16.0%	2,410	4.4%
4-5 years	253,038	29,458	23,126	78.5%	4,435	15.1%	1,138	3.9%
5-6 years	138,456	15,615	12,577	80.5%	2,174	13.9%	551	3.5%
6-7 years	73,838	7,867	6,544	83.2%	1,002	12.7%	222	2.8%
7+ years	37,943	6,270	3,377	53.9%	1,848	29.5%	769	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,458,472	1,285,136	88.1%	66,090	4.5%	41,120	2.8%
1-2 years	3,756,719	475,970	393,227	82.6%	42,763	9.0%	18,027	3.8%
2-3 years	2,243,787	258,913	188,615	72.8%	43,622	16.8%	12,838	5.0%
3-4 years	1,290,390	149,365	111,929	74.9%	24,085	16.1%	6,694	4.5%
4-5 years	759,943	87,069	66,729	76.6%	13,371	15.4%	3,666	4.2%
5-6 years	451,504	51,544	40,112	77.8%	7,825	15.2%	2,049	4.0%
6-7 years	267,682	29,466	23,566	80.0%	4,235	14.4%	1,053	3.6%
7+ years	157,482	32,080	14,049	43.8%	9,452	29.5%	5,886	18.3%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	35,918	29,984	83.5%	2,159	6.0%	1,425	4.0%
1-2 years	43,206	6,109	4,690	76.8%	674	11.0%	316	5.2%
2-3 years	*****	2,652	1,846	69.6%	442	16.7%	177	6.7%
3-4 years	*****	1,215	904	74.4%	207	17.0%	61	5.0%
4-5 years	*****	602	481	79.9%	72	12.0%	34	5.6%
5-6 years	*****	307	246	80.1%	46	15.0%	*****	*****
6-7 years	*****	146	124	84.9%	*****	*****	*****	*****
7+ years	*****	115	65	56.5%	29	25.2%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	177,317	159,118	89.7%	7,047	4.0%	4,425	2.5%
1-2 years	231,141	39,085	32,192	82.4%	3,296	8.4%	1,545	4.0%
2-3 years	120,390	17,639	12,418	70.4%	3,055	17.3%	970	5.5%
3-4 years	60,491	8,423	6,081	72.2%	1,337	15.9%	471	5.6%
4-5 years	31,830	3,967	3,020	76.1%	608	15.3%	165	4.2%
5-6 years	*****	2,146	1,650	76.9%	340	15.8%	85	4.0%
6-7 years	*****	1,046	827	79.1%	149	14.2%	41	3.9%
7+ years	*****	941	425	45.2%	265	28.2%	166	17.6%
Torsemide Users (Washout)								
0-1 years	172,362	29,234	24,423	83.5%	1,810	6.2%	1,132	3.9%
1-2 years	*****	5,573	4,341	77.9%	568	10.2%	297	5.3%
2-3 years	*****	2,539	1,766	69.6%	446	17.6%	145	5.7%
3-4 years	*****	1,204	896	74.4%	195	16.2%	53	4.4%
4-5 years	*****	596	464	77.9%	77	12.9%	33	5.5%
5-6 years	*****	339	256	75.5%	*****	*****	*****	*****
6-7 years	*****	136	112	82.4%	*****	*****	*****	*****
7+ years	*****	111	61	55.0%	32	28.8%	*****	*****

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	154,135	139,464	90.5%	5,833	3.8%	3,464	2.2%
1-2 years	249,185	37,494	31,445	83.9%	2,956	7.9%	1,342	3.6%
2-3 years	131,368	16,799	12,228	72.8%	2,822	16.8%	806	4.8%
3-4 years	66,841	8,271	6,219	75.2%	1,302	15.7%	357	4.3%
4-5 years	35,645	4,283	3,265	76.2%	627	14.6%	219	5.1%
5-6 years	*****	2,345	1,779	75.9%	351	15.0%	101	4.3%
6-7 years	*****	1,135	914	80.5%	141	12.4%	54	4.8%
7+ years	*****	1,077	482	44.8%	308	28.6%	183	17.0%
Furosemide Users (Washout)								
0-1 years	5,031,471	878,615	751,191	85.5%	48,672	5.5%	30,780	3.5%
1-2 years	1,570,858	200,462	161,002	80.3%	21,113	10.5%	8,808	4.4%
2-3 years	857,233	100,783	73,409	72.8%	17,302	17.2%	5,158	5.1%
3-4 years	462,012	54,485	41,390	76.0%	8,741	16.0%	2,410	4.4%
4-5 years	253,038	29,458	23,126	78.5%	4,435	15.1%	1,138	3.9%
5-6 years	138,456	15,615	12,577	80.5%	2,174	13.9%	551	3.5%
6-7 years	73,838	7,867	6,544	83.2%	1,002	12.7%	222	2.8%
7+ years	37,943	6,270	3,377	53.9%	1,848	29.5%	769	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,458,472	1,285,136	88.1%	66,090	4.5%	41,120	2.8%
1-2 years	3,756,719	475,970	393,227	82.6%	42,763	9.0%	18,027	3.8%
2-3 years	2,243,787	258,913	188,615	72.8%	43,622	16.8%	12,838	5.0%
3-4 years	1,290,390	149,365	111,929	74.9%	24,085	16.1%	6,694	4.5%
4-5 years	759,943	87,069	66,729	76.6%	13,371	15.4%	3,666	4.2%
5-6 years	451,504	51,544	40,112	77.8%	7,825	15.2%	2,049	4.0%
6-7 years	267,682	29,466	23,566	80.0%	4,235	14.4%	1,053	3.6%
7+ years	157,482	32,080	14,049	43.8%	9,452	29.5%	5,886	18.3%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	35,918	29,984	83.5%	2,159	6.0%	1,425	4.0%
1-2 years	43,206	6,109	4,690	76.8%	674	11.0%	316	5.2%
2-3 years	*****	2,652	1,846	69.6%	442	16.7%	177	6.7%
3-4 years	*****	1,215	904	74.4%	207	17.0%	61	5.0%
4-5 years	*****	602	481	79.9%	72	12.0%	34	5.6%
5-6 years	*****	307	246	80.1%	46	15.0%	*****	*****
6-7 years	*****	146	124	84.9%	*****	*****	*****	*****
7+ years	*****	115	65	56.5%	29	25.2%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	177,317	159,118	89.7%	7,047	4.0%	4,425	2.5%
1-2 years	231,141	39,085	32,192	82.4%	3,296	8.4%	1,545	4.0%
2-3 years	120,390	17,639	12,418	70.4%	3,055	17.3%	970	5.5%
3-4 years	60,491	8,423	6,081	72.2%	1,337	15.9%	471	5.6%
4-5 years	31,830	3,967	3,020	76.1%	608	15.3%	165	4.2%
5-6 years	*****	2,146	1,650	76.9%	340	15.8%	85	4.0%
6-7 years	*****	1,046	827	79.1%	149	14.2%	41	3.9%
7+ years	*****	941	425	45.2%	265	28.2%	166	17.6%
Torsemide Users (Washout)								
0-1 years	172,362	29,234	24,423	83.5%	1,810	6.2%	1,132	3.9%
1-2 years	*****	5,573	4,341	77.9%	568	10.2%	297	5.3%
2-3 years	*****	2,539	1,766	69.6%	446	17.6%	145	5.7%
3-4 years	*****	1,204	896	74.4%	195	16.2%	53	4.4%
4-5 years	*****	596	464	77.9%	77	12.9%	33	5.5%
5-6 years	*****	339	256	75.5%	*****	*****	*****	*****
6-7 years	*****	136	112	82.4%	*****	*****	*****	*****
7+ years	*****	111	61	55.0%	32	28.8%	*****	*****

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	154,135	139,464	90.5%	5,833	3.8%	3,464	2.2%
1-2 years	249,185	37,494	31,445	83.9%	2,956	7.9%	1,342	3.6%
2-3 years	131,368	16,799	12,228	72.8%	2,822	16.8%	806	4.8%
3-4 years	66,841	8,271	6,219	75.2%	1,302	15.7%	357	4.3%
4-5 years	35,645	4,283	3,265	76.2%	627	14.6%	219	5.1%
5-6 years	*****	2,345	1,779	75.9%	351	15.0%	101	4.3%
6-7 years	*****	1,135	914	80.5%	141	12.4%	54	4.8%
7+ years	*****	1,077	482	44.8%	308	28.6%	183	17.0%
Furosemide Users (Washout)								
0-1 years	5,031,471	878,615	751,191	85.5%	48,672	5.5%	30,780	3.5%
1-2 years	1,570,858	200,462	161,002	80.3%	21,113	10.5%	8,808	4.4%
2-3 years	857,233	100,783	73,409	72.8%	17,302	17.2%	5,158	5.1%
3-4 years	462,012	54,485	41,390	76.0%	8,741	16.0%	2,410	4.4%
4-5 years	253,038	29,458	23,126	78.5%	4,435	15.1%	1,138	3.9%
5-6 years	138,456	15,615	12,577	80.5%	2,174	13.9%	551	3.5%
6-7 years	73,838	7,867	6,544	83.2%	1,002	12.7%	222	2.8%
7+ years	37,943	6,270	3,377	53.9%	1,848	29.5%	769	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,458,472	1,285,136	88.1%	66,090	4.5%	41,120	2.8%
1-2 years	3,756,719	475,970	393,227	82.6%	42,763	9.0%	18,027	3.8%
2-3 years	2,243,787	258,913	188,615	72.8%	43,622	16.8%	12,838	5.0%
3-4 years	1,290,390	149,365	111,929	74.9%	24,085	16.1%	6,694	4.5%
4-5 years	759,943	87,069	66,729	76.6%	13,371	15.4%	3,666	4.2%
5-6 years	451,504	51,544	40,112	77.8%	7,825	15.2%	2,049	4.0%
6-7 years	267,682	29,466	23,566	80.0%	4,235	14.4%	1,053	3.6%
7+ years	157,482	32,080	14,049	43.8%	9,452	29.5%	5,886	18.3%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	35,918	29,984	83.5%	2,159	6.0%	1,425	4.0%
1-2 years	43,206	6,109	4,690	76.8%	674	11.0%	316	5.2%
2-3 years	*****	2,652	1,846	69.6%	442	16.7%	177	6.7%
3-4 years	*****	1,215	904	74.4%	207	17.0%	61	5.0%
4-5 years	*****	602	481	79.9%	72	12.0%	34	5.6%
5-6 years	*****	307	246	80.1%	46	15.0%	*****	*****
6-7 years	*****	146	124	84.9%	*****	*****	*****	*****
7+ years	*****	115	65	56.5%	29	25.2%	*****	*****
Bumetanide Users (No Washout)								
0-1 years	681,044	177,317	159,118	89.7%	7,047	4.0%	4,425	2.5%
1-2 years	231,141	39,085	32,192	82.4%	3,296	8.4%	1,545	4.0%
2-3 years	120,390	17,639	12,418	70.4%	3,055	17.3%	970	5.5%
3-4 years	60,491	8,423	6,081	72.2%	1,337	15.9%	471	5.6%
4-5 years	31,830	3,967	3,020	76.1%	608	15.3%	165	4.2%
5-6 years	*****	2,146	1,650	76.9%	340	15.8%	85	4.0%
6-7 years	*****	1,046	827	79.1%	149	14.2%	41	3.9%
7+ years	*****	941	425	45.2%	265	28.2%	166	17.6%
Torsemide Users (Washout)								
0-1 years	172,362	29,234	24,423	83.5%	1,810	6.2%	1,132	3.9%
1-2 years	*****	5,573	4,341	77.9%	568	10.2%	297	5.3%
2-3 years	*****	2,539	1,766	69.6%	446	17.6%	145	5.7%
3-4 years	*****	1,204	896	74.4%	195	16.2%	53	4.4%
4-5 years	*****	596	464	77.9%	77	12.9%	33	5.5%
5-6 years	*****	339	256	75.5%	63	18.6%	*****	*****
6-7 years	*****	136	112	82.4%	*****	*****	*****	*****
7+ years	*****	111	61	55.0%	32	28.8%	*****	*****

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Evidence of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	154,135	139,464	90.5%	5,833	3.8%	3,464	2.2%
1-2 years	249,185	37,494	31,445	83.9%	2,956	7.9%	1,342	3.6%
2-3 years	131,368	16,799	12,228	72.8%	2,822	16.8%	806	4.8%
3-4 years	66,841	8,271	6,219	75.2%	1,302	15.7%	357	4.3%
4-5 years	35,645	4,283	3,265	76.2%	627	14.6%	219	5.1%
5-6 years	*****	2,345	1,779	75.9%	351	15.0%	101	4.3%
6-7 years	*****	1,135	914	80.5%	141	12.4%	54	4.8%
7+ years	*****	1,077	482	44.8%	308	28.6%	183	17.0%
Furosemide Users (Washout)								
0-1 years	5,031,471	878,615	751,191	85.5%	48,672	5.5%	30,780	3.5%
1-2 years	1,570,858	200,462	161,002	80.3%	21,113	10.5%	8,808	4.4%
2-3 years	857,233	100,783	73,409	72.8%	17,302	17.2%	5,158	5.1%
3-4 years	462,012	54,485	41,390	76.0%	8,741	16.0%	2,410	4.4%
4-5 years	253,038	29,458	23,126	78.5%	4,435	15.1%	1,138	3.9%
5-6 years	138,456	15,615	12,577	80.5%	2,174	13.9%	551	3.5%
6-7 years	73,838	7,867	6,544	83.2%	1,002	12.7%	222	2.8%
7+ years	37,943	6,270	3,377	53.9%	1,848	29.5%	769	12.3%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,458,472	1,285,136	88.1%	66,090	4.5%	41,120	2.8%
1-2 years	3,756,719	475,970	393,227	82.6%	42,763	9.0%	18,027	3.8%
2-3 years	2,243,787	258,913	188,615	72.8%	43,622	16.8%	12,838	5.0%
3-4 years	1,290,390	149,365	111,929	74.9%	24,085	16.1%	6,694	4.5%
4-5 years	759,943	87,069	66,729	76.6%	13,371	15.4%	3,666	4.2%
5-6 years	451,504	51,544	40,112	77.8%	7,825	15.2%	2,049	4.0%
6-7 years	267,682	29,466	23,566	80.0%	4,235	14.4%	1,053	3.6%
7+ years	157,482	32,080	14,049	43.8%	9,452	29.5%	5,886	18.3%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	915	2.5%	582	1.6%	370	1.0%	259	0.7%	224	0.6%
1-2 years	169	2.8%	114	1.9%	76	1.2%	44	0.7%	26	0.4%
2-3 years	90	3.4%	49	1.8%	29	1.1%	*****	*****	*****	*****
3-4 years	13	1.1%	17	1.4%	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,715	1.5%	1,746	1.0%	1,019	0.6%	637	0.4%	610	0.3%
1-2 years	862	2.2%	511	1.3%	327	0.8%	189	0.5%	163	0.4%
2-3 years	492	2.8%	285	1.6%	199	1.1%	114	0.6%	106	0.6%
3-4 years	206	2.4%	139	1.7%	98	1.2%	57	0.7%	34	0.4%
4-5 years	78	2.0%	52	1.3%	30	0.8%	*****	*****	*****	*****
5-6 years	47	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	65	6.9%	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0-1 years	707	2.4%	483	1.7%	332	1.1%	201	0.7%	146	0.5%
1-2 years	150	2.7%	112	2.0%	54	1.0%	27	0.5%	24	0.4%
2-3 years	100	3.9%	40	1.6%	29	1.1%	*****	*****	*****	*****
3-4 years	31	2.6%	15	1.2%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	11	3.2%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,136	1.4%	1,343	0.9%	902	0.6%	509	0.3%	484	0.3%
1-2 years	748	2.0%	458	1.2%	244	0.7%	143	0.4%	158	0.4%
2-3 years	439	2.6%	227	1.4%	148	0.9%	74	0.4%	55	0.3%
3-4 years	177	2.1%	100	1.2%	71	0.9%	34	0.4%	11	0.1%
4-5 years	79	1.8%	53	1.2%	*****	*****	*****	*****	*****	*****
5-6 years	72	3.1%	27	1.2%	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	84	7.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	19,867	2.3%	12,307	1.4%	7,798	0.9%	4,484	0.5%	3,516	0.4%
1-2 years	4,615	2.3%	2,395	1.2%	1,403	0.7%	663	0.3%	463	0.2%
2-3 years	2,503	2.5%	1,284	1.3%	652	0.6%	316	0.3%	159	0.2%
3-4 years	1,056	1.9%	517	0.9%	252	0.5%	85	0.2%	34	0.1%
4-5 years	467	1.6%	188	0.6%	75	0.3%	*****	*****	*****	*****
5-6 years	225	1.4%	62	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	79	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	192	3.1%	44	0.7%	22	0.4%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	26,437	1.8%	16,743	1.1%	10,675	0.7%	6,471	0.4%	5,800	0.4%
1-2 years	9,679	2.0%	5,515	1.2%	3,220	0.7%	1,818	0.4%	1,721	0.4%
2-3 years	6,414	2.5%	3,474	1.3%	1,969	0.8%	1,123	0.4%	858	0.3%
3-4 years	3,226	2.2%	1,771	1.2%	932	0.6%	518	0.3%	210	0.1%
4-5 years	1,754	2.0%	885	1.0%	491	0.6%	143	0.2%	30	0.0%
5-6 years	920	1.8%	469	0.9%	153	0.3%	*****	*****	*****	*****
6-7 years	472	1.6%	120	0.4%	12	0.0%	*****	*****	*****	*****
7+ years	2,203	6.9%	237	0.7%	153	0.5%	76	0.2%	24	0.1%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	915	2.5%	582	1.6%	370	1.0%	259	0.7%	224	0.6%
1-2 years	169	2.8%	114	1.9%	76	1.2%	44	0.7%	26	0.4%
2-3 years	90	3.4%	49	1.8%	29	1.1%	*****	*****	*****	*****
3-4 years	13	1.1%	17	1.4%	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,715	1.5%	1,746	1.0%	1,019	0.6%	637	0.4%	610	0.3%
1-2 years	862	2.2%	511	1.3%	327	0.8%	189	0.5%	163	0.4%
2-3 years	492	2.8%	285	1.6%	199	1.1%	114	0.6%	106	0.6%
3-4 years	206	2.4%	139	1.7%	98	1.2%	57	0.7%	34	0.4%
4-5 years	78	2.0%	52	1.3%	30	0.8%	*****	*****	*****	*****
5-6 years	47	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	65	6.9%	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0-1 years	707	2.4%	483	1.7%	332	1.1%	201	0.7%	146	0.5%
1-2 years	150	2.7%	112	2.0%	54	1.0%	27	0.5%	24	0.4%
2-3 years	100	3.9%	40	1.6%	29	1.1%	*****	*****	*****	*****
3-4 years	31	2.6%	15	1.2%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	11	3.2%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,136	1.4%	1,343	0.9%	902	0.6%	509	0.3%	484	0.3%
1-2 years	748	2.0%	458	1.2%	244	0.7%	143	0.4%	158	0.4%
2-3 years	439	2.6%	227	1.4%	148	0.9%	74	0.4%	55	0.3%
3-4 years	177	2.1%	100	1.2%	71	0.9%	34	0.4%	11	0.1%
4-5 years	79	1.8%	53	1.2%	*****	*****	*****	*****	*****	*****
5-6 years	72	3.1%	27	1.2%	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	84	7.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	19,867	2.3%	12,307	1.4%	7,798	0.9%	4,484	0.5%	3,516	0.4%
1-2 years	4,615	2.3%	2,395	1.2%	1,403	0.7%	663	0.3%	463	0.2%
2-3 years	2,503	2.5%	1,284	1.3%	652	0.6%	316	0.3%	159	0.2%
3-4 years	1,056	1.9%	517	0.9%	252	0.5%	85	0.2%	34	0.1%
4-5 years	467	1.6%	188	0.6%	75	0.3%	*****	*****	*****	*****
5-6 years	225	1.4%	62	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	79	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	192	3.1%	44	0.7%	22	0.4%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	26,437	1.8%	16,743	1.1%	10,675	0.7%	6,471	0.4%	5,800	0.4%
1-2 years	9,679	2.0%	5,515	1.2%	3,220	0.7%	1,818	0.4%	1,721	0.4%
2-3 years	6,414	2.5%	3,474	1.3%	1,969	0.8%	1,123	0.4%	858	0.3%
3-4 years	3,226	2.2%	1,771	1.2%	932	0.6%	518	0.3%	210	0.1%
4-5 years	1,754	2.0%	885	1.0%	491	0.6%	143	0.2%	30	0.0%
5-6 years	920	1.8%	469	0.9%	153	0.3%	*****	*****	*****	*****
6-7 years	472	1.6%	120	0.4%	12	0.0%	*****	*****	*****	*****
7+ years	2,203	6.9%	237	0.7%	153	0.5%	76	0.2%	24	0.1%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	915	2.5%	582	1.6%	370	1.0%	259	0.7%	224	0.6%
1-2 years	169	2.8%	114	1.9%	76	1.2%	44	0.7%	26	0.4%
2-3 years	90	3.4%	49	1.8%	29	1.1%	*****	*****	*****	*****
3-4 years	13	1.1%	17	1.4%	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,715	1.5%	1,746	1.0%	1,019	0.6%	637	0.4%	610	0.3%
1-2 years	862	2.2%	511	1.3%	327	0.8%	189	0.5%	163	0.4%
2-3 years	492	2.8%	285	1.6%	199	1.1%	114	0.6%	106	0.6%
3-4 years	206	2.4%	139	1.7%	98	1.2%	57	0.7%	34	0.4%
4-5 years	78	2.0%	52	1.3%	30	0.8%	*****	*****	*****	*****
5-6 years	47	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	65	6.9%	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0-1 years	707	2.4%	483	1.7%	332	1.1%	201	0.7%	146	0.5%
1-2 years	150	2.7%	112	2.0%	54	1.0%	27	0.5%	24	0.4%
2-3 years	100	3.9%	40	1.6%	29	1.1%	*****	*****	*****	*****
3-4 years	31	2.6%	15	1.2%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	11	3.2%	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,136	1.4%	1,343	0.9%	902	0.6%	509	0.3%	484	0.3%
1-2 years	748	2.0%	458	1.2%	244	0.7%	143	0.4%	158	0.4%
2-3 years	439	2.6%	227	1.4%	148	0.9%	74	0.4%	55	0.3%
3-4 years	177	2.1%	100	1.2%	71	0.9%	34	0.4%	11	0.1%
4-5 years	79	1.8%	53	1.2%	*****	*****	*****	*****	*****	*****
5-6 years	72	3.1%	27	1.2%	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	84	7.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	19,867	2.3%	12,307	1.4%	7,798	0.9%	4,484	0.5%	3,516	0.4%
1-2 years	4,615	2.3%	2,395	1.2%	1,403	0.7%	663	0.3%	463	0.2%
2-3 years	2,503	2.5%	1,284	1.3%	652	0.6%	316	0.3%	159	0.2%
3-4 years	1,056	1.9%	517	0.9%	252	0.5%	85	0.2%	34	0.1%
4-5 years	467	1.6%	188	0.6%	75	0.3%	*****	*****	*****	*****
5-6 years	225	1.4%	62	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	79	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	192	3.1%	44	0.7%	22	0.4%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	26,437	1.8%	16,743	1.1%	10,675	0.7%	6,471	0.4%	5,800	0.4%
1-2 years	9,679	2.0%	5,515	1.2%	3,220	0.7%	1,818	0.4%	1,721	0.4%
2-3 years	6,414	2.5%	3,474	1.3%	1,969	0.8%	1,123	0.4%	858	0.3%
3-4 years	3,226	2.2%	1,771	1.2%	932	0.6%	518	0.3%	210	0.1%
4-5 years	1,754	2.0%	885	1.0%	491	0.6%	143	0.2%	30	0.0%
5-6 years	920	1.8%	469	0.9%	153	0.3%	*****	*****	*****	*****
6-7 years	472	1.6%	120	0.4%	12	0.0%	*****	*****	*****	*****
7+ years	2,203	6.9%	237	0.7%	153	0.5%	76	0.2%	24	0.1%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	915	2.5%	582	1.6%	370	1.0%	259	0.7%	224	0.6%
1-2 years	169	2.8%	114	1.9%	76	1.2%	44	0.7%	26	0.4%
2-3 years	90	3.4%	49	1.8%	29	1.1%	*****	*****	*****	*****
3-4 years	13	1.1%	17	1.4%	*****	*****	*****	*****	0	0.0%
4-5 years	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
5-6 years	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	2,715	1.5%	1,746	1.0%	1,019	0.6%	637	0.4%	610	0.3%
1-2 years	862	2.2%	511	1.3%	327	0.8%	189	0.5%	163	0.4%
2-3 years	492	2.8%	285	1.6%	199	1.1%	114	0.6%	106	0.6%
3-4 years	206	2.4%	139	1.7%	98	1.2%	57	0.7%	34	0.4%
4-5 years	78	2.0%	52	1.3%	30	0.8%	*****	*****	*****	*****
5-6 years	47	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	65	6.9%	*****	*****	*****	*****	*****	*****	*****	*****
Torsemide Users (Washout)										
0-1 years	707	2.4%	483	1.7%	332	1.1%	201	0.7%	146	0.5%
1-2 years	150	2.7%	112	2.0%	54	1.0%	27	0.5%	24	0.4%
2-3 years	100	3.9%	40	1.6%	29	1.1%	*****	*****	*****	*****
3-4 years	31	2.6%	15	1.2%	*****	*****	*****	*****	*****	*****
4-5 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
5-6 years	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
6-7 years	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	2,136	1.4%	1,343	0.9%	902	0.6%	509	0.3%	484	0.3%
1-2 years	748	2.0%	458	1.2%	244	0.7%	143	0.4%	158	0.4%
2-3 years	439	2.6%	227	1.4%	148	0.9%	74	0.4%	55	0.3%
3-4 years	177	2.1%	100	1.2%	71	0.9%	34	0.4%	11	0.1%
4-5 years	79	1.8%	53	1.2%	*****	*****	*****	*****	*****	*****
5-6 years	72	3.1%	27	1.2%	*****	*****	*****	*****	0	0.0%
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	84	7.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Furosemide Users (Washout)										
0-1 years	19,867	2.3%	12,307	1.4%	7,798	0.9%	4,484	0.5%	3,516	0.4%
1-2 years	4,615	2.3%	2,395	1.2%	1,403	0.7%	663	0.3%	463	0.2%
2-3 years	2,503	2.5%	1,284	1.3%	652	0.6%	316	0.3%	159	0.2%
3-4 years	1,056	1.9%	517	0.9%	252	0.5%	85	0.2%	34	0.1%
4-5 years	467	1.6%	188	0.6%	75	0.3%	*****	*****	*****	*****
5-6 years	225	1.4%	62	0.4%	*****	*****	*****	*****	*****	*****
6-7 years	79	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	192	3.1%	44	0.7%	22	0.4%	*****	*****	*****	*****
Furosemide Users (No Washout)										
0-1 years	26,437	1.8%	16,743	1.1%	10,675	0.7%	6,471	0.4%	5,800	0.4%
1-2 years	9,679	2.0%	5,515	1.2%	3,220	0.7%	1,818	0.4%	1,721	0.4%
2-3 years	6,414	2.5%	3,474	1.3%	1,969	0.8%	1,123	0.4%	858	0.3%
3-4 years	3,226	2.2%	1,771	1.2%	932	0.6%	518	0.3%	210	0.1%
4-5 years	1,754	2.0%	885	1.0%	491	0.6%	143	0.2%	30	0.0%
5-6 years	920	1.8%	469	0.9%	153	0.3%	*****	*****	*****	*****

Table 15c. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Evidence of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	472	1.6%	120	0.4%	12	0.0%	*****	*****	*****	*****
7+ years	2,203	6.9%	237	0.7%	153	0.5%	76	0.2%	24	0.1%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	34,692	26,260	75.7%	2,945	8.5%	2,049	5.9%
>0 - <700,000 ppm	*****	11,750	9,611	81.8%	1,190	10.1%	591	5.0%
700,000 - 1,000,000 ppm	*****	317	247	77.9%	41	12.9%	*****	*****
1,000,000 - 1,500,000 ppm	*****	189	136	72.0%	38	20.1%	*****	*****
1,500,000 - 2,000,000 ppm	*****	61	49	80.3%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	55	28	50.9%	13	23.6%	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	191,300	152,604	79.8%	14,405	7.5%	9,411	4.9%
>0 - <700,000 ppm	*****	54,941	46,758	85.1%	4,650	8.5%	2,283	4.2%
700,000 - 1,000,000 ppm	*****	2,005	1,612	80.4%	284	14.2%	73	3.6%
1,000,000 - 1,500,000 ppm	*****	1,343	1,021	76.0%	232	17.3%	72	5.4%
1,500,000 - 2,000,000 ppm	*****	481	375	78.0%	69	14.3%	*****	*****
≥ 2,000,000 ppm	*****	494	281	56.9%	123	24.9%	66	13.4%
Torsemide Users (Washout)								
0 ppm	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	34,692	26,260	75.7%	2,945	8.5%	2,049	5.9%
>0 - <700,000 ppm	*****	11,750	9,611	81.8%	1,190	10.1%	591	5.0%
700,000 - 1,000,000 ppm	*****	317	247	77.9%	41	12.9%	*****	*****
1,000,000 - 1,500,000 ppm	*****	189	136	72.0%	38	20.1%	*****	*****
1,500,000 - 2,000,000 ppm	*****	61	49	80.3%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	55	28	50.9%	13	23.6%	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	191,300	152,604	79.8%	14,405	7.5%	9,411	4.9%
>0 - <700,000 ppm	*****	54,941	46,758	85.1%	4,650	8.5%	2,283	4.2%
700,000 - 1,000,000 ppm	*****	2,005	1,612	80.4%	284	14.2%	73	3.6%
1,000,000 - 1,500,000 ppm	*****	1,343	1,021	76.0%	232	17.3%	72	5.4%
1,500,000 - 2,000,000 ppm	*****	481	375	78.0%	69	14.3%	*****	*****
≥ 2,000,000 ppm	*****	494	281	56.9%	123	24.9%	66	13.4%

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	34,692	26,260	75.7%	2,945	8.5%	2,049	5.9%
>0 - <700,000 ppm	*****	11,750	9,611	81.8%	1,190	10.1%	591	5.0%
700,000 - 1,000,000 ppm	*****	317	247	77.9%	41	12.9%	*****	*****
1,000,000 - 1,500,000 ppm	*****	189	136	72.0%	38	20.1%	*****	*****
1,500,000 - 2,000,000 ppm	*****	61	49	80.3%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	55	28	50.9%	13	23.6%	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	191,300	152,604	79.8%	14,405	7.5%	9,411	4.9%
>0 - <700,000 ppm	*****	54,941	46,758	85.1%	4,650	8.5%	2,283	4.2%
700,000 - 1,000,000 ppm	*****	2,005	1,612	80.4%	284	14.2%	73	3.6%
1,000,000 - 1,500,000 ppm	*****	1,343	1,021	76.0%	232	17.3%	72	5.4%
1,500,000 - 2,000,000 ppm	*****	481	375	78.0%	69	14.3%	*****	*****
≥ 2,000,000 ppm	*****	494	281	56.9%	123	24.9%	66	13.4%
Torsemide Users (Washout)								
0 ppm	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	34,692	26,260	75.7%	2,945	8.5%	2,049	5.9%
>0 - <700,000 ppm	*****	11,750	9,611	81.8%	1,190	10.1%	591	5.0%
700,000 - 1,000,000 ppm	*****	317	247	77.9%	41	12.9%	*****	*****
1,000,000 - 1,500,000 ppm	*****	189	136	72.0%	38	20.1%	*****	*****
1,500,000 - 2,000,000 ppm	*****	61	49	80.3%	*****	*****	*****	*****
≥ 2,000,000 ppm	*****	55	28	50.9%	13	23.6%	*****	*****
Bumetanide Users (No Washout)								
0 ppm	*****	191,300	152,604	79.8%	14,405	7.5%	9,411	4.9%
>0 - <700,000 ppm	*****	54,941	46,758	85.1%	4,650	8.5%	2,283	4.2%
700,000 - 1,000,000 ppm	*****	2,005	1,612	80.4%	284	14.2%	73	3.6%
1,000,000 - 1,500,000 ppm	*****	1,343	1,021	76.0%	232	17.3%	72	5.4%
1,500,000 - 2,000,000 ppm	*****	481	375	78.0%	69	14.3%	*****	*****
≥ 2,000,000 ppm	*****	494	281	56.9%	123	24.9%	66	13.4%
Torsemide Users (Washout)								

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	172,362	39,732	29,584	74.5%	3,642	9.2%	2,424	6.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	225,539	178,344	79.1%	17,665	7.8%	11,078	4.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	1,293,555	937,001	72.4%	122,333	9.5%	84,829	6.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Evidence Of Death by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Evidence Of Death[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,542,879	1,773,225	69.7%	248,852	9.8%	174,464	6.9%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,325	3.8%	871	2.5%	573	1.7%	356	1.0%	313	0.9%
>0 - <700,000 ppm	241	2.1%	91	0.8%	25	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,905	3.1%	3,794	2.0%	2,335	1.2%	1,399	0.7%	1,447	0.8%
>0 - <700,000 ppm	842	1.5%	311	0.6%	96	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	24	4.9%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,325	3.8%	871	2.5%	573	1.7%	356	1.0%	313	0.9%
>0 - <700,000 ppm	241	2.1%	91	0.8%	25	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,905	3.1%	3,794	2.0%	2,335	1.2%	1,399	0.7%	1,447	0.8%
>0 - <700,000 ppm	842	1.5%	311	0.6%	96	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	24	4.9%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,325	3.8%	871	2.5%	573	1.7%	356	1.0%	313	0.9%
>0 - <700,000 ppm	241	2.1%	91	0.8%	25	0.2%	1	0.0%	0	0.0%

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,905	3.1%	3,794	2.0%	2,335	1.2%	1,399	0.7%	1,447	0.8%
>0 - <700,000 ppm	842	1.5%	311	0.6%	96	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	24	4.9%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,325	3.8%	871	2.5%	573	1.7%	356	1.0%	313	0.9%
>0 - <700,000 ppm	241	2.1%	91	0.8%	25	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	5,905	3.1%	3,794	2.0%	2,335	1.2%	1,399	0.7%	1,447	0.8%
>0 - <700,000 ppm	842	1.5%	311	0.6%	96	0.2%	1	0.0%	0	0.0%
700,000 - 1,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	24	4.9%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	1,577	4.0%	1,069	2.7%	717	1.8%	409	1.0%	310	0.8%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	7,114	3.2%	4,617	2.0%	2,956	1.3%	1,841	0.8%	1,924	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	58,546	4.5%	38,674	3.0%	25,058	1.9%	15,096	1.2%	12,018	0.9%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 15d. Summary of Time to End of At-Risk Period due to Evidence Of Death for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Evidence Of Death by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 ppm	122,144	4.8%	85,441	3.4%	58,029	2.3%	38,307	1.5%	42,417	1.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 16a. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	105,300	72,141	68.5%	10,060	9.6%	7,188	6.8%
Bumetanide Users (No Washout)	681,044	356,075	256,234	72.0%	31,392	8.8%	21,534	6.0%
Torsemide Users (Washout)	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
Torsemide Users (No Washout)	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
Furosemide Users (Washout)	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
Furosemide Users (No Washout)	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	105,300	72,141	68.5%	10,060	9.6%	7,188	6.8%
Bumetanide Users (No Washout)	681,044	356,075	256,234	72.0%	31,392	8.8%	21,534	6.0%
Torsemide Users (Washout)	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
Torsemide Users (No Washout)	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
Furosemide Users (Washout)	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
Furosemide Users (No Washout)	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	105,300	72,141	68.5%	10,060	9.6%	7,188	6.8%
Bumetanide Users (No Washout)	681,044	356,075	256,234	72.0%	31,392	8.8%	21,534	6.0%
Torsemide Users (Washout)	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
Torsemide Users (No Washout)	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
Furosemide Users (Washout)	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
Furosemide Users (No Washout)	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	105,300	72,141	68.5%	10,060	9.6%	7,188	6.8%
Bumetanide Users (No Washout)	681,044	356,075	256,234	72.0%	31,392	8.8%	21,534	6.0%
Torsemide Users (Washout)	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
Torsemide Users (No Washout)	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
Furosemide Users (Washout)	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
Furosemide Users (No Washout)	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%

Table 16a. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	5,049	4.8%	3,571	3.4%	2,417	2.3%	2,024	1.9%	2,850	2.7%
Bumetanide Users (No Washout)	14,487	4.1%	9,821	2.8%	6,968	2.0%	5,395	1.5%	10,244	2.9%
Torsemide Users (Washout)	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
Torsemide Users (No Washout)	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
Furosemide Users (Washout)	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
Furosemide Users (No Washout)	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
Bladder Cancer Outcome										
Bumetanide Users (Washout)	5,049	4.8%	3,571	3.4%	2,417	2.3%	2,024	1.9%	2,850	2.7%
Bumetanide Users (No Washout)	14,487	4.1%	9,821	2.8%	6,968	2.0%	5,395	1.5%	10,244	2.9%
Torsemide Users (Washout)	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
Torsemide Users (No Washout)	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
Furosemide Users (Washout)	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
Furosemide Users (No Washout)	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	5,049	4.8%	3,571	3.4%	2,417	2.3%	2,024	1.9%	2,850	2.7%
Bumetanide Users (No Washout)	14,487	4.1%	9,821	2.8%	6,968	2.0%	5,395	1.5%	10,244	2.9%
Torsemide Users (Washout)	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
Torsemide Users (No Washout)	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
Furosemide Users (Washout)	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
Furosemide Users (No Washout)	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	5,049	4.8%	3,571	3.4%	2,417	2.3%	2,024	1.9%	2,850	2.7%
Bumetanide Users (No Washout)	14,487	4.1%	9,821	2.8%	6,968	2.0%	5,395	1.5%	10,244	2.9%
Torsemide Users (Washout)	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
Torsemide Users (No Washout)	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
Furosemide Users (Washout)	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
Furosemide Users (No Washout)	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%

Table 16a. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	601	6,459	428.9	730.4
Bumetanide Users (No Washout)	0	0	0	485	6,568	388.8	721.0
Torsemide Users (Washout)	0	0	0	502	6,363	380.4	684.1
Torsemide Users (No Washout)	0	0	0	399	6,412	352.4	683.4
Furosemide Users (Washout)	0	0	0	705	6,567	477.8	766.8
Furosemide Users (No Washout)	0	0	0	729	6,576	508.4	825.4
Bladder Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	601	6,459	428.9	730.4
Bumetanide Users (No Washout)	0	0	0	485	6,568	388.8	721.0
Torsemide Users (Washout)	0	0	0	502	6,363	380.4	684.1
Torsemide Users (No Washout)	0	0	0	399	6,412	352.4	683.4
Furosemide Users (Washout)	0	0	0	705	6,567	477.8	766.8
Furosemide Users (No Washout)	0	0	0	729	6,576	508.4	825.4
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	601	6,459	428.9	730.4
Bumetanide Users (No Washout)	0	0	0	485	6,568	388.8	721.0
Torsemide Users (Washout)	0	0	0	502	6,363	380.4	684.1
Torsemide Users (No Washout)	0	0	0	399	6,412	352.4	683.4
Furosemide Users (Washout)	0	0	0	705	6,567	477.8	766.8
Furosemide Users (No Washout)	0	0	0	729	6,576	508.4	825.4

Table 16a. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	0	0	0	601	6,459	428.9	730.4
Bumetanide Users (No Washout)	0	0	0	485	6,568	388.8	721.0
Torsemide Users (Washout)	0	0	0	502	6,363	380.4	684.1
Torsemide Users (No Washout)	0	0	0	399	6,412	352.4	683.4
Furosemide Users (Washout)	0	0	0	705	6,567	477.8	766.8
Furosemide Users (No Washout)	0	0	0	729	6,576	508.4	825.4

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	77,075	57,791	75.0%	5,992	7.8%	4,145	5.4%
30,000 - <60,000 mg	*****	12,560	9,204	73.3%	1,411	11.2%	736	5.9%
60,000 - <90,000 mg	*****	5,878	4,304	73.2%	780	13.3%	314	5.3%
90,000 - <120,000 mg	*****	3,118	2,388	76.6%	349	11.2%	162	5.2%
120,000 - <150,000 mg	*****	2,028	1,567	77.3%	241	11.9%	93	4.6%
150,000 - <180,000 mg	*****	1,322	1,080	81.7%	138	10.4%	39	3.0%
180,000 - <210,000 mg	*****	860	684	79.5%	89	10.3%	40	4.7%
≥ 210,000 mg	*****	2,459	965	39.2%	564	22.9%	371	15.1%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	205,050	166,512	81.2%	12,548	6.1%	8,410	4.1%
30,000 - <60,000 mg	304,791	54,203	43,945	81.1%	4,199	7.7%	2,187	4.0%
60,000 - <90,000 mg	201,271	29,192	23,211	79.5%	2,758	9.4%	1,185	4.1%
90,000 - <120,000 mg	141,898	18,090	14,689	81.2%	1,568	8.7%	681	3.8%
120,000 - <150,000 mg	104,735	12,138	9,770	80.5%	1,107	9.1%	492	4.1%
150,000 - <180,000 mg	*****	8,500	7,036	82.8%	667	7.8%	274	3.2%
180,000 - <210,000 mg	*****	6,082	4,999	82.2%	509	8.4%	216	3.6%
≥ 210,000 mg	47,345	22,820	9,043	39.6%	4,895	21.5%	3,079	13.5%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	85,638	66,676	77.9%	6,532	7.6%	4,170	4.9%
30,000 - <60,000 mg	*****	12,720	9,059	71.2%	1,853	14.6%	755	5.9%
60,000 - <90,000 mg	*****	5,308	3,861	72.7%	800	15.1%	279	5.3%
90,000 - <120,000 mg	*****	2,614	1,999	76.5%	353	13.5%	105	4.0%
120,000 - <150,000 mg	*****	1,629	1,297	79.6%	204	12.5%	57	3.5%
150,000 - <180,000 mg	*****	929	756	81.4%	104	11.2%	36	3.9%
180,000 - <210,000 mg	*****	649	515	79.4%	70	10.8%	23	3.5%
≥ 210,000 mg	*****	1,884	871	46.2%	418	22.2%	249	13.2%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	224,674	187,990	83.7%	12,545	5.6%	8,089	3.6%
30,000 - <60,000 mg	297,231	57,452	46,221	80.5%	5,405	9.4%	2,314	4.0%
60,000 - <90,000 mg	191,137	29,491	23,620	80.1%	3,097	10.5%	1,095	3.7%
90,000 - <120,000 mg	132,972	17,556	14,438	82.2%	1,649	9.4%	561	3.2%
120,000 - <150,000 mg	97,900	11,844	9,828	83.0%	1,091	9.2%	373	3.1%
150,000 - <180,000 mg	73,732	7,831	6,633	84.7%	645	8.2%	236	3.0%
180,000 - <210,000 mg	57,843	5,738	4,848	84.5%	461	8.0%	171	3.0%
≥ 210,000 mg	46,087	22,464	10,154	45.2%	4,605	20.5%	2,768	12.3%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	2,734,480	1,956,337	71.5%	257,419	9.4%	169,614	6.2%
30,000 - <60,000 mg	664,489	228,717	114,164	49.9%	59,451	26.0%	26,715	11.7%
60,000 - <90,000 mg	230,504	72,175	40,749	56.5%	19,438	26.9%	6,667	9.2%
90,000 - <120,000 mg	97,370	28,830	17,973	62.3%	7,162	24.8%	2,151	7.5%
120,000 - <150,000 mg	46,460	13,174	9,092	69.0%	2,858	21.7%	726	5.5%
150,000 - <180,000 mg	24,013	6,016	4,540	75.5%	994	16.5%	271	4.5%
180,000 - <210,000 mg	*****	3,143	2,420	77.0%	481	15.3%	139	4.4%
≥ 210,000 mg	*****	5,788	2,622	45.3%	1,522	26.3%	718	12.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	4,073,493	3,055,352	75.0%	346,028	8.5%	220,607	5.4%
30,000 - <60,000 mg	1,997,151	525,844	274,646	52.2%	126,723	24.1%	56,371	10.7%
60,000 - <90,000 mg	852,245	197,231	109,207	55.4%	50,271	25.5%	19,977	10.1%
90,000 - <120,000 mg	422,980	90,577	54,358	60.0%	22,442	24.8%	7,166	7.9%
120,000 - <150,000 mg	231,140	48,313	30,606	63.3%	11,455	23.7%	3,796	7.9%
150,000 - <180,000 mg	133,068	26,110	19,319	74.0%	4,371	16.7%	1,236	4.7%
180,000 - <210,000 mg	81,274	14,241	10,479	73.6%	2,393	16.8%	671	4.7%
≥ 210,000 mg	53,201	29,533	9,711	32.9%	7,143	24.2%	4,505	15.3%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	77,075	57,791	75.0%	5,992	7.8%	4,145	5.4%
30,000 - <60,000 mg	*****	12,560	9,204	73.3%	1,411	11.2%	736	5.9%
60,000 - <90,000 mg	*****	5,878	4,304	73.2%	780	13.3%	314	5.3%
90,000 - <120,000 mg	*****	3,118	2,388	76.6%	349	11.2%	162	5.2%
120,000 - <150,000 mg	*****	2,028	1,567	77.3%	241	11.9%	93	4.6%
150,000 - <180,000 mg	*****	1,322	1,080	81.7%	138	10.4%	39	3.0%
180,000 - <210,000 mg	*****	860	684	79.5%	89	10.3%	40	4.7%
≥ 210,000 mg	*****	2,459	965	39.2%	564	22.9%	371	15.1%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	205,050	166,512	81.2%	12,548	6.1%	8,410	4.1%
30,000 - <60,000 mg	304,791	54,203	43,945	81.1%	4,199	7.7%	2,187	4.0%
60,000 - <90,000 mg	201,271	29,192	23,211	79.5%	2,758	9.4%	1,185	4.1%
90,000 - <120,000 mg	141,898	18,090	14,689	81.2%	1,568	8.7%	681	3.8%
120,000 - <150,000 mg	104,735	12,138	9,770	80.5%	1,107	9.1%	492	4.1%
150,000 - <180,000 mg	*****	8,500	7,036	82.8%	667	7.8%	274	3.2%
180,000 - <210,000 mg	*****	6,082	4,999	82.2%	509	8.4%	216	3.6%
≥ 210,000 mg	47,345	22,820	9,043	39.6%	4,895	21.5%	3,079	13.5%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	85,638	66,676	77.9%	6,532	7.6%	4,170	4.9%
30,000 - <60,000 mg	*****	12,720	9,059	71.2%	1,853	14.6%	755	5.9%
60,000 - <90,000 mg	*****	5,308	3,861	72.7%	800	15.1%	279	5.3%
90,000 - <120,000 mg	*****	2,614	1,999	76.5%	353	13.5%	105	4.0%
120,000 - <150,000 mg	*****	1,629	1,297	79.6%	204	12.5%	57	3.5%
150,000 - <180,000 mg	*****	929	756	81.4%	104	11.2%	36	3.9%
180,000 - <210,000 mg	*****	649	515	79.4%	70	10.8%	23	3.5%
≥ 210,000 mg	*****	1,884	871	46.2%	418	22.2%	249	13.2%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	224,674	187,990	83.7%	12,545	5.6%	8,089	3.6%
30,000 - <60,000 mg	297,231	57,452	46,221	80.5%	5,405	9.4%	2,314	4.0%
60,000 - <90,000 mg	191,137	29,491	23,620	80.1%	3,097	10.5%	1,095	3.7%
90,000 - <120,000 mg	132,972	17,556	14,438	82.2%	1,649	9.4%	561	3.2%
120,000 - <150,000 mg	97,900	11,844	9,828	83.0%	1,091	9.2%	373	3.1%
150,000 - <180,000 mg	73,732	7,831	6,633	84.7%	645	8.2%	236	3.0%
180,000 - <210,000 mg	57,843	5,738	4,848	84.5%	461	8.0%	171	3.0%
≥ 210,000 mg	46,087	22,464	10,154	45.2%	4,605	20.5%	2,768	12.3%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	2,734,480	1,956,337	71.5%	257,419	9.4%	169,614	6.2%
30,000 - <60,000 mg	664,489	228,717	114,164	49.9%	59,451	26.0%	26,715	11.7%
60,000 - <90,000 mg	230,504	72,175	40,749	56.5%	19,438	26.9%	6,667	9.2%
90,000 - <120,000 mg	97,370	28,830	17,973	62.3%	7,162	24.8%	2,151	7.5%
120,000 - <150,000 mg	46,460	13,174	9,092	69.0%	2,858	21.7%	726	5.5%
150,000 - <180,000 mg	24,013	6,016	4,540	75.5%	994	16.5%	271	4.5%
180,000 - <210,000 mg	*****	3,143	2,420	77.0%	481	15.3%	139	4.4%
≥ 210,000 mg	*****	5,788	2,622	45.3%	1,522	26.3%	718	12.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	4,073,493	3,055,352	75.0%	346,028	8.5%	220,607	5.4%
30,000 - <60,000 mg	1,997,151	525,844	274,646	52.2%	126,723	24.1%	56,371	10.7%
60,000 - <90,000 mg	852,245	197,231	109,207	55.4%	50,271	25.5%	19,977	10.1%
90,000 - <120,000 mg	422,980	90,577	54,358	60.0%	22,442	24.8%	7,166	7.9%
120,000 - <150,000 mg	231,140	48,313	30,606	63.3%	11,455	23.7%	3,796	7.9%
150,000 - <180,000 mg	133,068	26,110	19,319	74.0%	4,371	16.7%	1,236	4.7%
180,000 - <210,000 mg	81,274	14,241	10,479	73.6%	2,393	16.8%	671	4.7%
≥ 210,000 mg	53,201	29,533	9,711	32.9%	7,143	24.2%	4,505	15.3%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	77,075	57,791	75.0%	5,992	7.8%	4,145	5.4%
30,000 - <60,000 mg	*****	12,560	9,204	73.3%	1,411	11.2%	736	5.9%
60,000 - <90,000 mg	*****	5,878	4,304	73.2%	780	13.3%	314	5.3%
90,000 - <120,000 mg	*****	3,118	2,388	76.6%	349	11.2%	162	5.2%
120,000 - <150,000 mg	*****	2,028	1,567	77.3%	241	11.9%	93	4.6%
150,000 - <180,000 mg	*****	1,322	1,080	81.7%	138	10.4%	39	3.0%
180,000 - <210,000 mg	*****	860	684	79.5%	89	10.3%	40	4.7%
≥ 210,000 mg	*****	2,459	965	39.2%	564	22.9%	371	15.1%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	205,050	166,512	81.2%	12,548	6.1%	8,410	4.1%
30,000 - <60,000 mg	304,791	54,203	43,945	81.1%	4,199	7.7%	2,187	4.0%
60,000 - <90,000 mg	201,271	29,192	23,211	79.5%	2,758	9.4%	1,185	4.1%
90,000 - <120,000 mg	141,898	18,090	14,689	81.2%	1,568	8.7%	681	3.8%
120,000 - <150,000 mg	104,735	12,138	9,770	80.5%	1,107	9.1%	492	4.1%
150,000 - <180,000 mg	*****	8,500	7,036	82.8%	667	7.8%	274	3.2%
180,000 - <210,000 mg	*****	6,082	4,999	82.2%	509	8.4%	216	3.6%
≥ 210,000 mg	47,345	22,820	9,043	39.6%	4,895	21.5%	3,079	13.5%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	85,638	66,676	77.9%	6,532	7.6%	4,170	4.9%
30,000 - <60,000 mg	*****	12,720	9,059	71.2%	1,853	14.6%	755	5.9%
60,000 - <90,000 mg	*****	5,308	3,861	72.7%	800	15.1%	279	5.3%
90,000 - <120,000 mg	*****	2,614	1,999	76.5%	353	13.5%	105	4.0%
120,000 - <150,000 mg	*****	1,629	1,297	79.6%	204	12.5%	57	3.5%
150,000 - <180,000 mg	*****	929	756	81.4%	104	11.2%	36	3.9%
180,000 - <210,000 mg	*****	649	515	79.4%	70	10.8%	23	3.5%
≥ 210,000 mg	*****	1,884	871	46.2%	418	22.2%	249	13.2%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	224,674	187,990	83.7%	12,545	5.6%	8,089	3.6%
30,000 - <60,000 mg	297,231	57,452	46,221	80.5%	5,405	9.4%	2,314	4.0%
60,000 - <90,000 mg	191,137	29,491	23,620	80.1%	3,097	10.5%	1,095	3.7%
90,000 - <120,000 mg	132,972	17,556	14,438	82.2%	1,649	9.4%	561	3.2%
120,000 - <150,000 mg	97,900	11,844	9,828	83.0%	1,091	9.2%	373	3.1%
150,000 - <180,000 mg	73,732	7,831	6,633	84.7%	645	8.2%	236	3.0%
180,000 - <210,000 mg	57,843	5,738	4,848	84.5%	461	8.0%	171	3.0%
≥ 210,000 mg	46,087	22,464	10,154	45.2%	4,605	20.5%	2,768	12.3%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	2,734,480	1,956,337	71.5%	257,419	9.4%	169,614	6.2%
30,000 - <60,000 mg	664,489	228,717	114,164	49.9%	59,451	26.0%	26,715	11.7%
60,000 - <90,000 mg	230,504	72,175	40,749	56.5%	19,438	26.9%	6,667	9.2%
90,000 - <120,000 mg	97,370	28,830	17,973	62.3%	7,162	24.8%	2,151	7.5%
120,000 - <150,000 mg	46,460	13,174	9,092	69.0%	2,858	21.7%	726	5.5%
150,000 - <180,000 mg	24,013	6,016	4,540	75.5%	994	16.5%	271	4.5%
180,000 - <210,000 mg	*****	3,143	2,420	77.0%	481	15.3%	139	4.4%
≥ 210,000 mg	*****	5,788	2,622	45.3%	1,522	26.3%	718	12.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	4,073,493	3,055,352	75.0%	346,028	8.5%	220,607	5.4%
30,000 - <60,000 mg	1,997,151	525,844	274,646	52.2%	126,723	24.1%	56,371	10.7%
60,000 - <90,000 mg	852,245	197,231	109,207	55.4%	50,271	25.5%	19,977	10.1%
90,000 - <120,000 mg	422,980	90,577	54,358	60.0%	22,442	24.8%	7,166	7.9%
120,000 - <150,000 mg	231,140	48,313	30,606	63.3%	11,455	23.7%	3,796	7.9%
150,000 - <180,000 mg	133,068	26,110	19,319	74.0%	4,371	16.7%	1,236	4.7%
180,000 - <210,000 mg	81,274	14,241	10,479	73.6%	2,393	16.8%	671	4.7%
≥ 210,000 mg	53,201	29,533	9,711	32.9%	7,143	24.2%	4,505	15.3%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	77,075	57,791	75.0%	5,992	7.8%	4,145	5.4%
30,000 - <60,000 mg	*****	12,560	9,204	73.3%	1,411	11.2%	736	5.9%
60,000 - <90,000 mg	*****	5,878	4,304	73.2%	780	13.3%	314	5.3%
90,000 - <120,000 mg	*****	3,118	2,388	76.6%	349	11.2%	162	5.2%
120,000 - <150,000 mg	*****	2,028	1,567	77.3%	241	11.9%	93	4.6%
150,000 - <180,000 mg	*****	1,322	1,080	81.7%	138	10.4%	39	3.0%
180,000 - <210,000 mg	*****	860	684	79.5%	89	10.3%	40	4.7%
≥ 210,000 mg	*****	2,459	965	39.2%	564	22.9%	371	15.1%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	205,050	166,512	81.2%	12,548	6.1%	8,410	4.1%
30,000 - <60,000 mg	304,791	54,203	43,945	81.1%	4,199	7.7%	2,187	4.0%
60,000 - <90,000 mg	201,271	29,192	23,211	79.5%	2,758	9.4%	1,185	4.1%
90,000 - <120,000 mg	141,898	18,090	14,689	81.2%	1,568	8.7%	681	3.8%
120,000 - <150,000 mg	104,735	12,138	9,770	80.5%	1,107	9.1%	492	4.1%
150,000 - <180,000 mg	*****	8,500	7,036	82.8%	667	7.8%	274	3.2%
180,000 - <210,000 mg	*****	6,082	4,999	82.2%	509	8.4%	216	3.6%
≥ 210,000 mg	47,345	22,820	9,043	39.6%	4,895	21.5%	3,079	13.5%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	85,638	66,676	77.9%	6,532	7.6%	4,170	4.9%
30,000 - <60,000 mg	*****	12,720	9,059	71.2%	1,853	14.6%	755	5.9%
60,000 - <90,000 mg	*****	5,308	3,861	72.7%	800	15.1%	279	5.3%
90,000 - <120,000 mg	*****	2,614	1,999	76.5%	353	13.5%	105	4.0%
120,000 - <150,000 mg	*****	1,629	1,297	79.6%	204	12.5%	57	3.5%
150,000 - <180,000 mg	*****	929	756	81.4%	104	11.2%	36	3.9%
180,000 - <210,000 mg	*****	649	515	79.4%	70	10.8%	23	3.5%
≥ 210,000 mg	*****	1,884	871	46.2%	418	22.2%	249	13.2%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	224,674	187,990	83.7%	12,545	5.6%	8,089	3.6%
30,000 - <60,000 mg	297,231	57,452	46,221	80.5%	5,405	9.4%	2,314	4.0%
60,000 - <90,000 mg	191,137	29,491	23,620	80.1%	3,097	10.5%	1,095	3.7%
90,000 - <120,000 mg	132,972	17,556	14,438	82.2%	1,649	9.4%	561	3.2%
120,000 - <150,000 mg	97,900	11,844	9,828	83.0%	1,091	9.2%	373	3.1%
150,000 - <180,000 mg	73,732	7,831	6,633	84.7%	645	8.2%	236	3.0%
180,000 - <210,000 mg	57,843	5,738	4,848	84.5%	461	8.0%	171	3.0%
≥ 210,000 mg	46,087	22,464	10,154	45.2%	4,605	20.5%	2,768	12.3%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	2,734,480	1,956,337	71.5%	257,419	9.4%	169,614	6.2%
30,000 - <60,000 mg	664,489	228,717	114,164	49.9%	59,451	26.0%	26,715	11.7%
60,000 - <90,000 mg	230,504	72,175	40,749	56.5%	19,438	26.9%	6,667	9.2%
90,000 - <120,000 mg	97,370	28,830	17,973	62.3%	7,162	24.8%	2,151	7.5%
120,000 - <150,000 mg	46,460	13,174	9,092	69.0%	2,858	21.7%	726	5.5%
150,000 - <180,000 mg	24,013	6,016	4,540	75.5%	994	16.5%	271	4.5%
180,000 - <210,000 mg	*****	3,143	2,420	77.0%	481	15.3%	139	4.4%
≥ 210,000 mg	*****	5,788	2,622	45.3%	1,522	26.3%	718	12.4%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	4,073,493	3,055,352	75.0%	346,028	8.5%	220,607	5.4%
30,000 - <60,000 mg	1,997,151	525,844	274,646	52.2%	126,723	24.1%	56,371	10.7%
60,000 - <90,000 mg	852,245	197,231	109,207	55.4%	50,271	25.5%	19,977	10.1%
90,000 - <120,000 mg	422,980	90,577	54,358	60.0%	22,442	24.8%	7,166	7.9%
120,000 - <150,000 mg	231,140	48,313	30,606	63.3%	11,455	23.7%	3,796	7.9%
150,000 - <180,000 mg	133,068	26,110	19,319	74.0%	4,371	16.7%	1,236	4.7%
180,000 - <210,000 mg	81,274	14,241	10,479	73.6%	2,393	16.8%	671	4.7%
≥ 210,000 mg	53,201	29,533	9,711	32.9%	7,143	24.2%	4,505	15.3%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	2,901	3.8%	2,021	2.6%	1,376	1.8%	1,178	1.5%	1,671	2.2%
30,000 - <60,000 mg	452	3.6%	262	2.1%	186	1.5%	142	1.1%	167	1.3%
60,000 - <90,000 mg	184	3.1%	103	1.8%	80	1.4%	45	0.8%	68	1.2%
90,000 - <120,000 mg	93	3.0%	58	1.9%	28	0.9%	14	0.4%	26	0.8%
120,000 - <150,000 mg	42	2.1%	34	1.7%	22	1.1%	17	0.8%	12	0.6%
150,000 - <180,000 mg	17	1.3%	17	1.3%	*****	*****	*****	*****	13	1.0%
180,000 - <210,000 mg	23	2.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	245	10.0%	132	5.4%	95	3.9%	55	2.2%	32	1.3%
Bumetanide Users (No Washout)										
0 - <30,000 mg	5,631	2.7%	3,803	1.9%	2,650	1.3%	2,151	1.0%	3,345	1.6%
30,000 - <60,000 mg	1,300	2.4%	831	1.5%	544	1.0%	459	0.8%	738	1.4%
60,000 - <90,000 mg	684	2.3%	422	1.4%	306	1.0%	232	0.8%	394	1.3%
90,000 - <120,000 mg	368	2.0%	259	1.4%	162	0.9%	121	0.7%	242	1.3%
120,000 - <150,000 mg	253	2.1%	172	1.4%	111	0.9%	97	0.8%	136	1.1%
150,000 - <180,000 mg	174	2.0%	106	1.2%	82	1.0%	52	0.6%	109	1.3%
180,000 - <210,000 mg	133	2.2%	84	1.4%	43	0.7%	33	0.5%	65	1.1%
≥ 210,000 mg	2,112	9.3%	1,241	5.4%	895	3.9%	670	2.9%	885	3.9%
Torsemide Users (Washout)										
0 - <30,000 mg	2,622	3.1%	1,947	2.3%	1,361	1.6%	929	1.1%	1,401	1.6%
30,000 - <60,000 mg	419	3.3%	256	2.0%	158	1.2%	106	0.8%	114	0.9%
60,000 - <90,000 mg	149	2.8%	92	1.7%	52	1.0%	40	0.8%	35	0.7%
90,000 - <120,000 mg	69	2.6%	35	1.3%	24	0.9%	14	0.5%	15	0.6%
120,000 - <150,000 mg	25	1.5%	21	1.3%	12	0.7%	*****	*****	*****	*****
150,000 - <180,000 mg	17	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	25	3.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	145	7.7%	92	4.9%	55	2.9%	35	1.9%	19	1.0%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	5,170	2.3%	3,577	1.6%	2,644	1.2%	1,697	0.8%	2,962	1.3%
30,000 - <60,000 mg	1,263	2.2%	815	1.4%	551	1.0%	339	0.6%	544	0.9%
60,000 - <90,000 mg	611	2.1%	354	1.2%	272	0.9%	178	0.6%	264	0.9%
90,000 - <120,000 mg	349	2.0%	225	1.3%	122	0.7%	91	0.5%	121	0.7%
120,000 - <150,000 mg	205	1.7%	130	1.1%	92	0.8%	65	0.5%	60	0.5%
150,000 - <180,000 mg	126	1.6%	71	0.9%	50	0.6%	29	0.4%	41	0.5%
180,000 - <210,000 mg	104	1.8%	62	1.1%	43	0.7%	20	0.3%	29	0.5%
≥ 210,000 mg	1,923	8.6%	1,076	4.8%	739	3.3%	504	2.2%	695	3.1%
Furosemide Users (Washout)										
0 - <30,000 mg	114,117	4.2%	81,160	3.0%	57,457	2.1%	39,374	1.4%	59,002	2.2%
30,000 - <60,000 mg	13,775	6.0%	6,941	3.0%	3,708	1.6%	2,082	0.9%	1,881	0.8%
60,000 - <90,000 mg	2,717	3.8%	1,339	1.9%	694	1.0%	307	0.4%	264	0.4%
90,000 - <120,000 mg	871	3.0%	389	1.3%	142	0.5%	85	0.3%	57	0.2%
120,000 - <150,000 mg	253	1.9%	120	0.9%	69	0.5%	30	0.2%	26	0.2%
150,000 - <180,000 mg	120	2.0%	58	1.0%	17	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	45	1.4%	30	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	413	7.1%	238	4.1%	129	2.2%	71	1.2%	75	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	142,208	3.5%	100,228	2.5%	72,582	1.8%	49,460	1.2%	87,028	2.1%
30,000 - <60,000 mg	29,694	5.6%	15,390	2.9%	9,160	1.7%	6,678	1.3%	7,182	1.4%
60,000 - <90,000 mg	8,044	4.1%	4,118	2.1%	2,538	1.3%	1,791	0.9%	1,285	0.7%
90,000 - <120,000 mg	3,197	3.5%	1,925	2.1%	669	0.7%	409	0.5%	411	0.5%
120,000 - <150,000 mg	1,104	2.3%	593	1.2%	373	0.8%	236	0.5%	150	0.3%
150,000 - <180,000 mg	577	2.2%	310	1.2%	171	0.7%	58	0.2%	68	0.3%
180,000 - <210,000 mg	334	2.3%	205	1.4%	81	0.6%	42	0.3%	36	0.3%
≥ 210,000 mg	3,651	12.4%	1,644	5.6%	1,219	4.1%	847	2.9%	813	2.8%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	2,901	3.8%	2,021	2.6%	1,376	1.8%	1,178	1.5%	1,671	2.2%
30,000 - <60,000 mg	452	3.6%	262	2.1%	186	1.5%	142	1.1%	167	1.3%
60,000 - <90,000 mg	184	3.1%	103	1.8%	80	1.4%	45	0.8%	68	1.2%
90,000 - <120,000 mg	93	3.0%	58	1.9%	28	0.9%	14	0.4%	26	0.8%
120,000 - <150,000 mg	42	2.1%	34	1.7%	22	1.1%	17	0.8%	12	0.6%
150,000 - <180,000 mg	17	1.3%	17	1.3%	11	0.8%	*****	*****	*****	*****
180,000 - <210,000 mg	23	2.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	245	10.0%	132	5.4%	95	3.9%	55	2.2%	32	1.3%
Bumetanide Users (No Washout)										
0 - <30,000 mg	5,631	2.7%	3,803	1.9%	2,650	1.3%	2,151	1.0%	3,345	1.6%
30,000 - <60,000 mg	1,300	2.4%	831	1.5%	544	1.0%	459	0.8%	738	1.4%
60,000 - <90,000 mg	684	2.3%	422	1.4%	306	1.0%	232	0.8%	394	1.3%
90,000 - <120,000 mg	368	2.0%	259	1.4%	162	0.9%	121	0.7%	242	1.3%
120,000 - <150,000 mg	253	2.1%	172	1.4%	111	0.9%	97	0.8%	136	1.1%
150,000 - <180,000 mg	174	2.0%	106	1.2%	82	1.0%	52	0.6%	109	1.3%
180,000 - <210,000 mg	133	2.2%	84	1.4%	43	0.7%	33	0.5%	65	1.1%
≥ 210,000 mg	2,112	9.3%	1,241	5.4%	895	3.9%	670	2.9%	885	3.9%
Torsemide Users (Washout)										
0 - <30,000 mg	2,622	3.1%	1,947	2.3%	1,361	1.6%	929	1.1%	1,401	1.6%
30,000 - <60,000 mg	419	3.3%	256	2.0%	158	1.2%	106	0.8%	114	0.9%
60,000 - <90,000 mg	149	2.8%	92	1.7%	52	1.0%	40	0.8%	35	0.7%
90,000 - <120,000 mg	69	2.6%	35	1.3%	24	0.9%	14	0.5%	15	0.6%
120,000 - <150,000 mg	25	1.5%	21	1.3%	12	0.7%	*****	*****	*****	*****
150,000 - <180,000 mg	17	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	25	3.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	145	7.7%	92	4.9%	55	2.9%	35	1.9%	19	1.0%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	5,170	2.3%	3,577	1.6%	2,644	1.2%	1,697	0.8%	2,962	1.3%
30,000 - <60,000 mg	1,263	2.2%	815	1.4%	551	1.0%	339	0.6%	544	0.9%
60,000 - <90,000 mg	611	2.1%	354	1.2%	272	0.9%	178	0.6%	264	0.9%
90,000 - <120,000 mg	349	2.0%	225	1.3%	122	0.7%	91	0.5%	121	0.7%
120,000 - <150,000 mg	205	1.7%	130	1.1%	92	0.8%	65	0.5%	60	0.5%
150,000 - <180,000 mg	126	1.6%	71	0.9%	50	0.6%	29	0.4%	41	0.5%
180,000 - <210,000 mg	104	1.8%	62	1.1%	43	0.7%	20	0.3%	29	0.5%
≥ 210,000 mg	1,923	8.6%	1,076	4.8%	739	3.3%	504	2.2%	695	3.1%
Furosemide Users (Washout)										
0 - <30,000 mg	114,117	4.2%	81,160	3.0%	57,457	2.1%	39,374	1.4%	59,002	2.2%
30,000 - <60,000 mg	13,775	6.0%	6,941	3.0%	3,708	1.6%	2,082	0.9%	1,881	0.8%
60,000 - <90,000 mg	2,717	3.8%	1,339	1.9%	694	1.0%	307	0.4%	264	0.4%
90,000 - <120,000 mg	871	3.0%	389	1.3%	142	0.5%	85	0.3%	57	0.2%
120,000 - <150,000 mg	253	1.9%	120	0.9%	69	0.5%	30	0.2%	26	0.2%
150,000 - <180,000 mg	120	2.0%	58	1.0%	17	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	45	1.4%	30	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	413	7.1%	238	4.1%	129	2.2%	71	1.2%	75	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	142,208	3.5%	100,228	2.5%	72,582	1.8%	49,460	1.2%	87,028	2.1%
30,000 - <60,000 mg	29,694	5.6%	15,390	2.9%	9,160	1.7%	6,678	1.3%	7,182	1.4%
60,000 - <90,000 mg	8,044	4.1%	4,118	2.1%	2,538	1.3%	1,791	0.9%	1,285	0.7%
90,000 - <120,000 mg	3,197	3.5%	1,925	2.1%	669	0.7%	409	0.5%	411	0.5%
120,000 - <150,000 mg	1,104	2.3%	593	1.2%	373	0.8%	236	0.5%	150	0.3%
150,000 - <180,000 mg	577	2.2%	310	1.2%	171	0.7%	58	0.2%	68	0.3%
180,000 - <210,000 mg	334	2.3%	205	1.4%	81	0.6%	42	0.3%	36	0.3%
≥ 210,000 mg	3,651	12.4%	1,644	5.6%	1,219	4.1%	847	2.9%	813	2.8%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	2,901	3.8%	2,021	2.6%	1,376	1.8%	1,178	1.5%	1,671	2.2%
30,000 - <60,000 mg	452	3.6%	262	2.1%	186	1.5%	142	1.1%	167	1.3%
60,000 - <90,000 mg	184	3.1%	103	1.8%	80	1.4%	45	0.8%	68	1.2%
90,000 - <120,000 mg	93	3.0%	58	1.9%	28	0.9%	14	0.4%	26	0.8%
120,000 - <150,000 mg	42	2.1%	34	1.7%	22	1.1%	17	0.8%	12	0.6%
150,000 - <180,000 mg	17	1.3%	17	1.3%	11	0.8%	*****	*****	*****	*****
180,000 - <210,000 mg	23	2.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	245	10.0%	132	5.4%	95	3.9%	55	2.2%	32	1.3%
Bumetanide Users (No Washout)										
0 - <30,000 mg	5,631	2.7%	3,803	1.9%	2,650	1.3%	2,151	1.0%	3,345	1.6%
30,000 - <60,000 mg	1,300	2.4%	831	1.5%	544	1.0%	459	0.8%	738	1.4%
60,000 - <90,000 mg	684	2.3%	422	1.4%	306	1.0%	232	0.8%	394	1.3%
90,000 - <120,000 mg	368	2.0%	259	1.4%	162	0.9%	121	0.7%	242	1.3%
120,000 - <150,000 mg	253	2.1%	172	1.4%	111	0.9%	97	0.8%	136	1.1%
150,000 - <180,000 mg	174	2.0%	106	1.2%	82	1.0%	52	0.6%	109	1.3%
180,000 - <210,000 mg	133	2.2%	84	1.4%	43	0.7%	33	0.5%	65	1.1%
≥ 210,000 mg	2,112	9.3%	1,241	5.4%	895	3.9%	670	2.9%	885	3.9%
Torsemide Users (Washout)										
0 - <30,000 mg	2,622	3.1%	1,947	2.3%	1,361	1.6%	929	1.1%	1,401	1.6%
30,000 - <60,000 mg	419	3.3%	256	2.0%	158	1.2%	106	0.8%	114	0.9%
60,000 - <90,000 mg	149	2.8%	92	1.7%	52	1.0%	40	0.8%	35	0.7%
90,000 - <120,000 mg	69	2.6%	35	1.3%	24	0.9%	14	0.5%	15	0.6%
120,000 - <150,000 mg	25	1.5%	21	1.3%	12	0.7%	*****	*****	*****	*****
150,000 - <180,000 mg	17	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	25	3.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	145	7.7%	92	4.9%	55	2.9%	35	1.9%	19	1.0%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	5,170	2.3%	3,577	1.6%	2,644	1.2%	1,697	0.8%	2,962	1.3%
30,000 - <60,000 mg	1,263	2.2%	815	1.4%	551	1.0%	339	0.6%	544	0.9%
60,000 - <90,000 mg	611	2.1%	354	1.2%	272	0.9%	178	0.6%	264	0.9%
90,000 - <120,000 mg	349	2.0%	225	1.3%	122	0.7%	91	0.5%	121	0.7%
120,000 - <150,000 mg	205	1.7%	130	1.1%	92	0.8%	65	0.5%	60	0.5%
150,000 - <180,000 mg	126	1.6%	71	0.9%	50	0.6%	29	0.4%	41	0.5%
180,000 - <210,000 mg	104	1.8%	62	1.1%	43	0.7%	20	0.3%	29	0.5%
≥ 210,000 mg	1,923	8.6%	1,076	4.8%	739	3.3%	504	2.2%	695	3.1%
Furosemide Users (Washout)										
0 - <30,000 mg	114,117	4.2%	81,160	3.0%	57,457	2.1%	39,374	1.4%	59,002	2.2%
30,000 - <60,000 mg	13,775	6.0%	6,941	3.0%	3,708	1.6%	2,082	0.9%	1,881	0.8%
60,000 - <90,000 mg	2,717	3.8%	1,339	1.9%	694	1.0%	307	0.4%	264	0.4%
90,000 - <120,000 mg	871	3.0%	389	1.3%	142	0.5%	85	0.3%	57	0.2%
120,000 - <150,000 mg	253	1.9%	120	0.9%	69	0.5%	30	0.2%	26	0.2%
150,000 - <180,000 mg	120	2.0%	58	1.0%	17	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	45	1.4%	30	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	413	7.1%	238	4.1%	129	2.2%	71	1.2%	75	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	142,208	3.5%	100,228	2.5%	72,582	1.8%	49,460	1.2%	87,028	2.1%
30,000 - <60,000 mg	29,694	5.6%	15,390	2.9%	9,160	1.7%	6,678	1.3%	7,182	1.4%
60,000 - <90,000 mg	8,044	4.1%	4,118	2.1%	2,538	1.3%	1,791	0.9%	1,285	0.7%
90,000 - <120,000 mg	3,197	3.5%	1,925	2.1%	669	0.7%	409	0.5%	411	0.5%
120,000 - <150,000 mg	1,104	2.3%	593	1.2%	373	0.8%	236	0.5%	150	0.3%
150,000 - <180,000 mg	577	2.2%	310	1.2%	171	0.7%	58	0.2%	68	0.3%
180,000 - <210,000 mg	334	2.3%	205	1.4%	81	0.6%	42	0.3%	36	0.3%
≥ 210,000 mg	3,651	12.4%	1,644	5.6%	1,219	4.1%	847	2.9%	813	2.8%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	2,901	3.8%	2,021	2.6%	1,376	1.8%	1,178	1.5%	1,671	2.2%
30,000 - <60,000 mg	452	3.6%	262	2.1%	186	1.5%	142	1.1%	167	1.3%
60,000 - <90,000 mg	184	3.1%	103	1.8%	80	1.4%	45	0.8%	68	1.2%
90,000 - <120,000 mg	93	3.0%	58	1.9%	28	0.9%	14	0.4%	26	0.8%
120,000 - <150,000 mg	42	2.1%	34	1.7%	22	1.1%	17	0.8%	12	0.6%
150,000 - <180,000 mg	17	1.3%	17	1.3%	11	0.8%	*****	*****	*****	*****
180,000 - <210,000 mg	23	2.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	245	10.0%	132	5.4%	95	3.9%	55	2.2%	32	1.3%
Bumetanide Users (No Washout)										
0 - <30,000 mg	5,631	2.7%	3,803	1.9%	2,650	1.3%	2,151	1.0%	3,345	1.6%
30,000 - <60,000 mg	1,300	2.4%	831	1.5%	544	1.0%	459	0.8%	738	1.4%
60,000 - <90,000 mg	684	2.3%	422	1.4%	306	1.0%	232	0.8%	394	1.3%
90,000 - <120,000 mg	368	2.0%	259	1.4%	162	0.9%	121	0.7%	242	1.3%
120,000 - <150,000 mg	253	2.1%	172	1.4%	111	0.9%	97	0.8%	136	1.1%
150,000 - <180,000 mg	174	2.0%	106	1.2%	82	1.0%	52	0.6%	109	1.3%
180,000 - <210,000 mg	133	2.2%	84	1.4%	43	0.7%	33	0.5%	65	1.1%
≥ 210,000 mg	2,112	9.3%	1,241	5.4%	895	3.9%	670	2.9%	885	3.9%
Torsemide Users (Washout)										
0 - <30,000 mg	2,622	3.1%	1,947	2.3%	1,361	1.6%	929	1.1%	1,401	1.6%
30,000 - <60,000 mg	419	3.3%	256	2.0%	158	1.2%	106	0.8%	114	0.9%
60,000 - <90,000 mg	149	2.8%	92	1.7%	52	1.0%	40	0.8%	35	0.7%
90,000 - <120,000 mg	69	2.6%	35	1.3%	24	0.9%	14	0.5%	15	0.6%
120,000 - <150,000 mg	25	1.5%	21	1.3%	12	0.7%	*****	*****	*****	*****
150,000 - <180,000 mg	17	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	25	3.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	145	7.7%	92	4.9%	55	2.9%	35	1.9%	19	1.0%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	5,170	2.3%	3,577	1.6%	2,644	1.2%	1,697	0.8%	2,962	1.3%
30,000 - <60,000 mg	1,263	2.2%	815	1.4%	551	1.0%	339	0.6%	544	0.9%
60,000 - <90,000 mg	611	2.1%	354	1.2%	272	0.9%	178	0.6%	264	0.9%
90,000 - <120,000 mg	349	2.0%	225	1.3%	122	0.7%	91	0.5%	121	0.7%
120,000 - <150,000 mg	205	1.7%	130	1.1%	92	0.8%	65	0.5%	60	0.5%
150,000 - <180,000 mg	126	1.6%	71	0.9%	50	0.6%	29	0.4%	41	0.5%
180,000 - <210,000 mg	104	1.8%	62	1.1%	43	0.7%	20	0.3%	29	0.5%
≥ 210,000 mg	1,923	8.6%	1,076	4.8%	739	3.3%	504	2.2%	695	3.1%
Furosemide Users (Washout)										
0 - <30,000 mg	114,117	4.2%	81,160	3.0%	57,457	2.1%	39,374	1.4%	59,002	2.2%
30,000 - <60,000 mg	13,775	6.0%	6,941	3.0%	3,708	1.6%	2,082	0.9%	1,881	0.8%
60,000 - <90,000 mg	2,717	3.8%	1,339	1.9%	694	1.0%	307	0.4%	264	0.4%
90,000 - <120,000 mg	871	3.0%	389	1.3%	142	0.5%	85	0.3%	57	0.2%
120,000 - <150,000 mg	253	1.9%	120	0.9%	69	0.5%	30	0.2%	26	0.2%
150,000 - <180,000 mg	120	2.0%	58	1.0%	17	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	45	1.4%	30	1.0%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	413	7.1%	238	4.1%	129	2.2%	71	1.2%	75	1.3%
Furosemide Users (No Washout)										
0 - <30,000 mg	142,208	3.5%	100,228	2.5%	72,582	1.8%	49,460	1.2%	87,028	2.1%
30,000 - <60,000 mg	29,694	5.6%	15,390	2.9%	9,160	1.7%	6,678	1.3%	7,182	1.4%
60,000 - <90,000 mg	8,044	4.1%	4,118	2.1%	2,538	1.3%	1,791	0.9%	1,285	0.7%
90,000 - <120,000 mg	3,197	3.5%	1,925	2.1%	669	0.7%	409	0.5%	411	0.5%
120,000 - <150,000 mg	1,104	2.3%	593	1.2%	373	0.8%	236	0.5%	150	0.3%
150,000 - <180,000 mg	577	2.2%	310	1.2%	171	0.7%	58	0.2%	68	0.3%

Table 16b. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	334	2.3%	205	1.4%	81	0.6%	42	0.3%	36	0.3%
≥ 210,000 mg	3,651	12.4%	1,644	5.6%	1,219	4.1%	847	2.9%	813	2.8%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	81,068	61,244	75.5%	6,185	7.6%	4,291	5.3%
1-2 years	43,206	12,705	9,253	72.8%	1,470	11.6%	727	5.7%
2-3 years	*****	5,569	3,896	70.0%	844	15.2%	318	5.7%
3-4 years	*****	2,661	1,936	72.8%	412	15.5%	136	5.1%
4-5 years	*****	1,534	1,166	76.0%	214	14.0%	73	4.8%
5-6 years	*****	851	676	79.4%	110	12.9%	32	3.8%
6-7 years	*****	421	347	82.4%	51	12.1%	11	2.6%
7+ years	*****	491	202	41.1%	129	26.3%	101	20.6%
Bumetanide Users (No Washout)								
0-1 years	681,044	243,191	200,549	82.5%	13,997	5.8%	9,377	3.9%
1-2 years	231,141	56,441	44,707	79.2%	5,018	8.9%	2,440	4.3%
2-3 years	120,390	26,228	18,798	71.7%	3,799	14.5%	1,337	5.1%
3-4 years	60,491	13,027	9,543	73.3%	1,846	14.2%	564	4.3%
4-5 years	31,830	7,328	5,633	76.9%	916	12.5%	308	4.2%
5-6 years	*****	4,121	3,185	77.3%	519	12.6%	170	4.1%
6-7 years	*****	2,281	1,829	80.2%	263	11.5%	90	3.9%
7+ years	*****	3,458	1,181	34.2%	783	22.6%	681	19.7%
Torsemide Users (Washout)								
0-1 years	172,362	83,081	65,559	78.9%	5,921	7.1%	3,834	4.6%
1-2 years	*****	14,826	11,463	77.3%	1,508	10.2%	741	5.0%
2-3 years	*****	6,520	4,725	72.5%	1,002	15.4%	316	4.8%
3-4 years	*****	3,254	2,484	76.3%	436	13.4%	146	4.5%
4-5 years	*****	1,654	1,317	79.6%	202	12.2%	60	3.6%
5-6 years	*****	951	754	79.3%	117	12.3%	41	4.3%
6-7 years	*****	513	424	82.7%	65	12.7%	*****	*****
7+ years	*****	572	250	43.7%	163	28.5%	105	18.4%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,111	212,677	85.4%	12,432	5.0%	8,035	3.2%
1-2 years	249,185	64,009	52,823	82.5%	5,074	7.9%	2,348	3.7%
2-3 years	131,368	29,909	22,437	75.0%	4,224	14.1%	1,231	4.1%
3-4 years	66,841	14,849	11,412	76.9%	1,983	13.4%	575	3.9%
4-5 years	35,645	7,961	6,202	77.9%	987	12.4%	286	3.6%
5-6 years	*****	4,591	3,551	77.3%	562	12.2%	201	4.4%
6-7 years	*****	2,668	2,126	79.7%	339	12.7%	81	3.0%
7+ years	*****	3,952	1,373	34.7%	932	23.6%	738	18.7%
Furosemide Users (Washout)								
0-1 years	5,031,471	2,230,649	1,685,338	75.6%	175,030	7.8%	118,250	5.3%
1-2 years	1,570,858	403,089	297,341	73.8%	47,461	11.8%	23,545	5.8%
2-3 years	857,233	198,471	140,070	70.6%	31,541	15.9%	11,482	5.8%
3-4 years	462,012	109,450	81,545	74.5%	15,881	14.5%	5,329	4.9%
4-5 years	253,038	62,665	48,374	77.2%	8,388	13.4%	2,795	4.5%
5-6 years	138,456	37,904	30,049	79.3%	4,961	13.1%	1,452	3.8%
6-7 years	73,838	22,569	18,581	82.3%	2,606	11.5%	784	3.5%
7+ years	37,943	27,526	11,375	41.3%	7,876	28.6%	4,925	17.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,169,564	2,523,413	79.6%	207,561	6.5%	139,731	4.4%
1-2 years	3,756,719	790,290	612,493	77.5%	77,828	9.8%	38,484	4.9%
2-3 years	2,243,787	408,831	291,517	71.3%	62,569	15.3%	22,100	5.4%
3-4 years	1,290,390	238,235	176,398	74.0%	33,995	14.3%	11,110	4.7%
4-5 years	759,943	145,401	110,549	76.0%	19,111	13.1%	6,484	4.5%
5-6 years	451,504	90,940	69,512	76.4%	12,110	13.3%	4,062	4.5%
6-7 years	267,682	58,579	46,098	78.7%	7,385	12.6%	2,310	3.9%
7+ years	157,482	103,502	32,654	31.5%	24,288	23.5%	19,396	18.7%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	81,068	61,244	75.5%	6,185	7.6%	4,291	5.3%
1-2 years	43,206	12,705	9,253	72.8%	1,470	11.6%	727	5.7%
2-3 years	*****	5,569	3,896	70.0%	844	15.2%	318	5.7%
3-4 years	*****	2,661	1,936	72.8%	412	15.5%	136	5.1%
4-5 years	*****	1,534	1,166	76.0%	214	14.0%	73	4.8%
5-6 years	*****	851	676	79.4%	110	12.9%	32	3.8%
6-7 years	*****	421	347	82.4%	51	12.1%	11	2.6%
7+ years	*****	491	202	41.1%	129	26.3%	101	20.6%
Bumetanide Users (No Washout)								
0-1 years	681,044	243,191	200,549	82.5%	13,997	5.8%	9,377	3.9%
1-2 years	231,141	56,441	44,707	79.2%	5,018	8.9%	2,440	4.3%
2-3 years	120,390	26,228	18,798	71.7%	3,799	14.5%	1,337	5.1%
3-4 years	60,491	13,027	9,543	73.3%	1,846	14.2%	564	4.3%
4-5 years	31,830	7,328	5,633	76.9%	916	12.5%	308	4.2%
5-6 years	*****	4,121	3,185	77.3%	519	12.6%	170	4.1%
6-7 years	*****	2,281	1,829	80.2%	263	11.5%	90	3.9%
7+ years	*****	3,458	1,181	34.2%	783	22.6%	681	19.7%
Torsemide Users (Washout)								
0-1 years	172,362	83,081	65,559	78.9%	5,921	7.1%	3,834	4.6%
1-2 years	*****	14,826	11,463	77.3%	1,508	10.2%	741	5.0%
2-3 years	*****	6,520	4,725	72.5%	1,002	15.4%	316	4.8%
3-4 years	*****	3,254	2,484	76.3%	436	13.4%	146	4.5%
4-5 years	*****	1,654	1,317	79.6%	202	12.2%	60	3.6%
5-6 years	*****	951	754	79.3%	117	12.3%	41	4.3%
6-7 years	*****	513	424	82.7%	65	12.7%	*****	*****
7+ years	*****	572	250	43.7%	163	28.5%	105	18.4%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,111	212,677	85.4%	12,432	5.0%	8,035	3.2%
1-2 years	249,185	64,009	52,823	82.5%	5,074	7.9%	2,348	3.7%
2-3 years	131,368	29,909	22,437	75.0%	4,224	14.1%	1,231	4.1%
3-4 years	66,841	14,849	11,412	76.9%	1,983	13.4%	575	3.9%
4-5 years	35,645	7,961	6,202	77.9%	987	12.4%	286	3.6%
5-6 years	*****	4,591	3,551	77.3%	562	12.2%	201	4.4%
6-7 years	*****	2,668	2,126	79.7%	339	12.7%	81	3.0%
7+ years	*****	3,952	1,373	34.7%	932	23.6%	738	18.7%
Furosemide Users (Washout)								
0-1 years	5,031,471	2,230,649	1,685,338	75.6%	175,030	7.8%	118,250	5.3%
1-2 years	1,570,858	403,089	297,341	73.8%	47,461	11.8%	23,545	5.8%
2-3 years	857,233	198,471	140,070	70.6%	31,541	15.9%	11,482	5.8%
3-4 years	462,012	109,450	81,545	74.5%	15,881	14.5%	5,329	4.9%
4-5 years	253,038	62,665	48,374	77.2%	8,388	13.4%	2,795	4.5%
5-6 years	138,456	37,904	30,049	79.3%	4,961	13.1%	1,452	3.8%
6-7 years	73,838	22,569	18,581	82.3%	2,606	11.5%	784	3.5%
7+ years	37,943	27,526	11,375	41.3%	7,876	28.6%	4,925	17.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,169,564	2,523,413	79.6%	207,561	6.5%	139,731	4.4%
1-2 years	3,756,719	790,290	612,493	77.5%	77,828	9.8%	38,484	4.9%
2-3 years	2,243,787	408,831	291,517	71.3%	62,569	15.3%	22,100	5.4%
3-4 years	1,290,390	238,235	176,398	74.0%	33,995	14.3%	11,110	4.7%
4-5 years	759,943	145,401	110,549	76.0%	19,111	13.1%	6,484	4.5%
5-6 years	451,504	90,940	69,512	76.4%	12,110	13.3%	4,062	4.5%
6-7 years	267,682	58,579	46,098	78.7%	7,385	12.6%	2,310	3.9%
7+ years	157,482	103,502	32,654	31.5%	24,288	23.5%	19,396	18.7%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	81,068	61,244	75.5%	6,185	7.6%	4,291	5.3%
1-2 years	43,206	12,705	9,253	72.8%	1,470	11.6%	727	5.7%
2-3 years	*****	5,569	3,896	70.0%	844	15.2%	318	5.7%
3-4 years	*****	2,661	1,936	72.8%	412	15.5%	136	5.1%
4-5 years	*****	1,534	1,166	76.0%	214	14.0%	73	4.8%
5-6 years	*****	851	676	79.4%	110	12.9%	32	3.8%
6-7 years	*****	421	347	82.4%	51	12.1%	11	2.6%
7+ years	*****	491	202	41.1%	129	26.3%	101	20.6%
Bumetanide Users (No Washout)								
0-1 years	681,044	243,191	200,549	82.5%	13,997	5.8%	9,377	3.9%
1-2 years	231,141	56,441	44,707	79.2%	5,018	8.9%	2,440	4.3%
2-3 years	120,390	26,228	18,798	71.7%	3,799	14.5%	1,337	5.1%
3-4 years	60,491	13,027	9,543	73.3%	1,846	14.2%	564	4.3%
4-5 years	31,830	7,328	5,633	76.9%	916	12.5%	308	4.2%
5-6 years	*****	4,121	3,185	77.3%	519	12.6%	170	4.1%
6-7 years	*****	2,281	1,829	80.2%	263	11.5%	90	3.9%
7+ years	*****	3,458	1,181	34.2%	783	22.6%	681	19.7%
Torsemide Users (Washout)								
0-1 years	172,362	83,081	65,559	78.9%	5,921	7.1%	3,834	4.6%
1-2 years	*****	14,826	11,463	77.3%	1,508	10.2%	741	5.0%
2-3 years	*****	6,520	4,725	72.5%	1,002	15.4%	316	4.8%
3-4 years	*****	3,254	2,484	76.3%	436	13.4%	146	4.5%
4-5 years	*****	1,654	1,317	79.6%	202	12.2%	60	3.6%
5-6 years	*****	951	754	79.3%	117	12.3%	41	4.3%
6-7 years	*****	513	424	82.7%	65	12.7%	*****	*****
7+ years	*****	572	250	43.7%	163	28.5%	105	18.4%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,111	212,677	85.4%	12,432	5.0%	8,035	3.2%
1-2 years	249,185	64,009	52,823	82.5%	5,074	7.9%	2,348	3.7%
2-3 years	131,368	29,909	22,437	75.0%	4,224	14.1%	1,231	4.1%
3-4 years	66,841	14,849	11,412	76.9%	1,983	13.4%	575	3.9%
4-5 years	35,645	7,961	6,202	77.9%	987	12.4%	286	3.6%
5-6 years	*****	4,591	3,551	77.3%	562	12.2%	201	4.4%
6-7 years	*****	2,668	2,126	79.7%	339	12.7%	81	3.0%
7+ years	*****	3,952	1,373	34.7%	932	23.6%	738	18.7%
Furosemide Users (Washout)								
0-1 years	5,031,471	2,230,649	1,685,338	75.6%	175,030	7.8%	118,250	5.3%
1-2 years	1,570,858	403,089	297,341	73.8%	47,461	11.8%	23,545	5.8%
2-3 years	857,233	198,471	140,070	70.6%	31,541	15.9%	11,482	5.8%
3-4 years	462,012	109,450	81,545	74.5%	15,881	14.5%	5,329	4.9%
4-5 years	253,038	62,665	48,374	77.2%	8,388	13.4%	2,795	4.5%
5-6 years	138,456	37,904	30,049	79.3%	4,961	13.1%	1,452	3.8%
6-7 years	73,838	22,569	18,581	82.3%	2,606	11.5%	784	3.5%
7+ years	37,943	27,526	11,375	41.3%	7,876	28.6%	4,925	17.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,169,564	2,523,413	79.6%	207,561	6.5%	139,731	4.4%
1-2 years	3,756,719	790,290	612,493	77.5%	77,828	9.8%	38,484	4.9%
2-3 years	2,243,787	408,831	291,517	71.3%	62,569	15.3%	22,100	5.4%
3-4 years	1,290,390	238,235	176,398	74.0%	33,995	14.3%	11,110	4.7%
4-5 years	759,943	145,401	110,549	76.0%	19,111	13.1%	6,484	4.5%
5-6 years	451,504	90,940	69,512	76.4%	12,110	13.3%	4,062	4.5%
6-7 years	267,682	58,579	46,098	78.7%	7,385	12.6%	2,310	3.9%
7+ years	157,482	103,502	32,654	31.5%	24,288	23.5%	19,396	18.7%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	81,068	61,244	75.5%	6,185	7.6%	4,291	5.3%
1-2 years	43,206	12,705	9,253	72.8%	1,470	11.6%	727	5.7%
2-3 years	*****	5,569	3,896	70.0%	844	15.2%	318	5.7%
3-4 years	*****	2,661	1,936	72.8%	412	15.5%	136	5.1%
4-5 years	*****	1,534	1,166	76.0%	214	14.0%	73	4.8%
5-6 years	*****	851	676	79.4%	110	12.9%	32	3.8%
6-7 years	*****	421	347	82.4%	51	12.1%	11	2.6%
7+ years	*****	491	202	41.1%	129	26.3%	101	20.6%
Bumetanide Users (No Washout)								
0-1 years	681,044	243,191	200,549	82.5%	13,997	5.8%	9,377	3.9%
1-2 years	231,141	56,441	44,707	79.2%	5,018	8.9%	2,440	4.3%
2-3 years	120,390	26,228	18,798	71.7%	3,799	14.5%	1,337	5.1%
3-4 years	60,491	13,027	9,543	73.3%	1,846	14.2%	564	4.3%
4-5 years	31,830	7,328	5,633	76.9%	916	12.5%	308	4.2%
5-6 years	*****	4,121	3,185	77.3%	519	12.6%	170	4.1%
6-7 years	*****	2,281	1,829	80.2%	263	11.5%	90	3.9%
7+ years	*****	3,458	1,181	34.2%	783	22.6%	681	19.7%
Torsemide Users (Washout)								
0-1 years	172,362	83,081	65,559	78.9%	5,921	7.1%	3,834	4.6%
1-2 years	*****	14,826	11,463	77.3%	1,508	10.2%	741	5.0%
2-3 years	*****	6,520	4,725	72.5%	1,002	15.4%	316	4.8%
3-4 years	*****	3,254	2,484	76.3%	436	13.4%	146	4.5%
4-5 years	*****	1,654	1,317	79.6%	202	12.2%	60	3.6%
5-6 years	*****	951	754	79.3%	117	12.3%	41	4.3%
6-7 years	*****	513	424	82.7%	65	12.7%	*****	*****
7+ years	*****	572	250	43.7%	163	28.5%	105	18.4%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	249,111	212,677	85.4%	12,432	5.0%	8,035	3.2%
1-2 years	249,185	64,009	52,823	82.5%	5,074	7.9%	2,348	3.7%
2-3 years	131,368	29,909	22,437	75.0%	4,224	14.1%	1,231	4.1%
3-4 years	66,841	14,849	11,412	76.9%	1,983	13.4%	575	3.9%
4-5 years	35,645	7,961	6,202	77.9%	987	12.4%	286	3.6%
5-6 years	*****	4,591	3,551	77.3%	562	12.2%	201	4.4%
6-7 years	*****	2,668	2,126	79.7%	339	12.7%	81	3.0%
7+ years	*****	3,952	1,373	34.7%	932	23.6%	738	18.7%
Furosemide Users (Washout)								
0-1 years	5,031,471	2,230,649	1,685,338	75.6%	175,030	7.8%	118,250	5.3%
1-2 years	1,570,858	403,089	297,341	73.8%	47,461	11.8%	23,545	5.8%
2-3 years	857,233	198,471	140,070	70.6%	31,541	15.9%	11,482	5.8%
3-4 years	462,012	109,450	81,545	74.5%	15,881	14.5%	5,329	4.9%
4-5 years	253,038	62,665	48,374	77.2%	8,388	13.4%	2,795	4.5%
5-6 years	138,456	37,904	30,049	79.3%	4,961	13.1%	1,452	3.8%
6-7 years	73,838	22,569	18,581	82.3%	2,606	11.5%	784	3.5%
7+ years	37,943	27,526	11,375	41.3%	7,876	28.6%	4,925	17.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	3,169,564	2,523,413	79.6%	207,561	6.5%	139,731	4.4%
1-2 years	3,756,719	790,290	612,493	77.5%	77,828	9.8%	38,484	4.9%
2-3 years	2,243,787	408,831	291,517	71.3%	62,569	15.3%	22,100	5.4%
3-4 years	1,290,390	238,235	176,398	74.0%	33,995	14.3%	11,110	4.7%
4-5 years	759,943	145,401	110,549	76.0%	19,111	13.1%	6,484	4.5%
5-6 years	451,504	90,940	69,512	76.4%	12,110	13.3%	4,062	4.5%
6-7 years	267,682	58,579	46,098	78.7%	7,385	12.6%	2,310	3.9%
7+ years	157,482	103,502	32,654	31.5%	24,288	23.5%	19,396	18.7%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	2,969	3.7%	2,073	2.6%	1,413	1.7%	1,211	1.5%	1,682	2.1%
1-2 years	436	3.4%	278	2.2%	188	1.5%	152	1.2%	201	1.6%
2-3 years	204	3.7%	122	2.2%	76	1.4%	40	0.7%	69	1.2%
3-4 years	71	2.7%	47	1.8%	25	0.9%	14	0.5%	20	0.8%
4-5 years	33	2.2%	25	1.6%	*****	*****	*****	*****	*****	*****
5-6 years	15	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	43	8.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	6,165	2.5%	4,243	1.7%	2,858	1.2%	2,401	1.0%	3,601	1.5%
1-2 years	1,410	2.5%	868	1.5%	631	1.1%	477	0.8%	890	1.6%
2-3 years	772	2.9%	476	1.8%	328	1.3%	209	0.8%	509	1.9%
3-4 years	335	2.6%	239	1.8%	146	1.1%	120	0.9%	234	1.8%
4-5 years	186	2.5%	112	1.5%	87	1.2%	70	1.0%	16	0.2%
5-6 years	106	2.6%	70	1.7%	59	1.4%	*****	*****	*****	*****
6-7 years	49	2.1%	37	1.6%	*****	*****	*****	*****	*****	*****
7+ years	697	20.2%	50	1.4%	32	0.9%	19	0.5%	15	0.4%
Torsemide Users (Washout)										
0-1 years	2,437	2.9%	1,819	2.2%	1,294	1.6%	882	1.1%	1,335	1.6%
1-2 years	424	2.9%	252	1.7%	180	1.2%	114	0.8%	144	1.0%
2-3 years	197	3.0%	111	1.7%	67	1.0%	50	0.8%	52	0.8%
3-4 years	83	2.6%	45	1.4%	25	0.8%	20	0.6%	15	0.5%
4-5 years	32	1.9%	21	1.3%	*****	*****	*****	*****	*****	*****
5-6 years	19	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	39	6.8%	*****	*****	*****	*****	*****	*****	*****	*****

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	5,167	2.1%	3,561	1.4%	2,637	1.1%	1,701	0.7%	2,901	1.2%
1-2 years	1,316	2.1%	791	1.2%	606	0.9%	375	0.6%	676	1.1%
2-3 years	742	2.5%	450	1.5%	300	1.0%	206	0.7%	319	1.1%
3-4 years	339	2.3%	204	1.4%	122	0.8%	91	0.6%	123	0.8%
4-5 years	187	2.3%	104	1.3%	90	1.1%	91	1.1%	14	0.2%
5-6 years	117	2.5%	79	1.7%	67	1.5%	*****	*****	*****	*****
6-7 years	55	2.1%	55	2.1%	*****	*****	*****	*****	*****	*****
7+ years	786	19.9%	44	1.1%	42	1.1%	15	0.4%	22	0.6%
Furosemide Users (Washout)										
0-1 years	81,739	3.7%	58,291	2.6%	41,006	1.8%	28,180	1.3%	42,815	1.9%
1-2 years	13,563	3.4%	8,385	2.1%	5,359	1.3%	3,303	0.8%	4,132	1.0%
2-3 years	6,235	3.1%	3,873	2.0%	2,316	1.2%	1,479	0.7%	1,475	0.7%
3-4 years	3,020	2.8%	1,682	1.5%	1,021	0.9%	568	0.5%	404	0.4%
4-5 years	1,499	2.4%	836	1.3%	482	0.8%	200	0.3%	91	0.1%
5-6 years	776	2.0%	418	1.1%	178	0.5%	36	0.1%	34	0.1%
6-7 years	366	1.6%	168	0.7%	34	0.2%	16	0.1%	14	0.1%
7+ years	2,473	9.0%	397	1.4%	240	0.9%	128	0.5%	112	0.4%
Furosemide Users (No Washout)										
0-1 years	94,360	3.0%	67,079	2.1%	48,152	1.5%	33,000	1.0%	56,268	1.8%
1-2 years	22,022	2.8%	13,776	1.7%	9,424	1.2%	6,007	0.8%	10,256	1.3%
2-3 years	11,802	2.9%	7,565	1.9%	4,988	1.2%	3,280	0.8%	5,010	1.2%
3-4 years	6,346	2.7%	4,009	1.7%	2,495	1.0%	1,774	0.7%	2,108	0.9%
4-5 years	3,773	2.6%	2,277	1.6%	1,525	1.0%	1,394	1.0%	288	0.2%
5-6 years	2,220	2.4%	1,491	1.6%	1,322	1.5%	91	0.1%	132	0.1%
6-7 years	1,374	2.3%	1,220	2.1%	93	0.2%	43	0.1%	56	0.1%
7+ years	23,476	22.7%	1,469	1.4%	991	1.0%	697	0.7%	531	0.5%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	2,969	3.7%	2,073	2.6%	1,413	1.7%	1,211	1.5%	1,682	2.1%
1-2 years	436	3.4%	278	2.2%	188	1.5%	152	1.2%	201	1.6%
2-3 years	204	3.7%	122	2.2%	76	1.4%	40	0.7%	69	1.2%
3-4 years	71	2.7%	47	1.8%	25	0.9%	14	0.5%	20	0.8%
4-5 years	33	2.2%	25	1.6%	*****	*****	*****	*****	*****	*****
5-6 years	15	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	43	8.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	6,165	2.5%	4,243	1.7%	2,858	1.2%	2,401	1.0%	3,601	1.5%
1-2 years	1,410	2.5%	868	1.5%	631	1.1%	477	0.8%	890	1.6%
2-3 years	772	2.9%	476	1.8%	328	1.3%	209	0.8%	509	1.9%
3-4 years	335	2.6%	239	1.8%	146	1.1%	120	0.9%	234	1.8%
4-5 years	186	2.5%	112	1.5%	87	1.2%	70	1.0%	16	0.2%
5-6 years	106	2.6%	70	1.7%	59	1.4%	*****	*****	*****	*****
6-7 years	49	2.1%	37	1.6%	*****	*****	*****	*****	*****	*****
7+ years	697	20.2%	50	1.4%	32	0.9%	19	0.5%	15	0.4%
Torsemide Users (Washout)										
0-1 years	2,437	2.9%	1,819	2.2%	1,294	1.6%	882	1.1%	1,335	1.6%
1-2 years	424	2.9%	252	1.7%	180	1.2%	114	0.8%	144	1.0%
2-3 years	197	3.0%	111	1.7%	67	1.0%	50	0.8%	52	0.8%
3-4 years	83	2.6%	45	1.4%	25	0.8%	20	0.6%	15	0.5%
4-5 years	32	1.9%	21	1.3%	*****	*****	*****	*****	*****	*****
5-6 years	19	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	39	6.8%	*****	*****	*****	*****	*****	*****	*****	*****

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	5,167	2.1%	3,561	1.4%	2,637	1.1%	1,701	0.7%	2,901	1.2%
1-2 years	1,316	2.1%	791	1.2%	606	0.9%	375	0.6%	676	1.1%
2-3 years	742	2.5%	450	1.5%	300	1.0%	206	0.7%	319	1.1%
3-4 years	339	2.3%	204	1.4%	122	0.8%	91	0.6%	123	0.8%
4-5 years	187	2.3%	104	1.3%	90	1.1%	91	1.1%	14	0.2%
5-6 years	117	2.5%	79	1.7%	67	1.5%	*****	*****	*****	*****
6-7 years	55	2.1%	55	2.1%	*****	*****	*****	*****	*****	*****
7+ years	786	19.9%	44	1.1%	42	1.1%	15	0.4%	22	0.6%
Furosemide Users (Washout)										
0-1 years	81,739	3.7%	58,291	2.6%	41,006	1.8%	28,180	1.3%	42,815	1.9%
1-2 years	13,563	3.4%	8,385	2.1%	5,359	1.3%	3,303	0.8%	4,132	1.0%
2-3 years	6,235	3.1%	3,873	2.0%	2,316	1.2%	1,479	0.7%	1,475	0.7%
3-4 years	3,020	2.8%	1,682	1.5%	1,021	0.9%	568	0.5%	404	0.4%
4-5 years	1,499	2.4%	836	1.3%	482	0.8%	200	0.3%	91	0.1%
5-6 years	776	2.0%	418	1.1%	178	0.5%	36	0.1%	34	0.1%
6-7 years	366	1.6%	168	0.7%	34	0.2%	16	0.1%	14	0.1%
7+ years	2,473	9.0%	397	1.4%	240	0.9%	128	0.5%	112	0.4%
Furosemide Users (No Washout)										
0-1 years	94,360	3.0%	67,079	2.1%	48,152	1.5%	33,000	1.0%	56,268	1.8%
1-2 years	22,022	2.8%	13,776	1.7%	9,424	1.2%	6,007	0.8%	10,256	1.3%
2-3 years	11,802	2.9%	7,565	1.9%	4,988	1.2%	3,280	0.8%	5,010	1.2%
3-4 years	6,346	2.7%	4,009	1.7%	2,495	1.0%	1,774	0.7%	2,108	0.9%
4-5 years	3,773	2.6%	2,277	1.6%	1,525	1.0%	1,394	1.0%	288	0.2%
5-6 years	2,220	2.4%	1,491	1.6%	1,322	1.5%	91	0.1%	132	0.1%
6-7 years	1,374	2.3%	1,220	2.1%	93	0.2%	43	0.1%	56	0.1%
7+ years	23,476	22.7%	1,469	1.4%	991	1.0%	697	0.7%	531	0.5%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	2,969	3.7%	2,073	2.6%	1,413	1.7%	1,211	1.5%	1,682	2.1%
1-2 years	436	3.4%	278	2.2%	188	1.5%	152	1.2%	201	1.6%
2-3 years	204	3.7%	122	2.2%	76	1.4%	40	0.7%	69	1.2%
3-4 years	71	2.7%	47	1.8%	25	0.9%	14	0.5%	20	0.8%
4-5 years	33	2.2%	25	1.6%	*****	*****	*****	*****	*****	*****
5-6 years	15	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	43	8.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	6,165	2.5%	4,243	1.7%	2,858	1.2%	2,401	1.0%	3,601	1.5%
1-2 years	1,410	2.5%	868	1.5%	631	1.1%	477	0.8%	890	1.6%
2-3 years	772	2.9%	476	1.8%	328	1.3%	209	0.8%	509	1.9%
3-4 years	335	2.6%	239	1.8%	146	1.1%	120	0.9%	234	1.8%
4-5 years	186	2.5%	112	1.5%	87	1.2%	70	1.0%	16	0.2%
5-6 years	106	2.6%	70	1.7%	59	1.4%	*****	*****	*****	*****
6-7 years	49	2.1%	37	1.6%	*****	*****	*****	*****	*****	*****
7+ years	697	20.2%	50	1.4%	32	0.9%	19	0.5%	15	0.4%
Torsemide Users (Washout)										
0-1 years	2,437	2.9%	1,819	2.2%	1,294	1.6%	882	1.1%	1,335	1.6%
1-2 years	424	2.9%	252	1.7%	180	1.2%	114	0.8%	144	1.0%
2-3 years	197	3.0%	111	1.7%	67	1.0%	50	0.8%	52	0.8%
3-4 years	83	2.6%	45	1.4%	25	0.8%	20	0.6%	15	0.5%
4-5 years	32	1.9%	21	1.3%	*****	*****	*****	*****	*****	*****
5-6 years	19	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	39	6.8%	*****	*****	*****	*****	*****	*****	*****	*****

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	5,167	2.1%	3,561	1.4%	2,637	1.1%	1,701	0.7%	2,901	1.2%
1-2 years	1,316	2.1%	791	1.2%	606	0.9%	375	0.6%	676	1.1%
2-3 years	742	2.5%	450	1.5%	300	1.0%	206	0.7%	319	1.1%
3-4 years	339	2.3%	204	1.4%	122	0.8%	91	0.6%	123	0.8%
4-5 years	187	2.3%	104	1.3%	90	1.1%	91	1.1%	14	0.2%
5-6 years	117	2.5%	79	1.7%	67	1.5%	*****	*****	*****	*****
6-7 years	55	2.1%	55	2.1%	*****	*****	*****	*****	*****	*****
7+ years	786	19.9%	44	1.1%	42	1.1%	15	0.4%	22	0.6%
Furosemide Users (Washout)										
0-1 years	81,739	3.7%	58,291	2.6%	41,006	1.8%	28,180	1.3%	42,815	1.9%
1-2 years	13,563	3.4%	8,385	2.1%	5,359	1.3%	3,303	0.8%	4,132	1.0%
2-3 years	6,235	3.1%	3,873	2.0%	2,316	1.2%	1,479	0.7%	1,475	0.7%
3-4 years	3,020	2.8%	1,682	1.5%	1,021	0.9%	568	0.5%	404	0.4%
4-5 years	1,499	2.4%	836	1.3%	482	0.8%	200	0.3%	91	0.1%
5-6 years	776	2.0%	418	1.1%	178	0.5%	36	0.1%	34	0.1%
6-7 years	366	1.6%	168	0.7%	34	0.2%	16	0.1%	14	0.1%
7+ years	2,473	9.0%	397	1.4%	240	0.9%	128	0.5%	112	0.4%
Furosemide Users (No Washout)										
0-1 years	94,360	3.0%	67,079	2.1%	48,152	1.5%	33,000	1.0%	56,268	1.8%
1-2 years	22,022	2.8%	13,776	1.7%	9,424	1.2%	6,007	0.8%	10,256	1.3%
2-3 years	11,802	2.9%	7,565	1.9%	4,988	1.2%	3,280	0.8%	5,010	1.2%
3-4 years	6,346	2.7%	4,009	1.7%	2,495	1.0%	1,774	0.7%	2,108	0.9%
4-5 years	3,773	2.6%	2,277	1.6%	1,525	1.0%	1,394	1.0%	288	0.2%
5-6 years	2,220	2.4%	1,491	1.6%	1,322	1.5%	91	0.1%	132	0.1%
6-7 years	1,374	2.3%	1,220	2.1%	93	0.2%	43	0.1%	56	0.1%
7+ years	23,476	22.7%	1,469	1.4%	991	1.0%	697	0.7%	531	0.5%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	2,969	3.7%	2,073	2.6%	1,413	1.7%	1,211	1.5%	1,682	2.1%
1-2 years	436	3.4%	278	2.2%	188	1.5%	152	1.2%	201	1.6%
2-3 years	204	3.7%	122	2.2%	76	1.4%	40	0.7%	69	1.2%
3-4 years	71	2.7%	47	1.8%	25	0.9%	14	0.5%	20	0.8%
4-5 years	33	2.2%	25	1.6%	*****	*****	*****	*****	*****	*****
5-6 years	15	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	43	8.8%	*****	*****	*****	*****	*****	*****	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	6,165	2.5%	4,243	1.7%	2,858	1.2%	2,401	1.0%	3,601	1.5%
1-2 years	1,410	2.5%	868	1.5%	631	1.1%	477	0.8%	890	1.6%
2-3 years	772	2.9%	476	1.8%	328	1.3%	209	0.8%	509	1.9%
3-4 years	335	2.6%	239	1.8%	146	1.1%	120	0.9%	234	1.8%
4-5 years	186	2.5%	112	1.5%	87	1.2%	70	1.0%	16	0.2%
5-6 years	106	2.6%	70	1.7%	59	1.4%	*****	*****	*****	*****
6-7 years	49	2.1%	37	1.6%	*****	*****	*****	*****	*****	*****
7+ years	697	20.2%	50	1.4%	32	0.9%	19	0.5%	15	0.4%
Torsemide Users (Washout)										
0-1 years	2,437	2.9%	1,819	2.2%	1,294	1.6%	882	1.1%	1,335	1.6%
1-2 years	424	2.9%	252	1.7%	180	1.2%	114	0.8%	144	1.0%
2-3 years	197	3.0%	111	1.7%	67	1.0%	50	0.8%	52	0.8%
3-4 years	83	2.6%	45	1.4%	25	0.8%	20	0.6%	15	0.5%
4-5 years	32	1.9%	21	1.3%	*****	*****	*****	*****	*****	*****
5-6 years	19	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
7+ years	39	6.8%	*****	*****	*****	*****	*****	*****	*****	*****

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	5,167	2.1%	3,561	1.4%	2,637	1.1%	1,701	0.7%	2,901	1.2%
1-2 years	1,316	2.1%	791	1.2%	606	0.9%	375	0.6%	676	1.1%
2-3 years	742	2.5%	450	1.5%	300	1.0%	206	0.7%	319	1.1%
3-4 years	339	2.3%	204	1.4%	122	0.8%	91	0.6%	123	0.8%
4-5 years	187	2.3%	104	1.3%	90	1.1%	91	1.1%	14	0.2%
5-6 years	117	2.5%	79	1.7%	67	1.5%	*****	*****	*****	*****
6-7 years	55	2.1%	55	2.1%	*****	*****	*****	*****	*****	*****
7+ years	786	19.9%	44	1.1%	42	1.1%	15	0.4%	22	0.6%
Furosemide Users (Washout)										
0-1 years	81,739	3.7%	58,291	2.6%	41,006	1.8%	28,180	1.3%	42,815	1.9%
1-2 years	13,563	3.4%	8,385	2.1%	5,359	1.3%	3,303	0.8%	4,132	1.0%
2-3 years	6,235	3.1%	3,873	2.0%	2,316	1.2%	1,479	0.7%	1,475	0.7%
3-4 years	3,020	2.8%	1,682	1.5%	1,021	0.9%	568	0.5%	404	0.4%
4-5 years	1,499	2.4%	836	1.3%	482	0.8%	200	0.3%	91	0.1%
5-6 years	776	2.0%	418	1.1%	178	0.5%	36	0.1%	34	0.1%
6-7 years	366	1.6%	168	0.7%	34	0.2%	16	0.1%	14	0.1%
7+ years	2,473	9.0%	397	1.4%	240	0.9%	128	0.5%	112	0.4%
Furosemide Users (No Washout)										
0-1 years	94,360	3.0%	67,079	2.1%	48,152	1.5%	33,000	1.0%	56,268	1.8%
1-2 years	22,022	2.8%	13,776	1.7%	9,424	1.2%	6,007	0.8%	10,256	1.3%
2-3 years	11,802	2.9%	7,565	1.9%	4,988	1.2%	3,280	0.8%	5,010	1.2%
3-4 years	6,346	2.7%	4,009	1.7%	2,495	1.0%	1,774	0.7%	2,108	0.9%
4-5 years	3,773	2.6%	2,277	1.6%	1,525	1.0%	1,394	1.0%	288	0.2%
5-6 years	2,220	2.4%	1,491	1.6%	1,322	1.5%	91	0.1%	132	0.1%

Table 16c. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	1,374	2.3%	1,220	2.1%	93	0.2%	43	0.1%	56	0.1%
7+ years	23,476	22.7%	1,469	1.4%	991	1.0%	697	0.7%	531	0.5%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	62,115	41,437	66.7%	5,586	9.0%	4,160	6.7%
>0 - <700,000 ppm	*****	40,878	30,985	75.8%	4,405	10.8%	2,835	6.9%
700,000 - 1,000,000 ppm	*****	1,240	840	67.7%	225	18.1%	111	9.0%
1,000,000 - 1,500,000 ppm	*****	640	401	62.7%	118	18.4%	99	15.5%
1,500,000 - 2,000,000 ppm	*****	240	168	70.0%	48	20.0%	*****	*****
≥ 2,000,000 ppm	*****	187	84	44.9%	52	27.8%	37	19.8%
Bumetanide Users (No Washout)								
0 ppm	*****	209,170	149,617	71.5%	17,149	8.2%	12,355	5.9%
>0 - <700,000 ppm	*****	134,134	105,577	78.7%	13,038	9.7%	7,797	5.8%
700,000 - 1,000,000 ppm	*****	5,866	4,353	74.2%	857	14.6%	429	7.3%
1,000,000 - 1,500,000 ppm	*****	3,903	2,637	67.6%	699	17.9%	395	10.1%
1,500,000 - 2,000,000 ppm	*****	1,563	1,093	69.9%	304	19.4%	110	7.0%
≥ 2,000,000 ppm	*****	1,439	719	50.0%	345	24.0%	224	15.6%
Torsemide Users (Washout)								
0 ppm	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	62,115	41,437	66.7%	5,586	9.0%	4,160	6.7%
>0 - <700,000 ppm	*****	40,878	30,985	75.8%	4,405	10.8%	2,835	6.9%
700,000 - 1,000,000 ppm	*****	1,240	840	67.7%	225	18.1%	111	9.0%
1,000,000 - 1,500,000 ppm	*****	640	401	62.7%	118	18.4%	99	15.5%
1,500,000 - 2,000,000 ppm	*****	240	168	70.0%	48	20.0%	*****	*****
≥ 2,000,000 ppm	*****	187	84	44.9%	52	27.8%	37	19.8%
Bumetanide Users (No Washout)								
0 ppm	*****	209,170	149,617	71.5%	17,149	8.2%	12,355	5.9%
>0 - <700,000 ppm	*****	134,134	105,577	78.7%	13,038	9.7%	7,797	5.8%
700,000 - 1,000,000 ppm	*****	5,866	4,353	74.2%	857	14.6%	429	7.3%
1,000,000 - 1,500,000 ppm	*****	3,903	2,637	67.6%	699	17.9%	395	10.1%
1,500,000 - 2,000,000 ppm	*****	1,563	1,093	69.9%	304	19.4%	110	7.0%
≥ 2,000,000 ppm	*****	1,439	719	50.0%	345	24.0%	224	15.6%

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	62,115	41,437	66.7%	5,586	9.0%	4,160	6.7%
>0 - <700,000 ppm	*****	40,878	30,985	75.8%	4,405	10.8%	2,835	6.9%
700,000 - 1,000,000 ppm	*****	1,240	840	67.7%	225	18.1%	111	9.0%
1,000,000 - 1,500,000 ppm	*****	640	401	62.7%	118	18.4%	99	15.5%
1,500,000 - 2,000,000 ppm	*****	240	168	70.0%	48	20.0%	*****	*****
≥ 2,000,000 ppm	*****	187	84	44.9%	52	27.8%	37	19.8%
Bumetanide Users (No Washout)								
0 ppm	*****	209,170	149,617	71.5%	17,149	8.2%	12,355	5.9%
>0 - <700,000 ppm	*****	134,134	105,577	78.7%	13,038	9.7%	7,797	5.8%
700,000 - 1,000,000 ppm	*****	5,866	4,353	74.2%	857	14.6%	429	7.3%
1,000,000 - 1,500,000 ppm	*****	3,903	2,637	67.6%	699	17.9%	395	10.1%
1,500,000 - 2,000,000 ppm	*****	1,563	1,093	69.9%	304	19.4%	110	7.0%
≥ 2,000,000 ppm	*****	1,439	719	50.0%	345	24.0%	224	15.6%
Torsemide Users (Washout)								
0 ppm	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	62,115	41,437	66.7%	5,586	9.0%	4,160	6.7%
>0 - <700,000 ppm	*****	40,878	30,985	75.8%	4,405	10.8%	2,835	6.9%
700,000 - 1,000,000 ppm	*****	1,240	840	67.7%	225	18.1%	111	9.0%
1,000,000 - 1,500,000 ppm	*****	640	401	62.7%	118	18.4%	99	15.5%
1,500,000 - 2,000,000 ppm	*****	240	168	70.0%	48	20.0%	*****	*****
≥ 2,000,000 ppm	*****	187	84	44.9%	52	27.8%	37	19.8%
Bumetanide Users (No Washout)								
0 ppm	*****	209,170	149,617	71.5%	17,149	8.2%	12,355	5.9%
>0 - <700,000 ppm	*****	134,134	105,577	78.7%	13,038	9.7%	7,797	5.8%
700,000 - 1,000,000 ppm	*****	5,866	4,353	74.2%	857	14.6%	429	7.3%
1,000,000 - 1,500,000 ppm	*****	3,903	2,637	67.6%	699	17.9%	395	10.1%
1,500,000 - 2,000,000 ppm	*****	1,563	1,093	69.9%	304	19.4%	110	7.0%
≥ 2,000,000 ppm	*****	1,439	719	50.0%	345	24.0%	224	15.6%
Torsemide Users (Washout)								

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	172,362	111,371	79,266	71.2%	10,606	9.5%	6,984	6.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	377,050	279,360	74.1%	32,320	8.6%	21,167	5.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	3,092,323	2,023,691	65.4%	313,098	10.1%	225,065	7.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to Disenrollment by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to Disenrollment[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 ppm	8,853,836	5,005,342	3,270,257	65.3%	485,033	9.7%	354,340	7.1%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	3,029	4.9%	2,451	3.9%	1,749	2.8%	1,496	2.4%	2,207	3.6%
>0 - <700,000 ppm	1,758	4.3%	552	1.4%	330	0.8%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	50	4.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	8,440	4.0%	6,302	3.0%	4,644	2.2%	3,711	1.8%	6,952	3.3%
>0 - <700,000 ppm	5,061	3.8%	1,493	1.1%	1,118	0.8%	50	0.0%	0	0.0%
700,000 - 1,000,000 ppm	180	3.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	138	3.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	105	7.3%	46	3.2%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	3,029	4.9%	2,451	3.9%	1,749	2.8%	1,496	2.4%	2,207	3.6%
>0 - <700,000 ppm	1,758	4.3%	552	1.4%	330	0.8%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	50	4.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	8,440	4.0%	6,302	3.0%	4,644	2.2%	3,711	1.8%	6,952	3.3%
>0 - <700,000 ppm	5,061	3.8%	1,493	1.1%	1,118	0.8%	50	0.0%	0	0.0%
700,000 - 1,000,000 ppm	180	3.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	138	3.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	105	7.3%	46	3.2%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	3,029	4.9%	2,451	3.9%	1,749	2.8%	1,496	2.4%	2,207	3.6%
>0 - <700,000 ppm	1,758	4.3%	552	1.4%	330	0.8%	13	0.0%	0	0.0%

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	50	4.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	8,440	4.0%	6,302	3.0%	4,644	2.2%	3,711	1.8%	6,952	3.3%
>0 - <700,000 ppm	5,061	3.8%	1,493	1.1%	1,118	0.8%	50	0.0%	0	0.0%
700,000 - 1,000,000 ppm	180	3.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	138	3.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	105	7.3%	46	3.2%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	3,029	4.9%	2,451	3.9%	1,749	2.8%	1,496	2.4%	2,207	3.6%
>0 - <700,000 ppm	1,758	4.3%	552	1.4%	330	0.8%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	50	4.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	8,440	4.0%	6,302	3.0%	4,644	2.2%	3,711	1.8%	6,952	3.3%
>0 - <700,000 ppm	5,061	3.8%	1,493	1.1%	1,118	0.8%	50	0.0%	0	0.0%
700,000 - 1,000,000 ppm	180	3.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	138	3.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	105	7.3%	46	3.2%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	4,670	4.2%	3,359	3.0%	2,437	2.2%	1,639	1.5%	2,410	2.2%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 16d. Summary of Time to End of At-Risk Period due to Disenrollment for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to Disenrollment by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	13,808	3.7%	9,495	2.5%	7,219	1.9%	4,605	1.2%	9,076	2.4%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	161,955	5.2%	120,419	3.9%	88,790	2.9%	62,964	2.0%	96,341	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	247,807	5.0%	184,048	3.7%	143,994	2.9%	102,807	2.1%	217,056	4.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 17a. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)	172,936	56,703	35,599	62.8%	5,518	9.7%	4,358	7.7%
Bumetanide Users (No Washout)	681,044	184,360	123,932	67.2%	16,634	9.0%	12,192	6.6%
Torsemide Users (Washout)	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
Torsemide Users (No Washout)	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
Furosemide Users (Washout)	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
Furosemide Users (No Washout)	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
Bladder Cancer Outcome								
Bumetanide Users (Washout)	172,936	56,703	35,599	62.8%	5,518	9.7%	4,358	7.7%
Bumetanide Users (No Washout)	681,044	184,360	123,932	67.2%	16,634	9.0%	12,192	6.6%
Torsemide Users (Washout)	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
Torsemide Users (No Washout)	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
Furosemide Users (Washout)	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
Furosemide Users (No Washout)	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
Colorectal Cancer Outcome								
Bumetanide Users (Washout)	172,936	56,703	35,599	62.8%	5,518	9.7%	4,358	7.7%
Bumetanide Users (No Washout)	681,044	184,360	123,932	67.2%	16,634	9.0%	12,192	6.6%
Torsemide Users (Washout)	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
Torsemide Users (No Washout)	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
Furosemide Users (Washout)	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
Furosemide Users (No Washout)	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
Esophageal Cancer Outcome								
Bumetanide Users (Washout)	172,936	56,703	35,599	62.8%	5,518	9.7%	4,358	7.7%
Bumetanide Users (No Washout)	681,044	184,360	123,932	67.2%	16,634	9.0%	12,192	6.6%
Torsemide Users (Washout)	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
Torsemide Users (No Washout)	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
Furosemide Users (Washout)	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
Furosemide Users (No Washout)	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%

Table 17a. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)	3,244	5.7%	2,404	4.2%	1,638	2.9%	1,516	2.7%	2,426	4.3%
Bumetanide Users (No Washout)	8,744	4.7%	6,198	3.4%	4,400	2.4%	3,713	2.0%	8,547	4.6%
Torsemide Users (Washout)	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
Torsemide Users (No Washout)	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
Furosemide Users (Washout)	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
Furosemide Users (No Washout)	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
Bladder Cancer Outcome										
Bumetanide Users (Washout)	3,244	5.7%	2,404	4.2%	1,638	2.9%	1,516	2.7%	2,426	4.3%
Bumetanide Users (No Washout)	8,744	4.7%	6,198	3.4%	4,400	2.4%	3,713	2.0%	8,547	4.6%
Torsemide Users (Washout)	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
Torsemide Users (No Washout)	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
Furosemide Users (Washout)	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
Furosemide Users (No Washout)	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
Colorectal Cancer Outcome										
Bumetanide Users (Washout)	3,244	5.7%	2,404	4.2%	1,638	2.9%	1,516	2.7%	2,426	4.3%
Bumetanide Users (No Washout)	8,744	4.7%	6,198	3.4%	4,400	2.4%	3,713	2.0%	8,547	4.6%
Torsemide Users (Washout)	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
Torsemide Users (No Washout)	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
Furosemide Users (Washout)	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
Furosemide Users (No Washout)	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
Esophageal Cancer Outcome										
Bumetanide Users (Washout)	3,244	5.7%	2,404	4.2%	1,638	2.9%	1,516	2.7%	2,426	4.3%
Bumetanide Users (No Washout)	8,744	4.7%	6,198	3.4%	4,400	2.4%	3,713	2.0%	8,547	4.6%
Torsemide Users (Washout)	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
Torsemide Users (No Washout)	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
Furosemide Users (Washout)	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
Furosemide Users (No Washout)	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%

Table 17a. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Liver Cancer Outcome							
Bumetanide Users (Washout)	0	0	37	847	6,459	542.0	829.0
Bumetanide Users (No Washout)	0	0	0	676	6,568	489.2	828.8
Torsemide Users (Washout)	0	0	0	630	6,363	449.8	754.6
Torsemide Users (No Washout)	0	0	0	521	6,412	415.7	761.8
Furosemide Users (Washout)	0	0	183	1,045	6,567	640.6	883.2
Furosemide Users (No Washout)	0	0	165	1,126	6,576	695.9	974.2
Bladder Cancer Outcome							
Bumetanide Users (Washout)	0	0	37	847	6,459	542.0	829.0
Bumetanide Users (No Washout)	0	0	0	676	6,568	489.2	828.8
Torsemide Users (Washout)	0	0	0	630	6,363	449.8	754.6
Torsemide Users (No Washout)	0	0	0	521	6,412	415.7	761.8
Furosemide Users (Washout)	0	0	183	1,045	6,567	640.6	883.2
Furosemide Users (No Washout)	0	0	165	1,126	6,576	695.9	974.2
Colorectal Cancer Outcome							
Bumetanide Users (Washout)	0	0	37	847	6,459	542.0	829.0
Bumetanide Users (No Washout)	0	0	0	676	6,568	489.2	828.8
Torsemide Users (Washout)	0	0	0	630	6,363	449.8	754.6
Torsemide Users (No Washout)	0	0	0	521	6,412	415.7	761.8
Furosemide Users (Washout)	0	0	183	1,045	6,567	640.6	883.2
Furosemide Users (No Washout)	0	0	165	1,126	6,576	695.9	974.2
Esophageal Cancer Outcome							
Bumetanide Users (Washout)	0	0	37	847	6,459	542.0	829.0
Bumetanide Users (No Washout)	0	0	0	676	6,568	489.2	828.8
Torsemide Users (Washout)	0	0	0	630	6,363	449.8	754.6
Torsemide Users (No Washout)	0	0	0	521	6,412	415.7	761.8
Furosemide Users (Washout)	0	0	183	1,045	6,567	640.6	883.2
Furosemide Users (No Washout)	0	0	165	1,126	6,576	695.9	974.2

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	39,691	27,748	69.9%	3,165	8.0%	2,423	6.1%
30,000 - <60,000 mg	*****	7,189	5,044	70.2%	836	11.6%	461	6.4%
60,000 - <90,000 mg	*****	3,487	2,510	72.0%	440	12.6%	194	5.6%
90,000 - <120,000 mg	*****	1,918	1,434	74.8%	225	11.7%	102	5.3%
120,000 - <150,000 mg	*****	1,274	969	76.1%	149	11.7%	60	4.7%
150,000 - <180,000 mg	*****	868	705	81.2%	88	10.1%	24	2.8%
180,000 - <210,000 mg	*****	576	447	77.6%	69	12.0%	22	3.8%
≥ 210,000 mg	*****	1,700	627	36.9%	374	22.0%	264	15.5%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	100,865	77,790	77.1%	6,429	6.4%	4,729	4.7%
30,000 - <60,000 mg	304,791	28,470	22,433	78.8%	2,260	7.9%	1,219	4.3%
60,000 - <90,000 mg	201,271	15,567	12,088	77.7%	1,468	9.4%	671	4.3%
90,000 - <120,000 mg	141,898	9,889	7,855	79.4%	869	8.8%	383	3.9%
120,000 - <150,000 mg	104,735	6,903	5,475	79.3%	649	9.4%	264	3.8%
150,000 - <180,000 mg	*****	4,976	4,055	81.5%	398	8.0%	167	3.4%
180,000 - <210,000 mg	*****	3,509	2,826	80.5%	292	8.3%	139	4.0%
≥ 210,000 mg	47,345	14,181	5,162	36.4%	2,962	20.9%	1,905	13.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	49,198	36,907	75.0%	3,869	7.9%	2,553	5.2%
30,000 - <60,000 mg	*****	8,028	5,537	69.0%	1,217	15.2%	505	6.3%
60,000 - <90,000 mg	*****	3,479	2,505	72.0%	533	15.3%	201	5.8%
90,000 - <120,000 mg	*****	1,748	1,318	75.4%	240	13.7%	69	3.9%
120,000 - <150,000 mg	*****	1,114	893	80.2%	134	12.0%	37	3.3%
150,000 - <180,000 mg	*****	648	532	82.1%	73	11.3%	24	3.7%
180,000 - <210,000 mg	*****	446	352	78.9%	49	11.0%	17	3.8%
≥ 210,000 mg	*****	1,335	604	45.2%	296	22.2%	179	13.4%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	121,748	99,260	81.5%	6,961	5.7%	4,646	3.8%
30,000 - <60,000 mg	297,231	32,809	25,858	78.8%	3,200	9.8%	1,395	4.3%
60,000 - <90,000 mg	191,137	17,071	13,557	79.4%	1,771	10.4%	655	3.8%
90,000 - <120,000 mg	132,972	10,494	8,526	81.2%	1,003	9.6%	340	3.2%
120,000 - <150,000 mg	97,900	7,173	5,895	82.2%	658	9.2%	241	3.4%
150,000 - <180,000 mg	73,732	4,880	4,121	84.4%	405	8.3%	142	2.9%
180,000 - <210,000 mg	57,843	3,497	2,929	83.8%	290	8.3%	102	2.9%
≥ 210,000 mg	46,087	14,259	6,090	42.7%	2,912	20.4%	1,761	12.4%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,336,205	857,327	64.2%	137,595	10.3%	97,058	7.3%
30,000 - <60,000 mg	664,489	138,185	62,443	45.2%	36,959	26.7%	17,719	12.8%
60,000 - <90,000 mg	230,504	47,431	25,176	53.1%	13,400	28.3%	4,808	10.1%
90,000 - <120,000 mg	97,370	19,841	11,758	59.3%	5,210	26.3%	1,663	8.4%
120,000 - <150,000 mg	46,460	9,352	6,205	66.3%	2,198	23.5%	577	6.2%
150,000 - <180,000 mg	24,013	4,297	3,195	74.4%	744	17.3%	194	4.5%
180,000 - <210,000 mg	*****	2,255	1,704	75.6%	359	15.9%	105	4.7%
≥ 210,000 mg	*****	3,358	1,291	38.4%	855	25.5%	564	16.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,834,241	1,248,422	68.1%	169,947	9.3%	115,590	6.3%
30,000 - <60,000 mg	1,997,151	263,211	120,235	45.7%	65,229	24.8%	31,645	12.0%
60,000 - <90,000 mg	852,245	107,143	52,334	48.8%	28,920	27.0%	13,225	12.3%
90,000 - <120,000 mg	422,980	51,751	28,018	54.1%	14,034	27.1%	4,717	9.1%
120,000 - <150,000 mg	231,140	29,443	16,814	57.1%	7,930	26.9%	2,903	9.9%
150,000 - <180,000 mg	133,068	16,666	12,033	72.2%	2,923	17.5%	835	5.0%
180,000 - <210,000 mg	81,274	8,721	6,089	69.8%	1,626	18.6%	475	5.4%
≥ 210,000 mg	53,201	17,786	4,904	27.6%	3,695	20.8%	3,071	17.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	39,691	27,748	69.9%	3,165	8.0%	2,423	6.1%
30,000 - <60,000 mg	*****	7,189	5,044	70.2%	836	11.6%	461	6.4%
60,000 - <90,000 mg	*****	3,487	2,510	72.0%	440	12.6%	194	5.6%
90,000 - <120,000 mg	*****	1,918	1,434	74.8%	225	11.7%	102	5.3%
120,000 - <150,000 mg	*****	1,274	969	76.1%	149	11.7%	60	4.7%
150,000 - <180,000 mg	*****	868	705	81.2%	88	10.1%	24	2.8%
180,000 - <210,000 mg	*****	576	447	77.6%	69	12.0%	22	3.8%
≥ 210,000 mg	*****	1,700	627	36.9%	374	22.0%	264	15.5%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	100,865	77,790	77.1%	6,429	6.4%	4,729	4.7%
30,000 - <60,000 mg	304,791	28,470	22,433	78.8%	2,260	7.9%	1,219	4.3%
60,000 - <90,000 mg	201,271	15,567	12,088	77.7%	1,468	9.4%	671	4.3%
90,000 - <120,000 mg	141,898	9,889	7,855	79.4%	869	8.8%	383	3.9%
120,000 - <150,000 mg	104,735	6,903	5,475	79.3%	649	9.4%	264	3.8%
150,000 - <180,000 mg	*****	4,976	4,055	81.5%	398	8.0%	167	3.4%
180,000 - <210,000 mg	*****	3,509	2,826	80.5%	292	8.3%	139	4.0%
≥ 210,000 mg	47,345	14,181	5,162	36.4%	2,962	20.9%	1,905	13.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	49,198	36,907	75.0%	3,869	7.9%	2,553	5.2%
30,000 - <60,000 mg	*****	8,028	5,537	69.0%	1,217	15.2%	505	6.3%
60,000 - <90,000 mg	*****	3,479	2,505	72.0%	533	15.3%	201	5.8%
90,000 - <120,000 mg	*****	1,748	1,318	75.4%	240	13.7%	69	3.9%
120,000 - <150,000 mg	*****	1,114	893	80.2%	134	12.0%	37	3.3%
150,000 - <180,000 mg	*****	648	532	82.1%	73	11.3%	24	3.7%
180,000 - <210,000 mg	*****	446	352	78.9%	49	11.0%	17	3.8%
≥ 210,000 mg	*****	1,335	604	45.2%	296	22.2%	179	13.4%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	121,748	99,260	81.5%	6,961	5.7%	4,646	3.8%
30,000 - <60,000 mg	297,231	32,809	25,858	78.8%	3,200	9.8%	1,395	4.3%
60,000 - <90,000 mg	191,137	17,071	13,557	79.4%	1,771	10.4%	655	3.8%
90,000 - <120,000 mg	132,972	10,494	8,526	81.2%	1,003	9.6%	340	3.2%
120,000 - <150,000 mg	97,900	7,173	5,895	82.2%	658	9.2%	241	3.4%
150,000 - <180,000 mg	73,732	4,880	4,121	84.4%	405	8.3%	142	2.9%
180,000 - <210,000 mg	57,843	3,497	2,929	83.8%	290	8.3%	102	2.9%
≥ 210,000 mg	46,087	14,259	6,090	42.7%	2,912	20.4%	1,761	12.4%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,336,205	857,327	64.2%	137,595	10.3%	97,058	7.3%
30,000 - <60,000 mg	664,489	138,185	62,443	45.2%	36,959	26.7%	17,719	12.8%
60,000 - <90,000 mg	230,504	47,431	25,176	53.1%	13,400	28.3%	4,808	10.1%
90,000 - <120,000 mg	97,370	19,841	11,758	59.3%	5,210	26.3%	1,663	8.4%
120,000 - <150,000 mg	46,460	9,352	6,205	66.3%	2,198	23.5%	577	6.2%
150,000 - <180,000 mg	24,013	4,297	3,195	74.4%	744	17.3%	194	4.5%
180,000 - <210,000 mg	*****	2,255	1,704	75.6%	359	15.9%	105	4.7%
≥ 210,000 mg	*****	3,358	1,291	38.4%	855	25.5%	564	16.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,834,241	1,248,422	68.1%	169,947	9.3%	115,590	6.3%
30,000 - <60,000 mg	1,997,151	263,211	120,235	45.7%	65,229	24.8%	31,645	12.0%
60,000 - <90,000 mg	852,245	107,143	52,334	48.8%	28,920	27.0%	13,225	12.3%
90,000 - <120,000 mg	422,980	51,751	28,018	54.1%	14,034	27.1%	4,717	9.1%
120,000 - <150,000 mg	231,140	29,443	16,814	57.1%	7,930	26.9%	2,903	9.9%
150,000 - <180,000 mg	133,068	16,666	12,033	72.2%	2,923	17.5%	835	5.0%
180,000 - <210,000 mg	81,274	8,721	6,089	69.8%	1,626	18.6%	475	5.4%
≥ 210,000 mg	53,201	17,786	4,904	27.6%	3,695	20.8%	3,071	17.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	39,691	27,748	69.9%	3,165	8.0%	2,423	6.1%
30,000 - <60,000 mg	*****	7,189	5,044	70.2%	836	11.6%	461	6.4%
60,000 - <90,000 mg	*****	3,487	2,510	72.0%	440	12.6%	194	5.6%
90,000 - <120,000 mg	*****	1,918	1,434	74.8%	225	11.7%	102	5.3%
120,000 - <150,000 mg	*****	1,274	969	76.1%	149	11.7%	60	4.7%
150,000 - <180,000 mg	*****	868	705	81.2%	88	10.1%	24	2.8%
180,000 - <210,000 mg	*****	576	447	77.6%	69	12.0%	22	3.8%
≥ 210,000 mg	*****	1,700	627	36.9%	374	22.0%	264	15.5%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	100,865	77,790	77.1%	6,429	6.4%	4,729	4.7%
30,000 - <60,000 mg	304,791	28,470	22,433	78.8%	2,260	7.9%	1,219	4.3%
60,000 - <90,000 mg	201,271	15,567	12,088	77.7%	1,468	9.4%	671	4.3%
90,000 - <120,000 mg	141,898	9,889	7,855	79.4%	869	8.8%	383	3.9%
120,000 - <150,000 mg	104,735	6,903	5,475	79.3%	649	9.4%	264	3.8%
150,000 - <180,000 mg	*****	4,976	4,055	81.5%	398	8.0%	167	3.4%
180,000 - <210,000 mg	*****	3,509	2,826	80.5%	292	8.3%	139	4.0%
≥ 210,000 mg	47,345	14,181	5,162	36.4%	2,962	20.9%	1,905	13.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	49,198	36,907	75.0%	3,869	7.9%	2,553	5.2%
30,000 - <60,000 mg	*****	8,028	5,537	69.0%	1,217	15.2%	505	6.3%
60,000 - <90,000 mg	*****	3,479	2,505	72.0%	533	15.3%	201	5.8%
90,000 - <120,000 mg	*****	1,748	1,318	75.4%	240	13.7%	69	3.9%
120,000 - <150,000 mg	*****	1,114	893	80.2%	134	12.0%	37	3.3%
150,000 - <180,000 mg	*****	648	532	82.1%	73	11.3%	24	3.7%
180,000 - <210,000 mg	*****	446	352	78.9%	49	11.0%	17	3.8%
≥ 210,000 mg	*****	1,335	604	45.2%	296	22.2%	179	13.4%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	121,748	99,260	81.5%	6,961	5.7%	4,646	3.8%
30,000 - <60,000 mg	297,231	32,809	25,858	78.8%	3,200	9.8%	1,395	4.3%
60,000 - <90,000 mg	191,137	17,071	13,557	79.4%	1,771	10.4%	655	3.8%
90,000 - <120,000 mg	132,972	10,494	8,526	81.2%	1,003	9.6%	340	3.2%
120,000 - <150,000 mg	97,900	7,173	5,895	82.2%	658	9.2%	241	3.4%
150,000 - <180,000 mg	73,732	4,880	4,121	84.4%	405	8.3%	142	2.9%
180,000 - <210,000 mg	57,843	3,497	2,929	83.8%	290	8.3%	102	2.9%
≥ 210,000 mg	46,087	14,259	6,090	42.7%	2,912	20.4%	1,761	12.4%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,336,205	857,327	64.2%	137,595	10.3%	97,058	7.3%
30,000 - <60,000 mg	664,489	138,185	62,443	45.2%	36,959	26.7%	17,719	12.8%
60,000 - <90,000 mg	230,504	47,431	25,176	53.1%	13,400	28.3%	4,808	10.1%
90,000 - <120,000 mg	97,370	19,841	11,758	59.3%	5,210	26.3%	1,663	8.4%
120,000 - <150,000 mg	46,460	9,352	6,205	66.3%	2,198	23.5%	577	6.2%
150,000 - <180,000 mg	24,013	4,297	3,195	74.4%	744	17.3%	194	4.5%
180,000 - <210,000 mg	*****	2,255	1,704	75.6%	359	15.9%	105	4.7%
≥ 210,000 mg	*****	3,358	1,291	38.4%	855	25.5%	564	16.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,834,241	1,248,422	68.1%	169,947	9.3%	115,590	6.3%
30,000 - <60,000 mg	1,997,151	263,211	120,235	45.7%	65,229	24.8%	31,645	12.0%
60,000 - <90,000 mg	852,245	107,143	52,334	48.8%	28,920	27.0%	13,225	12.3%
90,000 - <120,000 mg	422,980	51,751	28,018	54.1%	14,034	27.1%	4,717	9.1%
120,000 - <150,000 mg	231,140	29,443	16,814	57.1%	7,930	26.9%	2,903	9.9%
150,000 - <180,000 mg	133,068	16,666	12,033	72.2%	2,923	17.5%	835	5.0%
180,000 - <210,000 mg	81,274	8,721	6,089	69.8%	1,626	18.6%	475	5.4%
≥ 210,000 mg	53,201	17,786	4,904	27.6%	3,695	20.8%	3,071	17.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 - <30,000 mg	172,933	39,691	27,748	69.9%	3,165	8.0%	2,423	6.1%
30,000 - <60,000 mg	*****	7,189	5,044	70.2%	836	11.6%	461	6.4%
60,000 - <90,000 mg	*****	3,487	2,510	72.0%	440	12.6%	194	5.6%
90,000 - <120,000 mg	*****	1,918	1,434	74.8%	225	11.7%	102	5.3%
120,000 - <150,000 mg	*****	1,274	969	76.1%	149	11.7%	60	4.7%
150,000 - <180,000 mg	*****	868	705	81.2%	88	10.1%	24	2.8%
180,000 - <210,000 mg	*****	576	447	77.6%	69	12.0%	22	3.8%
≥ 210,000 mg	*****	1,700	627	36.9%	374	22.0%	264	15.5%
Bumetanide Users (No Washout)								
0 - <30,000 mg	681,031	100,865	77,790	77.1%	6,429	6.4%	4,729	4.7%
30,000 - <60,000 mg	304,791	28,470	22,433	78.8%	2,260	7.9%	1,219	4.3%
60,000 - <90,000 mg	201,271	15,567	12,088	77.7%	1,468	9.4%	671	4.3%
90,000 - <120,000 mg	141,898	9,889	7,855	79.4%	869	8.8%	383	3.9%
120,000 - <150,000 mg	104,735	6,903	5,475	79.3%	649	9.4%	264	3.8%
150,000 - <180,000 mg	*****	4,976	4,055	81.5%	398	8.0%	167	3.4%
180,000 - <210,000 mg	*****	3,509	2,826	80.5%	292	8.3%	139	4.0%
≥ 210,000 mg	47,345	14,181	5,162	36.4%	2,962	20.9%	1,905	13.4%
Torsemide Users (Washout)								
0 - <30,000 mg	172,357	49,198	36,907	75.0%	3,869	7.9%	2,553	5.2%
30,000 - <60,000 mg	*****	8,028	5,537	69.0%	1,217	15.2%	505	6.3%
60,000 - <90,000 mg	*****	3,479	2,505	72.0%	533	15.3%	201	5.8%
90,000 - <120,000 mg	*****	1,748	1,318	75.4%	240	13.7%	69	3.9%
120,000 - <150,000 mg	*****	1,114	893	80.2%	134	12.0%	37	3.3%
150,000 - <180,000 mg	*****	648	532	82.1%	73	11.3%	24	3.7%
180,000 - <210,000 mg	*****	446	352	78.9%	49	11.0%	17	3.8%
≥ 210,000 mg	*****	1,335	604	45.2%	296	22.2%	179	13.4%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time*					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0 - <30,000 mg	680,286	121,748	99,260	81.5%	6,961	5.7%	4,646	3.8%
30,000 - <60,000 mg	297,231	32,809	25,858	78.8%	3,200	9.8%	1,395	4.3%
60,000 - <90,000 mg	191,137	17,071	13,557	79.4%	1,771	10.4%	655	3.8%
90,000 - <120,000 mg	132,972	10,494	8,526	81.2%	1,003	9.6%	340	3.2%
120,000 - <150,000 mg	97,900	7,173	5,895	82.2%	658	9.2%	241	3.4%
150,000 - <180,000 mg	73,732	4,880	4,121	84.4%	405	8.3%	142	2.9%
180,000 - <210,000 mg	57,843	3,497	2,929	83.8%	290	8.3%	102	2.9%
≥ 210,000 mg	46,087	14,259	6,090	42.7%	2,912	20.4%	1,761	12.4%
Furosemide Users (Washout)								
0 - <30,000 mg	5,031,366	1,336,205	857,327	64.2%	137,595	10.3%	97,058	7.3%
30,000 - <60,000 mg	664,489	138,185	62,443	45.2%	36,959	26.7%	17,719	12.8%
60,000 - <90,000 mg	230,504	47,431	25,176	53.1%	13,400	28.3%	4,808	10.1%
90,000 - <120,000 mg	97,370	19,841	11,758	59.3%	5,210	26.3%	1,663	8.4%
120,000 - <150,000 mg	46,460	9,352	6,205	66.3%	2,198	23.5%	577	6.2%
150,000 - <180,000 mg	24,013	4,297	3,195	74.4%	744	17.3%	194	4.5%
180,000 - <210,000 mg	*****	2,255	1,704	75.6%	359	15.9%	105	4.7%
≥ 210,000 mg	*****	3,358	1,291	38.4%	855	25.5%	564	16.8%
Furosemide Users (No Washout)								
0 - <30,000 mg	8,853,716	1,834,241	1,248,422	68.1%	169,947	9.3%	115,590	6.3%
30,000 - <60,000 mg	1,997,151	263,211	120,235	45.7%	65,229	24.8%	31,645	12.0%
60,000 - <90,000 mg	852,245	107,143	52,334	48.8%	28,920	27.0%	13,225	12.3%
90,000 - <120,000 mg	422,980	51,751	28,018	54.1%	14,034	27.1%	4,717	9.1%
120,000 - <150,000 mg	231,140	29,443	16,814	57.1%	7,930	26.9%	2,903	9.9%
150,000 - <180,000 mg	133,068	16,666	12,033	72.2%	2,923	17.5%	835	5.0%
180,000 - <210,000 mg	81,274	8,721	6,089	69.8%	1,626	18.6%	475	5.4%
≥ 210,000 mg	53,201	17,786	4,904	27.6%	3,695	20.8%	3,071	17.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,829	4.6%	1,344	3.4%	901	2.3%	870	2.2%	1,411	3.6%
30,000 - <60,000 mg	299	4.2%	173	2.4%	125	1.7%	109	1.5%	142	2.0%
60,000 - <90,000 mg	123	3.5%	73	2.1%	52	1.5%	32	0.9%	63	1.8%
90,000 - <120,000 mg	63	3.3%	37	1.9%	21	1.1%	11	0.6%	25	1.3%
120,000 - <150,000 mg	32	2.5%	21	1.6%	19	1.5%	13	1.0%	11	0.9%
150,000 - <180,000 mg	12	1.4%	13	1.5%	*****	*****	*****	*****	12	1.4%
180,000 - <210,000 mg	20	3.5%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	179	10.5%	104	6.1%	78	4.6%	45	2.6%	29	1.7%
Bumetanide Users (No Washout)										
0 - <30,000 mg	3,443	3.4%	2,414	2.4%	1,692	1.7%	1,555	1.5%	2,813	2.8%
30,000 - <60,000 mg	759	2.7%	507	1.8%	334	1.2%	327	1.1%	631	2.2%
60,000 - <90,000 mg	407	2.6%	252	1.6%	188	1.2%	156	1.0%	337	2.2%
90,000 - <120,000 mg	223	2.3%	158	1.6%	101	1.0%	85	0.9%	215	2.2%
120,000 - <150,000 mg	155	2.2%	100	1.4%	74	1.1%	72	1.0%	114	1.7%
150,000 - <180,000 mg	100	2.0%	68	1.4%	55	1.1%	33	0.7%	100	2.0%
180,000 - <210,000 mg	89	2.5%	48	1.4%	30	0.9%	28	0.8%	57	1.6%
≥ 210,000 mg	1,470	10.4%	848	6.0%	606	4.3%	496	3.5%	732	5.2%
Torsemide Users (Washout)										
0 - <30,000 mg	1,716	3.5%	1,313	2.7%	969	2.0%	706	1.4%	1,165	2.4%
30,000 - <60,000 mg	294	3.7%	189	2.4%	109	1.4%	75	0.9%	102	1.3%
60,000 - <90,000 mg	82	2.4%	65	1.9%	33	0.9%	31	0.9%	29	0.8%
90,000 - <120,000 mg	56	3.2%	26	1.5%	16	0.9%	*****	*****	*****	*****
120,000 - <150,000 mg	18	1.6%	14	1.3%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	17	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	102	7.6%	66	4.9%	42	3.1%	29	2.2%	17	1.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	3,142	2.6%	2,285	1.9%	1,842	1.5%	1,193	1.0%	2,419	2.0%
30,000 - <60,000 mg	794	2.4%	521	1.6%	360	1.1%	233	0.7%	448	1.4%
60,000 - <90,000 mg	347	2.0%	225	1.3%	175	1.0%	127	0.7%	214	1.3%
90,000 - <120,000 mg	228	2.2%	151	1.4%	81	0.8%	68	0.6%	97	0.9%
120,000 - <150,000 mg	126	1.8%	91	1.3%	59	0.8%	52	0.7%	51	0.7%
150,000 - <180,000 mg	80	1.6%	45	0.9%	38	0.8%	17	0.3%	32	0.7%
180,000 - <210,000 mg	66	1.9%	46	1.3%	26	0.7%	13	0.4%	25	0.7%
≥ 210,000 mg	1,314	9.2%	740	5.2%	502	3.5%	373	2.6%	567	4.0%
Furosemide Users (Washout)										
0 - <30,000 mg	71,076	5.3%	53,920	4.0%	40,068	3.0%	29,172	2.2%	49,989	3.7%
30,000 - <60,000 mg	9,854	7.1%	5,156	3.7%	2,832	2.0%	1,654	1.2%	1,568	1.1%
60,000 - <90,000 mg	2,011	4.2%	1,027	2.2%	533	1.1%	271	0.6%	205	0.4%
90,000 - <120,000 mg	680	3.4%	307	1.5%	119	0.6%	65	0.3%	39	0.2%
120,000 - <150,000 mg	191	2.0%	86	0.9%	55	0.6%	23	0.2%	17	0.2%
150,000 - <180,000 mg	94	2.2%	43	1.0%	13	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	24	1.1%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	290	8.6%	182	5.4%	91	2.7%	48	1.4%	37	1.1%
Furosemide Users (No Washout)										
0 - <30,000 mg	83,129	4.5%	62,799	3.4%	48,040	2.6%	34,023	1.9%	72,291	3.9%
30,000 - <60,000 mg	18,799	7.1%	9,975	3.8%	6,236	2.4%	5,123	1.9%	5,969	2.3%
60,000 - <90,000 mg	5,389	5.0%	2,869	2.7%	1,864	1.7%	1,518	1.4%	1,024	1.0%
90,000 - <120,000 mg	2,333	4.5%	1,513	2.9%	485	0.9%	319	0.6%	332	0.6%
120,000 - <150,000 mg	790	2.7%	419	1.4%	276	0.9%	199	0.7%	112	0.4%
150,000 - <180,000 mg	409	2.5%	230	1.4%	138	0.8%	45	0.3%	53	0.3%
180,000 - <210,000 mg	257	2.9%	155	1.8%	60	0.7%	30	0.3%	29	0.3%
≥ 210,000 mg	2,764	15.5%	1,126	6.3%	913	5.1%	660	3.7%	653	3.7%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,829	4.6%	1,344	3.4%	901	2.3%	870	2.2%	1,411	3.6%
30,000 - <60,000 mg	299	4.2%	173	2.4%	125	1.7%	109	1.5%	142	2.0%
60,000 - <90,000 mg	123	3.5%	73	2.1%	52	1.5%	32	0.9%	63	1.8%
90,000 - <120,000 mg	63	3.3%	37	1.9%	21	1.1%	11	0.6%	25	1.3%
120,000 - <150,000 mg	32	2.5%	21	1.6%	19	1.5%	13	1.0%	11	0.9%
150,000 - <180,000 mg	12	1.4%	13	1.5%	*****	*****	*****	*****	12	1.4%
180,000 - <210,000 mg	20	3.5%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	179	10.5%	104	6.1%	78	4.6%	45	2.6%	29	1.7%
Bumetanide Users (No Washout)										
0 - <30,000 mg	3,443	3.4%	2,414	2.4%	1,692	1.7%	1,555	1.5%	2,813	2.8%
30,000 - <60,000 mg	759	2.7%	507	1.8%	334	1.2%	327	1.1%	631	2.2%
60,000 - <90,000 mg	407	2.6%	252	1.6%	188	1.2%	156	1.0%	337	2.2%
90,000 - <120,000 mg	223	2.3%	158	1.6%	101	1.0%	85	0.9%	215	2.2%
120,000 - <150,000 mg	155	2.2%	100	1.4%	74	1.1%	72	1.0%	114	1.7%
150,000 - <180,000 mg	100	2.0%	68	1.4%	55	1.1%	33	0.7%	100	2.0%
180,000 - <210,000 mg	89	2.5%	48	1.4%	30	0.9%	28	0.8%	57	1.6%
≥ 210,000 mg	1,470	10.4%	848	6.0%	606	4.3%	496	3.5%	732	5.2%
Torsemide Users (Washout)										
0 - <30,000 mg	1,716	3.5%	1,313	2.7%	969	2.0%	706	1.4%	1,165	2.4%
30,000 - <60,000 mg	294	3.7%	189	2.4%	109	1.4%	75	0.9%	102	1.3%
60,000 - <90,000 mg	82	2.4%	65	1.9%	33	0.9%	31	0.9%	29	0.8%
90,000 - <120,000 mg	56	3.2%	26	1.5%	16	0.9%	*****	*****	*****	*****
120,000 - <150,000 mg	18	1.6%	14	1.3%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	17	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	102	7.6%	66	4.9%	42	3.1%	29	2.2%	17	1.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	3,142	2.6%	2,285	1.9%	1,842	1.5%	1,193	1.0%	2,419	2.0%
30,000 - <60,000 mg	794	2.4%	521	1.6%	360	1.1%	233	0.7%	448	1.4%
60,000 - <90,000 mg	347	2.0%	225	1.3%	175	1.0%	127	0.7%	214	1.3%
90,000 - <120,000 mg	228	2.2%	151	1.4%	81	0.8%	68	0.6%	97	0.9%
120,000 - <150,000 mg	126	1.8%	91	1.3%	59	0.8%	52	0.7%	51	0.7%
150,000 - <180,000 mg	80	1.6%	45	0.9%	38	0.8%	17	0.3%	32	0.7%
180,000 - <210,000 mg	66	1.9%	46	1.3%	26	0.7%	13	0.4%	25	0.7%
≥ 210,000 mg	1,314	9.2%	740	5.2%	502	3.5%	373	2.6%	567	4.0%
Furosemide Users (Washout)										
0 - <30,000 mg	71,076	5.3%	53,920	4.0%	40,068	3.0%	29,172	2.2%	49,989	3.7%
30,000 - <60,000 mg	9,854	7.1%	5,156	3.7%	2,832	2.0%	1,654	1.2%	1,568	1.1%
60,000 - <90,000 mg	2,011	4.2%	1,027	2.2%	533	1.1%	271	0.6%	205	0.4%
90,000 - <120,000 mg	680	3.4%	307	1.5%	119	0.6%	65	0.3%	39	0.2%
120,000 - <150,000 mg	191	2.0%	86	0.9%	55	0.6%	23	0.2%	17	0.2%
150,000 - <180,000 mg	94	2.2%	43	1.0%	13	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	24	1.1%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	290	8.6%	182	5.4%	91	2.7%	48	1.4%	37	1.1%
Furosemide Users (No Washout)										
0 - <30,000 mg	83,129	4.5%	62,799	3.4%	48,040	2.6%	34,023	1.9%	72,291	3.9%
30,000 - <60,000 mg	18,799	7.1%	9,975	3.8%	6,236	2.4%	5,123	1.9%	5,969	2.3%
60,000 - <90,000 mg	5,389	5.0%	2,869	2.7%	1,864	1.7%	1,518	1.4%	1,024	1.0%
90,000 - <120,000 mg	2,333	4.5%	1,513	2.9%	485	0.9%	319	0.6%	332	0.6%
120,000 - <150,000 mg	790	2.7%	419	1.4%	276	0.9%	199	0.7%	112	0.4%
150,000 - <180,000 mg	409	2.5%	230	1.4%	138	0.8%	45	0.3%	53	0.3%
180,000 - <210,000 mg	257	2.9%	155	1.8%	60	0.7%	30	0.3%	29	0.3%
≥ 210,000 mg	2,764	15.5%	1,126	6.3%	913	5.1%	660	3.7%	653	3.7%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,829	4.6%	1,344	3.4%	901	2.3%	870	2.2%	1,411	3.6%
30,000 - <60,000 mg	299	4.2%	173	2.4%	125	1.7%	109	1.5%	142	2.0%
60,000 - <90,000 mg	123	3.5%	73	2.1%	52	1.5%	32	0.9%	63	1.8%
90,000 - <120,000 mg	63	3.3%	37	1.9%	21	1.1%	11	0.6%	25	1.3%
120,000 - <150,000 mg	32	2.5%	21	1.6%	19	1.5%	13	1.0%	11	0.9%
150,000 - <180,000 mg	12	1.4%	13	1.5%	*****	*****	*****	*****	12	1.4%
180,000 - <210,000 mg	20	3.5%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	179	10.5%	104	6.1%	78	4.6%	45	2.6%	29	1.7%
Bumetanide Users (No Washout)										
0 - <30,000 mg	3,443	3.4%	2,414	2.4%	1,692	1.7%	1,555	1.5%	2,813	2.8%
30,000 - <60,000 mg	759	2.7%	507	1.8%	334	1.2%	327	1.1%	631	2.2%
60,000 - <90,000 mg	407	2.6%	252	1.6%	188	1.2%	156	1.0%	337	2.2%
90,000 - <120,000 mg	223	2.3%	158	1.6%	101	1.0%	85	0.9%	215	2.2%
120,000 - <150,000 mg	155	2.2%	100	1.4%	74	1.1%	72	1.0%	114	1.7%
150,000 - <180,000 mg	100	2.0%	68	1.4%	55	1.1%	33	0.7%	100	2.0%
180,000 - <210,000 mg	89	2.5%	48	1.4%	30	0.9%	28	0.8%	57	1.6%
≥ 210,000 mg	1,470	10.4%	848	6.0%	606	4.3%	496	3.5%	732	5.2%
Torsemide Users (Washout)										
0 - <30,000 mg	1,716	3.5%	1,313	2.7%	969	2.0%	706	1.4%	1,165	2.4%
30,000 - <60,000 mg	294	3.7%	189	2.4%	109	1.4%	75	0.9%	102	1.3%
60,000 - <90,000 mg	82	2.4%	65	1.9%	33	0.9%	31	0.9%	29	0.8%
90,000 - <120,000 mg	56	3.2%	26	1.5%	16	0.9%	*****	*****	*****	*****
120,000 - <150,000 mg	18	1.6%	14	1.3%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	17	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	102	7.6%	66	4.9%	42	3.1%	29	2.2%	17	1.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	3,142	2.6%	2,285	1.9%	1,842	1.5%	1,193	1.0%	2,419	2.0%
30,000 - <60,000 mg	794	2.4%	521	1.6%	360	1.1%	233	0.7%	448	1.4%
60,000 - <90,000 mg	347	2.0%	225	1.3%	175	1.0%	127	0.7%	214	1.3%
90,000 - <120,000 mg	228	2.2%	151	1.4%	81	0.8%	68	0.6%	97	0.9%
120,000 - <150,000 mg	126	1.8%	91	1.3%	59	0.8%	52	0.7%	51	0.7%
150,000 - <180,000 mg	80	1.6%	45	0.9%	38	0.8%	17	0.3%	32	0.7%
180,000 - <210,000 mg	66	1.9%	46	1.3%	26	0.7%	13	0.4%	25	0.7%
≥ 210,000 mg	1,314	9.2%	740	5.2%	502	3.5%	373	2.6%	567	4.0%
Furosemide Users (Washout)										
0 - <30,000 mg	71,076	5.3%	53,920	4.0%	40,068	3.0%	29,172	2.2%	49,989	3.7%
30,000 - <60,000 mg	9,854	7.1%	5,156	3.7%	2,832	2.0%	1,654	1.2%	1,568	1.1%
60,000 - <90,000 mg	2,011	4.2%	1,027	2.2%	533	1.1%	271	0.6%	205	0.4%
90,000 - <120,000 mg	680	3.4%	307	1.5%	119	0.6%	65	0.3%	39	0.2%
120,000 - <150,000 mg	191	2.0%	86	0.9%	55	0.6%	23	0.2%	17	0.2%
150,000 - <180,000 mg	94	2.2%	43	1.0%	13	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	24	1.1%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	290	8.6%	182	5.4%	91	2.7%	48	1.4%	37	1.1%
Furosemide Users (No Washout)										
0 - <30,000 mg	83,129	4.5%	62,799	3.4%	48,040	2.6%	34,023	1.9%	72,291	3.9%
30,000 - <60,000 mg	18,799	7.1%	9,975	3.8%	6,236	2.4%	5,123	1.9%	5,969	2.3%
60,000 - <90,000 mg	5,389	5.0%	2,869	2.7%	1,864	1.7%	1,518	1.4%	1,024	1.0%
90,000 - <120,000 mg	2,333	4.5%	1,513	2.9%	485	0.9%	319	0.6%	332	0.6%
120,000 - <150,000 mg	790	2.7%	419	1.4%	276	0.9%	199	0.7%	112	0.4%
150,000 - <180,000 mg	409	2.5%	230	1.4%	138	0.8%	45	0.3%	53	0.3%
180,000 - <210,000 mg	257	2.9%	155	1.8%	60	0.7%	30	0.3%	29	0.3%
≥ 210,000 mg	2,764	15.5%	1,126	6.3%	913	5.1%	660	3.7%	653	3.7%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 - <30,000 mg	1,829	4.6%	1,344	3.4%	901	2.3%	870	2.2%	1,411	3.6%
30,000 - <60,000 mg	299	4.2%	173	2.4%	125	1.7%	109	1.5%	142	2.0%
60,000 - <90,000 mg	123	3.5%	73	2.1%	52	1.5%	32	0.9%	63	1.8%
90,000 - <120,000 mg	63	3.3%	37	1.9%	21	1.1%	11	0.6%	25	1.3%
120,000 - <150,000 mg	32	2.5%	21	1.6%	19	1.5%	13	1.0%	11	0.9%
150,000 - <180,000 mg	12	1.4%	13	1.5%	*****	*****	*****	*****	12	1.4%
180,000 - <210,000 mg	20	3.5%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	179	10.5%	104	6.1%	78	4.6%	45	2.6%	29	1.7%
Bumetanide Users (No Washout)										
0 - <30,000 mg	3,443	3.4%	2,414	2.4%	1,692	1.7%	1,555	1.5%	2,813	2.8%
30,000 - <60,000 mg	759	2.7%	507	1.8%	334	1.2%	327	1.1%	631	2.2%
60,000 - <90,000 mg	407	2.6%	252	1.6%	188	1.2%	156	1.0%	337	2.2%
90,000 - <120,000 mg	223	2.3%	158	1.6%	101	1.0%	85	0.9%	215	2.2%
120,000 - <150,000 mg	155	2.2%	100	1.4%	74	1.1%	72	1.0%	114	1.7%
150,000 - <180,000 mg	100	2.0%	68	1.4%	55	1.1%	33	0.7%	100	2.0%
180,000 - <210,000 mg	89	2.5%	48	1.4%	30	0.9%	28	0.8%	57	1.6%
≥ 210,000 mg	1,470	10.4%	848	6.0%	606	4.3%	496	3.5%	732	5.2%
Torsemide Users (Washout)										
0 - <30,000 mg	1,716	3.5%	1,313	2.7%	969	2.0%	706	1.4%	1,165	2.4%
30,000 - <60,000 mg	294	3.7%	189	2.4%	109	1.4%	75	0.9%	102	1.3%
60,000 - <90,000 mg	82	2.4%	65	1.9%	33	0.9%	31	0.9%	29	0.8%
90,000 - <120,000 mg	56	3.2%	26	1.5%	16	0.9%	*****	*****	*****	*****
120,000 - <150,000 mg	18	1.6%	14	1.3%	*****	*****	*****	*****	*****	*****
150,000 - <180,000 mg	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
180,000 - <210,000 mg	17	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	102	7.6%	66	4.9%	42	3.1%	29	2.2%	17	1.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0 - <30,000 mg	3,142	2.6%	2,285	1.9%	1,842	1.5%	1,193	1.0%	2,419	2.0%
30,000 - <60,000 mg	794	2.4%	521	1.6%	360	1.1%	233	0.7%	448	1.4%
60,000 - <90,000 mg	347	2.0%	225	1.3%	175	1.0%	127	0.7%	214	1.3%
90,000 - <120,000 mg	228	2.2%	151	1.4%	81	0.8%	68	0.6%	97	0.9%
120,000 - <150,000 mg	126	1.8%	91	1.3%	59	0.8%	52	0.7%	51	0.7%
150,000 - <180,000 mg	80	1.6%	45	0.9%	38	0.8%	17	0.3%	32	0.7%
180,000 - <210,000 mg	66	1.9%	46	1.3%	26	0.7%	13	0.4%	25	0.7%
≥ 210,000 mg	1,314	9.2%	740	5.2%	502	3.5%	373	2.6%	567	4.0%
Furosemide Users (Washout)										
0 - <30,000 mg	71,076	5.3%	53,920	4.0%	40,068	3.0%	29,172	2.2%	49,989	3.7%
30,000 - <60,000 mg	9,854	7.1%	5,156	3.7%	2,832	2.0%	1,654	1.2%	1,568	1.1%
60,000 - <90,000 mg	2,011	4.2%	1,027	2.2%	533	1.1%	271	0.6%	205	0.4%
90,000 - <120,000 mg	680	3.4%	307	1.5%	119	0.6%	65	0.3%	39	0.2%
120,000 - <150,000 mg	191	2.0%	86	0.9%	55	0.6%	23	0.2%	17	0.2%
150,000 - <180,000 mg	94	2.2%	43	1.0%	13	0.3%	*****	*****	*****	*****
180,000 - <210,000 mg	41	1.8%	24	1.1%	*****	*****	*****	*****	*****	*****
≥ 210,000 mg	290	8.6%	182	5.4%	91	2.7%	48	1.4%	37	1.1%
Furosemide Users (No Washout)										
0 - <30,000 mg	83,129	4.5%	62,799	3.4%	48,040	2.6%	34,023	1.9%	72,291	3.9%
30,000 - <60,000 mg	18,799	7.1%	9,975	3.8%	6,236	2.4%	5,123	1.9%	5,969	2.3%
60,000 - <90,000 mg	5,389	5.0%	2,869	2.7%	1,864	1.7%	1,518	1.4%	1,024	1.0%
90,000 - <120,000 mg	2,333	4.5%	1,513	2.9%	485	0.9%	319	0.6%	332	0.6%
120,000 - <150,000 mg	790	2.7%	419	1.4%	276	0.9%	199	0.7%	112	0.4%
150,000 - <180,000 mg	409	2.5%	230	1.4%	138	0.8%	45	0.3%	53	0.3%

Table 17b. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Dose*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time*									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
180,000 - <210,000 mg	257	2.9%	155	1.8%	60	0.7%	30	0.3%	29	0.3%
≥ 210,000 mg	2,764	15.5%	1,126	6.3%	913	5.1%	660	3.7%	653	3.7%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	41,416	29,259	70.6%	3,224	7.8%	2,491	6.0%
1-2 years	43,206	7,430	5,245	70.6%	827	11.1%	455	6.1%
2-3 years	*****	3,537	2,495	70.5%	480	13.6%	207	5.9%
3-4 years	*****	1,812	1,309	72.2%	283	15.6%	86	4.7%
4-5 years	*****	1,103	837	75.9%	145	13.1%	53	4.8%
5-6 years	*****	638	502	78.7%	80	12.5%	25	3.9%
6-7 years	*****	341	277	81.2%	44	12.9%	*****	*****
7+ years	*****	426	171	40.1%	110	25.8%	94	22.1%
Bumetanide Users (No Washout)								
0-1 years	681,044	118,866	93,713	78.8%	7,083	6.0%	5,205	4.4%
1-2 years	231,141	30,412	23,765	78.1%	2,536	8.3%	1,322	4.3%
2-3 years	120,390	15,058	10,829	71.9%	2,032	13.5%	716	4.8%
3-4 years	60,491	7,966	5,764	72.4%	1,074	13.5%	341	4.3%
4-5 years	31,830	4,764	3,638	76.4%	563	11.8%	202	4.2%
5-6 years	*****	2,854	2,179	76.3%	340	11.9%	126	4.4%
6-7 years	*****	1,664	1,316	79.1%	197	11.8%	70	4.2%
7+ years	*****	2,776	893	32.2%	572	20.6%	559	20.1%
Torsemide Users (Washout)								
0-1 years	172,362	46,805	35,696	76.3%	3,397	7.3%	2,281	4.9%
1-2 years	*****	9,465	7,265	76.8%	920	9.7%	484	5.1%
2-3 years	*****	4,480	3,266	72.9%	674	15.0%	203	4.5%
3-4 years	*****	2,349	1,799	76.6%	299	12.7%	107	4.6%
4-5 years	*****	1,231	987	80.2%	147	11.9%	45	3.7%
5-6 years	*****	749	593	79.2%	89	11.9%	34	4.5%
6-7 years	*****	426	353	82.9%	53	12.4%	*****	*****
7+ years	*****	491	205	41.8%	138	28.1%	96	19.6%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	132,516	110,782	83.6%	6,659	5.0%	4,477	3.4%
1-2 years	249,185	37,548	31,020	82.6%	2,744	7.3%	1,342	3.6%
2-3 years	131,368	18,588	14,046	75.6%	2,483	13.4%	716	3.9%
3-4 years	66,841	9,579	7,333	76.6%	1,243	13.0%	373	3.9%
4-5 years	35,645	5,325	4,147	77.9%	625	11.7%	197	3.7%
5-6 years	*****	3,240	2,505	77.3%	375	11.6%	145	4.5%
6-7 years	*****	1,964	1,557	79.3%	241	12.3%	63	3.2%
7+ years	*****	3,171	1,035	32.6%	708	22.3%	596	18.8%
Furosemide Users (Washout)								
0-1 years	5,031,471	1,045,737	715,353	68.4%	90,466	8.7%	66,185	6.3%
1-2 years	1,570,858	214,539	150,400	70.1%	25,856	12.1%	14,008	6.5%
2-3 years	857,233	117,949	81,393	69.0%	18,127	15.4%	7,201	6.1%
3-4 years	462,012	70,590	51,765	73.3%	9,948	14.1%	3,683	5.2%
4-5 years	253,038	43,230	33,003	76.3%	5,702	13.2%	2,012	4.7%
5-6 years	138,456	27,926	21,940	78.6%	3,647	13.1%	1,124	4.0%
6-7 years	73,838	17,539	14,311	81.6%	2,057	11.7%	653	3.7%
7+ years	37,943	23,414	9,244	39.5%	6,724	28.7%	4,428	18.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,368,002	995,529	72.8%	100,538	7.3%	72,932	5.3%
1-2 years	3,756,719	366,369	271,561	74.1%	35,844	9.8%	19,497	5.3%
2-3 years	2,243,787	202,537	139,731	69.0%	29,230	14.4%	11,701	5.8%
3-4 years	1,290,390	126,929	90,937	71.6%	17,403	13.7%	6,672	5.3%
4-5 years	759,943	83,816	61,716	73.6%	11,089	13.2%	4,069	4.9%
5-6 years	451,504	58,544	43,848	74.9%	7,676	13.1%	2,795	4.8%
6-7 years	267,682	40,176	30,976	77.1%	5,097	12.7%	1,711	4.3%
7+ years	157,482	82,589	23,576	28.5%	18,060	21.9%	15,715	19.0%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	41,416	29,259	70.6%	3,224	7.8%	2,491	6.0%
1-2 years	43,206	7,430	5,245	70.6%	827	11.1%	455	6.1%
2-3 years	*****	3,537	2,495	70.5%	480	13.6%	207	5.9%
3-4 years	*****	1,812	1,309	72.2%	283	15.6%	86	4.7%
4-5 years	*****	1,103	837	75.9%	145	13.1%	53	4.8%
5-6 years	*****	638	502	78.7%	80	12.5%	25	3.9%
6-7 years	*****	341	277	81.2%	44	12.9%	*****	*****
7+ years	*****	426	171	40.1%	110	25.8%	94	22.1%
Bumetanide Users (No Washout)								
0-1 years	681,044	118,866	93,713	78.8%	7,083	6.0%	5,205	4.4%
1-2 years	231,141	30,412	23,765	78.1%	2,536	8.3%	1,322	4.3%
2-3 years	120,390	15,058	10,829	71.9%	2,032	13.5%	716	4.8%
3-4 years	60,491	7,966	5,764	72.4%	1,074	13.5%	341	4.3%
4-5 years	31,830	4,764	3,638	76.4%	563	11.8%	202	4.2%
5-6 years	*****	2,854	2,179	76.3%	340	11.9%	126	4.4%
6-7 years	*****	1,664	1,316	79.1%	197	11.8%	70	4.2%
7+ years	*****	2,776	893	32.2%	572	20.6%	559	20.1%
Torsemide Users (Washout)								
0-1 years	172,362	46,805	35,696	76.3%	3,397	7.3%	2,281	4.9%
1-2 years	*****	9,465	7,265	76.8%	920	9.7%	484	5.1%
2-3 years	*****	4,480	3,266	72.9%	674	15.0%	203	4.5%
3-4 years	*****	2,349	1,799	76.6%	299	12.7%	107	4.6%
4-5 years	*****	1,231	987	80.2%	147	11.9%	45	3.7%
5-6 years	*****	749	593	79.2%	89	11.9%	34	4.5%
6-7 years	*****	426	353	82.9%	53	12.4%	*****	*****
7+ years	*****	491	205	41.8%	138	28.1%	96	19.6%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	132,516	110,782	83.6%	6,659	5.0%	4,477	3.4%
1-2 years	249,185	37,548	31,020	82.6%	2,744	7.3%	1,342	3.6%
2-3 years	131,368	18,588	14,046	75.6%	2,483	13.4%	716	3.9%
3-4 years	66,841	9,579	7,333	76.6%	1,243	13.0%	373	3.9%
4-5 years	35,645	5,325	4,147	77.9%	625	11.7%	197	3.7%
5-6 years	*****	3,240	2,505	77.3%	375	11.6%	145	4.5%
6-7 years	*****	1,964	1,557	79.3%	241	12.3%	63	3.2%
7+ years	*****	3,171	1,035	32.6%	708	22.3%	596	18.8%
Furosemide Users (Washout)								
0-1 years	5,031,471	1,045,737	715,353	68.4%	90,466	8.7%	66,185	6.3%
1-2 years	1,570,858	214,539	150,400	70.1%	25,856	12.1%	14,008	6.5%
2-3 years	857,233	117,949	81,393	69.0%	18,127	15.4%	7,201	6.1%
3-4 years	462,012	70,590	51,765	73.3%	9,948	14.1%	3,683	5.2%
4-5 years	253,038	43,230	33,003	76.3%	5,702	13.2%	2,012	4.7%
5-6 years	138,456	27,926	21,940	78.6%	3,647	13.1%	1,124	4.0%
6-7 years	73,838	17,539	14,311	81.6%	2,057	11.7%	653	3.7%
7+ years	37,943	23,414	9,244	39.5%	6,724	28.7%	4,428	18.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,368,002	995,529	72.8%	100,538	7.3%	72,932	5.3%
1-2 years	3,756,719	366,369	271,561	74.1%	35,844	9.8%	19,497	5.3%
2-3 years	2,243,787	202,537	139,731	69.0%	29,230	14.4%	11,701	5.8%
3-4 years	1,290,390	126,929	90,937	71.6%	17,403	13.7%	6,672	5.3%
4-5 years	759,943	83,816	61,716	73.6%	11,089	13.2%	4,069	4.9%
5-6 years	451,504	58,544	43,848	74.9%	7,676	13.1%	2,795	4.8%
6-7 years	267,682	40,176	30,976	77.1%	5,097	12.7%	1,711	4.3%
7+ years	157,482	82,589	23,576	28.5%	18,060	21.9%	15,715	19.0%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	41,416	29,259	70.6%	3,224	7.8%	2,491	6.0%
1-2 years	43,206	7,430	5,245	70.6%	827	11.1%	455	6.1%
2-3 years	*****	3,537	2,495	70.5%	480	13.6%	207	5.9%
3-4 years	*****	1,812	1,309	72.2%	283	15.6%	86	4.7%
4-5 years	*****	1,103	837	75.9%	145	13.1%	53	4.8%
5-6 years	*****	638	502	78.7%	80	12.5%	25	3.9%
6-7 years	*****	341	277	81.2%	44	12.9%	*****	*****
7+ years	*****	426	171	40.1%	110	25.8%	94	22.1%
Bumetanide Users (No Washout)								
0-1 years	681,044	118,866	93,713	78.8%	7,083	6.0%	5,205	4.4%
1-2 years	231,141	30,412	23,765	78.1%	2,536	8.3%	1,322	4.3%
2-3 years	120,390	15,058	10,829	71.9%	2,032	13.5%	716	4.8%
3-4 years	60,491	7,966	5,764	72.4%	1,074	13.5%	341	4.3%
4-5 years	31,830	4,764	3,638	76.4%	563	11.8%	202	4.2%
5-6 years	*****	2,854	2,179	76.3%	340	11.9%	126	4.4%
6-7 years	*****	1,664	1,316	79.1%	197	11.8%	70	4.2%
7+ years	*****	2,776	893	32.2%	572	20.6%	559	20.1%
Torsemide Users (Washout)								
0-1 years	172,362	46,805	35,696	76.3%	3,397	7.3%	2,281	4.9%
1-2 years	*****	9,465	7,265	76.8%	920	9.7%	484	5.1%
2-3 years	*****	4,480	3,266	72.9%	674	15.0%	203	4.5%
3-4 years	*****	2,349	1,799	76.6%	299	12.7%	107	4.6%
4-5 years	*****	1,231	987	80.2%	147	11.9%	45	3.7%
5-6 years	*****	749	593	79.2%	89	11.9%	34	4.5%
6-7 years	*****	426	353	82.9%	53	12.4%	*****	*****
7+ years	*****	491	205	41.8%	138	28.1%	96	19.6%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	132,516	110,782	83.6%	6,659	5.0%	4,477	3.4%
1-2 years	249,185	37,548	31,020	82.6%	2,744	7.3%	1,342	3.6%
2-3 years	131,368	18,588	14,046	75.6%	2,483	13.4%	716	3.9%
3-4 years	66,841	9,579	7,333	76.6%	1,243	13.0%	373	3.9%
4-5 years	35,645	5,325	4,147	77.9%	625	11.7%	197	3.7%
5-6 years	*****	3,240	2,505	77.3%	375	11.6%	145	4.5%
6-7 years	*****	1,964	1,557	79.3%	241	12.3%	63	3.2%
7+ years	*****	3,171	1,035	32.6%	708	22.3%	596	18.8%
Furosemide Users (Washout)								
0-1 years	5,031,471	1,045,737	715,353	68.4%	90,466	8.7%	66,185	6.3%
1-2 years	1,570,858	214,539	150,400	70.1%	25,856	12.1%	14,008	6.5%
2-3 years	857,233	117,949	81,393	69.0%	18,127	15.4%	7,201	6.1%
3-4 years	462,012	70,590	51,765	73.3%	9,948	14.1%	3,683	5.2%
4-5 years	253,038	43,230	33,003	76.3%	5,702	13.2%	2,012	4.7%
5-6 years	138,456	27,926	21,940	78.6%	3,647	13.1%	1,124	4.0%
6-7 years	73,838	17,539	14,311	81.6%	2,057	11.7%	653	3.7%
7+ years	37,943	23,414	9,244	39.5%	6,724	28.7%	4,428	18.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,368,002	995,529	72.8%	100,538	7.3%	72,932	5.3%
1-2 years	3,756,719	366,369	271,561	74.1%	35,844	9.8%	19,497	5.3%
2-3 years	2,243,787	202,537	139,731	69.0%	29,230	14.4%	11,701	5.8%
3-4 years	1,290,390	126,929	90,937	71.6%	17,403	13.7%	6,672	5.3%
4-5 years	759,943	83,816	61,716	73.6%	11,089	13.2%	4,069	4.9%
5-6 years	451,504	58,544	43,848	74.9%	7,676	13.1%	2,795	4.8%
6-7 years	267,682	40,176	30,976	77.1%	5,097	12.7%	1,711	4.3%
7+ years	157,482	82,589	23,576	28.5%	18,060	21.9%	15,715	19.0%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0-1 years	172,936	41,416	29,259	70.6%	3,224	7.8%	2,491	6.0%
1-2 years	43,206	7,430	5,245	70.6%	827	11.1%	455	6.1%
2-3 years	*****	3,537	2,495	70.5%	480	13.6%	207	5.9%
3-4 years	*****	1,812	1,309	72.2%	283	15.6%	86	4.7%
4-5 years	*****	1,103	837	75.9%	145	13.1%	53	4.8%
5-6 years	*****	638	502	78.7%	80	12.5%	25	3.9%
6-7 years	*****	341	277	81.2%	44	12.9%	*****	*****
7+ years	*****	426	171	40.1%	110	25.8%	94	22.1%
Bumetanide Users (No Washout)								
0-1 years	681,044	118,866	93,713	78.8%	7,083	6.0%	5,205	4.4%
1-2 years	231,141	30,412	23,765	78.1%	2,536	8.3%	1,322	4.3%
2-3 years	120,390	15,058	10,829	71.9%	2,032	13.5%	716	4.8%
3-4 years	60,491	7,966	5,764	72.4%	1,074	13.5%	341	4.3%
4-5 years	31,830	4,764	3,638	76.4%	563	11.8%	202	4.2%
5-6 years	*****	2,854	2,179	76.3%	340	11.9%	126	4.4%
6-7 years	*****	1,664	1,316	79.1%	197	11.8%	70	4.2%
7+ years	*****	2,776	893	32.2%	572	20.6%	559	20.1%
Torsemide Users (Washout)								
0-1 years	172,362	46,805	35,696	76.3%	3,397	7.3%	2,281	4.9%
1-2 years	*****	9,465	7,265	76.8%	920	9.7%	484	5.1%
2-3 years	*****	4,480	3,266	72.9%	674	15.0%	203	4.5%
3-4 years	*****	2,349	1,799	76.6%	299	12.7%	107	4.6%
4-5 years	*****	1,231	987	80.2%	147	11.9%	45	3.7%
5-6 years	*****	749	593	79.2%	89	11.9%	34	4.5%
6-7 years	*****	426	353	82.9%	53	12.4%	*****	*****
7+ years	*****	491	205	41.8%	138	28.1%	96	19.6%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)								
0-1 years	680,304	132,516	110,782	83.6%	6,659	5.0%	4,477	3.4%
1-2 years	249,185	37,548	31,020	82.6%	2,744	7.3%	1,342	3.6%
2-3 years	131,368	18,588	14,046	75.6%	2,483	13.4%	716	3.9%
3-4 years	66,841	9,579	7,333	76.6%	1,243	13.0%	373	3.9%
4-5 years	35,645	5,325	4,147	77.9%	625	11.7%	197	3.7%
5-6 years	*****	3,240	2,505	77.3%	375	11.6%	145	4.5%
6-7 years	*****	1,964	1,557	79.3%	241	12.3%	63	3.2%
7+ years	*****	3,171	1,035	32.6%	708	22.3%	596	18.8%
Furosemide Users (Washout)								
0-1 years	5,031,471	1,045,737	715,353	68.4%	90,466	8.7%	66,185	6.3%
1-2 years	1,570,858	214,539	150,400	70.1%	25,856	12.1%	14,008	6.5%
2-3 years	857,233	117,949	81,393	69.0%	18,127	15.4%	7,201	6.1%
3-4 years	462,012	70,590	51,765	73.3%	9,948	14.1%	3,683	5.2%
4-5 years	253,038	43,230	33,003	76.3%	5,702	13.2%	2,012	4.7%
5-6 years	138,456	27,926	21,940	78.6%	3,647	13.1%	1,124	4.0%
6-7 years	73,838	17,539	14,311	81.6%	2,057	11.7%	653	3.7%
7+ years	37,943	23,414	9,244	39.5%	6,724	28.7%	4,428	18.9%
Furosemide Users (No Washout)								
0-1 years	8,853,836	1,368,002	995,529	72.8%	100,538	7.3%	72,932	5.3%
1-2 years	3,756,719	366,369	271,561	74.1%	35,844	9.8%	19,497	5.3%
2-3 years	2,243,787	202,537	139,731	69.0%	29,230	14.4%	11,701	5.8%
3-4 years	1,290,390	126,929	90,937	71.6%	17,403	13.7%	6,672	5.3%
4-5 years	759,943	83,816	61,716	73.6%	11,089	13.2%	4,069	4.9%
5-6 years	451,504	58,544	43,848	74.9%	7,676	13.1%	2,795	4.8%
6-7 years	267,682	40,176	30,976	77.1%	5,097	12.7%	1,711	4.3%
7+ years	157,482	82,589	23,576	28.5%	18,060	21.9%	15,715	19.0%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,858	4.5%	1,373	3.3%	912	2.2%	891	2.2%	1,408	3.4%
1-2 years	285	3.8%	182	2.4%	136	1.8%	120	1.6%	180	2.4%
2-3 years	140	4.0%	82	2.3%	45	1.3%	29	0.8%	59	1.7%
3-4 years	46	2.5%	35	1.9%	19	1.0%	15	0.8%	19	1.0%
4-5 years	25	2.3%	20	1.8%	*****	*****	*****	*****	*****	*****
5-6 years	14	2.2%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	39	9.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	3,709	3.1%	2,648	2.2%	1,798	1.5%	1,713	1.4%	2,997	2.5%
1-2 years	818	2.7%	511	1.7%	388	1.3%	320	1.1%	752	2.5%
2-3 years	449	3.0%	280	1.9%	177	1.2%	137	0.9%	438	2.9%
3-4 years	207	2.6%	162	2.0%	96	1.2%	100	1.3%	222	2.8%
4-5 years	134	2.8%	80	1.7%	67	1.4%	64	1.3%	16	0.3%
5-6 years	87	3.0%	57	2.0%	*****	*****	*****	*****	*****	*****
6-7 years	40	2.4%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	658	23.7%	39	1.4%	29	1.0%	13	0.5%	13	0.5%
Torsemide Users (Washout)										
0-1 years	1,535	3.3%	1,221	2.6%	910	1.9%	662	1.4%	1,103	2.4%
1-2 years	285	3.0%	175	1.8%	130	1.4%	79	0.8%	127	1.3%
2-3 years	138	3.1%	73	1.6%	44	1.0%	37	0.8%	45	1.0%
3-4 years	59	2.5%	34	1.4%	22	0.9%	17	0.7%	12	0.5%
4-5 years	23	1.9%	12	1.0%	*****	*****	*****	*****	*****	*****
5-6 years	15	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	36	7.3%	*****	*****	*****	*****	*****	*****	*****	*****

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	3,071	2.3%	2,241	1.7%	1,785	1.3%	1,167	0.9%	2,334	1.8%
1-2 years	759	2.0%	485	1.3%	398	1.1%	250	0.7%	550	1.5%
2-3 years	434	2.3%	293	1.6%	206	1.1%	145	0.8%	265	1.4%
3-4 years	228	2.4%	132	1.4%	86	0.9%	75	0.8%	109	1.1%
4-5 years	126	2.4%	69	1.3%	66	1.2%	83	1.6%	12	0.2%
5-6 years	86	2.7%	57	1.8%	*****	*****	*****	*****	*****	*****
6-7 years	42	2.1%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	730	23.0%	28	0.9%	47	1.5%	*****	*****	*****	*****
Furosemide Users (Washout)										
0-1 years	50,198	4.8%	38,487	3.7%	28,301	2.7%	20,679	2.0%	36,068	3.4%
1-2 years	8,742	4.1%	5,622	2.6%	3,904	1.8%	2,530	1.2%	3,477	1.6%
2-3 years	4,249	3.6%	2,802	2.4%	1,749	1.5%	1,194	1.0%	1,234	1.0%
3-4 years	2,242	3.2%	1,280	1.8%	827	1.2%	487	0.7%	358	0.5%
4-5 years	1,182	2.7%	657	1.5%	415	1.0%	183	0.4%	76	0.2%
5-6 years	628	2.2%	367	1.3%	166	0.6%	27	0.1%	27	0.1%
6-7 years	319	1.8%	150	0.9%	22	0.1%	*****	*****	*****	*****
7+ years	2,305	9.8%	329	1.4%	203	0.9%	96	0.4%	85	0.4%
Furosemide Users (No Washout)										
0-1 years	55,238	4.0%	42,335	3.1%	31,948	2.3%	22,884	1.7%	46,598	3.4%
1-2 years	12,493	3.4%	8,366	2.3%	6,144	1.7%	4,022	1.1%	8,442	2.3%
2-3 years	7,026	3.5%	4,890	2.4%	3,371	1.7%	2,373	1.2%	4,215	2.1%
3-4 years	4,138	3.3%	2,742	2.2%	1,737	1.4%	1,377	1.1%	1,923	1.5%
4-5 years	2,606	3.1%	1,623	1.9%	1,173	1.4%	1,310	1.6%	230	0.3%
5-6 years	1,625	2.8%	1,190	2.0%	1,232	2.1%	70	0.1%	108	0.2%
6-7 years	1,095	2.7%	1,142	2.8%	65	0.2%	42	0.1%	48	0.1%
7+ years	22,175	26.8%	1,201	1.5%	890	1.1%	561	0.7%	411	0.5%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,858	4.5%	1,373	3.3%	912	2.2%	891	2.2%	1,408	3.4%
1-2 years	285	3.8%	182	2.4%	136	1.8%	120	1.6%	180	2.4%
2-3 years	140	4.0%	82	2.3%	45	1.3%	29	0.8%	59	1.7%
3-4 years	46	2.5%	35	1.9%	19	1.0%	15	0.8%	19	1.0%
4-5 years	25	2.3%	20	1.8%	*****	*****	*****	*****	*****	*****
5-6 years	14	2.2%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	39	9.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	3,709	3.1%	2,648	2.2%	1,798	1.5%	1,713	1.4%	2,997	2.5%
1-2 years	818	2.7%	511	1.7%	388	1.3%	320	1.1%	752	2.5%
2-3 years	449	3.0%	280	1.9%	177	1.2%	137	0.9%	438	2.9%
3-4 years	207	2.6%	162	2.0%	96	1.2%	100	1.3%	222	2.8%
4-5 years	134	2.8%	80	1.7%	67	1.4%	64	1.3%	16	0.3%
5-6 years	87	3.0%	57	2.0%	*****	*****	*****	*****	*****	*****
6-7 years	40	2.4%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	658	23.7%	39	1.4%	29	1.0%	13	0.5%	13	0.5%
Torsemide Users (Washout)										
0-1 years	1,535	3.3%	1,221	2.6%	910	1.9%	662	1.4%	1,103	2.4%
1-2 years	285	3.0%	175	1.8%	130	1.4%	79	0.8%	127	1.3%
2-3 years	138	3.1%	73	1.6%	44	1.0%	37	0.8%	45	1.0%
3-4 years	59	2.5%	34	1.4%	22	0.9%	17	0.7%	12	0.5%
4-5 years	23	1.9%	12	1.0%	*****	*****	*****	*****	*****	*****
5-6 years	15	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	36	7.3%	*****	*****	*****	*****	*****	*****	*****	*****

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	3,071	2.3%	2,241	1.7%	1,785	1.3%	1,167	0.9%	2,334	1.8%
1-2 years	759	2.0%	485	1.3%	398	1.1%	250	0.7%	550	1.5%
2-3 years	434	2.3%	293	1.6%	206	1.1%	145	0.8%	265	1.4%
3-4 years	228	2.4%	132	1.4%	86	0.9%	75	0.8%	109	1.1%
4-5 years	126	2.4%	69	1.3%	66	1.2%	83	1.6%	12	0.2%
5-6 years	86	2.7%	57	1.8%	*****	*****	*****	*****	*****	*****
6-7 years	42	2.1%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	730	23.0%	28	0.9%	47	1.5%	*****	*****	*****	*****
Furosemide Users (Washout)										
0-1 years	50,198	4.8%	38,487	3.7%	28,301	2.7%	20,679	2.0%	36,068	3.4%
1-2 years	8,742	4.1%	5,622	2.6%	3,904	1.8%	2,530	1.2%	3,477	1.6%
2-3 years	4,249	3.6%	2,802	2.4%	1,749	1.5%	1,194	1.0%	1,234	1.0%
3-4 years	2,242	3.2%	1,280	1.8%	827	1.2%	487	0.7%	358	0.5%
4-5 years	1,182	2.7%	657	1.5%	415	1.0%	183	0.4%	76	0.2%
5-6 years	628	2.2%	367	1.3%	166	0.6%	27	0.1%	27	0.1%
6-7 years	319	1.8%	150	0.9%	22	0.1%	*****	*****	*****	*****
7+ years	2,305	9.8%	329	1.4%	203	0.9%	96	0.4%	85	0.4%
Furosemide Users (No Washout)										
0-1 years	55,238	4.0%	42,335	3.1%	31,948	2.3%	22,884	1.7%	46,598	3.4%
1-2 years	12,493	3.4%	8,366	2.3%	6,144	1.7%	4,022	1.1%	8,442	2.3%
2-3 years	7,026	3.5%	4,890	2.4%	3,371	1.7%	2,373	1.2%	4,215	2.1%
3-4 years	4,138	3.3%	2,742	2.2%	1,737	1.4%	1,377	1.1%	1,923	1.5%
4-5 years	2,606	3.1%	1,623	1.9%	1,173	1.4%	1,310	1.6%	230	0.3%
5-6 years	1,625	2.8%	1,190	2.0%	1,232	2.1%	70	0.1%	108	0.2%
6-7 years	1,095	2.7%	1,142	2.8%	65	0.2%	42	0.1%	48	0.1%
7+ years	22,175	26.8%	1,201	1.5%	890	1.1%	561	0.7%	411	0.5%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,858	4.5%	1,373	3.3%	912	2.2%	891	2.2%	1,408	3.4%
1-2 years	285	3.8%	182	2.4%	136	1.8%	120	1.6%	180	2.4%
2-3 years	140	4.0%	82	2.3%	45	1.3%	29	0.8%	59	1.7%
3-4 years	46	2.5%	35	1.9%	19	1.0%	15	0.8%	19	1.0%
4-5 years	25	2.3%	20	1.8%	*****	*****	*****	*****	*****	*****
5-6 years	14	2.2%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	39	9.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	3,709	3.1%	2,648	2.2%	1,798	1.5%	1,713	1.4%	2,997	2.5%
1-2 years	818	2.7%	511	1.7%	388	1.3%	320	1.1%	752	2.5%
2-3 years	449	3.0%	280	1.9%	177	1.2%	137	0.9%	438	2.9%
3-4 years	207	2.6%	162	2.0%	96	1.2%	100	1.3%	222	2.8%
4-5 years	134	2.8%	80	1.7%	67	1.4%	64	1.3%	16	0.3%
5-6 years	87	3.0%	57	2.0%	*****	*****	*****	*****	*****	*****
6-7 years	40	2.4%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	658	23.7%	39	1.4%	29	1.0%	13	0.5%	13	0.5%
Torsemide Users (Washout)										
0-1 years	1,535	3.3%	1,221	2.6%	910	1.9%	662	1.4%	1,103	2.4%
1-2 years	285	3.0%	175	1.8%	130	1.4%	79	0.8%	127	1.3%
2-3 years	138	3.1%	73	1.6%	44	1.0%	37	0.8%	45	1.0%
3-4 years	59	2.5%	34	1.4%	22	0.9%	17	0.7%	12	0.5%
4-5 years	23	1.9%	12	1.0%	*****	*****	*****	*****	*****	*****
5-6 years	15	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	36	7.3%	*****	*****	*****	*****	*****	*****	*****	*****

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	3,071	2.3%	2,241	1.7%	1,785	1.3%	1,167	0.9%	2,334	1.8%
1-2 years	759	2.0%	485	1.3%	398	1.1%	250	0.7%	550	1.5%
2-3 years	434	2.3%	293	1.6%	206	1.1%	145	0.8%	265	1.4%
3-4 years	228	2.4%	132	1.4%	86	0.9%	75	0.8%	109	1.1%
4-5 years	126	2.4%	69	1.3%	66	1.2%	83	1.6%	12	0.2%
5-6 years	86	2.7%	57	1.8%	*****	*****	*****	*****	*****	*****
6-7 years	42	2.1%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	730	23.0%	28	0.9%	47	1.5%	*****	*****	*****	*****
Furosemide Users (Washout)										
0-1 years	50,198	4.8%	38,487	3.7%	28,301	2.7%	20,679	2.0%	36,068	3.4%
1-2 years	8,742	4.1%	5,622	2.6%	3,904	1.8%	2,530	1.2%	3,477	1.6%
2-3 years	4,249	3.6%	2,802	2.4%	1,749	1.5%	1,194	1.0%	1,234	1.0%
3-4 years	2,242	3.2%	1,280	1.8%	827	1.2%	487	0.7%	358	0.5%
4-5 years	1,182	2.7%	657	1.5%	415	1.0%	183	0.4%	76	0.2%
5-6 years	628	2.2%	367	1.3%	166	0.6%	27	0.1%	27	0.1%
6-7 years	319	1.8%	150	0.9%	22	0.1%	*****	*****	*****	*****
7+ years	2,305	9.8%	329	1.4%	203	0.9%	96	0.4%	85	0.4%
Furosemide Users (No Washout)										
0-1 years	55,238	4.0%	42,335	3.1%	31,948	2.3%	22,884	1.7%	46,598	3.4%
1-2 years	12,493	3.4%	8,366	2.3%	6,144	1.7%	4,022	1.1%	8,442	2.3%
2-3 years	7,026	3.5%	4,890	2.4%	3,371	1.7%	2,373	1.2%	4,215	2.1%
3-4 years	4,138	3.3%	2,742	2.2%	1,737	1.4%	1,377	1.1%	1,923	1.5%
4-5 years	2,606	3.1%	1,623	1.9%	1,173	1.4%	1,310	1.6%	230	0.3%
5-6 years	1,625	2.8%	1,190	2.0%	1,232	2.1%	70	0.1%	108	0.2%
6-7 years	1,095	2.7%	1,142	2.8%	65	0.2%	42	0.1%	48	0.1%
7+ years	22,175	26.8%	1,201	1.5%	890	1.1%	561	0.7%	411	0.5%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0-1 years	1,858	4.5%	1,373	3.3%	912	2.2%	891	2.2%	1,408	3.4%
1-2 years	285	3.8%	182	2.4%	136	1.8%	120	1.6%	180	2.4%
2-3 years	140	4.0%	82	2.3%	45	1.3%	29	0.8%	59	1.7%
3-4 years	46	2.5%	35	1.9%	19	1.0%	15	0.8%	19	1.0%
4-5 years	25	2.3%	20	1.8%	*****	*****	*****	*****	*****	*****
5-6 years	14	2.2%	*****	*****	*****	*****	*****	*****	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	39	9.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0-1 years	3,709	3.1%	2,648	2.2%	1,798	1.5%	1,713	1.4%	2,997	2.5%
1-2 years	818	2.7%	511	1.7%	388	1.3%	320	1.1%	752	2.5%
2-3 years	449	3.0%	280	1.9%	177	1.2%	137	0.9%	438	2.9%
3-4 years	207	2.6%	162	2.0%	96	1.2%	100	1.3%	222	2.8%
4-5 years	134	2.8%	80	1.7%	67	1.4%	64	1.3%	16	0.3%
5-6 years	87	3.0%	57	2.0%	*****	*****	*****	*****	*****	*****
6-7 years	40	2.4%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	658	23.7%	39	1.4%	29	1.0%	13	0.5%	13	0.5%
Torsemide Users (Washout)										
0-1 years	1,535	3.3%	1,221	2.6%	910	1.9%	662	1.4%	1,103	2.4%
1-2 years	285	3.0%	175	1.8%	130	1.4%	79	0.8%	127	1.3%
2-3 years	138	3.1%	73	1.6%	44	1.0%	37	0.8%	45	1.0%
3-4 years	59	2.5%	34	1.4%	22	0.9%	17	0.7%	12	0.5%
4-5 years	23	1.9%	12	1.0%	*****	*****	*****	*****	*****	*****
5-6 years	15	2.0%	*****	*****	*****	*****	0	0.0%	*****	*****
6-7 years	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
7+ years	36	7.3%	*****	*****	*****	*****	*****	*****	*****	*****

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (No Washout)										
0-1 years	3,071	2.3%	2,241	1.7%	1,785	1.3%	1,167	0.9%	2,334	1.8%
1-2 years	759	2.0%	485	1.3%	398	1.1%	250	0.7%	550	1.5%
2-3 years	434	2.3%	293	1.6%	206	1.1%	145	0.8%	265	1.4%
3-4 years	228	2.4%	132	1.4%	86	0.9%	75	0.8%	109	1.1%
4-5 years	126	2.4%	69	1.3%	66	1.2%	83	1.6%	12	0.2%
5-6 years	86	2.7%	57	1.8%	*****	*****	*****	*****	*****	*****
6-7 years	42	2.1%	*****	*****	*****	*****	*****	*****	*****	*****
7+ years	730	23.0%	28	0.9%	47	1.5%	*****	*****	*****	*****
Furosemide Users (Washout)										
0-1 years	50,198	4.8%	38,487	3.7%	28,301	2.7%	20,679	2.0%	36,068	3.4%
1-2 years	8,742	4.1%	5,622	2.6%	3,904	1.8%	2,530	1.2%	3,477	1.6%
2-3 years	4,249	3.6%	2,802	2.4%	1,749	1.5%	1,194	1.0%	1,234	1.0%
3-4 years	2,242	3.2%	1,280	1.8%	827	1.2%	487	0.7%	358	0.5%
4-5 years	1,182	2.7%	657	1.5%	415	1.0%	183	0.4%	76	0.2%
5-6 years	628	2.2%	367	1.3%	166	0.6%	27	0.1%	27	0.1%
6-7 years	319	1.8%	150	0.9%	22	0.1%	*****	*****	*****	*****
7+ years	2,305	9.8%	329	1.4%	203	0.9%	96	0.4%	85	0.4%
Furosemide Users (No Washout)										
0-1 years	55,238	4.0%	42,335	3.1%	31,948	2.3%	22,884	1.7%	46,598	3.4%
1-2 years	12,493	3.4%	8,366	2.3%	6,144	1.7%	4,022	1.1%	8,442	2.3%
2-3 years	7,026	3.5%	4,890	2.4%	3,371	1.7%	2,373	1.2%	4,215	2.1%
3-4 years	4,138	3.3%	2,742	2.2%	1,737	1.4%	1,377	1.1%	1,923	1.5%
4-5 years	2,606	3.1%	1,623	1.9%	1,173	1.4%	1,310	1.6%	230	0.3%
5-6 years	1,625	2.8%	1,190	2.0%	1,232	2.1%	70	0.1%	108	0.2%

Table 17c. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Duration*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
6-7 years	1,095	2.7%	1,142	2.8%	65	0.2%	42	0.1%	48	0.1%
7+ years	22,175	26.8%	1,201	1.5%	890	1.1%	561	0.7%	411	0.5%

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	24,234	13,310	54.9%	1,989	8.2%	1,890	7.8%
>0 - <700,000 ppm	*****	30,594	22,363	73.1%	3,423	11.2%	2,373	7.8%
700,000 - 1,000,000 ppm	*****	1,012	664	65.6%	193	19.1%	97	9.6%
1,000,000 - 1,500,000 ppm	*****	512	298	58.2%	99	19.3%	92	18.0%
1,500,000 - 2,000,000 ppm	*****	193	132	68.4%	40	20.7%	*****	*****
≥ 2,000,000 ppm	*****	158	70	44.3%	41	25.9%	34	21.5%
Bumetanide Users (No Washout)								
0 ppm	*****	75,443	46,873	62.1%	5,646	7.5%	4,882	6.5%
>0 - <700,000 ppm	*****	98,802	75,760	76.7%	9,771	9.9%	6,329	6.4%
700,000 - 1,000,000 ppm	*****	4,617	3,301	71.5%	725	15.7%	379	8.2%
1,000,000 - 1,500,000 ppm	*****	3,084	2,006	65.0%	558	18.1%	349	11.3%
1,500,000 - 2,000,000 ppm	*****	1,267	863	68.1%	256	20.2%	94	7.4%
≥ 2,000,000 ppm	*****	1,147	546	47.6%	267	23.3%	191	16.7%
Torsemide Users (Washout)								
0 ppm	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (Washout)								
0 ppm	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	24,234	13,310	54.9%	1,989	8.2%	1,890	7.8%
>0 - <700,000 ppm	*****	30,594	22,363	73.1%	3,423	11.2%	2,373	7.8%
700,000 - 1,000,000 ppm	*****	1,012	664	65.6%	193	19.1%	97	9.6%
1,000,000 - 1,500,000 ppm	*****	512	298	58.2%	99	19.3%	92	18.0%
1,500,000 - 2,000,000 ppm	*****	193	132	68.4%	40	20.7%	*****	*****
≥ 2,000,000 ppm	*****	158	70	44.3%	41	25.9%	34	21.5%
Bumetanide Users (No Washout)								
0 ppm	*****	75,443	46,873	62.1%	5,646	7.5%	4,882	6.5%
>0 - <700,000 ppm	*****	98,802	75,760	76.7%	9,771	9.9%	6,329	6.4%
700,000 - 1,000,000 ppm	*****	4,617	3,301	71.5%	725	15.7%	379	8.2%
1,000,000 - 1,500,000 ppm	*****	3,084	2,006	65.0%	558	18.1%	349	11.3%
1,500,000 - 2,000,000 ppm	*****	1,267	863	68.1%	256	20.2%	94	7.4%
≥ 2,000,000 ppm	*****	1,147	546	47.6%	267	23.3%	191	16.7%

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Torsemide Users (Washout)								
0 ppm	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome								

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Bumetanide Users (Washout)								
0 ppm	*****	24,234	13,310	54.9%	1,989	8.2%	1,890	7.8%
>0 - <700,000 ppm	*****	30,594	22,363	73.1%	3,423	11.2%	2,373	7.8%
700,000 - 1,000,000 ppm	*****	1,012	664	65.6%	193	19.1%	97	9.6%
1,000,000 - 1,500,000 ppm	*****	512	298	58.2%	99	19.3%	92	18.0%
1,500,000 - 2,000,000 ppm	*****	193	132	68.4%	40	20.7%	*****	*****
≥ 2,000,000 ppm	*****	158	70	44.3%	41	25.9%	34	21.5%
Bumetanide Users (No Washout)								
0 ppm	*****	75,443	46,873	62.1%	5,646	7.5%	4,882	6.5%
>0 - <700,000 ppm	*****	98,802	75,760	76.7%	9,771	9.9%	6,329	6.4%
700,000 - 1,000,000 ppm	*****	4,617	3,301	71.5%	725	15.7%	379	8.2%
1,000,000 - 1,500,000 ppm	*****	3,084	2,006	65.0%	558	18.1%	349	11.3%
1,500,000 - 2,000,000 ppm	*****	1,267	863	68.1%	256	20.2%	94	7.4%
≥ 2,000,000 ppm	*****	1,147	546	47.6%	267	23.3%	191	16.7%
Torsemide Users (Washout)								
0 ppm	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome								
Bumetanide Users (Washout)								
0 ppm	*****	24,234	13,310	54.9%	1,989	8.2%	1,890	7.8%
>0 - <700,000 ppm	*****	30,594	22,363	73.1%	3,423	11.2%	2,373	7.8%
700,000 - 1,000,000 ppm	*****	1,012	664	65.6%	193	19.1%	97	9.6%
1,000,000 - 1,500,000 ppm	*****	512	298	58.2%	99	19.3%	92	18.0%
1,500,000 - 2,000,000 ppm	*****	193	132	68.4%	40	20.7%	*****	*****
≥ 2,000,000 ppm	*****	158	70	44.3%	41	25.9%	34	21.5%
Bumetanide Users (No Washout)								
0 ppm	*****	75,443	46,873	62.1%	5,646	7.5%	4,882	6.5%
>0 - <700,000 ppm	*****	98,802	75,760	76.7%	9,771	9.9%	6,329	6.4%
700,000 - 1,000,000 ppm	*****	4,617	3,301	71.5%	725	15.7%	379	8.2%
1,000,000 - 1,500,000 ppm	*****	3,084	2,006	65.0%	558	18.1%	349	11.3%
1,500,000 - 2,000,000 ppm	*****	1,267	863	68.1%	256	20.2%	94	7.4%
≥ 2,000,000 ppm	*****	1,147	546	47.6%	267	23.3%	191	16.7%
Torsemide Users (Washout)								

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	172,362	65,996	44,561	67.5%	6,534	9.9%	4,440	6.7%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)								
0 ppm	680,304	211,931	150,594	71.1%	18,627	8.8%	12,626	6.0%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)								
0 ppm	5,031,471	1,560,924	888,898	56.9%	167,433	10.7%	129,939	8.3%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

			Number of Users Censored due to End of Data Partner Data by Follow-up Time					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Users	Total Number of Users Censored due to End of Data Partner Data[1]	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)								
0 ppm	8,853,836	2,328,962	1,328,042	57.0%	228,832	9.8%	177,644	7.6%
>0 - <700,000 ppm	0	0	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	0	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	0	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Liver Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,549	6.4%	1,498	6.2%	1,081	4.5%	1,080	4.5%	1,837	7.6%
>0 - <700,000 ppm	1,615	5.3%	486	1.6%	321	1.0%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	45	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	3,941	5.2%	3,398	4.5%	2,599	3.4%	2,420	3.2%	5,684	7.5%
>0 - <700,000 ppm	4,507	4.6%	1,293	1.3%	1,091	1.1%	51	0.1%	0	0.0%
700,000 - 1,000,000 ppm	168	3.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	137	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	97	8.5%	46	4.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
0 ppm	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bladder Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,549	6.4%	1,498	6.2%	1,081	4.5%	1,080	4.5%	1,837	7.6%
>0 - <700,000 ppm	1,615	5.3%	486	1.6%	321	1.0%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	45	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	3,941	5.2%	3,398	4.5%	2,599	3.4%	2,420	3.2%	5,684	7.5%
>0 - <700,000 ppm	4,507	4.6%	1,293	1.3%	1,091	1.1%	51	0.1%	0	0.0%
700,000 - 1,000,000 ppm	168	3.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	137	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	97	8.5%	46	4.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Colorectal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,549	6.4%	1,498	6.2%	1,081	4.5%	1,080	4.5%	1,837	7.6%
>0 - <700,000 ppm	1,615	5.3%	486	1.6%	321	1.0%	13	0.0%	0	0.0%

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
700,000 - 1,000,000 ppm	45	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	3,941	5.2%	3,398	4.5%	2,599	3.4%	2,420	3.2%	5,684	7.5%
>0 - <700,000 ppm	4,507	4.6%	1,293	1.3%	1,091	1.1%	51	0.1%	0	0.0%
700,000 - 1,000,000 ppm	168	3.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	137	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	97	8.5%	46	4.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (No Washout)										
0 ppm	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Esophageal Cancer Outcome										
Bumetanide Users (Washout)										
0 ppm	1,549	6.4%	1,498	6.2%	1,081	4.5%	1,080	4.5%	1,837	7.6%
>0 - <700,000 ppm	1,615	5.3%	486	1.6%	321	1.0%	13	0.0%	0	0.0%
700,000 - 1,000,000 ppm	45	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Bumetanide Users (No Washout)										
0 ppm	3,941	5.2%	3,398	4.5%	2,599	3.4%	2,420	3.2%	5,684	7.5%
>0 - <700,000 ppm	4,507	4.6%	1,293	1.3%	1,091	1.1%	51	0.1%	0	0.0%
700,000 - 1,000,000 ppm	168	3.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,000,000 - 1,500,000 ppm	137	4.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
1,500,000 - 2,000,000 ppm	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 2,000,000 ppm	97	8.5%	46	4.0%	0	0.0%	0	0.0%	0	0.0%
Torsemide Users (Washout)										
0 ppm	3,113	4.7%	2,304	3.5%	1,756	2.7%	1,266	1.9%	2,022	3.1%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Torsemide Users (No Washout)										
0 ppm	8,467	4.0%	6,129	2.9%	4,955	2.3%	3,150	1.5%	7,383	3.5%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Furosemide Users (Washout)										
0 ppm	102,074	6.5%	80,789	5.2%	62,674	4.0%	47,128	3.0%	81,989	5.3%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 17d. Summary of Time to End of At-Risk Period due to End Of Data Partner Data for Loop Diuretic Exposure in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022, by Cumulative Exposure to N-Nitroso-dimethylamine (NDMA)*

	Number of Users Censored due to End of Data Partner Data by Follow-up Time									
	1,095-1,460 days		1,461-1,825 days		1,826-2,190 days		2,191-2,555 days		2,556+ days	
	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users	Number of Users	Percent of Users
Furosemide Users (No Washout)										
0 ppm	141,198	6.1%	112,285	4.8%	93,177	4.0%	67,868	2.9%	179,916	7.7%
>0 - <700,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
700,000 - 1,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,000,000 - 1,500,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
1,500,000 - 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
≥ 2,000,000 ppm	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Lower order categories include patients in the higher order categories

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 18. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Bumetanide Users (No Washout)		Bumetanide Users (Washout)		Torsemide Users (No Washout)	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	355,155,013	N/A	355,155,013	N/A	355,155,013	N/A
Had required coverage type (medical and/or drug coverage)	233,033,611	122,121,402	233,033,611	122,121,402	233,033,611	122,121,402
Enrolled during specified age range	233,033,486	125	233,033,486	125	233,033,486	125
Had requestable medical charts	233,033,486	0	233,033,486	0	233,033,486	0
Met demographic requirements (sex, race, and Hispanic origin)	233,014,167	19,319	233,014,167	19,319	233,014,167	19,319
Members with a valid index event						
Had any cohort-defining claim during the query period	1,394,874	231,619,293	1,394,874	231,619,293	1,395,576	231,618,591
Claim recorded during specified age range	1,394,868	6	1,394,868	6	1,395,570	6
Episode defining index claim recorded during the query period	1,394,868	0	1,394,867	1	1,395,570	0
Met exposure incidence criteria	1,394,868	0	729,496	665,371	1,395,570	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,156,666	238,202	333,834	395,662	1,170,064	225,506
Met inclusion and exclusion criteria[1]	681,044	475,622	172,936	160,898	680,304	489,760
Evidence of cancer_chemo	N/A	475,622	N/A	160,898	N/A	489,760
Met event incidence criteria	681,044	0	172,936	0	680,304	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	681,044	0	172,936	0	680,304	0
Had minimum days' supply on index date	681,044	0	172,936	0	680,304	0
Had index episode of at least required length	681,044	0	172,936	0	680,304	0
Had index episode longer than blackout period	681,044	0	172,936	0	680,304	0
Did not have an event during blackout period	681,044	0	172,936	0	680,304	0
Final cohort						
Number of members	681,044	N/A	172,936	N/A	680,304	N/A
Number of episodes	681,044	N/A	172,936	N/A	680,304	N/A

Table 18. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2000 to February 28, 2022

	Torsemide Users (Washout)		Furosemide Users (No Washout)		Furosemide Users (Washout)	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	355,155,013	N/A	355,155,013	N/A	355,155,013	N/A
Had required coverage type (medical and/or drug coverage)	233,033,611	122,121,402	233,033,611	122,121,402	233,033,611	122,121,402
Enrolled during specified age range	233,033,486	125	233,033,486	125	233,033,486	125
Had requestable medical charts	233,033,486	0	233,033,486	0	233,033,486	0
Met demographic requirements (sex, race, and Hispanic origin)	233,014,167	19,319	233,014,167	19,319	233,014,167	19,319
Members with a valid index event						
Had any cohort-defining claim during the query period	1,395,576	231,618,591	17,173,540	215,840,627	17,173,540	215,840,627
Claim recorded during specified age range	1,395,570	6	17,173,437	103	17,173,437	103
Episode defining index claim recorded during the query period	1,395,570	0	17,173,437	0	17,173,436	1
Met exposure incidence criteria	746,872	648,698	17,173,437	0	16,945,792	227,644
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	343,084	403,788	14,052,991	3,120,446	9,449,777	7,496,015
Met inclusion and exclusion criteria[1]	172,362	170,722	8,853,836	5,199,155	5,031,471	4,418,306
Evidence of cancer_chemo	N/A	170,722	N/A	5,199,155	N/A	4,418,306
Met event incidence criteria	172,362	0	8,853,836	0	5,031,471	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	172,362	0	8,853,836	0	5,031,471	0
Had minimum days' supply on index date	172,362	0	8,853,836	0	5,031,471	0
Had index episode of at least required length	172,362	0	8,853,836	0	5,031,471	0
Had index episode longer than blackout period	172,362	0	8,853,836	0	5,031,471	0
Did not have an event during blackout period	172,362	0	8,853,836	0	5,031,471	0
Final cohort						
Number of members	172,362	N/A	8,853,836	N/A	5,031,471	N/A
Number of episodes	172,362	N/A	8,853,836	N/A	5,031,471	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

NaN: Not a Number

N/A: Not Applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 20, 2023)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2008	12/31/2021
DP02	01/01/2010	12/31/2021
DP03	01/01/2000	12/31/2020
DP04	01/01/2006	02/28/2022
DP05	01/01/2008	12/31/2021
DP06	01/01/2007	01/31/2022

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Ages Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
	Background Population Aged 0 - 85+		
0	0 year old	AN	Y
1	1 year old	AN	Y
2	2 years old	AN	Y
3	3 years old	AN	Y
4	4 years old	AN	Y
5	5 years old	AN	Y
6	6 years old	AN	Y
7	7 years old	AN	Y
8	8 years old	AN	Y
9	9 years old	AN	Y
10	10 years old	AN	Y
11	11 years old	AN	Y
12	12 years old	AN	Y
13	13 years old	AN	Y
14	14 years old	AN	Y
15	15 years old	AN	Y
16	16 years old	AN	Y
17	17 years old	AN	Y
18	18 years old	AN	Y
19	19 years old	AN	Y
20	20 years old	AN	Y
21	21 years old	AN	Y
22	22 years old	AN	Y
23	23 years old	AN	Y
24	24 years old	AN	Y
25	25 years old	AN	Y
26	26 years old	AN	Y
27	27 years old	AN	Y
28	28 years old	AN	Y
29	29 years old	AN	Y
30	30 years old	AN	Y
31	31 years old	AN	Y
32	32 years old	AN	Y
33	33 years old	AN	Y
34	34 years old	AN	Y
35	35 years old	AN	Y
36	36 years old	AN	Y
37	37 years old	AN	Y
38	38 years old	AN	Y
39	39 years old	AN	Y

Appendix B. List of Ages Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
40	40 years old	AN	Y
41	41 years old	AN	Y
42	42 years old	AN	Y
43	43 years old	AN	Y
44	44 years old	AN	Y
45	45 years old	AN	Y
46	46 years old	AN	Y
47	47 years old	AN	Y
48	48 years old	AN	Y
49	49 years old	AN	Y
50	50 years old	AN	Y
51	51 years old	AN	Y
52	52 years old	AN	Y
53	53 years old	AN	Y
54	54 years old	AN	Y
55	55 years old	AN	Y
56	56 years old	AN	Y
57	57 years old	AN	Y
58	58 years old	AN	Y
59	59 years old	AN	Y
60	60 years old	AN	Y
61	61 years old	AN	Y
62	62 years old	AN	Y
63	63 years old	AN	Y
64	64 years old	AN	Y
65	65 years old	AN	Y
66	66 years old	AN	Y
67	67 years old	AN	Y
68	68 years old	AN	Y
69	69 years old	AN	Y
70	70 years old	AN	Y
71	71 years old	AN	Y
72	72 years old	AN	Y
73	73 years old	AN	Y
74	74 years old	AN	Y
75	75 years old	AN	Y
76	76 years old	AN	Y
77	77 years old	AN	Y
78	78 years old	AN	Y
79	79 years old	AN	Y
80	80 years old	AN	Y

Appendix B. List of Ages Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
81	81 years old	AN	Y
82	82 years old	AN	Y
83	83 years old	AN	Y
84	84 years old	AN	Y
85	85 years old	AN	Y
86	86 years old	AN	Y
87	87 years old	AN	Y
88	88 years old	AN	Y
89	89 years old	AN	Y
90	90 years old	AN	Y
91	91 years old	AN	Y
92	92 years old	AN	Y
93	93 years old	AN	Y
94	94 years old	AN	Y
95	95 years old	AN	Y
96	96 years old	AN	Y
97	97 years old	AN	Y
98	98 years old	AN	Y
99	99 years old	AN	Y
100	100 years old	AN	Y
101	101 years old	AN	Y
102	102 years old	AN	Y
103	103 years old	AN	Y
104	104 years old	AN	Y
105	105 years old	AN	Y
106	106 years old	AN	Y
107	107 years old	AN	Y
108	108 years old	AN	Y
109	109 years old	AN	Y
110	110 years old	AN	Y
111	111 years old	AN	Y
112	112 years old	AN	Y
113	113 years old	AN	Y
114	114 years old	AN	Y
115	115 years old	AN	Y
116	116 years old	AN	Y
117	117 years old	AN	Y
118	118 years old	AN	Y
119	119 years old	AN	Y
120	120 years old	AN	Y

Appendix C. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Bumetanide	
bumetanide	Bumex
bumetanide	bumetanide
Torsemide	
torsemide	Demadex
torsemide	torsemide
Furosemide	
furosemide	Lasix
furosemide	furosemide

Appendix D. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

Non-Proprietary Name	Proprietary Name
Loop Diuretics	
bumetanide	Bumex
bumetanide	bumetanide
furosemide	Lasix
furosemide	furosemide
torsemide	Demadex
torsemide	torsemide

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
Chemotherapy	
BCG live	Theracys
BCG live	Tice BCG
BCG vaccine, live	Tice BCG Vaccine
Tositumomab Iodine-131 (with Maltose)	Bexxar 131 Iodine
abarelix	Plenaxis
abemaciclib	Verzenio
abiraterone acetate	Zytiga
abiraterone acetate	abiraterone
abiraterone acetate, submicronized	Yonsa
acalabrutinib	Calquence
ado-trastuzumab emtansine	Kadcyla
afatinib dimaleate	Gilotrif
aldesleukin	Proleukin
alectinib HCl	Alecensa
alemtuzumab	Campath
alemtuzumab	Lemtrada
alpelisib	Piqray
altretamine	Hexalen
amifostine crystalline	Ethyol
amifostine crystalline	amifostine crystalline
aminoglutethimide	Cytadren
amivantamab-vmjw	Rybrevant
anastrozole	Arimidex
anastrozole	Arimidex 30-day Pack
anastrozole	anastrozole
anastrozole	anastrozole (bulk)
apalutamide	Erleada
arsenic trioxide	Trisenox
arsenic trioxide	arsenic trioxide
arsenic trioxide	arsenic trioxide (bulk)
asparaginase	Elspar
asparaginase (Erwinia chrysanthemi)	Erwinase
asparaginase (Erwinia chrysanthemi)	Erwinaze
asparaginase Erwinia chrysanthemi (recombinant)-rywn	Rylaze
atezolizumab	Tecentriq
avapritinib	Ayvakit
avelumab	Bavencio
axicabtagene ciloleucel	Yescarta

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
axitinib	Inlyta
azacitidine	Onureg
azacitidine	Vidaza
azacitidine	azacitidine
belantamab mafodotin-blmf	Blenrep
belinostat	Beleodaq
bendamustine HCl	Belrapzo
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	bendamustine
bevacizumab	Avastin
bevacizumab	bevacizumab
bevacizumab-awwb	Mvasi
bevacizumab-bvzr	Zirabev
bexarotene	Targretin
bexarotene	bexarotene
bicalutamide	Casodex
bicalutamide	bicalutamide
binimetinib	Mektovi
bleomycin sulfate	Blenoxane
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
blinatumomab	Blincyto
bortezomib	Velcade
bortezomib	bortezomib
bosutinib	Bosulif
brentuximab vedotin	Adcetris
brexucabtagene autoleucel	Tecartus
brigatinib	Alunbrig
busulfan	Busulfex
busulfan	Myleran
busulfan	busulfan
cabazitaxel	Jevtana
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
calaspargase pegol-mknl	Asparlas
capecitabine	Xeloda
capecitabine	capecitabine
capmatinib hydrochloride	Tabrecta
carboplatin	Paraplatin

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
carboplatin	carboplatin
carfilzomib	Kyprolis
carmustine	BiCNU
carmustine	carmustine
carmustine in polifeprosan 20	Gliadel Wafer
cemiplimab-rwlc	Libtayo
ceritinib	Zykadia
cetuximab	Erbitux
chlorambucil	Leukeran
chlorambucil	chlorambucil (bulk)
cisplatin	Platinol AQ
cisplatin	cisplatin
cisplatin	cisplatin (bulk)
cladribine	Leustatin
cladribine	Mavenclad (10 tablet pack)
cladribine	Mavenclad (4 tablet pack)
cladribine	Mavenclad (5 tablet pack)
cladribine	Mavenclad (6 tablet pack)
cladribine	Mavenclad (7 tablet pack)
cladribine	Mavenclad (8 tablet pack)
cladribine	Mavenclad (9 tablet pack)
cladribine	cladribine
clofarabine	Clolar
clofarabine	clofarabine
cobimetinib fumarate	Cotellic
copanlisib di-HCl	Aliqopa
crizotinib	Xalkori
cromolyn sodium	Gastrocrom
cromolyn sodium	cromolyn
cromolyn sodium	cromolyn (bulk)
cyclophosphamide	Cytoxan
cyclophosphamide	Cytoxan Lyophilized
cyclophosphamide	Neosar
cyclophosphamide	cyclophosphamide
cyclophosphamide	cyclophosphamide (bulk)
cytarabine	Cytosar-U
cytarabine	Tarabine Pfs
cytarabine	cytarabine
cytarabine liposome/PF	DepoCyt (PF)
cytarabine/PF	cytarabine (PF)

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
dabrafenib mesylate	Tafinlar
dacarbazine	DTIC-Dome
dacarbazine	dacarbazine
dacarbazine	dacarbazine (bulk)
dacomitinib	Vizimpro
dactinomycin	Cosmegen
dactinomycin	dactinomycin
daratumumab	Darzalex
daratumumab-hyaluronidase-fihj	Darzalex Faspro
darolutamide	Nubeqa
dasatinib	Sprycel
daunorubicin HCl	Cerubidine
daunorubicin HCl	daunorubicin
daunorubicin citrate liposomal	DaunoXome
daunorubicin/cytarabine liposomal	Vyxeos
decitabine	Dacogen
decitabine	decitabine
decitabine/cedazuridine	Inqovi
degarelix acetate	Firmagon
degarelix acetate	Firmagon kit w diluent syringe
denileukin diftitox	Ontak
dexrazoxane HCl	Totect
dexrazoxane HCl	Zinecard (as HCl)
dexrazoxane HCl	dexrazoxane HCl
diethylstilbestrol	diethylstilbestrol (bulk)
diethylstilbestrol diphosphate	Stilphostrol
dinutuximab	Unituxin
docetaxel	Docefrez
docetaxel	Taxotere
docetaxel	docetaxel
dostarlimab-gxly	Jemperli
doxorubicin HCl	Adriamycin
doxorubicin HCl	Adriamycin PFS
doxorubicin HCl	Adriamycin RDF
doxorubicin HCl	Rubex
doxorubicin HCl	doxorubicin
doxorubicin HCl pegylated liposomal	Doxil
doxorubicin HCl pegylated liposomal	Lipodox
doxorubicin HCl pegylated liposomal	Lipodox 50
doxorubicin HCl pegylated liposomal	doxorubicin, peg-liposomal

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
durvalumab	Imfinzi
duvelisib	Copiktra
elotuzumab	Empliciti
enasidenib mesylate	Idhifa
encorafenib	Braftovi
enfortumab vedotin-ejfv	Padcev
entrectinib	Rozlytrek
enzalutamide	Xtandi
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
erdafitinib	Balversa
eribulin mesylate	Halaven
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
estramustine phosphate sodium	Emcyt
etoposide	Toposar
etoposide	VePesid
etoposide	etoposide
etoposide	etoposide (bulk)
etoposide phosphate	Etopophos
everolimus	Afinitor
everolimus	Afinitor Disperz
everolimus	Zortress
everolimus	everolimus (antineoplastic)
everolimus	everolimus (immunosuppressive)
exemestane	Aromasin
exemestane	exemestane
fam-trastuzumab deruxtecan-nxki	Enhertu
fedratinib dihydrochloride	Inrebic
floxuridine	FUDR
floxuridine	floxuridine
floxuridine	floxuridine (bulk)
fludarabine phosphate	Fludara
fludarabine phosphate	Oforta
fludarabine phosphate	fludarabine
fluorouracil	Adrucil
fluorouracil	Carac
fluorouracil	Efudex
fluorouracil	Fluoroplex
fluorouracil	Tolak

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
fluorouracil	fluorouracil
fluorouracil	fluorouracil (bulk)
flutamide	Eulexin
flutamide	flutamide
fostamatinib disodium	Tavalisse
fulvestrant	Faslodex
fulvestrant	fulvestrant
gefitinib	Iressa
gemcitabine HCl	Gemzar
gemcitabine HCl	gemcitabine
gemcitabine HCl in 0.9 % sodium chloride	Infugem
gemtuzumab ozogamicin	Mylotarg
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
glucarpidase	Voraxaze
goserelin acetate	Zoladex
histrelin acetate	Vantas
hydroxyurea	Droxia
hydroxyurea	Hydrea
hydroxyurea	Mylocel
hydroxyurea	Siklos
hydroxyurea	hydroxyurea
hydroxyurea	hydroxyurea (bulk)
ibrutinib	Imbruvica
idarubicin HCl	Idamycin
idarubicin HCl	Idamycin PFS
idarubicin HCl	idarubicin
idecabtagene vicleucel	Abecma
idelalisib	Zydelig
ifosfamide	Ifex
ifosfamide	ifosfamide
ifosfamide/mesna	Ifex/Mesnex
ifosfamide/mesna	ifosfamide-mesna
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
infigratinib phosphate	Truseltiq
inotuzumab ozogamicin	Besponsa
interferon alfa-2a,recomb.	Roferon-A
interferon alfa-2b,recomb.	Intron A
interferon alfa-n3	Alferon N

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
interferon gamma-1b,recomb.	Actimmune
iobenguane iodine-131	Azedra Dosimetric
iobenguane iodine-131	Azedra Therapeutic
ipilimumab	Yervoy
irinotecan HCl	Camptosar
irinotecan HCl	irinotecan
irinotecan liposomal	Onivyde
isatuximab-irfc	Sarclisa
ivosidenib	Tibsovo
ixabepilone	Ixempra
ixazomib citrate	Ninlaro
kit for prep indium-111/ibritumomab tiuxetan/albumin human	Zevalin (In-111)
kit for prep yttrium-90/ibritumomab tiuxetan/albumin human	Zevalin (Y-90)
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vitrakvi
lenalidomide	Revlimid
lenvatinib mesylate	Lenvima
letrozole	Femara
letrozole	letrozole
letrozole	letrozole (bulk)
leucovorin calcium	Calcium Folinate (leucovorin)
leucovorin calcium	leucovorin calcium
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Lupron
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (bulk)
leuprolide acetate/lidocaine HCl	Viadur
levamisole HCl	Ergamisol
levamisole HCl	levamisole (bulk)
levoleucovorin	Khapzory

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
levoleucovorin calcium	Fusilev
levoleucovorin calcium	levoleucovorin calcium
lisocabtagene maraleucel	Breyanzi
lisocabtagene maraleucel, CD4 component, 2 of 2	Breyanzi CD4 Component (2of 2)
lisocabtagene maraleucel, CD8 component, 1 of 2	Breyanzi CD8 Component (1of 2)
lomustine	CeeNU
lomustine	Gleostine
lomustine	lomustine
loncastuximab tesirine-lpyl	Zynlonta
lorlatinib	Lorbrena
lurbinectedin	Zepzelca
lutetium Lu 177 dotatate	Lutathera
margetuximab-cmkb	Margenza
mechlorethamine HCl	Mustargen
mechlorethamine HCl	Valchlor
mechlorethamine HCl	mechlorethamine (bulk)
medroxyprogesterone acetate	Depo-Provera
megestrol acetate	Megace
megestrol acetate	megestrol
megestrol acetate,micronized	megestrol acetate,micro (bulk)
melphalan	Alkeran
melphalan	melphalan
melphalan HCl	Alkeran (as HCl)
melphalan HCl	melphalan HCl
melphalan HCl/betadex sulfobutyl ether sodium	Evomela
melphalan flufenamide hydrochloride	Pepaxto
mercaptopurine	Purinethol
mercaptopurine	Purixan
mercaptopurine	mercaptopurine
mercaptopurine	mercaptopurine (bulk)
mesna	Mesnex
mesna	mesna
methotrexate	Xatmep
methotrexate	methotrexate (bulk)
methotrexate sodium	Methotrexate (Anti-Rheumatic)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	Methotrexate LPF
methotrexate sodium/PF	methotrexate sodium (PF)

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)
methoxsalen	Uvadex
methoxsalen	methoxsalen (bulk)
midostaurin	Rydapt
mitomycin	Jelmyto
mitomycin	Mitosol
mitomycin	Mutamycin
mitomycin	mitomycin
mitomycin	mitomycin (bulk)
mitotane	Lysodren
mitotane	mitotane (bulk)
mitoxantrone HCl	Novantrone
mitoxantrone HCl	mitoxantrone
mogamulizumab-kpkc	Poteligeo
moxetumomab pasudotox-tdfk	Lumoxiti
naxitamab-gqgk	Danyelza
necitumumab	Portrazza
nelarabine	Arranon
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nilutamide	Nilandron
nilutamide	nilutamide
nintedanib esylate	Ofev
niraparib tosylate	Zejula
nivolumab	Opdivo
obinutuzumab	Gazyva
ofatumumab	Arzerra
ofatumumab	Kesimpta Pen
olaparib	Lynparza
olaratumab	Lartruvo
omacetaxine mepesuccinate	Synribo
osimertinib mesylate	Tagrisso
oxaliplatin	Eloxatin
oxaliplatin	oxaliplatin
paclitaxel	Onxol
paclitaxel	Taxol
paclitaxel	paclitaxel
paclitaxel protein-bound	Abraxane

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
palbociclib	Ibrance
panitumumab	Vectibix
panobinostat lactate	Farydak
pazopanib HCl	Votrient
pegaspargase	Oncaspar
peginterferon alfa-2b	PegIntron
peginterferon alfa-2b	PegIntron Redipen
peginterferon alfa-2b	Sylatron
peginterferon alfa-2b	Sylatron 4-Pack
pembrolizumab	Keytruda
pemetrexed disodium	Alimta
pemigatinib	Pemazyre
pentostatin	Nipent
pentostatin	pentostatin
pertuzumab	Perjeta
pertuzumab-trastuzumab-hyaluronidase-zzxf	Phesgo
pexidartinib hydrochloride	Turalio
plicamycin	Mithracin
polatuzumab vedotin-piiq	Polivy
pomalidomide	Pomalyst
ponatinib HCl	Iclusig
porfimer sodium	Photofrin
pralatrexate	Folotyn
pralsetinib	Gavreto
procarbazine HCl	Matulane
procarbazine HCl	procarbazine HCl (bulk)
radium-223 dichloride	Xofigo
ramucirumab	Cyramza
regorafenib	Stivarga
relugolix	Orgovyx
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
ripretinib	Qinlock
rituximab	Rituxan
rituximab-abbs	Truxima
rituximab-arrx	Riabni
rituximab-pvvr	Ruxience
rituximab/hyaluronidase, human recombinant	Rituxan Hycela
romidepsin	Istodax
romidepsin	romidepsin

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
rucaparib camsylate	Rubraca
ruxolitinib phosphate	Jakafi
sacituzumab govitecan-hziy	Trodelvy
samarium Sm 153 lexidronam	Quadramet
selinexor	Xpovio
selpercatinib	Retevmo
selumetinib sulfate/vitamin E TPGS	Koselugo
siltuximab	Sylvant
sipuleucel-T/lactated ringers solution	Provenge
sodium butyrate	sodium butyrate (bulk)
sodium iodide-131	Hicon
sonidegib phosphate	Odomzo
sorafenib tosylate	Nexavar
sotorasib	Lumakras
streptozocin	Zanosar
strontium-89 chloride	Metastron
strontium-89 chloride	strontium-89 chloride
sunitinib malate	Sutent
tafasitamab-cxix	Monjuvi
tagraxofusp-erzs	Elzonris
talazoparib tosylate	Talzenna
talimogene laherparepvec	Imlygic
tamoxifen citrate	Nolvadex
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tamoxifen citrate	tamoxifen (bulk)
tazemetostat hydrobromide	Tazverik
temozolomide	Temodar
temozolomide	temozolomide
temsirolimus	Torisel
temsirolimus	temsirolimus
teniposide	Vumon
teniposide	teniposide
tepotinib HCl	Tepmetko
testolactone	Teslac
thalidomide	Thalomid
thioguanine	Tabloid
thioguanine	thioguanine (bulk)
thiotepa	Tepadina
thiotepa	Thioplex

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
thiotepa	thiotepa
thiotepa	thiotepa (bulk)
tisagenlecleucel	Kymriah
tivozanib HCl	Fotivda
topotecan HCl	Hycamtin
topotecan HCl	topotecan
toremifene citrate	Fareston
toremifene citrate	toremifene
tositumomab (with maltose)	Bexxar Dosimetric
tositumomab (with maltose)	Bexxar Therapeutic
trabectedin	Yondelis
trametinib dimethyl sulfoxide	Mekinist
trastuzumab	Herceptin
trastuzumab-anns	Kanjinti
trastuzumab-dkst	Ogivri
trastuzumab-dttb	Ontruzant
trastuzumab-hyaluronidase-oysk	Herceptin Hylecta
trastuzumab-pkrb	Herzuma
trastuzumab-qyyp	Trazimera
tretinoin	Vesanoid
tretinoin	tretinoin (antineoplastic)
trifluridine/tipiracil HCl	Lonsurf
trilaciclib dihydrochloride	Cosela
triptorelin pamoate	Trelstar
triptorelin pamoate	Trelstar Depot
triptorelin pamoate	Trelstar LA
tucatinib	Tukysa
umbralisib tosylate	Ukoniq
uracil mustard	uracil mustard
uridine	uridine (bulk)
uridine triacetate	Vistogard
valrubicin	Valstar
valrubicin	valrubicin
vandetanib	Caprelsa
vandetanib	vandetanib
vemurafenib	Zelboraf
venetoclax	Venclexta
venetoclax	Venclexta Starting Pack
vinblastine sulfate	Velban
vinblastine sulfate	vinblastine

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Non-Proprietary Name	Proprietary Name
vincristine sulfate	Oncovin
vincristine sulfate	Vincasar PFS
vincristine sulfate	vincristine
vincristine sulfate liposomal	Marqibo
vinorelbine tartrate	Navelbine
vinorelbine tartrate	vinorelbine
vismodegib	Erivedge
vorinostat	Zolinza
zanubrutinib	Brukinsa
ziv-aflibercept	Zaltrap

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
	Cancer, Chemotherapy, and Radiation		
00.10	Implantation of chemotherapeutic agent	Procedure	ICD-9-CM
00.15	High-dose infusion interleukin-2 [IL-2]	Procedure	ICD-9-CM
00.18	Infusion of immunosuppressive antibody therapy	Procedure	ICD-9-CM
11600	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.5 cm or less	Procedure	CPT-4
11601	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11602	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11603	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11604	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11606	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm	Procedure	CPT-4
11620	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less	Procedure	CPT-4
11621	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11622	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11623	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11624	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11626	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm	Procedure	CPT-4
11640	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less	Procedure	CPT-4
11641	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11642	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11643	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11644	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11646	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm	Procedure	CPT-4
140	Malignant neoplasm of lip	Diagnosis	ICD-9-CM
140.0	Malignant neoplasm of upper lip, vermilion border	Diagnosis	ICD-9-CM
140.1	Malignant neoplasm of lower lip, vermilion border	Diagnosis	ICD-9-CM
140.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-9-CM
140.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
140.5	Malignant neoplasm of lip, inner aspect, unspecified as to upper or lower	Diagnosis	ICD-9-CM
140.6	Malignant neoplasm of commissure of lip	Diagnosis	ICD-9-CM
140.8	Malignant neoplasm of other sites of lip	Diagnosis	ICD-9-CM
140.9	Malignant neoplasm of lip, vermilion border, unspecified as to upper or lower	Diagnosis	ICD-9-CM
141	Malignant neoplasm of tongue	Diagnosis	ICD-9-CM
141.0	Malignant neoplasm of base of tongue	Diagnosis	ICD-9-CM
141.1	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-9-CM
141.2	Malignant neoplasm of tip and lateral border of tongue	Diagnosis	ICD-9-CM
141.3	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-9-CM
141.4	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-9-CM
141.5	Malignant neoplasm of junctional zone of tongue	Diagnosis	ICD-9-CM
141.6	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-9-CM
141.8	Malignant neoplasm of other sites of tongue	Diagnosis	ICD-9-CM
141.9	Malignant neoplasm of tongue, unspecified site	Diagnosis	ICD-9-CM
142	Malignant neoplasm of major salivary glands	Diagnosis	ICD-9-CM
142.0	Malignant neoplasm of parotid gland	Diagnosis	ICD-9-CM
142.1	Malignant neoplasm of submandibular gland	Diagnosis	ICD-9-CM
142.2	Malignant neoplasm of sublingual gland	Diagnosis	ICD-9-CM
142.8	Malignant neoplasm of other major salivary glands	Diagnosis	ICD-9-CM
142.9	Malignant neoplasm of salivary gland, unspecified	Diagnosis	ICD-9-CM
143	Malignant neoplasm of gum	Diagnosis	ICD-9-CM
143.0	Malignant neoplasm of upper gum	Diagnosis	ICD-9-CM
143.1	Malignant neoplasm of lower gum	Diagnosis	ICD-9-CM
143.8	Malignant neoplasm of other sites of gum	Diagnosis	ICD-9-CM
143.9	Malignant neoplasm of gum, unspecified site	Diagnosis	ICD-9-CM
144	Malignant neoplasm of floor of mouth	Diagnosis	ICD-9-CM
144.0	Malignant neoplasm of anterior portion of floor of mouth	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
144.1	Malignant neoplasm of lateral portion of floor of mouth	Diagnosis	ICD-9-CM
144.8	Malignant neoplasm of other sites of floor of mouth	Diagnosis	ICD-9-CM
144.9	Malignant neoplasm of floor of mouth, part unspecified	Diagnosis	ICD-9-CM
145	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-9-CM
145.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-9-CM
145.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-9-CM
145.2	Malignant neoplasm of hard palate	Diagnosis	ICD-9-CM
145.3	Malignant neoplasm of soft palate	Diagnosis	ICD-9-CM
145.4	Malignant neoplasm of uvula	Diagnosis	ICD-9-CM
145.5	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-9-CM
145.6	Malignant neoplasm of retromolar area	Diagnosis	ICD-9-CM
145.8	Malignant neoplasm of other specified parts of mouth	Diagnosis	ICD-9-CM
145.9	Malignant neoplasm of mouth, unspecified site	Diagnosis	ICD-9-CM
146	Malignant neoplasm of oropharynx	Diagnosis	ICD-9-CM
146.0	Malignant neoplasm of tonsil	Diagnosis	ICD-9-CM
146.1	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-9-CM
146.2	Malignant neoplasm of tonsillar pillars (anterior) (posterior)	Diagnosis	ICD-9-CM
146.3	Malignant neoplasm of vallecula	Diagnosis	ICD-9-CM
146.4	Malignant neoplasm of anterior aspect of epiglottis	Diagnosis	ICD-9-CM
146.5	Malignant neoplasm of junctional region of oropharynx	Diagnosis	ICD-9-CM
146.6	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-9-CM
146.7	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-9-CM
146.8	Malignant neoplasm of other specified sites of oropharynx	Diagnosis	ICD-9-CM
146.9	Malignant neoplasm of oropharynx, unspecified site	Diagnosis	ICD-9-CM
147	Malignant neoplasm of nasopharynx	Diagnosis	ICD-9-CM
147.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-9-CM
147.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
147.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-9-CM
147.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.8	Malignant neoplasm of other specified sites of nasopharynx	Diagnosis	ICD-9-CM
147.9	Malignant neoplasm of nasopharynx, unspecified site	Diagnosis	ICD-9-CM
148	Malignant neoplasm of hypopharynx	Diagnosis	ICD-9-CM
148.0	Malignant neoplasm of postcricoid region of hypopharynx	Diagnosis	ICD-9-CM
148.1	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-9-CM
148.2	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-9-CM
148.3	Malignant neoplasm of posterior hypopharyngeal wall	Diagnosis	ICD-9-CM
148.8	Malignant neoplasm of other specified sites of hypopharynx	Diagnosis	ICD-9-CM
148.9	Malignant neoplasm of hypopharynx, unspecified site	Diagnosis	ICD-9-CM
149	Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
149.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-9-CM
149.1	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-9-CM
149.8	Malignant neoplasm of other sites within the lip and oral cavity	Diagnosis	ICD-9-CM
149.9	Malignant neoplasm of ill-defined sites of lip and oral cavity	Diagnosis	ICD-9-CM
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM
151	Malignant neoplasm of stomach	Diagnosis	ICD-9-CM
151.0	Malignant neoplasm of cardia	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
151.1	Malignant neoplasm of pylorus	Diagnosis	ICD-9-CM
151.2	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-9-CM
151.3	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-9-CM
151.4	Malignant neoplasm of body of stomach	Diagnosis	ICD-9-CM
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.8	Malignant neoplasm of other specified sites of stomach	Diagnosis	ICD-9-CM
151.9	Malignant neoplasm of stomach, unspecified site	Diagnosis	ICD-9-CM
152	Malignant neoplasm of small intestine, including duodenum	Diagnosis	ICD-9-CM
152.0	Malignant neoplasm of duodenum	Diagnosis	ICD-9-CM
152.1	Malignant neoplasm of jejunum	Diagnosis	ICD-9-CM
152.2	Malignant neoplasm of ileum	Diagnosis	ICD-9-CM
152.3	Malignant neoplasm of Meckel's diverticulum	Diagnosis	ICD-9-CM
152.8	Malignant neoplasm of other specified sites of small intestine	Diagnosis	ICD-9-CM
152.9	Malignant neoplasm of small intestine, unspecified site	Diagnosis	ICD-9-CM
153	Malignant neoplasm of colon	Diagnosis	ICD-9-CM
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154	Malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
154.2	Malignant neoplasm of anal canal	Diagnosis	ICD-9-CM
154.3	Malignant neoplasm of anus, unspecified site	Diagnosis	ICD-9-CM
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.2	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-9-CM
156	Malignant neoplasm of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.0	Malignant neoplasm of gallbladder	Diagnosis	ICD-9-CM
156.1	Malignant neoplasm of extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.2	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-9-CM
156.8	Malignant neoplasm of other specified sites of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.9	Malignant neoplasm of biliary tract, part unspecified site	Diagnosis	ICD-9-CM
157	Malignant neoplasm of pancreas	Diagnosis	ICD-9-CM
157.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-9-CM
157.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-9-CM
157.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-9-CM
157.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-9-CM
157.4	Malignant neoplasm of islets of Langerhans	Diagnosis	ICD-9-CM
157.8	Malignant neoplasm of other specified sites of pancreas	Diagnosis	ICD-9-CM
157.9	Malignant neoplasm of pancreas, part unspecified	Diagnosis	ICD-9-CM
158	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
158.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-9-CM
158.8	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-9-CM
158.9	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
159	Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum	Diagnosis	ICD-9-CM
159.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-9-CM
159.1	Malignant neoplasm of spleen, not elsewhere classified	Diagnosis	ICD-9-CM
159.8	Malignant neoplasm of other sites of digestive system and intra-abdominal organs	Diagnosis	ICD-9-CM
159.9	Malignant neoplasm of ill-defined sites of digestive organs and peritoneum	Diagnosis	ICD-9-CM
160	Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.0	Malignant neoplasm of nasal cavities	Diagnosis	ICD-9-CM
160.1	Malignant neoplasm of auditory tube, middle ear, and mastoid air cells	Diagnosis	ICD-9-CM
160.2	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-9-CM
160.3	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-9-CM
160.4	Malignant neoplasm of frontal sinus	Diagnosis	ICD-9-CM
160.5	Malignant neoplasm of sphenoidal sinus	Diagnosis	ICD-9-CM
160.8	Malignant neoplasm of other sites of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.9	Malignant neoplasm of site of nasal cavities, middle ear, and accessory sinus, unspecified site	Diagnosis	ICD-9-CM
161	Malignant neoplasm of larynx	Diagnosis	ICD-9-CM
161.0	Malignant neoplasm of glottis	Diagnosis	ICD-9-CM
161.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-9-CM
161.2	Malignant neoplasm of subglottis	Diagnosis	ICD-9-CM
161.3	Malignant neoplasm of laryngeal cartilages	Diagnosis	ICD-9-CM
161.8	Malignant neoplasm of other specified sites of larynx	Diagnosis	ICD-9-CM
161.9	Malignant neoplasm of larynx, unspecified site	Diagnosis	ICD-9-CM
162	Malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
162.0	Malignant neoplasm of trachea	Diagnosis	ICD-9-CM
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
163	Malignant neoplasm of pleura	Diagnosis	ICD-9-CM
163.0	Malignant neoplasm of parietal pleura	Diagnosis	ICD-9-CM
163.1	Malignant neoplasm of visceral pleura	Diagnosis	ICD-9-CM
163.8	Malignant neoplasm of other specified sites of pleura	Diagnosis	ICD-9-CM
163.9	Malignant neoplasm of pleura, unspecified site	Diagnosis	ICD-9-CM
164	Malignant neoplasm of thymus, heart, and mediastinum	Diagnosis	ICD-9-CM
164.0	Malignant neoplasm of thymus	Diagnosis	ICD-9-CM
164.1	Malignant neoplasm of heart	Diagnosis	ICD-9-CM
164.2	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-9-CM
164.3	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-9-CM
164.8	Malignant neoplasm of other parts of mediastinum	Diagnosis	ICD-9-CM
164.9	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-9-CM
165	Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-9-CM
165.8	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.9	Malignant neoplasm of ill-defined sites within the respiratory system	Diagnosis	ICD-9-CM
17.70	Intravenous infusion of clofarabine	Procedure	ICD-9-CM
170	Malignant neoplasm of bone and articular cartilage	Diagnosis	ICD-9-CM
170.0	Malignant neoplasm of bones of skull and face, except mandible	Diagnosis	ICD-9-CM
170.1	Malignant neoplasm of mandible	Diagnosis	ICD-9-CM
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx	Diagnosis	ICD-9-CM
170.3	Malignant neoplasm of ribs, sternum, and clavicle	Diagnosis	ICD-9-CM
170.4	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-9-CM
170.5	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-9-CM
170.6	Malignant neoplasm of pelvic bones, sacrum, and coccyx	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
170.7	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-9-CM
170.8	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-9-CM
170.9	Malignant neoplasm of bone and articular cartilage, site unspecified	Diagnosis	ICD-9-CM
171	Malignant neoplasm of connective and other soft tissue	Diagnosis	ICD-9-CM
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	Diagnosis	ICD-9-CM
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	Diagnosis	ICD-9-CM
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	Diagnosis	ICD-9-CM
171.4	Malignant neoplasm of connective and other soft tissue of thorax	Diagnosis	ICD-9-CM
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	Diagnosis	ICD-9-CM
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	Diagnosis	ICD-9-CM
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified site	Diagnosis	ICD-9-CM
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	Diagnosis	ICD-9-CM
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	Diagnosis	ICD-9-CM
172	Malignant melanoma of skin	Diagnosis	ICD-9-CM
172.0	Malignant melanoma of skin of lip	Diagnosis	ICD-9-CM
172.1	Malignant melanoma of skin of eyelid, including canthus	Diagnosis	ICD-9-CM
172.2	Malignant melanoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
172.3	Malignant melanoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
172.4	Malignant melanoma of skin of scalp and neck	Diagnosis	ICD-9-CM
172.5	Malignant melanoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
172.6	Malignant melanoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
172.7	Malignant melanoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
172.8	Malignant melanoma of other specified sites of skin	Diagnosis	ICD-9-CM
172.9	Melanoma of skin, site unspecified	Diagnosis	ICD-9-CM
17260	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.5 cm or less	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
17261	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17262	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17263	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17264	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17266	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter over 4.0 cm	Procedure	CPT-4
17270	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less	Procedure	CPT-4
17271	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17272	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17273	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17274	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17276	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter over 4.0 cm	Procedure	CPT-4
17280	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less	Procedure	CPT-4
17281	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17282	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
17283	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17284	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17286	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter over 4.0 cm	Procedure	CPT-4
173	Other and unspecified malignant neoplasm of skin	Diagnosis	ICD-9-CM
173.0	Other and unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.1	Other and unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.10	Unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.11	Basal cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.12	Squamous cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.19	Other specified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.2	Other and unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.20	Unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.21	Basal cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.22	Squamous cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.29	Other specified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.3	Other and unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.30	Unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.31	Basal cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.32	Squamous cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.39	Other specified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
173.4	Other and unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.40	Unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.41	Basal cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.42	Squamous cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.49	Other specified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.5	Other and unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.50	Unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.51	Basal cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.52	Squamous cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.59	Other specified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.6	Other and unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.60	Unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.61	Basal cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.62	Squamous cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.69	Other specified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.7	Other and unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.70	Unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.71	Basal cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.72	Squamous cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.79	Other specified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.8	Other and unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.80	Unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.81	Basal cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.82	Squamous cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.89	Other specified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.9	Other and unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
173.90	Unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
173.91	Basal cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
173.92	Squamous cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
173.99	Other specified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
17304	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); first stage, fresh tissue technique, up to 5 specimens	Procedure	CPT-4
17305	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); second stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17306	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); third stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17307	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); additional stage(s), up to 5 specimens, each stage	Procedure	CPT-4
17310	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); each additional specimen, after the first 5 specimens, fixed or fresh tissue, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
17311	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
17312	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17313	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks	Procedure	CPT-4
17314	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17315	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
174	Malignant neoplasm of female breast	Diagnosis	ICD-9-CM
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175	Malignant neoplasm of male breast	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
176	Kaposi's sarcoma	Diagnosis	ICD-9-CM
176.0	Kaposi's sarcoma of skin	Diagnosis	ICD-9-CM
176.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-9-CM
176.2	Kaposi's sarcoma of palate	Diagnosis	ICD-9-CM
176.3	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-9-CM
176.4	Kaposi's sarcoma of lung	Diagnosis	ICD-9-CM
176.5	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-9-CM
176.8	Kaposi's sarcoma of other specified sites	Diagnosis	ICD-9-CM
176.9	Kaposi's sarcoma of unspecified site	Diagnosis	ICD-9-CM
179	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-9-CM
180	Malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
180.0	Malignant neoplasm of endocervix	Diagnosis	ICD-9-CM
180.1	Malignant neoplasm of exocervix	Diagnosis	ICD-9-CM
180.8	Malignant neoplasm of other specified sites of cervix	Diagnosis	ICD-9-CM
180.9	Malignant neoplasm of cervix uteri, unspecified site	Diagnosis	ICD-9-CM
181	Malignant neoplasm of placenta	Diagnosis	ICD-9-CM
182	Malignant neoplasm of body of uterus	Diagnosis	ICD-9-CM
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
182.1	Malignant neoplasm of isthmus	Diagnosis	ICD-9-CM
182.8	Malignant neoplasm of other specified sites of body of uterus	Diagnosis	ICD-9-CM
183	Malignant neoplasm of ovary and other uterine adnexa	Diagnosis	ICD-9-CM
183.0	Malignant neoplasm of ovary	Diagnosis	ICD-9-CM
183.2	Malignant neoplasm of fallopian tube	Diagnosis	ICD-9-CM
183.3	Malignant neoplasm of broad ligament of uterus	Diagnosis	ICD-9-CM
183.4	Malignant neoplasm of parametrium of uterus	Diagnosis	ICD-9-CM
183.5	Malignant neoplasm of round ligament of uterus	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
183.8	Malignant neoplasm of other specified sites of uterine adnexa	Diagnosis	ICD-9-CM
183.9	Malignant neoplasm of uterine adnexa, unspecified site	Diagnosis	ICD-9-CM
184	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-9-CM
184.0	Malignant neoplasm of vagina	Diagnosis	ICD-9-CM
184.1	Malignant neoplasm of labia majora	Diagnosis	ICD-9-CM
184.2	Malignant neoplasm of labia minora	Diagnosis	ICD-9-CM
184.3	Malignant neoplasm of clitoris	Diagnosis	ICD-9-CM
184.4	Malignant neoplasm of vulva, unspecified site	Diagnosis	ICD-9-CM
184.8	Malignant neoplasm of other specified sites of female genital organs	Diagnosis	ICD-9-CM
184.9	Malignant neoplasm of female genital organ, site unspecified	Diagnosis	ICD-9-CM
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
186	Malignant neoplasm of testis	Diagnosis	ICD-9-CM
186.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-9-CM
186.9	Malignant neoplasm of other and unspecified testis	Diagnosis	ICD-9-CM
187	Malignant neoplasm of penis and other male genital organs	Diagnosis	ICD-9-CM
187.1	Malignant neoplasm of prepuce	Diagnosis	ICD-9-CM
187.2	Malignant neoplasm of glans penis	Diagnosis	ICD-9-CM
187.3	Malignant neoplasm of body of penis	Diagnosis	ICD-9-CM
187.4	Malignant neoplasm of penis, part unspecified	Diagnosis	ICD-9-CM
187.5	Malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
187.6	Malignant neoplasm of spermatic cord	Diagnosis	ICD-9-CM
187.7	Malignant neoplasm of scrotum	Diagnosis	ICD-9-CM
187.8	Malignant neoplasm of other specified sites of male genital organs	Diagnosis	ICD-9-CM
187.9	Malignant neoplasm of male genital organ, site unspecified	Diagnosis	ICD-9-CM
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
189	Malignant neoplasm of kidney and other and unspecified urinary organs	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.1	Malignant neoplasm of renal pelvis	Diagnosis	ICD-9-CM
189.2	Malignant neoplasm of ureter	Diagnosis	ICD-9-CM
189.3	Malignant neoplasm of urethra	Diagnosis	ICD-9-CM
189.4	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-9-CM
189.8	Malignant neoplasm of other specified sites of urinary organs	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
190	Malignant neoplasm of eye	Diagnosis	ICD-9-CM
190.0	Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and choroid	Diagnosis	ICD-9-CM
190.1	Malignant neoplasm of orbit	Diagnosis	ICD-9-CM
190.2	Malignant neoplasm of lacrimal gland	Diagnosis	ICD-9-CM
190.3	Malignant neoplasm of conjunctiva	Diagnosis	ICD-9-CM
190.4	Malignant neoplasm of cornea	Diagnosis	ICD-9-CM
190.5	Malignant neoplasm of retina	Diagnosis	ICD-9-CM
190.6	Malignant neoplasm of choroid	Diagnosis	ICD-9-CM
190.7	Malignant neoplasm of lacrimal duct	Diagnosis	ICD-9-CM
190.8	Malignant neoplasm of other specified sites of eye	Diagnosis	ICD-9-CM
190.9	Malignant neoplasm of eye, part unspecified	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
191	Malignant neoplasm of brain	Diagnosis	ICD-9-CM
191.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-9-CM
191.1	Malignant neoplasm of frontal lobe of brain	Diagnosis	ICD-9-CM
191.2	Malignant neoplasm of temporal lobe of brain	Diagnosis	ICD-9-CM
191.3	Malignant neoplasm of parietal lobe of brain	Diagnosis	ICD-9-CM
191.4	Malignant neoplasm of occipital lobe of brain	Diagnosis	ICD-9-CM
191.5	Malignant neoplasm of ventricles of brain	Diagnosis	ICD-9-CM
191.6	Malignant neoplasm of cerebellum NOS	Diagnosis	ICD-9-CM
191.7	Malignant neoplasm of brain stem	Diagnosis	ICD-9-CM
191.8	Malignant neoplasm of other parts of brain	Diagnosis	ICD-9-CM
191.9	Malignant neoplasm of brain, unspecified site	Diagnosis	ICD-9-CM
192	Malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
192.0	Malignant neoplasm of cranial nerves	Diagnosis	ICD-9-CM
192.1	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-9-CM
192.2	Malignant neoplasm of spinal cord	Diagnosis	ICD-9-CM
192.3	Malignant neoplasm of spinal meninges	Diagnosis	ICD-9-CM
192.8	Malignant neoplasm of other specified sites of nervous system	Diagnosis	ICD-9-CM
192.9	Malignant neoplasm of nervous system, part unspecified	Diagnosis	ICD-9-CM
193	Malignant neoplasm of thyroid gland	Diagnosis	ICD-9-CM
194	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.0	Malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
194.1	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-9-CM
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
194.4	Malignant neoplasm of pineal gland	Diagnosis	ICD-9-CM
194.5	Malignant neoplasm of carotid body	Diagnosis	ICD-9-CM
194.6	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-9-CM
194.8	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
194.9	Malignant neoplasm of endocrine gland, site unspecified	Diagnosis	ICD-9-CM
195	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-9-CM
195.0	Malignant neoplasm of head, face, and neck	Diagnosis	ICD-9-CM
195.1	Malignant neoplasm of thorax	Diagnosis	ICD-9-CM
195.2	Malignant neoplasm of abdomen	Diagnosis	ICD-9-CM
195.3	Malignant neoplasm of pelvis	Diagnosis	ICD-9-CM
195.4	Malignant neoplasm of upper limb	Diagnosis	ICD-9-CM
195.5	Malignant neoplasm of lower limb	Diagnosis	ICD-9-CM
195.8	Malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
196	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-9-CM
196.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
196.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
196.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
196.3	Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
196.5	Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
196.6	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
196.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
196.9	Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified	Diagnosis	ICD-9-CM
197	Secondary malignant neoplasm of respiratory and digestive systems	Diagnosis	ICD-9-CM
197.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-9-CM
197.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-9-CM
197.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-9-CM
197.3	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-9-CM
197.4	Secondary malignant neoplasm of small intestine including duodenum	Diagnosis	ICD-9-CM
197.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-9-CM
197.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
197.7	Secondary malignant neoplasm of liver	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
197.8	Secondary malignant neoplasm of other digestive organs and spleen	Diagnosis	ICD-9-CM
198	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.0	Secondary malignant neoplasm of kidney	Diagnosis	ICD-9-CM
198.1	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-9-CM
198.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-9-CM
198.3	Secondary malignant neoplasm of brain and spinal cord	Diagnosis	ICD-9-CM
198.4	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
198.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-9-CM
198.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-9-CM
198.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
198.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-9-CM
198.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
198.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
199	Malignant neoplasm without specification of site	Diagnosis	ICD-9-CM
199.0	Disseminated malignant neoplasm	Diagnosis	ICD-9-CM
199.1	Other malignant neoplasm of unspecified site	Diagnosis	ICD-9-CM
199.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-9-CM
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	Diagnosis	ICD-9-CM
200.0	Reticulosarcoma	Diagnosis	ICD-9-CM
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.01	Reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.02	Reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.03	Reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.04	Reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.05	Reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.06	Reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
200.07	Reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.08	Reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.1	Lymphosarcoma	Diagnosis	ICD-9-CM
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.11	Lymphosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.12	Lymphosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.13	Lymphosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.14	Lymphosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.15	Lymphosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.16	Lymphosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.17	Lymphosarcoma of spleen	Diagnosis	ICD-9-CM
200.18	Lymphosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.2	Burkitt's tumor or lymphoma	Diagnosis	ICD-9-CM
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.21	Burkitt's tumor or lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.22	Burkitt's tumor or lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.23	Burkitt's tumor or lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.24	Burkitt's tumor or lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.25	Burkitt's tumor or lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.26	Burkitt's tumor or lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.27	Burkitt's tumor or lymphoma of spleen	Diagnosis	ICD-9-CM
200.28	Burkitt's tumor or lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.3	Marginal zone lymphoma	Diagnosis	ICD-9-CM
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.31	Marginal zone lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.32	Marginal zone lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.33	Marginal zone lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
200.34	Marginal zone lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.35	Marginal zone lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.36	Marginal zone lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.37	Marginal zone lymphoma, spleen	Diagnosis	ICD-9-CM
200.38	Marginal zone lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.4	Mantle cell lymphoma	Diagnosis	ICD-9-CM
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.41	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.42	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.43	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.44	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.45	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.46	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.47	Mantle cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.48	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.5	Primary central nervous system lymphoma	Diagnosis	ICD-9-CM
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.51	Primary central nervous system lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.52	Primary central nervous system lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.53	Primary central nervous system lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.54	Primary central nervous system lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.55	Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.56	Primary central nervous system lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.57	Primary central nervous system lymphoma, spleen	Diagnosis	ICD-9-CM
200.58	Primary central nervous system lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.6	Anaplastic large cell lymphoma	Diagnosis	ICD-9-CM
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
200.61	Anaplastic large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.62	Anaplastic large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.63	Anaplastic large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.64	Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.65	Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.66	Anaplastic large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.67	Anaplastic large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.68	Anaplastic large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.7	Large cell lymphoma	Diagnosis	ICD-9-CM
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.71	Large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.72	Large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.73	Large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.74	Large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.75	Large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.76	Large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.77	Large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.78	Large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.8	Other named variants of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
200.80	Other named variants, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.81	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.82	Other named variants of lymphosarcoma and reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.83	Other named variants of lymphosarcoma and reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.84	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.85	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.86	Other named variants of lymphosarcoma and reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.87	Other named variants of lymphosarcoma and reticulosarcoma of spleen	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
200.88	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201	Hodgkin's disease	Diagnosis	ICD-9-CM
201.0	Hodgkin's paragranuloma	Diagnosis	ICD-9-CM
201.00	Hodgkin's paragranuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.01	Hodgkin's paragranuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.02	Hodgkin's paragranuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.03	Hodgkin's paragranuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.04	Hodgkin's paragranuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.05	Hodgkin's paragranuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.06	Hodgkin's paragranuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.07	Hodgkin's paragranuloma of spleen	Diagnosis	ICD-9-CM
201.08	Hodgkin's paragranuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.1	Hodgkin's granuloma	Diagnosis	ICD-9-CM
201.10	Hodgkin's granuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.11	Hodgkin's granuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.12	Hodgkin's granuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.13	Hodgkin's granuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.14	Hodgkin's granuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.15	Hodgkin's granuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.16	Hodgkin's granuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.17	Hodgkin's granuloma of spleen	Diagnosis	ICD-9-CM
201.18	Hodgkin's granuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.2	Hodgkin's sarcoma	Diagnosis	ICD-9-CM
201.20	Hodgkin's sarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.21	Hodgkin's sarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.22	Hodgkin's sarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.23	Hodgkin's sarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
201.24	Hodgkin's sarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.25	Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.26	Hodgkin's sarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.27	Hodgkin's sarcoma of spleen	Diagnosis	ICD-9-CM
201.28	Hodgkin's sarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.4	Hodgkin's disease, lymphocytic-histiocytic predominance	Diagnosis	ICD-9-CM
201.40	Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.41	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.42	Hodgkin's disease, lymphocytic-histiocytic predominance of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.43	Hodgkin's disease, lymphocytic-histiocytic predominance of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.44	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.45	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.46	Hodgkin's disease, lymphocytic-histiocytic predominance of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.47	Hodgkin's disease, lymphocytic-histiocytic predominance of spleen	Diagnosis	ICD-9-CM
201.48	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.5	Hodgkin's disease, nodular sclerosis	Diagnosis	ICD-9-CM
201.50	Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.51	Hodgkin's disease, nodular sclerosis, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.52	Hodgkin's disease, nodular sclerosis, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.53	Hodgkin's disease, nodular sclerosis, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.54	Hodgkin's disease, nodular sclerosis, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.55	Hodgkin's disease, nodular sclerosis, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.56	Hodgkin's disease, nodular sclerosis, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.57	Hodgkin's disease, nodular sclerosis, of spleen	Diagnosis	ICD-9-CM
201.58	Hodgkin's disease, nodular sclerosis, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.6	Hodgkin's disease, mixed cellularity	Diagnosis	ICD-9-CM
201.60	Hodgkin's disease, mixed cellularity, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
201.61	Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.62	Hodgkin's disease, mixed cellularity, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.63	Hodgkin's disease, mixed cellularity, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.64	Hodgkin's disease, mixed cellularity, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.65	Hodgkin's disease, mixed cellularity, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.66	Hodgkin's disease, mixed cellularity, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.67	Hodgkin's disease, mixed cellularity, of spleen	Diagnosis	ICD-9-CM
201.68	Hodgkin's disease, mixed cellularity, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.7	Hodgkin's disease, lymphocytic depletion	Diagnosis	ICD-9-CM
201.70	Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.71	Hodgkin's disease, lymphocytic depletion, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.72	Hodgkin's disease, lymphocytic depletion, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.73	Hodgkin's disease, lymphocytic depletion, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.74	Hodgkin's disease, lymphocytic depletion, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.75	Hodgkin's disease, lymphocytic depletion, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.76	Hodgkin's disease, lymphocytic depletion, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.77	Hodgkin's disease, lymphocytic depletion, of spleen	Diagnosis	ICD-9-CM
201.78	Hodgkin's disease, lymphocytic depletion, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.9	Hodgkin's disease, unspecified type	Diagnosis	ICD-9-CM
201.90	Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.91	Hodgkin's disease, unspecified type, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.92	Hodgkin's disease, unspecified type, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.93	Hodgkin's disease, unspecified type, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.94	Hodgkin's disease, unspecified type, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.95	Hodgkin's disease, unspecified type, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.96	Hodgkin's disease, unspecified type, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.97	Hodgkin's disease, unspecified type, of spleen	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
201.98	Hodgkin's disease, unspecified type, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202	Other malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.0	Nodular lymphoma	Diagnosis	ICD-9-CM
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.01	Nodular lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.02	Nodular lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.03	Nodular lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.04	Nodular lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.05	Nodular lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.06	Nodular lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.07	Nodular lymphoma of spleen	Diagnosis	ICD-9-CM
202.08	Nodular lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.1	Mycosis fungoides	Diagnosis	ICD-9-CM
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.11	Mycosis fungoides of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.12	Mycosis fungoides of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.13	Mycosis fungoides of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.14	Mycosis fungoides of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.15	Mycosis fungoides of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.16	Mycosis fungoides of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.17	Mycosis fungoides of spleen	Diagnosis	ICD-9-CM
202.18	Mycosis fungoides of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.2	Sezary's disease	Diagnosis	ICD-9-CM
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.21	Sezary's disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.22	Sezary's disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.23	Sezary's disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
202.24	Sezary's disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.25	Sezary's disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.26	Sezary's disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.27	Sezary's disease of spleen	Diagnosis	ICD-9-CM
202.28	Sezary's disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.3	Malignant histiocytosis	Diagnosis	ICD-9-CM
202.30	Malignant histiocytosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.31	Malignant histiocytosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.32	Malignant histiocytosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.33	Malignant histiocytosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.34	Malignant histiocytosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.35	Malignant histiocytosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.36	Malignant histiocytosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.37	Malignant histiocytosis of spleen	Diagnosis	ICD-9-CM
202.38	Malignant histiocytosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.4	Leukemic reticuloendotheliosis	Diagnosis	ICD-9-CM
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.41	Leukemic reticuloendotheliosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.42	Leukemic reticuloendotheliosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.43	Leukemic reticuloendotheliosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.44	Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.45	Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.46	Leukemic reticuloendotheliosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.47	Leukemic reticuloendotheliosis of spleen	Diagnosis	ICD-9-CM
202.48	Leukemic reticuloendotheliosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.5	Letterer-Siwe disease	Diagnosis	ICD-9-CM
202.50	Letterer-Siwe disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
202.51	Letterer-Siwe disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.52	Letterer-Siwe disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.53	Letterer-Siwe disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.54	Letterer-Siwe disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.55	Letterer-Siwe disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.56	Letterer-Siwe disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.57	Letterer-Siwe disease of spleen	Diagnosis	ICD-9-CM
202.58	Letterer-Siwe disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.6	Malignant mast cell tumors	Diagnosis	ICD-9-CM
202.60	Malignant mast cell tumors, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.61	Malignant mast cell tumors of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.62	Malignant mast cell tumors of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.63	Malignant mast cell tumors of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.64	Malignant mast cell tumors of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.65	Malignant mast cell tumors of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.66	Malignant mast cell tumors of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.67	Malignant mast cell tumors of spleen	Diagnosis	ICD-9-CM
202.68	Malignant mast cell tumors of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.7	Peripheral T-cell lymphoma	Diagnosis	ICD-9-CM
202.70	Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.71	Peripheral T-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.72	Peripheral T-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.73	Peripheral T-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.74	Peripheral T-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.75	Peripheral T-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.76	Peripheral T-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.77	Peripheral T-cell lymphoma, spleen	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
202.78	Peripheral T-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.8	Other malignant lymphomas	Diagnosis	ICD-9-CM
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.81	Other malignant lymphomas of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.82	Other malignant lymphomas of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.83	Other malignant lymphomas of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.84	Other malignant lymphomas of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.85	Other malignant lymphomas of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.86	Other malignant lymphomas of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.87	Other malignant lymphomas of spleen	Diagnosis	ICD-9-CM
202.88	Other malignant lymphomas of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.9	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid	Diagnosis	ICD-9-CM
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of inguinal region and	Diagnosis	ICD-9-CM
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of spleen	Diagnosis	ICD-9-CM
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
203	Multiple myeloma and immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.0	Multiple myeloma	Diagnosis	ICD-9-CM
203.00	Multiple myeloma, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.01	Multiple myeloma in remission	Diagnosis	ICD-9-CM
203.02	Multiple myeloma, in relapse	Diagnosis	ICD-9-CM
203.1	Plasma cell leukemia	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
203.10	Plasma cell leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.11	Plasma cell leukemia in remission	Diagnosis	ICD-9-CM
203.12	Plasma cell leukemia, in relapse	Diagnosis	ICD-9-CM
203.8	Other immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.80	Other immunoproliferative neoplasms, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.81	Other immunoproliferative neoplasms in remission	Diagnosis	ICD-9-CM
203.82	Other immunoproliferative neoplasms, in relapse	Diagnosis	ICD-9-CM
204	Lymphoid leukemia	Diagnosis	ICD-9-CM
204.0	Acute lymphoid leukemia	Diagnosis	ICD-9-CM
204.00	Acute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.01	Acute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.02	Acute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.1	Chronic lymphoid leukemia	Diagnosis	ICD-9-CM
204.10	Chronic lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.11	Chronic lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.12	Chronic lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.2	Subacute lymphoid leukemia	Diagnosis	ICD-9-CM
204.20	Subacute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.21	Subacute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.22	Subacute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.8	Other lymphoid leukemia	Diagnosis	ICD-9-CM
204.80	Other lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.81	Other lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.82	Other lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.9	Unspecified lymphoid leukemia	Diagnosis	ICD-9-CM
204.90	Unspecified lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.91	Unspecified lymphoid leukemia in remission	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
204.92	Unspecified lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
205	Myeloid leukemia	Diagnosis	ICD-9-CM
205.0	Acute myeloid leukemia	Diagnosis	ICD-9-CM
205.00	Acute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.01	Acute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.02	Acute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.1	Chronic myeloid leukemia	Diagnosis	ICD-9-CM
205.10	Chronic myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.11	Chronic myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.12	Chronic myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.2	Subacute myeloid leukemia	Diagnosis	ICD-9-CM
205.20	Subacute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.21	Subacute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.22	Subacute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.3	Myeloid sarcoma	Diagnosis	ICD-9-CM
205.30	Myeloid sarcoma, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.31	Myeloid sarcoma in remission	Diagnosis	ICD-9-CM
205.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-9-CM
205.8	Other myeloid leukemia	Diagnosis	ICD-9-CM
205.80	Other myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.81	Other myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.82	Other myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.9	Unspecified myeloid leukemia	Diagnosis	ICD-9-CM
205.90	Unspecified myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.91	Unspecified myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.92	Unspecified myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
206	Monocytic leukemia	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
206.0	Acute monocytic leukemia	Diagnosis	ICD-9-CM
206.00	Acute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.01	Acute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.02	Acute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.1	Chronic monocytic leukemia	Diagnosis	ICD-9-CM
206.10	Chronic monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.11	Chronic monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.12	Chronic monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.2	Subacute monocytic leukemia	Diagnosis	ICD-9-CM
206.20	Subacute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.21	Subacute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.22	Subacute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.8	Other monocytic leukemia	Diagnosis	ICD-9-CM
206.80	Other monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.81	Other monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.82	Other monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.9	Unspecified monocytic leukemia	Diagnosis	ICD-9-CM
206.90	Unspecified monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.91	Unspecified monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.92	Unspecified monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207	Other specified leukemia	Diagnosis	ICD-9-CM
207.0	Acute erythremia and erythroleukemia	Diagnosis	ICD-9-CM
207.00	Acute erythremia and erythroleukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.01	Acute erythremia and erythroleukemia in remission	Diagnosis	ICD-9-CM
207.02	Acute erythremia and erythroleukemia, in relapse	Diagnosis	ICD-9-CM
207.1	Chronic erythremia	Diagnosis	ICD-9-CM
207.10	Chronic erythremia, without mention of having achieved remission	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
207.11	Chronic erythremia in remission	Diagnosis	ICD-9-CM
207.12	Chronic erythremia, in relapse	Diagnosis	ICD-9-CM
207.2	Megakaryocytic leukemia	Diagnosis	ICD-9-CM
207.20	Megakaryocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.21	Megakaryocytic leukemia in remission	Diagnosis	ICD-9-CM
207.22	Megakaryocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207.8	Other specified leukemia	Diagnosis	ICD-9-CM
207.80	Other specified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.81	Other specified leukemia in remission	Diagnosis	ICD-9-CM
207.82	Other specified leukemia, in relapse	Diagnosis	ICD-9-CM
208	Leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.00	Acute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.01	Acute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.10	Chronic leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.11	Chronic leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.2	Subacute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.20	Subacute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.21	Subactue leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.22	Subacute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.8	Other leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.80	Other leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.81	Other leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.82	Other leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
208.9	Unspecified leukemia	Diagnosis	ICD-9-CM
208.90	Unspecified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.91	Unspecified leukemia in remission	Diagnosis	ICD-9-CM
208.92	Unspecified leukemia, in relapse	Diagnosis	ICD-9-CM
209	Neuroendocrine tumors	Diagnosis	ICD-9-CM
209.0	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.00	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.01	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.02	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.03	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.1	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.11	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.12	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.13	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.14	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.15	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.16	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.17	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.2	Malignant carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.20	Malignant carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.21	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.22	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.23	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.24	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.25	Malignant carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.26	Malignant carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
209.27	Malignant carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.29	Malignant carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.3	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-9-CM
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site	Diagnosis	ICD-9-CM
209.31	Merkel cell carcinoma of the face	Diagnosis	ICD-9-CM
209.32	Merkel cell carcinoma of the scalp and neck	Diagnosis	ICD-9-CM
209.33	Merkel cell carcinoma of the upper limb	Diagnosis	ICD-9-CM
209.34	Merkel cell carcinoma of the lower limb	Diagnosis	ICD-9-CM
209.35	Merkel cell carcinoma of the trunk	Diagnosis	ICD-9-CM
209.36	Merkel cell carcinoma of other sites	Diagnosis	ICD-9-CM
209.4	Benign carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.40	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.41	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.42	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.43	Benign carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.5	Benign carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.50	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.51	Benign carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.52	Benign carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.53	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.54	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.55	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.56	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.57	Benign carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.6	Benign carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.60	Benign carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.61	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
209.62	Benign carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.63	Benign carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.64	Benign carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.65	Benign carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.66	Benign carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.67	Benign carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.69	Benign carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.7	Secondary neuroendocrine tumors	Diagnosis	ICD-9-CM
209.70	Secondary neuroendocrine tumor, unspecified site	Diagnosis	ICD-9-CM
209.71	Secondary neuroendocrine tumor of distant lymph nodes	Diagnosis	ICD-9-CM
209.72	Secondary neuroendocrine tumor of liver	Diagnosis	ICD-9-CM
209.73	Secondary neuroendocrine tumor of bone	Diagnosis	ICD-9-CM
209.74	Secondary neuroendocrine tumor of peritoneum	Diagnosis	ICD-9-CM
209.75	Secondary Merkel cell carcinoma	Diagnosis	ICD-9-CM
209.79	Secondary neuroendocrine tumor of other sites	Diagnosis	ICD-9-CM
230	Carcinoma in situ of digestive organs	Diagnosis	ICD-9-CM
230.0	Carcinoma in situ of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
230.1	Carcinoma in situ of esophagus	Diagnosis	ICD-9-CM
230.2	Carcinoma in situ of stomach	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
230.5	Carcinoma in situ of anal canal	Diagnosis	ICD-9-CM
230.6	Carcinoma in situ of anus, unspecified	Diagnosis	ICD-9-CM
230.7	Carcinoma in situ of other and unspecified parts of intestine	Diagnosis	ICD-9-CM
230.8	Carcinoma in situ of liver and biliary system	Diagnosis	ICD-9-CM
230.9	Carcinoma in situ of other and unspecified digestive organs	Diagnosis	ICD-9-CM
231	Carcinoma in situ of respiratory system	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
231.0	Carcinoma in situ of larynx	Diagnosis	ICD-9-CM
231.1	Carcinoma in situ of trachea	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
231.8	Carcinoma in situ of other specified parts of respiratory system	Diagnosis	ICD-9-CM
231.9	Carcinoma in situ of respiratory system, part unspecified	Diagnosis	ICD-9-CM
232	Carcinoma in situ of skin	Diagnosis	ICD-9-CM
232.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-9-CM
232.1	Carcinoma in situ of eyelid, including canthus	Diagnosis	ICD-9-CM
232.2	Carcinoma in situ of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
232.3	Carcinoma in situ of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
232.4	Carcinoma in situ of scalp and skin of neck	Diagnosis	ICD-9-CM
232.5	Carcinoma in situ of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
232.6	Carcinoma in situ of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
232.7	Carcinoma in situ of skin of lower limb, including hip	Diagnosis	ICD-9-CM
232.8	Carcinoma in situ of other specified sites of skin	Diagnosis	ICD-9-CM
232.9	Carcinoma in situ of skin, site unspecified	Diagnosis	ICD-9-CM
233	Carcinoma in situ of breast and genitourinary system	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
233.1	Carcinoma in situ of cervix uteri	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
233.3	Carcinoma in situ, other and unspecified female genital organs	Diagnosis	ICD-9-CM
233.30	Carcinoma in situ, unspecified female genital organ	Diagnosis	ICD-9-CM
233.31	Carcinoma in situ, vagina	Diagnosis	ICD-9-CM
233.32	Carcinoma in situ, vulva	Diagnosis	ICD-9-CM
233.39	Carcinoma in situ, other female genital organ	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
233.5	Carcinoma in situ of penis	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
233.6	Carcinoma in situ of other and unspecified male genital organs	Diagnosis	ICD-9-CM
233.7	Carcinoma in situ of bladder	Diagnosis	ICD-9-CM
233.9	Carcinoma in situ of other and unspecified urinary organs	Diagnosis	ICD-9-CM
234	Carcinoma in situ of other and unspecified sites	Diagnosis	ICD-9-CM
234.0	Carcinoma in situ of eye	Diagnosis	ICD-9-CM
234.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-9-CM
234.9	Carcinoma in situ, site unspecified	Diagnosis	ICD-9-CM
235	Neoplasm of uncertain behavior of digestive and respiratory systems	Diagnosis	ICD-9-CM
235.0	Neoplasm of uncertain behavior of major salivary glands	Diagnosis	ICD-9-CM
235.1	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
235.2	Neoplasm of uncertain behavior of stomach, intestines, and rectum	Diagnosis	ICD-9-CM
235.3	Neoplasm of uncertain behavior of liver and biliary passages	Diagnosis	ICD-9-CM
235.4	Neoplasm of uncertain behavior of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
235.5	Neoplasm of uncertain behavior of other and unspecified digestive organs	Diagnosis	ICD-9-CM
235.6	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-9-CM
235.7	Neoplasm of uncertain behavior of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
235.8	Neoplasm of uncertain behavior of pleura, thymus, and mediastinum	Diagnosis	ICD-9-CM
235.9	Neoplasm of uncertain behavior of other and unspecified respiratory organs	Diagnosis	ICD-9-CM
236	Neoplasm of uncertain behavior of genitourinary organs	Diagnosis	ICD-9-CM
236.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-9-CM
236.1	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-9-CM
236.2	Neoplasm of uncertain behavior of ovary	Diagnosis	ICD-9-CM
236.3	Neoplasm of uncertain behavior of other and unspecified female genital organs	Diagnosis	ICD-9-CM
236.4	Neoplasm of uncertain behavior of testis	Diagnosis	ICD-9-CM
236.5	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-9-CM
236.6	Neoplasm of uncertain behavior of other and unspecified male genital organs	Diagnosis	ICD-9-CM
236.7	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
236.9	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
236.90	Neoplasm of uncertain behavior of urinary organ, unspecified	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
236.99	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
237	Neoplasm of uncertain behavior of endocrine glands and nervous system	Diagnosis	ICD-9-CM
237.0	Neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
237.1	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-9-CM
237.2	Neoplasm of uncertain behavior of adrenal gland	Diagnosis	ICD-9-CM
237.3	Neoplasm of uncertain behavior of paraganglia	Diagnosis	ICD-9-CM
237.4	Neoplasm of uncertain behavior of other and unspecified endocrine glands	Diagnosis	ICD-9-CM
237.5	Neoplasm of uncertain behavior of brain and spinal cord	Diagnosis	ICD-9-CM
237.6	Neoplasm of uncertain behavior of meninges	Diagnosis	ICD-9-CM
237.7	Neurofibromatosis	Diagnosis	ICD-9-CM
237.70	Neurofibromatosis, unspecified	Diagnosis	ICD-9-CM
237.71	Neurofibromatosis, Type 1 (von Recklinghausen's disease)	Diagnosis	ICD-9-CM
237.72	Neurofibromatosis, Type 2 (acoustic neurofibromatosis)	Diagnosis	ICD-9-CM
237.73	Schwannomatosis	Diagnosis	ICD-9-CM
237.79	Other neurofibromatosis	Diagnosis	ICD-9-CM
237.9	Neoplasm of uncertain behavior of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
238	Neoplasm of uncertain behavior of other and unspecified sites and tissues	Diagnosis	ICD-9-CM
238.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-9-CM
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-9-CM
238.2	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-9-CM
238.3	Neoplasm of uncertain behavior of breast	Diagnosis	ICD-9-CM
238.4	Neoplasm of uncertain behavior of polycythemia vera	Diagnosis	ICD-9-CM
238.5	Neoplasm of uncertain behavior of histiocytic and mast cells	Diagnosis	ICD-9-CM
238.6	Neoplasm of uncertain behavior of plasma cells	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
238.7	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.71	Essential thrombocythemia	Diagnosis	ICD-9-CM
238.72	Low grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.73	High grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.74	Myelodysplastic syndrome with 5q deletion	Diagnosis	ICD-9-CM
238.75	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-9-CM
238.76	Myelofibrosis with myeloid metaplasia	Diagnosis	ICD-9-CM
238.77	Post-transplant lymphoproliferative disorder [PTLD]	Diagnosis	ICD-9-CM
238.79	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.8	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-9-CM
238.9	Neoplasm of uncertain behavior, site unspecified	Diagnosis	ICD-9-CM
239	Neoplasms of unspecified nature	Diagnosis	ICD-9-CM
239.0	Neoplasm of unspecified nature of digestive system	Diagnosis	ICD-9-CM
239.1	Neoplasm of unspecified nature of respiratory system	Diagnosis	ICD-9-CM
239.2	Neoplasms of unspecified nature of bone, soft tissue, and skin	Diagnosis	ICD-9-CM
239.3	Neoplasm of unspecified nature of breast	Diagnosis	ICD-9-CM
239.4	Neoplasm of unspecified nature of bladder	Diagnosis	ICD-9-CM
239.5	Neoplasm of unspecified nature of other genitourinary organs	Diagnosis	ICD-9-CM
239.6	Neoplasm of unspecified nature of brain	Diagnosis	ICD-9-CM
239.7	Neoplasm of unspecified nature of endocrine glands and other parts of nervous system	Diagnosis	ICD-9-CM
239.8	Neoplasm of unspecified nature of other specified sites	Diagnosis	ICD-9-CM
239.81	Neoplasms of unspecified nature, retina and choroid	Diagnosis	ICD-9-CM
239.89	Neoplasms of unspecified nature, other specified sites	Diagnosis	ICD-9-CM
239.9	Neoplasm of unspecified nature, site unspecified	Diagnosis	ICD-9-CM
273.3	Macroglobulinemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E00X0M	Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E0130M	Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E0230M	Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03003	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03005	Introduction of Other Antineoplastic into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300M	Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330M	Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04005	Introduction of Other Antineoplastic into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400M	Introduction of Monoclonal Antibody into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430M	Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E05003	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05005	Introduction of Other Antineoplastic into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500M	Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530M	Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06003	Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06005	Introduction of Other Antineoplastic into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600M	Introduction of Monoclonal Antibody into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630M	Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E09305	Introduction of Other Antineoplastic into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E0930M	Introduction of Monoclonal Antibody into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E09705	Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0970M	Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E09X05	Introduction of Other Antineoplastic into Nose, External Approach	Procedure	ICD-10-PCS
3E09X0M	Introduction of Monoclonal Antibody into Nose, External Approach	Procedure	ICD-10-PCS
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0A30M	Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E0B305	Introduction of Other Antineoplastic into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B30M	Introduction of Monoclonal Antibody into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B705	Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0B70M	Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0BX05	Introduction of Other Antineoplastic into Ear, External Approach	Procedure	ICD-10-PCS
3E0BX0M	Introduction of Monoclonal Antibody into Ear, External Approach	Procedure	ICD-10-PCS
3E0C305	Introduction of Other Antineoplastic into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C30M	Introduction of Monoclonal Antibody into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C705	Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0C70M	Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0CX05	Introduction of Other Antineoplastic into Eye, External Approach	Procedure	ICD-10-PCS
3E0CX0M	Introduction of Monoclonal Antibody into Eye, External Approach	Procedure	ICD-10-PCS
3E0D305	Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D30M	Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D705	Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0D70M	Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0DX05	Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0DX0M	Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0E305	Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E30M	Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E705	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E70M	Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E805	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0E80M	Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F30M	Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E0F70M	Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F80M	Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G30M	Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G70M	Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G80M	Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H30M	Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H70M	Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H80M	Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J30M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J70M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J80M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K30M	Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K70M	Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K80M	Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L30M	Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0L70M	Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M30M	Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M70M	Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N30M	Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N70M	Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0N80M	Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P30M	Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P70M	Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P80M	Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0Q005	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q00M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q30M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Q70M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
3E0R303	Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R30M	Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S303	Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S30M	Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U305	Introduction of Other Antineoplastic into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U30M	Introduction of Monoclonal Antibody into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V30M	Introduction of Monoclonal Antibody into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W30M	Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y30M	Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Y70M	Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
76950	Ultrasonic guidance for placement of radiation therapy fields	Procedure	CPT-4
76960	Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography	Procedure	CPT-4
77280	Therapeutic radiology simulation-aided field setting; simple	Procedure	CPT-4
77285	Therapeutic radiology simulation-aided field setting; intermediate	Procedure	CPT-4
77290	Therapeutic radiology simulation-aided field setting; complex	Procedure	CPT-4
77295	3-dimensional radiotherapy plan, including dose-volume histograms	Procedure	CPT-4
77299	Unlisted procedure, therapeutic radiology clinical treatment planning	Procedure	CPT-4
77300	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
77305	Teletherapy, isodose plan (whether hand or computer calculated); simple (1 or 2 parallel opposed unmodified ports directed to a single area of interest)	Procedure	CPT-4
77310	Teletherapy, isodose plan (whether hand or computer calculated); intermediate (3 or more treatment ports directed to a single area of interest)	Procedure	CPT-4
77315	Teletherapy, isodose plan (whether hand or computer calculated); complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex blocking, rotational beam, or special beam considerations)	Procedure	CPT-4
77321	Special teletherapy port plan, particles, hemibody, total body	Procedure	CPT-4
77326	Brachytherapy isodose plan; simple (calculation made from single plane, 1 to 4 sources/ribbon application, remote afterloading brachytherapy, 1 to 8 sources)	Procedure	CPT-4
77327	Brachytherapy isodose plan; intermediate (multiplane dosage calculations, application involving 5 to 10 sources/ribbons, remote afterloading brachytherapy, 9 to 12 sources)	Procedure	CPT-4
77328	Brachytherapy isodose plan; complex (multiplane isodose plan, volume implant calculations, over 10 sources/ribbons used, special spatial reconstruction, remote afterloading brachytherapy, over 12 sources)	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day	Procedure	CPT-4
77402	Radiation treatment delivery,=>1 MeV; simple	Procedure	CPT-4
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks;	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks;	Procedure	CPT-4
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks;	Procedure	CPT-4
77407	Radiation treatment delivery, =>1 MeV; intermediate	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, =>1 MeV; complex	Procedure	CPT-4
77413	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
77416	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)	Procedure	CPT-4
77761	Intracavitary radiation source application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radiation source application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radiation source application; intermediate	Procedure	CPT-4
77778	Interstitial radiation source application; complex	Procedure	CPT-4
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of low dose rate radionuclide source	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4
79005	Radiopharmaceutical therapy, by oral administration	Procedure	CPT-4
79101	Radiopharmaceutical therapy, by intravenous administration	Procedure	CPT-4
79200	Radiopharmaceutical therapy, by intracavitary administration	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
79400	Radiopharmaceutical therapy, nonthyroid, nonhematologic by intervenous injection	Procedure	CPT-4
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion	Procedure	CPT-4
79420	Intravascular radiopharmaceutical therapy, particulate	Procedure	CPT-4
79440	Radiopharmaceutical therapy, by intra-articular administration	Procedure	CPT-4
79900	Provision of therapeutic radiopharmaceutical(s)	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	Chemotherapy administration, intra-arterial; push technique	Procedure	CPT-4
96422	Chemotherapy administration, intra-arterial; infusion technique, up to 1 hour	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96440	Chemotherapy administration into pleural cavity, requiring and including thoracentesis	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
96542	Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents	Procedure	CPT-4
96549	Unlisted chemotherapy procedure	Procedure	CPT-4
99.25	Injection or infusion of cancer chemotherapeutic substance	Procedure	ICD-9-CM
99.28	Injection or infusion of biological response modifier [BRM] as an antineoplastic agent	Procedure	ICD-9-CM
999.81	Extravasation of vesicant chemotherapy	Diagnosis	ICD-9-CM
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	Procedure	HCPCS
C00	Malignant neoplasm of lip	Diagnosis	ICD-10-CM
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02	Malignant neoplasm of other and unspecified parts of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM
C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03	Malignant neoplasm of gum	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04	Malignant neoplasm of floor of mouth	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05	Malignant neoplasm of palate	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM
C06.8	Malignant neoplasm of overlapping sites of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08	Malignant neoplasm of other and unspecified major salivary glands	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM
C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09	Malignant neoplasm of tonsil	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10	Malignant neoplasm of oropharynx	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C1084	Denileukin diftitox, 300 mcg, ontak iv	Procedure	HCPCS
C1086	Temozolomide, 5 mg, temodar	Procedure	HCPCS
C11	Malignant neoplasm of nasopharynx	Diagnosis	ICD-10-CM
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM
C1166	Injection, cytarabine liposome, per 10 mg	Procedure	HCPCS
C1167	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
C1178	Injection, busulfan, per 6 mg	Procedure	HCPCS
C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13	Malignant neoplasm of hypopharynx	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15	Malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16	Malignant neoplasm of stomach	Diagnosis	ICD-10-CM
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM
C17	Malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM
C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18	Malignant neoplasm of colon	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21	Malignant neoplasm of anus and anal canal	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24	Malignant neoplasm of other and unspecified parts of biliary tract	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25	Malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26	Malignant neoplasm of other and ill-defined digestive organs	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30	Malignant neoplasm of nasal cavity and middle ear	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM
C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31	Malignant neoplasm of accessory sinuses	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32	Malignant neoplasm of larynx	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34	Malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
C34.0	Malignant neoplasm of main bronchus	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.1	Malignant neoplasm of upper lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.3	Malignant neoplasm of lower lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.8	Malignant neoplasm of overlapping sites of bronchus and lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.9	Malignant neoplasm of unspecified part of bronchus or lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM
C38	Malignant neoplasm of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40	Malignant neoplasm of bone and articular cartilage of limbs	Diagnosis	ICD-10-CM
C40.0	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.1	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.2	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM
C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.3	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.8	Malignant neoplasm of overlapping sites of bone and articular cartilage of limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.9	Malignant neoplasm of unspecified bones and articular cartilage of limb	Diagnosis	ICD-10-CM
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41	Malignant neoplasm of bone and articular cartilage of other and unspecified sites	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43	Malignant melanoma of skin	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C43.1	Malignant melanoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.111	Malignant melanoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.112	Malignant melanoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.121	Malignant melanoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.122	Malignant melanoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.2	Malignant melanoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.3	Malignant melanoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.5	Malignant melanoma of trunk	Diagnosis	ICD-10-CM
C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.6	Malignant melanoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.7	Malignant melanoma of lower limb, including hip	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.101	Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.102	Unspecified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.109	Unspecified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.112	Basal cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.119	Basal cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.122	Squamous cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.129	Squamous cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.191	Other specified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.192	Other specified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.199	Other specified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.201	Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.202	Unspecified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.209	Unspecified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.291	Other specified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.292	Other specified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.299	Other specified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face	Diagnosis	ICD-10-CM
C44.301	Unspecified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.309	Unspecified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.310	Basal cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.311	Basal cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.319	Basal cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.320	Squamous cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.321	Squamous cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.329	Squamous cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.390	Other specified malignant neoplasm of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.391	Other specified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.399	Other specified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.40	Unspecified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.41	Basal cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.42	Squamous cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.49	Other specified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.500	Unspecified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.501	Unspecified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.509	Unspecified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.510	Basal cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.511	Basal cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.519	Basal cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C44.520	Squamous cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.521	Squamous cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.529	Squamous cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.590	Other specified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.591	Other specified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.599	Other specified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.601	Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.602	Unspecified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.609	Unspecified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.691	Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.692	Other specified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.699	Other specified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.701	Unspecified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.702	Unspecified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.709	Unspecified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.712	Basal cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.719	Basal cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C44.791	Other specified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.792	Other specified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.799	Other specified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.80	Unspecified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.81	Basal cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.82	Squamous cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.89	Other specified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.90	Unspecified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C44.91	Basal cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.92	Squamous cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.99	Other specified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C45	Mesothelioma	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM
C46	Kaposi's sarcoma	Diagnosis	ICD-10-CM
C46.0	Kaposi's sarcoma of skin	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.5	Kaposi's sarcoma of lung	Diagnosis	ICD-10-CM
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM
C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47	Malignant neoplasm of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.1	Malignant neoplasm of peripheral nerves of upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.2	Malignant neoplasm of peripheral nerves of lower limb, including hip	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49	Malignant neoplasm of other connective and soft tissue	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.1	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.2	Malignant neoplasm of connective and soft tissue of lower limb, including hip	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM
C49.A	Gastrointestinal stromal tumor	Diagnosis	ICD-10-CM
C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A	Merkel cell carcinoma	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.1	Merkel cell carcinoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.2	Merkel cell carcinoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.3	Merkel cell carcinoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.5	Merkel cell carcinoma of trunk	Diagnosis	ICD-10-CM
C4A.51	Merkel cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C4A.52	Merkel cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.6	Merkel cell carcinoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.7	Merkel cell carcinoma of lower limb, including hip	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50	Malignant neoplasm of breast	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C50.0	Malignant neoplasm of nipple and areola	Diagnosis	ICD-10-CM
C50.01	Malignant neoplasm of nipple and areola, female	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.02	Malignant neoplasm of nipple and areola, male	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.1	Malignant neoplasm of central portion of breast	Diagnosis	ICD-10-CM
C50.11	Malignant neoplasm of central portion of breast, female	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.12	Malignant neoplasm of central portion of breast, male	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.2	Malignant neoplasm of upper-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.21	Malignant neoplasm of upper-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.22	Malignant neoplasm of upper-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C50.3	Malignant neoplasm of lower-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.31	Malignant neoplasm of lower-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.32	Malignant neoplasm of lower-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.4	Malignant neoplasm of upper-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.41	Malignant neoplasm of upper-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.42	Malignant neoplasm of upper-outer quadrant of breast, male	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.5	Malignant neoplasm of lower-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.51	Malignant neoplasm of lower-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.52	Malignant neoplasm of lower-outer quadrant of breast, male	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C50.6	Malignant neoplasm of axillary tail of breast	Diagnosis	ICD-10-CM
C50.61	Malignant neoplasm of axillary tail of breast, female	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.62	Malignant neoplasm of axillary tail of breast, male	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.8	Malignant neoplasm of overlapping sites of breast	Diagnosis	ICD-10-CM
C50.81	Malignant neoplasm of overlapping sites of breast, female	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.82	Malignant neoplasm of overlapping sites of breast, male	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.9	Malignant neoplasm of breast of unspecified site	Diagnosis	ICD-10-CM
C50.91	Malignant neoplasm of breast of unspecified site, female	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.92	Malignant neoplasm of breast of unspecified site, male	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C51	Malignant neoplasm of vulva	Diagnosis	ICD-10-CM
C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53	Malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54	Malignant neoplasm of corpus uteri	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56	Malignant neoplasm of ovary	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-10-CM
C57.0	Malignant neoplasm of fallopian tube	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.1	Malignant neoplasm of broad ligament	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.2	Malignant neoplasm of round ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM
C60	Malignant neoplasm of penis	Diagnosis	ICD-10-CM
C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62	Malignant neoplasm of testis	Diagnosis	ICD-10-CM
C62.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.1	Malignant neoplasm of descended testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM
C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.9	Malignant neoplasm of testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63	Malignant neoplasm of other and unspecified male genital organs	Diagnosis	ICD-10-CM
C63.0	Malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.1	Malignant neoplasm of spermatic cord	Diagnosis	ICD-10-CM
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM
C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64	Malignant neoplasm of kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65	Malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66	Malignant neoplasm of ureter	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67	Malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68	Malignant neoplasm of other and unspecified urinary organs	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69	Malignant neoplasm of eye and adnexa	Diagnosis	ICD-10-CM
C69.0	Malignant neoplasm of conjunctiva	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.1	Malignant neoplasm of cornea	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM
C69.2	Malignant neoplasm of retina	Diagnosis	ICD-10-CM
C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.3	Malignant neoplasm of choroid	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.4	Malignant neoplasm of ciliary body	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.5	Malignant neoplasm of lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.6	Malignant neoplasm of orbit	Diagnosis	ICD-10-CM
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM
C69.8	Malignant neoplasm of overlapping sites of eye and adnexa	Diagnosis	ICD-10-CM
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.9	Malignant neoplasm of unspecified site of eye	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70	Malignant neoplasm of meninges	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71	Malignant neoplasm of brain	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM
C72	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system	Diagnosis	ICD-10-CM
C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.2	Malignant neoplasm of olfactory nerve	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.3	Malignant neoplasm of optic nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.4	Malignant neoplasm of acoustic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM
C72.5	Malignant neoplasm of other and unspecified cranial nerves	Diagnosis	ICD-10-CM
C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74	Malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM
C74.0	Malignant neoplasm of cortex of adrenal gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.1	Malignant neoplasm of medulla of adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.9	Malignant neoplasm of unspecified part of adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C75	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.4	Malignant neoplasm of upper limb	Diagnosis	ICD-10-CM
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.5	Malignant neoplasm of lower limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78	Secondary malignant neoplasm of respiratory and digestive organs	Diagnosis	ICD-10-CM
C78.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.3	Secondary malignant neoplasm of other and unspecified respiratory organs	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.8	Secondary malignant neoplasm of other and unspecified digestive organs	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79	Secondary malignant neoplasm of other and unspecified sites	Diagnosis	ICD-10-CM
C79.0	Secondary malignant neoplasm of kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C79.1	Secondary malignant neoplasm of bladder and other and unspecified urinary organs	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-10-CM
C79.3	Secondary malignant neoplasm of brain and cerebral meninges	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM
C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.4	Secondary malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-10-CM
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM
C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C7A	Malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.0	Malignant carcinoid tumors	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.01	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.02	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.09	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B	Secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B.0	Secondary carcinoid tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80	Malignant neoplasm without specification of site	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM
C81	Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.0	Nodular lymphocyte predominant Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C81.1	Nodular sclerosis Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.2	Mixed cellularity Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.3	Lymphocyte depleted Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.4	Lymphocyte-rich Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.7	Other Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.9	Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82	Follicular lymphoma	Diagnosis	ICD-10-CM
C82.0	Follicular lymphoma grade I	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.1	Follicular lymphoma grade II	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.2	Follicular lymphoma grade III, unspecified	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.3	Follicular lymphoma grade IIIa	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.4	Follicular lymphoma grade IIIb	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.5	Diffuse follicle center lymphoma	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.6	Cutaneous follicle center lymphoma	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.8	Other types of follicular lymphoma	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.9	Follicular lymphoma, unspecified	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83	Non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.0	Small cell B-cell lymphoma	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.1	Mantle cell lymphoma	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C83.3	Diffuse large B-cell lymphoma	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.5	Lymphoblastic (diffuse) lymphoma	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.7	Burkitt lymphoma	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.8	Other non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.9	Non-follicular (diffuse) lymphoma, unspecified	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84	Mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.0	Mycosis fungoides	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.1	Sezary disease	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.4	Peripheral T-cell lymphoma, not classified	Diagnosis	ICD-10-CM
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.6	Anaplastic large cell lymphoma, ALK-positive	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.7	Anaplastic large cell lymphoma, ALK-negative	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.9	Mature T/NK-cell lymphomas, unspecified	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A	Cutaneous T-cell lymphoma, unspecified	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z	Other mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85	Other specified and unspecified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.1	Unspecified B-cell lymphoma	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.2	Mediastinal (thymic) large B-cell lymphoma	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.8	Other specified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.9	Non-Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C86	Other specified types of T/NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88	Malignant immunoproliferative diseases and certain other B-cell lymphomas	Diagnosis	ICD-10-CM
C88.0	Waldenstrom macroglobulinemia	Diagnosis	ICD-10-CM
C88.2	Heavy chain disease	Diagnosis	ICD-10-CM
C88.3	Immunoproliferative small intestinal disease	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C88.9	Malignant immunoproliferative disease, unspecified	Diagnosis	ICD-10-CM
C90	Multiple myeloma and malignant plasma cell neoplasms	Diagnosis	ICD-10-CM
C90.0	Multiple myeloma	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.1	Plasma cell leukemia	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.11	Plasma cell leukemia in remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.2	Extramedullary plasmacytoma	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.21	Extramedullary plasmacytoma in remission	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.3	Solitary plasmacytoma	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.31	Solitary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C9004	Injection, gemtuzumab ozogamicin, per 5 mg	Procedure	HCPCS
C9012	Injection, arsenic trioxide, per 1 mg/kg	Procedure	HCPCS
C9017	Lomustine, 10 mg	Procedure	HCPCS
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9024	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
C91	Lymphoid leukemia	Diagnosis	ICD-10-CM
C91.0	Acute lymphoblastic leukemia [ALL]	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.01	Acute lymphoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C91.1	Chronic lymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.11	Chronic lymphocytic leukemia of B-cell type in remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.3	Prolymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.31	Prolymphocytic leukemia of B-cell type, in remission	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.4	Hairy cell leukemia	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.41	Hairy cell leukemia, in remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.5	Adult T-cell lymphoma/leukemia (HTLV-1-associated)	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission	Diagnosis	ICD-10-CM
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.6	Prolymphocytic leukemia of T-cell type	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.61	Prolymphocytic leukemia of T-cell type, in remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.9	Lymphoid leukemia, unspecified	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.91	Lymphoid leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A	Mature B-cell leukemia Burkitt-type	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A1	Mature B-cell leukemia Burkitt-type, in remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z	Other lymphoid leukemia	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z1	Other lymphoid leukemia, in remission	Diagnosis	ICD-10-CM
C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C9110	Injection, alemtuzumab, per 10 mg/ ml	Procedure	HCPCS
C9127	Injection, paclitaxel protein-bound particles, per 1 mg	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C9129	Injection, clofarabine, per 1 mg	Procedure	HCPCS
C92	Myeloid leukemia	Diagnosis	ICD-10-CM
C92.0	Acute myeloblastic leukemia	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.01	Acute myeloblastic leukemia, in remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.1	Chronic myeloid leukemia, BCR/ABL-positive	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.2	Atypical chronic myeloid leukemia, BCR/ABL-negative	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.3	Myeloid sarcoma	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.31	Myeloid sarcoma, in remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.4	Acute promyelocytic leukemia	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.41	Acute promyelocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.5	Acute myelomonocytic leukemia	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.51	Acute myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.6	Acute myeloid leukemia with 11q23-abnormality	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.9	Myeloid leukemia, unspecified	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.91	Myeloid leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A	Acute myeloid leukemia with multilineage dysplasia	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z	Other myeloid leukemia	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z1	Other myeloid leukemia, in remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM
C9205	Injection, oxaliplatin, per 5 mg	Procedure	HCPCS
C9207	Injection, bortezomib, per 3.5 mg	Procedure	HCPCS
C9213	Injection, pemetrexed, per 10 mg	Procedure	HCPCS
C9214	Injection, bevacizumab, per 10 mg	Procedure	HCPCS
C9215	Injection, cetuximab, per 10 mg	Procedure	HCPCS
C9218	Injection, azacitidine, per 1 mg	Procedure	HCPCS
C9231	Injection, decitabine, per 1 mg	Procedure	HCPCS
C9235	Injection, panitumumab, 10 mg	Procedure	HCPCS
C9239	Injection, temsirolimus, 1 mg	Procedure	HCPCS
C9240	Injection, ixabepilone, 1 mg	Procedure	HCPCS
C9243	Injection, bendamustine hcl, 1 mg	Procedure	HCPCS
C9253	Injection, temozolomide, 1mg	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C93	Monocytic leukemia	Diagnosis	ICD-10-CM
C93.0	Acute monoblastic/monocytic leukemia	Diagnosis	ICD-10-CM
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.1	Chronic myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.3	Juvenile myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C93.9	Monocytic leukemia, unspecified	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z	Other monocytic leukemia	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94	Other leukemias of specified cell type	Diagnosis	ICD-10-CM
C94.0	Acute erythroid leukemia	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.2	Acute megakaryoblastic leukemia	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.3	Mast cell leukemia	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.4	Acute panmyelosis with myelofibrosis	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.41	Acute panmyelosis with myelofibrosis, in remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.8	Other specified leukemias	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS
C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS
C9440	Vinorelbine tartrate, brand name, per 10 mg	Procedure	HCPCS
C9474	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
C95	Leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.9	Leukemia, unspecified	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.2	Malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.6	Unifocal Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D00.00	Carcinoma in situ of oral cavity, unspecified site	Diagnosis	ICD-10-CM
D00.01	Carcinoma in situ of labial mucosa and vermilion border	Diagnosis	ICD-10-CM
D00.02	Carcinoma in situ of buccal mucosa	Diagnosis	ICD-10-CM
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge	Diagnosis	ICD-10-CM
D00.04	Carcinoma in situ of soft palate	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D00.05	Carcinoma in situ of hard palate	Diagnosis	ICD-10-CM
D00.06	Carcinoma in situ of floor of mouth	Diagnosis	ICD-10-CM
D00.07	Carcinoma in situ of tongue	Diagnosis	ICD-10-CM
D00.08	Carcinoma in situ of pharynx	Diagnosis	ICD-10-CM
D00.1	Carcinoma in situ of esophagus	Diagnosis	ICD-10-CM
D00.2	Carcinoma in situ of stomach	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
D01.3	Carcinoma in situ of anus and anal canal	Diagnosis	ICD-10-CM
D01.40	Carcinoma in situ of unspecified part of intestine	Diagnosis	ICD-10-CM
D01.49	Carcinoma in situ of other parts of intestine	Diagnosis	ICD-10-CM
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D01.7	Carcinoma in situ of other specified digestive organs	Diagnosis	ICD-10-CM
D01.9	Carcinoma in situ of digestive organ, unspecified	Diagnosis	ICD-10-CM
D02.0	Carcinoma in situ of larynx	Diagnosis	ICD-10-CM
D02.1	Carcinoma in situ of trachea	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
D02.3	Carcinoma in situ of other parts of respiratory system	Diagnosis	ICD-10-CM
D02.4	Carcinoma in situ of respiratory system, unspecified	Diagnosis	ICD-10-CM
D03.0	Melanoma in situ of lip	Diagnosis	ICD-10-CM
D03.10	Melanoma in situ of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D03.11	Melanoma in situ of right eyelid, including canthus	Diagnosis	ICD-10-CM
D03.12	Melanoma in situ of left eyelid, including canthus	Diagnosis	ICD-10-CM
D03.20	Melanoma in situ of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D03.21	Melanoma in situ of right ear and external auricular canal	Diagnosis	ICD-10-CM
D03.22	Melanoma in situ of left ear and external auricular canal	Diagnosis	ICD-10-CM
D03.30	Melanoma in situ of unspecified part of face	Diagnosis	ICD-10-CM
D03.39	Melanoma in situ of other parts of face	Diagnosis	ICD-10-CM
D03.4	Melanoma in situ of scalp and neck	Diagnosis	ICD-10-CM
D03.51	Melanoma in situ of anal skin	Diagnosis	ICD-10-CM
D03.52	Melanoma in situ of breast (skin) (soft tissue)	Diagnosis	ICD-10-CM
D03.59	Melanoma in situ of other part of trunk	Diagnosis	ICD-10-CM
D03.60	Melanoma in situ of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.61	Melanoma in situ of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.62	Melanoma in situ of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.70	Melanoma in situ of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D03.71	Melanoma in situ of right lower limb, including hip	Diagnosis	ICD-10-CM
D03.72	Melanoma in situ of left lower limb, including hip	Diagnosis	ICD-10-CM
D03.8	Melanoma in situ of other sites	Diagnosis	ICD-10-CM
D03.9	Melanoma in situ, unspecified	Diagnosis	ICD-10-CM
D04.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-10-CM
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D04.11	Carcinoma in situ of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
D04.12	Carcinoma in situ of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D04.21	Carcinoma in situ of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
D04.22	Carcinoma in situ of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
D04.30	Carcinoma in situ of skin of unspecified part of face	Diagnosis	ICD-10-CM
D04.39	Carcinoma in situ of skin of other parts of face	Diagnosis	ICD-10-CM
D04.4	Carcinoma in situ of skin of scalp and neck	Diagnosis	ICD-10-CM
D04.5	Carcinoma in situ of skin of trunk	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D04.71	Carcinoma in situ of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
D04.72	Carcinoma in situ of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
D04.8	Carcinoma in situ of skin of other sites	Diagnosis	ICD-10-CM
D04.9	Carcinoma in situ of skin, unspecified	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D06.0	Carcinoma in situ of endocervix	Diagnosis	ICD-10-CM
D06.1	Carcinoma in situ of exocervix	Diagnosis	ICD-10-CM
D06.7	Carcinoma in situ of other parts of cervix	Diagnosis	ICD-10-CM
D06.9	Carcinoma in situ of cervix, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
D07.1	Carcinoma in situ of vulva	Diagnosis	ICD-10-CM
D07.2	Carcinoma in situ of vagina	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D07.30	Carcinoma in situ of unspecified female genital organs	Diagnosis	ICD-10-CM
D07.39	Carcinoma in situ of other female genital organs	Diagnosis	ICD-10-CM
D07.4	Carcinoma in situ of penis	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
D07.60	Carcinoma in situ of unspecified male genital organs	Diagnosis	ICD-10-CM
D07.61	Carcinoma in situ of scrotum	Diagnosis	ICD-10-CM
D07.69	Carcinoma in situ of other male genital organs	Diagnosis	ICD-10-CM
D09.0	Carcinoma in situ of bladder	Diagnosis	ICD-10-CM
D09.10	Carcinoma in situ of unspecified urinary organ	Diagnosis	ICD-10-CM
D09.19	Carcinoma in situ of other urinary organs	Diagnosis	ICD-10-CM
D09.20	Carcinoma in situ of unspecified eye	Diagnosis	ICD-10-CM
D09.21	Carcinoma in situ of right eye	Diagnosis	ICD-10-CM
D09.22	Carcinoma in situ of left eye	Diagnosis	ICD-10-CM
D09.3	Carcinoma in situ of thyroid and other endocrine glands	Diagnosis	ICD-10-CM
D09.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-10-CM
D09.9	Carcinoma in situ, unspecified	Diagnosis	ICD-10-CM
D25.0	Submucous leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.1	Intramural leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.2	Subserosal leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.9	Leiomyoma of uterus, unspecified	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.1	Neoplasm of uncertain behavior of stomach	Diagnosis	ICD-10-CM
D37.2	Neoplasm of uncertain behavior of small intestine	Diagnosis	ICD-10-CM
D37.3	Neoplasm of uncertain behavior of appendix	Diagnosis	ICD-10-CM
D37.4	Neoplasm of uncertain behavior of colon	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D3A.00	Benign carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
D3A.010	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
D3A.011	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D3A.012	Benign carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.020	Benign carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
D3A.021	Benign carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
D3A.022	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
D3A.023	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
D3A.024	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
D3A.025	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
D3A.026	Benign carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.090	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
D3A.091	Benign carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
D3A.092	Benign carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
D3A.093	Benign carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
D3A.094	Benign carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
D3A.095	Benign carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
D3A.096	Benign carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
D3A.098	Benign carcinoid tumors of other sites	Diagnosis	ICD-10-CM
D3A.8	Other benign neuroendocrine tumors	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.3	Essential (hemorrhagic) thrombocythemia	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z2	Castleman disease	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D70.1	Agranulocytosis secondary to cancer chemotherapy	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	Procedure	HCPCS
G3001	Administration and supply of tositumomab, 450 mg	Procedure	HCPCS
G9835	Trastuzumab administered within 12 months of diagnosis	Procedure	HCPCS
G9837	Trastuzumab not administered within 12 months of diagnosis	Procedure	HCPCS
J0202	Injection, alemtuzumab, 1 mg	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J0594	Injection, busulfan, 1 mg	Procedure	HCPCS
J0894	Injection, decitabine, 1 mg	Procedure	HCPCS
J7527	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8510	Busulfan, oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8561	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
J8600	Melphalan, oral, 2 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, NOS	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9001	Injection, doxorubicin HCl, all lipid formulations, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
J9010	Injection, alemtuzumab, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9027	Injection, clofarabine, 1 mg	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9034	Injection, bendamustine HCl (Bendeka), 1 mg	Procedure	HCPCS
J9035	Injection, bevacizumab, 10 mg	Procedure	HCPCS
J9036	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9041	Injection, bortezomib (Velcade), 0.1 mg	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS
J9050	Injection, carmustine, 100 mg	Procedure	HCPCS
J9055	Injection, cetuximab, 10 mg	Procedure	HCPCS
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9098	Injection, cytarabine liposome, 10 mg	Procedure	HCPCS
J9100	Injection, cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
J9160	Injection, denileukin diftitox, 300 mcg	Procedure	HCPCS
J9170	Injection, docetaxel, 20 mg	Procedure	HCPCS
J9171	Injection, docetaxel, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9178	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9180	Epirubicin HCl, 50 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9182	Etoposide, 100 mg	Procedure	HCPCS
J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
J9200	Injection, floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9205	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS
J9211	Injection, idarubicin HCl, 5 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9261	Injection, nelarabine, 50 mg	Procedure	HCPCS
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Injection, pentostatin, 10 mg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9270	Injection, plicamycin, 2.5 mg	Procedure	HCPCS
J9280	Injection, mitomycin, 5 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS
J9305	Injection, pemetrexed, NOS, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9307	Injection, pralatrexate, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9311	Injection, rituximab 10 mg and hyaluronidase	Procedure	HCPCS
J9312	Injection, rituximab, 10 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9320	Injection, streptozocin, 1 g	Procedure	HCPCS
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS
J9340	Injection, thiotepa, 15 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	Procedure	HCPCS
J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Injection, vinorelbine tartrate, 10 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
O9A.1	Malignant neoplasm complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O9A.11	Malignant neoplasm complicating pregnancy	Diagnosis	ICD-10-CM
O9A.111	Malignant neoplasm complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A.112	Malignant neoplasm complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A.113	Malignant neoplasm complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A.119	Malignant neoplasm complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.13	Malignant neoplasm complicating the puerperium	Diagnosis	ICD-10-CM
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM
Q9979	Injection, Alemtuzumab, 1 mg	Procedure	HCPCS
R97.21	Rising PSA following treatment for malignant neoplasm of prostate	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
S0087	Injection, alemtuzumab, 30 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
S0108	Mercaptopurine, oral, 50 mg	Procedure	HCPCS
S0115	Bortezomib, 3.5 mg	Procedure	HCPCS
S0116	Bevacizumab, 100 mg	Procedure	HCPCS
S0168	Injection, azacitidine, 100 mg	Procedure	HCPCS
S0172	Chlorambucil, oral, 2 mg	Procedure	HCPCS
S0176	Hydroxyurea, oral, 500 mg	Procedure	HCPCS
S0178	Lomustine, oral, 10 mg	Procedure	HCPCS
S0182	Procarbazine HCl, oral, 50 mg	Procedure	HCPCS
T80.810	Extravasation of vesicant antineoplastic chemotherapy	Diagnosis	ICD-10-CM
T80.810A	Extravasation of vesicant antineoplastic chemotherapy, initial encounter	Diagnosis	ICD-10-CM
T80.810D	Extravasation of vesicant antineoplastic chemotherapy, subsequent encounter	Diagnosis	ICD-10-CM
V10	Personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.0	Personal history of malignant neoplasm of gastrointestinal tract	Diagnosis	ICD-9-CM
V10.00	Personal history of malignant neoplasm of unspecified site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.01	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-9-CM
V10.02	Personal history of malignant neoplasm of other and unspecified parts of oral cavity and pharynx	Diagnosis	ICD-9-CM
V10.03	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
V10.04	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-9-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
V10.07	Personal history of malignant neoplasm of liver	Diagnosis	ICD-9-CM
V10.09	Personal history of malignant neoplasm of other site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.1	Personal history of malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
V10.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
V10.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-9-CM
V10.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-9-CM
V10.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
V10.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
V10.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
V10.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-9-CM
V10.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
V10.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-9-CM
V10.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-9-CM
V10.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-9-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
V10.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-9-CM
V10.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
V10.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-9-CM
V10.5	Personal history of malignant neoplasm of urinary organs	Diagnosis	ICD-9-CM
V10.50	Personal history of malignant neoplasm of unspecified urinary organ	Diagnosis	ICD-9-CM
V10.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-9-CM
V10.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-9-CM
V10.53	Personal history of malignant neoplasm, renal pelvis	Diagnosis	ICD-9-CM
V10.59	Personal history of malignant neoplasm of other urinary organ	Diagnosis	ICD-9-CM
V10.6	Personal history of leukemia	Diagnosis	ICD-9-CM
V10.60	Personal history of unspecified leukemia	Diagnosis	ICD-9-CM
V10.61	Personal history of lymphoid leukemia	Diagnosis	ICD-9-CM
V10.62	Personal history of myeloid leukemia	Diagnosis	ICD-9-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
V10.63	Personal history of monocytic leukemia	Diagnosis	ICD-9-CM
V10.69	Personal history of other leukemia	Diagnosis	ICD-9-CM
V10.7	Personal history of other lymphatic and hematopoietic neoplasms	Diagnosis	ICD-9-CM
V10.71	Personal history of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
V10.72	Personal history of Hodgkin's disease	Diagnosis	ICD-9-CM
V10.79	Personal history of other lymphatic and hematopoietic neoplasm	Diagnosis	ICD-9-CM
V10.8	Personal history of malignant neoplasm of other sites	Diagnosis	ICD-9-CM
V10.81	Personal history of malignant neoplasm of bone	Diagnosis	ICD-9-CM
V10.82	Personal history of malignant melanoma of skin	Diagnosis	ICD-9-CM
V10.83	Personal history of other malignant neoplasm of skin	Diagnosis	ICD-9-CM
V10.84	Personal history of malignant neoplasm of eye	Diagnosis	ICD-9-CM
V10.85	Personal history of malignant neoplasm of brain	Diagnosis	ICD-9-CM
V10.86	Personal history of malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
V10.87	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-9-CM
V10.88	Personal history of malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
V10.89	Personal history of malignant neoplasm of other site	Diagnosis	ICD-9-CM
V10.9	Other and unspecified personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.90	Personal history of unspecified malignant neoplasm	Diagnosis	ICD-9-CM
V10.91	Personal history of malignant neuroendocrine tumor	Diagnosis	ICD-9-CM
V58.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-9-CM
V58.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-9-CM
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New	Procedure	ICD-10-PCS
XW033B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach,	Procedure	ICD-10-PCS
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group	Procedure	ICD-10-PCS
XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group	Procedure	ICD-10-PCS

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New	Procedure	ICD-10-PCS
XW043B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New	Procedure	ICD-10-PCS
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXR5	Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy	Diagnosis	ICD-10-CM
Z51.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-10-CM
Z51.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-10-CM
Z85	Personal history of malignant neoplasm	Diagnosis	ICD-10-CM
Z85.0	Personal history of malignant neoplasm of digestive organs	Diagnosis	ICD-10-CM
Z85.00	Personal history of malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
Z85.01	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
Z85.02	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.020	Personal history of malignant carcinoid tumor of stomach	Diagnosis	ICD-10-CM
Z85.028	Personal history of other malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.03	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.04	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.05	Personal history of malignant neoplasm of liver	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
Z85.06	Personal history of malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.060	Personal history of malignant carcinoid tumor of small intestine	Diagnosis	ICD-10-CM
Z85.068	Personal history of other malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.07	Personal history of malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
Z85.09	Personal history of malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
Z85.1	Personal history of malignant neoplasm of trachea, bronchus and lung	Diagnosis	ICD-10-CM
Z85.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-10-CM
Z85.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
Z85.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-10-CM
Z85.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-10-CM
Z85.23	Personal history of malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.230	Personal history of malignant carcinoid tumor of thymus	Diagnosis	ICD-10-CM
Z85.238	Personal history of other malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z85.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
Z85.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-10-CM
Z85.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Z85.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-10-CM
Z85.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-10-CM
Z85.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
Z85.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-10-CM
Z85.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
Z85.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-10-CM
Z85.5	Personal history of malignant neoplasm of urinary tract	Diagnosis	ICD-10-CM
Z85.50	Personal history of malignant neoplasm of unspecified urinary tract organ	Diagnosis	ICD-10-CM
Z85.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-10-CM
Z85.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.520	Personal history of malignant carcinoid tumor of kidney	Diagnosis	ICD-10-CM
Z85.528	Personal history of other malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.53	Personal history of malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
Z85.54	Personal history of malignant neoplasm of ureter	Diagnosis	ICD-10-CM
Z85.59	Personal history of malignant neoplasm of other urinary tract organ	Diagnosis	ICD-10-CM
Z85.6	Personal history of leukemia	Diagnosis	ICD-10-CM
Z85.7	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.71	Personal history of Hodgkin lymphoma	Diagnosis	ICD-10-CM
Z85.72	Personal history of non-Hodgkin lymphomas	Diagnosis	ICD-10-CM
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.8	Personal history of malignant neoplasms of other organs and systems	Diagnosis	ICD-10-CM
Z85.81	Personal history of malignant neoplasm of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.810	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-10-CM
Z85.818	Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.819	Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.82	Personal history of malignant neoplasm of skin	Diagnosis	ICD-10-CM
Z85.820	Personal history of malignant melanoma of skin	Diagnosis	ICD-10-CM
Z85.821	Personal history of Merkel cell carcinoma	Diagnosis	ICD-10-CM
Z85.828	Personal history of other malignant neoplasm of skin	Diagnosis	ICD-10-CM
Z85.83	Personal history of malignant neoplasm of bone and soft tissue	Diagnosis	ICD-10-CM

Appendix F. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
Z85.830	Personal history of malignant neoplasm of bone	Diagnosis	ICD-10-CM
Z85.831	Personal history of malignant neoplasm of soft tissue	Diagnosis	ICD-10-CM
Z85.84	Personal history of malignant neoplasm of eye and nervous tissue	Diagnosis	ICD-10-CM
Z85.840	Personal history of malignant neoplasm of eye	Diagnosis	ICD-10-CM
Z85.841	Personal history of malignant neoplasm of brain	Diagnosis	ICD-10-CM
Z85.848	Personal history of malignant neoplasm of other parts of nervous tissue	Diagnosis	ICD-10-CM
Z85.85	Personal history of malignant neoplasm of endocrine glands	Diagnosis	ICD-10-CM
Z85.850	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-10-CM
Z85.858	Personal history of malignant neoplasm of other endocrine glands	Diagnosis	ICD-10-CM
Z85.89	Personal history of malignant neoplasm of other organs and systems	Diagnosis	ICD-10-CM
Z85.9	Personal history of malignant neoplasm, unspecified	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
	Liver Cancer		
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
livc	LiverCancer	Diagnosis	CB
	Bladder Cancer		
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
	Colorectal Cancer		
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
crc	ColorectalCancer	Diagnosis	CB
	Esophageal Cancer		
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM

Appendix H. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcome Incidence Criteria in this Request

Code	Description	Code Category	Code Type
	Liver Cancer		
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
livc	LiverCancer	Diagnosis	CB
	Bladder Cancer		
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM

Appendix H. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcome Incidence Criteria in this Request

Code	Description	Code Category	Code Type
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
	Colorectal Cancer		
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM

Appendix H. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcome Incidence Criteria in this Request

Code	Description	Code Category	Code Type
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
crc	ColorectalCancer	Diagnosis	CB
	Esophageal Cancer		
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM

Appendix H. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Outcome Incidence Criteria in this Request

Code	Description	Code Category	Code Type
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
Chemotherapy	
BCG live	Theracys
BCG live	Tice BCG
BCG vaccine, live	Tice BCG Vaccine
Tositumomab Iodine-131 (with Maltose)	Bexxar 131 Iodine
abarelix	Plenaxis
abemaciclib	Verzenio
abiraterone acetate	Zytiga
abiraterone acetate	abiraterone
abiraterone acetate, submicronized	Yonsa
acalabrutinib	Calquence
ado-trastuzumab emtansine	Kadcyla
afatinib dimaleate	Gilotrif
aldesleukin	Proleukin
alectinib HCl	Alecensa
alemtuzumab	Campath
alemtuzumab	Lemtrada
alpelisib	Piqray
altretamine	Hexalen
amifostine crystalline	Ethyol
amifostine crystalline	amifostine crystalline
aminoglutethimide	Cytadren
amivantamab-vmjw	Rybrevant
anastrozole	Arimidex
anastrozole	Arimidex 30-day Pack
anastrozole	anastrozole
anastrozole	anastrozole (bulk)
apalutamide	Erleada
arsenic trioxide	Trisenox
arsenic trioxide	arsenic trioxide
arsenic trioxide	arsenic trioxide (bulk)
asparaginase	Elspar
asparaginase (Erwinia chrysanthemi)	Erwinase
asparaginase (Erwinia chrysanthemi)	Erwinaze
asparaginase Erwinia chrysanthemi (recombinant)-rywn	Rylaze
atezolizumab	Tecentriq
avapritinib	Ayvakit
avelumab	Bavencio
axicabtagene ciloleucel	Yescarta
axitinib	Inlyta

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
azacitidine	Onureg
azacitidine	Vidaza
azacitidine	azacitidine
belantamab mafodotin-blmf	Blenrep
belinostat	Beleodaq
bendamustine HCl	Belrapzo
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	bendamustine
bevacizumab	Avastin
bevacizumab	bevacizumab
bevacizumab-awwb	Mvasi
bevacizumab-bvzr	Zirabev
bexarotene	Targretin
bexarotene	bexarotene
bicalutamide	Casodex
bicalutamide	bicalutamide
binimetinib	Mektovi
bleomycin sulfate	Blenoxane
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
blinatumomab	Blincyto
bortezomib	Velcade
bortezomib	bortezomib
bosutinib	Bosulif
brentuximab vedotin	Adcetris
brexucabtagene autoleucel	Tecartus
brigatinib	Alunbrig
busulfan	Busulfex
busulfan	Myleran
busulfan	busulfan
cabazitaxel	Jevtana
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
calaspargase pegol-mknl	Asparlas
capecitabine	Xeloda
capecitabine	capecitabine
capmatinib hydrochloride	Tabrecta
carboplatin	Paraplatin
carboplatin	carboplatin

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
carfilzomib	Kyprolis
carmustine	BiCNU
carmustine	carmustine
carmustine in polifeprosan 20	Gliadel Wafer
cemiplimab-rwlc	Libtayo
ceritinib	Zykadia
cetuximab	Erbitux
chlorambucil	Leukeran
chlorambucil	chlorambucil (bulk)
cisplatin	Platinol AQ
cisplatin	cisplatin
cisplatin	cisplatin (bulk)
cladribine	Leustatin
cladribine	Mavenclad (10 tablet pack)
cladribine	Mavenclad (4 tablet pack)
cladribine	Mavenclad (5 tablet pack)
cladribine	Mavenclad (6 tablet pack)
cladribine	Mavenclad (7 tablet pack)
cladribine	Mavenclad (8 tablet pack)
cladribine	Mavenclad (9 tablet pack)
cladribine	cladribine
clofarabine	Clolar
clofarabine	clofarabine
cobimetinib fumarate	Cotellic
copanlisib di-HCl	Aliqopa
crizotinib	Xalkori
cromolyn sodium	Gastrocrom
cromolyn sodium	cromolyn
cromolyn sodium	cromolyn (bulk)
cyclophosphamide	Cytoxan
cyclophosphamide	Cytoxan Lyophilized
cyclophosphamide	Neosar
cyclophosphamide	cyclophosphamide
cyclophosphamide	cyclophosphamide (bulk)
cytarabine	Cytosar-U
cytarabine	Tarabine Pfs
cytarabine	cytarabine
cytarabine liposome/PF	DepoCyt (PF)
cytarabine/PF	cytarabine (PF)
dabrafenib mesylate	Tafinlar

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
dacarbazine	DTIC-Dome
dacarbazine	dacarbazine
dacarbazine	dacarbazine (bulk)
dacomitinib	Vizimpro
dactinomycin	Cosmegen
dactinomycin	dactinomycin
daratumumab	Darzalex
daratumumab-hyaluronidase-fihj	Darzalex Faspro
darolutamide	Nubeqa
dasatinib	Sprycel
daunorubicin HCl	Cerubidine
daunorubicin HCl	daunorubicin
daunorubicin citrate liposomal	DaunoXome
daunorubicin/cytarabine liposomal	Vyxeos
decitabine	Dacogen
decitabine	decitabine
decitabine/cedazuridine	Inqovi
degarelix acetate	Firmagon
degarelix acetate	Firmagon kit w diluent syringe
denileukin diftitox	Ontak
dexrazoxane HCl	Totect
dexrazoxane HCl	Zinecard (as HCl)
dexrazoxane HCl	dexrazoxane HCl
diethylstilbestrol	diethylstilbestrol (bulk)
diethylstilbestrol diphosphate	Stilphostrol
dinutuximab	Unituxin
docetaxel	Docefrez
docetaxel	Taxotere
docetaxel	docetaxel
dostarlimab-gxly	Jemperli
doxorubicin HCl	Adriamycin
doxorubicin HCl	Adriamycin PFS
doxorubicin HCl	Adriamycin RDF
doxorubicin HCl	Rubex
doxorubicin HCl	doxorubicin
doxorubicin HCl pegylated liposomal	Doxil
doxorubicin HCl pegylated liposomal	Lipodox
doxorubicin HCl pegylated liposomal	Lipodox 50
doxorubicin HCl pegylated liposomal	doxorubicin, peg-liposomal
durvalumab	Imfinzi

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
duvelisib	Copiktra
elotuzumab	Empliciti
enasidenib mesylate	Idhifa
encorafenib	Braftovi
enfortumab vedotin-ejfv	Padcev
entrectinib	Rozlytrek
enzalutamide	Xtandi
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
erdafitinib	Balversa
eribulin mesylate	Halaven
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
estramustine phosphate sodium	Emcyt
etoposide	Toposar
etoposide	VePesid
etoposide	etoposide
etoposide	etoposide (bulk)
etoposide phosphate	Etopophos
everolimus	Afinitor
everolimus	Afinitor Disperz
everolimus	Zortress
everolimus	everolimus (antineoplastic)
everolimus	everolimus (immunosuppressive)
exemestane	Aromasin
exemestane	exemestane
fam-trastuzumab deruxtecan-nxki	Enhertu
fedratinib dihydrochloride	Inrebic
floxuridine	FUDR
floxuridine	floxuridine
floxuridine	floxuridine (bulk)
fludarabine phosphate	Fludara
fludarabine phosphate	Oforta
fludarabine phosphate	fludarabine
fluorouracil	Adrucil
fluorouracil	Carac
fluorouracil	Efudex
fluorouracil	Fluoroplex
fluorouracil	Tolak
fluorouracil	fluorouracil

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
fluorouracil	fluorouracil (bulk)
flutamide	Eulexin
flutamide	flutamide
fostamatinib disodium	Tavalisse
fulvestrant	Faslodex
fulvestrant	fulvestrant
gefitinib	Iressa
gemcitabine HCl	Gemzar
gemcitabine HCl	gemcitabine
gemcitabine HCl in 0.9 % sodium chloride	Infugem
gemtuzumab ozogamicin	Mylotarg
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
glucarpidase	Voraxaze
goserelin acetate	Zoladex
histrelin acetate	Vantas
hydroxyurea	Droxia
hydroxyurea	Hydrea
hydroxyurea	Mylocel
hydroxyurea	Siklos
hydroxyurea	hydroxyurea
hydroxyurea	hydroxyurea (bulk)
ibrutinib	Imbruvica
idarubicin HCl	Idamycin
idarubicin HCl	Idamycin PFS
idarubicin HCl	idarubicin
idecabtagene vicleucel	Abecma
idelalisib	Zydelig
ifosfamide	Ifex
ifosfamide	ifosfamide
ifosfamide/mesna	Ifex/Mesnex
ifosfamide/mesna	ifosfamide-mesna
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
infigratinib phosphate	Truseltiq
inotuzumab ozogamicin	Besponsa
interferon alfa-2a,recomb.	Roferon-A
interferon alfa-2b,recomb.	Intron A
interferon alfa-n3	Alferon N
interferon gamma-1b,recomb.	Actimmune

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
iobenguane iodine-131	Azedra Dosimetric
iobenguane iodine-131	Azedra Therapeutic
ipilimumab	Yervoy
irinotecan HCl	Camptosar
irinotecan HCl	irinotecan
irinotecan liposomal	Onivyde
isatuximab-irfc	Sarclisa
ivosidenib	Tibsovo
ixabepilone	Ixempra
ixazomib citrate	Ninlaro
kit for prep indium-111/ibritumomab tiuxetan/albumin human	Zevalin (In-111)
kit for prep yttrium-90/ibritumomab tiuxetan/albumin human	Zevalin (Y-90)
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vitrakvi
lenalidomide	Revlimid
lenvatinib mesylate	Lenvima
letrozole	Femara
letrozole	letrozole
letrozole	letrozole (bulk)
leucovorin calcium	Calcium Folinate (leucovorin)
leucovorin calcium	leucovorin calcium
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Lupron
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (bulk)
leuprolide acetate/lidocaine HCl	Viadur
levamisole HCl	Ergamisol
levamisole HCl	levamisole (bulk)
levoleucovorin	Khapzory
levoleucovorin calcium	Fusilev
levoleucovorin calcium	levoleucovorin calcium
lisocabtagene maraleucel	Breyanzi

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
lisocabtagene maraleucel, CD4 component, 2 of 2	Breyanzi CD4 Component (2of 2)
lisocabtagene maraleucel, CD8 component, 1 of 2	Breyanzi CD8 Component (1of 2)
lomustine	CeeNU
lomustine	Gleostine
lomustine	lomustine
loncastuximab tesirine-lpyl	Zynlonta
lorlatinib	Lorbrena
lurbinectedin	Zepzelca
lutetium Lu 177 dotatate	Lutathera
margetuximab-cmkb	Margenza
mechlorethamine HCl	Mustargen
mechlorethamine HCl	Valchlor
mechlorethamine HCl	mechlorethamine (bulk)
medroxyprogesterone acetate	Depo-Provera
megestrol acetate	Megace
megestrol acetate	megestrol
megestrol acetate,micronized	megestrol acetate,micro (bulk)
melphalan	Alkeran
melphalan	melphalan
melphalan HCl	Alkeran (as HCl)
melphalan HCl	melphalan HCl
melphalan HCl/betadex sulfobutyl ether sodium	Evomela
melphalan flufenamide hydrochloride	Pepaxto
mercaptopurine	Purinethol
mercaptopurine	Purixan
mercaptopurine	mercaptopurine
mercaptopurine	mercaptopurine (bulk)
mesna	Mesnex
mesna	mesna
methotrexate	Xatmep
methotrexate	methotrexate (bulk)
methotrexate sodium	Methotrexate (Anti-Rheumatic)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	Methotrexate LPF
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
methotrexate/PF	RediTrex (PF)
methoxsalen	Uvadex
methoxsalen	methoxsalen (bulk)
midostaurin	Rydapt
mitomycin	Jelmyto
mitomycin	Mitosol
mitomycin	Mutamycin
mitomycin	mitomycin
mitomycin	mitomycin (bulk)
mitotane	Lysodren
mitotane	mitotane (bulk)
mitoxantrone HCl	Novantrone
mitoxantrone HCl	mitoxantrone
mogamulizumab-kpkc	Poteligeo
moxetumomab pasudotox-tdfk	Lumoxiti
naxitamab-gqgk	Danyelza
necitumumab	Portrazza
nelarabine	Arranon
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nilutamide	Nilandron
nilutamide	nilutamide
nintedanib esylate	Ofev
niraparib tosylate	Zejula
nivolumab	Opdivo
obinutuzumab	Gazyva
ofatumumab	Arzerra
ofatumumab	Kesimpta Pen
olaparib	Lynparza
olaratumab	Lartruvo
omacetaxine mepesuccinate	Synribo
osimertinib mesylate	Tagrisso
oxaliplatin	Eloxatin
oxaliplatin	oxaliplatin
paclitaxel	Onxol
paclitaxel	Taxol
paclitaxel	paclitaxel
paclitaxel protein-bound	Abraxane
palbociclib	Ibrance
panitumumab	Vectibix

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
panobinostat lactate	Farydak
pazopanib HCl	Votrient
pegaspargase	Oncaspar
peginterferon alfa-2b	PegIntron
peginterferon alfa-2b	PegIntron Redipen
peginterferon alfa-2b	Sylatron
peginterferon alfa-2b	Sylatron 4-Pack
pembrolizumab	Keytruda
pemetrexed disodium	Alimta
pemigatinib	Pemazyre
pentostatin	Nipent
pentostatin	pentostatin
pertuzumab	Perjeta
pertuzumab-trastuzumab-hyaluronidase-zzxf	Phesgo
pexidartinib hydrochloride	Turalio
plicamycin	Mithracin
polatuzumab vedotin-piiq	Polivy
pomalidomide	Pomalyst
ponatinib HCl	Iclusig
porfimer sodium	Photofrin
pralatrexate	Folotyn
pralsetinib	Gavreto
procarbazine HCl	Matulane
procarbazine HCl	procarbazine HCl (bulk)
radium-223 dichloride	Xofigo
ramucirumab	Cyramza
regorafenib	Stivarga
relugolix	Orgovyx
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
ripretinib	Qinlock
rituximab	Rituxan
rituximab-abbs	Truxima
rituximab-arrx	Riabni
rituximab-pvvr	Ruxience
rituximab/hyaluronidase, human recombinant	Rituxan Hycela
romidepsin	Istodax
romidepsin	romidepsin
rucaparib camsylate	Rubraca
ruxolitinib phosphate	Jakafi

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
sacituzumab govitecan-hziy	Trodelvy
samarium Sm 153 lexidronam	Quadramet
selinexor	Xpovio
selpercatinib	Retevmo
selumetinib sulfate/vitamin E TPGS	Koselugo
siltuximab	Sylvant
sipuleucel-T/lactated ringers solution	Provenge
sodium butyrate	sodium butyrate (bulk)
sodium iodide-131	Hicon
sonidegib phosphate	Odomzo
sorafenib tosylate	Nexavar
sotorasib	Lumakras
streptozocin	Zanosar
strontium-89 chloride	Metastron
strontium-89 chloride	strontium-89 chloride
sunitinib malate	Sutent
tafasitamab-cxix	Monjuvi
tagraxofusp-erzs	Elzonris
talazoparib tosylate	Talzenna
talimogene laherparepvec	Imlygic
tamoxifen citrate	Nolvadex
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tamoxifen citrate	tamoxifen (bulk)
tazemetostat hydrobromide	Tazverik
temozolomide	Temodar
temozolomide	temozolomide
temsirolimus	Torisel
temsirolimus	temsirolimus
teniposide	Vumon
teniposide	teniposide
tepotinib HCl	Tepmetko
testolactone	Teslac
thalidomide	Thalomid
thioguanine	Tabloid
thioguanine	thioguanine (bulk)
thiotepa	Tepadina
thiotepa	Thioplex
thiotepa	thiotepa
thiotepa	thiotepa (bulk)

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
tisagenlecleucel	Kymriah
tivozanib HCl	Fotivda
topotecan HCl	Hycamtin
topotecan HCl	topotecan
toremifene citrate	Fareston
toremifene citrate	toremifene
tositumomab (with maltose)	Bexxar Dosimetric
tositumomab (with maltose)	Bexxar Therapeutic
trabectedin	Yondelis
trametinib dimethyl sulfoxide	Mekinist
trastuzumab	Herceptin
trastuzumab-anns	Kanjinti
trastuzumab-dkst	Ogivri
trastuzumab-dttb	Ontruzant
trastuzumab-hyaluronidase-oysk	Herceptin Hylecta
trastuzumab-pkrb	Herzuma
trastuzumab-qyyp	Trazimera
tretinoin	Vesanoid
tretinoin	tretinoin (antineoplastic)
trifluridine/tipiracil HCl	Lonsurf
trilaciclib dihydrochloride	Cosela
triptorelin pamoate	Trelstar
triptorelin pamoate	Trelstar Depot
triptorelin pamoate	Trelstar LA
tucatinib	Tukysa
umbralisib tosylate	Ukoniq
uracil mustard	uracil mustard
uridine	uridine (bulk)
uridine triacetate	Vistogard
valrubicin	Valstar
valrubicin	valrubicin
vandetanib	Caprelsa
vandetanib	vandetanib
vemurafenib	Zelboraf
venetoclax	Venclexta
venetoclax	Venclexta Starting Pack
vinblastine sulfate	Velban
vinblastine sulfate	vinblastine
vincristine sulfate	Oncovin
vincristine sulfate	Vincasar PFS

Appendix I. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Non-Proprietary Name	Proprietary Name
vincristine sulfate	vincristine
vincristine sulfate liposomal	Marqibo
vinorelbine tartrate	Navelbine
vinorelbine tartrate	vinorelbine
vismodegib	Erivedge
vorinostat	Zolinza
zanubrutinib	Brukinsa
ziv-aflibercept	Zaltrap

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Cancer, Chemotherapy, and Radiation		
00.10	Implantation of chemotherapeutic agent	Procedure	ICD-9-CM
00.15	High-dose infusion interleukin-2 [IL-2]	Procedure	ICD-9-CM
00.18	Infusion of immunosuppressive antibody therapy	Procedure	ICD-9-CM
11600	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.5 cm or less	Procedure	CPT-4
11601	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11602	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11603	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11604	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11606	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm	Procedure	CPT-4
11620	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less	Procedure	CPT-4
11621	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11622	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11623	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11624	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11626	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm	Procedure	CPT-4
11640	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less	Procedure	CPT-4
11641	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11642	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11643	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11644	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11646	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm	Procedure	CPT-4
140	Malignant neoplasm of lip	Diagnosis	ICD-9-CM
140.0	Malignant neoplasm of upper lip, vermilion border	Diagnosis	ICD-9-CM
140.1	Malignant neoplasm of lower lip, vermilion border	Diagnosis	ICD-9-CM
140.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-9-CM
140.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
140.5	Malignant neoplasm of lip, inner aspect, unspecified as to upper or lower	Diagnosis	ICD-9-CM
140.6	Malignant neoplasm of commissure of lip	Diagnosis	ICD-9-CM
140.8	Malignant neoplasm of other sites of lip	Diagnosis	ICD-9-CM
140.9	Malignant neoplasm of lip, vermilion border, unspecified as to upper or lower	Diagnosis	ICD-9-CM
141	Malignant neoplasm of tongue	Diagnosis	ICD-9-CM
141.0	Malignant neoplasm of base of tongue	Diagnosis	ICD-9-CM
141.1	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-9-CM
141.2	Malignant neoplasm of tip and lateral border of tongue	Diagnosis	ICD-9-CM
141.3	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-9-CM
141.4	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-9-CM
141.5	Malignant neoplasm of junctional zone of tongue	Diagnosis	ICD-9-CM
141.6	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-9-CM
141.8	Malignant neoplasm of other sites of tongue	Diagnosis	ICD-9-CM
141.9	Malignant neoplasm of tongue, unspecified site	Diagnosis	ICD-9-CM
142	Malignant neoplasm of major salivary glands	Diagnosis	ICD-9-CM
142.0	Malignant neoplasm of parotid gland	Diagnosis	ICD-9-CM
142.1	Malignant neoplasm of submandibular gland	Diagnosis	ICD-9-CM
142.2	Malignant neoplasm of sublingual gland	Diagnosis	ICD-9-CM
142.8	Malignant neoplasm of other major salivary glands	Diagnosis	ICD-9-CM
142.9	Malignant neoplasm of salivary gland, unspecified	Diagnosis	ICD-9-CM
143	Malignant neoplasm of gum	Diagnosis	ICD-9-CM
143.0	Malignant neoplasm of upper gum	Diagnosis	ICD-9-CM
143.1	Malignant neoplasm of lower gum	Diagnosis	ICD-9-CM
143.8	Malignant neoplasm of other sites of gum	Diagnosis	ICD-9-CM
143.9	Malignant neoplasm of gum, unspecified site	Diagnosis	ICD-9-CM
144	Malignant neoplasm of floor of mouth	Diagnosis	ICD-9-CM
144.0	Malignant neoplasm of anterior portion of floor of mouth	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
144.1	Malignant neoplasm of lateral portion of floor of mouth	Diagnosis	ICD-9-CM
144.8	Malignant neoplasm of other sites of floor of mouth	Diagnosis	ICD-9-CM
144.9	Malignant neoplasm of floor of mouth, part unspecified	Diagnosis	ICD-9-CM
145	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-9-CM
145.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-9-CM
145.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-9-CM
145.2	Malignant neoplasm of hard palate	Diagnosis	ICD-9-CM
145.3	Malignant neoplasm of soft palate	Diagnosis	ICD-9-CM
145.4	Malignant neoplasm of uvula	Diagnosis	ICD-9-CM
145.5	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-9-CM
145.6	Malignant neoplasm of retromolar area	Diagnosis	ICD-9-CM
145.8	Malignant neoplasm of other specified parts of mouth	Diagnosis	ICD-9-CM
145.9	Malignant neoplasm of mouth, unspecified site	Diagnosis	ICD-9-CM
146	Malignant neoplasm of oropharynx	Diagnosis	ICD-9-CM
146.0	Malignant neoplasm of tonsil	Diagnosis	ICD-9-CM
146.1	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-9-CM
146.2	Malignant neoplasm of tonsillar pillars (anterior) (posterior)	Diagnosis	ICD-9-CM
146.3	Malignant neoplasm of vallecula	Diagnosis	ICD-9-CM
146.4	Malignant neoplasm of anterior aspect of epiglottis	Diagnosis	ICD-9-CM
146.5	Malignant neoplasm of junctional region of oropharynx	Diagnosis	ICD-9-CM
146.6	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-9-CM
146.7	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-9-CM
146.8	Malignant neoplasm of other specified sites of oropharynx	Diagnosis	ICD-9-CM
146.9	Malignant neoplasm of oropharynx, unspecified site	Diagnosis	ICD-9-CM
147	Malignant neoplasm of nasopharynx	Diagnosis	ICD-9-CM
147.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-9-CM
147.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
147.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-9-CM
147.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.8	Malignant neoplasm of other specified sites of nasopharynx	Diagnosis	ICD-9-CM
147.9	Malignant neoplasm of nasopharynx, unspecified site	Diagnosis	ICD-9-CM
148	Malignant neoplasm of hypopharynx	Diagnosis	ICD-9-CM
148.0	Malignant neoplasm of postcricoid region of hypopharynx	Diagnosis	ICD-9-CM
148.1	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-9-CM
148.2	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-9-CM
148.3	Malignant neoplasm of posterior hypopharyngeal wall	Diagnosis	ICD-9-CM
148.8	Malignant neoplasm of other specified sites of hypopharynx	Diagnosis	ICD-9-CM
148.9	Malignant neoplasm of hypopharynx, unspecified site	Diagnosis	ICD-9-CM
149	Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
149.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-9-CM
149.1	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-9-CM
149.8	Malignant neoplasm of other sites within the lip and oral cavity	Diagnosis	ICD-9-CM
149.9	Malignant neoplasm of ill-defined sites of lip and oral cavity	Diagnosis	ICD-9-CM
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM
151	Malignant neoplasm of stomach	Diagnosis	ICD-9-CM
151.0	Malignant neoplasm of cardia	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
151.1	Malignant neoplasm of pylorus	Diagnosis	ICD-9-CM
151.2	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-9-CM
151.3	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-9-CM
151.4	Malignant neoplasm of body of stomach	Diagnosis	ICD-9-CM
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.8	Malignant neoplasm of other specified sites of stomach	Diagnosis	ICD-9-CM
151.9	Malignant neoplasm of stomach, unspecified site	Diagnosis	ICD-9-CM
152	Malignant neoplasm of small intestine, including duodenum	Diagnosis	ICD-9-CM
152.0	Malignant neoplasm of duodenum	Diagnosis	ICD-9-CM
152.1	Malignant neoplasm of jejunum	Diagnosis	ICD-9-CM
152.2	Malignant neoplasm of ileum	Diagnosis	ICD-9-CM
152.3	Malignant neoplasm of Meckel's diverticulum	Diagnosis	ICD-9-CM
152.8	Malignant neoplasm of other specified sites of small intestine	Diagnosis	ICD-9-CM
152.9	Malignant neoplasm of small intestine, unspecified site	Diagnosis	ICD-9-CM
153	Malignant neoplasm of colon	Diagnosis	ICD-9-CM
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154	Malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
154.2	Malignant neoplasm of anal canal	Diagnosis	ICD-9-CM
154.3	Malignant neoplasm of anus, unspecified site	Diagnosis	ICD-9-CM
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.2	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-9-CM
156	Malignant neoplasm of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.0	Malignant neoplasm of gallbladder	Diagnosis	ICD-9-CM
156.1	Malignant neoplasm of extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.2	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-9-CM
156.8	Malignant neoplasm of other specified sites of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.9	Malignant neoplasm of biliary tract, part unspecified site	Diagnosis	ICD-9-CM
157	Malignant neoplasm of pancreas	Diagnosis	ICD-9-CM
157.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-9-CM
157.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-9-CM
157.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-9-CM
157.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-9-CM
157.4	Malignant neoplasm of islets of Langerhans	Diagnosis	ICD-9-CM
157.8	Malignant neoplasm of other specified sites of pancreas	Diagnosis	ICD-9-CM
157.9	Malignant neoplasm of pancreas, part unspecified	Diagnosis	ICD-9-CM
158	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
158.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-9-CM
158.8	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-9-CM
158.9	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
159	Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum	Diagnosis	ICD-9-CM
159.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-9-CM
159.1	Malignant neoplasm of spleen, not elsewhere classified	Diagnosis	ICD-9-CM
159.8	Malignant neoplasm of other sites of digestive system and intra-abdominal organs	Diagnosis	ICD-9-CM
159.9	Malignant neoplasm of ill-defined sites of digestive organs and peritoneum	Diagnosis	ICD-9-CM
160	Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.0	Malignant neoplasm of nasal cavities	Diagnosis	ICD-9-CM
160.1	Malignant neoplasm of auditory tube, middle ear, and mastoid air cells	Diagnosis	ICD-9-CM
160.2	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-9-CM
160.3	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-9-CM
160.4	Malignant neoplasm of frontal sinus	Diagnosis	ICD-9-CM
160.5	Malignant neoplasm of sphenoidal sinus	Diagnosis	ICD-9-CM
160.8	Malignant neoplasm of other sites of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.9	Malignant neoplasm of site of nasal cavities, middle ear, and accessory sinus, unspecified site	Diagnosis	ICD-9-CM
161	Malignant neoplasm of larynx	Diagnosis	ICD-9-CM
161.0	Malignant neoplasm of glottis	Diagnosis	ICD-9-CM
161.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-9-CM
161.2	Malignant neoplasm of subglottis	Diagnosis	ICD-9-CM
161.3	Malignant neoplasm of laryngeal cartilages	Diagnosis	ICD-9-CM
161.8	Malignant neoplasm of other specified sites of larynx	Diagnosis	ICD-9-CM
161.9	Malignant neoplasm of larynx, unspecified site	Diagnosis	ICD-9-CM
162	Malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
162.0	Malignant neoplasm of trachea	Diagnosis	ICD-9-CM
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
163	Malignant neoplasm of pleura	Diagnosis	ICD-9-CM
163.0	Malignant neoplasm of parietal pleura	Diagnosis	ICD-9-CM
163.1	Malignant neoplasm of visceral pleura	Diagnosis	ICD-9-CM
163.8	Malignant neoplasm of other specified sites of pleura	Diagnosis	ICD-9-CM
163.9	Malignant neoplasm of pleura, unspecified site	Diagnosis	ICD-9-CM
164	Malignant neoplasm of thymus, heart, and mediastinum	Diagnosis	ICD-9-CM
164.0	Malignant neoplasm of thymus	Diagnosis	ICD-9-CM
164.1	Malignant neoplasm of heart	Diagnosis	ICD-9-CM
164.2	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-9-CM
164.3	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-9-CM
164.8	Malignant neoplasm of other parts of mediastinum	Diagnosis	ICD-9-CM
164.9	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-9-CM
165	Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-9-CM
165.8	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.9	Malignant neoplasm of ill-defined sites within the respiratory system	Diagnosis	ICD-9-CM
17.70	Intravenous infusion of clofarabine	Procedure	ICD-9-CM
170	Malignant neoplasm of bone and articular cartilage	Diagnosis	ICD-9-CM
170.0	Malignant neoplasm of bones of skull and face, except mandible	Diagnosis	ICD-9-CM
170.1	Malignant neoplasm of mandible	Diagnosis	ICD-9-CM
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx	Diagnosis	ICD-9-CM
170.3	Malignant neoplasm of ribs, sternum, and clavicle	Diagnosis	ICD-9-CM
170.4	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-9-CM
170.5	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-9-CM
170.6	Malignant neoplasm of pelvic bones, sacrum, and coccyx	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
170.7	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-9-CM
170.8	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-9-CM
170.9	Malignant neoplasm of bone and articular cartilage, site unspecified	Diagnosis	ICD-9-CM
171	Malignant neoplasm of connective and other soft tissue	Diagnosis	ICD-9-CM
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	Diagnosis	ICD-9-CM
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	Diagnosis	ICD-9-CM
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	Diagnosis	ICD-9-CM
171.4	Malignant neoplasm of connective and other soft tissue of thorax	Diagnosis	ICD-9-CM
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	Diagnosis	ICD-9-CM
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	Diagnosis	ICD-9-CM
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified site	Diagnosis	ICD-9-CM
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	Diagnosis	ICD-9-CM
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	Diagnosis	ICD-9-CM
172	Malignant melanoma of skin	Diagnosis	ICD-9-CM
172.0	Malignant melanoma of skin of lip	Diagnosis	ICD-9-CM
172.1	Malignant melanoma of skin of eyelid, including canthus	Diagnosis	ICD-9-CM
172.2	Malignant melanoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
172.3	Malignant melanoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
172.4	Malignant melanoma of skin of scalp and neck	Diagnosis	ICD-9-CM
172.5	Malignant melanoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
172.6	Malignant melanoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
172.7	Malignant melanoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
172.8	Malignant melanoma of other specified sites of skin	Diagnosis	ICD-9-CM
172.9	Melanoma of skin, site unspecified	Diagnosis	ICD-9-CM
17260	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.5 cm or less	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17261	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17262	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17263	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17264	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17266	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter over 4.0 cm	Procedure	CPT-4
17270	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less	Procedure	CPT-4
17271	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17272	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17273	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17274	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17276	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter over 4.0 cm	Procedure	CPT-4
17280	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less	Procedure	CPT-4
17281	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17282	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17283	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17284	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17286	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter over 4.0 cm	Procedure	CPT-4
173	Other and unspecified malignant neoplasm of skin	Diagnosis	ICD-9-CM
173.0	Other and unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.1	Other and unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.10	Unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.11	Basal cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.12	Squamous cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.19	Other specified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.2	Other and unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.20	Unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.21	Basal cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.22	Squamous cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.29	Other specified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.3	Other and unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.30	Unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.31	Basal cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.32	Squamous cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.39	Other specified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.4	Other and unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.40	Unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
173.41	Basal cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.42	Squamous cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.49	Other specified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.5	Other and unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.50	Unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.51	Basal cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.52	Squamous cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.59	Other specified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.6	Other and unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.60	Unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.61	Basal cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.62	Squamous cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.69	Other specified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.7	Other and unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.70	Unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.71	Basal cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.72	Squamous cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.79	Other specified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.8	Other and unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.80	Unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.81	Basal cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.82	Squamous cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.89	Other specified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.9	Other and unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
173.90	Unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
173.91	Basal cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
173.92	Squamous cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
173.99	Other specified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
17304	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); first stage, fresh tissue technique, up to 5 specimens	Procedure	CPT-4
17305	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); second stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17306	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); third stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17307	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); additional stage(s), up to 5 specimens, each stage	Procedure	CPT-4
17310	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); each additional specimen, after the first 5 specimens, fixed or fresh tissue, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
17311	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17312	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17313	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks	Procedure	CPT-4
17314	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17315	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
174	Malignant neoplasm of female breast	Diagnosis	ICD-9-CM
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175	Malignant neoplasm of male breast	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
176	Kaposi's sarcoma	Diagnosis	ICD-9-CM
176.0	Kaposi's sarcoma of skin	Diagnosis	ICD-9-CM
176.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-9-CM
176.2	Kaposi's sarcoma of palate	Diagnosis	ICD-9-CM
176.3	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-9-CM
176.4	Kaposi's sarcoma of lung	Diagnosis	ICD-9-CM
176.5	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-9-CM
176.8	Kaposi's sarcoma of other specified sites	Diagnosis	ICD-9-CM
176.9	Kaposi's sarcoma of unspecified site	Diagnosis	ICD-9-CM
179	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-9-CM
180	Malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
180.0	Malignant neoplasm of endocervix	Diagnosis	ICD-9-CM
180.1	Malignant neoplasm of exocervix	Diagnosis	ICD-9-CM
180.8	Malignant neoplasm of other specified sites of cervix	Diagnosis	ICD-9-CM
180.9	Malignant neoplasm of cervix uteri, unspecified site	Diagnosis	ICD-9-CM
181	Malignant neoplasm of placenta	Diagnosis	ICD-9-CM
182	Malignant neoplasm of body of uterus	Diagnosis	ICD-9-CM
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
182.1	Malignant neoplasm of isthmus	Diagnosis	ICD-9-CM
182.8	Malignant neoplasm of other specified sites of body of uterus	Diagnosis	ICD-9-CM
183	Malignant neoplasm of ovary and other uterine adnexa	Diagnosis	ICD-9-CM
183.0	Malignant neoplasm of ovary	Diagnosis	ICD-9-CM
183.2	Malignant neoplasm of fallopian tube	Diagnosis	ICD-9-CM
183.3	Malignant neoplasm of broad ligament of uterus	Diagnosis	ICD-9-CM
183.4	Malignant neoplasm of parametrium of uterus	Diagnosis	ICD-9-CM
183.5	Malignant neoplasm of round ligament of uterus	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
183.8	Malignant neoplasm of other specified sites of uterine adnexa	Diagnosis	ICD-9-CM
183.9	Malignant neoplasm of uterine adnexa, unspecified site	Diagnosis	ICD-9-CM
184	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-9-CM
184.0	Malignant neoplasm of vagina	Diagnosis	ICD-9-CM
184.1	Malignant neoplasm of labia majora	Diagnosis	ICD-9-CM
184.2	Malignant neoplasm of labia minora	Diagnosis	ICD-9-CM
184.3	Malignant neoplasm of clitoris	Diagnosis	ICD-9-CM
184.4	Malignant neoplasm of vulva, unspecified site	Diagnosis	ICD-9-CM
184.8	Malignant neoplasm of other specified sites of female genital organs	Diagnosis	ICD-9-CM
184.9	Malignant neoplasm of female genital organ, site unspecified	Diagnosis	ICD-9-CM
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
186	Malignant neoplasm of testis	Diagnosis	ICD-9-CM
186.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-9-CM
186.9	Malignant neoplasm of other and unspecified testis	Diagnosis	ICD-9-CM
187	Malignant neoplasm of penis and other male genital organs	Diagnosis	ICD-9-CM
187.1	Malignant neoplasm of prepuce	Diagnosis	ICD-9-CM
187.2	Malignant neoplasm of glans penis	Diagnosis	ICD-9-CM
187.3	Malignant neoplasm of body of penis	Diagnosis	ICD-9-CM
187.4	Malignant neoplasm of penis, part unspecified	Diagnosis	ICD-9-CM
187.5	Malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
187.6	Malignant neoplasm of spermatic cord	Diagnosis	ICD-9-CM
187.7	Malignant neoplasm of scrotum	Diagnosis	ICD-9-CM
187.8	Malignant neoplasm of other specified sites of male genital organs	Diagnosis	ICD-9-CM
187.9	Malignant neoplasm of male genital organ, site unspecified	Diagnosis	ICD-9-CM
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
189	Malignant neoplasm of kidney and other and unspecified urinary organs	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.1	Malignant neoplasm of renal pelvis	Diagnosis	ICD-9-CM
189.2	Malignant neoplasm of ureter	Diagnosis	ICD-9-CM
189.3	Malignant neoplasm of urethra	Diagnosis	ICD-9-CM
189.4	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-9-CM
189.8	Malignant neoplasm of other specified sites of urinary organs	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
190	Malignant neoplasm of eye	Diagnosis	ICD-9-CM
190.0	Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and choroid	Diagnosis	ICD-9-CM
190.1	Malignant neoplasm of orbit	Diagnosis	ICD-9-CM
190.2	Malignant neoplasm of lacrimal gland	Diagnosis	ICD-9-CM
190.3	Malignant neoplasm of conjunctiva	Diagnosis	ICD-9-CM
190.4	Malignant neoplasm of cornea	Diagnosis	ICD-9-CM
190.5	Malignant neoplasm of retina	Diagnosis	ICD-9-CM
190.6	Malignant neoplasm of choroid	Diagnosis	ICD-9-CM
190.7	Malignant neoplasm of lacrimal duct	Diagnosis	ICD-9-CM
190.8	Malignant neoplasm of other specified sites of eye	Diagnosis	ICD-9-CM
190.9	Malignant neoplasm of eye, part unspecified	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
191	Malignant neoplasm of brain	Diagnosis	ICD-9-CM
191.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-9-CM
191.1	Malignant neoplasm of frontal lobe of brain	Diagnosis	ICD-9-CM
191.2	Malignant neoplasm of temporal lobe of brain	Diagnosis	ICD-9-CM
191.3	Malignant neoplasm of parietal lobe of brain	Diagnosis	ICD-9-CM
191.4	Malignant neoplasm of occipital lobe of brain	Diagnosis	ICD-9-CM
191.5	Malignant neoplasm of ventricles of brain	Diagnosis	ICD-9-CM
191.6	Malignant neoplasm of cerebellum NOS	Diagnosis	ICD-9-CM
191.7	Malignant neoplasm of brain stem	Diagnosis	ICD-9-CM
191.8	Malignant neoplasm of other parts of brain	Diagnosis	ICD-9-CM
191.9	Malignant neoplasm of brain, unspecified site	Diagnosis	ICD-9-CM
192	Malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
192.0	Malignant neoplasm of cranial nerves	Diagnosis	ICD-9-CM
192.1	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-9-CM
192.2	Malignant neoplasm of spinal cord	Diagnosis	ICD-9-CM
192.3	Malignant neoplasm of spinal meninges	Diagnosis	ICD-9-CM
192.8	Malignant neoplasm of other specified sites of nervous system	Diagnosis	ICD-9-CM
192.9	Malignant neoplasm of nervous system, part unspecified	Diagnosis	ICD-9-CM
193	Malignant neoplasm of thyroid gland	Diagnosis	ICD-9-CM
194	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.0	Malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
194.1	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-9-CM
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
194.4	Malignant neoplasm of pineal gland	Diagnosis	ICD-9-CM
194.5	Malignant neoplasm of carotid body	Diagnosis	ICD-9-CM
194.6	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-9-CM
194.8	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
194.9	Malignant neoplasm of endocrine gland, site unspecified	Diagnosis	ICD-9-CM
195	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-9-CM
195.0	Malignant neoplasm of head, face, and neck	Diagnosis	ICD-9-CM
195.1	Malignant neoplasm of thorax	Diagnosis	ICD-9-CM
195.2	Malignant neoplasm of abdomen	Diagnosis	ICD-9-CM
195.3	Malignant neoplasm of pelvis	Diagnosis	ICD-9-CM
195.4	Malignant neoplasm of upper limb	Diagnosis	ICD-9-CM
195.5	Malignant neoplasm of lower limb	Diagnosis	ICD-9-CM
195.8	Malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
196	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-9-CM
196.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
196.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
196.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
196.3	Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
196.5	Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
196.6	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
196.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
196.9	Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified	Diagnosis	ICD-9-CM
197	Secondary malignant neoplasm of respiratory and digestive systems	Diagnosis	ICD-9-CM
197.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-9-CM
197.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-9-CM
197.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-9-CM
197.3	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-9-CM
197.4	Secondary malignant neoplasm of small intestine including duodenum	Diagnosis	ICD-9-CM
197.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-9-CM
197.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
197.7	Secondary malignant neoplasm of liver	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
197.8	Secondary malignant neoplasm of other digestive organs and spleen	Diagnosis	ICD-9-CM
198	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.0	Secondary malignant neoplasm of kidney	Diagnosis	ICD-9-CM
198.1	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-9-CM
198.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-9-CM
198.3	Secondary malignant neoplasm of brain and spinal cord	Diagnosis	ICD-9-CM
198.4	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
198.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-9-CM
198.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-9-CM
198.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
198.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-9-CM
198.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
198.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
199	Malignant neoplasm without specification of site	Diagnosis	ICD-9-CM
199.0	Disseminated malignant neoplasm	Diagnosis	ICD-9-CM
199.1	Other malignant neoplasm of unspecified site	Diagnosis	ICD-9-CM
199.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-9-CM
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	Diagnosis	ICD-9-CM
200.0	Reticulosarcoma	Diagnosis	ICD-9-CM
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.01	Reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.02	Reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.03	Reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.04	Reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.05	Reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.06	Reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.07	Reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.08	Reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.1	Lymphosarcoma	Diagnosis	ICD-9-CM
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.11	Lymphosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.12	Lymphosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.13	Lymphosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.14	Lymphosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.15	Lymphosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.16	Lymphosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.17	Lymphosarcoma of spleen	Diagnosis	ICD-9-CM
200.18	Lymphosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.2	Burkitt's tumor or lymphoma	Diagnosis	ICD-9-CM
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.21	Burkitt's tumor or lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.22	Burkitt's tumor or lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.23	Burkitt's tumor or lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.24	Burkitt's tumor or lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.25	Burkitt's tumor or lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.26	Burkitt's tumor or lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.27	Burkitt's tumor or lymphoma of spleen	Diagnosis	ICD-9-CM
200.28	Burkitt's tumor or lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.3	Marginal zone lymphoma	Diagnosis	ICD-9-CM
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.31	Marginal zone lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.32	Marginal zone lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.33	Marginal zone lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.34	Marginal zone lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.35	Marginal zone lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.36	Marginal zone lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.37	Marginal zone lymphoma, spleen	Diagnosis	ICD-9-CM
200.38	Marginal zone lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.4	Mantle cell lymphoma	Diagnosis	ICD-9-CM
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.41	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.42	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.43	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.44	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.45	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.46	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.47	Mantle cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.48	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.5	Primary central nervous system lymphoma	Diagnosis	ICD-9-CM
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.51	Primary central nervous system lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.52	Primary central nervous system lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.53	Primary central nervous system lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.54	Primary central nervous system lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.55	Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.56	Primary central nervous system lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.57	Primary central nervous system lymphoma, spleen	Diagnosis	ICD-9-CM
200.58	Primary central nervous system lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.6	Anaplastic large cell lymphoma	Diagnosis	ICD-9-CM
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.61	Anaplastic large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.62	Anaplastic large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.63	Anaplastic large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.64	Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.65	Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.66	Anaplastic large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.67	Anaplastic large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.68	Anaplastic large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.7	Large cell lymphoma	Diagnosis	ICD-9-CM
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.71	Large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.72	Large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.73	Large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.74	Large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.75	Large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.76	Large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.77	Large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.78	Large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.8	Other named variants of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
200.80	Other named variants, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.81	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.82	Other named variants of lymphosarcoma and reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.83	Other named variants of lymphosarcoma and reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.84	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.85	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.86	Other named variants of lymphosarcoma and reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.87	Other named variants of lymphosarcoma and reticulosarcoma of spleen	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.88	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201	Hodgkin's disease	Diagnosis	ICD-9-CM
201.0	Hodgkin's paragranuloma	Diagnosis	ICD-9-CM
201.00	Hodgkin's paragranuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.01	Hodgkin's paragranuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.02	Hodgkin's paragranuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.03	Hodgkin's paragranuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.04	Hodgkin's paragranuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.05	Hodgkin's paragranuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.06	Hodgkin's paragranuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.07	Hodgkin's paragranuloma of spleen	Diagnosis	ICD-9-CM
201.08	Hodgkin's paragranuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.1	Hodgkin's granuloma	Diagnosis	ICD-9-CM
201.10	Hodgkin's granuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.11	Hodgkin's granuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.12	Hodgkin's granuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.13	Hodgkin's granuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.14	Hodgkin's granuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.15	Hodgkin's granuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.16	Hodgkin's granuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.17	Hodgkin's granuloma of spleen	Diagnosis	ICD-9-CM
201.18	Hodgkin's granuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.2	Hodgkin's sarcoma	Diagnosis	ICD-9-CM
201.20	Hodgkin's sarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.21	Hodgkin's sarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.22	Hodgkin's sarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.23	Hodgkin's sarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
201.24	Hodgkin's sarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.25	Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.26	Hodgkin's sarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.27	Hodgkin's sarcoma of spleen	Diagnosis	ICD-9-CM
201.28	Hodgkin's sarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.4	Hodgkin's disease, lymphocytic-histiocytic predominance	Diagnosis	ICD-9-CM
201.40	Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.41	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.42	Hodgkin's disease, lymphocytic-histiocytic predominance of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.43	Hodgkin's disease, lymphocytic-histiocytic predominance of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.44	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.45	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.46	Hodgkin's disease, lymphocytic-histiocytic predominance of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.47	Hodgkin's disease, lymphocytic-histiocytic predominance of spleen	Diagnosis	ICD-9-CM
201.48	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.5	Hodgkin's disease, nodular sclerosis	Diagnosis	ICD-9-CM
201.50	Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.51	Hodgkin's disease, nodular sclerosis, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.52	Hodgkin's disease, nodular sclerosis, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.53	Hodgkin's disease, nodular sclerosis, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.54	Hodgkin's disease, nodular sclerosis, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.55	Hodgkin's disease, nodular sclerosis, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.56	Hodgkin's disease, nodular sclerosis, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.57	Hodgkin's disease, nodular sclerosis, of spleen	Diagnosis	ICD-9-CM
201.58	Hodgkin's disease, nodular sclerosis, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.6	Hodgkin's disease, mixed cellularity	Diagnosis	ICD-9-CM
201.60	Hodgkin's disease, mixed cellularity, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
201.61	Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.62	Hodgkin's disease, mixed cellularity, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.63	Hodgkin's disease, mixed cellularity, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.64	Hodgkin's disease, mixed cellularity, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.65	Hodgkin's disease, mixed cellularity, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.66	Hodgkin's disease, mixed cellularity, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.67	Hodgkin's disease, mixed cellularity, of spleen	Diagnosis	ICD-9-CM
201.68	Hodgkin's disease, mixed cellularity, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.7	Hodgkin's disease, lymphocytic depletion	Diagnosis	ICD-9-CM
201.70	Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.71	Hodgkin's disease, lymphocytic depletion, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.72	Hodgkin's disease, lymphocytic depletion, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.73	Hodgkin's disease, lymphocytic depletion, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.74	Hodgkin's disease, lymphocytic depletion, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.75	Hodgkin's disease, lymphocytic depletion, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.76	Hodgkin's disease, lymphocytic depletion, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.77	Hodgkin's disease, lymphocytic depletion, of spleen	Diagnosis	ICD-9-CM
201.78	Hodgkin's disease, lymphocytic depletion, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.9	Hodgkin's disease, unspecified type	Diagnosis	ICD-9-CM
201.90	Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.91	Hodgkin's disease, unspecified type, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.92	Hodgkin's disease, unspecified type, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.93	Hodgkin's disease, unspecified type, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.94	Hodgkin's disease, unspecified type, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.95	Hodgkin's disease, unspecified type, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.96	Hodgkin's disease, unspecified type, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.97	Hodgkin's disease, unspecified type, of spleen	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
201.98	Hodgkin's disease, unspecified type, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202	Other malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.0	Nodular lymphoma	Diagnosis	ICD-9-CM
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.01	Nodular lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.02	Nodular lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.03	Nodular lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.04	Nodular lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.05	Nodular lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.06	Nodular lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.07	Nodular lymphoma of spleen	Diagnosis	ICD-9-CM
202.08	Nodular lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.1	Mycosis fungoides	Diagnosis	ICD-9-CM
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.11	Mycosis fungoides of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.12	Mycosis fungoides of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.13	Mycosis fungoides of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.14	Mycosis fungoides of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.15	Mycosis fungoides of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.16	Mycosis fungoides of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.17	Mycosis fungoides of spleen	Diagnosis	ICD-9-CM
202.18	Mycosis fungoides of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.2	Sezary's disease	Diagnosis	ICD-9-CM
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.21	Sezary's disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.22	Sezary's disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.23	Sezary's disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.24	Sezary's disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.25	Sezary's disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.26	Sezary's disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.27	Sezary's disease of spleen	Diagnosis	ICD-9-CM
202.28	Sezary's disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.3	Malignant histiocytosis	Diagnosis	ICD-9-CM
202.30	Malignant histiocytosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.31	Malignant histiocytosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.32	Malignant histiocytosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.33	Malignant histiocytosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.34	Malignant histiocytosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.35	Malignant histiocytosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.36	Malignant histiocytosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.37	Malignant histiocytosis of spleen	Diagnosis	ICD-9-CM
202.38	Malignant histiocytosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.4	Leukemic reticuloendotheliosis	Diagnosis	ICD-9-CM
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.41	Leukemic reticuloendotheliosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.42	Leukemic reticuloendotheliosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.43	Leukemic reticuloendotheliosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.44	Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.45	Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.46	Leukemic reticuloendotheliosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.47	Leukemic reticuloendotheliosis of spleen	Diagnosis	ICD-9-CM
202.48	Leukemic reticuloendotheliosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.5	Letterer-Siwe disease	Diagnosis	ICD-9-CM
202.50	Letterer-Siwe disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.51	Letterer-Siwe disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.52	Letterer-Siwe disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.53	Letterer-Siwe disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.54	Letterer-Siwe disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.55	Letterer-Siwe disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.56	Letterer-Siwe disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.57	Letterer-Siwe disease of spleen	Diagnosis	ICD-9-CM
202.58	Letterer-Siwe disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.6	Malignant mast cell tumors	Diagnosis	ICD-9-CM
202.60	Malignant mast cell tumors, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.61	Malignant mast cell tumors of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.62	Malignant mast cell tumors of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.63	Malignant mast cell tumors of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.64	Malignant mast cell tumors of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.65	Malignant mast cell tumors of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.66	Malignant mast cell tumors of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.67	Malignant mast cell tumors of spleen	Diagnosis	ICD-9-CM
202.68	Malignant mast cell tumors of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.7	Peripheral T-cell lymphoma	Diagnosis	ICD-9-CM
202.70	Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.71	Peripheral T-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.72	Peripheral T-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.73	Peripheral T-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.74	Peripheral T-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.75	Peripheral T-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.76	Peripheral T-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.77	Peripheral T-cell lymphoma, spleen	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.78	Peripheral T-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.8	Other malignant lymphomas	Diagnosis	ICD-9-CM
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.81	Other malignant lymphomas of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.82	Other malignant lymphomas of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.83	Other malignant lymphomas of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.84	Other malignant lymphomas of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.85	Other malignant lymphomas of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.86	Other malignant lymphomas of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.87	Other malignant lymphomas of spleen	Diagnosis	ICD-9-CM
202.88	Other malignant lymphomas of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.9	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of spleen	Diagnosis	ICD-9-CM
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
203	Multiple myeloma and immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.0	Multiple myeloma	Diagnosis	ICD-9-CM
203.00	Multiple myeloma, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.01	Multiple myeloma in remission	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
203.02	Multiple myeloma, in relapse	Diagnosis	ICD-9-CM
203.1	Plasma cell leukemia	Diagnosis	ICD-9-CM
203.10	Plasma cell leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.11	Plasma cell leukemia in remission	Diagnosis	ICD-9-CM
203.12	Plasma cell leukemia, in relapse	Diagnosis	ICD-9-CM
203.8	Other immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.80	Other immunoproliferative neoplasms, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.81	Other immunoproliferative neoplasms in remission	Diagnosis	ICD-9-CM
203.82	Other immunoproliferative neoplasms, in relapse	Diagnosis	ICD-9-CM
204	Lymphoid leukemia	Diagnosis	ICD-9-CM
204.0	Acute lymphoid leukemia	Diagnosis	ICD-9-CM
204.00	Acute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.01	Acute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.02	Acute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.1	Chronic lymphoid leukemia	Diagnosis	ICD-9-CM
204.10	Chronic lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.11	Chronic lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.12	Chronic lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.2	Subacute lymphoid leukemia	Diagnosis	ICD-9-CM
204.20	Subacute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.21	Subacute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.22	Subacute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.8	Other lymphoid leukemia	Diagnosis	ICD-9-CM
204.80	Other lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.81	Other lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.82	Other lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.9	Unspecified lymphoid leukemia	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
204.90	Unspecified lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.91	Unspecified lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.92	Unspecified lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
205	Myeloid leukemia	Diagnosis	ICD-9-CM
205.0	Acute myeloid leukemia	Diagnosis	ICD-9-CM
205.00	Acute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.01	Acute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.02	Acute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.1	Chronic myeloid leukemia	Diagnosis	ICD-9-CM
205.10	Chronic myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.11	Chronic myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.12	Chronic myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.2	Subacute myeloid leukemia	Diagnosis	ICD-9-CM
205.20	Subacute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.21	Subacute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.22	Subacute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.3	Myeloid sarcoma	Diagnosis	ICD-9-CM
205.30	Myeloid sarcoma, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.31	Myeloid sarcoma in remission	Diagnosis	ICD-9-CM
205.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-9-CM
205.8	Other myeloid leukemia	Diagnosis	ICD-9-CM
205.80	Other myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.81	Other myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.82	Other myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.9	Unspecified myeloid leukemia	Diagnosis	ICD-9-CM
205.90	Unspecified myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.91	Unspecified myeloid leukemia in remission	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
205.92	Unspecified myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
206	Monocytic leukemia	Diagnosis	ICD-9-CM
206.0	Acute monocytic leukemia	Diagnosis	ICD-9-CM
206.00	Acute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.01	Acute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.02	Acute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.1	Chronic monocytic leukemia	Diagnosis	ICD-9-CM
206.10	Chronic monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.11	Chronic monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.12	Chronic monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.2	Subacute monocytic leukemia	Diagnosis	ICD-9-CM
206.20	Subacute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.21	Subacute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.22	Subacute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.8	Other monocytic leukemia	Diagnosis	ICD-9-CM
206.80	Other monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.81	Other monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.82	Other monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.9	Unspecified monocytic leukemia	Diagnosis	ICD-9-CM
206.90	Unspecified monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.91	Unspecified monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.92	Unspecified monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207	Other specified leukemia	Diagnosis	ICD-9-CM
207.0	Acute erythremia and erythroleukemia	Diagnosis	ICD-9-CM
207.00	Acute erythremia and erythroleukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.01	Acute erythremia and erythroleukemia in remission	Diagnosis	ICD-9-CM
207.02	Acute erythremia and erythroleukemia, in relapse	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
207.1	Chronic erythremia	Diagnosis	ICD-9-CM
207.10	Chronic erythremia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.11	Chronic erythremia in remission	Diagnosis	ICD-9-CM
207.12	Chronic erythremia, in relapse	Diagnosis	ICD-9-CM
207.2	Megakaryocytic leukemia	Diagnosis	ICD-9-CM
207.20	Megakaryocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.21	Megakaryocytic leukemia in remission	Diagnosis	ICD-9-CM
207.22	Megakaryocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207.8	Other specified leukemia	Diagnosis	ICD-9-CM
207.80	Other specified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.81	Other specified leukemia in remission	Diagnosis	ICD-9-CM
207.82	Other specified leukemia, in relapse	Diagnosis	ICD-9-CM
208	Leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.00	Acute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.01	Acute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.10	Chronic leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.11	Chronic leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.2	Subacute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.20	Subacute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.21	Subactue leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.22	Subacute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.8	Other leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.80	Other leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
208.81	Other leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.82	Other leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.9	Unspecified leukemia	Diagnosis	ICD-9-CM
208.90	Unspecified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.91	Unspecified leukemia in remission	Diagnosis	ICD-9-CM
208.92	Unspecified leukemia, in relapse	Diagnosis	ICD-9-CM
209	Neuroendocrine tumors	Diagnosis	ICD-9-CM
209.0	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.00	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.01	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.02	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.03	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.1	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.11	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.12	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.13	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.14	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.15	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.16	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.17	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.2	Malignant carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.20	Malignant carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.21	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.22	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.23	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.24	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
209.25	Malignant carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.26	Malignant carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.27	Malignant carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.29	Malignant carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.3	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-9-CM
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site	Diagnosis	ICD-9-CM
209.31	Merkel cell carcinoma of the face	Diagnosis	ICD-9-CM
209.32	Merkel cell carcinoma of the scalp and neck	Diagnosis	ICD-9-CM
209.33	Merkel cell carcinoma of the upper limb	Diagnosis	ICD-9-CM
209.34	Merkel cell carcinoma of the lower limb	Diagnosis	ICD-9-CM
209.35	Merkel cell carcinoma of the trunk	Diagnosis	ICD-9-CM
209.36	Merkel cell carcinoma of other sites	Diagnosis	ICD-9-CM
209.4	Benign carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.40	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.41	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.42	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.43	Benign carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.5	Benign carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.50	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.51	Benign carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.52	Benign carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.53	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.54	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.55	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.56	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.57	Benign carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.6	Benign carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
209.60	Benign carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.61	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.62	Benign carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.63	Benign carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.64	Benign carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.65	Benign carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.66	Benign carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.67	Benign carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.69	Benign carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.7	Secondary neuroendocrine tumors	Diagnosis	ICD-9-CM
209.70	Secondary neuroendocrine tumor, unspecified site	Diagnosis	ICD-9-CM
209.71	Secondary neuroendocrine tumor of distant lymph nodes	Diagnosis	ICD-9-CM
209.72	Secondary neuroendocrine tumor of liver	Diagnosis	ICD-9-CM
209.73	Secondary neuroendocrine tumor of bone	Diagnosis	ICD-9-CM
209.74	Secondary neuroendocrine tumor of peritoneum	Diagnosis	ICD-9-CM
209.75	Secondary Merkel cell carcinoma	Diagnosis	ICD-9-CM
209.79	Secondary neuroendocrine tumor of other sites	Diagnosis	ICD-9-CM
230	Carcinoma in situ of digestive organs	Diagnosis	ICD-9-CM
230.0	Carcinoma in situ of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
230.1	Carcinoma in situ of esophagus	Diagnosis	ICD-9-CM
230.2	Carcinoma in situ of stomach	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
230.5	Carcinoma in situ of anal canal	Diagnosis	ICD-9-CM
230.6	Carcinoma in situ of anus, unspecified	Diagnosis	ICD-9-CM
230.7	Carcinoma in situ of other and unspecified parts of intestine	Diagnosis	ICD-9-CM
230.8	Carcinoma in situ of liver and biliary system	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
230.9	Carcinoma in situ of other and unspecified digestive organs	Diagnosis	ICD-9-CM
231	Carcinoma in situ of respiratory system	Diagnosis	ICD-9-CM
231.0	Carcinoma in situ of larynx	Diagnosis	ICD-9-CM
231.1	Carcinoma in situ of trachea	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
231.8	Carcinoma in situ of other specified parts of respiratory system	Diagnosis	ICD-9-CM
231.9	Carcinoma in situ of respiratory system, part unspecified	Diagnosis	ICD-9-CM
232	Carcinoma in situ of skin	Diagnosis	ICD-9-CM
232.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-9-CM
232.1	Carcinoma in situ of eyelid, including canthus	Diagnosis	ICD-9-CM
232.2	Carcinoma in situ of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
232.3	Carcinoma in situ of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
232.4	Carcinoma in situ of scalp and skin of neck	Diagnosis	ICD-9-CM
232.5	Carcinoma in situ of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
232.6	Carcinoma in situ of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
232.7	Carcinoma in situ of skin of lower limb, including hip	Diagnosis	ICD-9-CM
232.8	Carcinoma in situ of other specified sites of skin	Diagnosis	ICD-9-CM
232.9	Carcinoma in situ of skin, site unspecified	Diagnosis	ICD-9-CM
233	Carcinoma in situ of breast and genitourinary system	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
233.1	Carcinoma in situ of cervix uteri	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
233.3	Carcinoma in situ, other and unspecified female genital organs	Diagnosis	ICD-9-CM
233.30	Carcinoma in situ, unspecified female genital organ	Diagnosis	ICD-9-CM
233.31	Carcinoma in situ, vagina	Diagnosis	ICD-9-CM
233.32	Carcinoma in situ, vulva	Diagnosis	ICD-9-CM
233.39	Carcinoma in situ, other female genital organ	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
233.5	Carcinoma in situ of penis	Diagnosis	ICD-9-CM
233.6	Carcinoma in situ of other and unspecified male genital organs	Diagnosis	ICD-9-CM
233.7	Carcinoma in situ of bladder	Diagnosis	ICD-9-CM
233.9	Carcinoma in situ of other and unspecified urinary organs	Diagnosis	ICD-9-CM
234	Carcinoma in situ of other and unspecified sites	Diagnosis	ICD-9-CM
234.0	Carcinoma in situ of eye	Diagnosis	ICD-9-CM
234.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-9-CM
234.9	Carcinoma in situ, site unspecified	Diagnosis	ICD-9-CM
235	Neoplasm of uncertain behavior of digestive and respiratory systems	Diagnosis	ICD-9-CM
235.0	Neoplasm of uncertain behavior of major salivary glands	Diagnosis	ICD-9-CM
235.1	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
235.2	Neoplasm of uncertain behavior of stomach, intestines, and rectum	Diagnosis	ICD-9-CM
235.3	Neoplasm of uncertain behavior of liver and biliary passages	Diagnosis	ICD-9-CM
235.4	Neoplasm of uncertain behavior of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
235.5	Neoplasm of uncertain behavior of other and unspecified digestive organs	Diagnosis	ICD-9-CM
235.6	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-9-CM
235.7	Neoplasm of uncertain behavior of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
235.8	Neoplasm of uncertain behavior of pleura, thymus, and mediastinum	Diagnosis	ICD-9-CM
235.9	Neoplasm of uncertain behavior of other and unspecified respiratory organs	Diagnosis	ICD-9-CM
236	Neoplasm of uncertain behavior of genitourinary organs	Diagnosis	ICD-9-CM
236.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-9-CM
236.1	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-9-CM
236.2	Neoplasm of uncertain behavior of ovary	Diagnosis	ICD-9-CM
236.3	Neoplasm of uncertain behavior of other and unspecified female genital organs	Diagnosis	ICD-9-CM
236.4	Neoplasm of uncertain behavior of testis	Diagnosis	ICD-9-CM
236.5	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
236.6	Neoplasm of uncertain behavior of other and unspecified male genital organs	Diagnosis	ICD-9-CM
236.7	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-9-CM
236.9	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
236.90	Neoplasm of uncertain behavior of urinary organ, unspecified	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
236.99	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
237	Neoplasm of uncertain behavior of endocrine glands and nervous system	Diagnosis	ICD-9-CM
237.0	Neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
237.1	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-9-CM
237.2	Neoplasm of uncertain behavior of adrenal gland	Diagnosis	ICD-9-CM
237.3	Neoplasm of uncertain behavior of paraganglia	Diagnosis	ICD-9-CM
237.4	Neoplasm of uncertain behavior of other and unspecified endocrine glands	Diagnosis	ICD-9-CM
237.5	Neoplasm of uncertain behavior of brain and spinal cord	Diagnosis	ICD-9-CM
237.6	Neoplasm of uncertain behavior of meninges	Diagnosis	ICD-9-CM
237.7	Neurofibromatosis	Diagnosis	ICD-9-CM
237.70	Neurofibromatosis, unspecified	Diagnosis	ICD-9-CM
237.71	Neurofibromatosis, Type 1 (von Recklinghausen's disease)	Diagnosis	ICD-9-CM
237.72	Neurofibromatosis, Type 2 (acoustic neurofibromatosis)	Diagnosis	ICD-9-CM
237.73	Schwannomatosis	Diagnosis	ICD-9-CM
237.79	Other neurofibromatosis	Diagnosis	ICD-9-CM
237.9	Neoplasm of uncertain behavior of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
238	Neoplasm of uncertain behavior of other and unspecified sites and tissues	Diagnosis	ICD-9-CM
238.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-9-CM
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-9-CM
238.2	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-9-CM
238.3	Neoplasm of uncertain behavior of breast	Diagnosis	ICD-9-CM
238.4	Neoplasm of uncertain behavior of polycythemia vera	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
238.5	Neoplasm of uncertain behavior of histiocytic and mast cells	Diagnosis	ICD-9-CM
238.6	Neoplasm of uncertain behavior of plasma cells	Diagnosis	ICD-9-CM
238.7	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.71	Essential thrombocythemia	Diagnosis	ICD-9-CM
238.72	Low grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.73	High grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.74	Myelodysplastic syndrome with 5q deletion	Diagnosis	ICD-9-CM
238.75	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-9-CM
238.76	Myelofibrosis with myeloid metaplasia	Diagnosis	ICD-9-CM
238.77	Post-transplant lymphoproliferative disorder [PTLD]	Diagnosis	ICD-9-CM
238.79	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.8	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-9-CM
238.9	Neoplasm of uncertain behavior, site unspecified	Diagnosis	ICD-9-CM
239	Neoplasms of unspecified nature	Diagnosis	ICD-9-CM
239.0	Neoplasm of unspecified nature of digestive system	Diagnosis	ICD-9-CM
239.1	Neoplasm of unspecified nature of respiratory system	Diagnosis	ICD-9-CM
239.2	Neoplasms of unspecified nature of bone, soft tissue, and skin	Diagnosis	ICD-9-CM
239.3	Neoplasm of unspecified nature of breast	Diagnosis	ICD-9-CM
239.4	Neoplasm of unspecified nature of bladder	Diagnosis	ICD-9-CM
239.5	Neoplasm of unspecified nature of other genitourinary organs	Diagnosis	ICD-9-CM
239.6	Neoplasm of unspecified nature of brain	Diagnosis	ICD-9-CM
239.7	Neoplasm of unspecified nature of endocrine glands and other parts of nervous system	Diagnosis	ICD-9-CM
239.8	Neoplasm of unspecified nature of other specified sites	Diagnosis	ICD-9-CM
239.81	Neoplasms of unspecified nature, retina and choroid	Diagnosis	ICD-9-CM
239.89	Neoplasms of unspecified nature, other specified sites	Diagnosis	ICD-9-CM
239.9	Neoplasm of unspecified nature, site unspecified	Diagnosis	ICD-9-CM
273.3	Macroglobulinemia	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E00X0M	Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E0130M	Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E0230M	Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03003	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03005	Introduction of Other Antineoplastic into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300M	Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330M	Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04005	Introduction of Other Antineoplastic into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400M	Introduction of Monoclonal Antibody into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430M	Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05003	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05005	Introduction of Other Antineoplastic into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500M	Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530M	Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06003	Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06005	Introduction of Other Antineoplastic into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600M	Introduction of Monoclonal Antibody into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630M	Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E09305	Introduction of Other Antineoplastic into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E0930M	Introduction of Monoclonal Antibody into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E09705	Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0970M	Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E09X05	Introduction of Other Antineoplastic into Nose, External Approach	Procedure	ICD-10-PCS
3E09X0M	Introduction of Monoclonal Antibody into Nose, External Approach	Procedure	ICD-10-PCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0A30M	Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B305	Introduction of Other Antineoplastic into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B30M	Introduction of Monoclonal Antibody into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B705	Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0B70M	Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0BX05	Introduction of Other Antineoplastic into Ear, External Approach	Procedure	ICD-10-PCS
3E0BX0M	Introduction of Monoclonal Antibody into Ear, External Approach	Procedure	ICD-10-PCS
3E0C305	Introduction of Other Antineoplastic into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C30M	Introduction of Monoclonal Antibody into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C705	Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0C70M	Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0CX05	Introduction of Other Antineoplastic into Eye, External Approach	Procedure	ICD-10-PCS
3E0CX0M	Introduction of Monoclonal Antibody into Eye, External Approach	Procedure	ICD-10-PCS
3E0D305	Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D30M	Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D705	Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0D70M	Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0DX05	Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0DX0M	Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0E305	Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E30M	Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E705	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E70M	Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E805	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0E80M	Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0F30M	Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F70M	Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F80M	Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G30M	Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G70M	Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G80M	Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H30M	Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H70M	Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H80M	Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J30M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J70M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J80M	Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K30M	Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K70M	Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K80M	Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L30M	Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0L70M	Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M30M	Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M70M	Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N30M	Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N70M	Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0N80M	Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P30M	Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P70M	Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P80M	Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0Q005	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q00M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q30M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0Q70M	Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R303	Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R30M	Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S303	Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S30M	Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U305	Introduction of Other Antineoplastic into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U30M	Introduction of Monoclonal Antibody into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V30M	Introduction of Monoclonal Antibody into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W30M	Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y30M	Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Y70M	Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
55859	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	Exposure of prostate, any approach, for insertion of radioactive substance; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	Procedure	CPT-4
55865	Exposure of prostate, any approach, for insertion of radioactive substance; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	Procedure	CPT-4
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
76950	Ultrasonic guidance for placement of radiation therapy fields	Procedure	CPT-4
76960	Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography	Procedure	CPT-4
77280	Therapeutic radiology simulation-aided field setting; simple	Procedure	CPT-4
77285	Therapeutic radiology simulation-aided field setting; intermediate	Procedure	CPT-4
77290	Therapeutic radiology simulation-aided field setting; complex	Procedure	CPT-4
77295	3-dimensional radiotherapy plan, including dose-volume histograms	Procedure	CPT-4
77299	Unlisted procedure, therapeutic radiology clinical treatment planning	Procedure	CPT-4
77300	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	Procedure	CPT-4
77305	Teletherapy, isodose plan (whether hand or computer calculated); simple (1 or 2 parallel opposed unmodified ports directed to a single area of interest)	Procedure	CPT-4
77310	Teletherapy, isodose plan (whether hand or computer calculated); intermediate (3 or more treatment ports directed to a single area of interest)	Procedure	CPT-4
77315	Teletherapy, isodose plan (whether hand or computer calculated); complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex blocking, rotational beam, or special beam considerations)	Procedure	CPT-4
77321	Special teletherapy port plan, particles, hemibody, total body	Procedure	CPT-4
77326	Brachytherapy isodose plan; simple (calculation made from single plane, 1 to 4 sources/ribbon application, remote afterloading brachytherapy, 1 to 8 sources)	Procedure	CPT-4
77327	Brachytherapy isodose plan; intermediate (multiplane dosage calculations, application involving 5 to 10 sources/ribbons, remote afterloading brachytherapy, 9 to 12 sources)	Procedure	CPT-4
77328	Brachytherapy isodose plan; complex (multiplane isodose plan, volume implant calculations, over 10 sources/ribbons used, special spatial reconstruction, remote afterloading brachytherapy, over 12 sources)	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day	Procedure	CPT-4
77402	Radiation treatment delivery,=>1 MeV; simple	Procedure	CPT-4
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater	Procedure	CPT-4
77407	Radiation treatment delivery, =>1 MeV; intermediate	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 6-10 MeV	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 11-19 MeV	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, =>1 MeV; complex	Procedure	CPT-4
77413	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4
77416	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)	Procedure	CPT-4
77761	Intracavitary radiation source application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radiation source application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radiation source application; intermediate	Procedure	CPT-4
77778	Interstitial radiation source application; complex	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of low dose rate radionuclide source	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4
79005	Radiopharmaceutical therapy, by oral administration	Procedure	CPT-4
79101	Radiopharmaceutical therapy, by intravenous administration	Procedure	CPT-4
79200	Radiopharmaceutical therapy, by intracavitary administration	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4
79400	Radiopharmaceutical therapy, nonthyroid, nonhematologic by intervenous injection	Procedure	CPT-4
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion	Procedure	CPT-4
79420	Intravascular radiopharmaceutical therapy, particulate	Procedure	CPT-4
79440	Radiopharmaceutical therapy, by intra-articular administration	Procedure	CPT-4
79900	Provision of therapeutic radiopharmaceutical(s)	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	Chemotherapy administration, intra-arterial; push technique	Procedure	CPT-4
96422	Chemotherapy administration, intra-arterial; infusion technique, up to 1 hour	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96440	Chemotherapy administration into pleural cavity, requiring and including thoracentesis	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4
96542	Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents	Procedure	CPT-4
96549	Unlisted chemotherapy procedure	Procedure	CPT-4
99.25	Injection or infusion of cancer chemotherapeutic substance	Procedure	ICD-9-CM
99.28	Injection or infusion of biological response modifier [BRM] as an antineoplastic agent	Procedure	ICD-9-CM
999.81	Extravasation of vesicant chemotherapy	Diagnosis	ICD-9-CM
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	Procedure	HCPCS
C00	Malignant neoplasm of lip	Diagnosis	ICD-10-CM
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02	Malignant neoplasm of other and unspecified parts of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM
C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03	Malignant neoplasm of gum	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04	Malignant neoplasm of floor of mouth	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05	Malignant neoplasm of palate	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM
C06.8	Malignant neoplasm of overlapping sites of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08	Malignant neoplasm of other and unspecified major salivary glands	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM
C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09	Malignant neoplasm of tonsil	Diagnosis	ICD-10-CM
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10	Malignant neoplasm of oropharynx	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C1084	Denileukin diftitox, 300 mcg, ontak iv	Procedure	HCPCS
C1086	Temozolomide, 5 mg, temodar	Procedure	HCPCS
C11	Malignant neoplasm of nasopharynx	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM
C1166	Injection, cytarabine liposome, per 10 mg	Procedure	HCPCS
C1167	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
C1178	Injection, busulfan, per 6 mg	Procedure	HCPCS
C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13	Malignant neoplasm of hypopharynx	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15	Malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16	Malignant neoplasm of stomach	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM
C17	Malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM
C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18	Malignant neoplasm of colon	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21	Malignant neoplasm of anus and anal canal	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24	Malignant neoplasm of other and unspecified parts of biliary tract	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25	Malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26	Malignant neoplasm of other and ill-defined digestive organs	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30	Malignant neoplasm of nasal cavity and middle ear	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM
C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31	Malignant neoplasm of accessory sinuses	Diagnosis	ICD-10-CM
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32	Malignant neoplasm of larynx	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34	Malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C34.0	Malignant neoplasm of main bronchus	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.1	Malignant neoplasm of upper lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.3	Malignant neoplasm of lower lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.8	Malignant neoplasm of overlapping sites of bronchus and lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.9	Malignant neoplasm of unspecified part of bronchus or lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM
C38	Malignant neoplasm of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40	Malignant neoplasm of bone and articular cartilage of limbs	Diagnosis	ICD-10-CM
C40.0	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.1	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.2	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM
C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.3	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.8	Malignant neoplasm of overlapping sites of bone and articular cartilage of limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.9	Malignant neoplasm of unspecified bones and articular cartilage of limb	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41	Malignant neoplasm of bone and articular cartilage of other and unspecified sites	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43	Malignant melanoma of skin	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.1	Malignant melanoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.111	Malignant melanoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.112	Malignant melanoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.121	Malignant melanoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.122	Malignant melanoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.2	Malignant melanoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.3	Malignant melanoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.5	Malignant melanoma of trunk	Diagnosis	ICD-10-CM
C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.6	Malignant melanoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.7	Malignant melanoma of lower limb, including hip	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.101	Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.102	Unspecified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.109	Unspecified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.112	Basal cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.119	Basal cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C44.122	Squamous cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.129	Squamous cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.191	Other specified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.192	Other specified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.199	Other specified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.201	Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.202	Unspecified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.209	Unspecified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.291	Other specified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.292	Other specified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.299	Other specified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face	Diagnosis	ICD-10-CM
C44.301	Unspecified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.309	Unspecified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.310	Basal cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.311	Basal cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.319	Basal cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.320	Squamous cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.321	Squamous cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.329	Squamous cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.390	Other specified malignant neoplasm of skin of unspecified parts of face	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C44.391	Other specified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.399	Other specified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.40	Unspecified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.41	Basal cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.42	Squamous cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.49	Other specified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.500	Unspecified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.501	Unspecified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.509	Unspecified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.510	Basal cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.511	Basal cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.519	Basal cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.520	Squamous cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.521	Squamous cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.529	Squamous cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.590	Other specified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.591	Other specified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.599	Other specified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.601	Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.602	Unspecified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.609	Unspecified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C44.691	Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.692	Other specified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.699	Other specified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.701	Unspecified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.702	Unspecified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.709	Unspecified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.712	Basal cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.719	Basal cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.791	Other specified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.792	Other specified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.799	Other specified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.80	Unspecified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.81	Basal cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.82	Squamous cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.89	Other specified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.90	Unspecified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C44.91	Basal cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.92	Squamous cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.99	Other specified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C45	Mesothelioma	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM
C46	Kaposi's sarcoma	Diagnosis	ICD-10-CM
C46.0	Kaposi's sarcoma of skin	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.5	Kaposi's sarcoma of lung	Diagnosis	ICD-10-CM
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM
C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47	Malignant neoplasm of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.1	Malignant neoplasm of peripheral nerves of upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.2	Malignant neoplasm of peripheral nerves of lower limb, including hip	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49	Malignant neoplasm of other connective and soft tissue	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.1	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.2	Malignant neoplasm of connective and soft tissue of lower limb, including hip	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM
C49.A	Gastrointestinal stromal tumor	Diagnosis	ICD-10-CM
C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A	Merkel cell carcinoma	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.1	Merkel cell carcinoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.2	Merkel cell carcinoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.3	Merkel cell carcinoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.5	Merkel cell carcinoma of trunk	Diagnosis	ICD-10-CM
C4A.51	Merkel cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C4A.52	Merkel cell carcinoma of skin of breast	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.6	Merkel cell carcinoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.7	Merkel cell carcinoma of lower limb, including hip	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50	Malignant neoplasm of breast	Diagnosis	ICD-10-CM
C50.0	Malignant neoplasm of nipple and areola	Diagnosis	ICD-10-CM
C50.01	Malignant neoplasm of nipple and areola, female	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.02	Malignant neoplasm of nipple and areola, male	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.1	Malignant neoplasm of central portion of breast	Diagnosis	ICD-10-CM
C50.11	Malignant neoplasm of central portion of breast, female	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.12	Malignant neoplasm of central portion of breast, male	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.2	Malignant neoplasm of upper-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.21	Malignant neoplasm of upper-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.22	Malignant neoplasm of upper-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.3	Malignant neoplasm of lower-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.31	Malignant neoplasm of lower-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.32	Malignant neoplasm of lower-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.4	Malignant neoplasm of upper-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.41	Malignant neoplasm of upper-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.42	Malignant neoplasm of upper-outer quadrant of breast, male	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.5	Malignant neoplasm of lower-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.51	Malignant neoplasm of lower-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.52	Malignant neoplasm of lower-outer quadrant of breast, male	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.6	Malignant neoplasm of axillary tail of breast	Diagnosis	ICD-10-CM
C50.61	Malignant neoplasm of axillary tail of breast, female	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.62	Malignant neoplasm of axillary tail of breast, male	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.8	Malignant neoplasm of overlapping sites of breast	Diagnosis	ICD-10-CM
C50.81	Malignant neoplasm of overlapping sites of breast, female	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.82	Malignant neoplasm of overlapping sites of breast, male	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.9	Malignant neoplasm of breast of unspecified site	Diagnosis	ICD-10-CM
C50.91	Malignant neoplasm of breast of unspecified site, female	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.92	Malignant neoplasm of breast of unspecified site, male	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
C51	Malignant neoplasm of vulva	Diagnosis	ICD-10-CM
C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53	Malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54	Malignant neoplasm of corpus uteri	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56	Malignant neoplasm of ovary	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-10-CM
C57.0	Malignant neoplasm of fallopian tube	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.1	Malignant neoplasm of broad ligament	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.2	Malignant neoplasm of round ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM
C60	Malignant neoplasm of penis	Diagnosis	ICD-10-CM
C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62	Malignant neoplasm of testis	Diagnosis	ICD-10-CM
C62.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.1	Malignant neoplasm of descended testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM
C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.9	Malignant neoplasm of testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63	Malignant neoplasm of other and unspecified male genital organs	Diagnosis	ICD-10-CM
C63.0	Malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.1	Malignant neoplasm of spermatic cord	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM
C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64	Malignant neoplasm of kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65	Malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66	Malignant neoplasm of ureter	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67	Malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68	Malignant neoplasm of other and unspecified urinary organs	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69	Malignant neoplasm of eye and adnexa	Diagnosis	ICD-10-CM
C69.0	Malignant neoplasm of conjunctiva	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.1	Malignant neoplasm of cornea	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM
C69.2	Malignant neoplasm of retina	Diagnosis	ICD-10-CM
C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.3	Malignant neoplasm of choroid	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.4	Malignant neoplasm of ciliary body	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.5	Malignant neoplasm of lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.6	Malignant neoplasm of orbit	Diagnosis	ICD-10-CM
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM
C69.8	Malignant neoplasm of overlapping sites of eye and adnexa	Diagnosis	ICD-10-CM
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.9	Malignant neoplasm of unspecified site of eye	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70	Malignant neoplasm of meninges	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71	Malignant neoplasm of brain	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM
C72	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system	Diagnosis	ICD-10-CM
C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.2	Malignant neoplasm of olfactory nerve	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.3	Malignant neoplasm of optic nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.4	Malignant neoplasm of acoustic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM
C72.5	Malignant neoplasm of other and unspecified cranial nerves	Diagnosis	ICD-10-CM
C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74	Malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C74.0	Malignant neoplasm of cortex of adrenal gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.1	Malignant neoplasm of medulla of adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.9	Malignant neoplasm of unspecified part of adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.4	Malignant neoplasm of upper limb	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.5	Malignant neoplasm of lower limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78	Secondary malignant neoplasm of respiratory and digestive organs	Diagnosis	ICD-10-CM
C78.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.3	Secondary malignant neoplasm of other and unspecified respiratory organs	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.8	Secondary malignant neoplasm of other and unspecified digestive organs	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79	Secondary malignant neoplasm of other and unspecified sites	Diagnosis	ICD-10-CM
C79.0	Secondary malignant neoplasm of kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.1	Secondary malignant neoplasm of bladder and other and unspecified urinary organs	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-10-CM
C79.3	Secondary malignant neoplasm of brain and cerebral meninges	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM
C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.4	Secondary malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM
C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM
C7A	Malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.0	Malignant carcinoid tumors	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.01	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.02	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.09	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B	Secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B.0	Secondary carcinoid tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80	Malignant neoplasm without specification of site	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C81	Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.0	Nodular lymphocyte predominant Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.1	Nodular sclerosis Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.2	Mixed cellularity Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.3	Lymphocyte depleted Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.4	Lymphocyte-rich Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.7	Other Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.9	Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82	Follicular lymphoma	Diagnosis	ICD-10-CM
C82.0	Follicular lymphoma grade I	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.1	Follicular lymphoma grade II	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.2	Follicular lymphoma grade III, unspecified	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.3	Follicular lymphoma grade IIIa	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.4	Follicular lymphoma grade IIIb	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.5	Diffuse follicle center lymphoma	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.6	Cutaneous follicle center lymphoma	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.8	Other types of follicular lymphoma	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.9	Follicular lymphoma, unspecified	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83	Non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.0	Small cell B-cell lymphoma	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.1	Mantle cell lymphoma	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.3	Diffuse large B-cell lymphoma	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.5	Lymphoblastic (diffuse) lymphoma	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.7	Burkitt lymphoma	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.8	Other non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.9	Non-follicular (diffuse) lymphoma, unspecified	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84	Mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.0	Mycosis fungoides	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.1	Sezary disease	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.4	Peripheral T-cell lymphoma, not classified	Diagnosis	ICD-10-CM
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.6	Anaplastic large cell lymphoma, ALK-positive	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.7	Anaplastic large cell lymphoma, ALK-negative	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.9	Mature T/NK-cell lymphomas, unspecified	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A	Cutaneous T-cell lymphoma, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z	Other mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85	Other specified and unspecified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.1	Unspecified B-cell lymphoma	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.2	Mediastinal (thymic) large B-cell lymphoma	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.8	Other specified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.9	Non-Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86	Other specified types of T/NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88	Malignant immunoproliferative diseases and certain other B-cell lymphomas	Diagnosis	ICD-10-CM
C88.0	Waldenstrom macroglobulinemia	Diagnosis	ICD-10-CM
C88.2	Heavy chain disease	Diagnosis	ICD-10-CM
C88.3	Immunoproliferative small intestinal disease	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C88.9	Malignant immunoproliferative disease, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C90	Multiple myeloma and malignant plasma cell neoplasms	Diagnosis	ICD-10-CM
C90.0	Multiple myeloma	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.1	Plasma cell leukemia	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.11	Plasma cell leukemia in remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.2	Extramedullary plasmacytoma	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.21	Extramedullary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.3	Solitary plasmacytoma	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.31	Solitary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C9004	Injection, gemtuzumab ozogamicin, per 5 mg	Procedure	HCPCS
C9012	Injection, arsenic trioxide, per 1 mg/kg	Procedure	HCPCS
C9017	Lomustine, 10 mg	Procedure	HCPCS
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9024	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C91	Lymphoid leukemia	Diagnosis	ICD-10-CM
C91.0	Acute lymphoblastic leukemia [ALL]	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.01	Acute lymphoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C91.1	Chronic lymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.11	Chronic lymphocytic leukemia of B-cell type in remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.3	Prolymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.31	Prolymphocytic leukemia of B-cell type, in remission	Diagnosis	ICD-10-CM
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.4	Hairy cell leukemia	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.41	Hairy cell leukemia, in remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.5	Adult T-cell lymphoma/leukemia (HTLV-1-associated)	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission	Diagnosis	ICD-10-CM
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.6	Prolymphocytic leukemia of T-cell type	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.61	Prolymphocytic leukemia of T-cell type, in remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.9	Lymphoid leukemia, unspecified	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C91.91	Lymphoid leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A	Mature B-cell leukemia Burkitt-type	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A1	Mature B-cell leukemia Burkitt-type, in remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z	Other lymphoid leukemia	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z1	Other lymphoid leukemia, in remission	Diagnosis	ICD-10-CM
C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C9110	Injection, alemtuzumab, per 10 mg/ ml	Procedure	HCPCS
C9127	Injection, paclitaxel protein-bound particles, per 1 mg	Procedure	HCPCS
C9129	Injection, clofarabine, per 1 mg	Procedure	HCPCS
C92	Myeloid leukemia	Diagnosis	ICD-10-CM
C92.0	Acute myeloblastic leukemia	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.01	Acute myeloblastic leukemia, in remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.1	Chronic myeloid leukemia, BCR/ABL-positive	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.2	Atypical chronic myeloid leukemia, BCR/ABL-negative	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.3	Myeloid sarcoma	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.31	Myeloid sarcoma, in remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.4	Acute promyelocytic leukemia	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.41	Acute promyelocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.5	Acute myelomonocytic leukemia	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.51	Acute myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.6	Acute myeloid leukemia with 11q23-abnormality	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.9	Myeloid leukemia, unspecified	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.91	Myeloid leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A	Acute myeloid leukemia with multilineage dysplasia	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z	Other myeloid leukemia	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z1	Other myeloid leukemia, in remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C9205	Injection, oxaliplatin, per 5 mg	Procedure	HCPCS
C9207	Injection, bortezomib, per 3.5 mg	Procedure	HCPCS
C9213	Injection, pemetrexed, per 10 mg	Procedure	HCPCS
C9214	Injection, bevacizumab, per 10 mg	Procedure	HCPCS
C9215	Injection, cetuximab, per 10 mg	Procedure	HCPCS
C9218	Injection, azacitidine, per 1 mg	Procedure	HCPCS
C9231	Injection, decitabine, per 1 mg	Procedure	HCPCS
C9235	Injection, panitumumab, 10 mg	Procedure	HCPCS
C9239	Injection, temsirolimus, 1 mg	Procedure	HCPCS
C9240	Injection, ixabepilone, 1 mg	Procedure	HCPCS
C9243	Injection, bendamustine hcl, 1 mg	Procedure	HCPCS
C9253	Injection, temozolomide, 1mg	Procedure	HCPCS
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C93	Monocytic leukemia	Diagnosis	ICD-10-CM
C93.0	Acute monoblastic/monocytic leukemia	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.1	Chronic myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.3	Juvenile myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.9	Monocytic leukemia, unspecified	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z	Other monocytic leukemia	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94	Other leukemias of specified cell type	Diagnosis	ICD-10-CM
C94.0	Acute erythroid leukemia	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.2	Acute megakaryoblastic leukemia	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.3	Mast cell leukemia	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.4	Acute panmyelosis with myelofibrosis	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.41	Acute panmyelosis with myelofibrosis, in remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.8	Other specified leukemias	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS
C9440	Vinorelbine tartrate, brand name, per 10 mg	Procedure	HCPCS
C9474	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
C95	Leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.9	Leukemia, unspecified	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.2	Malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.6	Unifocal Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D00.00	Carcinoma in situ of oral cavity, unspecified site	Diagnosis	ICD-10-CM
D00.01	Carcinoma in situ of labial mucosa and vermilion border	Diagnosis	ICD-10-CM
D00.02	Carcinoma in situ of buccal mucosa	Diagnosis	ICD-10-CM
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge	Diagnosis	ICD-10-CM
D00.04	Carcinoma in situ of soft palate	Diagnosis	ICD-10-CM
D00.05	Carcinoma in situ of hard palate	Diagnosis	ICD-10-CM
D00.06	Carcinoma in situ of floor of mouth	Diagnosis	ICD-10-CM
D00.07	Carcinoma in situ of tongue	Diagnosis	ICD-10-CM
D00.08	Carcinoma in situ of pharynx	Diagnosis	ICD-10-CM
D00.1	Carcinoma in situ of esophagus	Diagnosis	ICD-10-CM
D00.2	Carcinoma in situ of stomach	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
D01.3	Carcinoma in situ of anus and anal canal	Diagnosis	ICD-10-CM
D01.40	Carcinoma in situ of unspecified part of intestine	Diagnosis	ICD-10-CM
D01.49	Carcinoma in situ of other parts of intestine	Diagnosis	ICD-10-CM
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D01.7	Carcinoma in situ of other specified digestive organs	Diagnosis	ICD-10-CM
D01.9	Carcinoma in situ of digestive organ, unspecified	Diagnosis	ICD-10-CM
D02.0	Carcinoma in situ of larynx	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D02.1	Carcinoma in situ of trachea	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
D02.3	Carcinoma in situ of other parts of respiratory system	Diagnosis	ICD-10-CM
D02.4	Carcinoma in situ of respiratory system, unspecified	Diagnosis	ICD-10-CM
D03.0	Melanoma in situ of lip	Diagnosis	ICD-10-CM
D03.10	Melanoma in situ of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D03.11	Melanoma in situ of right eyelid, including canthus	Diagnosis	ICD-10-CM
D03.12	Melanoma in situ of left eyelid, including canthus	Diagnosis	ICD-10-CM
D03.20	Melanoma in situ of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D03.21	Melanoma in situ of right ear and external auricular canal	Diagnosis	ICD-10-CM
D03.22	Melanoma in situ of left ear and external auricular canal	Diagnosis	ICD-10-CM
D03.30	Melanoma in situ of unspecified part of face	Diagnosis	ICD-10-CM
D03.39	Melanoma in situ of other parts of face	Diagnosis	ICD-10-CM
D03.4	Melanoma in situ of scalp and neck	Diagnosis	ICD-10-CM
D03.51	Melanoma in situ of anal skin	Diagnosis	ICD-10-CM
D03.52	Melanoma in situ of breast (skin) (soft tissue)	Diagnosis	ICD-10-CM
D03.59	Melanoma in situ of other part of trunk	Diagnosis	ICD-10-CM
D03.60	Melanoma in situ of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.61	Melanoma in situ of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.62	Melanoma in situ of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.70	Melanoma in situ of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D03.71	Melanoma in situ of right lower limb, including hip	Diagnosis	ICD-10-CM
D03.72	Melanoma in situ of left lower limb, including hip	Diagnosis	ICD-10-CM
D03.8	Melanoma in situ of other sites	Diagnosis	ICD-10-CM
D03.9	Melanoma in situ, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D04.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-10-CM
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D04.11	Carcinoma in situ of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
D04.12	Carcinoma in situ of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D04.21	Carcinoma in situ of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
D04.22	Carcinoma in situ of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
D04.30	Carcinoma in situ of skin of unspecified part of face	Diagnosis	ICD-10-CM
D04.39	Carcinoma in situ of skin of other parts of face	Diagnosis	ICD-10-CM
D04.4	Carcinoma in situ of skin of scalp and neck	Diagnosis	ICD-10-CM
D04.5	Carcinoma in situ of skin of trunk	Diagnosis	ICD-10-CM
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D04.71	Carcinoma in situ of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
D04.72	Carcinoma in situ of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
D04.8	Carcinoma in situ of skin of other sites	Diagnosis	ICD-10-CM
D04.9	Carcinoma in situ of skin, unspecified	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D06.0	Carcinoma in situ of endocervix	Diagnosis	ICD-10-CM
D06.1	Carcinoma in situ of exocervix	Diagnosis	ICD-10-CM
D06.7	Carcinoma in situ of other parts of cervix	Diagnosis	ICD-10-CM
D06.9	Carcinoma in situ of cervix, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
D07.1	Carcinoma in situ of vulva	Diagnosis	ICD-10-CM
D07.2	Carcinoma in situ of vagina	Diagnosis	ICD-10-CM
D07.30	Carcinoma in situ of unspecified female genital organs	Diagnosis	ICD-10-CM
D07.39	Carcinoma in situ of other female genital organs	Diagnosis	ICD-10-CM
D07.4	Carcinoma in situ of penis	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
D07.60	Carcinoma in situ of unspecified male genital organs	Diagnosis	ICD-10-CM
D07.61	Carcinoma in situ of scrotum	Diagnosis	ICD-10-CM
D07.69	Carcinoma in situ of other male genital organs	Diagnosis	ICD-10-CM
D09.0	Carcinoma in situ of bladder	Diagnosis	ICD-10-CM
D09.10	Carcinoma in situ of unspecified urinary organ	Diagnosis	ICD-10-CM
D09.19	Carcinoma in situ of other urinary organs	Diagnosis	ICD-10-CM
D09.20	Carcinoma in situ of unspecified eye	Diagnosis	ICD-10-CM
D09.21	Carcinoma in situ of right eye	Diagnosis	ICD-10-CM
D09.22	Carcinoma in situ of left eye	Diagnosis	ICD-10-CM
D09.3	Carcinoma in situ of thyroid and other endocrine glands	Diagnosis	ICD-10-CM
D09.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-10-CM
D09.9	Carcinoma in situ, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D25.0	Submucous leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.1	Intramural leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.2	Subserosal leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.9	Leiomyoma of uterus, unspecified	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.1	Neoplasm of uncertain behavior of stomach	Diagnosis	ICD-10-CM
D37.2	Neoplasm of uncertain behavior of small intestine	Diagnosis	ICD-10-CM
D37.3	Neoplasm of uncertain behavior of appendix	Diagnosis	ICD-10-CM
D37.4	Neoplasm of uncertain behavior of colon	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D3A.00	Benign carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
D3A.010	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
D3A.011	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
D3A.012	Benign carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.020	Benign carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
D3A.021	Benign carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
D3A.022	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
D3A.023	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
D3A.024	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
D3A.025	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
D3A.026	Benign carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.090	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
D3A.091	Benign carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
D3A.092	Benign carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
D3A.093	Benign carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
D3A.094	Benign carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
D3A.095	Benign carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D3A.096	Benign carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
D3A.098	Benign carcinoid tumors of other sites	Diagnosis	ICD-10-CM
D3A.8	Other benign neuroendocrine tumors	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.3	Essential (hemorrhagic) thrombocythemia	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z2	Castleman disease	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D70.1	Agranulocytosis secondary to cancer chemotherapy	Diagnosis	ICD-10-CM
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	Procedure	HCPCS
G3001	Administration and supply of tositumomab, 450 mg	Procedure	HCPCS
G9835	Trastuzumab administered within 12 months of diagnosis	Procedure	HCPCS
G9837	Trastuzumab not administered within 12 months of diagnosis	Procedure	HCPCS
J0202	Injection, alemtuzumab, 1 mg	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J0594	Injection, busulfan, 1 mg	Procedure	HCPCS
J0894	Injection, decitabine, 1 mg	Procedure	HCPCS
J7527	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8510	Busulfan, oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8561	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
J8600	Melphalan, oral, 2 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, NOS	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9001	Injection, doxorubicin HCl, all lipid formulations, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS
J9010	Injection, alemtuzumab, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9027	Injection, clofarabine, 1 mg	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9034	Injection, bendamustine HCl (Bendeka), 1 mg	Procedure	HCPCS
J9035	Injection, bevacizumab, 10 mg	Procedure	HCPCS
J9036	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9041	Injection, bortezomib (Velcade), 0.1 mg	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS
J9050	Injection, carmustine, 100 mg	Procedure	HCPCS
J9055	Injection, cetuximab, 10 mg	Procedure	HCPCS
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9098	Injection, cytarabine liposome, 10 mg	Procedure	HCPCS
J9100	Injection, cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
J9160	Injection, denileukin diftitox, 300 mcg	Procedure	HCPCS
J9170	Injection, docetaxel, 20 mg	Procedure	HCPCS
J9171	Injection, docetaxel, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9178	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9180	Epirubicin HCl, 50 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9182	Etoposide, 100 mg	Procedure	HCPCS
J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS
J9200	Injection, floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9205	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS
J9211	Injection, idarubicin HCl, 5 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9261	Injection, nelarabine, 50 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Injection, pentostatin, 10 mg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9270	Injection, plicamycin, 2.5 mg	Procedure	HCPCS
J9280	Injection, mitomycin, 5 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS
J9305	Injection, pemetrexed, NOS, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9307	Injection, pralatrexate, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9311	Injection, rituximab 10 mg and hyaluronidase	Procedure	HCPCS
J9312	Injection, rituximab, 10 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9320	Injection, streptozocin, 1 g	Procedure	HCPCS
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9340	Injection, thiotepa, 15 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	Procedure	HCPCS
J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Injection, vinorelbine tartrate, 10 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS
O9A.1	Malignant neoplasm complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O9A.11	Malignant neoplasm complicating pregnancy	Diagnosis	ICD-10-CM
O9A.111	Malignant neoplasm complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A.112	Malignant neoplasm complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A.113	Malignant neoplasm complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A.119	Malignant neoplasm complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.13	Malignant neoplasm complicating the puerperium	Diagnosis	ICD-10-CM
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM
Q9979	Injection, Alemtuzumab, 1 mg	Procedure	HCPCS
R97.21	Rising PSA following treatment for malignant neoplasm of prostate	Diagnosis	ICD-10-CM
S0087	Injection, alemtuzumab, 30 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
S0108	Mercaptopurine, oral, 50 mg	Procedure	HCPCS
S0115	Bortezomib, 3.5 mg	Procedure	HCPCS
S0116	Bevacizumab, 100 mg	Procedure	HCPCS
S0168	Injection, azacitidine, 100 mg	Procedure	HCPCS
S0172	Chlorambucil, oral, 2 mg	Procedure	HCPCS
S0176	Hydroxyurea, oral, 500 mg	Procedure	HCPCS
S0178	Lomustine, oral, 10 mg	Procedure	HCPCS
S0182	Procarbazine HCl, oral, 50 mg	Procedure	HCPCS
T80.810	Extravasation of vesicant antineoplastic chemotherapy	Diagnosis	ICD-10-CM
T80.810A	Extravasation of vesicant antineoplastic chemotherapy, initial encounter	Diagnosis	ICD-10-CM
T80.810D	Extravasation of vesicant antineoplastic chemotherapy, subsequent encounter	Diagnosis	ICD-10-CM
V10	Personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.0	Personal history of malignant neoplasm of gastrointestinal tract	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
V10.00	Personal history of malignant neoplasm of unspecified site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.01	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-9-CM
V10.02	Personal history of malignant neoplasm of other and unspecified parts of oral cavity and pharynx	Diagnosis	ICD-9-CM
V10.03	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
V10.04	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-9-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
V10.07	Personal history of malignant neoplasm of liver	Diagnosis	ICD-9-CM
V10.09	Personal history of malignant neoplasm of other site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.1	Personal history of malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
V10.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-9-CM
V10.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-9-CM
V10.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-9-CM
V10.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
V10.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
V10.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
V10.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-9-CM
V10.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
V10.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-9-CM
V10.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-9-CM
V10.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-9-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
V10.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
V10.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
V10.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-9-CM
V10.5	Personal history of malignant neoplasm of urinary organs	Diagnosis	ICD-9-CM
V10.50	Personal history of malignant neoplasm of unspecified urinary organ	Diagnosis	ICD-9-CM
V10.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-9-CM
V10.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-9-CM
V10.53	Personal history of malignant neoplasm, renal pelvis	Diagnosis	ICD-9-CM
V10.59	Personal history of malignant neoplasm of other urinary organ	Diagnosis	ICD-9-CM
V10.6	Personal history of leukemia	Diagnosis	ICD-9-CM
V10.60	Personal history of unspecified leukemia	Diagnosis	ICD-9-CM
V10.61	Personal history of lymphoid leukemia	Diagnosis	ICD-9-CM
V10.62	Personal history of myeloid leukemia	Diagnosis	ICD-9-CM
V10.63	Personal history of monocytic leukemia	Diagnosis	ICD-9-CM
V10.69	Personal history of other leukemia	Diagnosis	ICD-9-CM
V10.7	Personal history of other lymphatic and hematopoietic neoplasms	Diagnosis	ICD-9-CM
V10.71	Personal history of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
V10.72	Personal history of Hodgkin's disease	Diagnosis	ICD-9-CM
V10.79	Personal history of other lymphatic and hematopoietic neoplasm	Diagnosis	ICD-9-CM
V10.8	Personal history of malignant neoplasm of other sites	Diagnosis	ICD-9-CM
V10.81	Personal history of malignant neoplasm of bone	Diagnosis	ICD-9-CM
V10.82	Personal history of malignant melanoma of skin	Diagnosis	ICD-9-CM
V10.83	Personal history of other malignant neoplasm of skin	Diagnosis	ICD-9-CM
V10.84	Personal history of malignant neoplasm of eye	Diagnosis	ICD-9-CM
V10.85	Personal history of malignant neoplasm of brain	Diagnosis	ICD-9-CM
V10.86	Personal history of malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
V10.87	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-9-CM
V10.88	Personal history of malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
V10.89	Personal history of malignant neoplasm of other site	Diagnosis	ICD-9-CM
V10.9	Other and unspecified personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.90	Personal history of unspecified malignant neoplasm	Diagnosis	ICD-9-CM
V10.91	Personal history of malignant neuroendocrine tumor	Diagnosis	ICD-9-CM
V58.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-9-CM
V58.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-9-CM
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW033B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW043B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXR5	Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy	Diagnosis	ICD-10-CM
Z51.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z51.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-10-CM
Z85	Personal history of malignant neoplasm	Diagnosis	ICD-10-CM
Z85.0	Personal history of malignant neoplasm of digestive organs	Diagnosis	ICD-10-CM
Z85.00	Personal history of malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
Z85.01	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
Z85.02	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.020	Personal history of malignant carcinoid tumor of stomach	Diagnosis	ICD-10-CM
Z85.028	Personal history of other malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.03	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.04	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.05	Personal history of malignant neoplasm of liver	Diagnosis	ICD-10-CM
Z85.06	Personal history of malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.060	Personal history of malignant carcinoid tumor of small intestine	Diagnosis	ICD-10-CM
Z85.068	Personal history of other malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.07	Personal history of malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
Z85.09	Personal history of malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
Z85.1	Personal history of malignant neoplasm of trachea, bronchus and lung	Diagnosis	ICD-10-CM
Z85.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-10-CM
Z85.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z85.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-10-CM
Z85.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-10-CM
Z85.23	Personal history of malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.230	Personal history of malignant carcinoid tumor of thymus	Diagnosis	ICD-10-CM
Z85.238	Personal history of other malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z85.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
Z85.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-10-CM
Z85.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Z85.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-10-CM
Z85.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-10-CM
Z85.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Z85.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-10-CM
Z85.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
Z85.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-10-CM
Z85.5	Personal history of malignant neoplasm of urinary tract	Diagnosis	ICD-10-CM
Z85.50	Personal history of malignant neoplasm of unspecified urinary tract organ	Diagnosis	ICD-10-CM
Z85.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-10-CM
Z85.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.520	Personal history of malignant carcinoid tumor of kidney	Diagnosis	ICD-10-CM
Z85.528	Personal history of other malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.53	Personal history of malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
Z85.54	Personal history of malignant neoplasm of ureter	Diagnosis	ICD-10-CM
Z85.59	Personal history of malignant neoplasm of other urinary tract organ	Diagnosis	ICD-10-CM

Appendix J. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z85.6	Personal history of leukemia	Diagnosis	ICD-10-CM
Z85.7	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.71	Personal history of Hodgkin lymphoma	Diagnosis	ICD-10-CM
Z85.72	Personal history of non-Hodgkin lymphomas	Diagnosis	ICD-10-CM
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.8	Personal history of malignant neoplasms of other organs and systems	Diagnosis	ICD-10-CM
Z85.81	Personal history of malignant neoplasm of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.810	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-10-CM
Z85.818	Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.819	Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.82	Personal history of malignant neoplasm of skin	Diagnosis	ICD-10-CM
Z85.820	Personal history of malignant melanoma of skin	Diagnosis	ICD-10-CM
Z85.821	Personal history of Merkel cell carcinoma	Diagnosis	ICD-10-CM
Z85.828	Personal history of other malignant neoplasm of skin	Diagnosis	ICD-10-CM
Z85.83	Personal history of malignant neoplasm of bone and soft tissue	Diagnosis	ICD-10-CM
Z85.830	Personal history of malignant neoplasm of bone	Diagnosis	ICD-10-CM
Z85.831	Personal history of malignant neoplasm of soft tissue	Diagnosis	ICD-10-CM
Z85.84	Personal history of malignant neoplasm of eye and nervous tissue	Diagnosis	ICD-10-CM
Z85.840	Personal history of malignant neoplasm of eye	Diagnosis	ICD-10-CM
Z85.841	Personal history of malignant neoplasm of brain	Diagnosis	ICD-10-CM
Z85.848	Personal history of malignant neoplasm of other parts of nervous tissue	Diagnosis	ICD-10-CM
Z85.85	Personal history of malignant neoplasm of endocrine glands	Diagnosis	ICD-10-CM
Z85.850	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-10-CM
Z85.858	Personal history of malignant neoplasm of other endocrine glands	Diagnosis	ICD-10-CM
Z85.89	Personal history of malignant neoplasm of other organs and systems	Diagnosis	ICD-10-CM
Z85.9	Personal history of malignant neoplasm, unspecified	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
	Achalasia		
530.0	Achalasia and cardiospasm	Diagnosis	ICD-9-CM
K22.0	Achalasia of cardia	Diagnosis	ICD-10-CM
	Alcoholic Cirrhosis of the Liver		
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
	Alcoholic Hepatitis		
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
	Alcoholic Liver Damage		
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
	Alcoholic Liver Disease		
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
	Alcohol-Related Disorders		
291	Alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303	Alcohol dependence syndrome	Diagnosis	ICD-9-CM
303.0	Acute alcoholic intoxication	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.03	Acute alcoholic intoxication, in remission	Diagnosis	ICD-9-CM
303.9	Other and unspecified alcohol dependence	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
303.93	Other and unspecified alcohol dependence, in remission	Diagnosis	ICD-9-CM
305.0	Nondependent alcohol abuse	Diagnosis	ICD-9-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
V11.3	Personal history of alcoholism	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
	Alpha 1-Antitrypsin Deficiency		
273.4	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-9-CM
E88.01	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-10-CM
	Barrett's Esophagus		
530.85	Barrett's esophagus	Diagnosis	ICD-9-CM
K22.70	Barrett's esophagus without dysplasia	Diagnosis	ICD-10-CM
K22.710	Barrett's esophagus with low grade dysplasia	Diagnosis	ICD-10-CM
K22.711	Barrett's esophagus with high grade dysplasia	Diagnosis	ICD-10-CM
K22.719	Barrett's esophagus with dysplasia, unspecified	Diagnosis	ICD-10-CM
	Biliary Cirrhosis		
571.6	Biliary cirrhosis	Diagnosis	ICD-9-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
	Bladder Stones		
574.0	Calculus of gallbladder with acute cholecystitis	Diagnosis	ICD-9-CM
574.00	Calculus of gallbladder with acute cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.01	Calculus of gallbladder with acute cholecystitis and obstruction	Diagnosis	ICD-9-CM
574.1	Calculus of gallbladder with other cholecystitis	Diagnosis	ICD-9-CM
574.10	Calculus of gallbladder with other cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.11	Calculus of gallbladder with other cholecystitis and obstruction	Diagnosis	ICD-9-CM
574.2	Calculus of gallbladder without mention of cholecystitis	Diagnosis	ICD-9-CM
574.20	Calculus of gallbladder without mention of cholecystitis or obstruction	Diagnosis	ICD-9-CM
574.21	Calculus of gallbladder without mention of cholecystitis, with obstruction	Diagnosis	ICD-9-CM
574.6	Calculus of gallbladder and bile duct with acute cholecystitis	Diagnosis	ICD-9-CM
574.60	Calculus of gallbladder and bile duct with acute cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.61	Calculus of gallbladder and bile duct with acute cholecystitis, with obstruction	Diagnosis	ICD-9-CM
574.7	Calculus of gallbladder and bile duct with other cholecystitis	Diagnosis	ICD-9-CM
574.70	Calculus of gallbladder and bile duct with other cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.71	Calculus of gallbladder and bile duct with other cholecystitis, with obstruction	Diagnosis	ICD-9-CM
574.8	Calculus of gallbladder and bile duct with acute and chronic cholecystitis	Diagnosis	ICD-9-CM
574.80	Calculus of gallbladder and bile duct with acute and chronic cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.81	Calculus of gallbladder and bile duct with acute and chronic cholecystitis, with obstruction	Diagnosis	ICD-9-CM
574.9	Calculus of gallbladder and bile duct without cholecystitis	Diagnosis	ICD-9-CM
574.90	Calculus of gallbladder and bile duct without cholecystitis, without mention of obstruction	Diagnosis	ICD-9-CM
574.91	Calculus of gallbladder and bile duct without cholecystitis, with obstruction	Diagnosis	ICD-9-CM
594.0	Calculus in diverticulum of bladder	Diagnosis	ICD-9-CM
594.1	Other calculus in bladder	Diagnosis	ICD-9-CM
N20	Calculus of kidney and ureter	Diagnosis	ICD-10-CM
N20.0	Calculus of kidney	Diagnosis	ICD-10-CM
N20.1	Calculus of ureter	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N20.2	Calculus of kidney with calculus of ureter	Diagnosis	ICD-10-CM
N20.9	Urinary calculus, unspecified	Diagnosis	ICD-10-CM
N21	Calculus of lower urinary tract	Diagnosis	ICD-10-CM
N21.0	Calculus in bladder	Diagnosis	ICD-10-CM
N21.1	Calculus in urethra	Diagnosis	ICD-10-CM
N21.8	Other lower urinary tract calculus	Diagnosis	ICD-10-CM
N21.9	Calculus of lower urinary tract, unspecified	Diagnosis	ICD-10-CM
N22	Calculus of urinary tract in diseases classified elsewhere	Diagnosis	ICD-10-CM
N23	Unspecified renal colic	Diagnosis	ICD-10-CM
	Cholangitis		
576.1	Cholangitis	Diagnosis	ICD-9-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
	Cholelithiasis		
751.69	Other congenital anomaly of gallbladder, bile ducts, and liver	Diagnosis	ICD-9-CM
Q44.0	Agenesis, aplasia and hypoplasia of gallbladder	Diagnosis	ICD-10-CM
Q44.1	Other congenital malformations of gallbladder	Diagnosis	ICD-10-CM
Q44.4	Choledochal cyst	Diagnosis	ICD-10-CM
Q44.5	Other congenital malformations of bile ducts	Diagnosis	ICD-10-CM
Q44.7	Other congenital malformations of liver	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
	Cirrhosis		
571.5	Cirrhosis of liver without mention of alcohol	Diagnosis	ICD-9-CM
571.6	Biliary cirrhosis	Diagnosis	ICD-9-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
	Chronic Obstructive Pulmonary Disease		
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
	Colon Cancer Screening		
0D5E4ZZ	Destruction of Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5E8ZZ	Destruction of Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5F4ZZ	Destruction of Right Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5F8ZZ	Destruction of Right Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5G4ZZ	Destruction of Left Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5G8ZZ	Destruction of Left Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5H4ZZ	Destruction of Cecum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5H8ZZ	Destruction of Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5K4ZZ	Destruction of Ascending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5K8ZZ	Destruction of Ascending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5L4ZZ	Destruction of Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5L8ZZ	Destruction of Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D5M4ZZ	Destruction of Descending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5M8ZZ	Destruction of Descending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D5N4ZZ	Destruction of Sigmoid Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5N8ZZ	Destruction of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D9E3ZX	Drainage of Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9E4ZX	Drainage of Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9E7ZX	Drainage of Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9E8ZX	Drainage of Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9F3ZX	Drainage of Right Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9F4ZX	Drainage of Right Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9F7ZX	Drainage of Right Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9F8ZX	Drainage of Right Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9G3ZX	Drainage of Left Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9G4ZX	Drainage of Left Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9G7ZX	Drainage of Left Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9G8ZX	Drainage of Left Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9H3ZX	Drainage of Cecum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9H4ZX	Drainage of Cecum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9H7ZX	Drainage of Cecum, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9H8ZX	Drainage of Cecum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9K3ZX	Drainage of Ascending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9K4ZX	Drainage of Ascending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9K7ZX	Drainage of Ascending Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9K8ZX	Drainage of Ascending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9L3ZX	Drainage of Transverse Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9L4ZX	Drainage of Transverse Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9L7ZX	Drainage of Transverse Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9L8ZX	Drainage of Transverse Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9M3ZX	Drainage of Descending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D9M4ZX	Drainage of Descending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9M7ZX	Drainage of Descending Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9M8ZX	Drainage of Descending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9N3ZX	Drainage of Sigmoid Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9N4ZX	Drainage of Sigmoid Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9N7ZX	Drainage of Sigmoid Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9N8ZX	Drainage of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0D9P3ZX	Drainage of Rectum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0D9P4ZX	Drainage of Rectum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0D9P7ZX	Drainage of Rectum, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0D9P8ZX	Drainage of Rectum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBE0ZZ	Excision of Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBE3ZX	Excision of Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBE3ZZ	Excision of Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBE4ZX	Excision of Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBE4ZZ	Excision of Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBE7ZX	Excision of Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBE7ZZ	Excision of Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBE8ZX	Excision of Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBE8ZZ	Excision of Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBF0ZZ	Excision of Right Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBF3ZX	Excision of Right Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBF3ZZ	Excision of Right Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBF4ZX	Excision of Right Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBF7ZX	Excision of Right Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBF7ZZ	Excision of Right Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBF8ZX	Excision of Right Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0DBF8ZZ	Excision of Right Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBG0ZZ	Excision of Left Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBG3ZX	Excision of Left Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBG3ZZ	Excision of Left Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBG4ZX	Excision of Left Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBG7ZX	Excision of Left Large Intestine, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBG7ZZ	Excision of Left Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBG8ZX	Excision of Left Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBG8ZZ	Excision of Left Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBH0ZZ	Excision of Cecum, Open Approach	Procedure	ICD-10-PCS
0DBH3ZX	Excision of Cecum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBH3ZZ	Excision of Cecum, Percutaneous Approach	Procedure	ICD-10-PCS
0DBH4ZX	Excision of Cecum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBH7ZX	Excision of Cecum, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBH7ZZ	Excision of Cecum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBH8ZX	Excision of Cecum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBH8ZZ	Excision of Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBK0ZZ	Excision of Ascending Colon, Open Approach	Procedure	ICD-10-PCS
0DBK3ZX	Excision of Ascending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBK3ZZ	Excision of Ascending Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBK4ZX	Excision of Ascending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBK7ZX	Excision of Ascending Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBK7ZZ	Excision of Ascending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBK8ZX	Excision of Ascending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBK8ZZ	Excision of Ascending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBL0ZZ	Excision of Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0DBL3ZX	Excision of Transverse Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0DBL3ZZ	Excision of Transverse Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBL4ZX	Excision of Transverse Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBL7ZX	Excision of Transverse Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBL7ZZ	Excision of Transverse Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBL8ZX	Excision of Transverse Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBL8ZZ	Excision of Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBM0ZZ	Excision of Descending Colon, Open Approach	Procedure	ICD-10-PCS
0DBM3ZX	Excision of Descending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBM3ZZ	Excision of Descending Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBM4ZX	Excision of Descending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBM7ZX	Excision of Descending Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBM7ZZ	Excision of Descending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBM8ZX	Excision of Descending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBM8ZZ	Excision of Descending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBN0ZZ	Excision of Sigmoid Colon, Open Approach	Procedure	ICD-10-PCS
0DBN3ZX	Excision of Sigmoid Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBN3ZZ	Excision of Sigmoid Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBN4ZX	Excision of Sigmoid Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBN7ZX	Excision of Sigmoid Colon, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBN7ZZ	Excision of Sigmoid Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBN8ZX	Excision of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DBN8ZZ	Excision of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBP3ZX	Excision of Rectum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DBP4ZX	Excision of Rectum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DBP4ZZ	Excision of Rectum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBP7ZX	Excision of Rectum, Via Natural or Artificial Opening, Diagnostic	Procedure	ICD-10-PCS
0DBP8ZX	Excision of Rectum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0DBP8ZZ	Excision of Rectum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DDE3ZX	Extraction of Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDE4ZX	Extraction of Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDE8ZX	Extraction of Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDF3ZX	Extraction of Right Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDF4ZX	Extraction of Right Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDF8ZX	Extraction of Right Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDG3ZX	Extraction of Left Large Intestine, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDG4ZX	Extraction of Left Large Intestine, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDG8ZX	Extraction of Left Large Intestine, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDH3ZX	Extraction of Cecum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDH4ZX	Extraction of Cecum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDH8ZX	Extraction of Cecum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDK3ZX	Extraction of Ascending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDK4ZX	Extraction of Ascending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDK8ZX	Extraction of Ascending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDL3ZX	Extraction of Transverse Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDL4ZX	Extraction of Transverse Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDL8ZX	Extraction of Transverse Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDM3ZX	Extraction of Descending Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDM4ZX	Extraction of Descending Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDM8ZX	Extraction of Descending Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDN3ZX	Extraction of Sigmoid Colon, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDN4ZX	Extraction of Sigmoid Colon, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0DDN8ZX	Extraction of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DDP3ZX	Extraction of Rectum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0DDP4ZX	Extraction of Rectum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0DDP8ZX	Extraction of Rectum, Via Natural or Artificial Opening Endoscopic, Diagnostic	Procedure	ICD-10-PCS
0DJD4ZZ	Inspection of Lower Intestinal Tract, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DJD8ZZ	Inspection of Lower Intestinal Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
44388	Colonoscopy through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Procedure	CPT-4
44389	Colonoscopy through stoma; with biopsy, single or multiple	Procedure	CPT-4
44390	Colonoscopy through stoma; with removal of foreign body(s)	Procedure	CPT-4
44391	Colonoscopy through stoma; with control of bleeding, any method	Procedure	CPT-4
44392	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	Procedure	CPT-4
44393	Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	Procedure	CPT-4
44394	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	Procedure	CPT-4
44397	Colonoscopy through stoma; with transendoscopic stent placement (includes predilation)	Procedure	CPT-4
45.21	Transabdominal endoscopy of large intestine	Procedure	ICD-9-CM
45.22	Endoscopy of large intestine through artificial stoma	Procedure	ICD-9-CM
45.23	Colonoscopy	Procedure	ICD-9-CM
45.24	Flexible sigmoidoscopy	Procedure	ICD-9-CM
45.25	Closed [endoscopic] biopsy of large intestine	Procedure	ICD-9-CM
45.41	Excision of lesion or tissue of large intestine	Procedure	ICD-9-CM
45.42	Endoscopic polypectomy of large intestine	Procedure	ICD-9-CM
45.43	Endoscopic destruction of other lesion or tissue of large intestine	Procedure	ICD-9-CM
45300	Proctosigmoidoscopy, rigid; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)	Procedure	CPT-4
45303	Proctosigmoidoscopy, rigid; with dilation (eg, balloon, guide wire, bougie)	Procedure	CPT-4
45305	Proctosigmoidoscopy, rigid; with biopsy, single or multiple	Procedure	CPT-4
45307	Proctosigmoidoscopy, rigid; with removal of foreign body	Procedure	CPT-4
45308	Proctosigmoidoscopy, rigid; with removal of single tumor, polyp, or other lesion by hot biopsy forceps or bipolar cautery	Procedure	CPT-4

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
45309	Proctosigmoidoscopy, rigid; with removal of single tumor, polyp, or other lesion by snare technique	Procedure	CPT-4
45315	Proctosigmoidoscopy, rigid; with removal of multiple tumors, polyps, or other lesions by hot biopsy forceps, bipolar cautery or snare technique	Procedure	CPT-4
45317	Proctosigmoidoscopy, rigid; with control of bleeding (eg, injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)	Procedure	CPT-4
45320	Proctosigmoidoscopy, rigid; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique (eg, laser)	Procedure	CPT-4
45321	Proctosigmoidoscopy, rigid; with decompression of volvulus	Procedure	CPT-4
45327	Proctosigmoidoscopy, rigid; with transendoscopic stent placement (includes predilation)	Procedure	CPT-4
45330	Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Procedure	CPT-4
45331	Sigmoidoscopy, flexible; with biopsy, single or multiple	Procedure	CPT-4
45332	Sigmoidoscopy, flexible; with removal of foreign body(s)	Procedure	CPT-4
45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	Procedure	CPT-4
45334	Sigmoidoscopy, flexible; with control of bleeding, any method	Procedure	CPT-4
45335	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance	Procedure	CPT-4
45337	Sigmoidoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed	Procedure	CPT-4
45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	Procedure	CPT-4
45339	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	Procedure	CPT-4
45340	Sigmoidoscopy, flexible; with transendoscopic balloon dilation	Procedure	CPT-4
45341	Sigmoidoscopy, flexible; with endoscopic ultrasound examination	Procedure	CPT-4
45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)	Procedure	CPT-4
45345	Sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)	Procedure	CPT-4
45355	Colonoscopy, rigid or flexible, transabdominal via colotomy, single or multiple	Procedure	CPT-4
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Procedure	CPT-4

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
45379	Colonoscopy, flexible; with removal of foreign body(s)	Procedure	CPT-4
45380	Colonoscopy, flexible; with biopsy, single or multiple	Procedure	CPT-4
45381	Colonoscopy, flexible; with directed submucosal injection(s), any substance	Procedure	CPT-4
45382	Colonoscopy, flexible; with control of bleeding, any method	Procedure	CPT-4
45383	Colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	Procedure	CPT-4
45384	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	Procedure	CPT-4
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	Procedure	CPT-4
45386	Colonoscopy, flexible; with transendoscopic balloon dilation	Procedure	CPT-4
45387	Colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)	Procedure	CPT-4
45391	Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures	Procedure	CPT-4
48.21	Transabdominal proctosigmoidoscopy	Procedure	ICD-9-CM
48.22	Proctosigmoidoscopy through artificial stoma	Procedure	ICD-9-CM
48.23	Rigid proctosigmoidoscopy	Procedure	ICD-9-CM
48.24	Closed (endoscopic) biopsy of rectum	Procedure	ICD-9-CM
48.36	[Endoscopic] polypectomy of rectum	Procedure	ICD-9-CM
82270	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)	Procedure	CPT-4
82271	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources	Procedure	CPT-4
82272	Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening	Procedure	CPT-4
82273	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources	Procedure	CPT-4
82274	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous	Procedure	CPT-4
G0104	Colorectal cancer screening; flexible sigmoidoscopy	Procedure	HCPCS
G0105	Colorectal cancer screening; colonoscopy on individual at high risk	Procedure	HCPCS
G0107	Colorectal cancer screening; fecal-occult blood test, 1-3 simultaneous determinations	Procedure	HCPCS

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	Procedure	HCPCS
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, one to three simultaneous determinations	Procedure	HCPCS
	Cystitis		
595	Cystitis	Diagnosis	ICD-9-CM
595.0	Acute cystitis	Diagnosis	ICD-9-CM
595.1	Chronic interstitial cystitis	Diagnosis	ICD-9-CM
595.2	Other chronic cystitis	Diagnosis	ICD-9-CM
595.4	Cystitis in diseases classified elsewhere	Diagnosis	ICD-9-CM
595.8	Other specified types of cystitis	Diagnosis	ICD-9-CM
595.81	Cystitis cystica	Diagnosis	ICD-9-CM
595.82	Irradiation cystitis	Diagnosis	ICD-9-CM
595.89	Other specified types of cystitis	Diagnosis	ICD-9-CM
595.9	Unspecified cystitis	Diagnosis	ICD-9-CM
A56.01	Chlamydial cystitis and urethritis	Diagnosis	ICD-10-CM
N30.00	Acute cystitis without hematuria	Diagnosis	ICD-10-CM
N30.01	Acute cystitis with hematuria	Diagnosis	ICD-10-CM
N30.10	Interstitial cystitis (chronic) without hematuria	Diagnosis	ICD-10-CM
N30.11	Interstitial cystitis (chronic) with hematuria	Diagnosis	ICD-10-CM
N30.20	Other chronic cystitis without hematuria	Diagnosis	ICD-10-CM
N30.21	Other chronic cystitis with hematuria	Diagnosis	ICD-10-CM
N30.40	Irradiation cystitis without hematuria	Diagnosis	ICD-10-CM
N30.41	Irradiation cystitis with hematuria	Diagnosis	ICD-10-CM
N30.80	Other cystitis without hematuria	Diagnosis	ICD-10-CM
N30.81	Other cystitis with hematuria	Diagnosis	ICD-10-CM
N30.90	Cystitis, unspecified without hematuria	Diagnosis	ICD-10-CM
N30.91	Cystitis, unspecified with hematuria	Diagnosis	ICD-10-CM
	Diabetes		

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
250	Diabetes mellitus	Diagnosis	ICD-9-CM
250.0	Diabetes mellitus without mention of complication	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.1	Diabetes with ketoacidosis	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.2	Diabetes with hyperosmolarity	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.3	Diabetes with other coma	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.4	Diabetes with renal manifestations	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.5	Diabetes with ophthalmic manifestations	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.6	Diabetes with neurological manifestations	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.7	Diabetes with peripheral circulatory disorders	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.8	Diabetes with other specified manifestations	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.9	Diabetes with unspecified complication	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Crohn's Disease		
555	Regional enteritis	Diagnosis	ICD-9-CM
555.0	Regional enteritis of small intestine	Diagnosis	ICD-9-CM
555.1	Regional enteritis of large intestine	Diagnosis	ICD-9-CM
555.2	Regional enteritis of small intestine with large intestine	Diagnosis	ICD-9-CM
555.9	Regional enteritis of unspecified site	Diagnosis	ICD-9-CM
K50.0	Crohn's disease of small intestine	Diagnosis	ICD-10-CM
K50.00	Crohn's disease of small intestine without complications	Diagnosis	ICD-10-CM
K50.01	Crohn's disease of small intestine with complications	Diagnosis	ICD-10-CM
K50.011	Crohn's disease of small intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.012	Crohn's disease of small intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.013	Crohn's disease of small intestine with fistula	Diagnosis	ICD-10-CM
K50.014	Crohn's disease of small intestine with abscess	Diagnosis	ICD-10-CM
K50.018	Crohn's disease of small intestine with other complication	Diagnosis	ICD-10-CM
K50.019	Crohn's disease of small intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.1	Crohn's disease of large intestine	Diagnosis	ICD-10-CM
K50.10	Crohn's disease of large intestine without complications	Diagnosis	ICD-10-CM
K50.11	Crohn's disease of large intestine with complications	Diagnosis	ICD-10-CM
K50.111	Crohn's disease of large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.112	Crohn's disease of large intestine with intestinal obstruction	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K50.113	Crohn's disease of large intestine with fistula	Diagnosis	ICD-10-CM
K50.114	Crohn's disease of large intestine with abscess	Diagnosis	ICD-10-CM
K50.118	Crohn's disease of large intestine with other complication	Diagnosis	ICD-10-CM
K50.119	Crohn's disease of large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.8	Crohn's disease of both small and large intestine	Diagnosis	ICD-10-CM
K50.80	Crohn's disease of both small and large intestine without complications	Diagnosis	ICD-10-CM
K50.81	Crohn's disease of both small and large intestine with complications	Diagnosis	ICD-10-CM
K50.811	Crohn's disease of both small and large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.813	Crohn's disease of both small and large intestine with fistula	Diagnosis	ICD-10-CM
K50.814	Crohn's disease of both small and large intestine with abscess	Diagnosis	ICD-10-CM
K50.818	Crohn's disease of both small and large intestine with other complication	Diagnosis	ICD-10-CM
K50.819	Crohn's disease of both small and large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.9	Crohn's disease, unspecified	Diagnosis	ICD-10-CM
K50.90	Crohn's disease, unspecified, without complications	Diagnosis	ICD-10-CM
K50.91	Crohn's disease, unspecified, with complications	Diagnosis	ICD-10-CM
K50.911	Crohn's disease, unspecified, with rectal bleeding	Diagnosis	ICD-10-CM
K50.912	Crohn's disease, unspecified, with intestinal obstruction	Diagnosis	ICD-10-CM
K50.913	Crohn's disease, unspecified, with fistula	Diagnosis	ICD-10-CM
K50.914	Crohn's disease, unspecified, with abscess	Diagnosis	ICD-10-CM
K50.918	Crohn's disease, unspecified, with other complication	Diagnosis	ICD-10-CM
K50.919	Crohn's disease, unspecified, with unspecified complications	Diagnosis	ICD-10-CM
	Ulcerative Colitis		
556.0	Ulcerative (chronic) enterocolitis	Diagnosis	ICD-9-CM
556.1	Ulcerative (chronic) ileocolitis	Diagnosis	ICD-9-CM
556.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-9-CM
556.3	Ulcerative (chronic) proctosigmoiditis	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
556.5	Left sided ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.6	Universal ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.8	Other ulcerative colitis	Diagnosis	ICD-9-CM
556.9	Unspecified ulcerative colitis	Diagnosis	ICD-9-CM
560.89	Other specified intestinal obstruction	Diagnosis	ICD-9-CM
569.5	Abscess of intestine	Diagnosis	ICD-9-CM
569.81	Fistula of intestine, excluding rectum and anus	Diagnosis	ICD-9-CM
K51.0	Ulcerative (chronic) pancolitis	Diagnosis	ICD-10-CM
K51.00	Ulcerative (chronic) pancolitis without complications	Diagnosis	ICD-10-CM
K51.01	Ulcerative (chronic) pancolitis with complications	Diagnosis	ICD-10-CM
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.013	Ulcerative (chronic) pancolitis with fistula	Diagnosis	ICD-10-CM
K51.014	Ulcerative (chronic) pancolitis with abscess	Diagnosis	ICD-10-CM
K51.018	Ulcerative (chronic) pancolitis with other complication	Diagnosis	ICD-10-CM
K51.019	Ulcerative (chronic) pancolitis with unspecified complications	Diagnosis	ICD-10-CM
K51.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-10-CM
K51.20	Ulcerative (chronic) proctitis without complications	Diagnosis	ICD-10-CM
K51.21	Ulcerative (chronic) proctitis with complications	Diagnosis	ICD-10-CM
K51.211	Ulcerative (chronic) proctitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.213	Ulcerative (chronic) proctitis with fistula	Diagnosis	ICD-10-CM
K51.214	Ulcerative (chronic) proctitis with abscess	Diagnosis	ICD-10-CM
K51.218	Ulcerative (chronic) proctitis with other complication	Diagnosis	ICD-10-CM
K51.219	Ulcerative (chronic) proctitis with unspecified complications	Diagnosis	ICD-10-CM
K51.3	Ulcerative (chronic) rectosigmoiditis	Diagnosis	ICD-10-CM
K51.30	Ulcerative (chronic) rectosigmoiditis without complications	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K51.31	Ulcerative (chronic) rectosigmoiditis with complications	Diagnosis	ICD-10-CM
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding	Diagnosis	ICD-10-CM
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula	Diagnosis	ICD-10-CM
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess	Diagnosis	ICD-10-CM
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication	Diagnosis	ICD-10-CM
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications	Diagnosis	ICD-10-CM
K51.5	Left sided colitis	Diagnosis	ICD-10-CM
K51.50	Left sided colitis without complications	Diagnosis	ICD-10-CM
K51.51	Left sided colitis with complications	Diagnosis	ICD-10-CM
K51.511	Left sided colitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.512	Left sided colitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.513	Left sided colitis with fistula	Diagnosis	ICD-10-CM
K51.514	Left sided colitis with abscess	Diagnosis	ICD-10-CM
K51.518	Left sided colitis with other complication	Diagnosis	ICD-10-CM
K51.519	Left sided colitis with unspecified complications	Diagnosis	ICD-10-CM
K51.8	Other ulcerative colitis	Diagnosis	ICD-10-CM
K51.80	Other ulcerative colitis without complications	Diagnosis	ICD-10-CM
K51.81	Other ulcerative colitis with complications	Diagnosis	ICD-10-CM
K51.811	Other ulcerative colitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.812	Other ulcerative colitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.813	Other ulcerative colitis with fistula	Diagnosis	ICD-10-CM
K51.814	Other ulcerative colitis with abscess	Diagnosis	ICD-10-CM
K51.818	Other ulcerative colitis with other complication	Diagnosis	ICD-10-CM
K51.819	Other ulcerative colitis with unspecified complications	Diagnosis	ICD-10-CM
K51.9	Ulcerative colitis, unspecified	Diagnosis	ICD-10-CM
K51.90	Ulcerative colitis, unspecified, without complications	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
K51.91	Ulcerative colitis, unspecified, with complications	Diagnosis	ICD-10-CM
K51.911	Ulcerative colitis, unspecified with rectal bleeding	Diagnosis	ICD-10-CM
K51.912	Ulcerative colitis, unspecified with intestinal obstruction	Diagnosis	ICD-10-CM
K51.913	Ulcerative colitis, unspecified with fistula	Diagnosis	ICD-10-CM
K51.914	Ulcerative colitis, unspecified with abscess	Diagnosis	ICD-10-CM
K51.918	Ulcerative colitis, unspecified with other complication	Diagnosis	ICD-10-CM
K51.919	Ulcerative colitis, unspecified with unspecified complications	Diagnosis	ICD-10-CM
	Dyslipoproteinemia		
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
272.5	Lipoprotein deficiencies	Diagnosis	ICD-9-CM
272.9	Unspecified disorder of lipoid metabolism	Diagnosis	ICD-9-CM
E75.6	Lipid storage disorder, unspecified	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
E78.6	Lipoprotein deficiency	Diagnosis	ICD-10-CM
E78.70	Disorder of bile acid and cholesterol metabolism, unspecified	Diagnosis	ICD-10-CM
E78.9	Disorder of lipoprotein metabolism, unspecified	Diagnosis	ICD-10-CM
	Family History of Colorectal Cancer		
V16.0	Family history of malignant neoplasm of gastrointestinal tract	Diagnosis	ICD-9-CM
Z80.0	Family history of malignant neoplasm of digestive organs	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
	Gastroesophageal Reflux Disease		
530.11	Reflux esophagitis	Diagnosis	ICD-9-CM
530.81	Esophageal reflux	Diagnosis	ICD-9-CM
K21.0	Gastro-esophageal reflux disease with esophagitis	Diagnosis	ICD-10-CM
K21.00	Gastro-esophageal reflux dis with esophagitis, without bleed	Diagnosis	ICD-10-CM
K21.01	Gastro-esophageal reflux dis with esophagitis, with bleed	Diagnosis	ICD-10-CM
K21.9	Gastro-esophageal reflux disease without esophagitis	Diagnosis	ICD-10-CM
P78.83	Newborn esophageal reflux	Diagnosis	ICD-10-CM
	Glycogen Storage Disease		
E74.0	Glycogen storage disease	Diagnosis	ICD-10-CM
E74.00	Glycogen storage disease, unspecified	Diagnosis	ICD-10-CM
E74.09	Other glycogen storage disease	Diagnosis	ICD-10-CM
	Hepatitis B Infection		
070.2	Viral hepatitis B with hepatic coma	Diagnosis	ICD-9-CM
070.20	Viral hepatitis B with hepatic coma, acute or unspecified, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.21	Viral hepatitis B with hepatic coma, acute or unspecified, with hepatitis delta	Diagnosis	ICD-9-CM
070.22	Viral hepatitis B with hepatic coma, chronic, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.23	Viral hepatitis B with hepatic coma, chronic, with hepatitis delta	Diagnosis	ICD-9-CM
070.3	Viral hepatitis B without mention of hepatic coma	Diagnosis	ICD-9-CM
070.30	Viral hepatitis B without mention of hepatic coma, acute or unspecified, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.31	Viral hepatitis B without mention of hepatic coma, acute or unspecified, with hepatitis delta	Diagnosis	ICD-9-CM
070.32	Viral hepatitis B without mention of hepatic coma, chronic, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.33	Viral hepatitis B without mention of hepatic coma, chronic, with hepatitis delta	Diagnosis	ICD-9-CM
070.42	Hepatitis delta without mention of active hepatitis B disease with hepatic coma	Diagnosis	ICD-9-CM
070.52	Hepatitis delta without mention of active hepatitis B disease or hepatic coma	Diagnosis	ICD-9-CM
70.21	Viral hepatitis B with hepatic coma, acute or unspecified, with hepatitis delta	Diagnosis	ICD-9-CM
B16	Acute hepatitis B	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
B16.0	Acute hepatitis B with delta-agent with hepatic coma	Diagnosis	ICD-10-CM
B16.1	Acute hepatitis B with delta-agent without hepatic coma	Diagnosis	ICD-10-CM
B16.2	Acute hepatitis B without delta-agent with hepatic coma	Diagnosis	ICD-10-CM
B16.9	Acute hepatitis B without delta-agent and without hepatic coma	Diagnosis	ICD-10-CM
B17.0	Acute delta-(super) infection of hepatitis B carrier	Diagnosis	ICD-10-CM
B18.0	Chronic viral hepatitis B with delta-agent	Diagnosis	ICD-10-CM
B18.1	Chronic viral hepatitis B without delta-agent	Diagnosis	ICD-10-CM
B19.1	Unspecified viral hepatitis B	Diagnosis	ICD-10-CM
B19.10	Unspecified viral hepatitis B without hepatic coma	Diagnosis	ICD-10-CM
B19.11	Unspecified viral hepatitis B with hepatic coma	Diagnosis	ICD-10-CM
V02.61	Hepatitis B carrier	Diagnosis	ICD-9-CM
Z22.51	Carrier of viral hepatitis B	Diagnosis	ICD-10-CM
	Hepatitis C Infection		
070.41	Acute hepatitis C with hepatic coma	Diagnosis	ICD-9-CM
070.44	Chronic hepatitis C with hepatic coma	Diagnosis	ICD-9-CM
070.51	Acute hepatitis C without mention of hepatic coma	Diagnosis	ICD-9-CM
070.54	Chronic hepatitis C without mention of hepatic coma	Diagnosis	ICD-9-CM
070.7	Unspecified viral hepatitis C	Diagnosis	ICD-9-CM
070.7	Unspecified viral hepatitis C without hepatic coma	Diagnosis	ICD-9-CM
070.71	Unspecified viral hepatitis C with hepatic coma	Diagnosis	ICD-9-CM
B17.1	Acute hepatitis C	Diagnosis	ICD-10-CM
B17.10	Acute hepatitis C without hepatic coma	Diagnosis	ICD-10-CM
B17.11	Acute hepatitis C with hepatic coma	Diagnosis	ICD-10-CM
B18.2	Chronic viral hepatitis C	Diagnosis	ICD-10-CM
B19.2	Unspecified viral hepatitis C	Diagnosis	ICD-10-CM
B19.20	Unspecified viral hepatitis C without hepatic coma	Diagnosis	ICD-10-CM
B19.21	Unspecified viral hepatitis C with hepatic coma	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
O98.4	Viral hepatitis complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O98.41	Viral hepatitis complicating pregnancy	Diagnosis	ICD-10-CM
O98.411	Viral hepatitis complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98.412	Viral hepatitis complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98.413	Viral hepatitis complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O98.419	Viral hepatitis complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O98.42	Viral hepatitis complicating childbirth	Diagnosis	ICD-10-CM
O98.43	Viral hepatitis complicating the puerperium	Diagnosis	ICD-10-CM
V02.62	Hepatitis C carrier	Diagnosis	ICD-9-CM
Z22.52	Carrier of viral hepatitis C	Diagnosis	ICD-10-CM
	Congestive Heart Failure		
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
425.0	Endomyocardial fibrosis	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
425.11	Hypertrophic obstructive cardiomyopathy	Diagnosis	ICD-9-CM
425.18	Other hypertrophic cardiomyopathy	Diagnosis	ICD-9-CM
425.2	Obscure cardiomyopathy of Africa	Diagnosis	ICD-9-CM
425.3	Endocardial fibroelastosis	Diagnosis	ICD-9-CM
425.4	Other primary cardiomyopathies	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
425.7	Nutritional and metabolic cardiomyopathy	Diagnosis	ICD-9-CM
425.8	Cardiomyopathy in other diseases classified elsewhere	Diagnosis	ICD-9-CM
425.9	Unspecified secondary cardiomyopathy	Diagnosis	ICD-9-CM
428	Heart failure	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.2	Systolic heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.3	Diastolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.4	Combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
514	Pulmonary congestion and hypostasis	Diagnosis	ICD-9-CM
518.4	Unspecified acute edema of lung	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42	Cardiomyopathy	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM
I42.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I42.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50	Heart failure	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.3	Diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.4	Combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.8	Other heart failure	Diagnosis	ICD-10-CM
I50.81	Right heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
J81	Pulmonary edema	Diagnosis	ICD-10-CM
J81.0	Acute pulmonary edema	Diagnosis	ICD-10-CM
J81.1	Chronic pulmonary edema	Diagnosis	ICD-10-CM
	Hemochromatosis		

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
275.01	Hereditary hemochromatosis	Diagnosis	ICD-9-CM
275.02	Hemochromatosis due to repeated red blood cell transfusions	Diagnosis	ICD-9-CM
275.03	Other hemochromatosis	Diagnosis	ICD-9-CM
E83.11	Hemochromatosis	Diagnosis	ICD-10-CM
E83.110	Hereditary hemochromatosis	Diagnosis	ICD-10-CM
E83.111	Hemochromatosis due to repeated red blood cell transfusions	Diagnosis	ICD-10-CM
E83.118	Other hemochromatosis	Diagnosis	ICD-10-CM
E83.119	Hemochromatosis, unspecified	Diagnosis	ICD-10-CM
	Human Papillomavirus		
079.4	Human papilloma virus in conditions classified elsewhere and of unspecified site	Diagnosis	ICD-9-CM
795.05	Cervical high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-9-CM
795.09	Other abnormal Papanicolaou smear of cervix and cervical HPV	Diagnosis	ICD-9-CM
795.15	Vaginal high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-9-CM
795.19	Other abnormal Papanicolaou smear of vagina and vaginal HPV	Diagnosis	ICD-9-CM
B97.7	Papillomavirus as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
R87.81	High risk human papillomavirus (HPV) DNA test positive from female genital organs	Diagnosis	ICD-10-CM
R87.810	Cervical high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
R87.811	Vaginal high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
R87.82	Low risk human papillomavirus (HPV) DNA test positive from female genital organs	Diagnosis	ICD-10-CM
R87.820	Cervical low risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
R87.821	Vaginal low risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
	Hypertension		
278.1	Localized adiposity	Diagnosis	ICD-9-CM
401	Essential hypertension	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
402.0	Malignant hypertensive heart disease	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.1	Benign hypertensive heart disease	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.9	Unspecified hypertensive heart disease	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.0	Hypertensive chronic kidney disease, malignant	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.1	Hypertensive chronic kidney disease, benign	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.9	Hypertensive chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404	Hypertensive heart and chronic kidney disease	Diagnosis	ICD-9-CM
404.0	Hypertensive heart and chronic kidney disease, malignant	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
404.1	Hypertensive heart and chronic kidney disease, benign	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.9	Hypertensive heart and chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I16.0	Hypertensive urgency	Diagnosis	ICD-10-CM
I16.1	Hypertensive emergency	Diagnosis	ICD-10-CM
I16.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
	Liver Flukes		
121.0	Opisthorchiasis	Diagnosis	ICD-9-CM
121.3	Fascioliasis	Diagnosis	ICD-9-CM
B66.0	Opisthorchiasis	Diagnosis	ICD-10-CM
B66.3	Fascioliasis	Diagnosis	ICD-10-CM
	Hormone Replacement Therapy		
V07.4	Hormone replacement therapy (postmenopausal)	Diagnosis	ICD-9-CM
Z79.890	Hormone replacement therapy	Diagnosis	ICD-10-CM
	Non-Alcoholic Steatohepatitis		
571.8	Other chronic nonalcoholic liver disease	Diagnosis	ICD-9-CM
573.3	Unspecified hepatitis	Diagnosis	ICD-9-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
	Obesity		
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.02	Overweight	Diagnosis	ICD-9-CM
278.1	Localized adiposity	Diagnosis	ICD-9-CM
783.1	Abnormal weight gain	Diagnosis	ICD-9-CM
E65	Localized adiposity	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.3	Overweight	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
R63.5	Abnormal weight gain	Diagnosis	ICD-10-CM
V77	Special screening for endocrine, nutritional, metabolic, and immunity disorders	Diagnosis	ICD-9-CM
V77.8	Screening for obesity	Diagnosis	ICD-9-CM
	Plummer-Vinson Syndrome		
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
	Porphyria Cutanea Tarda		
E80.1	Porphyria cutanea tarda	Diagnosis	ICD-10-CM
	History of Smoking		
305.1	Nondependent tobacco use disorder	Diagnosis	ICD-9-CM
649.0	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM
649.00	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
649.01	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
649.02	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication	Diagnosis	ICD-9-CM
649.03	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
649.04	Toxic effect of tobacco	Diagnosis	ICD-9-CM
989.84	Personal history of tobacco use, presenting hazards to health	Diagnosis	ICD-9-CM
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
V15.82	Nondependent tobacco use disorder	Diagnosis	ICD-9-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
	Tylosis		
A66.3	Hyperkeratosis of yaws	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
L84	Corns and callosities	Diagnosis	ICD-10-CM
	Tyrosinemia		
E70.21	Tyrosinemia	Diagnosis	ICD-10-CM
	Urinary Incontinence		
788.3	Urinary incontinence	Diagnosis	ICD-9-CM
788.30	Unspecified urinary incontinence	Diagnosis	ICD-9-CM
788.31	Urge incontinence	Diagnosis	ICD-9-CM
788.32	Stress incontinence, male	Diagnosis	ICD-9-CM
788.33	Mixed incontinence urge and stress (male)(female)	Diagnosis	ICD-9-CM
788.34	Incontinence without sensory awareness	Diagnosis	ICD-9-CM
788.35	Post-void dribbling	Diagnosis	ICD-9-CM
788.36	Nocturnal enuresis	Diagnosis	ICD-9-CM
788.37	Continuous leakage	Diagnosis	ICD-9-CM
788.38	Overflow incontinence	Diagnosis	ICD-9-CM
788.39	Other urinary incontinence	Diagnosis	ICD-9-CM
788.91	Functional urinary incontinence	Diagnosis	ICD-9-CM
N39.3	Stress incontinence (female) (male)	Diagnosis	ICD-10-CM
N39.4	Other specified urinary incontinence	Diagnosis	ICD-10-CM
N39.41	Urge incontinence	Diagnosis	ICD-10-CM
N39.42	Incontinence without sensory awareness	Diagnosis	ICD-10-CM
N39.43	Post-void dribbling	Diagnosis	ICD-10-CM
N39.44	Nocturnal enuresis	Diagnosis	ICD-10-CM
N39.45	Continuous leakage	Diagnosis	ICD-10-CM
N39.46	Mixed incontinence	Diagnosis	ICD-10-CM
N39.49	Other specified urinary incontinence	Diagnosis	ICD-10-CM
N39.490	Overflow incontinence	Diagnosis	ICD-10-CM
N39.491	Coital incontinence	Diagnosis	ICD-10-CM

Appendix K. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N39.492	Postural (urinary) incontinence	Diagnosis	ICD-10-CM
N39.498	Other specified urinary incontinence	Diagnosis	ICD-10-CM
R32	Unspecified urinary incontinence	Diagnosis	ICD-10-CM
R39.81	Functional urinary incontinence	Diagnosis	ICD-10-CM
	Urolithiasis		
592.9	Unspecified urinary calculus	Diagnosis	ICD-9-CM
N13.9	Obstructive and reflux uropathy, unspecified	Diagnosis	ICD-10-CM
N20.9	Urinary calculus, unspecified	Diagnosis	ICD-10-CM
N22	Calculus of urinary tract in diseases classified elsewhere	Diagnosis	ICD-10-CM
	Urinary Tract Infections		
599.0	Urinary tract infection, site not specified	Diagnosis	ICD-9-CM
N39.0	Urinary tract infection, site not specified	Diagnosis	ICD-10-CM
	Viral Hepatitis		
070.49	Other specified viral hepatitis with hepatic coma	Diagnosis	ICD-9-CM
070.59	Other specified viral hepatitis without mention of hepatic coma	Diagnosis	ICD-9-CM
070.9	Unspecified viral hepatitis without mention of hepatic coma	Diagnosis	ICD-9-CM
B17.8	Other specified acute viral hepatitis	Diagnosis	ICD-10-CM
B17.9	Acute viral hepatitis, unspecified	Diagnosis	ICD-10-CM
B18.8	Other chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.9	Chronic viral hepatitis, unspecified	Diagnosis	ICD-10-CM
B19.9	Unspecified viral hepatitis without hepatic coma	Diagnosis	ICD-10-CM
	Wilson's Disease		
275.1	Disorders of copper metabolism	Diagnosis	ICD-9-CM
E83.00	Disorder of copper metabolism, unspecified	Diagnosis	ICD-10-CM
E83.01	Wilson's disease	Diagnosis	ICD-10-CM
E83.09	Other disorders of copper metabolism	Diagnosis	ICD-10-CM

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Hormone Replacement Therapy	
2-methoxyestradiol	2-methoxyestradiol (bulk)
Ca/soy isofla/blk cohosh rt/magnolia/green tea leaf/caffeine	Estroplus Max Strength
PROGESTERONE,MICRONIZED	FIRST-Progesterone MC 10
PROGESTERONE,MICRONIZED	FIRST-Progesterone MC 5
TESTOSTERONE PROPIONATE	FIRST-Testosterone MC
TESTOSTERONE PROPIONATE	First-Testosterone
abiraterone acetate	Zytiga
abiraterone acetate	abiraterone
abiraterone acetate, submicronized	Yonsa
androstenedione	androstenedione (bulk)
apalutamide	Erleada
bicalutamide	Casodex
bicalutamide	bicalutamide
calcium carb/D3/soy isoflav/horsetail extract/lactobacillus	Estromineral
calcium citrate/cholecalciferol (vit D3)/isoflavonones no.2	Menopause Relief
calcium comb no.19/phosphate/genistein/D3/citrated zinc/K2	Fosteum Plus
clascoterone	Winlevi
danazol	danazol (bulk)
darolutamide	Nubeqa
dienestrol	Ortho-Dienestrol
dienestrol	dienestrol (bulk)
dietary supplement,misc.comb.20/folic acid	NewPhase Complete
diethylstilbestrol	diethylstilbestrol (bulk)
dihydrotestosterone propionate	Dihydrotestosterone Propionate
drospirenone	Slynd
drospirenone/estradiol	Angeliq
elagolix sodium/estradiol/norethindrone acetate	Oriahnn
enzalutamide	Xtandi

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
estradiol	Alora
estradiol	Climara
estradiol	Divigel
estradiol	Dotti
estradiol	Elestrin
estradiol	Esclim
estradiol	Estrace
estradiol	Estraderm
estradiol	Estradiol Transdermal Patch
estradiol	Estrasorb
estradiol	Estring
estradiol	EstroGel
estradiol	Evamist
estradiol	Gynodiol
estradiol	Lyllana
estradiol	Menostar
estradiol	Minivelle
estradiol	Vagifem
estradiol	Vivelle
estradiol	Vivelle-Dot
estradiol	Yuvafem
estradiol	estradiol
estradiol	estradiol (bulk)
estradiol acetate	Femring
estradiol acetate	Femtrace
estradiol benzoate	estradiol benzoate (bulk)
estradiol cypionate	Depo-Estradiol
estradiol cypionate	Depogen
estradiol cypionate	estradiol cypionate

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
estradiol cypionate	estradiol cypionate (bulk)
estradiol cypionate/medroxyprogesterone acetate	Lunelle
estradiol cypionate/medroxyprogesterone acetate	medroxyprogest-estradiol cyp
estradiol hemihydrate	estradiol hemihydrate (bulk)
estradiol hemihydrate, micronized	estradiol hemihyd,micro (bulk)
estradiol micronized	estradiol micronized (bulk)
estradiol valerate	Delestrogen
estradiol valerate	Dioval XX
estradiol valerate	Estroval-40
estradiol valerate	Valergen 20
estradiol valerate	estradiol valerate
estradiol valerate	estradiol valerate (bulk)
estradiol/levonorgestrel	Climara Pro
estradiol/norethindrone acetate	Activella
estradiol/norethindrone acetate	Amabelz
estradiol/norethindrone acetate	CombiPatch
estradiol/norethindrone acetate	Lopreeza
estradiol/norethindrone acetate	Mimvey
estradiol/norethindrone acetate	Mimvey Lo
estradiol/norethindrone acetate	estradiol-norethindrone acet
estradiol/norgestimate	Ortho-Prefest
estradiol/norgestimate	Prefest
estradiol/progesterone	Bijuva
estramustine phosphate sodium	Emcyt
estriol	estriol (bulk)
estriol micronized	estriol micronized (bulk)
estrogens, conjugated	Premarin
estrogens, conjugated	conjugated estrogens
estrogens, conjugated	conjugated estrogens (bulk)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
estrogens, conjugated, synthetic A	Cenestin
estrogens, conjugated, synthetic B	Enjuvia
estrogens, conjugated/bazedoxifene acetate	Duavee
estrogens, conjugated/medroxyprogesterone acetate	Premphase
estrogens, conjugated/medroxyprogesterone acetate	Prempro
estrogens,esterified	Estratab
estrogens,esterified	Menest
estrogens,esterified/methyltestosterone	Covaryx
estrogens,esterified/methyltestosterone	Covaryx H.S.
estrogens,esterified/methyltestosterone	EEMT
estrogens,esterified/methyltestosterone	EEMT HS
estrogens,esterified/methyltestosterone	Essian
estrogens,esterified/methyltestosterone	Essian H.S.
estrogens,esterified/methyltestosterone	Estratest
estrogens,esterified/methyltestosterone	Estratest H.S.
estrogens,esterified/methyltestosterone	Syntest D.S.
estrogens,esterified/methyltestosterone	Syntest H.S.
estrogens,esterified/methyltestosterone	estrogens-methyltestosterone
estrone	Estro-5
estrone	Kestrone
estrone	estrone
estrone	estrone (bulk)
estropipate	Ogen
estropipate	Ogen 0.625
estropipate	Ogen 1.25
estropipate	Ogen 2.5
estropipate	Ortho-Est 0.625
estropipate	Ortho-Est 1.25
estropipate	estropipate

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
estropipate	estropipate (bulk)
ethinyl estradiol	Estinyl
ethinyl estradiol	ethinyl estradiol (bulk)
etonogestrel	Implanon
etonogestrel	Nexplanon
etonogestrel/ethinyl estradiol	EluRyng
etonogestrel/ethinyl estradiol	NuvaRing
etonogestrel/ethinyl estradiol	etonogestrel-ethinyl estradiol
fluoxymesterone	Androxy
fluoxymesterone	Halotestin
fluoxymesterone	fluoxymesterone
fluoxymesterone	fluoxymesterone (bulk)
flutamide	Eulexin
flutamide	flutamide
fulvestrant	Faslodex
fulvestrant	fulvestrant
genistein	Stay Cool
genistein	genistein (bulk)
genistein	i-Cool
genistein/citrated zinc bisglycinate/vitamin D3	Fosteum
genistein/citrated zinc bisglycinate/vitamin D3	VP-GSTN
hydroxyprogesterone caproate	Makena
hydroxyprogesterone caproate	hydroxyprogesterone cap(ppres)
hydroxyprogesterone caproate	hydroxyprogesterone capr(bulk)
hydroxyprogesterone caproate	hydroxyprogesterone caproate
hydroxyprogesterone caproate/PF	Makena
hydroxyprogesterone caproate/PF	Makena (PF)
hydroxyprogesterone caproate/PF	hydroxyprogest(PF)(preg presv)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (1 month)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
leuprolide acetate/norethindrone acetate	Lupaneta Pack (3 month)
levonorgestrel	After Pill
levonorgestrel	Aftera
levonorgestrel	EContra EZ
levonorgestrel	Econtra One-Step
levonorgestrel	Fallback Solo
levonorgestrel	My Choice
levonorgestrel	My Way
levonorgestrel	New Day
levonorgestrel	Next Choice
levonorgestrel	Next Choice One Dose
levonorgestrel	Norplant System
levonorgestrel	Opcicon One-Step
levonorgestrel	Option-2
levonorgestrel	Plan B
levonorgestrel	Plan B One-Step
levonorgestrel	React
levonorgestrel	Take Action
levonorgestrel	levonorgestrel
levonorgestrel-ethinyl estradiol/pregnancy test kit	Preven Emergency Contraceptive
levonorgestrel/ethinyl estradiol	Twirla
medroxyprogesterone acetate	Amen
medroxyprogesterone acetate	Cycrin
medroxyprogesterone acetate	Depo-Provera
medroxyprogesterone acetate	Depo-SubQ provera 104
medroxyprogesterone acetate	Provera
medroxyprogesterone acetate	medroxyprogesterone
medroxyprogesterone acetate, micronized	medroxyprogest, ac micro(bulk)
megestrol acetate	Megace

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
megestrol acetate	Megace ES
megestrol acetate	megestrol
megestrol acetate,micronized	megestrol acetate,micro (bulk)
methyltestosterone	Android
methyltestosterone	Methitest
methyltestosterone	Testred
methyltestosterone	Virilon
methyltestosterone	methyltestosterone
methyltestosterone	methyltestosterone (bulk)
methyltestosterone, micronized	methyltestosterone,micro(bulk)
multivit with calcium and minerals/folic acid/herbal no.157	Estroven Maximum Strength
multivit with calcium and minerals/folic acid/herbal no.157	Menopause Supplement
multivit with calcium and minerals/folic acid/herbal no.176	Estro Support ES
multivit with calcium,minerals/folic acid/Herbal No.160	Estroven PMS
multivit with calcium,minerals/folic acid/herbal no.187	Estroven Maximum Strength
nandrolone decanoate	Deca-Durabolin
nandrolone decanoate	nandrolone decanoate
nandrolone decanoate	nandrolone decanoate (bulk)
nilutamide	Nilandron
nilutamide	nilutamide
norelgestromin/ethinyl estradiol	Ortho Evra
norelgestromin/ethinyl estradiol	Xulane
norelgestromin/ethinyl estradiol	Zafemy
norethindrone	Camila
norethindrone	Deblitane
norethindrone	Errin
norethindrone	Heather
norethindrone	Incassia
norethindrone	Jencycla

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
norethindrone	Jolivette
norethindrone	Lyleq
norethindrone	Lyza
norethindrone	Micronor (28)
norethindrone	Nor-Q-D
norethindrone	Nora-BE
norethindrone	Norlyda
norethindrone	Norlyroc
norethindrone	Ortho Micronor
norethindrone	Sharobel
norethindrone	Tulana
norethindrone	norethindrone (bulk)
norethindrone	norethindrone (contraceptive)
norethindrone acetate	Aygestin
norethindrone acetate	norethindrone acetate
norethindrone acetate	norethindrone acetate (bulk)
norethindrone acetate-ethinyl estradiol	Femhrt 1/5
norethindrone acetate-ethinyl estradiol	Femhrt Low Dose
norethindrone acetate-ethinyl estradiol	Fyavolv
norethindrone acetate-ethinyl estradiol	Jevantique
norethindrone acetate-ethinyl estradiol	Jevantique Lo
norethindrone acetate-ethinyl estradiol	Jinteli
norethindrone acetate-ethinyl estradiol	norethindrone ac-eth estradiol
norgestrel	Ovrette
ospemifene	Osphena
oxandrolone	Oxandrin
oxandrolone	oxandrolone
oxandrolone	oxandrolone (bulk)
oxymetholone	Anadrol-50

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
oxymetholone	oxymetholone (bulk)
prasterone (DHEA)	DHEA
prasterone (DHEA)	Dehydroepiandrosterone
prasterone (DHEA)	prasterone (dhea)
prasterone (DHEA)	prasterone (dhea) (bulk)
prasterone (DHEA), micronized	DHEA, Micronized
prasterone (DHEA), micronized	Dehydroepiandrosterone (micro)
prasterone (DHEA), micronized	prasterone (dhea), micro(bulk)
prasterone (DHEA)/calcium carbonate	DHEA
prasterone (DHEA)/calcium phosphate	DHEA
prasterone acetate	Dehydroepiandrosterone Acetate
pregnenolone	pregnenolone (bulk)
pregnenolone, micronized	pregnenolone, micronized(bulk)
progesterone	Progesterone in Oil
progesterone	progesterone
progesterone	progesterone (bulk)
progesterone, micronized	Crinone
progesterone, micronized	Prochieve
progesterone, micronized	Prometrium
progesterone, micronized	progesterone micronized
progesterone, micronized	progesterone micronized (bulk)
raloxifene HCl	Evista
raloxifene HCl	raloxifene
relugolix/estradiol/norethindrone acetate	Myfembree
segesterone acetate/ethinyl estradiol	Annovera
soy isoflav/blk cohosh rt xt/grn tea lf xt/yerba mate lf xt	Estroven Energy
soy isoflavone	IsoRel
soy isoflavone	Soy
soy isoflavone	Soy Isoflavones

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
soy isoflavone	Soy Menopause
soy isoflavone	soy isoflavone
soy isoflavone/black cohosh root ext/Cissus quadrangular ext	Estroven Weight Management
soy isoflavone/black cohosh root/magnolia bark	Estroven
soy isoflavone/soybean extract	Soy Balance
soy protein/soy isoflavone	Soy Care Menopause
soybean oil/chlorophyllin	Chlorophyll
stanolone	4-Dihydrotestosterone (Bulk)
stanozolol	Winstrol
stanozolol	stanozolol (bulk)
stanozolol micronized	stanozolol micronized (bulk)
tamoxifen citrate	Nolvadex
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tamoxifen citrate	tamoxifen (bulk)
testolactone	Teslac
testosterone	AndroGel
testosterone	Androderm
testosterone	Axiron
testosterone	Fortesta
testosterone	Natesto
testosterone	Striant
testosterone	Tesamone-100
testosterone	Testim
testosterone	Testoderm
testosterone	Testoderm TTS
testosterone	Testopel
testosterone	Testosterone Aqueous
testosterone	Vogelxo

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
testosterone	testosterone
testosterone	testosterone (bulk)
testosterone cypionate	Depo-Testosterone
testosterone cypionate	Testone CIK
testosterone cypionate	testosterone cypionate
testosterone cypionate	testosterone cypionate (bulk)
testosterone cypionate, micronized	testosterone cyp, micro (bulk)
testosterone cypionate/estradiol cypionate	Depo-Testadiol
testosterone enanthate	Delatestryl
testosterone enanthate	Xyosted
testosterone enanthate	testosterone enanthate
testosterone enanthate	testosterone enanthate (bulk)
testosterone enanthate/estradiol valerate	estradiol val-testosteron enan
testosterone micronized	testosterone micronized (bulk)
testosterone propionate	testosterone propionate
testosterone propionate	testosterone propionate (bulk)
testosterone undecanoate	Aveed
testosterone undecanoate	Jatenzo
toremifene citrate	Fareston
toremifene citrate	toremifene
vit B complex/vit E acet/folic acid/minerals no.35/soybean	Menopause Support
vitamin B complex/vit E acet/folic acid/Min Cmb No.26/soyb	Menopause Support
vitamin B complex/vit E acet/mineral combo no.3/soybean	Menopause Support
vitamin B complex/vitamin E/mineral combo no.3/Isoflav 1	Estroplus
5-Alpha Reductase Inhibitors	
dutasteride	Avodart
dutasteride	dutasteride
dutasteride	dutasteride (bulk)
finasteride	Propecia

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
finasteride	Propecia Pro-Pak
finasteride	Proscar
finasteride	finasteride
finasteride	finasteride (bulk)
Antidiabetic Drugs	
acarbose	Precose
acarbose	acarbose
acetohexamide	Dymelor
acetohexamide	acetohexamide
albiglutide	Tanzeum
alogliptin benzoate	Nesina
alogliptin benzoate	alogliptin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/pioglitazone HCl	Oseni
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
bromocriptine mesylate	Cycloset
bromocriptine mesylate	bromocriptine (bulk)
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
chlorpropamide	Diabinese
chlorpropamide	chlorpropamide
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
dulaglutide	Trulicity
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide	glipizide
glipizide	glipizide (bulk)
glipizide/metformin HCl	Metaglip
glipizide/metformin HCl	glipizide-metformin
glyburide	Diabeta
glyburide	Micronase
glyburide	glyburide
glyburide	glyburide (bulk)
glyburide,micronized	Glycron
glyburide,micronized	Glynase
glyburide,micronized	glyburide micronized
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
linagliptin	Tradjenta

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin
metformin HCl	metformin (bulk)
metformin HCl/blood sugar diagnostic	DM2
metformin/amino acids no.7/herbal cmb.125/choline bitartrate	Appformin-D
metformin/caffeine/amino acids 7/herbal comb 125/choline bit	Appformin
mifepristone	Korlym
miglitol	Glyset
miglitol	miglitol
nateglinide	Starlix
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR
pioglitazone HCl/metformin HCl	pioglitazone-metformin
pramlintide acetate	Symlin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
pramlintide acetate	SymlinPen 120
pramlintide acetate	SymlinPen 60
repaglinide	Prandin
repaglinide	repaglinide
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate	Avandia
rosiglitazone maleate/glimepiride	Avandaryl
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl	Onglyza
saxagliptin HCl/metformin HCl	Kombiglyze XR
semaglutide	Ozempic
semaglutide	Rybelsus
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
sitagliptin phosphate/simvastatin	Juvisync
tolazamide	Tolinase
tolazamide	tolazamide
tolbutamide	Orinase
tolbutamide	tolbutamide
troglitazone	Rezulin
Acetylsalicylic Acid	
acetaminophen	Acetaminophen Non Aspirin
acetaminophen	Aspirin Free
acetaminophen	Aspirin Free Childs
acetaminophen	Aspirin Free Extra Strength
acetaminophen	Aspirin-Free Infant
acetaminophen	Aspirin-Free Relief

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
acetaminophen	Child Non-Aspirin
acetaminophen	Child Non-Aspirin Pain Relief
acetaminophen	Child Non-Aspirin Quick Melts
acetaminophen	Child Pain Reliever No Aspirin
acetaminophen	Children's Aspirin Free
acetaminophen	Children's Non-Aspirin
acetaminophen	Children's Non-Aspirin Pain
acetaminophen	Childs Aspirin Free
acetaminophen	Infant Non Aspirin Pain Relief
acetaminophen	Infant's Non-Aspirin
acetaminophen	Infants Aspirin Free
acetaminophen	Jr Str Non-Aspirin Quick Melts
acetaminophen	Jr. Str Non-Aspirin Pain
acetaminophen	NON-ASPIRIN 8 HOUR
acetaminophen	Non Aspirin Extended Release
acetaminophen	Non-Aspirin
acetaminophen	Non-Aspirin Child
acetaminophen	Non-Aspirin Children's
acetaminophen	Non-Aspirin Childrens
acetaminophen	Non-Aspirin Extra Strength
acetaminophen	Non-Aspirin Infant
acetaminophen	Non-Aspirin Infant Pain Relief
acetaminophen	Non-Aspirin Infants
acetaminophen	Non-Aspirin Jr Strength
acetaminophen	Non-Aspirin Pain Relief
acetaminophen	Non-Aspirin Pain Relief Ex Str
acetaminophen	Non-Aspirin Pain Reliever
acetaminophen	Pain Relief without Aspirin
acetaminophen	Pain Reliever Non-Aspirin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
acetaminophen	Pain Reliever W/Out Aspirin
acetaminophen	Pain Reliever w/o Aspirin
acetaminophen	Pain Reliever without Aspirin
acetaminophen	St. Joseph Aspirin-Free Adult
acetaminophen	Un-Aspirin
acetaminophen/caffeine	Excedrin Aspirin Free
acetaminophen/calcium carbonate	Non Aspirin Pain Rlf W/Antacid
acetaminophen/diphenhydramine HCl	Aspirin Free Headache PM
acetaminophen/diphenhydramine HCl	Non-Aspirin Nightime
acetaminophen/diphenhydramine HCl	Non-Aspirin PM
acetaminophen/diphenhydramine HCl	Non-Aspirin Pain Relief PM
acetaminophen/diphenhydramine HCl	Non-Aspirin Severe Allergy
acetaminophen/diphenhydramine HCl	Non-Aspirin Sleep Aid
acetaminophen/diphenhydramine citrate	Non-Aspirin PM
acetaminophen/phenyltoloxamine citrate	Aspirin Free Analgesic
aspirin	Adult Aspirin
aspirin	Adult Aspirin EC Low Strength
aspirin	Adult Aspirin Regimen
aspirin	Adult Low Dose Aspirin
aspirin	Analgesic
aspirin	AsperDrink
aspirin	Aspergum
aspirin	Aspir-81
aspirin	Aspir-Low
aspirin	Aspir-Trin
aspirin	Aspirin Child
aspirin	Aspirin Childrens
aspirin	Aspirin Extra Strength
aspirin	Aspirin Lite-Coat

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin	Aspirin Low Dose
aspirin	Aspirin Low-Strength
aspirin	Aspirin Maximum Strength
aspirin	Aspirina
aspirin	Baby Aspirin
aspirin	Bayer 8-Hour
aspirin	Bayer Advanced
aspirin	Bayer Arthritis Pain Regimen
aspirin	Bayer Aspirin
aspirin	Bayer Chewable Aspirin
aspirin	Child Aspirin
aspirin	Children's Aspirin
aspirin	Durlaza
aspirin	E.C. Prin
aspirin	EC Aspirin
aspirin	Easprin
aspirin	Eco-10
aspirin	Eco-5
aspirin	Ecotrin
aspirin	Ecotrin Low Strength
aspirin	Ecotrin Maximum Strength
aspirin	Empirin
aspirin	Encoprin
aspirin	Encoprin Extra Strength
aspirin	Entercote
aspirin	Enteric Coated Aspirin
aspirin	Extra Strength Bayer
aspirin	Genacote
aspirin	Genprin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin	Halfprin
aspirin	Lite Coat Aspirin
aspirin	Lo-Dose Aspirin
aspirin	Low-Dose Aspirin
aspirin	Miniprin
aspirin	Minitabs
aspirin	Ninoprin
aspirin	Norwich Aspirin
aspirin	Quality Aspirin
aspirin	Regriprin
aspirin	Sloprin
aspirin	St Joseph Aspirin
aspirin	St. Joseph Aspirin
aspirin	St. Joseph Aspirin Children
aspirin	St. Joseph Low-Dose Aspirin
aspirin	Stanback Headache Powder
aspirin	Sureprin 81
aspirin	Tasprin
aspirin	Vazalore
aspirin	YSP Aspirin
aspirin	Zero-Order Release Aspirin
aspirin	Zorprin
aspirin	aspirin
aspirin	aspirin (bulk)
aspirin (calcium carb & magnesium buffers)/pravastatin	PRAVIGARD PAC
aspirin/acetaminophen	Goody's BODY PAIN
aspirin/acetaminophen/caffeine	Added Strength Headache Relief
aspirin/acetaminophen/caffeine	Added Strength Pain Relief
aspirin/acetaminophen/caffeine	Added Strength Pain Reliever

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin/acetaminophen/caffeine	Analgesic
aspirin/acetaminophen/caffeine	Ex-Pain
aspirin/acetaminophen/caffeine	Excedrin Extra Strength
aspirin/acetaminophen/caffeine	Excedrin Menstrual Complete
aspirin/acetaminophen/caffeine	Excedrin Migraine
aspirin/acetaminophen/caffeine	Extra Pain Relief
aspirin/acetaminophen/caffeine	Extra Strength Pain Reliever
aspirin/acetaminophen/caffeine	Extraprin
aspirin/acetaminophen/caffeine	Gelpirin
aspirin/acetaminophen/caffeine	Genaced
aspirin/acetaminophen/caffeine	Goody's Extra Strength
aspirin/acetaminophen/caffeine	Goody's Migraine Relief
aspirin/acetaminophen/caffeine	Headache Formula
aspirin/acetaminophen/caffeine	Headache Formula Added Str
aspirin/acetaminophen/caffeine	Headache Relief (ASA-acet-caf)
aspirin/acetaminophen/caffeine	Migraine
aspirin/acetaminophen/caffeine	Migraine Formula
aspirin/acetaminophen/caffeine	Migraine Pain Reliever
aspirin/acetaminophen/caffeine	Migraine Relief
aspirin/acetaminophen/caffeine	Pain Relief (acetamin-asp-caf)
aspirin/acetaminophen/caffeine	Pain Relief Plus
aspirin/acetaminophen/caffeine	Pain Reliever (acetam-aspirin)
aspirin/acetaminophen/caffeine	Pain Reliever Added Strength
aspirin/acetaminophen/caffeine	Pain Reliever Plus
aspirin/acetaminophen/caffeine	Pain-Off
aspirin/acetaminophen/caffeine	Painaid Extra Strength Formula
aspirin/acetaminophen/caffeine	Pamprin Max
aspirin/acetaminophen/caffeine	Super Pain Relief
aspirin/acetaminophen/caffeine	Super Strength Pain Reliever

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin/acetaminophen/caffeine	Super Strength Reliever
aspirin/acetaminophen/caffeine	Vanquish
aspirin/acetaminophen/caffeine	X-Str Pain Reliever
aspirin/acetaminophen/caffeine	aspirin-acetaminophen-caffeine
aspirin/acetaminophen/caffeine/calcium	Supac
aspirin/acetaminophen/caffeine/potassium	Goody's Headache Powder
aspirin/acetaminophen/calcium carbonate	Excedrin Back and Body
aspirin/acetaminophen/diphenhydramine citrate	Pain Relief PM (w-aspirin)
aspirin/caffeine	AA and C
aspirin/caffeine	Adult Analgesic
aspirin/caffeine	Adult Strength Analgesic
aspirin/caffeine	Adult Strength Pain Relief
aspirin/caffeine	Adult Strength Pain Reliever
aspirin/caffeine	Anacin
aspirin/caffeine	Anacin Maximum Strength
aspirin/caffeine	Analgesic (aspirin/caffeine)
aspirin/caffeine	Analgesic Adult Strength
aspirin/caffeine	Aspircaf
aspirin/caffeine	BC Arthritis
aspirin/caffeine	BC Pain Relief
aspirin/caffeine	Back and Body Pain Reliever
aspirin/caffeine	Bayer Aspirin (with caffeine)
aspirin/caffeine	Bayer Back and Body
aspirin/caffeine	Biocin
aspirin/caffeine	CP-2
aspirin/caffeine	Gensan
aspirin/caffeine	Majorcin
aspirin/caffeine	Pain Relief Fast Acting
aspirin/caffeine	Q-Acin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin/caffeine	Stanback
aspirin/caffeine	aspirin-caffeine
aspirin/caffeine/dihydrocodeine	Synalgos-DC
aspirin/caffeine/dihydrocodeine bitartrate	Synalgos-DC
aspirin/caffeine/dihydrocodeine bitartrate	aspirin-caffeine-dihydrocodein
aspirin/calcium carbonate	Aspirin Regimen Bayer/Calcium
aspirin/calcium carbonate	Women's Aspirin with Calcium
aspirin/calcium carbonate/magnesium	Aspir-Mox
aspirin/calcium carbonate/magnesium	Aspirin Tri-Buffered
aspirin/calcium carbonate/magnesium	Buffered Aspirin
aspirin/calcium carbonate/magnesium	Bufferin
aspirin/calcium carbonate/magnesium	Bufferin Analgesic
aspirin/calcium carbonate/magnesium	Bufferin Arthritis Strength
aspirin/calcium carbonate/magnesium	Bufferin Extra Strength
aspirin/calcium carbonate/magnesium	Bufpirin
aspirin/calcium carbonate/magnesium	Tri-Buffered Aspirin
aspirin/calcium carbonate/magnesium	Tri-Buffered Bufferin
aspirin/calcium carbonate/magnesium	aspirin,buffd-calcium carb-mag
aspirin/calcium carbonate/magnesium/aluminum hydroxide	ASA-calcium carb-mag-aluminum
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin A/D
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin AP
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin MS
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspercin
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Lox
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Lox AD
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Mox IB
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin AD/Antacid
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin Plus Antacid

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin Tri Buffered
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspralum
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspralum E.B.
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspridrox
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Asprimox
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Asprimox ID
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Bayer Plus Extra Strength
aspirin/calcium carbonate/magnesium/aluminum hydroxide	Bufferin Extra Str (al hydrox)
aspirin/codeine phosphate	Aspirin-Codeine #3
aspirin/codeine phosphate	Aspirin-Codeine #4
aspirin/codeine phosphate	aspirin-codeine
aspirin/diphenhydramine HCl	Extra Strength Bayer PM
aspirin/diphenhydramine citrate	Bayer PM
aspirin/diphenhydramine/sodium bicarbonate/citric acid	Alka-Seltzer PM
aspirin/dipyridamole	Aggrenox
aspirin/dipyridamole	aspirin-dipyridamole
aspirin/magnesium carbonate/dihydroxyaluminum aminoacetate	Gennin-FC
aspirin/magnesium hydroxide/aluminum hydroxide	Arthritis Pain Formula
aspirin/magnesium hydroxide/aluminum hydroxide	Arthritis Pain Formula Max St
aspirin/magnesium hydroxide/aluminum hydroxide	Magnaprin
aspirin/magnesium hydroxide/aluminum hydroxide/caffeine	Cope
aspirin/meprobamate	Equagesic
aspirin/meprobamate	Micrainin
aspirin/meprobamate	meprobamate-aspirin
aspirin/omeprazole	Yosprala
aspirin/omeprazole	aspirin-omeprazole
aspirin/salicylamide/acetaminophen/caffeine	Back Pain-Off
aspirin/salicylamide/acetaminophen/caffeine	Levacet
aspirin/salicylamide/acetaminophen/caffeine	Pain Relief(with salicylamide)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
aspirin/salicylamide/acetaminophen/caffeine	Pain-Off Extra Strength
aspirin/salicylamide/acetaminophen/caffeine	Painaid
aspirin/salicylamide/acetaminophen/caffeine	Rumalon
aspirin/salicylamide/acetaminophen/caffeine	Saleto
aspirin/salicylamide/caffeine	Arthritis Strength BC Powder
aspirin/salicylamide/caffeine	BC Headache
aspirin/salicylamide/caffeine	BC Headache Powder
aspirin/sodium bicarbonate/citric acid	Alka-Seltzer
aspirin/sodium bicarbonate/citric acid	Alka-Seltzer Extra Strength
aspirin/sodium bicarbonate/citric acid	Alka-Seltzer Original
aspirin/sodium bicarbonate/citric acid	Antacid Pain Reliever
aspirin/sodium bicarbonate/citric acid	Antacid and Pain Relief
aspirin/sodium bicarbonate/citric acid	Efferves Pain Relief Antacid
aspirin/sodium bicarbonate/citric acid	Efferves Pain-Antacid Relief
aspirin/sodium bicarbonate/citric acid	Effervescent
aspirin/sodium bicarbonate/citric acid	Effervescent Antacid
aspirin/sodium bicarbonate/citric acid	Effervescent Pain Relief
aspirin/sodium bicarbonate/citric acid	Effervescent Pain Reliever
aspirin/sodium bicarbonate/citric acid	Medi-Seltzer
aspirin/sodium bicarbonate/citric acid	Zee-Seltzer
butalbital/aspirin/caffeine	Butalbital Compound
butalbital/aspirin/caffeine	Farbital
butalbital/aspirin/caffeine	Fiorinal
butalbital/aspirin/caffeine	Fiortal
butalbital/aspirin/caffeine	Fortabs
butalbital/aspirin/caffeine	butalbital-aspirin-caffeine
carisoprodol/aspirin	Carisoprodol Compound
carisoprodol/aspirin	Soma Compound
carisoprodol/aspirin	carisoprodol-aspirin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
carisoprodol/aspirin/codeine phosphate	Carisoprodol Compound-Codeine
carisoprodol/aspirin/codeine phosphate	Soma Compound with Codeine
carisoprodol/aspirin/codeine phosphate	carisoprodol-aspirin-codeine
chlorpheniramine mal/phenylephrine/d-methorphan Hb/aspirin	Alka-Seltzer Plus C/C(PE,DM)
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Alka-Seltzer Plus Cold (PE)
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief Plus
chlorpheniramine/phenylpropanolamine bitartrate/aspirin	Alka-Seltzer Plus Cold
chlorpheniramine/phenylpropanolamine bitartrate/aspirin	Effervescent Cold
cinnamedrine HCl/aspirin/caffeine	Menstrual
cinnamedrine HCl/aspirin/caffeine	Midol Maximum Strength
codeine phosphate/butalbital/aspirin/caffeine	Ascomp with Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound W/Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound-Codeine
codeine phosphate/butalbital/aspirin/caffeine	Fiorinal-Codeine #3
codeine phosphate/butalbital/aspirin/caffeine	Fiortal/Codeine
codeine phosphate/butalbital/aspirin/caffeine	codeine-butalbital-ASA-caff
codeine/aspirin/salicylamide/acetaminophen/caffeine	Rid-A-Pain
codeine/aspirin/salicylamide/acetaminophen/caffeine	Rid-A-Pain W/Codeine
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Complete Cold Non-Aspirin
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Infants' Non-Aspirin Cold
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Cold
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Cold Medicine
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Flu
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Flu Max St
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Flu Medicine
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Flu Relief Max Str
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Child Non-Aspirin Cough,Cold
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Children's Non-Aspirin Cold

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Children's Non-Aspirin Plus
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Cold Relief Without Aspirin
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Cold Relief w/o Aspirin
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Complete Cold Non-Aspirin
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non Aspirin Cold Complete Form
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non Aspirin Cold Plus Cough
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non-Aspirin Cold
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non-Aspirin Cold Formula
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non-Aspirin Cold Medicine
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non-Aspirin Plus Cold, Cough
ephedrine/aspirin/acetanilide/caffeine	Haysma
hydrocodone bitartrate/aspirin	Alor
hydrocodone bitartrate/aspirin	Damason-P
hydrocodone bitartrate/aspirin	Lortab ASA
methocarbamol/aspirin	Robaxisal
methocarbamol/aspirin	methocarbamol-aspirin
orphenadrine citrate/aspirin/caffeine	Norgesic
orphenadrine citrate/aspirin/caffeine	Norgesic Forte
orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound
orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound Forte
orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound-DS
orphenadrine citrate/aspirin/caffeine	Orphengesic
orphenadrine citrate/aspirin/caffeine	Orphengesic Forte
orphenadrine citrate/aspirin/caffeine	orphenadrine-ASA-caffeine
oxycodone HCl/aspirin	Endodan
oxycodone HCl/aspirin	Percodan
oxycodone HCl/aspirin	oxycodone-aspirin
oxycodone HCl/oxycodone terephthalate/aspirin	Endodan (Old Formula)
oxycodone HCl/oxycodone terephthalate/aspirin	Percodan

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
oxycodone HCl/oxycodone terephthalate/aspirin	oxycodone HCl-oxycodone-ASA
oxycodone/aspirin	Percodan Demi
pentazocine HCl/aspirin	Talwin Compound
phenylephrine HCl/acetaminophen	Non-Aspirin Sinus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Non-Aspirin Severe Congest M-S
phenylpropanolamine HCl/acetaminophen/chlorpheniramine	Aspirin Free Cold
phenylpropanolamine HCl/aspirin	BC Cold Powder/Cold-Sinus
phenylpropanolamine HCl/aspirin/chlorpheniramine	BC Cold Powder/Cold-Sinus
phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold
phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold Medicine
phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold Relief
phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Nite Cold Relief
phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Plus
phenylpropanolamine HCl/aspirin/chlorpheniramine	Medi-Seltzer Plus
phenylpropanolamine HCl/aspirin/chlorpheniramine/caffeine	Major-Stan
phenylpropanolamine HCl/aspirin/diphenhydramine	Alka-Seltzer Plus Night-Time
phenylpropanolamine HCl/aspirin/diphenhydramine	Cold Relief Nite
phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Cold Relief
phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Nite Cold Relief
phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Nite Relief
phenylpropanolamine HCl/aspirin/diphenhydramine	Night Time Cold Medicine
phenylpropanolamine bitartrate/aspirin	Alka-Seltzer Plus Sinus
propoxyphene HCl/aspirin/caffeine	Darvon Compound 32
propoxyphene HCl/aspirin/caffeine	Darvon Compound-65
propoxyphene HCl/aspirin/caffeine	PC-Cap
propoxyphene HCl/aspirin/caffeine	Propoxyphene Compound-65
pseudoephedrine HCl/acetaminophen	Non Aspirin
pseudoephedrine HCl/acetaminophen	Non-Aspirin
pseudoephedrine HCl/acetaminophen	Non-Aspirin Severe Sinus

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
pseudoephedrine HCl/acetaminophen	Non-Aspirin Sinus
pseudoephedrine HCl/acetaminophen	Non-Aspirin Sinus Max St
pseudoephedrine HCl/acetaminophen	Non-Aspirin Sinus Non-Drowsy
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Children's Non-Aspirin Cold
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Allergy Sinus
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Child's Cold
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Sinus
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Sinus Allergy
pseudoephedrine HCl/acetaminophen/diphenhydramine	Non-Aspirin Allergy Sinus Pm
pseudoephedrine HCl/acetaminophen/diphenhydramine	Non-Aspirin Flu
pseudoephedrine HCl/aspirin/chlorpheniramine	Effervescent Cold Relief
pseudoephedrine HCl/aspirin/chlorpheniramine	Effervescent Plus Cold Relief
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Non-Aspirin Cold Caplet
trolamine salicylate	Aspirin Free
Glucocorticoids	
HYDROCORTISONE	First-Hydrocortisone
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred Plus
acyclovir/hydrocortisone	Xerese
alclometasone dipropionate	Aclovate
alclometasone dipropionate	alclometasone
amcinonide	Cyclocort
amcinonide	amcinonide
beclomethasone dipropionate	Beclovent
beclomethasone dipropionate	Beclovent Refill
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
beclomethasone dipropionate	Vanceril
beclomethasone dipropionate	Vanceril Double Strength

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
beclomethasone dipropionate	beclomethasone diprop (bulk)
benzoyl peroxide/hydrocortisone	Bencort
benzoyl peroxide/hydrocortisone	Vanoxide-HC
benzoyl peroxide/hydrocortisone/skin cleanser comb no.14	Bencort
benzoyl peroxide/hydrocortisone/skin cleanser comb no.14	Vanoxide-HC
betamethasone	Celestone
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate and sodium phosph/norflurane/HFC 245fa	Betaloan SUIK
betamethasone acetate and sodium phosph/norflurane/HFC 245fa	Pod-Care 100CG
betamethasone acetate, micronized	betamethasone acet,micro(bulk)
betamethasone acetate/betamethasone sodium phosphate	BSP-0820
betamethasone acetate/betamethasone sodium phosphate	Beta-1
betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan
betamethasone acetate/betamethasone sodium phosphate	Pod-Care 100C
betamethasone acetate/betamethasone sodium phosphate	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium phosphate	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone dipropionate	Alphatrex
betamethasone dipropionate	Diprolene
betamethasone dipropionate	Diprosone
betamethasone dipropionate	Maxivate
betamethasone dipropionate	Sernivo
betamethasone dipropionate	betamethasone dipropion (bulk)
betamethasone dipropionate	betamethasone dipropionate
betamethasone dipropionate	betamethasone, augmented
betamethasone dipropionate/propylene glycol	Diprolene (augmented)
betamethasone dipropionate/propylene glycol	Diprolene AF
betamethasone dipropionate/propylene glycol	betamethasone, augmented
betamethasone sodium phos/chondroitin sulfate A sodium/PF	Klarity-B (betameth-chond)(PF)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
betamethasone sodium phosphate	Celestone
betamethasone sodium phosphate	betamethasone sod phos (bulk)
betamethasone sodium phosphate	betamethasone sodium phosphate
betamethasone valerate	Beta-Val
betamethasone valerate	Betatrex
betamethasone valerate	Luxiq
betamethasone valerate	betamethasone valerate
betamethasone valerate	betamethasone valerate (bulk)
budesonide	Entocort EC
budesonide	Ortikos
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	Pulmicort Turbuhaler
budesonide	Tarpeyo
budesonide	Uceris
budesonide	budesonide
budesonide, micronized	budesonide, micronized (bulk)
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
bupivacaine HCl/dexamethasone sodium phos in sterile water	bupivacaine-dexameth in water
calcipotriene/betamethasone dipropionate	Enstilar
calcipotriene/betamethasone dipropionate	Taclonex
calcipotriene/betamethasone dipropionate	Taclonex Scalp
calcipotriene/betamethasone dipropionate	Wynzora
calcipotriene/betamethasone dipropionate	calcipotriene-betamethasone
chlorcyclizine HCl/hydrocortisone acetate	Mantadil
chloroxylenol/benzocaine/hydrocortisone acetate	MyOxin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
chloroxylenol/benzocaine/hydrocortisone acetate	TriOxin
ciclesonide	Alvesco
ciclopirox olamine/clobetasol propionate	Haxchlo
ciclopirox olamine/clobetasol propionate	ciclopirox-clobetasol
ciclopirox olamine/clobetasol propionate/salicylic acid	ciclopirox-clobetasol-salicyl
ciclopirox/triamcinolone acetonide	Trilociclo
ciprofloxacin HCl/dexamethasone	Ciprodex
ciprofloxacin HCl/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/hydrocortisone	Cipro HC
clioquinol/hydrocortisone	Ala-Quin
clioquinol/hydrocortisone	Albaform HC
clioquinol/hydrocortisone	Iodochlorhydroxyquin-HC
clioquinol/hydrocortisone	clioquinol-hydrocortisone
clioquinol/hydrocortisone/emollient combination no.88	Dermasorb AF Complete Kit
clioquinol/hydrocortisone/pramoxine	Pricort
clobetasol propionate	Clobevate
clobetasol propionate	Clobex
clobetasol propionate	Clodan
clobetasol propionate	Cormax
clobetasol propionate	Embeline
clobetasol propionate	Impeklo
clobetasol propionate	Impoyz
clobetasol propionate	Olux
clobetasol propionate	Temovate
clobetasol propionate	clobetasol
clobetasol propionate	clobetasol propionate (bulk)
clobetasol propionate/calcipotriene	Diochloy

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
clobetasol propionate/calcipotriene	clobetasol-calcipotriene
clobetasol propionate/coal tar	Clobeta+Plus
clobetasol propionate/coal tar	clobetasol-coal tar
clobetasol propionate/desloratadine	Clobetex
clobetasol propionate/emollient base	Embeline E
clobetasol propionate/emollient base	Olux-E
clobetasol propionate/emollient base	Olux-Olux-E
clobetasol propionate/emollient base	Olux-Olux-E (100/10)
clobetasol propionate/emollient base	Olux-Olux-E (50/50)
clobetasol propionate/emollient base	Temovate E
clobetasol propionate/emollient base	Tovet Emollient
clobetasol propionate/emollient base	clobetasol-emollient
clobetasol propionate/emollient combination no.65	Tovet Kit
clobetasol propionate/gauze bandage/silicone, adhesive	Tasoprol
clobetasol propionate/hydrocolloid dressing	Clobetavix
clobetasol propionate/levocetirizine dihydrochloride	clobetasol-levocetirizine
clobetasol propionate/niacinamide	Chlooxia
clobetasol propionate/niacinamide	clobetasol-niacinamide
clobetasol propionate/skin cleanser combination no.28	Clodan Kit
clocortolone pivalate	Cloderm
clocortolone pivalate	clocortolone pivalate
clotrimazole/betamethasone dipropionate	Lotrisone
clotrimazole/betamethasone dipropionate	clotrimazole-betamethasone
clotrimazole/betamethasone dipropionate/zinc oxide	DermacinRx Therazole Pak
cortisone acetate	cortisone
cortisone acetate	cortisone (bulk)
deflazacort	Emflaza
desonide	Delonide
desonide	DesOwen

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
desonide	DesRx
desonide	Desonate
desonide	LoKara
desonide	Tridesilon
desonide	Verdeso
desonide	desonide
desonide, micronized	desonide, micronized (bulk)
desonide/emollient combination no. 28	DesOwen
desonide/emollient combination no.3	Desonil
desonide/emollient combination no.3	Desonil + Plus
desonide/emollient combination no.30	DesOwen Cream and Lotion
desonide/emollient combination no.30	DesOwen Ointment and Lotion
desoximetasone	Topicort
desoximetasone	Topicort LP
desoximetasone	desoximetasone
desoximetasone	desoximetasone (bulk)
desoximetasone, micronized	desoximetasone, micro (bulk)
desoximetasone/niacinamide	desoximetasone-niacinamide
dexamethasone	Baycadron
dexamethasone	Decadron
dexamethasone	Decadron Dose Pack
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone Intensol
dexamethasone	Dexone
dexamethasone	Dextenza
dexamethasone	Dxevo

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
dexamethasone	Hemady
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	Maxidex
dexamethasone	Ozurdex
dexamethasone	TaperDex
dexamethasone	ZCort
dexamethasone	Zema-Pak
dexamethasone	ZoDex
dexamethasone	ZonaCort
dexamethasone	dexamethasone
dexamethasone acetate	Adrenocot LA
dexamethasone acetate	Dalalone D.P.
dexamethasone acetate	De-Sone LA
dexamethasone acetate	Dexacen LA-8
dexamethasone acetate	Dexone LA
dexamethasone acetate	Solurex LA
dexamethasone acetate	dexamethasone acetate
dexamethasone acetate	dexamethasone acetate (bulk)
dexamethasone acetate and sodium phosphate in sterile water	dexamethasone ac, sod ph-water
dexamethasone acetate in sodium chloride, iso-osmotic	dexamethasone ace-NaCl,iso-osm
dexamethasone acetate, micronized	dexamethasone ac, micro (bulk)
dexamethasone isonicotinate	dexamethasone isonic (bulk)
dexamethasone phosphate	Primethasone
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
dexamethasone sodium phosphate	AK-Dex
dexamethasone sodium phosphate	Adrenocot
dexamethasone sodium phosphate	Cpc-Cort-D

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
dexamethasone sodium phosphate	Decadron Phosphate
dexamethasone sodium phosphate	Decaject
dexamethasone sodium phosphate	Dexair
dexamethasone sodium phosphate	Dexasol
dexamethasone sodium phosphate	Dexone
dexamethasone sodium phosphate	Dexonto
dexamethasone sodium phosphate	ReadySharp dexamethasone
dexamethasone sodium phosphate	Solurex
dexamethasone sodium phosphate	dexamethasone sod phos (bulk)
dexamethasone sodium phosphate	dexamethasone sodium phosphate
dexamethasone sodium phosphate in 0.9 % sodium chloride	dexamethasone-0.9 % sod. chlor
dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
dexamethasone sodium phosphate/PF	DoubleDex (PF)
dexamethasone sodium phosphate/PF	MAS Care-Pak (PF)
dexamethasone sodium phosphate/PF	dexamethasone sodium phos (PF)
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
dexamethasone, micronized	dexamethasone,micronized(bulk)
dexamethasone/PF	Dexycu (PF)
dexamethasone/PF/norflurane/pentafluoropropane (HFC 245fa)	DMT SUIK
diflorasone diacetate	ApexiCon
diflorasone diacetate	Florone
diflorasone diacetate	Maxiflor
diflorasone diacetate	Psorcon
diflorasone diacetate	diflorasone
diflorasone diacetate/emollient base	ApexiCon E
diflorasone diacetate/emollient base	Florone-E
diflorasone diacetate/emollient base	Psorcon E
difluprednate	Durezol
difluprednate	difluprednate

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
diphenhydramine HCl/hydrocortisone	HC Derma-Pax
econazole nitrate/triamcinolone acetonide	Triamazole
flunisolide	Aerobid
flunisolide	Aerospan
flunisolide	flunisolide (bulk)
flunisolide/menthol	Aerobid-M
fluocinolone acetonide	Capex
fluocinolone acetonide	Derma-Smoothe/FS
fluocinolone acetonide	Derma-Smoothe/FS Body Oil
fluocinolone acetonide	Derma-Smoothe/FS Eczema
fluocinolone acetonide	FS Shampoo
fluocinolone acetonide	Iluvien
fluocinolone acetonide	Retisert
fluocinolone acetonide	Synalar
fluocinolone acetonide	Synalar-HP
fluocinolone acetonide	Yutiq
fluocinolone acetonide	fluocinolone
fluocinolone acetonide	fluocinolone acetonide (bulk)
fluocinolone acetonide oil	DermOtic Oil
fluocinolone acetonide oil	Flac Otic Oil
fluocinolone acetonide oil	fluocinolone acetonide oil
fluocinolone acetonide, micronized	fluocinolone acet, micro(bulk)
fluocinolone acetonide/emollient base	Derma-Smoothe/FS Atopic Pak
fluocinolone acetonide/emollient base	Synemol
fluocinolone acetonide/emollient combination no.65	Synalar Cream Kit
fluocinolone acetonide/emollient combination no.65	Synalar Ointment Kit
fluocinolone acetonide/niacinamide	fluocinolone-niacinamide
fluocinolone acetonide/shower cap	Derma-Smoothe/FS Scalp Oil
fluocinolone acetonide/shower cap	fluocinolone and shower cap

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
fluocinolone acetonide/skin cleanser comb no.28	Synalar TS
fluocinolone acetonide/skin cleanser no.10/silicone, tape	Xilapak
fluocinolone acetonide/urea/silicone, adhesive	Noxipak
fluocinonide	Lidex
fluocinonide	Vanos
fluocinonide	fluocinonide
fluocinonide, micronized	fluocinonide, micronized(bulk)
fluocinonide/dimethicone	Fluopar
fluocinonide/emollient base	Fluocinonide-E
fluocinonide/emollient base	Lidex-E
fluocinonide/emollient base	fluocinonide-emollient
fluocinonide/silicone, adhesive	Fluovix
fluocinonide/silicone, adhesive	Fluovix Plus
fluorometholone	FML Forte
fluorometholone	FML Liquifilm
fluorometholone	FML S.O.P.
fluorometholone	Fluor-Op
fluorometholone	fluorometholone
fluorometholone acetate	Eflone
fluorometholone acetate	Flarex
flurandrenolide	Cordran
flurandrenolide	Cordran Patch
flurandrenolide	Cordran SP
flurandrenolide	Cordran Tape Large Roll
flurandrenolide	Cordran Tape Small Roll
flurandrenolide	Nolix
flurandrenolide	flurandrenolide
fluticasone furoate	Arnuity Ellipta
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone propionate	ArmonAir Digihaler
fluticasone propionate	ArmonAir RespiClick
fluticasone propionate	Beser
fluticasone propionate	Cutivate
fluticasone propionate	Flovent
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
fluticasone propionate	Flovent Rotadisk
fluticasone propionate	fluticasone propionate
fluticasone propionate	fluticasone propionate (bulk)
fluticasone propionate, micronized	fluticasone prop, micro (bulk)
fluticasone propionate/emollient combination no.65	Beser Kit
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo Digihaler
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
gatifloxacin/dexamethasone sodium phosphate	gatifloxacin-dexamethasone
gentamicin sulfate/prednisolone acetate	Pred-G
gentamicin sulfate/prednisolone acetate	Pred-G S.O.P.
halcinonide	Halog
halcinonide	halcinonide
halcinonide/emollient base	Halog-E
halobetasol propionate	Bryhali
halobetasol propionate	Lexette
halobetasol propionate	Ultravate
halobetasol propionate	halobetasol propionate

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
halobetasol propionate/ammonium lactate	Halac
halobetasol propionate/ammonium lactate	Halonate
halobetasol propionate/ammonium lactate	Halonate Pac
halobetasol propionate/ammonium lactate	Ultravate PAC
halobetasol propionate/lactic acid	Ultravate X
halobetasol propionate/tazarotene	Duobrii
hydrocortisone	Acticort 100
hydrocortisone	Advanced Allergy Collect Kit
hydrocortisone	Ala-Cort
hydrocortisone	Ala-Scalp
hydrocortisone	Albacort
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Anti-Itch (HC)
hydrocortisone	Anusol-HC
hydrocortisone	Aquanil HC
hydrocortisone	Aquaphor Itch Relief
hydrocortisone	Balneol For Her
hydrocortisone	Beta-HC
hydrocortisone	Cetacort
hydrocortisone	Colocort
hydrocortisone	Cortaid
hydrocortisone	Cortaid FastStick Max St
hydrocortisone	Cortaid Intensive Therapy
hydrocortisone	Cortaid Maximum Strength
hydrocortisone	Cortef
hydrocortisone	Cortenema
hydrocortisone	Corticool
hydrocortisone	Cortinal
hydrocortisone	Cortisone (hydrocortisone)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone	Cortisone Cooling
hydrocortisone	Cortizone For Kids
hydrocortisone	Cortizone-10
hydrocortisone	Cortizone-10 Anal Itch Relief
hydrocortisone	Cortizone-10 Plus
hydrocortisone	Cortizone-5
hydrocortisone	Cotacort
hydrocortisone	Dermacort
hydrocortisone	Dermarest Eczema (hydrocort)
hydrocortisone	Dermolate Anti-Itch
hydrocortisone	Dr. Smith's Anti-Itch
hydrocortisone	Eczema Anti-Itch
hydrocortisone	HydroSkin
hydrocortisone	Hydrocortisone Plus
hydrocortisone	Hydrocortisone Plus 12
hydrocortisone	Hydrocortisone Scalp
hydrocortisone	Hydrocortone
hydrocortisone	Hydrocream
hydrocortisone	Hytone
hydrocortisone	ITCH-X
hydrocortisone	Instacort
hydrocortisone	Instacort Scalp
hydrocortisone	Itch-X HC
hydrocortisone	LactiCare-HC
hydrocortisone	Neosporin Anti-Itch
hydrocortisone	Neutrogena T/Scalp
hydrocortisone	Noble Formula HC
hydrocortisone	Nupercainal HC
hydrocortisone	Nutracort

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone	Obagi Nu-Derm Tolereen
hydrocortisone	P.P.C.
hydrocortisone	Preparation H Hydrocortisone
hydrocortisone	Procto-Kit
hydrocortisone	Procto-Med HC
hydrocortisone	Procto-Pak
hydrocortisone	ProctoCare-HC
hydrocortisone	ProctoCream-HC
hydrocortisone	Proctocort
hydrocortisone	Proctosol HC
hydrocortisone	Proctozone-HC
hydrocortisone	Recort Plus
hydrocortisone	Rederm
hydrocortisone	Sarnol-HC
hydrocortisone	Scalacort
hydrocortisone	Scalp Relief
hydrocortisone	Scalp-Cort
hydrocortisone	Scalpicin Anti-Itch
hydrocortisone	Soothing Care (hydrocortisone)
hydrocortisone	Summer's Eve
hydrocortisone	Texacort
hydrocortisone	Yeast-X External
hydrocortisone	hydrocortisone
hydrocortisone	hydrocortisone (bulk)
hydrocortisone acetate	Anu-Med
hydrocortisone acetate	Anu-Med HC
hydrocortisone acetate	Anucort-HC
hydrocortisone acetate	Anudil HC
hydrocortisone acetate	Anumed HC

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone acetate	Anurx-HC
hydrocortisone acetate	Anusert HC-1
hydrocortisone acetate	Anusol HC-1
hydrocortisone acetate	Anusol-HC
hydrocortisone acetate	Anuzone-HC
hydrocortisone acetate	Cortaid (hydrocortisone acet)
hydrocortisone acetate	Cortaid Maximum Strength
hydrocortisone acetate	Corticaine
hydrocortisone acetate	Corticreme
hydrocortisone acetate	Cortifoam
hydrocortisone acetate	Demarest Dricort
hydrocortisone acetate	GRx HiCort 25
hydrocortisone acetate	Gynecort
hydrocortisone acetate	Gynecort Maximum Strength
hydrocortisone acetate	HC-1% Hemorrhoid
hydrocortisone acetate	Hemmorex-HC
hydrocortisone acetate	Hemorrhoidal-HC
hydrocortisone acetate	Hemril-30
hydrocortisone acetate	Hemril-HC
hydrocortisone acetate	LanaCort
hydrocortisone acetate	Medi-Cortisone
hydrocortisone acetate	MiCort-HC
hydrocortisone acetate	Proctocort
hydrocortisone acetate	Proctosert HC
hydrocortisone acetate	Proctosol
hydrocortisone acetate	Proctozone H
hydrocortisone acetate	Rectacort-HC
hydrocortisone acetate	Rectasol-HC
hydrocortisone acetate	Tucks Hydrocortisone

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone acetate	Vanicream HC
hydrocortisone acetate	hydrocortisone acetate
hydrocortisone acetate	hydrocortisone acetate (bulk)
hydrocortisone acetate/aloe polysaccharide/iodoquinol	Hydro-Iodoquinol 2-1
hydrocortisone acetate/aloe polysaccharide/iodoquinol	Lodocortisone Aloe
hydrocortisone acetate/aloe vera	Cortaid with Aloe
hydrocortisone acetate/aloe vera	Cortalo
hydrocortisone acetate/aloe vera	Hydrocortisone Acetate-Aloe
hydrocortisone acetate/aloe vera	LanaCort
hydrocortisone acetate/aloe vera	Nucort
hydrocortisone acetate/aloe vera	Nuzon
hydrocortisone acetate/aloe vera	hydrocortisone acet-aloe vera
hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	Alcortin A
hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	hydrocortisone-iodoquinl-aloe2
hydrocortisone acetate/iodoquinol/aloe vera	Vytone
hydrocortisone acetate/iodoquinol/aloe vera	hydrocortisone-iodoquinol-aloe
hydrocortisone acetate/lidocaine HCl/aloe vera	Ana-Lex HC
hydrocortisone acetate/lidocaine HCl/aloe vera	Ana-Lex Kit
hydrocortisone acetate/lidocaine HCl/aloe vera	AnaMantle HC
hydrocortisone acetate/lidocaine HCl/aloe vera	Lidocort (with aloe)
hydrocortisone acetate/lidocaine HCl/aloe vera	Peranex HC
hydrocortisone acetate/lidocaine HCl/aloe vera	RectaGel HC
hydrocortisone acetate/lidocaine HCl/aloe vera	lidocaine-hydrocortisone-aloe
hydrocortisone acetate/lidocaine HCl/skin cleanser no.6	Xyralid
hydrocortisone acetate/lidocaine HCl/skin cleanser no.6	Xyralid LP
hydrocortisone acetate/pramoxine HCl	Analpram-HC
hydrocortisone acetate/pramoxine HCl	Analpram-HC Singles
hydrocortisone acetate/pramoxine HCl	EndaRoid
hydrocortisone acetate/pramoxine HCl	Enzone

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone acetate/pramoxine HCl	Epifoam
hydrocortisone acetate/pramoxine HCl	HC Pram
hydrocortisone acetate/pramoxine HCl	HC Pramoxine
hydrocortisone acetate/pramoxine HCl	Mezparox-HC
hydrocortisone acetate/pramoxine HCl	Novacort
hydrocortisone acetate/pramoxine HCl	PramCort
hydrocortisone acetate/pramoxine HCl	Pramosone
hydrocortisone acetate/pramoxine HCl	Procort
hydrocortisone acetate/pramoxine HCl	ProctoCream-HC(with pramoxine)
hydrocortisone acetate/pramoxine HCl	Proctofoam HC
hydrocortisone acetate/pramoxine HCl	Zone-A
hydrocortisone acetate/pramoxine HCl	Zone-A Forte
hydrocortisone acetate/pramoxine HCl	hydrocortisone-pramoxine
hydrocortisone acetate/pramoxine HCl/aloe polysaccharide	Hydropramox
hydrocortisone acetate/pramoxine HCl/aloe polysaccharide	Novacort (with aloe)
hydrocortisone acetate/pramoxine HCl/emollient base	Pramosone E
hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Pram-HCA
hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Z-Pram
hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Zypram
hydrocortisone acetate/pramoxine/emollient/pramoxine cmb no1	Analpram E
hydrocortisone acetate/pramoxine/emollient/pramoxine cmb no1	hydrocortisone-pramox-e-pram.1
hydrocortisone acetate/urea	CARMOL HC
hydrocortisone acetate/urea	Keratol HC
hydrocortisone acetate/urea	U-Cort
hydrocortisone butyrate	Locoid
hydrocortisone butyrate	hydrocortisone butyrate
hydrocortisone butyrate/emollient base	Locoid Lipocream
hydrocortisone butyrate/emollient base	hydrocortisone butyr-emollient
hydrocortisone cypionate	Cortef (as cypionate)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone hemisuccinate	hydrocortisone hemisucc (bulk)
hydrocortisone probutate	Pandel
hydrocortisone sod phosphate	Hydrocortone
hydrocortisone sod succinate	A-Hydrocort
hydrocortisone sod succinate	Solu-Cortef
hydrocortisone sod succinate	Solu-Cortef Act-O-Vial
hydrocortisone sod succinate	hydrocortisone sod succinate
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
hydrocortisone valerate	Westcort
hydrocortisone valerate	hydrocortisone valerate
hydrocortisone/acetic acid	Acetasol HC
hydrocortisone/acetic acid	Otosol-Hc
hydrocortisone/acetic acid	VoSol-HC
hydrocortisone/acetic acid	hydrocortisone-acetic acid
hydrocortisone/aloe polysaccharide/iodoquinol	Alcortin
hydrocortisone/aloe vera	Anti-Itch(hydrocortisone)-Aloe
hydrocortisone/aloe vera	Cortisone with Aloe
hydrocortisone/aloe vera	Cortizone-10 with aloe
hydrocortisone/aloe vera	Hydrocortisone Plus
hydrocortisone/aloe vera	Hydroskin with Aloe
hydrocortisone/aloe vera	hydrocortisone-aloe vera
hydrocortisone/aloe vera/vit E acet/vitamins A and D	Anti-Itch (HC) with Aloe-Vit E
hydrocortisone/aloe vera/vit E acet/vitamins A and D	Anti-Itch Plus
hydrocortisone/benzocaine/chloroxylenol	Oto-Care HC
hydrocortisone/colloidal oatmeal/aloe/vitamin E	Anti-Itch (HC) with Oatmeal
hydrocortisone/colloidal oatmeal/aloe/vitamin E	Aveeno Anti-Itch (hydrocortsn)
hydrocortisone/colloidal oatmeal/aloe/vitamin E	hydrocortisone-oatmeal-aloe-E
hydrocortisone/emollient combination no.45	Pediaderm HC
hydrocortisone/iodoquinol	Corti-Sav

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone/iodoquinol	Dermazene
hydrocortisone/iodoquinol	Vytone
hydrocortisone/iodoquinol	hydrocortisone-iodoquinol
hydrocortisone/mineral oil/petrolatum,white	hydrocortisone-min oil-wht pet
hydrocortisone/pramoxine HCl/chloroxylenol	Aero Otic HC
hydrocortisone/pramoxine HCl/chloroxylenol	Cortane-B
hydrocortisone/pramoxine HCl/chloroxylenol	Cortic
hydrocortisone/pramoxine HCl/chloroxylenol	Cortic-ND
hydrocortisone/pramoxine HCl/chloroxylenol	Cyotic
hydrocortisone/pramoxine HCl/chloroxylenol	Exotic-HC
hydrocortisone/pramoxine HCl/chloroxylenol	Genexotic-HC
hydrocortisone/pramoxine HCl/chloroxylenol	Ot-Ake HC
hydrocortisone/pramoxine HCl/chloroxylenol	OtiRx
hydrocortisone/pramoxine HCl/chloroxylenol	Oticin HC (BAK free)
hydrocortisone/pramoxine HCl/chloroxylenol	Oto-End 10
hydrocortisone/pramoxine HCl/chloroxylenol	Otomar
hydrocortisone/pramoxine HCl/chloroxylenol	Otomar-HC
hydrocortisone/pramoxine HCl/chloroxylenol	Otomax-HC
hydrocortisone/pramoxine HCl/chloroxylenol	Otozone
hydrocortisone/pramoxine HCl/chloroxylenol	Pramoxine-HC
hydrocortisone/pramoxine HCl/chloroxylenol	Tri-Otic
hydrocortisone/pramoxine HCl/chloroxylenol	Zolene HC
hydrocortisone/pramoxine HCl/chloroxylenol	Zoto-HC
hydrocortisone/pramoxine HCl/chloroxylenol/water	Cortane-B Aqueous
hydrocortisone/pramoxine HCl/chloroxylenol/water	Pramoxine-HC
hydrocortisone/pramoxine HCl/chloroxylenol/water	Zotane HC
hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Alba-3 HC
hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Hydro
hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Oticin HC

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
hydrocortisone/pramoxine/diosmin1/aloe polysac 1/policosanol	Analpram Advanced
hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Anusol-HC
hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	HC-Bismuth Subgal-Znox-Resor
hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Hemorrhoidal with HC
hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Hemorrhoidal-HC (bismuth-zinc)
hydrocortisone/salicylic acid/sulfur	Coraz
hydrocortisone/salicylic acid/sulfur/shampoo no. 1	Scalacort DK
hydrocortisone/skin cleanser combination no.25	Aqua Glycolic HC
hydrocortisone/skin cleanser combination no.35	Dermasorb HC Complete Kit
hydrocortisone/yerba santa	EarSol-HC
ketoconazole/hydrocortisone	Ketocon + Plus
ketoconazole/hydrocortisone	Pheyo
ketoconazole/hydrocortisone	Xolegel Corepak
ketoconazole/hydrocortisone	ketoconazole-hydrocortisone
ketoconazole/iodoquinol/hydrocortisone	Pheodoyo
ketoconazole/iodoquinol/hydrocortisone	ketoconazole-iodoquinol-hc
lidocaine HCl/hydrocortisone acetate	Ana-Lex
lidocaine HCl/hydrocortisone acetate	AnaMantle HC
lidocaine HCl/hydrocortisone acetate	AnaMantle HC Forte
lidocaine HCl/hydrocortisone acetate	LidaMantle HC
lidocaine HCl/hydrocortisone acetate	LidaZone HC
lidocaine HCl/hydrocortisone acetate	Lidocaine-HC
lidocaine HCl/hydrocortisone acetate	Lidocort
lidocaine HCl/hydrocortisone acetate	Peranex HC
lidocaine HCl/hydrocortisone acetate	Rectacreme HC
lidocaine HCl/hydrocortisone acetate	Senatec HC
lidocaine HCl/hydrocortisone acetate	lidocaine HCl-hydrocortison ac
lidocaine HCl/hydrocortisone acetate/psyllium husk	Xyralid RC
loteprednol etabonate	Alrex

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
loteprednol etabonate	Eysuvis
loteprednol etabonate	Inveltys
loteprednol etabonate	Lotemax
loteprednol etabonate	Lotemax SM
loteprednol etabonate	loteprednol etabonate
loteprednol etabonate/chondroitin sulfate A sodium/PF	Klarity-L (lotepred-chond)(PF)
medrysone	Liquifilm
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Meprolone Unipak
methylprednisolone	Methylpred
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	ReadySharp Methylprednisolone
methylprednisolone acetate	methylprednisolone acetate
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone acetate, micronized	methylprednisolon ac,mic(bulk)
methylprednisolone acetate/bupivacaine HCl	Physicians EZ Use M-Pred
methylprednisolone acetate/bupivacaine HCl in sterile water	methylprednisol ac-bupivac-wat
methylprednisolone acetate/norflurane/HFC 245fa	Medroloan II SUIK
methylprednisolone acetate/norflurane/HFC 245fa	Medroloan SUIK
methylprednisolone acetate/norflurane/HFC 245fa	P-Care D40G
methylprednisolone acetate/norflurane/HFC 245fa	P-Care D80G
methylprednisolone sodium succinate	A-Methapred
methylprednisolone sodium succinate	Solu-Medrol

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
methylprednisolone sodium succinate	methylprednisol sod suc(bulk)
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
methylprednisolone, micronized	methylprednisolone, mic (bulk)
mifepristone	Korlym
mometasone furoate	Asmanex HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate	Elocon
mometasone furoate	mometasone
mometasone furoate	mometasone furoate (bulk)
mometasone furoate/ammonium lactate	Momexin
mometasone furoate/ammonium lactate	Quinosone
mometasone furoate/dimethicone	Quinixil
mometasone furoate/formoterol fumarate	Dulera
neomycin sulf/colistin sul/hydrocortisone ac/thonzonium brom	Coly-Mycin S
neomycin sulf/colistin sul/hydrocortisone ac/thonzonium brom	Cortisporin-TC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	AK-Spore HC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Antibiotic HC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Cortisporin
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Cortomycin
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Neo-Poly-Bac-HC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Neo-Polycin HC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	Triple Antibiotic-HC
neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone	neomycin-bacitracin-poly-HC
neomycin sulfate/colistin sulfate/hydrocortisone	Coly-Mycin S
neomycin sulfate/dexamethasone sodium phosphate	Neo-Decadron
neomycin sulfate/dexamethasone sodium phosphate	Neo-Dex
neomycin sulfate/dexamethasone sodium phosphate	Neo-Dexair
neomycin sulfate/dexamethasone sodium phosphate	neomycin-dexamethasone

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
neomycin sulfate/fluocinolone acetonide	Neo-Synalar
neomycin sulfate/fluocinolone acetonide/emollient comb no.65	Neo-Synalar Kit
neomycin sulfate/hydrocortisone	neomycin-hydrocortisone
neomycin sulfate/polymyxin B sulfate/buffers/hydrocortisone	Pediotic
neomycin sulfate/polymyxin B sulfate/hydrocortisone	AK-Spore HC
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Antibiotic Ear
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Antibiotic HC
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Antibiotic Otic
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Aurobiotic-HC
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Bio-Cot
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Cort-Biotic
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Cortatrigen
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Cortisporin
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Cortomycin
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Oticin HC
neomycin sulfate/polymyxin B sulfate/hydrocortisone	Otocort
neomycin sulfate/polymyxin B sulfate/hydrocortisone	neomycin-polymyxin-HC
neomycin sulfate/polymyxin B sulfate/prednisolone	Poly-Pred
neomycin/bacitracin/polymyxin B/hydrocortisone	Cortisporin
neomycin/polymyxin B sulfate/dexamethasone	AK-Trol
neomycin/polymyxin B sulfate/dexamethasone	Dexacidin
neomycin/polymyxin B sulfate/dexamethasone	Dexacine
neomycin/polymyxin B sulfate/dexamethasone	Dexasporin
neomycin/polymyxin B sulfate/dexamethasone	Maxitrol
neomycin/polymyxin B sulfate/dexamethasone	Methadex
neomycin/polymyxin B sulfate/dexamethasone	Poly-Dex
neomycin/polymyxin B sulfate/dexamethasone	W-Dnp
neomycin/polymyxin B sulfate/dexamethasone	neomycin-polymyxin B-dexameth
nystatin/triamcinolone acetonide	Myco-Triacet II

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
nystatin/triamcinolone acetonide	Mycogen II
nystatin/triamcinolone acetonide	Mycolog II
nystatin/triamcinolone acetonide	Mycozin
nystatin/triamcinolone acetonide	Mytrex
nystatin/triamcinolone acetonide	N T A
nystatin/triamcinolone acetonide	NTA
nystatin/triamcinolone acetonide	nystatin-triamcinolone
oxytetracycline HCl/hydrocortisone acetate	Terra-Cortril
polymyxin B sulfate/hydrocortisone	Otobiotic
prednicarbate	Dermatop
prednicarbate	Dermatop E
prednicarbate	prednicarbate
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	Prednisolone Anhydrous
prednisolone	Prelone
prednisolone	prednisolone
prednisolone	prednisolone (bulk)
prednisolone acetate	Cotolone
prednisolone acetate	Econopred
prednisolone acetate	Econopred Plus
prednisolone acetate	Flo-Pred
prednisolone acetate	Key-Pred
prednisolone acetate	Omnipred
prednisolone acetate	Pred Forte
prednisolone acetate	Pred Mild
prednisolone acetate	Predicort-50
prednisolone acetate	Pri-Cortin 50
prednisolone acetate	UAD Pred

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
prednisolone acetate	prednisolone acetate
prednisolone acetate, micronized	prednisolone ac, micro (bulk)
prednisolone acetate/PF	prednisolone acetate (PF)
prednisolone acetate/bromfenac sodium	prednisolone acetate-bromfenac
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/gatifloxacin/nepafenac	prednisolone-gatiflox-nepafen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone acetate/nepafenac	prednisolone acetate-nepafenac
prednisolone sodium phosphate	AK-Pred
prednisolone sodium phosphate	Bubbli-Pred
prednisolone sodium phosphate	Inflamase Forte
prednisolone sodium phosphate	Inflamase Mild
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	Orapred
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Predair Forte
prednisolone sodium phosphate	Prednisol
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sod phos (bulk)
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisolone sodium phosphate/bromfenac sodium	prednisolone sod ph-bromfenac
prednisolone sodium phosphate/gatifloxacin	prednisolone sod ph-gatifloxac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
prednisolone, micronized	prednisolone, micro (bulk)
prednisone	Deltasone
prednisone	Deltasone Dose Pack
prednisone	Liquid Pred
prednisone	Meticorten
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	Sterapred
prednisone	Sterapred DS
prednisone	prednisone
prednisone	prednisone (bulk)
prednisone micronized	prednisone micronized (bulk)
rimexolone	Vexol
sulfacetamide sodium/fluorometholone	FML-S Liquifilm
sulfacetamide sodium/prednisolone acetate	AK-Cide
sulfacetamide sodium/prednisolone acetate	Blephamide
sulfacetamide sodium/prednisolone acetate	Blephamide S.O.P.
sulfacetamide sodium/prednisolone acetate	Cetapred
sulfacetamide sodium/prednisolone acetate	Isopto Cetapred
sulfacetamide sodium/prednisolone acetate	Metimyd
sulfacetamide sodium/prednisolone acetate	Vasocine
sulfacetamide sodium/prednisolone acetate	sulfacetamide-prednisolone
sulfacetamide sodium/prednisolone sodium phosphate	Sulfapred
sulfacetamide sodium/prednisolone sodium phosphate	Vasocidin
sulfacetamide sodium/prednisolone sodium phosphate	sulfacetamide-prednisolone
tobramycin/dexamethasone	TobraDex
tobramycin/dexamethasone	Tobradex ST
tobramycin/dexamethasone	tobramycin-dexamethasone
tobramycin/loteprednol etabonate	Zylet

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
triamcinolone	Aristocort
triamcinolone	triamcinolone
triamcinolone	triamcinolone (bulk)
triamcinolone acetonide	Acetocot
triamcinolone acetonide	Aristocort HP
triamcinolone acetonide	Aristocort R
triamcinolone acetonide	Arze-Ject-A
triamcinolone acetonide	Azmacort
triamcinolone acetonide	Cenocort A-40
triamcinolone acetonide	Cinalog
triamcinolone acetonide	Kenaject
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog in Orabase
triamcinolone acetonide	Kenalog-40
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	Oralone
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	ReadySharp Triamcinolone
triamcinolone acetonide	Tac-3
triamcinolone acetonide	Tri-Kort
triamcinolone acetonide	Triacet
triamcinolone acetonide	Triam-A
triamcinolone acetonide	Trianex
triamcinolone acetonide	Triderm
triamcinolone acetonide	Tritocin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
triamcinolone acetonide	Zilretta
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide	triamcinolone acetonide (bulk)
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone acetonide/PF	Triesence (PF)
triamcinolone acetonide/PF	Xipere (PF)
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	triamcinol ace-bupiv-0.9% NaCl
triamcinolone acetonide/dimethicone	Ellzia Pak
triamcinolone acetonide/dimethicone/silicone, adhesive	DermaSilkRx SDS
triamcinolone acetonide/dimethicone/silicone, adhesive	DermaWerx SDS
triamcinolone acetonide/dimethicone/silicone, adhesive	DermacinRx SilaPak
triamcinolone acetonide/dimethicone/silicone, adhesive	NuTriaRx
triamcinolone acetonide/dimethicone/silicone, adhesive	SanaDermRx
triamcinolone acetonide/dimethicone/silicone, adhesive	Sure Result Tac Pak
triamcinolone acetonide/dimethicone/silicone, adhesive	Tri-Sila
triamcinolone acetonide/dimethicone/silicone, adhesive	TriHeal-80
triamcinolone acetonide/dimethicone/silicone, adhesive	TriaDime-80
triamcinolone acetonide/dimethicone/silicone, adhesive	Trivix
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm TDPak
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Trilasil Pak
triamcinolone acetonide/emollient combination no.45	Pediaderm TA
triamcinolone acetonide/emollient combination no.86	Dermasorb TA Complete Kit
triamcinolone acetonide/gauze bandage/silicone, adhesive	Sila III
triamcinolone acetonide/lidocaine HCl	EZ Use Joint-Tunnel-Trigger
triamcinolone acetonide/lidocaine HCl	Lidocilone I
triamcinolone acetonide/lidocaine/prilocaine	DermacinRx Cinlone-I CPI
triamcinolone acetonide/low sensitizing base	Aristocort A
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
triamcinolone acetonide/niacinamide	triamcinolone-niacinamide
triamcinolone acetonide/silicones	DermacinRx SilaZone
triamcinolone acetonide/silicones	Dermazone
triamcinolone acetonide/silicones	SilaLite Pak
triamcinolone acetonide/silicones	Silazone-II
triamcinolone acetonide/skin clnsr6/Emollient 27	Zytopic
triamcinolone diacetate	Amcort
triamcinolone diacetate	Aristocort Forte
triamcinolone diacetate	Aristocort Intralesional
triamcinolone diacetate	Cenocort Forte Suspension
triamcinolone diacetate	Triam Forte
triamcinolone diacetate	Triamcot
triamcinolone diacetate	Tristoject
triamcinolone diacetate	U-Tri-Lone
triamcinolone diacetate	triamcinolone diacetate
triamcinolone diacetate	triamcinolone diacetate (bulk)
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
triamcinolone hexacetonide	triamcinolone hexaceton (bulk)
triamcinolone hexacetonide, micronized	triamcin hexacet, micro (bulk)
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	P-Care K40G
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	P-Care K80G
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Pod-Care 100KG
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Triloan II SUIK
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Triloan SUIK

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Metformin	
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet
glipizide/metformin HCl	Metaglip
glipizide/metformin HCl	glipizide-metformin
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin
metformin HCl	metformin (bulk)
metformin HCl/blood sugar diagnostic	DM2
metformin/amino acids no.7/herbal cmb.125/choline bitartrate	Appformin-D
metformin/caffeine/amino acids 7/herbal comb 125/choline bit	Appformin
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl/metformin HCl	Kombiglyze XR
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Non-ASA NSAIDs	
Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12	IC400
Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12	IC800
NAPROXEN	Napro
NAPROXEN	Naproderm
amlodipine besylate/celecoxib	Consensi
bromfenac sodium	BromSite
bromfenac sodium	Bromday
bromfenac sodium	Bromday TwinPack
bromfenac sodium	Prolensa
bromfenac sodium	XIBROM
bromfenac sodium	bromfenac
bromfenac sodium	bromfenac sodium (bulk)
bupivacaine/ketorolac/ketamine	bupivacaine-ketorolac-ketamine
bupivacaine/meloxicam	Zynrelef
celecoxib	Celebrex
celecoxib	Elyxyb
celecoxib	celecoxib
celecoxib	celecoxib (bulk)
celecoxib/capsaicin/menthol	CapXib
celecoxib/capsaicin/methyl salicylate/menthol	NuDroxiPAK
celecoxib/lidocaine/menthol	LidoXib

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Multi-Symptom Cold
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Children's Advil Allergy Sinus
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
diclofenac epolamine	Flector
diclofenac epolamine	Licart
diclofenac epolamine	diclofenac epolamine
diclofenac potassium	Cambia
diclofenac potassium	Cataflam
diclofenac potassium	Lofena
diclofenac potassium	Zipsor
diclofenac potassium	diclofenac potassium
diclofenac sodium	Arthritis Pain (diclofenac)
diclofenac sodium	Diclo Gel
diclofenac sodium	Diclofono
diclofenac sodium	Dicloprep-100
diclofenac sodium	Diclozor
diclofenac sodium	Dyloject
diclofenac sodium	Klofensaid II
diclofenac sodium	Pennsaid
diclofenac sodium	Solaraze
diclofenac sodium	VennGel One
diclofenac sodium	Voltaren
diclofenac sodium	Voltaren Arthritis Pain
diclofenac sodium	Voltaren-XR
diclofenac sodium	Vopac MDS
diclofenac sodium	diclofenac sodium
diclofenac sodium	diclofenac sodium (bulk)

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
diclofenac sodium, micronized	diclofenac sod, micro (bulk)
diclofenac sodium/benzalkonium chloride	DS Prep Pak
diclofenac sodium/capsaicin	CapsFenac Pak
diclofenac sodium/capsaicin	Dicloheal-60
diclofenac sodium/capsaicin	Diclopak
diclofenac sodium/capsaicin	Flexipak
diclofenac sodium/capsaicin	Inavix
diclofenac sodium/capsaicin	NuDiclo SoluPAK
diclofenac sodium/capsaicin	NuDiclo TabPAK
diclofenac sodium/capsaicin	Pennsaicin
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-50
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-75
diclofenac sodium/capsicum oleoresin	Capsinac
diclofenac sodium/capsicum oleoresin	DermaSilkRx DicloPak
diclofenac sodium/capsicum oleoresin	DermacinRx Lexitral
diclofenac sodium/capsicum oleoresin	Diclofex DC
diclofenac sodium/capsicum oleoresin	Diclosaicin
diclofenac sodium/capsicum oleoresin	Diclotral
diclofenac sodium/capsicum oleoresin	Iclofenac CP
diclofenac sodium/capsicum oleoresin	Inflammacin
diclofenac sodium/capsicum oleoresin	Kapzin DC
diclofenac sodium/capsicum oleoresin	PrevidolRx Plus Analgesic Pak
diclofenac sodium/capsicum oleoresin	Sure Result DSS Premium Pack
diclofenac sodium/capsicum oleoresin	Xelitral
diclofenac sodium/capsicum oleoresin	Xenaflamm
diclofenac sodium/capsicum oleoresin	Ziclopro
diclofenac sodium/hyaluronate sodium/niacinamide	Roaoxia
diclofenac sodium/hyaluronate sodium/niacinamide	diclofenac-hyaluronate-niacin
diclofenac sodium/kinesiology tape	Clofenax

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
diclofenac sodium/kinesiology tape	Diclo Gel-Xrylix Sheet
diclofenac sodium/kinesiology tape	Lexixryl
diclofenac sodium/kinesiology tape	Xrylix (diclofenac-kines tape)
diclofenac sodium/lidocaine	Lidovix
diclofenac sodium/lidocaine HCl/kinesiology tape	TriXylitral
diclofenac sodium/lidocaine/methyl salicylate/camphor	Diclovix
diclofenac sodium/menthol	DiThol
diclofenac sodium/menthol/camphor	Diclotrex
diclofenac sodium/menthol/camphor	Inflatherm(diclofenac-menthol)
diclofenac sodium/menthol/kinesiology tape	DiMentho
diclofenac sodium/menthol/kinesiology tape	Diclovix M
diclofenac sodium/methyl salicylate/menthol	DicloPR
diclofenac sodium/methyl salicylate/menthol	Varophen (diclofenac)
diclofenac sodium/methyl salicylate/menthol/camphor	Inflamma-K
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
diclofenac sodium/misoprostol	diclofenac-misoprostol
diclofenac sodium/silicone, adhesive	Solaravix
diclofenac sodium/trolamine salicylate	Inflatherm (diclofenac-trolam)
diclofenac submicronized	Zorvolex
diclofenac submicronized	diclofenac submicronized
etodolac	Lodine
etodolac	Lodine XL
etodolac	etodolac
etodolac	etodolac (bulk)
etodolac/capsaicin/methyl salicylate/menthol	NuDroxiPAK E-400
fenoprofen calcium	Fenortho
fenoprofen calcium	Nalfon
fenoprofen calcium	ProFeno

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
fenoprofen calcium	fenoprofen
fenoprofen calcium, dihydrate	fenoprofen calcium dihyd(bulk)
flurbiprofen	Ansaid
flurbiprofen	flurbiprofen
flurbiprofen	flurbiprofen (bulk)
flurbiprofen sodium	Ocufen
flurbiprofen sodium	flurbiprofen sodium
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Reprexain
hydrocodone/ibuprofen	Vicoprofen
hydrocodone/ibuprofen	Xylon 10
hydrocodone/ibuprofen	hydrocodone-ibuprofen
ibuprofen	A-G Profen
ibuprofen	Addaprin
ibuprofen	Advanced Pain Relief
ibuprofen	Advil
ibuprofen	Advil Junior Strength
ibuprofen	Advil Liqui-Gel
ibuprofen	Advil Migraine
ibuprofen	Bupranol FP
ibuprofen	Caldolor
ibuprofen	Cap-Profen
ibuprofen	Child Ibuprofen
ibuprofen	Children's Advil
ibuprofen	Children's Ibu-Drops
ibuprofen	Children's Ibuprofen
ibuprofen	Children's Medi-Profen
ibuprofen	Children's Motrin
ibuprofen	Children's Motrin Jr Strength

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
ibuprofen	Children's Profen IB
ibuprofen	Childs Ibuprofen
ibuprofen	ElixSure IB Suspension
ibuprofen	Genpril
ibuprofen	I-Prin
ibuprofen	IBU
ibuprofen	IBU-200
ibuprofen	IBU-Tab
ibuprofen	Ibu-Drops
ibuprofen	Ibupain-200
ibuprofen	Ibuprin
ibuprofen	Ibuprofen IB
ibuprofen	Ibuprofen Jr Strength
ibuprofen	Ibuprofen M
ibuprofen	Ibutab
ibuprofen	Infant's Advil
ibuprofen	Infant's Ibuprofen
ibuprofen	Infant's Medi-Profen
ibuprofen	Infant's Motrin
ibuprofen	Infants Ibu-Drops
ibuprofen	Infants ProfenIB
ibuprofen	Medi-Profen
ibuprofen	Menadol
ibuprofen	Midol Max St Cramp Formula
ibuprofen	Motrin
ibuprofen	Motrin IB
ibuprofen	Motrin Junior Strength
ibuprofen	Motrin Migraine
ibuprofen	Nuprin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
ibuprofen	Nuprin Menstrual Relief
ibuprofen	PediaCare Fever
ibuprofen	Profen IB
ibuprofen	Provil
ibuprofen	Q-Profen
ibuprofen	Tab-Profen
ibuprofen	Uni-Pro
ibuprofen	Wal-Profen
ibuprofen	Yaprofen
ibuprofen	ibuprofen
ibuprofen	ibuprofen (bulk)
ibuprofen lysine/PF	NeoProfen (ibuprofen lysn)(PF)
ibuprofen lysine/PF	ibuprofen lysine (PF)
ibuprofen/acetaminophen	Advil Dual Action
ibuprofen/capsaicin/methyl salicylate/menthol	NuDroxiPAK I-800
ibuprofen/dietary supplement,misc. cb.11	Theraprofen-60
ibuprofen/dietary supplement,misc. cb.11	Theraprofen-90
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/diphenhydramine HCl	ibuprofen-diphenhydramine HCl
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/diphenhydramine citrate	ibuprofen-diphenhydramine cit
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibuprofen/glycerin	Ibupak
ibuprofen/irritants counter-irritants combination no.2	Comfort Pac-Ibuprofen
ibuprofen/oxycodone HCl	Combunox

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
ibuprofen/phenylephrine HCl	Advil Congestion Relief
ibuprofen/phenylephrine HCl	Advil Sinus Congestion-Pain
ibuprofen/phenylephrine HCl	Congestion Relief (ibuprof-PE)
ibuprofen/phenylephrine HCl	Sudafed PE Head Congestn-Pain
ibuprofen/pseudoephedrine HCl	Advil Cold and Sinus
ibuprofen/pseudoephedrine HCl	Advil Flu and Body Ache
ibuprofen/pseudoephedrine HCl	Children's Advil Cold
ibuprofen/pseudoephedrine HCl	Children's Dimetapp Cold,Fever
ibuprofen/pseudoephedrine HCl	Children's Ibuprofen Cold
ibuprofen/pseudoephedrine HCl	Children's Motrin Cold
ibuprofen/pseudoephedrine HCl	Cold and Sinus Pain Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief (ibuprofen)
ibuprofen/pseudoephedrine HCl	DayQuil Sinus Pressure/Pain
ibuprofen/pseudoephedrine HCl	Dristan Sinus
ibuprofen/pseudoephedrine HCl	Ibup Sinus
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(with PSE)
ibuprofen/pseudoephedrine HCl	Iprin Cold and Sinus
ibuprofen/pseudoephedrine HCl	Medi-Profen
ibuprofen/pseudoephedrine HCl	Motrin Cold
ibuprofen/pseudoephedrine HCl	Motrin Cold and Sinus
ibuprofen/pseudoephedrine HCl	Motrin IB Sinus
ibuprofen/pseudoephedrine HCl	Nuprin Cold Relief
ibuprofen/pseudoephedrine HCl	Nuprin Flu Relief
ibuprofen/pseudoephedrine HCl	Profen IB Cold And Sinus
ibuprofen/pseudoephedrine HCl	Vicks DayQuil (pseudoeph-ibup)
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold and Sinus
ibuprofen/pseudoephedrine HCl	pseudoephedrine-ibuprofen
indomethacin	Indocin
indomethacin	Indocin SR
indomethacin	indomethacin
indomethacin	indomethacin (bulk)
indomethacin sodium	Indocin I.V.
indomethacin sodium	indomethacin sodium
indomethacin, submicronized	Tivorbex
indomethacin, submicronized	indomethacin submicronized
ketoprofen	Actron
ketoprofen	Frotek
ketoprofen	Orudis
ketoprofen	Orudis KT
ketoprofen	Oruvail
ketoprofen	ketoprofen
ketoprofen	ketoprofen (bulk)
ketoprofen, micronized	Frotek
ketoprofen, micronized	ketoprofen, micronized (bulk)
ketorolac tromethamine	Acular
ketorolac tromethamine	Acular LS
ketorolac tromethamine	Acular PF
ketorolac tromethamine	ReadySharp ketorolac
ketorolac tromethamine	Sprix
ketorolac tromethamine	Toradol
ketorolac tromethamine	ketorolac
ketorolac tromethamine	ketorolac (bulk)
ketorolac tromethamine/PF	Acuvail (PF)
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova II SUIK

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova SUIK
lansoprazole/naproxen	PREVACID NapraPAC
meclofenamate sodium	meclofenamate
mefenamic acid	Ponstel
mefenamic acid	mefenamic acid
mefenamic acid	mefenamic acid (bulk)
meloxicam	Anjeso
meloxicam	Mobic
meloxicam	Qmiiz ODT
meloxicam	meloxicam
meloxicam	meloxicam (bulk)
meloxicam, submicronized	Vivlodex
meloxicam, submicronized	meloxicam submicronized
meloxicam/irritants counter-irritants combination no.2	Comfort Pac-Meloxicam
nabumetone	Relafen
nabumetone	Relafen DS
nabumetone	nabumetone
nabumetone	nabumetone (bulk)
nabumetone, micronized	nabumetone, micronized (bulk)
nabumetone/capsaicin/methyl salicylate/menthol	NuDroxiPAK N-500
naproxen	EC-Naprosyn
naproxen	EC-Naproxen
naproxen	Naprosyn
naproxen	Romixen 500
naproxen	naproxen
naproxen	naproxen (bulk)
naproxen sodium	Aleve
naproxen sodium	All Day Pain Relief
naproxen sodium	All Day Relief

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
naproxen sodium	Anaprox
naproxen sodium	Anaprox DS
naproxen sodium	Flanax (naproxen)
naproxen sodium	Mediproxen
naproxen sodium	Midol (naproxen)
naproxen sodium	Naprelan
naproxen sodium	Naprelan CR
naproxen sodium	Naprelan CR Dose Card
naproxen sodium	Wal-Proxen
naproxen sodium	naproxen sodium
naproxen sodium	naproxen sodium (bulk)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen sodium/diphenhydramine HCl	Naproxen PM
naproxen sodium/menthol	NaproPak Cool
naproxen sodium/pseudoephedrine HCl	Aleve Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus and Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Cold
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Headache
naproxen sodium/pseudoephedrine HCl	All Day Cold and Sinus
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
naproxen sodium/pseudoephedrine HCl	Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Cold-Sinus Relief
naproxen sodium/pseudoephedrine HCl	Sinus and Cold-D
naproxen sodium/pseudoephedrine HCl	Sudafed 12 Hr Pressure-Pain
naproxen sodium/pseudoephedrine HCl	Sudafed 12 Hr Sinus-Pain
naproxen sodium/pseudoephedrine HCl	Sudafed Sinus 12Hr Pressr-Pain
naproxen/capsaicin/menthol	NaproPax
naproxen/capsaicin/menthol	NaproxenPax
naproxen/capsaicin/menthol/methyl salicylate	Pain Relief Collection

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
naproxen/dietary supplement,misc. cb.11	Theraproxen
naproxen/dietary supplement,misc. cb.11	Theraproxen-90
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/irritant counter-irritant combination no.2	Comfort Pac-Naproxen
nepafenac	Ilevro
nepafenac	Nevanac
oxaprozin	Daypro
oxaprozin	oxaprozin
phenylbutazone	phenylbutazone (bulk)
phenylephrine HCl/ketorolac tromethamine	Omidria
piroxicam	Feldene
piroxicam	piroxicam
piroxicam	piroxicam (bulk)
piroxicam/dietary supplement,misc. cb.11	Therafeldamine
prednisolone acetate/bromfenac sodium	prednisolone acetate-bromfenac
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/gatifloxacin/nepafenac	prednisolone-gatiflox-nepafen
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone acetate/nepafenac	prednisolone acetate-nepafenac
prednisolone sodium phosphate/bromfenac sodium	prednisolone sod ph-bromfenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
rofecoxib	Vioxx
ropivacaine HCl/clonidine HCl/ketorolac tromethamine	ropivacaine-clonidin-ketorolac
ropivacaine HCl/epinephrine/clonidine HCl/ketorolac trometh	ropivacaine-epi-clonid-ketorol
ropivacaine/ketorolac/ketamine	ropivacaine-ketorolac-ketamine
sulindac	Clinoril

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
sulindac	sulindac
sulindac	sulindac (bulk)
sumatriptan succinate/naproxen sodium	Treximet
sumatriptan succinate/naproxen sodium	sumatriptan-naproxen
suprofen	Profenal
tolmetin sodium	Tolectin
tolmetin sodium	Tolectin DS
tolmetin sodium	tolmetin
tropicamide/proparacaine/phenylephrine/ketorolac in water	Mydriatic4(trop-prop-PE-ktrlc)
tropicamide/proparacaine/phenylephrine/ketorolac in water	tropic-proparacai-pe-ketor-wat
valdecoxib	Bextra
Spironolactone	
dapsone/spironolactone/niacinamide	Diadimaxia
dapsone/spironolactone/niacinamide	Diasdimaxia
dapsone/spironolactone/niacinamide	dapsone-spironolactone-niacin
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
spironolactone	spironolactone (bulk)
spironolactone, micronized	spironolactone micro (bulk)
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
spironolactone/niacinamide	Dimoxia
spironolactone/niacinamide	spironolactone-niacinamide
tretinoin/clindamycin phosphate/spironolactone/niacinamide	tretinoin-clinda-spiron-niacin
tretinoin/spironolactone/niacinamide	Tardimaxia
tretinoin/spironolactone/niacinamide	Vardimaxia
tretinoin/spironolactone/niacinamide	tretinoin-spironolact-niacin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Selective Serotonin Reuptake Inhibitors	
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
fluoxetine	fluoxetine (bulk)
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly
fluoxetine HCl	Rapiflux
fluoxetine HCl	Sarafem
fluoxetine HCl	Selfemra
fluoxetine HCl	fluoxetine
fluoxetine HCl/dietary supplement no.17	Gaboxetine
fluoxetine HCl/dietary supplement no.8	Sentroxatine
fluvoxamine maleate	Luvox
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Pexeva
sertraline HCl	Zoloft
sertraline HCl	sertraline
sertraline HCl	sertraline (bulk)
Statins	
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/LIDOCAINE HCL/DIPHENHYDRAMINE HCL	First-BXN
NYSTATIN/TETRACYCLINE HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
Ubidecarenone/Pyridoxine/Vit B12/Pantothenic Ac/Mag Oxide	Rx Balance Statin

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
amlodipine besylate/atorvastatin calcium	Caduet
amlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
aspirin (calcium carb & magnesium buffers)/pravastatin	PRAVIGARD PAC
atorvastatin calcium	Lipitor
atorvastatin calcium	atorvastatin
cerivastatin sodium	Baycol
cladribine	Leustatin
ezetimibe/atorvastatin calcium	Liptruzet
ezetimibe/rosuvastatin calcium	Roszet
ezetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin
ezetimibe/simvastatin	Vytorin 10-10
ezetimibe/simvastatin	Vytorin 10-20
ezetimibe/simvastatin	Vytorin 10-40
ezetimibe/simvastatin	Vytorin 10-80
ezetimibe/simvastatin	ezetimibe-simvastatin
fluvastatin sodium	Lescol
fluvastatin sodium	Lescol XL
fluvastatin sodium	fluvastatin
imipenem/cilastatin sodium	Primaxin IM
imipenem/cilastatin sodium	Primaxin IV
imipenem/cilastatin sodium	imipenem-cilastatin
imipenem/cilastatin sodium/relebactam	Recarbrio
lovastatin	Altocor
lovastatin	Altoprev
lovastatin	Mevacor
lovastatin	lovastatin
lovastatin	lovastatin (bulk)
lutetium Lu 177 dotatate	Lutathera
niacin/lovastatin	Advicor

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
niacin/simvastatin	Simcor
nystatin	Bio-Statin
nystatin	Mycostatin
nystatin	Nilstat
nystatin	Nyamyc
nystatin	Nyata
nystatin	Nystat-Rx
nystatin	Nystex
nystatin	Nystop
nystatin	Pedi-Dri
nystatin	nystatin
nystatin	nystatin (bulk)
nystatin/emollient combination no.54	Pediaderm AF
nystatin/emollient combination no.88	Nyata (with Curatin)
nystatin/triamcinolone acetonide	Myco-Triacet II
nystatin/triamcinolone acetonide	Mycogen II
nystatin/triamcinolone acetonide	Mycolog II
nystatin/triamcinolone acetonide	Mycozin
nystatin/triamcinolone acetonide	Mytrex
nystatin/triamcinolone acetonide	N T A
nystatin/triamcinolone acetonide	NTA
nystatin/triamcinolone acetonide	nystatin-triamcinolone
octreotide acetate	Sandostatin
octreotide acetate, microspheres	Sandostatin LAR Depot
pentostatin	Nipent
pentostatin	pentostatin
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	Pravachol

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	Zocor
simvastatin	simvastatin
simvastatin	simvastatin (bulk)
sitagliptin phosphate/simvastatin	Juvisync
Long-Term Anabolic Steroids	
betamethasone	Celestone
budesonide	Entocort EC
budesonide	Ortikos
budesonide	Tarpeyo
budesonide	Uceris
budesonide	budesonide
cortisone acetate	cortisone
deflazacort	Emflaza
dexamethasone	Baycadron
dexamethasone	Decadron
dexamethasone	Decadron Dose Pack
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone Intensol
dexamethasone	Dexone
dexamethasone	Dxevo
dexamethasone	Hemady

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
dexamethasone	Hexadrol
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	ZCort
dexamethasone	Zema-Pak
dexamethasone	ZoDex
dexamethasone	ZonaCort
dexamethasone	dexamethasone
fludrocortisone acetate	Florinef
fludrocortisone acetate	fludrocortisone
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	Hydrocortone
hydrocortisone	hydrocortisone
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Meprolone Unipak
methylprednisolone	Methylpred
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	Prelone
prednisolone	prednisolone
prednisolone acetate	Flo-Pred
prednisolone sodium phosphate	Bubbli-Pred
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	Orapred

Appendix L. List ofNon-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Deltasone
prednisone	Deltasone Dose Pack
prednisone	Liquid Pred
prednisone	Meticorten
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	Sterapred
prednisone	Sterapred DS
prednisone	prednisone
triamcinolone	Aristo-Pak
triamcinolone	Aristocort
triamcinolone	triamcinolone

Appendix M. Specifications Used to Define Parameters for This Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool version 11.2.4 to estimate rates of cancer among loop diuretic users in the Sentinel Distributed Database (SDD).

Query period: January 1, 2000 - February 28, 2022
Coverage requirement: Medical & drug coverage
Pre-index enrollment requirement: 365 days
Enrollment gap: 45 days
Age groups: <20, 20-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+ years
Stratifications: Age, Race, Race*Sex*Age, Sex*Race, Cumulative dose, Cumulative duration
Censor output categorization: 0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years

	Exposure					
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes On Point Exposure?
1	Annivesary all ages (Background Population)	*First valid exposure episodes during query period;	0 days	N/A	N	N/A
2	Annivesary all ages (Background Population)	*First valid exposure episodes during query period;	0 days	N/A	N	N/A
3	Annivesary all ages (Background Population)	*First valid exposure episodes during query period;	0 days	N/A	N	N/A
4	Annivesary all ages (Background Population)	*First valid exposure episodes during query period;	0 days	N/A	N	N/A
5	Bumetanide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
6	Bumetanide	*First valid exosure episodes during query period;	0 days	N/A	N	*Yes

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes On Point Exposure?
7	Bumetanide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
8	Bumetanide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
9	Bumetanide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
10	Bumetanide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
11	Bumetanide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
12	Bumetanide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
13	Torsemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
14	Torsemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
15	Torsemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
16	Torsemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
17	Torsemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes On Point Exposure?
18	Torsemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
19	Torsemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
20	Torsemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
21	Furosemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
22	Furosemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
23	Furosemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
24	Furosemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
25	Furosemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
26	Furosemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes
27	Furosemide	*First valid exposure episodes during query period;	365 days	Any Loop Diuretic - Bumetanide, Torsemide, Furosemide	N	*Yes
28	Furosemide	*First valid exposure episodes during query period;	0 days	N/A	N	*Yes

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
1	N/A	N/A	N/A	N/A	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
2	N/A	N/A	N/A	N/A	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
3	N/A	N/A	N/A	N/A	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
4	N/A	N/A	N/A	N/A	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
5	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
6	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
7	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
8	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
9	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
10	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
11	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
12	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
13	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
14	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
15	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
16	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
17	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
18	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
19	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
20	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
21	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
22	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
23	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
24	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
25	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Exposure					
Scenario	Cumulative Days Supply Categories	Cumulative Dose Categories	Cumulative NDMA Impurity Categories	Evaluation Period For Cumulative Dose/NDMA Impurity Determination	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
26	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
27	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation
28	0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5-<6 years, 6-<7 years, 7+ years	0-<30,000; 30,000 - <60,000; 60,000 - <90,000; 90,000 - <120,000; 120,000 - <150,000; 150,000 - <180,000; 180,000 - <210,000; 210,000+mg	0-<700,000ppm; 700,000-<1,000,000ppm; 1,000,000-<1,500,000ppm; 1,500,000-<2,000,000ppm; 2,000,000+ppm	Dependent on date of meeting upper bound of cumulative category	Y	*Death; *DP end date; *Query end date; *Occurence of any cancer, chemotherapy, radiation

Appendix M. Specifications Used to Define Parameters for This Request

	Inclusion/Exclusion Criteria				Event Outcome			
Scenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End	Event	Incident Event Washout Period	Incident with Respect To:	Risk Window Interval Start
1	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	0	Liver Cancer (defined as combo)	365 Days	Liver Cancer	N/A
2	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	0	Bladder Cancer	365 Days	Bladder Cancer	N/A
3	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	0	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	N/A
4	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	0	Esophageal Cancer	365 Days	Esophageal Cancer	N/A
5	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
6	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
7	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)
8	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)

Appendix M. Specifications Used to Define Parameters for This Request

	Inclusion/Exclusion Criteria				Event Outcome			
Scenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End	Event	Incident Event Washout Period	Incident with Respect To:	Risk Window Interval Start
9	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
10	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
11	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)
12	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)
13	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
14	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
15	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)
16	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)

Appendix M. Specifications Used to Define Parameters for This Request

	Inclusion/Exclusion Criteria				Event Outcome			
Scenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End	Event	Incident Event Washout Period	Incident with Respect To:	Risk Window Interval Start
17	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
18	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
19	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)
20	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)
21	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
22	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Liver Cancer (defined as combo)	365 Days	Liver Cancer	365 (730 for sensitivity analysis)
23	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)
24	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Bladder Cancer	365 Days	Bladder Cancer	365 (730 for sensitivity analysis)

Appendix M. Specifications Used to Define Parameters for This Request

	Inclusion/Exclusion Criteria				Event Outcome			
Scenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End	Event	Incident Event Washout Period	Incident with Respect To:	Risk Window Interval Start
25	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
26	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Colorectal Cancer (defined as combo)	365 Days	Colorectal Cancer	365 (730 for sensitivity analysis)
27	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)
28	Cancer (Excl_Cancer), Chemotherapy (Excl_Chemo_DXPX, Excl_Chemo_NDC), or Radiation (Excl_Cancer)	*Exclusion	-365	365 (730 for sensitivity analysis)	Esophageal Cancer	365 Days	Esophageal Cancer	365 (730 for sensitivity analysis)

International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug Codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix N. Specifications Used to Define Parameters for Baseline Characteristics for This Request

Baseline Characteristics

Characteristic	Number	Characteristic	Evaluation Period Start	Evaluation Period End	Minimum RX Days
Age	1				
Sex	2				
Smoking, Ever	3		.	-1	N/A
Smoking, 1 year prior	4		-365	-1	N/A
Overweight, Obesity	5		-365	-1	N/A
Diabetes	6		-365	-1	N/A
COPD	7		-365	-1	N/A
Congestive Heart Failure	8		-365	-1	N/A
Hypertension	9		-365	-1	N/A
Liver Cancer Risk Factors	10	Liver flukes	-365	-1	N/A
Liver Cancer Risk Factors	11	Biliary cirrhosis	-365	-1	N/A
Liver Cancer Risk Factors	12	Cholangitis	-365	-1	N/A
Liver Cancer Risk Factors	13	Cholelithiasis	-365	-1	N/A
Liver Cancer Risk Factors	14	HBV Infection	-365	-1	N/A
Liver Cancer Risk Factors	15	HCV Infection	-365	-1	N/A
Liver Cancer Risk Factors	16	Unspecified Viral Hepatitis	-365	-1	N/A
Liver Cancer Risk Factors	17	Hemochromatosis	-365	-1	N/A
Liver Cancer Risk Factors	18	Wilson's Disease	-365	-1	N/A
Liver Cancer Risk Factors	19	Tyrosinemia	-365	-1	N/A
Liver Cancer Risk Factors	20	Alpha 1-antitrypsin Deficiency	-365	-1	N/A
Liver Cancer Risk Factors	21	Porphyria Cutanea Tarda	-365	-1	N/A
Liver Cancer Risk Factors	22	Glycogen storage	-365	-1	N/A
Liver Cancer Risk Factors	23	Long-term anabolic steroids	-365	-1	180
Liver Cancer Risk Factors	24	Alcoholic Liver Disease	-365	-1	N/A

Appendix N. Specifications Used to Define Parameters for Baseline Characteristics for This Request

Baseline Characteristics					
Characteristic	Number	Characteristic	Evaluation Period Start	Evaluation Period End	Minimum RX Days
Liver Cancer Risk Factors	25	Alcoholic Hepatitis	-365	-1	
Liver Cancer Risk Factors	26	Alcoholic Cirrhosis of the Liver	-365	-1	N/A
Liver Cancer Risk Factors	27	Alcoholic Liver Damage	-365	-1	
Liver Cancer Risk Factors	28	Cirrhosis	-365	-1	N/A
Liver Cancer Risk Factors	29	Alcohol-related Disorders	-365	-1	N/A
Liver Cancer Risk Factors	30	Dyslipoproteinemia	-365	-1	N/A
Liver Cancer Risk Factors	31	Non-alcoholic fatty liver disease (Non-alcoholic steatohepatitis)	-365	-1	N/A
Bladder Cancer Risk Factors	32	Antidiabetic Drugs	-365	-1	N/A
Bladder Cancer Risk Factors	33	Urinary Tract Infections	-365	-1	N/A
Bladder Cancer Risk Factors	34	Urinary Incontinence	-365	-1	N/A
Bladder Cancer Risk Factors	35	Urolithiasis	-365	-1	N/A
Bladder Cancer Risk Factors	36	Cystitis	-365	-1	N/A
Bladder Cancer Risk Factors	37	Bladder Stones	-365	-1	N/A
Colorectal Risk Factors	38	Crohn's Disease	-365	-1	N/A
Colorectal Risk Factors	39	Ulcerative Colitis	-365	-1	N/A
Colorectal Risk Factors	40	Colon Cancer Screening	-365	-1	N/A
Colorectal Risk Factors	41	Family history of colorectal cancer, adenomatous polyps	-365	-1	N/A
Esophageal Risk Factors	42	GERD	-365	-1	N/A
Esophageal Risk Factors	43	Barrett's Esophagus	-365	-1	N/A
Esophageal Risk Factors	44	Achalasia	-365	-1	N/A
Esophageal Risk Factors	45	HPV	-365	-1	N/A
Esophageal Risk Factors	46	Tylosis	-365	-1	N/A

Appendix N. Specifications Used to Define Parameters for Baseline Characteristics for This Request

Baseline Characteristics					
Characteristic	**Number**	**Characteristic**	**Evaluation Period Start**	**Evaluation Period End**	**Minimum RX Days**
Esophageal Risk Factors	47	Plummer-Vinson syndrome	-365	-1	N/A
Medications affecting Cancer Risk	48	Acetylsalicylic Acid	-365	-1	N/A
Medications affecting Cancer Risk	49	Non-ASA NSAIDs	-365	-1	N/A
Medications affecting Cancer Risk	50	5-alpha reductase inhibitors	-365	-1	N/A
Medications affecting Cancer Risk	51	statins	-365	-1	N/A
Medications affecting Cancer Risk	52	Spironolactone	-365	-1	N/A
Medications affecting Cancer Risk	53	Glucocorticoids	-365	-1	N/A
Medications affecting Cancer Risk	54	Selective Serotonin Reuptake inhibitors	-365	-1	N/A
Medications affecting Cancer Risk	55	Hormone replacement therapy	-365	-1	N/A
Medications affecting Cancer Risk	56	Metformin	-365	-1	N/A




Figure 1. Loop Diuretics Exposure Cohort (Sensitivity Analysis)